<SEC-DOCUMENT>0001213900-25-057905.txt : 20250626
<SEC-HEADER>0001213900-25-057905.hdr.sgml : 20250626
<ACCEPTANCE-DATETIME>20250625173153
ACCESSION NUMBER:		0001213900-25-057905
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		25
CONFORMED PERIOD OF REPORT:	20250625
FILED AS OF DATE:		20250626
DATE AS OF CHANGE:		20250625

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			180 Life Sciences Corp.
		CENTRAL INDEX KEY:			0001690080
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				813832378
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38105
		FILM NUMBER:		251074599

	BUSINESS ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306
		BUSINESS PHONE:		650-507-0669

	MAIL ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KBL MERGER CORP. IV
		DATE OF NAME CHANGE:	20161115
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>ea0246830-pre14a_180life.htm
<DESCRIPTION>PRELIMINARY PROXY STATEMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Jun 25 21:05:44 UTC 2025 -->
<html xmlns:atnf="http://www.180lifesciences.com/20250625" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://xbrl.us/us-types/2009-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SCHEDULE <span style="-sec-ix-hidden: hidden-fact-0">14A</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proxy Statement Pursuant to Section&#160;14(a)<br/>
of the Securities Exchange&#160;Act&#160;of&#160;1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 30%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Filed&#160;by&#160;the&#160;Registrant</span></td>
    <td style="width: 70%; font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Filed&#160;by&#160;party&#160;other&#160;than&#160;the&#160;registrant</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Preliminary&#160;Proxy&#160;Statement</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><b>Confidential,&#160;for&#160;use&#160;of&#160;the&#160;Commission&#160;only&#160;(as&#160;permitted&#160;by&#160;Rule&#160;14a-6(e)(2))</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Definitive&#160;Proxy&#160;Statement</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Definitive&#160;additional&#160;materials</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Soliciting&#160;material&#160;under&#160;Rule&#160;14a-12</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-100"><span style="text-decoration:underline">180 LIFE SCIENCES CORP.</span></ix:nonNumeric><br/>
</b>(Name of Registrant as Specified in Charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment of Filing Fee (Check all boxes that apply):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No fee required</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fee paid previously with preliminary materials</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fee&#160;computed&#160;on&#160;table&#160;in&#160;exhibit&#160;required&#160;by&#160;Item&#160;25(b)&#160;per&#160;Exchange&#160;Act&#160;Rules&#160;14a-6(i)(1)&#160;and&#160;0-11</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3000 El Camino Rd., Bldg.&#160;4, Suite 200<br/>
Palo Alto, California 94306</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">__________, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To Our Stockholders:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors (&#8220;<span style="text-decoration:underline">Board</span>&#8221;)&#160;and
officers of 180 Life Sciences Corp., a Delaware corporation (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;), join us in extending to you a cordial
invitation to attend the 2025 annual meeting of our stockholders, which we refer to as the annual meeting or the Meeting, to be held
(subject to postponement(s)&#160;or adjournment(s)&#160;thereof):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 20%; text-align: justify"><span style="font-size: 10pt">Date:</span></td>
    <td style="width: 80%; text-align: justify"><span style="font-size: 10pt">________, 2025</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">Time:</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">9:00 a.m. Pacific Time</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">Virtual Meeting Site:</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">https://agm.issuerdirect.com/ATNF</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You will not be able to attend
the annual meeting physically. The annual meeting will be held via an audio teleconference. Stockholders may attend, vote and submit
questions during the annual meeting via the Internet by logging in at&#160;<i>https://agm.issuerdirect.com/ATNF</i>, with your Control
ID and Request ID, and thereafter following the instructions to join the virtual meeting. In addition to voting by submitting your proxy
prior to the annual meeting and/or voting online as discussed herein, you also will be able to vote your shares electronically during
the annual meeting with your Request ID. Details regarding the business to be conducted are more fully described in the accompanying
Notice of Annual Meeting and Proxy Statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notice of Annual Meeting
and Proxy Statement, is also available at&#160;<i>https://www.iproxydirect.com/ATNF</i>. This website also includes copies of our Annual
Report on Form&#160;10-K&#160;for the year ended December&#160;31, 2024, which we refer to as the annual report. Stockholders may also
request a copy of the proxy statement and our annual report by contacting our main office at (650)&#160;507-0669.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the annual
meeting, you will be asked to consider and vote on certain proposals, which are more fully described in the accompanying proxy statement.
Whether or not you plan to attend the annual meeting, we urge you to read the proxy statement (and any documents incorporated into the
proxy statement by reference) and consider such information carefully before voting. The attached Notice of Annual Meeting and the Proxy
Statement describe the business to be considered and acted upon by the stockholders at the annual meeting. Please review these materials
and vote your shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your vote is very important.
Even if you plan to attend the annual meeting, if you are a holder of record of voting stock please submit your proxy by mail, fax, Internet
or telephone as soon as possible to make sure that your shares are represented at the annual meeting. If you hold your shares of Company
stock in &#8220;street name&#8221; through a bank, broker, or other nominee, you must vote in accordance with the voting instructions
provided to you by such bank, broker, or other nominee, which include instructions for voting by Internet or telephone.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors encourages
your participation in 180 Life Sciences Corp.&#8217;s electoral process and, to that end, solicits your proxy with respect to the matters
described in the Notice of Meeting and the proxy statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We look forward to seeing
you on _______, 2025. Your vote and participation in our governance is very important to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sincerely,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 40%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt"><i>/s/ Blair Jordan</i></span></td>
    <td style="width: 60%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">Blair Jordan</span></td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">Chief Executive Officer and Director</span></td>
    <td style="text-align: justify">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our proxy statement and Annual
Report on Form&#160;10-K&#160;for the year ended December 31, 2024 are available at the following cookies-free&#160;website that can
be accessed anonymously:&#160;<i>https://agm.issuerdirect.com/ATNF</i>.&#160;Stockholders may also vote prior to the meeting at&#160;<i>www.iproxydirect.com/ATNF</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>180 LIFE SCIENCES CORP.<br/>
</b>3000 El Camino Rd., Bldg. 4, Suite 200<br/>
Palo Alto, California 94306</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS<br/>
TO BE HELD ON _______, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Stockholders of 180 Life Sciences Corp.:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are pleased to provide
you notice of, and to invite you to attend, the 2025 annual meeting of the stockholders of 180 Life Sciences Corp., a Delaware corporation
(&#8220;<span style="text-decoration:underline">180 Life</span>&#8221;, the &#8220;<span style="text-decoration:underline">Company</span>&#8221;, &#8220;<span style="text-decoration:underline">we</span>&#8221; and &#8220;<span style="text-decoration:underline">us</span>&#8221;), which will be
held on ________, 2025, at 9:00 a.m., Pacific Time (subject to postponement(s)&#160;or adjournment(s)&#160;thereof), which
we refer to as the annual meeting, or the &#8220;<span style="text-decoration:underline">Meeting</span>&#8221;. The meeting will be held virtually via live audio webcast at&#160;<i>https://agm.issuerdirect.com/ATNF</i>.
See also &#8220;Instructions For The Virtual Annual Meeting&#8221;, beginning on page&#160;1. The annual meeting is being held for the
following purposes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b><i>To elect two Class&#160;I
directors to the Board of Directors (the &#8220;<span style="text-decoration:underline">Board</span>&#8221;)&#160;each to serve a term of two&#160;years and until their respective
successors have been elected and qualified, or until such director&#8217;s resignation or removal.</i></b>&#160;The Board has nominated
for re-election&#160;the following incumbent Class&#160;I directors: Lawrence Steinman, M.D. and Stephen H. Shoemaker.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>2.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b><i>To approve the adoption
of the Fourth Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan.&#160;</i></b>The Board of Directors recommends that
you approve and ratify the Fourth Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>3.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>To approve the adoption of the 180 Life Sciences
    Corp. 2025 Option Incentive Plan. </i></b>The Board of Directors recommends that you approve and ratify the 180 Life Sciences Corp.
    2025 Option Incentive Plan.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>4.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>To approve an advisory resolution on Named Executive Officer
    compensation</i>.</b>&#160;The Board of Directors recommends that you approve and ratify executive compensation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>5.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>To approve an Amendment to the Company&#8217;s Second
    Amended and Restated Certificate of Incorporation to approve a reverse stock split of the Company&#8217;s outstanding common stock.</i></b>&#160;The
    Board of Directors recommends that you grant discretionary authority to the Company&#8217;s Board of Directors to (A) approve an
    amendment to our Second Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued
    and outstanding shares of our common stock, par value $0.0001 per share, by a ratio of between&#160;one-for-four to one-for-forty,
    inclusive, with the exact ratio to be set at a whole number to be determined by our Board of Directors or a duly authorized committee
    thereof in its discretion, at any time after approval of the amendment and prior to ___________, 2026, and (B) determine whether
    to arrange for the disposition of fractional interests by shareholder entitled thereto, to pay in cash the fair value of fractions
    of a share of common stock as of the time when those entitled to receive such fractions are determined, or to entitle shareholder
    to receive from the Corporation&#8217;s transfer agent, in lieu of any fractional share, the number of shares of common stock rounded
    up to the next whole number (the &#8220;<span style="text-decoration:underline">Reverse Split Proposal</span>&#8221;).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>6.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>To approve an Amendment to the Company&#8217;s Second
    Amended and Restated Certificate of Incorporation to increase the Company&#8217;s authorized number of shares of common stock from
    one hundred million (100,000,000) shares to one billion (1,000,000,000) shares</i>.</b> The Board of Directors recommends that you
    approve an Amendment to the Company&#8217;s Second Amended and Restated Certificate of Incorporation to increase the Company&#8217;s
    authorized number of shares of common stock from one hundred million (100,000,000) shares to one billion (1,000,000,000) shares (the
    &#8220;<span style="text-decoration:underline">Authorized Share Increase Proposal</span>&#8221;).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>7.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>To ratify the appointment of M&amp;K CPAs, PLLC,
    an independent registered public accounting firm, as the Company&#8217;s independent auditors for the fiscal year ending December
    31, 2025.</i></b>&#160;The Board of Directors recommends that you approve and ratify the appointment of M&amp;K CPAs, PLLC as the
    Company&#8217;s independent auditors for the fiscal year ending December 31, 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>8.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>To approve the adjournment of the Annual Meeting,
    if necessary.&#160;</i></b>The Board of Directors recommends that you approve the adjournment of the Annual Meeting, if necessary,
    to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve the Reverse Split Proposal
    and/or Authorized Share Increase Proposal.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>9<i>.</i></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>To transact such other business as may properly come before the
    annual meeting.</i></b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>THE BOARD OF DIRECTORS
UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#8220;<span style="text-decoration:underline">FOR ALL</span>&#8221; FOR PROPOSAL ONE, AND &#8220;<span style="text-decoration:underline">FOR</span>&#8221; PROPOSALS TWO THROUGH
EIGHT.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any action may be taken on
any one of the foregoing proposals at the Meeting on the date specified above or on any date or dates to which the Meeting may be postponed
or adjourned. We do not expect to transact any other business at the annual meeting. Our Board of Directors has fixed the close of business
on June 30, 2025, as the record date for determining those stockholders entitled to vote at the annual meeting and any adjournment or
postponement thereof. Accordingly, only common and preferred stock stockholders of record at the close of business on that date are entitled
to notice of, and to vote at, the annual meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cordially invite you to
attend the annual meeting. However, to ensure your representation at the annual meeting, please authorize the individuals named on your
proxy card to vote your shares by calling the toll-free&#160;telephone number, faxing your proxy card or by using the Internet as described
in the instructions included with your proxy card or voting instruction card. Alternatively, if you received a paper copy of the proxy
card by mail, please complete, date, sign and promptly return the proxy card. This will not prevent you from voting at the meeting, but
will help to secure a quorum and avoid added solicitation costs. If your shares are held in &#8220;<span style="text-decoration:underline">street name</span>&#8221; by your
broker or other nominee, only that holder can vote your shares and the vote cannot be cast unless you provide instructions to your broker.
You should follow the directions provided by your broker regarding how to instruct your broker to vote your shares. Your proxy may be
revoked at any time before it is voted. Please review the proxy statement accompanying this notice for more complete information regarding
the matters to be voted on at the meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The enclosed proxy statement
is first being mailed to stockholders on or about [&#9679;], 2025, is also available at&#160;<i>https://www.iproxydirect.com/ATNF</i>.
This website also includes our Annual Report on Form&#160;10-K&#160;for the year ended December 31, 2024, which we refer to as the 2024
Annual Report. Stockholders may also request a copy of the proxy statement and our annual report by contacting our main office at (650)&#160;507-0669.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if you plan to attend
the annual meeting, we request that you submit a proxy by following the instructions on your proxy card as soon as possible and thus
ensure that your shares will be represented at the annual meeting if you are unable to attend.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you have any questions
or require any assistance with voting your shares, please contact our proxy agent, Issuer Direct Corporation at (919) 481-4000,&#160;or
1-866-752-VOTE (8683).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By Order of the Board of Directors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 40%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><i>/s/ Blair Jordan</i></span></td>
    <td style="width: 60%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">Blair Jordan</span></td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">Chief Executive Officer and Director</span></td>
    <td style="text-align: justify">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 40%; text-align: justify"><span style="font-size: 10pt">Palo Alto, California</span></td>
    <td style="width: 60%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">[&#9679;], 2025</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border: Black 1.5pt solid; padding: 5pt; width: 100%; text-align: justify"><span style="font-size: 10pt"><b>IMPORTANT:&#160;WHETHER
    OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING, WE ASK YOU TO VOTE BY TELEPHONE, MAIL, FAX OR ON THE INTERNET USING THE INSTRUCTIONS
    ON THE PROXY CARD.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 4 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif">General
    Information</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">1</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 2%">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 90%"><a href="#a_002">Information Contained in this Proxy Statement</a></td>
    <td style="text-align: center; width: 8%; vertical-align: bottom">1</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_003">Instructions For The Virtual Annual Meeting</a></td>
    <td style="text-align: center; vertical-align: bottom">1</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_004">Questions During the Annual Meeting</a></td>
    <td style="text-align: center; vertical-align: bottom">1</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_005">Technical Difficulties or Trouble Accessing the Virtual
    Meeting Website</a></td>
    <td style="text-align: center; vertical-align: bottom">2</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_006">Record Date and Shares Entitled to Vote</a></td>
    <td style="text-align: center; vertical-align: bottom">2</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_007">Voting Process</a></td>
    <td style="text-align: center; vertical-align: bottom">2</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_008">Providing and Revoking Proxies</a></td>
    <td style="text-align: center; vertical-align: bottom">3</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_009">Meeting Time and Location: Virtual Annual Meeting</a></td>
    <td style="text-align: center; vertical-align: bottom">3</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_010">Conduct at the Meeting</a></td>
    <td style="text-align: center; vertical-align: bottom">3</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_011">Voting Requirements for Each of the Proposals</a></td>
    <td style="text-align: center; vertical-align: bottom">4</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_166">Quorum</a></td>
    <td style="text-align: center; vertical-align: bottom">5</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_012">Board of Directors Voting Recommendations</a></td>
    <td style="text-align: center; vertical-align: bottom">5</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_013">Mailing Costs and Solicitation of Proxies</a></td>
    <td style="text-align: center; vertical-align: bottom">6</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_014">Inspector of Voting</a></td>
    <td style="text-align: center; vertical-align: bottom">6</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_015">Stockholders Entitled to Vote at the Meeting</a></td>
    <td style="text-align: center; vertical-align: bottom">6</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_016">Voting Instructions</a></td>
    <td style="text-align: center; vertical-align: bottom">6</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_017">Confidential Voting</a></td>
    <td style="text-align: center; vertical-align: bottom">6</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_018">Stockholder of Record and Shares Held in Brokerage Accounts</a></td>
    <td style="text-align: center; vertical-align: bottom">7</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_019">Multiple Stockholders Sharing the Same Address</a></td>
    <td style="text-align: center; vertical-align: bottom">7</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_020">Voting Results</a></td>
    <td style="text-align: center; vertical-align: bottom">7</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_021">Company Mailing Address</a></td>
    <td style="text-align: center; vertical-align: bottom">7</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_022">Other Matters</a></td>
    <td style="text-align: center; vertical-align: bottom">7</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif">Background
    of the Company</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">8</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif">Prior
    Reverse Stock Splits</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">8</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif">Definitions</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">8</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif">Forward-Looking
    Statements and Website Links</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">9</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif">Incorporation
    by Reference</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">9</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif">References
    to Additional Information</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">9</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif">Voting
    Rights and Principal Stockholders</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">10</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_030">Security Ownership of Management and Certain Beneficial
    Owners and Management</a></td>
    <td style="text-align: center; vertical-align: bottom">10</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_031">Change of Control</a></td>
    <td style="text-align: center; vertical-align: bottom">12</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_032"><span style="font-family: Times New Roman, Times, Serif">Corporate
    Governance</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">13</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_033">Board Leadership Structure</a></td>
    <td style="text-align: center; vertical-align: bottom">13</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_034">Risk Oversight</a></td>
    <td style="text-align: center; vertical-align: bottom">13</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_035">Family Relationships</a></td>
    <td style="text-align: center; vertical-align: bottom">14</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_036">Other Directorships</a></td>
    <td style="text-align: center; vertical-align: bottom">14</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_037">Involvement in Certain Legal Proceedings</a></td>
    <td style="text-align: center; vertical-align: bottom">14</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_038">Board of Directors Meetings</a></td>
    <td style="text-align: center; vertical-align: bottom">15</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_039">Board Committee Membership</a></td>
    <td style="text-align: center; vertical-align: bottom">15</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_040">Audit Committee</a></td>
    <td style="text-align: center; vertical-align: bottom">15</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_041">Compensation Committee</a></td>
    <td style="text-align: center; vertical-align: bottom">16</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_042">Compensation Committee Interlocks and Insider Participation</a></td>
    <td style="text-align: center; vertical-align: bottom">17</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_043">Nominating and Governance Committee</a></td>
    <td style="text-align: center; vertical-align: bottom">17</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_044">Strategy and Alternatives, Risk, Safety and Regulatory
    Committee</a></td>
    <td style="text-align: center; vertical-align: bottom">18</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_045">Website Availability of Documents</a></td>
    <td style="text-align: center; vertical-align: bottom">18</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_046">Stockholder Communications with the Board of Directors</a></td>
    <td style="text-align: center; vertical-align: bottom">18</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_047">Lead Independent Director</a></td>
    <td style="text-align: center; vertical-align: bottom">19</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 5; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 2%">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 90%"><a href="#a_048">Executive Sessions of the Board of Directors</a></td>
    <td style="text-align: center; width: 8%; vertical-align: bottom">19</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_049">Code of Ethics</a></td>
    <td style="text-align: center; vertical-align: bottom">19</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_050">Policy on Equity Ownership</a></td>
    <td style="text-align: center; vertical-align: bottom">19</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_051">Rule 10b5-1 Trading Plans</a></td>
    <td style="text-align: center; vertical-align: bottom">19</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_053">Insider Trading/Anti-Hedging Policies</a></td>
    <td style="text-align: center; vertical-align: bottom">20</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_054">Policy on Timing of Award Grants</a></td>
    <td style="text-align: center; vertical-align: bottom">21</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_055">Director Independence</a></td>
    <td style="text-align: center; vertical-align: bottom">21</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="2" style="text-transform: uppercase; font-weight: bold"><a href="#a_056"><span style="font-family: Times New Roman, Times, Serif">Audit
    Committee Report</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">22</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-transform: uppercase; font-weight: bold"><a href="#a_057"><span style="font-family: Times New Roman, Times, Serif">Information
    About Our Executive Officers and Directors</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">23</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_058">Executive Officers</a></td>
    <td style="text-align: center; vertical-align: bottom">23</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_059">Classified Board of Directors</a></td>
    <td style="text-align: center; vertical-align: bottom">23</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_060">Director Nominees</a></td>
    <td style="text-align: center; vertical-align: bottom">24</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_061">Board Nominees</a></td>
    <td style="text-align: center; vertical-align: bottom">25</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_062">Continuing Directors</a></td>
    <td style="text-align: center; vertical-align: bottom">26</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_063">Director Qualifications</a></td>
    <td style="text-align: center; vertical-align: bottom">27</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="2" style="text-transform: uppercase; font-weight: bold"><a href="#a_064"><span style="font-family: Times New Roman, Times, Serif">Executive
    and Director Compensation</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">27</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_065">Summary Executive Compensation Table</a></td>
    <td style="text-align: center; vertical-align: bottom">27</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_066">Bonuses</a></td>
    <td style="text-align: center; vertical-align: bottom">29</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_067">Current Compensation Agreements</a></td>
    <td style="text-align: center; vertical-align: bottom">29</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_068">Jordan Consulting Agreement</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">29</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_069">EVL Consulting Agreement</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">32</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_070">Prior Employment Agreements</a></td>
    <td style="text-align: center; vertical-align: bottom">33</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_071">James N. Woody Amended and Restated
    Employment Agreement (terminated); and Separation Agreement</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">33</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_072">Dr. Rothbard&#8217;s Employment Agreement
    (terminated); and Separation Agreement</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">35</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_073">Ozan Pamir Katexco Employment Agreement
    (Terminated)</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">35</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_074">Ozan Pamir Company Employment Agreement
    (Terminated)</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">36</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_075">Quan Anh Vu Executive Employment Agreement
    (terminated); and Separation Agreement</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">36</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_076">Description of Material Consulting Agreements</a></td>
    <td style="text-align: center; vertical-align: bottom">37</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_077">Service Agreement with Prof. Sir Marc
    Feldmann (former Co-Executive Chairman)(Terminated)</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">37</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_078">Consultancy Agreement and Consulting
    Agreement with Prof. Lawrence Steinman</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">39</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_079">Prof. Jagdeep Nanchahal Consulting Agreement</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">40</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_080">Payment of Back Pay; 2021 Bonuses and Increases in Salaries</a></td>
    <td style="text-align: center; vertical-align: bottom">42</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_081">2024 Accruals</a></td>
    <td style="text-align: center; vertical-align: bottom">42</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_082">2022, 2023 and 2024 Bonuses</a></td>
    <td style="text-align: center; vertical-align: bottom">42</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_083">Pay Versus Performance</a></td>
    <td style="text-align: center; vertical-align: bottom">43</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_084">Relationship Between &#8220;Compensation Actually Paid&#8221;
    and Performance</a></td>
    <td style="padding-left: -0.125in; text-align: center; vertical-align: bottom">46</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_085">Compensation Actually Paid and Net Loss</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">46</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_086">Compensation Actually Paid and Cumulative
    TSR</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">46</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_087">Outstanding Equity Awards at Fiscal Year End</a></td>
    <td style="text-align: center; vertical-align: bottom">47</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_088">Potential Payments Upon Termination</a></td>
    <td style="text-align: center; vertical-align: bottom">47</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_089">Director Compensation</a></td>
    <td style="text-align: center; vertical-align: bottom">48</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_090">Board of Director Fees</a></td>
    <td style="text-align: center; vertical-align: bottom">49</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_091">Release Agreement</a></td>
    <td style="text-align: center; vertical-align: bottom">49</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_092">Equity Compensation Plan Information</a></td>
    <td style="text-align: center; vertical-align: bottom">51</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_093">2020 Omnibus Incentive Plan</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">51</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_094">2022 Omnibus Incentive Plan</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">51</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-transform: uppercase; font-weight: bold"><a href="#a_095"><span style="font-family: Times New Roman, Times, Serif">Certain
    Relationships and Related Party Transactions</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">52</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_096">Related Party Agreements</a></td>
    <td style="text-align: center; vertical-align: bottom">52</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_097">Service Agreement with Prof. Sir Marc
    Feldmann</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">52</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_098">Prof. Jagdeep Nanchahal Consulting Agreement</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">53</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_099">Prof. Lawrence Steinman Consultancy
    Agreement and Consulting Agreement</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">53</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 2%; font-style: italic">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.375in; width: 90%; font-style: italic"><a href="#a_100">Jordan Consulting Agreement</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; width: 8%; font-style: italic; vertical-align: bottom">53</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.375in; font-style: italic"><a href="#a_101">EVL Consulting Agreement</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; font-style: italic; vertical-align: bottom">53</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.375in; font-style: italic"><a href="#a_102">Voting Agreements</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; font-style: italic; vertical-align: bottom">53</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_103">Conversion of Series B Convertible Preferred Stock</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">54</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_104">Elray and Luxor Settlement Agreement</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">54</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_105">General and Administrative - Related Parties</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">55</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_106">Accounts Payable - Related Parties</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">55</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_107">Research and Development Expenses &#8211; Related Parties</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">55</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_108">Related Party Litigation</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">56</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.375in; font-style: italic"><a href="#a_109">Action Against Former Executive of KBL</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; font-style: italic; vertical-align: bottom">56</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.375in; font-style: italic"><a href="#a_110">Action Against the Company by Dr. Krauss</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; font-style: italic; vertical-align: bottom">56</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.375in; font-style: italic"><a href="#a_111">Action Against Tyche Capital LLC</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; font-style: italic; vertical-align: bottom">57</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.375in; font-style: italic"><a href="#a_112">Action Against Ronald Bauer &amp; Samantha
    Bauer</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; font-style: italic; vertical-align: bottom">58</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.375in; font-style: italic"><a href="#a_113">Declaratory Relief Action Against the
    Company by AmTrust International</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; font-style: italic; vertical-align: bottom">58</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_114">Indemnification Agreements</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">60</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_115">Related Party Transaction Policy</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">60</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_116"><span style="font-family: Times New Roman, Times, Serif">Delinquent
    Section 16(a) Reports</span></a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">60</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_117"><span style="font-family: Times New Roman, Times, Serif">Proposal
    1 Election of Directors</span></a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">61</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_118">General</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">61</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_119">General Director Qualifications</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">61</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_120">What Vote Is Required To Elect the Director Nominees</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">61</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_121">Board Recommendation</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">61</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_122"><span style="font-family: Times New Roman, Times, Serif">Proposal
    2 Adoption of the Fourth Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan</span></a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">62</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_123">General</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">62</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_124">Background and Purpose of the Amended Plan</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">62</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_125">Current Overview of Outstanding Equity Information</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">63</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_126">Summary of the Material Terms of the Amended Plan</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">63</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_127">Federal Income Tax Consequences</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">68</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_128">Vote Required</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">70</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_129">Recommendation of the Board of Directors</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">70</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_167"><span style="font-family: Times New Roman, Times, Serif">Proposal
    3 Approval of an Advisory Resolution on Named Executive Officer Compensation</span></a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">71</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_130">General</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">71</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_131">Vote Required</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">77</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#via_001">Board Recommendation</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">77</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_132"><span style="font-family: Times New Roman, Times, Serif">Proposal
    4 Amendment to Second Amended and Restated Certificate of Incorporation, as Amended, to Effect a Reverse Stock Split</span></a></td>
    <td style="padding-left: 0in; text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">78</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_133">General</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">78</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in">Purpose</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in">Accounting Matters</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in">Risks of the Proposed Reverse Stock Split</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in">Principal Effects of the Reverse Stock Split</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in">Fractional Shares</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in">Determination of the Reverse Stock Split Ratio</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in">Potential Consequences if the Reverse Split Proposal is Not Approved</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in">Effective Date and Time of the Reverse Stock Split</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in">No Dissenters&#8217; Rights</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in">Certain United States Federal Income Tax Consequences</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in">Exchange of Stock Certificates</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in">Book-Entry Shares</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in">Interests of Directors and Executive Officers</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_134">Vote Required</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">78</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.25in; padding-left: 0.25in"><a href="#a_135">Board Recommendation</a></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; vertical-align: bottom">78</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_136"><span style="font-family: Times New Roman, Times, Serif">Proposal
    5 Approval of an Amendment to Our Second Amended and Restated Certificate of Incorporation to Increase the Company&#8217;s Authorized
    Number of Shares of Common Stock From One Hundred Million (100,000,000) to One Billion (1,000,000,000)</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">79</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 2%">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 90%"><a href="#a_137">General</a></td>
    <td style="text-align: center; width: 8%; vertical-align: bottom">79</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">Reasons for the Amendment</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">Summary Table of Potential Effects of Authorized Share Increase</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_138">No Dissenters&#8217; Rights</a></td>
    <td style="text-align: center; vertical-align: bottom">88</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">Effective Time and Implementation of the Authorized Shares Increase Amendment</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_139">Vote Required</a></td>
    <td style="text-align: center; vertical-align: bottom">92</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_140">Board Recommendation</a></td>
    <td style="text-align: center; vertical-align: bottom">92</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_141"><span style="font-family: Times New Roman, Times, Serif">Proposal
    6 Approval of the Issuance of More Than 20% of the Company&#8217;s Issued and Outstanding Common Stock in Connection with Certain
    Offerings</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">93</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_142">General</a></td>
    <td style="text-align: center; vertical-align: bottom">93</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">Terms of Potential Offerings</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic">General Terms</td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic">Offering Warrants</td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic">Underwriter Compensation</td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic">Potential Significant Dilution</td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic">Intended Use of Proceeds</td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic">Multiple Offerings</td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic">Additional Provisions</td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">Nasdaq Parameters</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">Reasons for the Proposal</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#via_002">Required Vote</a></td>
    <td style="text-align: center; vertical-align: bottom">96</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#via_003">Recommendation of the Board of Directors</a></td>
    <td style="text-align: center; vertical-align: bottom">96</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_143"><span style="font-family: Times New Roman, Times, Serif">Proposal
    7 Ratification of Appointment of Auditors</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">96</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_144">Audit Committee Policy for Pre-approval of Independent Registered Public
    Accounting Firm Services</a></td>
    <td style="text-align: center; vertical-align: bottom">98</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_145">Pre-Approval Policies</a></td>
    <td style="text-align: center; vertical-align: bottom">98</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_146">Vote Required</a></td>
    <td style="text-align: center; vertical-align: bottom">98</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_147">Board Recommendation</a></td>
    <td style="text-align: center; vertical-align: bottom">98</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_148"><span style="font-family: Times New Roman, Times, Serif">Proposal
    8 Adjournment of the Annual Meeting to Solicit Additional Proxies</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">99</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_149">Overview</a></td>
    <td style="text-align: center; vertical-align: bottom">99</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_150">Vote Required</a></td>
    <td style="text-align: center; vertical-align: bottom">99</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_151">Board Recommendation</a></td>
    <td style="text-align: center; vertical-align: bottom">99</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-transform: uppercase; font-weight: bold"><a href="#a_152"><span style="font-family: Times New Roman, Times, Serif">Other
    Matters</span></a></td>
    <td style="text-align: center; text-transform: uppercase; font-weight: bold; vertical-align: bottom">100</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_153">Proposals for 2026 Annual Meeting of Stockholders and 2026 Proxy Materials</a></td>
    <td style="text-align: center; vertical-align: bottom">100</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_154">Proxy Statement Proposals</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">100</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic"><a href="#a_155">Other Proposals and Nominations</a></td>
    <td style="text-align: center; font-style: italic; vertical-align: bottom">100</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_156">Annual Report</a></td>
    <td style="text-align: center; vertical-align: bottom">101</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_157">Additional Filings</a></td>
    <td style="text-align: center; vertical-align: bottom">101</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_158">Other Matters to be Presented at the Annual Meeting</a></td>
    <td style="text-align: center; vertical-align: bottom">101</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_159">Interest of Certain Persons in or Opposition to Matters to Be Acted Upon:</a></td>
    <td style="text-align: center; vertical-align: bottom">101</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_160">Incorporation by Reference</a></td>
    <td style="text-align: center; vertical-align: bottom">102</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 8 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Appendixes:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td style="width: 12%; text-align: justify"><span style="font-size: 10pt"><b>Appendix A </b></span></td>
    <td style="width: 3%">&#8212;</td>
    <td style="width: 85%; text-align: justify"><span style="font-size: 10pt">Fourth Amendment to the 180 Life Sciences Corp. 2022 Omnibus
    Incentive Plan</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Appendix B</b> </span></td>
    <td>&#8212;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fourth Amended and Restated 180 Life Sciences Corp. 2022 Omnibus Incentive
    Plan</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Appendix C </b></span></td>
    <td>&#8212;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">180 Life Sciences Corp. 2025 Option Incentive Plan</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Appendix D</b> </span></td>
    <td>&#8212;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Form of Certificate of Amendment of Second Amended and Restated Certificate
    of Incorporation of 180 Life Sciences Corp. in Connection with the Reverse Stock Split Proposal</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Appendix E</b>&#160;</span></td>
    <td>&#8212;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Form of Certificate of Amendment of Second Amended and Restated Certificate
    of Incorporation of 180 Life Sciences Corp. in Connection with the Authorized Share Increase Proposal</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1.5in"></p><div>

</div><!-- Field: Page; Sequence: 9 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROXY STATEMENT<br/>
FOR&#160;2025 ANNUAL MEETING OF STOCKHOLDERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">General Information</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">180 Life Sciences Corp. (&#8220;<span style="text-decoration:underline">we,</span>&#8221;
&#8220;<span style="text-decoration:underline">us</span>&#8221;, &#8220;<span style="text-decoration:underline">our</span>&#8221; or the &#8220;<span style="text-decoration:underline">Company</span>&#8221;) has provided these materials to you by mail, in
connection with the Company&#8217;s solicitation of proxies for use at our 2025 annual meeting of stockholders, which we refer to as
our annual meeting, or the &#8220;<span style="text-decoration:underline">Meeting</span>&#8221;, on ______________, 2025 at _______&#160;p.m., Pacific time, and at any postponement(s)&#160;or
adjournment(s)&#160;thereof. The meeting will be held virtually via live audio webcast at&#160;<i>https://agm.issuerdirect.com/ATNF</i>.
See also &#8220;Instructions For The Virtual Annual Meeting&#8221;, beginning on page&#160;1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These materials were first
sent or given to stockholders on or about [&#9679;], 2025. You are invited to attend the annual meeting online and are requested to vote
on the proposals described in this Proxy Statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Information Contained
in this Proxy Statement</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in this proxy
statement relates to the proposals to be voted on at the annual meeting, the voting process, the compensation of our directors and executive
officers, corporate governance, and certain other required information. Included with this proxy statement is a copy of the Company&#8217;s
Annual Report on Form&#160;10-K&#160;for the year ended December 31, 2024, as filed with the SEC on March 31, 2025 (the &#8220;<span style="text-decoration:underline">2024
Annual Report</span>&#8221;). If you requested printed versions of these materials by mail, these materials also include the proxy card
and vote instruction form for the annual meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Instructions For
The Virtual Annual Meeting</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This year our annual meeting
will be a completely virtual meeting. There will be no physical meeting location. The meeting will only be conducted via live audio webcast.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To participate in the virtual
meeting, visit&#160;<i>https://agm.issuerdirect.com/ATNF</i>&#160;and enter the control number on your proxy card, or on the instructions
that accompanied your proxy materials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recommend you check in/log
in to the annual meeting 15 minutes before the meeting is scheduled to start so that any technical difficulties may be addressed before
the meeting begins.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may vote during the meeting
by following the instructions available on the meeting website during the meeting. To the best of our knowledge, the virtual meeting
platform is fully supported across browsers (Internet Explorer, Firefox, Chrome, and Safari) and devices (desktops, laptops, tablets,
and cell phones) running the most updated version of applicable software and plugins. Participants should ensure they have a strong Internet
connection wherever they intend to participate in the meeting. Participants should also allow plenty of time to log in and ensure that
they can hear streaming audio prior to the start of the meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Questions During
the Annual Meeting</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to hold a question-and-answer&#160;session
with management immediately following the conclusion of the business to be conducted at the annual meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may submit a question
at any time during the meeting by following the instructions provided in the meeting portal at the address described above. The Chair
of the meeting has broad authority to conduct the annual meeting in an orderly manner, including establishing rules of conduct. A copy
of the rules of conduct will be available online at the annual meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Questions will be relayed
to the meeting organizers and forwarded to the Chairman of the meeting for review. Questions regarding matters to be acted upon at the
meeting will be answered after each matter has been presented, as appropriate. Questions from stockholders not relating to proposals
will be grouped by topic with a representative question read aloud and answered as time permits and to the extent such questions do not
relate to material non-public&#160;information, off-topic&#160;items or other matters which the Chairman in his discretion, believes
should not be addressed at the annual meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Technical Difficulties
or Trouble Accessing the Virtual Meeting Website</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Technicians will be available
to assist you if you experience technical difficulties accessing the virtual meeting website. If you encounter any difficulties accessing
the virtual meeting during the check-in&#160;or meeting time, please call&#160;844-399-3386&#160;for assistance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Record Date and
Shares Entitled to Vote</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are entitled to notice
of and to vote at the annual meeting if you were a stockholder of record as of the close of business on June 30, 2025 (the &#8220;<span style="text-decoration:underline">Record
Date</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the close of business
on the Record Date, there were (a)&#160;6,068,649 shares of our common stock outstanding; (b)&#160;no shares of our Series&#160;A Convertible
Preferred Stock outstanding; (c)&#160;no&#160;shares of our preferred Class&#160;C Special Voting Shares outstanding; (d)&#160;no&#160;shares
of our preferred Class&#160;K Special Voting Shares outstanding; and (e) no shares of our Series B Convertible Preferred Stock outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The common stock votes one
vote on all stockholder matters. As a result, we had an aggregate of 6,068,649 total voting shares as of the Record Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order for us to satisfy
our quorum requirements, the holders of at least one-third of the voting power of all outstanding shares of capital stock entitled to
vote at the meeting must be present. You will be deemed to be present if you attend the meeting or if you submit a proxy (including through
the mail, by fax or by telephone or the Internet) that is received at or prior to the meeting (and not revoked).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If your proxy is properly
executed and received by us in time to be voted at our annual meeting, the shares represented by your proxy (including those given through
the mail, by fax or by telephone or the Internet) will be voted in accordance with your instructions. If you execute your proxy but do
not provide us with any instructions, your shares will be voted &#8220;for all&#8221; for Proposal One, and &#8220;for&#8221; Proposals
Two, Three, Four, Five, Six, Seven and Eight, or otherwise determined by the proxies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The only matters that we
expect to be presented at our annual meeting are set forth in the notice of annual meeting. If any other matters properly come before
our annual meeting, the persons named in the proxy card will vote the shares represented by all properly executed proxies on such matters
in their best judgment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Voting Process</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are a stockholder
of record, there are five ways to vote:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>At the virtual annual meeting.&#160;</i>You may vote during the
    meeting by following the instructions available on the meeting website during the meeting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Via the Internet.&#160;</i>You may vote by proxy via the Internet
    by following the instructions provided in the notice.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>By Telephone.&#160;</i>If you request printed copies of the proxy
    materials by mail, you may vote by proxy by calling the toll-free&#160;number found on the proxy card or notice.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>By Fax.&#160;</i>If you request printed copies of the proxy materials
    by mail, you may vote by proxy by faxing your proxy to the number found on the proxy card or notice.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>By Mail.&#160;</i>If you request printed copies of the proxy materials
    by mail, you may vote by proxy by filling out the proxy card and returning it in the envelope provided.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you hold shares through
an account with a bank or broker, the voting of the shares by the bank or broker when you do not provide voting instructions is governed
by the rules of the New&#160;York Stock Exchange (the &#8220;<span style="text-decoration:underline">NYSE</span>&#8221;). NYSE rules allow brokers, banks and other nominees
to vote shares on certain &#8220;<span style="text-decoration:underline">routine</span>&#8221; matters for which their customers do not provide voting instructions. We believe
that only Proposal&#160;7 is a &#8220;<span style="text-decoration:underline">routine</span>&#8221; proposal (see also &#8220;Voting Requirements for Each of the Proposals&#8221;,
below). Therefore, if you do not instruct your broker, bank and other nominee how to vote, your broker, bank and other nominee will have
discretionary authority to vote your shares on Proposal 7. A broker&#160;non-vote&#160;occurs when your bank or broker submits a proxy
but does not vote on&#160;non-routine&#160;proposals, absent specific instructions from you. See also &#8220;Voting Requirements for
Each of the Proposals&#8221;, below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Providing and Revoking
Proxies</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The presence of a stockholder
at our annual meeting will not automatically revoke that stockholder&#8217;s proxy. However, a stockholder may revoke a proxy at any
time prior to its exercise by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">submitting a written revocation prior to the annual meeting to the
    Corporate Secretary, 180 Life Sciences Corp., 3000 El Camino Real, Bldg.&#160;4, Suite 200, Palo Alto, California 94306;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">submitting another signed and later dated proxy card and returning
    it by mail in time to be received before our annual meeting or by submitting a later dated proxy by the Internet or telephone prior
    to the annual meeting; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">attending our annual meeting and voting by following the instructions
    available on the meeting website during the meeting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Meeting Time and
Location: Virtual Annual Meeting</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Attendance at the annual
meeting is limited to holders of record of our common stock and preferred stock at the close of business on the record date, June 30,
2025, and our guests. You will be asked to provide your control number in order to be admitted into the annual meeting. If your shares
are held in the name of a bank, broker, or other nominee and you plan to attend the annual meeting, you must obtain your control number
from such bank, broker, or other nominee, or contact Issuer Direct Corporation at (919)&#160;481-4000,&#160;or&#160;1-866-752-VOTE&#160;(8683)&#160;to
obtain your control number, in order to be admitted. No recording of the meeting will be permitted. At the annual meeting, stockholders
of the Company will be afforded a reasonable opportunity to participate in the meeting and to vote on matters submitted to the stockholders,
including an opportunity to communicate, and to read or hear the proceedings of the meetings in a substantially concurrent manner with
such proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Conduct at the
Meeting</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Chairman of the meeting
has broad responsibility and legal authority to conduct the annual meeting in an orderly and timely manner. This authority includes establishing
rules for stockholders who wish to address the meeting. Only stockholders or their valid proxy holders may address the meeting. The Chairman
may exercise broad discretion in recognizing stockholders who wish to speak and in determining the extent of discussion on each item
of business. In light of the number of stockholders of the Company, the number of items on this year&#8217;s agenda and the need to conclude
the meeting within a reasonable period of time, we cannot ensure you that every stockholder who wishes to speak on an item of business
will be able to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Voting Requirements
for Each of the Proposals</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>Proposal</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Vote Required</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Broker<br/>
    Discretionary<br/>
    Voting<br/>
    Allowed*</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 2%; padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><b>1</b></span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.25pt">&#160;</td>
    <td style="width: 60%; text-align: justify"><span style="font-size: 10pt">Election of two Class&#160;I Directors</span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.25pt">&#160;</td>
    <td style="width: 22%; text-align: justify"><span style="font-size: 10pt">Plurality of Votes Cast</span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.25pt">&#160;</td>
    <td style="width: 13%; text-align: center"><span style="font-size: 10pt">No</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><b>2</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Adoption of the Fourth Amendment to the 180 Life Sciences Corp. 2022
    Omnibus Incentive Plan</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Affirmative vote of a majority of the votes cast on the proposal</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">No</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><b>3</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Adoption of the 180 Life Sciences Corp. 2015 Option Incentive Plan</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Affirmative vote of a majority of the votes cast on the proposal</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">No</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><b>4</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Approve an advisory resolution on Named Executive Officer compensation</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Affirmative vote of a majority of the votes cast on the proposal</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">No</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><b>5</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Grant discretionary authority to the Company&#8217;s Board of Directors
    to (A) approve an amendment to our Second Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock
    split of our issued and outstanding shares of our common stock, par value $0.0001 per share, by a ratio of between one-for-four to
    one-for-forty, inclusive, with the exact ratio to be set at a whole number to be determined by our Board of Directors or a duly authorized
    committee thereof in its discretion, at any time after approval of the amendment and prior to ___________, 2026, and (B) determine
    whether to arrange for the disposition of fractional interests by shareholder entitled thereto, to pay in cash the fair value of
    fractions of a share of common stock as of the time when those entitled to receive such fractions are determined, or to entitle shareholder
    to receive from the Corporation&#8217;s transfer agent, in lieu of any fractional share, the number of shares of common stock rounded
    up to the next whole number.</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">The votes cast for the amendment exceed the votes cast against the
    amendment</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">No</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><b>6</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Approval of an Amendment to the Company&#8217;s Second Amended and
    Restated Certificate of Incorporation to increase the Company&#8217;s authorized number of shares of common stock from one hundred
    million (100,000,000) shares to one billion (1,000,000,000) shares. </span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">The votes cast for the amendment exceed the votes cast against the
    amendment</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">No</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><b>7</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Ratification of the appointment of M&amp;K CPAs, PLLC, an independent
    registered public accounting firm, as the Company&#8217;s independent auditors for the fiscal year ending December 31, 2025</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Affirmative vote of a majority of the votes cast on the proposal</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Yes</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><b>8</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Approval of the adjournment of the Annual Meeting, if necessary.</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Affirmative vote of a majority of the votes cast on the proposal</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">No</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt"><i>*</i></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>See also &#8220;</i>Quorum<i>&#8221;, below. The column &#8220;Broker
    Discretionary Voting Allowed&#8221; is based on our belief as of the date of this proxy statement; however, the NYSE may determine
    that one or more of the proposals above, in addition to proposal 7, are discretionary matters. In that case brokers will have the
    ability to vote on such matter(s) even if you do not vote your shares at the Meeting.</i></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For Proposal&#160;1, the
two nominees receiving the highest number of affirmative votes of the shares entitled to be voted for them will be elected as directors
to serve for a term of two&#160;years and until their successors are duly elected and qualified, unless the elected director is removed
or resigns earlier. This means that the director nominees with the most &#8220;<span style="text-decoration:underline">for</span>&#8221; votes will be elected. Thus, shares
as to which a stockholder &#8220;<span style="text-decoration:underline">withholds</span>&#8221; voting authority and broker non-votes will not be counted towards any director
nominee&#8217;s achievement of a plurality and will not affect the outcome of the election of directors. Stockholders may not cumulate
their votes in favor of any one nominee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Approval of Proposals 2,
3, 4, 7, and 8 requires the affirmative vote of a majority of the votes cast on such proposals present in person or represented by proxy
at the annual meeting and entitled to vote thereon, provided that a quorum exists at the annual meeting, and provided further that proposal
4 is non-binding. Votes cast &#8220;<span style="text-decoration:underline">against</span>&#8221; Proposals 2, 3, 4, 7, and 8 will count against the approval of the proposals.
Abstentions will not be counted as votes cast and will have no effect on these proposals. Similarly, broker non-votes will not be counted
as votes cast, and are not entitled to vote on proposals where shareholders have not provided discretionary authority, and as such will
have no effect on these proposals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Approval of Proposals 5 and
6 require that the votes cast for the applicable amendment exceed the votes cast against the amendment pursuant to Delaware General Business
Law Section 242(d)(2), which provides that an amendment to increase or decrease the authorized number of shares of a class of capital
stock or an amendment to reclassify by combining the issued shares of a class of capital stock into a lesser number of issued shares
of the same class of stock may be made and effected, if: (A) the shares of such class are listed on a national securities exchange immediately
before such amendment becomes effective and meet the listing requirements of such national securities exchange relating to the minimum
number of holders immediately after such amendment becomes effective, and (B) at a duly called meeting of stockholders, a vote of the
stockholders entitled to vote thereon, voting as a single class, is taken for and against the proposed amendment, and the votes cast
for the amendment exceed the votes cast against the amendment. Abstentions and broker non-votes will have no effect on proposals 5 and
6.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a broker indicates on
the proxy that it does not have discretionary authority as to certain shares to vote on a particular matter, those shares will not be
considered as present and entitled to vote with respect to that matter. For your vote to be counted, you must submit your voting instruction
form to your broker.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As described above, although
the Company will include abstentions and broker non-votes&#160;as present or represented for purposes of establishing a quorum for the
transaction of business, the Company intends to exclude abstentions and broker non-votes&#160;from the tabulation of voting results on
the election of directors or on any issues requiring approval of a majority of the votes cast at the annual meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_166"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Quorum</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order for us to satisfy
our quorum requirements, the holders of at least one-third of the voting power of all outstanding shares of capital stock entitled to
vote at the meeting must be present. You will be deemed to be present if you attend the meeting or if you submit a proxy (including through
the mail, by fax or by telephone or the Internet) that is received at or prior to the meeting (and not revoked).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Board of Directors
Voting Recommendations</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board recommends that
you vote your shares:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">FOR</span>&#8221; each of the nominees to the Board of Directors
    (Proposal&#160;1).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -21pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">FOR</span>&#8221; approval of the Fourth Amendment to the 180
    Life Sciences Corp. 2022 Omnibus Incentive Plan (Proposal&#160;2).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -21pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">FOR</span>&#8221; approval of the 180 Life Sciences Corp. 2025
    Option Incentive Plan (Proposal&#160;3).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">FOR</span>&#8221; the approval of the advisory resolution on
    Named Executive Officer compensation (Proposal&#160;4).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -21pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">FOR</span>&#8221; approval of the grant of discretionary authority
    to the Company&#8217;s Board of Directors to (A) approve an amendment to our Second Amended and Restated Certificate of Incorporation,
    as amended, to effect a reverse stock split of our issued and outstanding shares of our common stock, par value $0.0001 per share,
    by a ratio of between one-for-four to one-for-forty, inclusive, with the exact ratio to be set at a whole number to be determined
    by our Board of Directors or a duly authorized committee thereof in its discretion, at any time after approval of the amendment and
    prior to ___________, 2026, and (B) determine whether to arrange for the disposition of fractional interests by shareholders entitled
    thereto, to pay in cash the fair value of fractions of a share of common stock as of the time when those entitled to receive such
    fractions are determined, or to entitle shareholders to receive from the Corporation&#8217;s transfer agent, in lieu of any fractional
    share, the number of shares of common stock rounded up to the next whole number. (Proposal&#160;5).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -21pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -21pt"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -21pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">FOR</span>&#8221; approval of an amendment to the Company&#8217;s
    Second Amended and Restated Certificate of Incorporation to increase the Company&#8217;s authorized number of shares of common stock
    from one hundred million (100,000,000) shares to one billion (1,000,000,000) shares. (Proposal&#160;6).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">FOR</span>&#8221; the ratification of the appointment of M&amp;K
    CPAs, PLLC, an independent registered public accounting firm, as the Company&#8217;s independent auditors for the fiscal year ending
    December 31, 2025 (Proposal&#160;7).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">FOR</span>&#8221; approval of the adjournment of the Annual
    Meeting, if necessary (Proposal 8).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Mailing Costs and
Solicitation of Proxies</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will pay the cost of soliciting
proxies. Proxies may be solicited on behalf of the Company by directors, officers or employees of the Company in person or by telephone,
facsimile or other electronic means. We may also pay Issuer Direct Corporation a fee not to exceed $10,000 plus costs and expenses. In
addition, Issuer Direct Corporation and certain related persons may be indemnified against certain liabilities arising out of or in connection
with the engagement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Arrangements may also be
made with brokerage firms and other custodians, nominees and fiduciaries for the forwarding of material to, and solicitation of proxies
from, the beneficial owners of our securities held of record at the close of business on the Record Date by such persons. We will reimburse
such brokerage firms, custodians, nominees and fiduciaries for the reasonable out-of-pocket&#160;expenses incurred by them in connection
with any such activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Inspector of Voting</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is anticipated that representatives
of Issuer Direct Corporation will tabulate the votes and act as inspector of election for the annual meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Stockholders Entitled
to Vote at the Meeting</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A complete list of stockholders
entitled to vote at the annual meeting will be available at our principal executive offices, for any purpose germane to the annual meeting,
during ordinary business&#160;hours, for a period of ten&#160;days prior to the annual meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Voting Instructions</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your vote is very important.
Whether or not you plan to attend the annual meeting, we encourage you to read this proxy statement and submit your proxy or voting instructions
as soon as possible. For specific instructions on how to vote your shares, please refer to your enclosed proxy card.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Confidential Voting</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Independent inspectors will
count the votes. Your individual vote is kept confidential from us unless special circumstances exist. For example, a copy of your proxy
card will be sent to us if you write comments on the card, as necessary to meet applicable legal requirements, or to assert or defend
claims for or against the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Stockholder of
Record and Shares Held in Brokerage Accounts</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If on the Record Date your
shares were registered in your name with the Company&#8217;s transfer agent, then you are a stockholder of record and you may vote in
person at the meeting, by proxy or by any other means supported by the Company. If on the Record Date your shares were held in an account
at a brokerage firm, bank, dealer, or other similar organization, then you are the beneficial owner of shares held in &#8220;<span style="text-decoration:underline">street
name</span>&#8221; and these proxy materials are required to be forwarded to you by that organization. The organization holding your account
is considered the stockholder of record for purposes of voting at the annual meeting. As a beneficial owner, you have the right to direct
your broker or other agent on how to vote the shares in your account. You are also invited to attend the annual meeting. However, you
must obtain your control number from such bank, broker, or other nominee, or contact Issuer Direct Corporation at (919)&#160;481-4000,&#160;or&#160;1-866-752-VOTE&#160;(8683)&#160;to
obtain your control number, in order to be admitted and since you are not the stockholder of record, you may not vote your shares by
following the instructions available on the meeting website during the meeting unless you request and obtain a valid proxy from your
broker or, other agent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Multiple Stockholders
Sharing the Same Address</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC has adopted rules
that permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy materials with respect to two or
more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. This process, which
is commonly referred to as &#8220;<span style="text-decoration:underline">householding</span>,&#8221; potentially provides extra convenience for stockholders and cost savings
for companies. The Company, as well as some brokers (or other nominees), household the Company&#8217;s Proxy Materials, which means that
we or they deliver a single Proxy Statement and 2024 Annual Report to multiple stockholders sharing an address unless contrary instructions
have been received from the affected stockholders. Once you have received notice from your broker (or other nominee) or from us that
they or we will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke
your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate Proxy Statement
or Annual Report in the future, or if you are receiving multiple copies of the Proxy Statement and Annual Report and wish for only one
copy to be delivered to your household in the future, please notify (i) your broker (or other nominee) if your shares are held in a brokerage
or similar account or (ii) the Company if you hold registered shares in your own name. We will promptly deliver a separate Proxy Statement
to record stockholders upon written or oral request. You can notify us of your instructions by telephone at (650) 507-0669&#160;or by
sending a written request to our Corporate Secretary at our principal executive offices at 3000 El Camino Real, Bldg.&#160;4, Suite 200,
Palo Alto, California 94306, or a stockholder may make a request by calling our Investor Relations at (650)&#160;507-0669.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you receive more than
one proxy statement, it means that your shares are registered differently and are held in more than one account. To ensure that all shares
are voted, please either vote each account as discussed above under &#8220;Voting Process&#8221; on page&#160;2, or sign and return
by mail all proxy cards or voting instruction forms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Voting Results</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preliminary voting results
will be announced at the annual meeting. The final voting results will be tallied by the inspector of voting and published in the Company&#8217;s
Current Report on Form&#160;8-K, which the Company is required to file with the SEC within four&#160;business days following the annual
meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Company Mailing
Address</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The mailing address of our
principal executive offices is 3000 El Camino Real, Bldg.&#160;4, Suite 200, Palo Alto, California 94306.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_022"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Other Matters</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this proxy
statement, the Board of Directors does not know of any business to be presented at the annual meeting other than as set forth in the
proxy statement. If any other matters should properly come before the annual meeting, it is intended that the shares represented by proxies
will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Background of the Company</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November&#160;6, 2020,
the Company (formerly known as KBL Merger Corp.&#160;IV (prior to the closing of the Business Combination (defined below), sometimes
referred to herein as &#8220;<span style="text-decoration:underline">KBL</span>&#8221;) consummated the previously announced business combination (the &#8220;<span style="text-decoration:underline">Business Combination</span>&#8221;)
following a special meeting of stockholders, where the stockholders of the Company considered and approved, among other matters, a proposal
to adopt that certain Business Combination Agreement (as amended, the &#8220;<span style="text-decoration:underline">Business Combination Agreement</span>&#8221;), dated as
of July&#160;25, 2019, entered into by and among the Company, KBL Merger Sub, Inc. (&#8220;<span style="text-decoration:underline">Merger Sub</span>&#8221;), 180 Life Corp.
(f/k/a 180 Life Sciences Corp.) (&#8220;<span style="text-decoration:underline">180</span>&#8221;), Katexco Pharmaceuticals Corp. (&#8220;<span style="text-decoration:underline">Katexco</span>&#8221;), CannBioRex
Pharmaceuticals Corp. (&#8220;<span style="text-decoration:underline">CBR Pharma</span>&#8221;), 180 Therapeutics L.P. (&#8220;<span style="text-decoration:underline">180 LP</span>&#8221; and together with Katexco
and CBR Pharma, the &#8220;<span style="text-decoration:underline">180 Subsidiaries</span>&#8221; and, together with 180, the &#8220;<span style="text-decoration:underline">180 Parties</span>&#8221;), and Lawrence
Pemble, in his capacity as representative of the stockholders of the 180 Parties (the &#8220;<span style="text-decoration:underline">Stockholder Representative</span>&#8221;).
Pursuant to the Business Combination Agreement, among other things, Merger Sub merged with and into 180, with 180 continuing as the surviving
entity and a wholly-owned&#160;subsidiary of the Company (the &#8220;<span style="text-decoration:underline">Merger</span>&#8221;). The Merger became effective on November&#160;6,
2020 (the closing of the Merger being referred to herein as the &#8220;<span style="text-decoration:underline">Closing</span>&#8221;). In connection with, and prior to, the
Closing, 180 filed a Certificate of Amendment of its Certificate of Incorporation in Delaware to change its name to 180 Life Corp., and
KBL Merger Corp.&#160;IV (the Company) changed its name to 180 Life Sciences Corp.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Prior Reverse Stock Splits</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective on December 19,
2022 at 12:01 a.m. Eastern Time, we affected a 1-for-20 reverse stock split of our then outstanding common stock, with any fractional
shares rounded up to the nearest whole share. Effective on February 28, 2024 at 12:01 a.m. Eastern Time, we affected a 1-for 19 reverse
stock split of our then outstanding common stock with any fractional shares rounded up to the nearest whole share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the reverse
splits discussed above (the &#8220;<span style="text-decoration:underline">Prior Reverse Stock Splits</span>&#8221;), all outstanding options, warrants, and other securities
entitling their holders to purchase or otherwise receive shares of common stock were adjusted, as required by the terms of each security.
The number of shares available to be awarded under the Company&#8217;s equity incentive plans were also appropriately adjusted. Following
the Prior Reverse Stock Splits, the par value of the common stock remained unchanged at $0.0001 par value per share. The Prior Reverse
Stock Splits did not change the authorized number of shares of common stock or preferred stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The effects of the Prior
Reverse Stock Splits have been retroactively reflected throughout this Proxy Statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_025"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Definitions</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the context requires
otherwise, references in this proxy statement to the &#8220;<span style="text-decoration:underline">Company,</span>&#8221; &#8220;<span style="text-decoration:underline">we,</span>&#8221; &#8220;<span style="text-decoration:underline">us,</span>&#8221;
&#8220;<span style="text-decoration:underline">our,</span>&#8221; &#8220;<span style="text-decoration:underline">180 Life</span>&#8221;, &#8220;<span style="text-decoration:underline">180LS</span>&#8221; and &#8220;<span style="text-decoration:underline">180 Life Sciences Corp.</span>&#8221;
refer specifically to 180 Life Sciences Corp. and its consolidated subsidiaries. References to &#8220;<span style="text-decoration:underline">KBL</span>&#8221; refer to the
Company prior to the November&#160;6, 2020 Business Combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, unless the context
otherwise requires and for the purposes of this Proxy Statement only:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">CAD</span>&#8221; refers to Canadian dollars;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Exchange&#160;Act</span>&#8221; refers to the Securities Exchange&#160;Act&#160;of&#160;1934,
    as amended;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">&#163;</span>&#8221; or &#8220;<span style="text-decoration:underline">GBP</span>&#8221; refers to
    British pounds sterling;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">SEC</span>&#8221; or the &#8220;<span style="text-decoration:underline">Commission</span>&#8221; refers
    to the United&#160;States Securities and Exchange Commission; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Securities Act</span>&#8221; refers to the Securities Act&#160;of&#160;1933,
    as amended.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Forward-Looking Statements
and Website Links</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Statements in this Proxy
Statement that are &#8220;<span style="text-decoration:underline">forward-looking&#160;statements</span>&#8221; are based on current expectations and assumptions that are subject
to risks and uncertainties. In some cases, forward-looking&#160;statements can be identified by terminology such as &#8220;<span style="text-decoration:underline">may,</span>&#8221;
&#8220;<span style="text-decoration:underline">should,</span>&#8221; &#8220;<span style="text-decoration:underline">potential,</span>&#8221; &#8220;<span style="text-decoration:underline">continue,</span>&#8221; &#8220;<span style="text-decoration:underline">expects,</span>&#8221; &#8220;<span style="text-decoration:underline">anticipates,</span>&#8221;
&#8220;<span style="text-decoration:underline">intends,</span>&#8221; &#8220;<span style="text-decoration:underline">plans,</span>&#8221; &#8220;<span style="text-decoration:underline">believes,</span>&#8221; &#8220;<span style="text-decoration:underline">estimates,</span>&#8221; and similar
expressions. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed
or implied by the forward-looking&#160;statements, including any failure to meet stated goals and commitments, and execute our strategies
in the time frame expected or at all, as a result of many factors, including the need for additional funding, the terms of such funding,
changing government regulations, the outcome of trials and our ability to market and commercialize future products. More information
on risks, uncertainties, and other potential factors that could affect our business and performance is included in our other filings
with the SEC, including in the &#8220;<span style="text-decoration:underline">Risk Factors</span>&#8221;, &#8220;<span style="text-decoration:underline">Cautionary Note Regarding Forward-Looking Statements</span>&#8221;
and &#8220;<span style="text-decoration:underline">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>&#8221; sections of our
most recently filed periodic reports on Form&#160;10-K&#160;and Form&#160;10-Q&#160;and subsequent filings. These forward-looking&#160;statements
are based on our current estimates and assumptions and, as such, involve uncertainty and risk. Actual results could differ materially
from projected results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not assume any obligation
to update information contained in this document, except as required by federal securities laws. Although this Proxy Statement may remain
available on our website or elsewhere, its continued availability does not indicate that we are reaffirming or confirming any of the
information contained herein. Neither our website nor its contents are a part of this Proxy Statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Website links included in
this Proxy Statement are for convenience only. The content in any website links included in this Proxy Statement is not incorporated
herein and does not constitute a part of this Proxy Statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Incorporation by Reference</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that this proxy
statement has been or will be specifically incorporated by reference into any other filing of the Company under the Securities or the
Exchange&#160;Act, the sections of this proxy statement titled &#8220;<span style="text-decoration:underline">Audit Committee Report</span>&#8221;, &#8220;<span style="text-decoration:underline">Pay Versus Performance</span>&#8221;
and &#8220;<span style="text-decoration:underline">Relationship Between &#8220;Compensation Actually Paid&#8221; and Performance</span>&#8221;, to the extent permitted by the
rules of the U.S.&#160;Securities and Exchange Commission (the &#8220;<span style="text-decoration:underline">SEC</span>&#8221; or the &#8220;<span style="text-decoration:underline">Commission</span>&#8221;), shall
not be deemed to be so incorporated, unless specifically provided otherwise in such filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_028"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">References to Additional
Information</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Included with this proxy
statement is a copy of the Company&#8217;s Annual Report on <a href="https://www.sec.gov/Archives/edgar/data/1690080/000121390025026273/ea0235286-10k_180life.htm">Form 10-K</a> for the year ended December 31, 2024, as filed with
the SEC on March 31, 2025 (the &#8220;<span style="text-decoration:underline">2024 Annual Report</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may also request a copy
of this proxy statement and the annual report from Issuer Direct Corporation, the Company&#8217;s proxy agent, at the following address
and telephone number:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Issuer Direct Corporation<br/>
One Glenwood Ave., Suite 1001, Raleigh, North Carolina, 27603<br/>
(919)&#160;481-4000,&#160;or&#160;1-866-752-VOTE (8683)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Options: NewSection; Value: 9 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_029"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Voting Rights and Principal
Stockholders</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of record of our
common stock and Series B Convertible Preferred Stock, at the close of business on the Record Date, will be entitled to vote at the annual
meeting, on all matters properly presented at the annual meeting and at any adjournment or postponement thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the close of business
on the Record Date, there were (a)&#160;6,068,649 shares of our common stock outstanding; (b)&#160;no shares of our Series&#160;A Convertible
Preferred Stock outstanding; (c)&#160;no&#160;shares of our Class&#160;C Special Voting Shares outstanding; (d)&#160;no&#160;shares of
our Class&#160;K Special Voting Shares outstanding; and (e) no shares of our Series B Convertible Preferred Stock outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The common stock votes one
vote on all stockholder matters. As a result, we had an aggregate of 6,068,649 total voting shares as of the Record Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our stockholders do not have
dissenters&#8217; rights or similar rights of appraisal with respect to the proposals described herein and, moreover, do not have cumulative
voting rights with respect to the election of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><div><a id="a_030"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Security Ownership
of Management and Certain Beneficial Owners and Management</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth, as of the Record Date, the number and percentage of outstanding shares of our common stock beneficially owned by: (a)&#160;each
person who is known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock; (b)&#160;each of our
directors; (c)&#160;each of our Named Executive Officers (as defined below under &#8220;Executive and Director Compensation&#160;&#8212;&#160;Summary
Executive Compensation Table&#8221;); and (d)&#160;all current directors and Named Executive Officers, as a group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership has
been determined in accordance with Rule&#160;13d-3&#160;under the Exchange&#160;Act. Under this rule, certain shares may be deemed to
be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares).
In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire shares (for example, upon
exercise of an option or warrant or upon conversion of a convertible security) within 60&#160;days of the date as of which the information
is provided. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially
owned by such person by reason of such acquisition rights. As a result, the percentage of outstanding shares of any person as shown in
the following table does not necessarily reflect the person&#8217;s actual voting power at any particular date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership as set
forth below is based on our review of our record stockholders list and public ownership reports filed by certain stockholders of the
Company, and may not include certain securities held in brokerage accounts or beneficially owned by the stockholders described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
we believe that all persons named in the table below have sole voting and investment power with respect to all shares of common stock
beneficially owned by them. Unless otherwise indicated, the business address of each of the entities, directors and executive officers
in this table is 3000 El Camino Real, Bldg.&#160;4, Suite 200, Palo Alto, California 94306.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Common Stock Shares Beneficially
    Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent of Common Stock**</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Directors, Officers and Named Executive Officers</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Blair Jordan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,900,812</td><td style="width: 1%; text-align: left"><sup>(1)</sup>&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">31.3</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Eric R. Van Lent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,763</td><td style="text-align: left"><sup>(2)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ryan Smith</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,541</td><td style="text-align: left"><sup>(3)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lawrence Steinman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,586</td><td style="text-align: left"><sup>(4)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stephen H. Shoemaker</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,297</td><td style="text-align: left"><sup>(5)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">James N. Woody<sup>&#163;</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Omar Jimenez<sup>&#163;</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Jonathan Rothbard<sup>&#163;</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,475</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Ozan Pamir<sup>&#163;</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Quan Anh Vu<sup>&#163;</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">All officers and directors as a group (5 persons)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,337,999</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">38.5</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">5% Stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Elray Resources Inc.<sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,318,000</td><td style="text-align: left"><sup>(7)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">AmTrust Financial Services, Inc.<sup>(8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">509,707</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.4</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Less than one percent.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Percentages based upon 6,068,649 shares of our common stock issued
    and outstanding as of the Record Date.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt"><sup>&#163;</sup></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Former Named Executive Officer, no longer serving as an officer or
    director of the Company. Beneficial ownership is based on either (a) the last beneficial ownership disclosed to the Company from
    such persons; or (b) the record shareholders list of the Company as of the Record Date, and may not reflect the total number of shares
    of common stock of the Company beneficially owned by the noted individual as of such date.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 179,646 Restricted Stock Shares subject to vesting at the
    rate of 1/2 of such shares on each of July 1, 2025 and December 31, 2025, subject to Mr. Jordan&#8217;s continued service to the
    Company (through his personal consulting company, Blair Jordan Strategy and Finance Consulting Inc., which shares he is deemed to
    beneficially own and control) on such vesting dates. On February 5, 2025, as a required condition to the entry into a First
    Amendment to Separation and Release Agreement with Dr. James Woody,&#160;the Company&#8217;s former Chief Executive Officer and
    director,&#160;the Company, Mr. Jordan and Dr. Woody, entered into a Voting Agreement, whereby Dr. Woody agreed to vote a total of
    43,166 shares of the Company&#8217;s common stock, as recommended by the Board of Directors of the Company, at any meeting of
    stockholders or via any written consent of stockholders, which may occur prior to February 5, 2026, the date after August 5, 2025,
    that Dr. Woody has sold all of the shares or the date that the Company terminates the Voting Agreement. In order to enforce the
    terms of the Voting Agreement, Dr. Woody provided Mr. Jordan (or his assigns), solely for the benefit of the Company, an irrevocable
    voting proxy to vote the 43,166 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written
    consent of stockholders. As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 43,166 shares
    of common stock of the Company held by Dr. Woody. On February 21, 2025, as a required condition to the entry into a Mutual
    Settlement and General Release Agreement with&#160;Dr. Marlene Krauss (&#8220;<span style="text-decoration:underline">Dr. Krauss</span>&#8221;), the former Chief Executive
    Officer and director of KBL Merger Corp. IV, the Company&#8217;s predecessor, and KBL IV Sponsor, LLC, the Company&#8217;s former
    sponsor,&#160;the Company, the Mr. Jordan and Dr. Krauss, entered into a Voting Agreement, whereby Dr. Krauss agreed to vote a total
    of 200,000 shares of the Company&#8217;s common stock, as recommended by the Board of Directors of the Company, at any meeting of
    stockholders or via any written consent of stockholders, which may occur prior to August 21, 2025. In order to enforce the terms of
    the Voting Agreement, Dr. Krauss provided Mr. Jordan (or his assigns), solely for the benefit of the Company, an irrevocable voting
    proxy to vote the 200,000 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written
    consent of stockholders. As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 200,000
    shares of common stock of the Company held by Dr. Krauss. Except for the limited right to vote such shares pursuant to the Voting
    Agreements, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein. On April 28, 2025, the
    Company, Mr. Jordan and Elray Resources, Inc. (&#8220;<span style="text-decoration:underline">Elray</span>&#8221;) entered into a Voting Agreement, whereby Elray agreed to
    vote a total of 1,318,000 shares of the Company&#8217;s common stock, as recommended by the Board of Directors of the Company, at
    any meeting of stockholders or via any written consent of stockholders, which may occur prior to April 28, 2026. In order to enforce
    the terms of the Voting Agreement, Elray provided Mr. Jordan (or his assigns), solely for the benefit of the Company, an irrevocable
    voting proxy to vote the 1,318,000 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any
    written consent of stockholders. As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the
    1,318,000 shares of common stock of the Company held by Elray. Except for the limited right to vote such shares pursuant to the
    Voting Agreement, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein. Does not include any
    options which have not vested to the holder to date, and which do not vest within 60 days of the Record Date.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 8,763 Restricted Stock Shares subject to vesting at the rate
    of 1/2 of such shares on each of July 1, 2025 and December 31, 2025, subject to Mr. Van Lent&#8217;s continued service to the Company
    on such vesting dates. Does not include any options which have not vested to the holder to date, and which do not vest within 60
    days of the Record Date.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 109,541 Restricted Stock Shares subject to vesting at the
    rate of 1/2 of such shares on each of July 1, 2025 and December 31, 2025, subject to the holder&#8217;s continued service to the
    Company on such vesting dates. Does not include any options which have not vested to the holder to date, and which do not vest within
    60 days of the Record Date.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 48,198 Restricted Stock Shares subject to vesting at the rate
    of 1/2 of such shares on each of July 1, 2025 and December 31, 2025, subject to the holder&#8217;s continued service to the Company
    on such vesting dates. Does not include any options which have not vested to the holder to date, and which do not vest within 60
    days of the Record Date.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 72,297 Restricted Stock Shares subject to vesting at the rate
    of 1/2 of such shares on each of July 1, 2025 and December 31, 2025, subject to the holder&#8217;s continued service to the Company
    on such vesting dates. Does not include any options which have not vested to the holder to date, and which do not vest within 60
    days of the Record Date.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Address: 3651 Lindell Road, Suite D131, Las Vegas, NV, 89103. The securities
    held by Elray Resources, Inc. are beneficially owned by Anthony Brian Goodman, its Chief Executive Officer. The information included
    in this footnote is based on information reported on Schedule 13D/A filed by Elray Resources, Inc. with the SEC on April 11, 2025,
    which we do not know or have reason to believe is not complete or accurate and on which we are relying pursuant to applicable SEC
    regulations. See also footnote (1) for a description of the Voting Agreement between Elray, Blair Jordan and the Company. On April
    28, 2025, the Company entered into a Settlement and Mutual Release Agreement (the &#8220;<span style="text-decoration:underline">Elray Settlement Agreement</span>&#8221;)
    with Elray, and Luxor Capital, LLC (&#8220;<span style="text-decoration:underline">Luxor</span>&#8221;). Luxor and Elray are each controlled by&#160;&#160;Anthony Brian
    Goodman, the father of Jay Goodman, our former director. The Elray Settlement Agreement resolved certain disputes which had arisen
    between the parties relating to among other things, certain potential acquisitions. Pursuant to the Elray Settlement Agreement: (a)
    the Company agreed to acquire all 1,318,000 of the shares of its common stock (the &#8220;<span style="text-decoration:underline">Elray Shares</span>&#8221;) held by Elray,
    in exchange for an aggregate settlement payment of $1 million, consisting of (i) $350,000 payable to Elray within five business days
    of the Elray Settlement Agreement (the &#8220;<span style="text-decoration:underline">Elray Payment</span>&#8221;) and (ii) $650,000 payable to Luxor (&#8220;<span style="text-decoration:underline">Luxor Payment</span>&#8221;).
    Amounts due to Luxor will be payable by way of 20% of proceeds raised by the Company in future capital raises until paid in full,
    but shall be paid no later than April 28, 2026; and (b) the Company, Elray, and Luxor exchanged mutual general releases from claims
    arising from prior negotiations and agreements, with limited exceptions for obligations under the Settlement Agreement and confidentiality
    requirements. In connection with the settlement, Elray agreed to deliver five stock powers authorizing cancellation of the Elray
    Shares, to be held in escrow and released proportionally at the option of the Company, as settlement payments are made, with all
    remaining shares canceled once the full amounts of the Elray Payment and Luxor Payment are made. The stock powers are to be released
    in tranches, with the stock power relating to the initial 461,300 Elray Shares eligible to be released from escrow upon payment of
    the Elray Payment, and the remaining four stock powers, each providing for the transfer of 214,175 shares, to be released upon the
    payment by the Company to Luxor of each additional $162,500. As of the Record Date, no Elray Shares have been returned to the Company
    or cancelled.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 3,000,000 shares of common stock issuable upon exercise of
    warrants to purchase shares of common stock held by Elray Resources, Inc., which each have an exercise price of $1.68 per share and
    cashless exercise rights, and an expiration date of September 30, 2031.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Address: 59 Maiden Lane, Fl 43, New York, New York 10038. These shares
    are beneficially owned by Barry Zyskind, the Chairman and Chief Executive Officer of AmTrust Financial Services, Inc.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_031"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Change of Control</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is not aware
of any arrangements which may at a subsequent date result in a change of control of the Company, except that Elray Resources, Inc., the
holder of 1,318,000 shares of our outstanding common stock, subject to a Voting Agreement (discussed above in Footnote (1) to the Security
Ownership of Management and Certain Beneficial Owners and Management Table) holds warrants to purchase up to 3,000,000 shares of common
stock with an exercise price of $1.68 per share. If converted and exercised in full (for cash), the 3,000,000 shares of common stock
issuable upon exercise of the warrants would constitute 47.6% of our then outstanding shares of common stock and would represent a change
of control of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_032"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Corporate Governance</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We promote accountability
for adherence to honest and ethical conduct; endeavor to provide full, fair, accurate, timely and understandable disclosure in reports
and documents that we file with the SEC and in other public communications made by us; and strive to be compliant with applicable governmental
laws, rules and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_033"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Board Leadership
Structure</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors has
the responsibility for selecting the appropriate leadership structure for the Company. In making leadership structure determinations,
the Board of Directors considers many factors, including the specific needs of the business and what is in the best interests of the
Company&#8217;s stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have
a Chairperson of our Board of Directors. The Board of Directors believes that because we only have five directors, that this leadership
structure is the most effective and efficient for the Company at this time. The Board of Directors does not have a policy as to whether
the Chairman should be an independent director, an affiliated director, or a member of management. The Board of Directors believes that
its programs for overseeing risk, as described below, would be effective under a variety of leadership frameworks and therefore do not
materially affect its choice of structure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board believes that this
leadership structure, including our strong independent Lead Director (Mr. Smith, as discussed below), best serves the Company and its
stockholders at this time by leveraging executive leadership experience while providing effective independent oversight. Independent
leadership remains an important pillar of the Board leadership structure and, as such, the Company continues to have an independent Lead
Director with robust, well-defined responsibilities as set forth below under &#8220;<span style="text-decoration:underline">Independent Lead Director</span>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board evaluates its structure
periodically, as well as when warranted by specific circumstances in order to assess which structure is in the best interests of the
Company and its stockholders based on the evolving needs of the Company. This approach provides the Board appropriate flexibility to
determine the leadership structure best suited to support the dynamic demands of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_034"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Risk Oversight</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective risk oversight
is an important priority of the Board of Directors. Because risks are considered in virtually every business decision, the Board of Directors
discusses risks throughout the year generally or in connection with specific proposed actions. The Board of Directors&#8217; approach
to risk oversight includes understanding the critical risks in the Company&#8217;s business and strategy, evaluating the Company&#8217;s
risk management processes, allocating responsibilities for risk oversight among the full Board of Directors, and fostering an appropriate
culture of integrity and compliance with legal responsibilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors exercises
direct oversight of strategic risks to the Company. The Audit Committee reviews and assesses the Company&#8217;s processes to manage
business and financial risk and financial reporting risk. It also reviews the Company&#8217;s policies for risk assessment and assesses
steps management has taken to control significant risks. The Compensation Committee oversees risks relating to compensation programs
and policies. In each case management periodically reports to our Board or relevant committee, which provides guidance on risk assessment
and mitigation. The Nominating and Corporate Governance Committee recommends the slate of director nominees for election to the Company&#8217;s
Board of Directors, identifies and recommends candidates to fill vacancies occurring between annual stockholder meetings, reviews, evaluates
and recommends changes to the Company&#8217;s Corporate Governance Guidelines, and establishes the process for conducting the review
of the Chief Executive Officer&#8217;s performance. The Strategy and Alternatives, Risk, Safety and Regulatory Committee oversees our
risk management policies and procedures, reviews our principal risk and compliance policies and our approach to risk management, deals
with risk identification and risk assessment for the principal operational, business, compliance, legal and ethics risks facing our company,
whether internal or external in nature. (The Company&#8217;s committees are described in greater detail below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event the Board has
appointed a Chairman, such Chairman can represent the board in communications with stockholders and other stakeholders but cannot individually
(however the full Board can) override our Chief Executive Officer on, any risk matters. Additionally, our Chairman has not traditionally
provided input on design of the Board itself, which instead comes from the full Board. As discussed above, we do not currently have a
Chairman of the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the Board and its committees
oversee the Company&#8217;s strategy, management is charged with its day-to-day execution. To monitor performance against the Company&#8217;s
strategy, the Board receives regular updates and actively engages in dialogue with management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_035"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Family Relationships</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
among executive officers and directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_036"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Other Directorships</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of the directors of
our Company are also directors of issuers with a class of securities registered under Section&#160;12 of the Exchange&#160;Act (or which
otherwise are required to file periodic reports under the Exchange&#160;Act), other than:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prof.
    Steinman (who serves on the Board of Directors of BioAtla, Inc. (NASDAQ:BCAB), on the Compensation Committee and Nominating and Corporate
    Governance Committee of BioAtla and on the Board of Directors of Pasithea Therapeutics Corp. (NASDAQ:KTTA)).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Jordan, who serves; as a member of the Board of Directors
    and Audit Committee, Governance Committee and Compensation Committee of Goldgroup Mining Inc. (TSXV:GG); as a member of the Board
    of Directors, Chairman of the Audit Committee and Governance Committee, and member of the Compensation Committee of Standard Uranium
    Ltd. (TSXV:STND); and as a member of the Board of Directors and Chairman of the Audit Committee of Timeless Capital Corp. (TSXV:TMC).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Smith, who serves as
    a member of the Board of Directors of U.S. Energy Corp. (USEG:NASDAQ).</span></td></tr>
  </table><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: none">&#160;</span></p><div>

</div><div><a id="a_037"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Involvement in
Certain Legal Proceedings</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the best of our knowledge,
except as disclosed in the biographies of such persons below, during the past ten&#160;years, none of our directors or executive officers
were involved in any of the following: (1)&#160;any bankruptcy petition filed by or against any business of which such person was a general
partner or executive officer either at the time of the bankruptcy or within two&#160;years prior to that time; (2)&#160;any conviction
in a criminal proceeding or being a named subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
(3)&#160;being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent
jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business,
securities or banking activities; (4)&#160;being found by a court of competent jurisdiction (in a civil action), the SEC or the Commodities
Futures Trading Commission to have violated a federal or state securities or commodities law; (5)&#160;being the subject of, or a party
to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated,
relating to an alleged violation of (i)&#160;any Federal or State securities or commodities law or regulation; (ii)&#160;any law or regulation
respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of
disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist&#160;order, or removal or prohibition order;
or (iii)&#160;any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or (6)&#160;being
the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory&#160;organization
(as defined in Section&#160;3(a)(26)&#160;of the Exchange&#160;Act), any registered entity (as defined in Section&#160;1(a)(29)&#160;of
the Commodity Exchange&#160;Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over
its members or persons associated with a member.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_038"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Board of Directors
Meetings</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the fiscal year that
ended on December 31, 2024, the Board held 30 meetings and took various other actions via the unanimous written consent of the Board
of Directors and the various committees described below. Each director attended at least 75% of all of the Board of Directors meetings
and committee meetings of the committees on which they served, during the fiscal year ended December 31, 2024. All nine of the then Company&#8217;s
directors attended the Company&#8217;s 2024 Annual meeting. Each director of the Company is expected to be present at annual meetings
of stockholders, absent exigent circumstances that prevent their attendance. Where a director is unable to attend an annual meeting in
person but is able to do so by electronic conferencing, the Company will arrange for the director&#8217;s participation by means where
the director can hear, and be heard, by those present at the meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_039"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Board Committee
Membership</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors has
four standing committees: an Audit Committee, a Compensation Committee, a Nominating and Corporate Governance Committee, and a Strategy
and Alternatives, Risk, Safety and Regulatory Committee. Our Audit Committee, Compensation Committee, and Nominating and Corporate Governance
Committee are composed solely of independent directors. You can review the charters for our standing Audit Committee, Compensation Committee,
and Nominating and Corporate Governance Committee by accessing our public filings at the SEC&#8217;s web site at&#160;<i>www.sec.gov</i>&#160;or
on our website at https://ir.180lifesciences.com/corporate-governance/board-committees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The current members of the
committees of our Board of Directors are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 52%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Director Name</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Audit<br/>
    Committee</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Compensation<br/>
    Committee</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Nominating,<br/>
    Corporate Governance<br/>
    Committee</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Strategy and<br/>
    Alternatives, Risk,<br/>
    Safety and<br/>
    Regulatory<br/>
    Committee</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Blair Jordan</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">C</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Lawrence Steinman, M.D.</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Ryan Smith<sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">M</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">C</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">C</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">M</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Stephen H. Shoemaker</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">C</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;M</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">M&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">M</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">C -</td><td style="text-align: justify">Chairperson of the Committee.</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">M -</td><td style="text-align: justify">Member of the Committee.</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify">Lead Independent
                                            Director</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of these committees
has the duties described below and operates under a charter that has been approved by our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_040"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Audit Committee</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nasdaq listing standards
and applicable SEC rules require that the Audit Committee of a listed company be comprised solely of independent directors. We have established
an Audit Committee of the Board of Directors, which currently consists of Mr. Ryan Smith and Mr. Stephen H. Shoemaker.&#160; Each member
of the Audit Committee meets the independent director standard under Nasdaq&#8217;s listing standards and under Rule&#160;10A-3(b)(1)&#160;of
the Exchange&#160;Act. Each member of the Audit Committee is financially literate and our Board of Directors has determined that Mr.&#160;Shoemaker
qualifies as an &#8220;audit committee financial expert&#8221; as defined in applicable SEC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Responsibilities of the Audit
Committee include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the appointment,
    compensation, retention, replacement, and oversight of the work of the independent registered public accounting firm and any other
    independent registered public accounting firm engaged by us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approving&#160;all
    audit and non-audit&#160;services to be provided by the independent registered public accounting firm or any other registered public
    accounting firm engaged by us, and establishing pre-approval&#160;policies and procedures;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and discussing
    with the independent registered public accounting firm all relationships the firm has with us in order to evaluate their continued
    independence;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">setting clear hiring policies
    for employees or former employees of the independent registered public accounting firm;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">setting clear policies
    for audit partner rotation in compliance with applicable laws and regulations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining and reviewing
    a report, at least annually, from the independent registered public accounting firm describing (i)&#160;the independent auditor&#8217;s
    internal quality-control&#160;procedures and (ii)&#160;any material issues raised by the most recent internal quality-control&#160;review,
    or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within, the preceding
    five&#160;years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving
    any related party transaction required to be disclosed pursuant to Item&#160;404 of Regulation&#160;S-K&#160;promulgated by the SEC
    prior to us entering into such transaction; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing with management,
    the independent registered public accounting firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters,
    including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material
    issues regarding our consolidated financial statements or accounting policies and any significant changes in accounting standards
    or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_041"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Compensation Committee</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have established a Compensation
Committee of the Board of Directors, which currently consists of Mr. Ryan Smith and Mr. Stephen Shoemaker.&#160; We have adopted a Compensation
Committee charter, which details the principal functions of the Compensation Committee, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer&#8217;s compensation,
    evaluating our Chief Executive Officer&#8217;s performance in light of such goals and objectives and determining and approving the
    remuneration (if any) of our Chief Executive Officer based on such evaluation in executive session at which the Chief Executive Officer
    is not present;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving
    the compensation of all of our other executive officers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing our executive
    compensation policies and plans;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing
    and administering our incentive compensation equity-based&#160;remuneration plans;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting management in
    complying with our proxy statement and annual report disclosure requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving all special perquisites,
    special cash payments and other special compensation and benefit arrangements for our executive officers and employees;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">producing a report on executive
    compensation to be included in our annual proxy statement; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing, evaluating and
    recommending changes, if appropriate, to the remuneration for directors.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
charter also provides that the Compensation Committee may, in its sole discretion, retain or obtain the advice of a compensation consultant,
legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such
adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the
Compensation Committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_042"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Compensation Committee
Interlocks and Insider Participation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As described above, the current
members of the Compensation Committee are independent members of our Board of Directors. No member of the Compensation Committee is an
employee or a former employee of the Company. During fiscal 2024, none of our executive officers served on the Compensation Committee
(or its equivalent) or Board of Directors of another entity whose executive officer served on our Compensation Committee. Accordingly,
the Compensation Committee members have no interlocking relationships required to be disclosed under SEC rules and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_043"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Nominating and
Governance Committee</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have established a Nominating
and Governance Compensation Committee of the Board of Directors, which currently consists of Mr. Ryan Smith (Chairman) and Mr. Stephen
Shoemaker.&#160; Our Board has determined that each member is independent under applicable Nasdaq listing standards. We have adopted
a Compensation Committee charter, which details the principal functions of the nominating and corporate governance committee. Specific
responsibilities of the Nominating and Corporate Governance Committee include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    recommendations to our Board regarding candidates for directorships;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making recommendations
    to our Board regarding the size and composition of our Board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing our corporate
    governance policies and reporting; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making recommendations
    to our Board concerning governance matters.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_044"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Strategy and Alternatives,
Risk, Safety and Regulatory Committee</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have a standing
Strategy and Alternatives, Risk, Safety and Regulatory Committee, including Mr. Blair Jordan (Chairman), Mr. Stephen Shoemaker, and Mr.
Ryan Smith. The Strategy and Alternatives, Risk, Safety and Regulatory Committee&#8217;s responsibilities encompass overseeing various
processes and strategies related to Company transactions, risk management, safety, and regulatory compliance, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Transaction
    Review</i></b>: Establishing and overseeing procedures for evaluating potential transactions, soliciting proposals, making recommendations,
    and negotiating terms.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risk Management</i></b>:
    Reviewing and guiding the Company&#8217;s approach to identifying and assessing key risks, including information security, cybersecurity,
    business continuity, and legal risks.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Strategic Evaluation</i></b>:
    Assessing both solicited and unsolicited strategic opportunities and recommend actions to the Board.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compliance Oversight</i></b>:
    Ensuring the Company&#8217;s adherence to compliance programs, relevant laws, regulations, and corporate policies. This includes
    reviewing whistleblower mechanisms, investigations, and legal inquiries.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cultural Awareness</i></b>:
    Working to foster a culture of risk awareness and proper risk handling within the Company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Privacy &amp; Data
    Security</i></b>: Overseeing privacy and data security risk exposures, mitigation strategies, and updates on legislative developments
    impacting these areas.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CEO Collaboration</i></b>:
    Meeting regularly with the CEO to discuss matters under the committee&#8217;s scope.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Strategy and Alternatives,
Risk, Safety and Regulatory Committee also reviews management&#8217;s risk tolerance approach from time to time and coordinates risk
mitigation efforts with the Board and other committees.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><div><a id="a_045"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Website Availability
of Documents</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The charters of the Audit
Committee, Compensation Committee and Nominating and Corporate Governance Committee and our Code of Business Conducts and Ethics can
be found on our website at&#160;<i>https://ir.180lifesciences.com/corporate-governance/governance-documents</i>. Unless specifically
stated herein, documents and information on our website are not incorporated by reference in this proxy statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><div><a id="a_046"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Stockholder Communications
with the Board of Directors</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our stockholders and other
interested parties may communicate with members of the Board of Directors by submitting such communications in writing to our Corporate
Secretary, 3000 El Camino Real, Bldg.&#160;4, Suite 200, Palo Alto, California 94306, who, upon receipt of any communication other than
one that is clearly marked &#8220;<span style="text-decoration:underline">Confidential</span>,&#8221; will note the date the communication was received, open the communication,
make a copy of it for our files and promptly forward the communication to the director(s)&#160;to whom it is addressed. Upon receipt
of any communication that is clearly marked &#8220;<span style="text-decoration:underline">Confidential</span>,&#8221; our Corporate Secretary will not open the communication,
but will note the date the communication was received and promptly forward the communication to the director(s)&#160;to whom it is addressed.
If the correspondence is not addressed to any particular board member or members, the communication will be forwarded to a board member
to bring to the attention of the Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><!-- Field: Split-Segment; Name: 001 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_047"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Lead Independent
Director</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 4, 2025, the
Board of Directors of the Company appointed independent director Ryan Smith, as Lead Independent Director of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As Lead Independent Director,
Mr. Smith: will preside at any meetings of the independent directors, including executive sessions, and as appropriate; will (a) assist
in the recruitment of board candidates; (b)&#160;have active involvement in board evaluations; (c) have active involvement in establishing
committee membership and committee chairs; and (d) have active involvement in the evaluation of the chief executive officer; will work
with committee chairs as necessary to ensure committee work is conducted at the committee level and appropriately reported to the board;
will communicate with the independent directors between meetings when appropriate; and will recommend consultants and outside advisors
to the board as necessary or appropriate. The lead director may also attend meetings of committees on which the lead director is not
a member.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><div><a id="a_048"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Executive Sessions
of the Board of Directors</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The independent members of
our Board of Directors meet in executive session (with no management directors or management present) from time to time. The executive
sessions include whatever topics the independent directors deem appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_049"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Code of Ethics</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a Code of
Ethics applicable to our directors, officers and employees.&#160;You can review our Code of Ethics by accessing our public filings at
the SEC&#8217;s web site at&#160;<i>www.sec.gov</i>. In addition, a copy of our Code of Ethics will be provided without charge upon request
from us. We intend to disclose any amendments to or waivers of certain provisions of our Code of Ethics in a Current Report on Form&#160;8-K.&#160;There
have been no waivers granted with respect to our Code of Ethics to any such officers or employees to date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_050"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Policy on Equity
Ownership</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company does not have
a policy on equity ownership at this time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_051"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Rule 10b5-1 Trading
Plans</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive officers and
directors are encouraged to conduct purchase or sale transactions under a trading plan established pursuant to Rule 10b5-1 under the
Exchange Act. Through a Rule 10b5-1 trading plan, the executive officer or director contracts with a broker to buy or sell shares of
our common stock on a periodic basis. The broker then executes trades pursuant to parameters established by the executive officer or
director when entering into the plan, without further direction from them. The executive officer or director may amend or terminate the
plan in specified circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><div><a id="a_052"></a></div><ix:nonNumeric contextRef="c1" continuedAt="_ErrCompAnalysisTextBlock-c1_cont_1" escape="true" name="ecd:ErrCompAnalysisTextBlock" id="ixv-3746"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Compensation Recovery
and Clawback Policies</span></i></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_ErrCompAnalysisTextBlock-c1_cont_2" id="_ErrCompAnalysisTextBlock-c1_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Sarbanes-Oxley
Act of 2002 (the &#8220;<span style="text-decoration:underline">Sarbanes-Oxley Act</span>&#8221;), in the event of misconduct that results in a financial restatement that would
have reduced a previously paid incentive amount, we can recoup those improper payments from our Chief Executive Officer and Chief Financial
Officer (if any). The SEC also recently adopted rules which direct national stock exchanges to require listed companies to implement
policies intended to recoup bonuses paid to executives if the company is found to have misstated its financial results.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_ErrCompAnalysisTextBlock-c1_cont_3" id="_ErrCompAnalysisTextBlock-c1_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 7, 2023, the
Board of Directors of the Company approved the adoption of a Policy for the Recovery of Erroneously Awarded Incentive Based Compensation
(the &#8220;<span style="text-decoration:underline">Clawback Policy</span>&#8221;), with an effective date of October 2, 2023, in order to comply with the final clawback rules
adopted by the SEC under Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (&#8220;<span style="text-decoration:underline">Rule 10D-1</span>&#8221;),
and the listing standards, as set forth in the Nasdaq Listing Rule 5608 (the &#8220;<span style="text-decoration:underline">Final Clawback Rules</span>&#8221;).</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_ErrCompAnalysisTextBlock-c1_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Clawback Policy provides
for the mandatory recovery of erroneously awarded incentive-based compensation from current and former executive officers as defined
in Rule 10D-1 (&#8220;<span style="text-decoration:underline">Covered Officers</span>&#8221;) of the Company in the event that the Company is required to prepare an accounting
restatement, in accordance with the Final Clawback Rules. The recovery of such compensation applies regardless of whether a Covered Officer
engaged in misconduct or otherwise caused or contributed to the requirement of an accounting restatement. Under the Clawback Policy,
the Board of Directors may recoup from the Covered Officers erroneously awarded incentive compensation received within a lookback period
of the three completed fiscal years preceding the date on which the Company is required to prepare an accounting restatement.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_053"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Insider Trading/Anti-Hedging&#160;Policies</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has an <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="ixv-14201">insider
trading policy</ix:nonNumeric> governing the purchase, sale and other dispositions of the Company&#8217;s securities that applies to all Company personnel,
including directors, officers, employees, and other covered persons. The Company also plans to follow procedures for the repurchase of
any shares of its securities. The Company believes that its insider trading policy and planned repurchase procedures are reasonably designed
to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To ensure compliance with
the policy and applicable federal and state securities laws, all individuals subject to the policy must refrain from the purchase or
sale of our securities except in designated trading windows or pursuant to preapproved 10b5-1 trading plans. The policy also prohibits
the unauthorized disclosure of any nonpublic information acquired in the workplace and the misuse of material nonpublic information in
securities trading and includes specific anti-hedging provisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the anti-hedging
provisions, the Company prohibits executive officers, directors, and employees from engaging in transactions involving derivative securities,
such as put and call options, and short sales, that could generate profit from a decline in the Company&#8217;s stock price. While other
hedging transactions are not outright banned, they are strongly discouraged as they may misalign the interests of Company insiders with
shareholders and encourage excessive risk-taking.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The above anti-hedging restriction
does not however apply to stock options granted by the Company, nor does it apply to using Company securities for option exercises or
tax payments in transactions directly with the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company also prohibits
holding Company securities in a margin account or pledging Company securities as collateral for a loan unless the pledgor has the clear
financial capability to repay the loan without resort to the pledged securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the Company&#8217;s
insider trading policy was filed as&#160;<span style="text-decoration:underline">Exhibit 19.1</span>&#160;to the 2024 Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_054"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Policy on Timing
of Award Grants</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ecd:AwardTmgMnpiDiscTextBlock" id="ixv-3838"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" escape="true" name="ecd:AwardTmgMethodTextBlock" id="ixv-14202">The Compensation Committee
and the Board have not established policies and practices (whether written or otherwise) regarding the timing of option grants, stock
appreciation rights and similar awards, or other awards, in relation to <ix:nonNumeric contextRef="c0" escape="true" name="ecd:AwardTmgHowMnpiCnsdrdTextBlock" id="ixv-14203">the release of <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:AwardTmgMnpiCnsdrdFlag" id="ixv-14204">material nonpublic information</ix:nonNumeric> (&#8220;MNPI&#8221;)</ix:nonNumeric>
and do not take MNPI into account when determining the timing and terms of stock option or other equity awards to executive officers,
provided that we do not currently grant stock options to employees or executives.</ix:nonNumeric> The Company <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:MnpiDiscTimedForCompValFlag" id="ixv-14205">does not time the disclosure of MNPI, whether
positive or negative, for the purpose of affecting the value of executive compensation.</ix:nonNumeric></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_055"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Director Independence</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In evaluating the independence
of each of our directors and director nominees, the Board considers transactions and relationships between each director or nominee,
or any member of his or her immediate family, and the Company and its subsidiaries and affiliates. The Board also examines transactions
and relationships between directors and director nominees or their known affiliates and members of the Company&#8217;s senior management
and their known affiliates. The purpose of this review is to determine whether any such relationships or transactions are inconsistent
with a determination that the director is independent under applicable laws and regulations and Nasdaq listing standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors has
affirmatively determined that Ryan Smith and Stephen H. Shoemaker are each an independent director as defined under the Nasdaq rules
governing members of boards of directors and as defined under Rule&#160;10A-3&#160;of the Exchange&#160;Act, and have no relationship
that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, the Board has
determined that each of the members of our Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee
are independent within the meaning of Nasdaq director independence standards applicable to members of such committees, as currently in
effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
members also qualify as &#8220;non-employee directors&#8221; within the meaning of Section 16 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>




</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i>&#160;</i></p><div>

</div><div><a id="a_056"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Audit Committee Report</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Audit Committee, which
is comprised exclusively of independent directors, represents and assists the Board of Directors in fulfilling its responsibilities for
general oversight of the integrity of the Company&#8217;s financial statements, the Company&#8217;s compliance with legal and regulatory
requirements, the independent registered public accounting firm&#8217;s qualifications and independence, the performance of the Company&#8217;s
internal audit function and independent registered public accounting firm, and risk assessment and risk management. The Audit Committee
manages the Company&#8217;s relationship with its independent registered public accounting firm (which reports directly to the Audit
Committee). The Audit Committee has the authority to obtain advice and assistance from outside legal, accounting or other advisors as
the Audit Committee deems necessary to carry out its duties and receives appropriate funding, as determined by the Audit Committee, from
the Company for such advice and assistance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the audited
financial statements of the Company for the year ended December 31, 2024, the Audit Committee of the Board of Directors of the Company
(1)&#160;reviewed and discussed the audited financial statements with the Company&#8217;s management and the Company&#8217;s independent
auditors; (2)&#160;discussed with the Company&#8217;s independent auditors the matters required to be discussed by the applicable requirements
of the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) and the Securities and Exchange Commission; (3)&#160;received
and reviewed the written disclosures and the letter from the independent auditors required by the applicable requirements of the PCAOB
regarding the independent auditors&#8217; communications with the Audit Committee concerning independence; (4)&#160;discussed with the
independent auditors the independent auditors&#8217; independence; and (5)&#160;considered whether the provision of non-audit&#160;services
by the Company&#8217;s principal auditors is compatible with maintaining auditor independence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon these reviews
and discussions, the Audit Committee recommended to the Board of Directors, and the Board of Directors approved, that the audited financial
statements for the year ended December 31, 2024 be included in the Company&#8217;s Annual Report on Form&#160;10-K&#160;for the year
ended December 31, 2024 for filing with the Securities and Exchange Commission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned members of
the Audit Committee have submitted this Report to the Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Respectfully submitted,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>/s/ Stephen H. Shoemaker, Chair</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>/s/ Ryan Smith, Member</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>

</div><div><a id="a_057"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Information About Our
Executive Officers and Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_058"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Executive Officers</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth certain information with respect to our executive officers:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 30%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 60%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Position</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Blair Jordan</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chief Executive Officer and Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">56</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">Eric R. Van Lent</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chief Accounting Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">42</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Below is information regarding
each executive officer&#8217;s biographical information, including their principal occupations or employment for at least the past five&#160;years,
and the names of other public companies in which such persons hold or have held directorships during the past five&#160;years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Blair Jordan &#8212; Chief
Executive Officer and Director&#160;<i>&#8212;</i>&#160;</b>Information regarding Mr. Jordan is set forth below under &#8220;<span style="text-decoration:underline">Classified
Board of Directors</span>&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Eric R. Van Lent &#8212;&#160;Chief
Accounting Officer (Principal Accounting/Financial Officer)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Eric R. Van Lent is a seasoned
finance and accounting professional with over 20 years of experience optimizing financial operations, streamlining processes, and driving
revenue growth in medium to large organizations. With expertise spanning financial reporting, strategic planning, and enterprise resource
planning (ERP)&#160;implementation, he has played a pivotal role in enhancing operational efficiency and profitability across manufacturing,
distribution, software, defense, &amp; Esports industries. Mr. Van Lent has served as a NetSuite advanced financials consultant with
Cumula3 Group since February 2024 and as the managing member of his own consulting firm, EVL Consulting LLC, since February 2020. Mr.
Van Lent previously served as Vice President and Corporate Controller of Engine Media Holdings, Inc., a software/gaming/racing/esports
company from January 2018 to December 2021. In that role, he managed the restructuring and financial oversight of a multi-site international
software business. He played a key role in the company&#8217;s successful uplisting from the TSX Venture Exchange to Nasdaq and led the
implementation of NetSuite ERP, streamlining financial reporting across multiple global operations. Mr. Van Lent has also held positions
at&#160;Assa Abloy, Lockheed Martin, and Flight Line Products, where he successfully executed ERP integrations, automated financial processes,
and led cost-reduction initiatives, achieving multimillion-dollar savings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Van Lent holds a&#160;Master
of Business Management in Finance from Norwich University&#160;and a&#160;Bachelor of Business Management from Pepperdine University.
He is a&#160;Certified Public Accountant (CPA)&#160;licensed in California. He also served in the United States Navy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_059"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Classified Board
of Directors</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors is
divided into two classes. At each annual general meeting of stockholders, the successors to directors whose terms then expire will be
elected to serve from the time of election and qualification until the second annual meeting following the election. The directors are
divided among the two classes as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the Class&#160;I directors are
Lawrence Steinman and Stephen H. Shoemaker, and their terms expire at the annual meeting of stockholders to be held on ___________, 2025,
subject to reappointment; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the Class&#160;II directors
are Blair Jordan and Ryan Smith, and their terms expire at the annual meeting of stockholders to be held in 2026.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any additional directorships
resulting from an increase in the number of directors will be distributed among the two classes so that, as nearly as possible, each
class will consist&#160;of&#160;one-half&#160;of&#160;the directors. The division of the Board of Directors into two classes with staggered
two-year&#160;terms may delay or prevent a change of our management or a change in control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current directors are
as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 30%"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 5%; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 21%; text-align: center"><span style="font-size: 10pt"><b>Position With Company</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 30%; text-align: center"><span style="font-size: 10pt"><b>Date First Appointed
    as Officer or Directors</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: center"><span style="font-size: 10pt"><b>Director Class*</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b><i>Class I Directors</i></b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Lawrence Steinman, M.D.</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">77</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">November 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Class I</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Stephen H. Shoemaker</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">64</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">December 2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Class I</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt"><b><i>Class II Directors</i></b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Blair Jordan</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">56</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">February 2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Class II</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Ryan Smith</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">41</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Class II</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Terms expire at the 2025 annual meeting of stockholders, subject to
    reappointment (Class I)&#160;and the annual meeting of stockholders to be held in 2026 (Class II).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;&#160;</i></p><div>

</div><div><a id="a_060"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Director Nominees</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the annual meeting, two
directors are to be re-elected&#160;as Class&#160;I directors, to hold office until the 2027 annual meeting of stockholders and until
their respective successors are duly elected and qualified. The Nominating and Corporate Governance Committee has recommended, and the
Board of Directors has selected, the following nominees for election: Lawrence Steinman, M.D., and Stephen H. Shoemaker, both of whom
are currently directors of our company. Each nominee for director has consented to being named in this proxy statement and has indicated
a willingness to serve if elected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no arrangement or
understanding between our directors and executive officers and any other person pursuant to which any director or officer was or is to
be selected as a director or officer, and there is no arrangement, plan or understanding as to whether non-management&#160;stockholders
will exercise their voting rights to continue to elect the current Board, except in connection with the Voting Agreements, discussed
below under &#8220;Certain Relationships and Related Transactions, and Director Independence&#8212;Related Party Agreements&#8212;Voting Agreements<i>&#8221;</i>. There are also no arrangements, agreements or understandings to our knowledge between non-management&#160;stockholders
that may directly or indirectly participate in or influence the management of our affairs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we do not anticipate
that any nominee will be unavailable for election, if a nominee is unavailable for election, the persons named as proxyholders will use
their discretion to vote for any substitute nominee in accordance with their best judgment as they deem advisable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Information regarding the director
nominees is provided below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_061"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Board Nominees</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>LAWRENCE STEINMAN &#8211; CLASS I DIRECTOR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lawrence Steinman, M.D. served
as Executive Co-Chairman of the Board of Directors of the Company from the Closing of the Business Combination in November 2020 to March
2024, and as Executive Chairman of the Board of Directors from March 2024 to May 2024. He also had primary scientific responsibility
for our &#945;7nAChR platform. Dr. Steinman served as Co-Chairman of 180 and as a member of its board of directors since April 2019.
Prior to joining 180, he served on the Board of Directors of Centocor Biotech, Inc., from 1989 to 1998, the Board of Directors of Neurocine
Biosciences from 1997 to 2005, the Board of Directors of Atreca from 2010 - 2019, the Board of Directors of BioAtla, Inc. (NASDAQ:BCAB)&#160;from
July 2020 to present (he also serves on the Compensation Committee and Nominating and Corporate Governance Committee of BioAtla), the
Board of Directors of Tolerion, Inc. from 2013 to 2020 and the Board of Directors of Alpha5 Integrin from November 2020 to June 2022,
and the Board of Directors of Pasithea Therapeutics Corp. (NASDAQ:KTTA)&#160;from August 2020 to the present. He is currently the George
A. Zimmermann Endowed Chair in the Neurology Department at Stanford University and previously served as the Chair of the Interdepartmental
Program in Immunology at Stanford University Medical School from 2003 to 2011. He is a member of the National Academy of Medicine and
the National Academy of Sciences. He also founded the Steinman Laboratory at Stanford University, which is dedicated to understanding
the pathogenesis of autoimmune diseases, particularly multiple sclerosis and neuromyelitis optica. He received the Frederic Sasse Award
from the Free University of Berlin in 1994, the Sen. Jacob Javits Award from the U.S. Congress from 1988 through 2002, the John Dystel
Prize in 2004 from the National MS Society in the U.S., the Charcot Prize for Lifetime Achievement in Multiple Sclerosis Research in
2011 from the International Federation of MS Societies and the Anthony Cerami Award in Translational Medicine by the Feinstein Institute
of Molecular Medicine in 2015. In 2023, he was honored as a Pioneer in Medicine by the Society for Brain Mapping and Therapeutics. He
also received an honorary Ph.D. from the Hasselt University in 2008, and from the University of Buenos Aires in 2022. He received his
BA (physics)&#160;from Dartmouth College in 1968 and his MD from Harvard University in 1973. He also completed a fellowship in chemical
immunology at the Weizmann Institute (1974 - 1977)&#160;and was an intern and resident at Stanford University Medical School.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe Dr. Steinman&#8217;s
extensive experience leading the research and development of numerous therapeutics qualify him to serve as a director.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>STEPHEN H. SHOEMAKER &#8211; CLASS I DIRECTOR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Shoemaker is a seasoned
senior executive with extensive leadership experience in the iGaming, hospitality, technology, and real estate development sectors. Over
his career, he has raised more than $2 billion across multiple Chief Executive Officer (CEO) and Chief Financial Officer (CFO) roles.
His expertise spans strategic planning, capital raising, and operations management, with a focus on building high-growth, team-oriented
organizations in both domestic and international markets, including Asia, Canada, and Europe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most recently, from July
2021 to January 2024, Mr. Shoemaker served as CEO of WIN Group, a leading global esports betting company, where he led the company&#8217;s
strategic direction and growth, focusing on esports content and online wagering. During his tenure, he doubled user registrations on
WIN&#8217;s content platform, and launched a new licensed iGaming platform aimed at eSports. Prior to that, he provided financial advisory
services to small and medium sized enterprises, including strategic support to WIN Group and financial advisory services for a greenfield
resort project in Colombia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From January 2018 to July
2019, Mr. Shoemaker served as the CEO of Engine Media Holdings, Inc. (TSX:GAME and NASDAQ:GAME), an international digital media, entertainment
and technology company, where he led capital raising efforts, streamlined operations, and grew revenue significantly. Earlier in his
career, he held various senior executive roles at Asian Coast Development Ltd. (CEO and Chairman of the Board (2014-2015) and President
and CFO (2008-2014)), an international development company specializing in integrated resort destinations; NuVox Inc., a telecommunications
company based in the southeast and Midwest US (CFO (2003-2008)); GT Group Telecom (CFO (1999-2002)), and Qwest Communications International
Inc. (various roles (1996-1999)), where he developed deep expertise in capital markets, mergers and acquisitions, and international business.
Mr. Shoemaker holds a B.S. in Commerce with a concentration in Accounting from the University of Virginia and is a Certified Public Accountant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have concluded that Mr.
Shoemaker is well qualified to serve on our Board of Directors based upon his significant experience with capital markets, mergers and
acquisitions, and international business, including his background and knowledge in the iGaming industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_062"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Continuing Directors</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>BLAIR JORDAN &#8211;CHIEF EXECUTIVE OFFICER
AND CLASS II DIRECTOR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Jordan is an experienced
senior executive and corporate director with experience in both private and public companies across a variety of sectors. Mr. Jordan is
also the Co-Founder and Chief Executive Officer of HighMont Advisors Inc., a Vancouver-based, globally focused strategy and finance consulting
company, specializing in helping clients facing corporate transition; advisory services offered include mergers and acquisitions (M&amp;A),
public and private financing, turnaround and restructuring, corporate and business development, positions he has held since January 2020.
Mr. Jordan also serves as a senior advisor at Evans &amp; Evans, Inc., a Vancouver based strategic finance consulting and advisory firm,
a position he has held since October 2023. Mr. Jordan, from March 2024 to May 2025, was a member of the Executive Committee of the Board
of Directors of Flair Airlines Ltd., a private company, where he shared responsibility for capital markets, corporate development, strategic
and risk management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Jordan has extensive public
company Board of Directors experience, including in his current roles as a member of the Board of Directors and Audit Committee, and chair
of the Governance Committee and Compensation Committee of Goldgroup Mining Inc. (TSX:GG); a member of the Board of Directors, Chairman
of the Audit Committee and Governance Committee, and member of the Compensation Committee of Standard Uranium Ltd. (TSXV:STND); and a
member of the Board of Directors and Audit Committee of Timeless Capital Corp. (TSXV:TMC). Mr. Jordan also serves on various private company
Board of Directors. From March 2023 to May 2025, Mr. Jordan also served as a member of the Board of Directors and Audit Committee of Universal
Digital Inc. (CSE:LFG), formerly Minas Metals Ltd. (CSE:MINA).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Jordan has served as
Chief Executive Officer of the Company since February 2025, previously serving as the Interim Chief Executive Officer of the Company
from May 2024 to February 2025, and also previously served as lead independent director of the Company from February 2024 to May 2024.
Mr. Jordan served as Chief Financial Officer of HeyBryan Media Inc. (CSE: HEY), a peer-to-peer marketplace app connecting independent
contractors to consumers with everyday home maintenance needs, from October 2019 to November 2020. Prior to that he served in several
roles with Ascent Industries Corp. (&#8220;<span style="text-decoration:underline">Ascent</span>&#8221;), including Vice President of Corporate Development (January 2018 &#8211;
July 2018); Chief Financial Officer (August 2018 &#8211; April 2019); and Interim Chief Executive Officer (November 2018 &#8211; April
2019), where he led the company&#8217;s go-public listing and financing transactions. Mr. Jordan was Interim CEO, CFO, and a director
of Ascent, when on March 1, 2019, the Supreme Court of British Columbia issued an order granting Ascent&#8217;s application for creditor
protection under the Companies&#8217; Creditors Arrangement Act (Canada) (&#8220;<span style="text-decoration:underline">CCAA</span>&#8221;). On April 26, 2019, Mr. Jordan resigned
as an officer and director of Ascent. On May 5, 2020, the receivership was terminated by the court. Mr. Jordan was also a director of
Mjardin Group Inc., a diversified cannabis company from May 26, 2021 to March 22, 2022.&#160; PwC, as receiver, determined to place Mjardin
Group Inc. into receivership on March 23, 2022. Mr. Jordan resigned as a director immediately prior to the Order of the Superior Court
of Ontario in that regard.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between 2012 and 2017, Mr.
Jordan served as Managing Director and Corporate Director with Echelon Wealth Partners Inc., an investment banking firm, with a focus
in the technology, biotech and diversified industries fields. Mr. Jordan also worked for Credit Suisse Group for nearly ten years in
roles that included Leveraged Finance/Restructuring in Europe, Principal Investing in New York, as well as Special Situations and Convertible
Bonds in Asia. Prior to Credit Suisse, Mr. Jordan was a corporate and securities lawyer with Bennett Jones LLP. Mr. Jordan also served in the Canadian Army.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">His management experience
also includes working as CFO and CEO of public companies, and director at a global investment bank. His board experience includes roles
at a Canadian investment bank, health sciences companies, mineral exploration and production companies (uranium and gold), an ultra-low
cost airline and a Capital Pool Corporation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Jordan holds an MBA from
The University of Chicago Booth School of Business, with concentrations in Accounting, Finance, Entrepreneurship and International Business.
He also has an LL.B from the University of British Columbia where he focused on corporate and securities law, and a BA from the University
of Victoria in British Columbia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have concluded that Mr.
Jordan is well qualified to serve on our Board of Directors based upon his significant business experience, including his background
in restructuring, mergers and acquisitions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>RYAN L. SMITH &#8211; CLASS II DIRECTOR, LEAD
DIRECTOR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since December 2019, Mr.
Smith has served as Chief Executive Officer of U.S. Energy Corp. (USEG:NASDAQ)(&#8220;<span style="text-decoration:underline">U.S. Energy</span>&#8221;), an energy company engaged
in the development and operation of high-quality energy and industrial gas assets in the United States. Mr. Smith served as Chief Financial
Officer of U.S. Energy from May 2017 to June 2023, and has served as a member of the Board of Directors of U.S. Energy since January
2021. Mr. Smith consulted for U.S. Energy from January 2017 to May 2017. Prior to holding that position, Mr. Smith served as Emerald
Oil Inc.&#8217;s Chief Financial Officer from September 2014 to January 2017 and Vice President of Capital Markets and Strategy from
July 2013 to September 2014. Emerald Oil Inc. filed for Chapter 11 bankruptcy protection in March 2016 and emerged from bankruptcy in
November 2016. Prior to joining Emerald, Mr. Smith was a Vice President in Canaccord Genuity&#8217;s Investment Banking Group focused
solely on the energy sector. Mr. Smith joined Canaccord Genuity in 2008 and was responsible for the execution of public and private financing
engagements along with mergers and acquisitions advisory services. Prior to joining Canaccord Genuity, Mr. Smith was an Analyst in the
Wells Fargo Energy Group, working solely with upstream and midstream oil and gas companies. Mr. Smith holds a Bachelor of Business Administration
degree in Finance from Texas A&amp;M University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have concluded that Mr.
Smith is well qualified to serve on our Board of Directors based upon his significant business experience, including his public company
background, and capital markets fund raising.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_063"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Director Qualifications</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board believes that each
of our directors is highly qualified to serve as a member of the Board. Each of the directors has contributed to the mix of skills, core
competencies and qualifications of the Board. When evaluating candidates for election to the Board, the Board seeks candidates with certain
qualities that it believes are important, including integrity, an objective perspective, good judgment, and leadership skills. Our directors
are highly educated and have diverse backgrounds and talents and extensive track records of success in what we believe are highly relevant
positions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_064"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Executive
and Director Compensation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_065"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Summary Executive
Compensation Table</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth certain information concerning compensation earned by or paid to certain persons who we refer to as our &#8220;<span style="text-decoration:underline">Named Executive
Officers</span>&#8221; for services provided for the fiscal years ended December 31, 2024 and 2023. Our Named Executive Officers include
persons who (i)&#160;served as our principal executive officer or acted in a similar capacity during the years ended December 31, 2024
and 2023, (ii)&#160;were serving at fiscal year-end as our two most highly compensated executive officers, other than the principal executive
officer, whose total compensation exceeded $100,000, and (iii)&#160;if applicable, up to two additional individuals for whom disclosure
would have been provided as a most highly compensated executive officer, but for the fact that the individual was not serving as an executive
officer at fiscal year-end.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name and Principal&#160;Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary<br/>
 ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus<br/>
 ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock<br/>
 Awards<br/>
 ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<br/>
 Awards<br/>
 ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-Equity<br/>
 Incentive<br/>
 Plan<br/>
 Compensation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other<br/>
 Compensation<br/>
 ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/>
 ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 6%; font-weight: bold; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt"><b>Blair Jordan<sup>(1)</sup></b></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">140,107</td><td style="width: 1%; text-align: left">&#160;<sup>(7)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">140,107</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Chief Executive Officer</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt"><b>James
    N.&#160;Woody<sup>(2)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,250</td><td style="text-align: left">&#160;<sup>(10)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Former CEO and Former Director</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">567,775</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">39,025</td><td style="text-align: left">&#160;<sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;<sup>(11)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">656,800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt"><b>Omar Jimenez<sup>(3)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">74,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">53,584</td><td style="text-align: left">&#160;<sup>(12)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">128,063</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Former CFO</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt"><b>Ozan Pamir<sup>(4)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">285,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">285,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Former CFO</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">387,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,805</td><td style="text-align: left">&#160;<sup>(9)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22,500</td><td style="text-align: left">&#160;<sup>(11)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">418,046</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt"><b>Quan
    Anh Vu<sup>(5)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">384,475</td><td style="text-align: left">&#160;<sup>(13)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">384,475</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Former COO and CBO</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt"><b>Jonathan Rothbard<sup>(6)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">200</td><td style="text-align: left">&#160;<sup>(14)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Former Chief Scientific Officer</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">250,342</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,805</td><td style="text-align: left">&#160;<sup>(9)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;<sup>(11)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">268,147</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Does not include perquisites
and other personal benefits or property, unless the aggregate amount of such compensation is more than $10,000. No executive officer
earned non-equity&#160;incentive plan compensation or nonqualified deferred compensation during the periods reported above. Option Awards
and Stock Awards represent the aggregate grant date fair value of awards computed in accordance with Financial Accounting Standards Board
Accounting Standard Codification Topic&#160;718. For additional information on the valuation assumptions with respect to the restricted
stock grants, refer to &#8220;Note 11 &#8212;&#160;Stockholders&#8217; (Deficit) Equity&#8221; to the Company&#8217;s December 31, 2024,
audited financial statements included in the 2024 Annual Report. No executive officer serving as a director received any compensation
for services on the Board of Directors separate from the compensation paid as an executive for the periods above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On February 28, 2024, Mr. Blair Jordan was appointed to the Board of
    Directors of the Company. On May 7, 2024, Mr. Jordan was appointed as Interim Chief Executive Officer of the Company. On February
    4, 2025, the Board of Directors of the Company approved the appointment of Mr. Blair Jordan as Chief Executive Officer of the Company. Mr. Jordan provides his services through, and is paid through, Blair
Jordan Strategy and Finance Consulting Inc., of which he is the sole owner and control person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On May 7, 2024, Dr. James N. Woody resigned as Chief Executive Officer
    (Principal Executive Officer), and as a member of the Board of Directors, of the Company effective the same date, and entered into
    a Separation and Release Agreement with the Company the total fair value of which is included above in &#8220;All Other Compensation&#8221;.
    The Separation and Release Agreement is discussed in greater detail below under Note (10).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Mr. Omar Jimenez was appointed as a member of the Board of Directors
    of the Company on March 7, 2024, and as Chief Financial Officer of the Company on September 11, 2024, effective September 30, 2024.
    Mr. Jimenez resigned as Chief Financial Officer of the Company on December 16, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On September 10, 2024, Mr. Ozan Pamir, the Chief Financial Officer
    (Principal Financial/Accounting Officer) and Secretary of the Company tendered his resignation to the Board effective September 30,
    2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On October&#160;29, 2021, the Board appointed Mr.&#160;Quan Anh Vu
    as Chief Operating Officer/Chief Business Officer (&#8220;<span style="text-decoration:underline">COO/CBO</span>&#8221;) of the Company. On October&#160;27, 2021, and effective
    on November&#160;1, 2021, the Company entered into an Employment Agreement with Quan Ahn Vu. In consideration for performing services
    under the agreement, the Company agreed to pay Mr.&#160;Vu a starting salary of $390,000 per year. Mr. Vu&#8217;s employment agreement
    was terminated effective January 15, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On May 7, 2024, Dr. Jonathan Rothbard resigned as Chief Scientific
    Officer of the Company of the Company effective the same date, and entered into a Separation and Release Agreement with the Company,
    the total fair value of which is included in &#8220;All Other Compensation&#8221;, above. The Separation and Release Agreement is
    discussed in greater detail below.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents amount paid through Blair Jordan Strategy and Finance Consulting
    Inc. (an entity owned by Mr. Jordan).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents the value of ten-year options to purchase 3,948&#160;shares
    of common stock with an exercise price of $12.73&#160;per share which were granted on September 4, 2023, which have since expired
    unexercised.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(9)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents the value of ten-year options to purchase 790&#160;shares
    of common stock with an exercise price of $12.73&#160;per share which were granted on September 4, 2023, which have since expired
    unexercised.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(10)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On May 7, 2024, Dr. James N. Woody resigned as Chief Executive Officer
    of the Company and entered into a Separation and Release Agreement with the Company. Under the Separation Agreement, the Company
    agreed to (a) pay Dr. Woody $50,000 in cash, less all applicable withholdings and required deductions; (b)&#160;issue Dr. Woody 25,000
    fully-vested shares of the Company&#8217;s common stock; and (c) provide Dr. Woody the right to earn an additional $50,000 in the
    event we complete a change of control transaction (the &#8220;<span style="text-decoration:underline">Change of Control Bonus</span>&#8221;) within 24 months of the resignation
    date or we raise at least $5 million within 12 months from the resignation date, the total fair value of which is included above
    in &#8220;All Other Compensation&#8221;. On February 5, 2025, we entered into a First Amendment to Separation and Release Agreement
    with Dr. Woody (the &#8220;<span style="text-decoration:underline">First Amendment</span>&#8221;). Pursuant to the First Amendment, Dr. Woody and the Company agreed to amend
    the terms of the May 7, 2024 Separation and Release Agreement, to terminate the Change of Control Bonus and for the Company to instead
    issue Dr. Woody $60,000 in shares of restricted common stock of the Company (or 43,166 shares of common stock, based on the closing
    sales price of the Company&#8217;s common stock on February 5, 2025, which closing price was $1.39 per share, the &#8220;<span style="text-decoration:underline">Separation
    Shares</span>&#8221;).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(11)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents amounts paid in consideration for a bonus for fiscal 2021,
    which were paid in fiscal 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(12)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes $48,334 paid as consideration for services rendered as a member
    of the Board of Directors during 2024 and $5,270 of health insurance premiums.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(13)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents $368,225 paid to Mr. Vu pursuant to the terms of a settlement
    agreement in connection with the termination of his employment agreement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(14)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On May 7, 2024, Dr. Jonathan Rothbard resigned as Chief Scientific
    Officer of the Company effective the same date, and entered into a Separation and Release Agreement with the Company. Under the Separation
    Agreement, the Company agreed to pay Dr. Rothbard $200 in cash, less all applicable withholdings and required deductions, the total
    fair value of which is included in &#8220;All Other Compensation&#8221;, above.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_066"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Bonuses</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No bonuses were paid to the
officers named in the table above during the fiscal year ended December 31, 2024 or 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_067"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Current Compensation
Agreements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_068"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jordan Consulting
Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 7, 2024, the Company
entered into an Executive Consulting Agreement with Mr. Blair Jordan and Blair Jordan Strategy and Finance Consulting Inc. (an entity
owned by Mr. Jordan) (&#8220;<span style="text-decoration:underline">Jordan Consulting</span>&#8221; and the &#8220;<span style="text-decoration:underline">Original Jordan Consulting Agreement</span>&#8221;). Pursuant
to the Original Jordan Consulting Agreement, the Company agreed to engage Jordan Consulting to provide the services of Mr. Jordan to
the Company as Interim Chief Executive Officer of the Company. The Original Jordan Consulting Agreement had a term through April 30,
2025, and provided for Mr. Jordan to act as Interim Chief Executive Officer of the Company, and to be paid $216,000 per year in consideration
for services rendered to the Company, plus a $250,000 bonus in the event that the Company completes a Corporate Transaction. A &#8220;<span style="text-decoration:underline">Corporate
Transaction</span>&#8221; includes any corporate transaction by the Company, which occurs during the term, including but not limited to
any merger, reverse merger, acquisition, disposal, joint-venture and/or investment involving the Company, which results in a Change of
Control of the Company. For the purpose of the Agreement &#8220;<span style="text-decoration:underline">Change of Control</span>&#8221; means any corporate transaction pursuant
to which the ownership of an aggregate of 50.1% or more of the outstanding shares of the Company is held by one or more parties after
completing the Corporate Transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">On February 4, 2025, the
Board of Directors of the Company approved the appointment of Mr. Blair Jordan as Chief Executive Officer of the Company and an increase
in Mr. Jordan&#8217;s compensation to $240,000 per year, effective January 1, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 20, 2024, the
Company entered into an Executive Consulting Agreement with Mr. Blair Jordan, and Jordan Consulting dated February 21, 2024 (the &#8220;<span style="text-decoration:underline">February
2024 Jordan Consulting Agreement</span>&#8221;). The Jordan Consulting Agreement replaced and superseded the Original Consulting Agreement
with Mr. Jordan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 17, 2025, the Company
entered into an Amended and Restated Executive Consulting Agreement with Mr. Jordan and Jordan Consulting dated June 17, 2025 (the &#8220;Jordan
Consulting Agreement&#8221;). The Jordan Consulting Agreement replaced and superseded the February 2024 Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Jordan Consulting
Agreement, the Company agreed to continue to engage Jordan Consulting to provide the services of Mr. Jordan to the Company as Chief Executive
Officer of the Company. The Jordan Consulting Agreement has a term beginning effective January 1, 2025, and continuing through December
31, 2027, unless otherwise terminated pursuant to the terms of the agreement (discussed below), provided that in the event that the parties
have not agreed to an extension or termination of the Jordan Consulting Agreement with at least 30 days written notice at the end of
the term, the agreement automatically renews for successive terms of one year upon the expiration of the primary term or any renewal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Jordan Consulting Agreement
provides for Mr. Jordan to act as Chief Executive Officer of the Company, and to be paid $240,000 per year in consideration for services
rendered to the Company, which shall increase to $350,000 per year in the event the Company completes any material transaction (the &#8220;<span style="text-decoration:underline">Fee</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The agreement also allows
the Company to pay Mr. Jordan or Jordan Consulting an incentive bonus of up to 100% of the Fee per year (but not less than 50% of the
Fee), in the form of cash or equity, in the discretion of the Compensation Committee and the Board. Any additional bonus payments in
2025, if any, and subsequent bonus payments in 2026 and 2027 from the Company to Mr. Jordan or Jordan Consulting, if any, will be based
on criteria to be determined by the Compensation Committee of the Board. The Board and Compensation Committee may also pay Mr. Jordan
or Jordan Consulting bonuses from time to time in cash or equity, in their sole discretion, with any bonus earned being paid by March
15th of the year following the date it is earned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Jordan Consulting Agreement
includes customary confidentiality, non-disclosure and proprietary right requirements of Jordan Consulting and Mr. Jordan, and a prohibition
on Jordan Consulting and Mr. Jordan competing against us during the term of the agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Jordan Consulting may terminate
the Jordan Consulting Agreement at any time for &#8220;<span style="text-decoration:underline">good reason</span>&#8221; (meaning, without Mr. Jordan&#8217;s consent, the failure
of the Company to pay any compensation pursuant to the agreement when due or to perform any other obligation of the Company under the
agreement, or the introduction of a requirement to be physically present in an office that is not located in Vancouver, British Columbia;
material diminution of duties; his reporting structure and budget authority is reduced; and any material reduction of compensation);
provided, however, prior to any such termination by Mr. Jordan for &#8220;<span style="text-decoration:underline">good reason</span>&#8221;, Mr. Jordan must first advise the
Company in writing (within 90 days of the occurrence of such event) and provide the Company with 30 days to cure, and such agreement
must be terminated within 30 days after the Company&#8217;s failure to cure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may terminate the Jordan
Consulting Agreement at any time for &#8220;<span style="text-decoration:underline">just cause</span>&#8221; (as described below) and for any reason other than &#8220;<span style="text-decoration:underline">just
cause</span>&#8221;. &#8220;J<span style="text-decoration:underline">ust cause</span>&#8221; means the occurrence of any of the following events: (i) any material or persistent
breach by Jordan Consulting or Mr. Jordan of the terms of the agreement; (ii) the conviction of Jordan Consulting or Mr. Jordan of a
felony offence, or the equivalent in a non-American jurisdiction, or of any crime involving moral turpitude, fraud or misrepresentation,
or misappropriation of money or property of the Company or any affiliate of the Company; (iii) a willful failure or refusal by Jordan
Consulting or Mr. Jordan to satisfy its respective obligations to the Company under the agreement including without limitation, specific
lawful directives, reasonably consistent with the agreement, or requests of the Board; (iv) any negligent or willful conduct or omissions
of Jordan Consulting or Mr. Jordan that directly results in substantial loss or injury to the Company; (v) fraud or embezzlement of funds
or property, or misappropriation involving the Company&#8217;s assets, business, customers, suppliers, or employees; (vi) any failure
to comply with any of the Company&#8217;s written policies and procedures, including, but not limited to, the Company&#8217;s Corporate
Code of Ethics and Insider Trading Policy, provided that subject to certain limited exceptions, we must first give written notice to
Jordan Consulting and Mr. Jordan, as applicable, advising them of the acts or omissions that constitute failure or refusal to perform
their obligations and that failure or refusal continues after Jordan Consulting and Mr. Jordan, as applicable, has had thirty (30) days
to correct the acts or omissions as set out in the notice, if such acts are correctable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also able to terminate
the Jordan Consulting Agreement at any time, without notice upon: (a) the death or physical or mental incapacity of Mr. Jordan, if as
a result of which Mr. Jordan is unable to perform services for a period in excess of 60 days; or (b) in the event Mr. Jordan or a related
party to Mr. Jordan ceases to own or control 100% of Jordan Consulting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the agreement is terminated
by Jordan Consulting for &#8220;<span style="text-decoration:underline">good reason</span>&#8221;, or by the Company without &#8220;<span style="text-decoration:underline">just cause</span>&#8221; (other than due
to death or disability), Jordan Consulting is required to be paid, in a lump sum on the tenth day following such termination, a severance
payment equal to: (i) two times the then current annualized Fee, together with all outstanding expenses and pro-rated Fee (through the
date of termination); (ii) any unvested equity grant (including but not limited to options, restricted shares, RSUs and other equity
incentives) will vest immediate (collectively, the &#8220;<span style="text-decoration:underline">Extended Obligations</span>&#8221;); and (iii) two times any unpaid annual
cash bonus in respect of any completed or partial fiscal year that has ended prior to the date of such termination with such amount determined
based on actual performance during such fiscal year (and/or partial year, as the case may be) as determined by the compensation committee,
which in any case shall be no less than 50% of the Fee before being multiplied by 2; and (iv) immediate vesting of any and all equity
or equity-related awards &#8211; which terms are amended from the Prior Agreement. Any equity awards that vest based on various performance
metrics will be vested only if such performance metrics have been met at the time of termination of service and will be determined solely
by the Compensation Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the agreement is terminated
without &#8220;<span style="text-decoration:underline">good reason</span>&#8221; by Jordan Consulting or for &#8220;<span style="text-decoration:underline">just cause</span>&#8221; by the Company, Jordan Consulting
is entitled to the Accrued Liabilities (as defined below), and any equity awards or equity-related awards that are not vested as of the
date of termination will be cancelled and forfeited and any vested awards will be exercisable pursuant to their terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the agreement is terminated
due to Mr. Jordan&#8217;s death or disability, Jordan Consulting or Mr. Jordan&#8217;s estate or his beneficiaries, as the case may be,
will be entitled to receive (i) any accrued but unpaid Fee through the date of termination, any unpaid or unreimbursed expenses incurred
in accordance with the terms of the agreement, (collectively, the &#8220;<span style="text-decoration:underline">Accrued Liabilities</span>&#8221;); (ii) any unpaid annual cash
bonus in respect of any completed fiscal year that has ended prior to the date of such termination, with such amount determined based
on actual performance during such fiscal year as determined by the Company&#8217;s Compensation Committee on the sixtieth day following
termination; (iii) a lump sum payment of any non-discretionary annual cash bonus that would have been payable based on actual performance
with respect to the year of termination in the absence of Mr. Jordan&#8217;s death or disability, pro-rated for the period that Mr. Jordan
worked prior to his death or disability, and payable at the same time as the bonus would have been paid in the absence of Mr. Jordan&#8217;s
death or disability; and (iv) immediate vesting of any and all equity or equity-related awards previously awarded to Jordan Consulting,
irrespective of the type of award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition precedent
to payment of any amount or provision of any benefit to Mr. Jordan upon termination (the &#8220;<span style="text-decoration:underline">Severance Benefits</span>&#8221;), Jordan
Consulting and Mr. Jordan or Mr. Jordan&#8217;s estate, as applicable, shall execute and shall not rescind, a release in favor of the
Company and all related companies, individuals, and entities, in a form satisfactory to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon termination of the agreement
or for any reason other than &#8220;<span style="text-decoration:underline">good reason</span>&#8221; by Jordan Consulting or the Company without &#8220;<span style="text-decoration:underline">just cause</span>&#8221;,
Jordan Consulting and Mr. Jordan agreed that, for a period ending six months from the date of termination, Jordan Consulting and Mr.
Jordan shall not (except on behalf of the Company or with the prior written consent of the Company), directly or indirectly, compete
with the Company for a period of one year, neither Mr. Jordan, nor Jordan Consulting shall solicit employees or consultants of the Company,
each as discussed in greater detail in the Jordan Consulting Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_069"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">EVL Consulting Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective on February 15,
2025, the Company entered into an Executive Consulting Agreement dated January 30, 2025 with Mr. Eric R. Van Lent and EVL Consulting,
LLC (an entity owned by Mr. Van Lent)(&#8221;<span style="text-decoration:underline">EVL Consulting</span>&#8221; and the &#8220;<span style="text-decoration:underline">EVL Consulting Agreement</span>&#8221;). Pursuant
to the EVL Consulting Agreement, the Company agreed to engage EVL Consulting to provide the services of Mr. Van Lent to the Company as
Chief Accounting Officer of the Company. The EVL Consulting Agreement has a term through July 30, 2025, unless otherwise terminated pursuant
to the terms of the agreement (discussed below)&#160;and provides for Mr. Van Lent to act as Chief Accounting Officer of the Company,
and to be paid $8,000 per month for an average of 10 hours of work per week, with any hours in excess of that amount being compensated
at the rate of $200 per hour, only if preapproved in writing by the Company. Notwithstanding the above, the Board of Directors, with
the recommendation of the Compensation Committee, may grant Mr. Van Lent bonuses from time to time in its discretion, in cash or equity.
The EVL Consulting Agreement includes customary confidentiality, non-disclosure and proprietary right requirements of EVL Consulting
and Mr. Van Lent, and a prohibition on EVL Consulting and Mr. Van Lent competing against us during the term of the agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have the right to terminate
the EVL Consulting Agreement at any time, provided that we pay EVL Consulting $10,000 upon such termination, payable within 60 days of
such termination date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also able to terminate
the EVL Consulting Agreement at any time, without notice upon: (a)&#160;the death or physical or mental incapacity of Mr. Van Lent if
as a result of which Mr. Van Lent is unable to perform services for a period in excess of 30 days; (b)&#160;in the event Mr. Van Lent
or a related party to Mr. Van Lent ceases to own or control 100% of EVL Consulting; or (c)&#160;&#8220;<span style="text-decoration:underline">just cause</span>&#8221;, which
means any of the following events: (i)&#160;any material or persistent breach by EVL Consulting or Mr. Van Lent of the terms of the agreement;
(ii)&#160;the conviction of EVL Consulting or Mr. Van Lent of a felony offence, or the equivalent in a non-American jurisdiction, or
of any crime involving moral turpitude, fraud or misrepresentation, or misappropriation of money or property of the Company or any affiliate
of the Company; (iii)&#160;a willful failure or refusal by EVL Consulting or Mr. Van Lent to satisfy its respective obligations to the
Company under the agreement including without limitation, specific lawful directives, reasonably consistent with the agreement, or requests
of the Board; (iv)&#160;any negligent or willful conduct or omissions of EVL Consulting or Mr. Van Lent that directly results in substantial
loss or injury to the Company; (v)&#160;fraud or embezzlement of funds or property, or misappropriation involving the Company&#8217;s
assets, business, customers, suppliers, or employees; (vi)&#160;any failure to comply with any of the Company&#8217;s written policies
and procedures, including, but not limited to, the Company&#8217;s Corporate Code of Ethics and Insider Trading Policy, provided that
subject to certain limited exceptions, we must first give written notice to EVL Consulting and Mr. Van Lent, as applicable, advising
them of the acts or omissions that constitute failure or refusal to perform their obligations and that failure or refusal continues after
EVL Consulting and Mr. Van Lent, as applicable, has had thirty (30)&#160;days to correct the acts or omissions as set out in the notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company terminates
the EVL Consulting Agreement for just cause, we are required to pay EVL Consulting any unpaid fees and/or unpaid and unreimbursed expenses
accrued but unpaid prior to the effective termination date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_070"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Prior Employment
Agreements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the salaries of the
executives described below and certain of the compensation payable to the consultants described below, were subject to the increases
in salary and the temporary salary accruals discussed below under &#8220;<i>Payment of Back Pay; 2021 Bonuses and Increases in Salaries</i>,&#8221;
and &#8220;<i>2024 Accruals</i>&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_071"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">James N. Woody Amended
and Restated Employment Agreement (terminated); and Separation Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 25, 2021, we
entered into an Amended and Restated Employment Agreement with Dr. James N. Woody (the &#8220;<span style="text-decoration:underline">A&amp;R Agreement</span>&#8221;), dated
February 24, 2021, and effective November 6, 2020, which replaced and superseded the July 2020 agreement with 180 as discussed above.
Pursuant to the A&amp;R Agreement, Dr. Woody agreed to serve as the Chief Executive Officer of the Company. The A&amp;R Agreement had
a term of three years from its effective date (through November 6, 2023)&#160;and was automatically renewable thereafter for additional
one-year periods, unless either party provided the other at least 90 days written notice of their intent to not renew the agreement.
Dr. Woody&#8217;s annual base salary under the agreement was initially increased to $450,000 per year, subject to automatic 5% yearly
increases. For the 2021 year, Dr. Woody&#8217;s salary was $450,000, for 2022, Dr. Woody&#8217;s salary was $463,500, and for the 2023
year, Dr. Woody&#8217;s salary was $490,000 (see also &#8220;<i>Payment of Back Pay; 2021 Bonuses and Increases in Salaries</i>,&#8221;
&#8220;<i>2024 Accruals</i>&#8221; and &#8220;<i>2022, 2023 and 2024 Bonuses</i>&#8221;, below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Woody was also eligible
to receive an annual bonus, with a target bonus equal to 45% of his then-current base salary, based upon our achievement of performance
and management objectives as set and approved by the Board of Directors and/or Compensation Committee in consultation with Dr. Woody.
At Dr. Woody&#8217;s option, the annual bonus could be paid in cash or the equivalent value of our common stock or a combination thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The A&amp;R Agreement contained
standard and customary invention assignment, indemnification, confidentiality and non-solicitation provisions, which remain in effect
for a period of 24 months following the termination of this agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 10, 2024, and
effective on January 1, 2024, the&#160;Company&#160;entered into a Fourth Amendment to Amended and Restated Employment Agreement with
Dr. Woody, whereby Dr. Woody agreed to a reduction of the base salary set forth in his amended employment agreements, by 50%, to $245,000
per year, accruing monthly in arrears, to be paid upon the Company raising at least $5,000,000 in funding subsequent to the date of the
amended agreement (the &#8220;<span style="text-decoration:underline">Funding Date</span>&#8221;), provided that in the event the Funding Date does not occur prior to March
15, 2025, the amount accrued will be forgiven in its entirety.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Woody resigned as Chief
Executive Officer of the Company on May 7, 2024, and the Amended and Restated Employment Agreement was terminated on May 15, 2024, in
connection with Dr. Woody&#8217;s entry into a Separation and Release Agreement with the Company on the same date, discussed in greater
detail below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 7, 2024, Dr. James
N. Woody resigned as Chief Executive Officer (Principal Executive Officer), and as a member of the Board of Directors, of the Company
effective the same date, and entered into a Separation and Release Agreement with the Company (the &#8220;<span style="text-decoration:underline">Woody Separation Agreement</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Woody Separation
Agreement, the Company agreed to (a) pay Dr. Woody $50,000 in cash, less all applicable withholdings and required deductions (the &#8220;<span style="text-decoration:underline">Severance
Cash</span>&#8221;); (b) issue Dr. Woody 25,000 fully-vested shares of the Company&#8217;s common stock; and (c) provide Dr. Woody the right
to earn the Future Contingent Payment (as defined below). The amounts above (except for the amounts payable pursuant to (c), which shall
be paid by the 15th day following the date such payment is due as discussed below), are required to be paid within 15 days of the date
of Dr. Woody&#8217;s resignation (the &#8220;<span style="text-decoration:underline">Payment Date</span>&#8221;). We also agreed to pay Dr. Woody a bonus of $50,000 (the &#8220;<span style="text-decoration:underline">Future
Contingent Payment</span>&#8221;), [A] if we, within the 24 months following the date of Dr. Woody&#8217;s resignation, complete any corporate
transaction, including but not limited to any merger, reverse merger, acquisition, disposal, joint-venture and/or investment involving
the Company (a &#8220;<span style="text-decoration:underline">Corporate Transaction</span>&#8221;), which results in a Change of Control (a &#8220;<span style="text-decoration:underline">Change of Control</span>&#8221;
means any Corporate Transaction pursuant to which the ownership of an aggregate of 50.1% or more of the outstanding shares of the Company
is held by one or more parties after completing the Corporate Transaction); or [B] if we raise at least $5 million from any source within
12 months from Dr. Woody&#8217;s resignation date. The Future Contingent Payment is to be forfeited from Dr. Woody in the event that
we are required to restate any financial statements of the Company for periods prior to Dr. Woody&#8217;s resignation date, if Dr. Woody
was Chief Executive Officer of the Company during such period(s), or any disclosure made the Company in any report or filing with the
SEC, is found by the Company to be materially incorrect or misleading, as determined by the reasonable discretion of the Board of Directors
of the Company (each a &#8220;<span style="text-decoration:underline">Forfeiture Trigger</span>&#8221;). In the event a Forfeiture Trigger occurs or is deemed to have occurred,
Dr. Woody is also required to promptly repay in full the Severance Cash.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Woody Separation
Agreement, Dr. Woody agreed to provide a customary general release to the Company, waived any severance pay that would have been due
pursuant to the terms of his employment agreement, agreed to the termination of his employment agreement, and also agreed to certain
confidentiality, non-disclosure, non-solicitation, non-disparagement, and cooperation covenants in favor of the Company. The 25,000 fully-vested
shares of the Company&#8217;s common stock due to Dr. Woody were issued under the Company&#8217;s Second Amended and Restated 2022 Omnibus
Incentive Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 5, 2025, the
Company entered into a First Amendment to Separation and Release Agreement with Dr. Woody (the &#8220;<span style="text-decoration:underline">First Amendment</span>&#8221;).
Pursuant to the First Amendment, Dr. Woody agreed to amend the terms of the Woody Separation Agreement, to terminate the prior requirement
of the Company to pay the&#160;<span style="text-decoration:underline">Future Contingent Payment</span>&#160;and instead, pursuant to the First Amendment, Dr. Woody agreed to
accept $60,000 in shares of restricted common stock of the Company (or 43,166 shares of common stock, based on the closing sales price
of the Company&#8217;s common stock on February 5, 2025, which closing price was $1.39 per share, the &#8220;<span style="text-decoration:underline">Separation Shares</span>&#8221;).
The Separation Shares include piggyback registration rights for a resale registration statement relative to the Separation Shares for
a period of six (6) months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The First Amendment also
required Dr. Woody to enter into a Voting Agreement with the Company. Pursuant to the Voting Agreement, which was entered into on February
5, 2025, by Dr. Woody, the Company, and Blair Jordan, the Company&#8217;s Chief Executive Officer, solely for the benefit of the Company,
Dr. Woody agreed to vote the Separation Shares as recommended by the Board of Directors of the Company, at any meeting of stockholders
or via any written consent of stockholders, which may occur prior to February 5, 2026; the date after August 5, 2025, that Dr. Woody
has sold all of the Separation Shares; or the date that the Company terminates the Voting Agreement. In order to enforce the terms of
the Voting Agreement, and solely for the benefit of the Company, Dr. Woody provided Mr. Jordan (or his assigns) an irrevocable voting
proxy to vote the Separation Shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent
of stockholders. The Voting Agreement also provides a restriction on Dr. Woody&#8217;s sale or transfer of any of the Separation Shares
until August 5, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_072"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Rothbard&#8217;s
Employment Agreement (terminated); and Separation Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 21, 2019, 180 entered
into an Employment Agreement with Dr. Rothbard which replaced a prior agreement, which was not effective until November 6, 2020, but
became effective on such date. The Employment Agreement had an initial term of three years from the Closing Date (i.e., until November
6, 2023), automatically extending for additional one-year terms thereafter unless either party terminates the agreement with at least
90 days prior written notice before the next renewal date, and since neither party provided notice of termination prior to November 6,
2023, the agreement was in place through November 6, 2024, subject to further automatic extensions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Employment Agreement
provided for Dr. Rothbard to be paid a salary of $375,000 per year, with automatic increases in salary, on the first anniversary of the
effective date, and each anniversary thereafter, of 10%. For the 2021 year, Dr. Rothbard&#8217;s salary was $375,000, for the 2022 year,
Dr. Rothbard&#8217;s salary was $268,906, and for 2023, Dr. Rothbard&#8217;s salary was $200,000 (see also &#8220;<i>Payment of Back
Pay; 2021 Bonuses and Increases in Salaries</i>&#8221;, &#8220;<i>Payment of Back Pay; 2021 Bonuses and Increases in Salaries</i>,&#8221;
&#8220;<i>2024 Accruals</i>&#8221; and &#8220;<i>2022, 2023 and 2024 Bonuses</i>&#8221;, below). The salary for the 2023 year represented
Dr. Rothbard&#8217;s commitment of 50% of his work-related time to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Employment Agreement
provided for Dr. Rothbard to receive an annual bonus subject to meeting certain objectives set by the Board of Directors, with a targeted
bonus amount of 50% of his then salary, payable on or before February 15<sup>th</sup>&#160;of each year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Employment Agreement
also provided for Dr. Rothbard to earn equity compensation in the discretion of the Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Employment Agreement
was amended effective January 1, 2022, to override the automatic annual salary increases of 10% per annum and instead provide for future
increases in the sole determination of the Board of Directors. The Employment Agreement was further amended effective June 1, 2022, to
adjust the base salary of Dr. Rothbard to $193,125.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 10, 2024, and
effective on January 1, 2024, the&#160;Company&#160;entered into a Fourth Amendment to Employment Agreement with Dr. Rothbard, whereby
Dr. Rothbard agreed to a reduction of the base salary set forth in his amended employment agreements, by 50%, to $100,000 per year, accruing
monthly in arrears, to be paid on the Funding Date, provided that in the event the Funding Date does not occur prior to March 15, 2025,
the amount accrued will be forgiven in its entirety.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 7, 2024, Dr. Jonathan
Rothbard resigned as Chief Scientific Officer of the Company effective the same date, and entered into a Separation and Release Agreement
with the Company (the &#8220;<span style="text-decoration:underline">Rothbard Separation Agreement</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Rothbard Separation
Agreement, the Company agreed to pay Dr. Rothbard $200 in cash, less all applicable withholdings and required deductions. Under the Rothbard
Separation Agreement, Dr. Rothbard agreed to provide a customary general release to the Company, waived any severance pay that would
have been due pursuant to the terms of his employment agreement, agreed to the termination of his employment agreement, and also agreed
to certain confidentiality, non-disclosure, non-solicitation, non-disparagement, and cooperation covenants in favor of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective on May 7, 2024,
the Company entered into a Consulting Agreement with Dr. Rothbard pursuant to which he agreed to provide general consulting services
to the Company for a term of six months, for $150 per hour (the &#8220;<span style="text-decoration:underline">Rothbard Consulting Agreement</span>&#8221;), which has expired
pursuant to its terms. The agreement contains standard and customary confidentiality requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_073"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ozan Pamir Katexco
Employment Agreement (Terminated)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our indirect wholly-owned
subsidiary Katexco Pharmaceuticals Corp. (&#8220;<span style="text-decoration:underline">Katexco</span>&#8221;) entered into an employment agreement with Mr. Ozan Pamir, on
October 22, 2018. The agreement provided for an indefinite term that continues until termination. The initial annual base salary set
forth in the agreement was CAD $120,000, with annual increases as determined by the Board of Directors. The agreement also provided Mr.
Pamir with a CAD $20,000 signing bonus. Any bonuses, including stock options, were in the sole discretion of Katexco, depending on financial
circumstances and the performance of the services under the agreement. In 2019, the compensation was increased to $120,000 per annum
in US dollars.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 1, 2020, there
was an amendment to Mr. Pamir&#8217;s consulting agreement with Katexco, whereby the contract was transferred from Katexco to Katexco
Pharmaceuticals Corp. - US.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_074"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ozan Pamir Company
Employment Agreement (Terminated)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 25, 2021, we
entered into an Employment Agreement dated February 24, 2021, and effective November 6, 2020, which agreement was amended and corrected
on March 1, 2021, to be effective as of the effective date of the original agreement (which amendment and correction is retroactively
updated in the discussion of the agreement), with Ozan Pamir, our then Interim Chief Financial Officer, which replaced and superseded
Mr. Pamir&#8217;s agreement with Katexco, as discussed above. Pursuant to the agreement, Mr. Pamir agreed to serve as the Interim Chief
Financial Officer of the Company; and we agreed to pay Mr. Pamir $300,000 per year for 2021, which was increased to $309,000 for the
2022 year, and, based on his appointment as Chief Financial Officer in April 2023, and $380,000 for the 2023 year (see also &#8220;<i>Payment
of Back Pay; 2021 Bonuses and Increases in Salaries</i>&#8221; and &#8220;<i>2022, 2023 and 2024 Bonuses</i>&#8221;, below). Such salary
was to be increased to a mutually determined amount upon the closing of a new financing, and shall also be increased on an annual basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the agreement, Mr.
Pamir was eligible to receive an annual bonus, in a targeted amount of 30% of his then salary for the 2021 and 2022 years, and 40% for
the 2023 year, based upon our achievement of performance and management objectives as set and approved by the Chief Executive Officer,
in consultation with Mr. Pamir. The bonus amount was subject to adjustment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the employment agreement,
Mr. Pamir was also eligible to participate in any stock option plans and receive other equity awards, as determined by the Board of Directors
from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The agreement contains standard
and customary invention assignment, indemnification, confidentiality and non-solicitation provisions, which remain in effect for a period
of 24 months following the termination of his agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 27, 2021, we entered
into a Second Amendment to Employment Agreement with Ozan Pamir (the &#8220;<span style="text-decoration:underline">Second Pamir Amendment</span>&#8221;). The Second Pamir Amendment
amended the terms of Mr. Pamir&#8217;s employment solely to provide that all compensation payable to Mr. Pamir under such agreement would
be paid directly by us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 14, 2021, the
Board of Directors authorized a discretionary bonus of $30,000 to Mr. Pamir in consideration for services rendered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The agreement was terminated
on September 30, 2024, in connection with Mr. Pamir&#8217;s resignation as Chief Financial Officer of the Company on that date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_075"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Quan Anh Vu Executive
Employment Agreement (terminated); and Separation Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 27, 2021, and
effective on November 1, 2021, we entered into an Employment Agreement with Quan Anh Vu, our then Chief Operating Officer/Chief Business
Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the employment
agreement, Mr. Vu agreed to serve as Chief Operating Officer/Chief Business Officer for the Company. In consideration therefore, we agreed
to pay Mr. Vu a starting salary of $390,000 per year, subject to annual increases of up to 5% (on each November 1, but effective as of
the following January 1, including a 3% increase to $401,700 for 2022). In addition to the base salary, Mr. Vu was eligible to receive
an annual bonus, with a target bonus opportunity of 50% of the then-current base salary, based on achievement of performance and management
objectives established by the CEO and the Compensation Committee, in consultation with Mr. Vu, payable on or before March 31<sup>st</sup>&#160;&#160;of
the year following the year in which the bonus is earned. Mr. Vu could elect the Annual Bonus to be paid in cash or the equivalent value
in our common stock, or a combination of the two.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Employment Agreement
contained standard and customary invention assignment, indemnification, confidentiality and non-solicitation provisions, which remain
in effect for a period of 24 months following the termination of the agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 18, 2023, Mr.
Vu resigned as Chief Operating/Chief Business Officer of the Company effective January 15, 2023, and entered into a Separation and Release
Agreement with us (as amended, the &#8220;<span style="text-decoration:underline">Separation Agreement</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Separation Agreement,
we agreed to pay Mr. Vu (a)&#160;$297,440, less all applicable withholdings and required deductions; and (b)&#160;reimburse up to $1,100
a month for eight months for Mr. Vu&#8217;s health insurance expenses, whether under COBRA or otherwise (collectively, (a)&#160;and (b),
the &#8220;<span style="text-decoration:underline">Severance Payment</span>&#8221;). The Severance Payment (except for the amounts payable pursuant to (b)&#160;which shall be
paid by the 15th day of each calendar month during the applicable eight-month period)&#160;was required to be paid within 30 days of
the Separation Date (the &#8220;<span style="text-decoration:underline">Payment Date</span>&#8221;). In addition to the Severance Payment, by the Payment Date, we agreed to
pay Mr. Vu $73,645 for accrued backpay and $36,050 for accrued paid time off. Under the Separation Agreement, Mr. Vu agreed that his
resignation was voluntary, provided a customary general release to us and also agreed to certain confidentiality, non-disclosure, non-solicitation,
non-disparagement, and cooperation covenants in favor of us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 29, 2023, an error
in the Separation Agreement was corrected by the parties&#8217; entry into the first amendment to Separation Agreement (the &#8220;<span style="text-decoration:underline">First
Separation Agreement Amendment</span>&#8221;), effective as of the date of the original agreement, which clarified that none of the amount
received by Mr. Vu pursuant to the Separation Agreement related to a bonus for 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_076"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Description of
Material Consulting Agreements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_077"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Service Agreement
with Prof. Sir Marc Feldmann (former Co-Executive Chairman)(Terminated)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 1, 2018, CannBioRex
Pharma Limited (&#8220;<span style="text-decoration:underline">CannBioRex</span>&#8221;), our wholly-owned subsidiary,&#160;and Prof. Sir Marc Feldmann Ph.D., our then Executive
Co-Chairman, entered into a Service Agreement (the &#8220;<span style="text-decoration:underline">Feldmann Employment Agreement</span>&#8221;). Pursuant to the Feldmann Employment
Agreement, Prof. Sir Marc Feldmann served as the Chairman, CEO and Executive Director of CannBioRex or in such other capacity consistent
with his status. Prof. Sir Marc Feldmann&#8217;s responsibilities included those customary for the roles in which he serves. Prof. Sir
Marc Feldmann received compensation of &#163;115,000 per year, with annual compensation reviewed by the Board and eligibility for discretionary
bonuses, as determined by the Board. CannBioRex also reimbursed Prof. Sir Marc Feldmann&#8217;s travel and other business expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Feldmann
Employment Agreement, all intellectual property rights created by Prof. Sir Marc Feldmann or related to his employment belonged to and
vested in CannBioRex.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Feldmann Employment Agreement
contains a customary non-compete clause prohibiting Prof. Sir Marc Feldmann from working for any competing businesses during the term
of his employment, or holding equity in other businesses, except he may hold or beneficially own securities of publicly-traded companies
if the aggregate beneficial interests of him and his family does not exceed 5% of that class of securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prof. Sir Marc Feldmann is
also prohibited for 12 months following termination (the &#8220;<span style="text-decoration:underline">Post-Termination Period</span>&#8221;)&#160;to be involved in any capacity
with a competing business or potential joint venture in the United Kingdom or in any other country. During the Post-Termination Period,
he may not solicit business from CannBioRex and its affiliates&#8217; customers; or any company with whom he was actively involved in
the course of his employment; or about which he holds confidential information. Prof. Sir Marc Feldmann further covenants to not interfere
with CannBioRex&#8217;s business relationships by inducing or attempting to induce suppliers to take adverse actions during the Post-Termination
Period. He also agrees not to induce or attempt to induce any CannBioRex employee to leave the company during the Post-Termination Period.
The Feldmann Employment Agreement contains customary non-disclosure and confidentiality obligations, sick leave and vacation time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Feldmann Employment Agreement
does not have a fixed term. Either party may terminate the agreement by delivering written notice 9 months in advance. CannBioRex may
also terminate the Feldmann Employment Agreement at any time with immediate effect by giving written notice. If CannBioRex terminates
Prof. Sir Marc Feldmann&#8217;s employment without providing 9 months written notice, he will become entitled to a payment equal to his
basic salary he would have been entitled to receive if 9 months&#8217; notice were given. The governing law for the Feldmann Employment
Agreement is the law of England.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board, as recommended
by the Compensation Committee of the Company (and/or the Compensation Committee)&#160;or separately, may also award Prof. Sir Marc Feldmann
bonuses from time to time (in stock, options, cash, or other forms of consideration)&#160;in its discretion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 17, 2021, the
Board, as recommended by the Compensation Committee, increased the salary of Prof. Sir Marc Feldmann to $225,000 per annum.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective on April 27, 2022,
CannBioRex and Prof. Sir Marc Feldmann entered into an amendment to the consulting agreement, pursuant to which the parties agreed effective
March 1, 2022, that Sir Marc Feldmann&#8217;s salary would be reduced by $225,000 (100%), and that such reduced amounts would be accrued
and paid on the Funding Determination Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 10, 2024, and
effective on January 1, 2024, the Company entered into a Second Amendment to Consulting Agreement with Prof. Sir Marc Feldmann. Pursuant
to the amendment, Prof. Sir Marc Feldmann, effective as of January 1, 2024, agreed to a reduction of his base salary set forth in his
consulting agreement by 100%, to &#163;0 per year, with the amount of such salary reduction &#163;14,167 per month or &#163;170,000
per year), accruing monthly in arrears, to be paid on the Funding Date, provided that in the event the Funding Date does not occur prior
to March 15, 2025, the amounts accrued will be forgiven in their entirety.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 7, 2024, Sir Marc
Feldmann, Ph.D. provided notice to the Board of Directors of his resignation as a member of the Board of Directors, effective on the
same date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective on September 5,
2024, our wholly-owned subsidiary, Cannbiorex and the Company, entered into a Separation and Release Agreement with Sir Marc Feldmann
(as amended, the &#8220;<span style="text-decoration:underline">Feldmann Separation Agreement</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Feldmann Separation
Agreement, the Company agreed to issue Sir Marc Feldmann 57,328 shares of common stock and options to purchase 20,000 shares of common
stock with a term of two years and an exercise price of $1.95 per share, the closing sales price of the Company&#8217;s common stock
on September 5, 2024, under the Company&#8217;s Second Amended and Restated Omnibus Incentive Plan to satisfy amounts owed to Sir Marc
Feldmann in consideration for services previously rendered to Cannbiorex. Under the Feldmann Separation Agreement, Sir Marc Feldmann
provided a customary general release to Cannbiorex and the Company, the Company and Cannbiorex provided a release to Sir Marc Feldmann,
subject to certain exceptions, and Sir Marc Feldmann also agreed to certain confidentiality, non-disclosure, non-solicitation, non-disparagement,
and cooperation covenants in favor of the Company and Cannbiorex. The shares have been issued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also effective on September
5, 2024, the Company entered into an Indemnification Agreement with Sir Marc Feldmann to provide for indemnification to Sir Marc Feldmann
under Delaware law. Among other things, consistent with the Company&#8217;s Bylaws, the Indemnification Agreement generally requires
that the Company (i) indemnify Sir Marc Feldmann from and against all expenses and liabilities with respect to proceedings to which Sir
Marc Feldmann may be subject by reason of Sir Marc Feldmann&#8217;s service to the Company and its subsidiaries to the fullest extent
authorized or permitted by Delaware law and (ii) advance all expenses incurred by Sir Marc Feldmann in connection with the investigation,
defense, settlement or appeal of any proceeding, and in connection with any proceeding to enforce Sir Marc Feldmann&#8217;s rights under
the Indemnification Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_078"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consultancy Agreement
and Consulting Agreement with Prof. Lawrence Steinman</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 17, 2021, and
effective on November 1, 2021, we entered into a Consulting Agreement with Lawrence Steinman, M.D., our then Executive Chairman (the
&#8220;<span style="text-decoration:underline">Consulting Agreement</span>&#8221;). Pursuant to the Consulting Agreement, Dr. Steinman agreed to provide certain consulting services
to us, including, but not limited to, participating in defining and setting strategic objectives of the Company; actively seeking out
acquisition and merger candidates; and having primary scientific responsibility for our &#945;7nAChR platform (collectively, the &#8220;<span style="text-decoration:underline">Services</span>&#8221;).
The initial term of the agreement was for one year (the &#8220;<span style="text-decoration:underline">Initial Term</span>&#8221;); provided that the agreement automatically
extends for additional one year periods after the Initial Term (each an &#8220;<span style="text-decoration:underline">Automatic Renewal Term</span>&#8221; and the Initial Term
together with all Automatic Renewal Terms, if any, the &#8220;<span style="text-decoration:underline">Term</span>&#8221;), subject to the Renewal Requirements (described below),
in the event that neither party provided the other written notice of their intent not to automatically extend the term of the agreement
at least 30 days prior to the end of the Initial Term or any Automatic Renewal Term, and since neither party has terminated the agreement,
the current term of the&#160;agreement is through November 1, 2025, subject to further automatic extensions. The Term can only be extended
for an Automatic Renewal Term, provided that (i)&#160;Dr. Steinman is re-elected to the Board at our Annual Meeting of Stockholders immediately
preceding the date that such Automatic Renewal Term begins; (ii)&#160;the Board affirms his appointment as Co-Chairman for the applicable
Automatic Renewal Term (or fails to appoint someone else as Co-Chairman prior to such applicable Automatic Renewal Term)&#160;and (iii)&#160;Dr.
Steinman is continuing in his role of having the responsibility for the scientific development for the Company&#8217;s &#945;7nAChR
platform (the &#8220;<span style="text-decoration:underline">Renewal Requirements</span>&#8221;).&#160;The Consulting Agreement also expires immediately upon the earlier of:
(i)&#160;the date upon which Dr. Steinman no longer serves as Co-Chairman and no longer has primary scientific responsibility for our
&#945;7nAChR platform; and (ii)&#160;any earlier date requested by either (1)&#160;us (as evidenced by a vote of a majority of the Board
(excluding Dr. Steinman)&#160;at a meeting of the Board), or (2)&#160;Dr. Steinman (as evidenced by written notice from Dr. Steinman
to the Board). Additionally, we may terminate the Consulting Agreement immediately and without prior notice if Dr. Steinman is unable
or refuses to perform the Services, and either party may terminate the Consulting Agreement immediately and without prior notice if the
other party is in breach of any material provision of the Consulting Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed to pay Dr. Steinman
$225,000 per year during the term of the agreement, along with a one-time payment of $43,750, representing the difference between his
old compensation and new compensation, dating back to April 1, 2021. Pursuant to the Consulting Agreement, Dr. Steinman agreed to not
compete against us, unless approved in writing by the Board, during the term of the agreement, and also agreed to certain customary confidentiality
provisions and assignment of inventions requirements. The Consulting Agreement also has a 12-month non-solicitation prohibition following
its termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective on April 27, 2022,
the Company and Dr. Steinman entered into an amendment to the consulting agreement, pursuant to which the parties agreed effective March
1, 2022, that Dr. Steinman&#8217;s salary would be reduced by $56,250 (25%), and that such reduced amount would be accrued and paid on
the Funding Determination Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 10, 2024, and
effective on January 1, 2024, the Company entered into a Third Amendment to Consulting Agreement with Lawrence Steinman. Pursuant to
the amendment, Dr. Steinman, effective as of January 1, 2024, agreed to a reduction of his base salary set forth in his consulting agreement
by 100%, to $0 per year, with the amount of such salary reduction ($18,750 per month or $225,000 per year), accruing monthly in arrears,
to be paid on the Funding Date, provided that in the event the Funding Date does not occur prior to March 15, 2025, the amounts accrued
will be forgiven in their entirety.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 7, 2024, the Company
entered into a Fourth Amendment to Consulting Agreement with Dr. Lawrence Steinman, the then Executive Chairman of the Board (the &#8220;<span style="text-decoration:underline">Fourth
Amendment</span>&#8221;). Pursuant to the Fourth Amendment, Dr. Steinman waived and forgave all amounts accrued and owed to him under the
Consulting Agreement through such date, and agreed that compensation payable to him under the Consulting Agreement moving forward would
be $0, provided that as long as Dr. Steinman remains a member of the Board of the Company, he is to receive the same compensation payable
to other non-executive members of the Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_079"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prof. Jagdeep Nanchahal
Consulting Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 25, 2021, we
(and CannBioRex Pharma Limited, which was added as a party to the agreement later), entered into a Consultancy Agreement dated February
22, 2021, and effective December 1, 2020, with Prof. Jagdeep Nanchahal (as amended, the &#8220;<span style="text-decoration:underline">Consulting Agreement</span>&#8221;). Prof.
Nanchahal has been providing services to us and/or our subsidiaries since 2014, was previously a greater than 5% stockholder of the Company,
and was previously the Chairman of our Clinical Advisory Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2021, we entered
into a first amendment to Consultancy Agreement with Prof. Jagdeep Nanchahal (the &#8220;<span style="text-decoration:underline">First Nanchahal Amendment</span>&#8221;), which
amended the Consultancy Agreement entered into with Prof. Nanchahal on February 25, 2021, to include CannBioRex, and an indirect wholly-owned
subsidiary of the Company, as a party thereto, and to update the prior Consultancy Agreement to provide for cash payments due to Prof.
Nanchahal to be paid by CannBioRex, for tax purposes, provide for CannBioRex to be party to certain other provisions of the agreement
and to provide for the timing of certain cash bonuses due under the terms of the agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prof. Nanchahal is a surgeon
scientist focusing on defining the molecular mechanisms of common diseases and translating his findings through to early phase clinical
trials. He undertook his Ph.D., funded by the U.K. Medical Research Council, whilst a medical student in London and led a lab group funded
by external grants throughout his surgical training. After completing fellowships in microsurgery and hand surgery in the USA and Australia,
he was appointed as a senior lecturer at Imperial College. His research is focused on promoting tissue regeneration by targeting endogenous
stem cells and reducing fibrosis. In 2013, his group identified anti-tumor necrosis factor (TNF)&#160;as therapeutic target for Dupuytren&#8217;s
Contracture, a common fibrotic condition of the hand. He previously led a Phase 2b clinical trial funded by the Wellcome Trust and Department
of Health to assess the efficacy of local administration of anti-TNF in patients with early-stage Dupuytren&#8217;s Contracture and a
clinical trial for patients with early-stage frozen shoulder. He is a proponent of evidence-based medicine and was the only plastic surgery
member of the NICE Guidance Development Groups on complex and non-complex fractures. He was a member of the group that wrote the Standards
for the Management of Open Fractures published in 2020. This is an open-source publication to facilitate the care of patients with these
severe injuries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Consulting
Agreement, Prof. Nanchahal agreed, during the term of the agreement, to serve as a consultant to us and provide such services as the
Chief Executive Officer and/or our Board shall request from time to time, including but not be limited to: (1)&#160;conducting clinical
trials in the fields of Dupuytren&#8217;s Contracture, frozen shoulder and post-operative delirium/cognitive decline; and (2)&#160;conducting
laboratory research in other fibrotic disorders, including fibrosis of the liver and lung (collectively, the &#8220;<span style="text-decoration:underline">Services</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration for providing
the Services, we (through CannBioRex Pharma Limited)&#160;agreed to pay Prof. Nanchahal 15,000 British Pounds (GBP)&#160;per month (approximately
$20,800)&#160;during the term of the agreement, increasing to GBP 23,000 (approximately $32,000)&#160;on the date (a)&#160;of publication
of the data from the phase 2b clinical trial for Dupuytren&#8217;s Contracture (RIDD)&#160;and (b)&#160;the date that we have successfully
raised over $15 million in capital. The fee will increase annually thereafter to reflect progression in other clinical trials and laboratory
research as approved by our Board. We also agreed to pay Prof. Nanchahal a bonus (&#8220;<span style="text-decoration:underline">Bonus 1</span>&#8221;)&#160;in the sum of GBP
100,000 upon submission of the Dupuytren&#8217;s Contracture clinical trial data for publication in a peer-reviewed journal, which submission
occurred in December 2021, and which bonus was paid in December 2021. In addition, for prior work performed, including completion of
the recruitment to the RIDD (Dupuytren&#8217;s)&#160;trial, we agreed to pay Prof. Nanchahal GBP 434,673 (approximately $605,000)&#160;(&#8220;<span style="text-decoration:underline">Bonus
2</span>&#8221;). At the election of Prof. Nanchahal, Bonus 2 shall be paid at least 50% (fifty percent)&#160;or more, as Prof. Nanchahal
elects, in shares of our common stock, at a share price of $1,140.00 per share, or the share price on the date of the grant, whichever
is lower, with the remainder paid in GBP. Bonus 2 shall be deemed earned and payable upon us raising a minimum of $15 million in additional
funding, through the sale of debt or equity, after December 1, 2020 (the &#8220;<span style="text-decoration:underline">Vesting Date</span>&#8221;)&#160;and shall not be accrued,
due or payable prior to such Vesting Date. Bonus 2 shall be payable by us within 30 calendar days of the Vesting Date. Finally, Prof.
Nanchahal shall receive another one-time bonus (&#8220;<span style="text-decoration:underline">Bonus 3</span>&#8221;)&#160;of GBP 5,000 (approximately $7,000)&#160;on enrollment
of the first patient to the phase 2 frozen shoulder trial, and another one-time bonus (&#8220;<span style="text-decoration:underline">Bonus 4</span>&#8221;)&#160;of GBP 5,000
(approximately $7,000)&#160;for enrollment of the first patient to the phase 2 delirium/POCD trial. On March 30, 2021, we issued Prof.
Nanchahal 265 shares of our common stock in lieu of GBP 217,337 and on April 15, 2021, we issued Prof. Nanchahal 99 shares of our common
stock in lieu of GBP 82,588. We also waived the requirement for the Company having to raise $15 million in order for Prof. Nanchahal
to agree to receive an aggregate of GBP 300,000 via the issuance of shares. Prof. Nanchahal agreed that the remaining GBP 134,673 that
is due pursuant to Bonus 2 shall be paid after we have raised a minimum of $15 million in additional funding. On August 23, 2021, at
the request of Prof. Nanchahal, we agreed to issue Prof. Nanchahal 161 shares of common stock in consideration for the remaining 31%
(or 134,749 GBP, or $184,606)&#160;of Bonus 2, based on a $1,140.00 per share price. The shares were issued under our 2020 Omnibus Incentive
Plan, which has been approved by stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective on April 27, 2022,
we and CannBioRex entered into a Second Amendment to Consulting Agreement with Prof. Jagdeep Nanchahal (the &#8220;<span style="text-decoration:underline">Second Nanchahal
Amendment</span>&#8221;). Pursuant to the Second Nanchahal Amendment, Prof. Nanchahal agreed that upon acceptance of the data for the phase
2b clinical trial for Dupuytren&#8217;s disease for publication (which occurred March 1, 2022, subject to editing and final approvals),
his monthly fee was increased to &#163;23,000, provided that &#163;4,000 of such increase shall be accrued and &#163;19,000 per month
of such fees shall be payable per our payroll practices in cash by us starting effective March 1, 2022, and until the earlier of (a)&#160;November
1, 2022 or (b)&#160;such time as our Board determines that we have sufficient cash on hand to pay such accrued amounts, which we expect
will not be until we have raised a minimum of $15,000,000 (the &#8220;<span style="text-decoration:underline">Funding Determination Date</span>&#8221;), at which time all accrued
amounts shall be due.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 28, 2022, we
and CannBioRex, entered into a Third Amendment to Consultancy Agreement with Prof. Nanchahal (the &#8220;<span style="text-decoration:underline">Third Nanchahal Amendment</span>&#8221;).
The Third Nanchahal Amendment amended the Consultancy Agreement to provide that the monthly cash fee payable to Prof. Nanchahal pursuant
to such agreement would remain at its then current rate, &#163;23,000 per month, through December 31, 2022, and then increase to &#163;35,000
per month during the term of the Consultancy Agreement from January 1, 2023, until the end of the term of the Consultancy Agreement (collectively,
the &#8220;<span style="text-decoration:underline">Fee</span>&#8221;). The Third Nanchahal Amendment also provided that the Fee will be adjusted yearly with the recommendation
of our Board or the Compensation Committee of the Company, which will consider in its determination of the amount of such increase, the
U.K. consumer price index and Prof. Nanchahal&#8217;s contributions to advancing our mission, among other things. The Third Nanchahal
Amendment also provided that in the event the Consultancy Agreement is terminated by us for any reason other than cause, Prof. Nanchahal
is entitled to a lump sum payment of 12 months of his monthly fee as of the date of termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above,
the Board or Compensation Committee of the Company may grant Prof. Nanchahal additional bonuses from time to time in their discretion,
in cash, stock or options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Consulting Agreement
has an initial term of three years, and renews thereafter for additional three-year terms, until terminated as provided in the agreement,
and currently has a term through December 1, 2026. The Consulting Agreement can be terminated by either party with 12 months prior written
notice (provided our right to terminate the agreement may only be exercised if Prof. Nanchahal fails to perform his required duties under
the Consulting Agreement), or by us immediately if (a)&#160;Prof. Nanchahal fails or neglects efficiently and diligently to perform the
Services or is guilty of any breach of his obligations under the agreement (including any consent granted under it); (b)&#160;Prof. Nanchahal
is guilty of any fraud or dishonesty or acts in a manner (whether in the performance of the Services or otherwise)&#160;which, in our
reasonable opinion, has brought or is likely to bring Prof. Nanchahal, the Company or any of its affiliates into disrepute or is convicted
of an arrestable offence (other than a road traffic offence for which a non-custodial penalty is imposed); or (c)&#160;Prof. Nanchahal
becomes bankrupt or makes any arrangement or composition with his creditors. If the Consulting Agreement is terminated by us for any
reason other than cause, Prof. Nanchahal is entitled to a lump sum payment of 12 months of his fee as at the date of termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Consulting Agreement
includes a 12 month non-compete and non-solicitation obligation of Prof. Nanchahal, preventing him from competing against us in any part
of any country in which he was actively engaged in our business, subject to certain exceptions, including research conducted at the University
of Oxford. The Consulting Agreement also includes customary confidentiality and assignment of inventions provisions, in each case subject
to our previously existing agreements with various universities, including the University of Oxford, where Prof. Nanchahal serves as
a Professor of Hand, Plastic and Reconstructive Surgery.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_080"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Payment of Back
Pay; 2021 Bonuses and Increases in Salaries</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 27, 2023, and effective
on January 1, 2023, we entered into (a)&#160;a Third Amendment to Employment Agreement with James N. Woody, M.D., Ph.D., the Chief Executive
Officer and Director of the Company; (b)&#160;a Third Amendment to Employment Agreement with Ozan Pamir, the Chief Financial Officer
of the Company; and (c)&#160;a Third Amendment to Employment Agreement with Jonathan Rothbard, Ph.D., Chief Scientific Officer of the
Company (collectively, the &#8220;<span style="text-decoration:underline">Third Amendments</span>&#8221;), which each amended the compensation agreements that were in place
with such individuals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Third Amendments reflected
(a)&#160;an increase in the salary of each of Dr. Woody, Mr. Pamir and Dr. Rothbard of 3.5%, effective as of January 1, 2023; and (b)&#160;in
the case of Mr. Pamir, a further increase in salary to $380,000 per annum and an increase in his target bonus to 40%, effective April
1, 2023, as well as a change in his title to Chief Financial Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 27, 2023, based
on the recommendation of the Compensation Committee, the Board of Directors determined discretionary bonus compensation for the year
ended December 31, 2021 for Dr. Woody ($50,000); Mr. Pamir ($22,500, which is in addition to $30,000 previously paid during 2021); and
Dr. Rothbard ($10,000). The Board of Directors also determined that no other bonuses would be paid to any executive officer of the Company
for fiscal 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective April 27, 2023,
the Board of Directors, with the recommendation of the Compensation Committee of the Board of Directors, approved the payment of $111,675
to Dr. Woody; $24,154 to Mr. Pamir; and $50,343 to Dr. Rothbard, in back pay owed to such officers. As a result, as of April 27, 2023,
no back pay was owed to Dr. Woody, Mr. Pamir or Dr. Rothbard.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_081"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">2024 Accruals</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 10, 2024, and
effective on January 1, 2024, we&#160;entered into (a) a Fourth Amendment to Amended and Restated Employment Agreement with James N.
Woody, M.D., Ph.D., the Chief Executive Officer and Director of the Company; and (b) a Fourth Amendment to Employment Agreement with
Jonathan Rothbard, Ph.D., Chief Scientific Officer of the Company (collectively, the &#8220;<span style="text-decoration:underline">Amendments</span>&#8221;), which each amended
the compensation agreements currently in place with such individuals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Amendments,
each of Dr. Woody and Dr. Rothbard, effective as of January&#160;1,&#160;2024, agreed to a reduction of the base salaries set forth in
their respective amended employment agreements, by 50%, to $245,000 per year for Dr. Woody and to $100,000 per year for Dr. Rothbard,
with the amount of such salary reductions ($20,416 per month for Dr. Woody and $8,333 per month for Dr. Rothbard), accruing monthly in
arrears, to be paid on the Funding Date, provided that in the event the Funding Date does not occur prior to March 15, 2025, the amounts
accrued will be forgiven in their entirety.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As discussed in greater detail
above, each of Dr. Woody and Dr. Rothbard have resigned from the Company and entered into separation agreements discussed in greater
detail above, pursuant to which they waived any rights to the amounts accrued pursuant to the Amendments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_082"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">2022, 2023 and
2024 Bonuses</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 29, 2024, the
Board of Directors of the Company determined that no bonuses would be granted to management for the years ended December 31, 2022 or
2023, and that no bonus amounts would be accrued for the year ended December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>




</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="a_083"></a></div><ix:nonNumeric contextRef="c0" continuedAt="_PvpTableTextBlock-c0_cont_1" escape="true" name="ecd:PvpTableTextBlock" id="ixv-5738"><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Pay Versus Performance</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This section provides disclosure
about the relationship between executive compensation actually paid to our principal executive officer (&#8220;<span style="text-decoration:underline">PEO</span>&#8221;) and
non-PEO Named Executive Officers (&#8220;<span style="text-decoration:underline">NEOs</span>&#8221;) and certain financial performance measures of the Company for the fiscal
years listed below. This disclosure has been prepared in accordance with Item 402(v) of Regulation S-K under the Exchange Act (the &#8220;<span style="text-decoration:underline">Pay
Versus Performance Rules</span>&#8221;) and does not necessarily reflect how the Compensation Committee evaluates compensation decisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Fiscal Year<sup>(1)</sup></b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-decoration: none; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><b>Summary Compensation Table Total for Blair Jordan <sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Compensation Actually Paid to Blair Jordan<sup>(3)(4)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Summary Compensation Table Total for James N. Woody <sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Compensation Actually Paid to James N. Woody<sup>(3)(4)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Average Summary Compensation Table Total for Non-PEO NEOs<sup>(5)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Average Compensation Actually Paid to Non-PEO NEOs<sup>(6)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Value of Initial Fixed $100 Investment Based on Total shareholder Return (&#8220;TSR&#8221;)<sup>(7)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Net Loss (in thousands)<sup>(8)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">(a)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(b)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(b)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(c)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(c)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(d)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(e)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(f)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(g)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td></tr> <tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 12%; text-align: left">2024</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="ecd:PeoTotalCompAmt" scale="0" unitRef="usd">140,107</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_15_fact" name="ecd:PeoActuallyPaidCompAmt" scale="0" unitRef="usd">140,107</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_4_fact" name="ecd:PeoTotalCompAmt" scale="0" unitRef="usd">100,250</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_16_fact" name="ecd:PeoActuallyPaidCompAmt" scale="0" unitRef="usd">100,250</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_5_fact" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="0" unitRef="usd">137,688</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_6_fact" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="0" unitRef="usd">137,688</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_21_fact" name="ecd:TotalShareholderRtnAmt" scale="0" unitRef="usd">0.12</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_17_fact" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">6,168</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">2023</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-2">&#8212;</span></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-3">&#8212;</span></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_7_fact" name="ecd:PeoTotalCompAmt" scale="0" unitRef="usd">656,800</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_18_fact" name="ecd:PeoActuallyPaidCompAmt" scale="0" unitRef="usd">605,147</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_8_fact" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="0" unitRef="usd">356,889</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_9_fact" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="0" unitRef="usd">351,330</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" id="ix_22_fact" name="ecd:TotalShareholderRtnAmt" scale="0" unitRef="usd">0.27</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" id="ix_10_fact" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">19,935</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">2022</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-4">&#8212;</span></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-5">&#8212;</span></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" id="ix_11_fact" name="ecd:PeoTotalCompAmt" scale="0" unitRef="usd">463,500</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="ecd:PeoActuallyPaidCompAmt" scale="0" sign="-" unitRef="usd">1,366,665</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" id="ix_12_fact" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="0" unitRef="usd">437,699</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" id="ix_20_fact" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="0" unitRef="usd">8,909</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" id="ix_23_fact" name="ecd:TotalShareholderRtnAmt" scale="0" unitRef="usd">4.35</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" id="ix_13_fact" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">38,726</ix:nonFraction></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14pt; text-indent: -14pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_NamedExecutiveOfficersFnTextBlock-c0_cont_1" escape="true" name="ecd:NamedExecutiveOfficersFnTextBlock" id="ixv-14226"><ix:footnote id="ix_0_footnote" xml:lang="en-US">The following table lists the PEO and non-PEO&#160;NEOs for each of fiscal years 2024, 2023 and 2022:</ix:footnote></ix:nonNumeric></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14pt; text-indent: -14pt">&#160;</p>

<ix:continuation id="_NamedExecutiveOfficersFnTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 7%"><span style="font-size: 10pt"><b>Year</b></span></td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 40%"><span style="font-size: 10pt"><b>PEO</b></span></td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 51%"><span style="font-size: 10pt"><b>Non-PEO NEOs</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt"><b>2024</b></span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><ix:nonNumeric contextRef="c0" name="ecd:PeoName" id="ixv-5960"><span style="font-size: 10pt">Blair Jordan and James N. Woody</span></ix:nonNumeric></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><span style="font-size: 10pt">Omar Jimenez, Ozan Pamir, Jonathan Rothbard</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt"><b>2023</b></span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><ix:nonNumeric contextRef="c6" name="ecd:PeoName" id="ixv-5971"><span style="font-size: 10pt">James N. Woody</span></ix:nonNumeric></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><span style="font-size: 10pt">Ozan Pamir, Jonathan Rothbard, and Quan Anh Vu</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt"><b>2022</b></span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><ix:nonNumeric contextRef="c9" name="ecd:PeoName" id="ixv-5982"><span style="font-size: 10pt">James N. Woody</span></ix:nonNumeric></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><span style="font-size: 10pt">Ozan Pamir, Jonathan Rothbard, and Quan Anh Vu</span></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><sup>(2)</sup></span></td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-size: 10pt">The dollar amounts reported in
column (b) are the amounts of total compensation reported for our CEOs for each corresponding year in the &#8220;Total&#8221; column
of the Summary Executive Compensation Table. Refer to &#8220;Executive and Director Compensation&#8212;Summary Executive Compensation
Table&#8221;.</span></ix:footnote></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(3)</sup></span></td> <td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-size: 10pt">The dollar amounts reported represent the amount of &#8220;compensation actually paid,&#8221; as calculated in accordance with the Pay Versus Performance Rules. These dollar amounts do not reflect the actual amounts of compensation earned by or paid to our PEOs during the applicable year. For purposes of calculating &#8220;compensation actually paid,&#8221; the fair value of equity awards is calculated in accordance with FASB ASC Topic 718 using the same assumption methodologies used to calculate the grant date fair value of awards for purposes of the Summary Compensation Table (refer to the Summary Compensation Table for additional information).</span></ix:footnote></td></tr>
</table></ix:nonNumeric><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_PvpTableTextBlock-c0_cont_2" id="_PvpTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(4)</sup></span></td> <td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US"><span style="font-size: 10pt">The following table shows the amounts deducted from and added to the Summary Compensation Table total to calculate &#8220;compensation actually paid&#8221; to our PEOs in accordance with the Pay Versus Performance Rules:</span></ix:footnote></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Blair Jordan</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Reported Summary Compensation<br/> Table Total for PEO</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Reported Value<br/> of Equity Awards (A)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity Award<br/> Adjustments (B)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Compensation<br/> Actually Paid to PEO</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 19%; text-align: left">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-14228">140,107</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-6">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-7">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-14229">140,107</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">James N. Woody</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Reported Summary Compensation<br/> Table Total for PEO</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Reported Value<br/> of Equity Awards (A)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity Award<br/> Adjustments (B)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Compensation<br/> Actually Paid to PEO</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 19%; text-align: left">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-14230">100,250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-8">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-9">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-14231">100,250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-14232">656,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" id="ix_14_fact" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd">39,025</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-10">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-14234">605,147</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-14235">463,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-11">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd">1,830,165</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-14237">1,366,665</ix:nonFraction></td><td style="text-align: left">)</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">(A)</span></td> <td style="text-align: justify"><ix:footnote id="ix_4_footnote" xml:lang="en-US"><span style="font-size: 10pt">The grant date fair value of equity awards represents the sum of the totals of the amounts reported in the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; columns in the Summary Executive Compensation Table for the applicable year.</span></ix:footnote></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">(B)</span></td> <td style="text-align: justify"><ix:footnote id="ix_5_footnote" xml:lang="en-US"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c0" escape="true" name="ecd:EqtyAwrdsAdjFnTextBlock" id="ixv-14238">The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards that are granted and vest in same applicable year, the fair value as of the vesting date; (iv) for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v) for awards granted in prior years that are determined to fail to meet the applicable vesting conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi) the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable year. The amounts deducted or added in calculating the equity award adjustments are as follows</ix:nonNumeric>:</span></ix:footnote></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">Blair Jordan</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; width: 17%; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Year</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year End Fair Value of<br/> Outstanding<br/> and Unvested<br/> Equity Awards<br/> Granted in<br/> Year</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year over Year<br/> Change in Fair Value of<br/> Outstanding<br/> and Unvested<br/> Equity Awards<br/> Granted in<br/> Prior Years</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Fair Value<br/> as of<br/> Vesting<br/> Date of<br/> Equity<br/> Awards<br/> Granted<br/> and<br/> Vested in<br/> the Year</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year over Year<br/> Change in<br/> Fair Value of<br/> Equity Awards Granted in Prior Years that Vested<br/> in&#160;the Year</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Fair Value<br/> at the End of<br/> the Prior<br/> Year of Equity<br/> Awards that<br/> Failed to Meet<br/> Vesting<br/> Conditions in<br/> the Year</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Value of<br/> Dividends or<br/> other<br/> Earnings Paid<br/> on Stock or<br/> Option Awards not<br/> Otherwise<br/> Reflected in<br/> Fair Value or<br/> Total<br/> Compensation</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; width: 1%; font-weight: bold">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 9%">Total Equity Award Adjustments</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-12">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-13">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-14">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-15">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-16">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-17">&#8212;</span></td><td style="text-align: left">&#160;</td><td>$</td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-18">&#8212;</span></td></tr> </table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation id="_PvpTableTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">James N. Woody</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year End Fair Value of<br/> Outstanding<br/> and Unvested<br/> Equity Awards<br/> Granted in<br/> Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year over Year<br/> Change in Fair Value of<br/> Outstanding<br/> and Unvested<br/> Equity Awards<br/> Granted in<br/> Prior Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value<br/> as of<br/> Vesting<br/> Date of<br/> Equity<br/> Awards<br/> Granted<br/> and<br/> Vested in<br/> the Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year over Year<br/> Change in<br/> Fair Value of<br/> Equity Awards Granted in Prior Years that Vested<br/> in&#160;the Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value<br/> at the End of<br/> the Prior<br/> Year of Equity<br/> Awards that<br/> Failed to Meet<br/> Vesting<br/> Conditions in<br/> the Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value of<br/> Dividends or<br/> other<br/> Earnings Paid<br/> on Stock or<br/> Option Awards not<br/> Otherwise<br/> Reflected in<br/> Fair Value or<br/> Total<br/> Compensation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Equity<br/> Award<br/> Adjustments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-19">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-20">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-21">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-22">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-23">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-24">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-25">&#8212;</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 16%; text-align: left">2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-14239">8,596</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-14240">8,108</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-14241">18,445</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-14242">31,561</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-26">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-27">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-14243">12,628</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-14244">40,138</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-14245">1,426,068</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-14246">406,256</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-14247">850,492</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-28">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-1">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-14248">1,830,165</ix:nonFraction></td><td style="text-align: left">)</td></tr> </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(5)</sup></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><ix:footnote id="ix_6_footnote" xml:lang="en-US">The dollar amounts reported in column (d) represent the average of the amounts reported for our company&#8217;s Non-PEO NEOs as a group in the &#8220;Total&#8221; column of the Summary Executive Compensation Table in each applicable year.</ix:footnote> </span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(6)</sup></span></td> <td style="text-align: justify"><ix:footnote id="ix_7_footnote" xml:lang="en-US"><span style="font-size: 10pt">The dollar amounts reported in column (e) represent the average amount of &#8220;compensation actually paid&#8221; to the Non-PEO NEOs as a group, as computed in accordance with the Pay Versus Performance Rules. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the Non-PEO NEOs as a group during the applicable year. In accordance with the Pay Versus Performance Rules, the following adjustments were made to average total compensation for the Non-PEO NEOs for each year to determine the compensation actually paid, using the same methodology described above in Note (4)(B):</span></ix:footnote></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Reported<br/> Summary<br/> Compensation<br/> Table Total<br/> for Non-PEO NEOs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Reported<br/> Value of Equity<br/> Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Average Equity<br/> Award Adjustments&#160;<sup>(a)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average<br/> Compensation<br/> Actually Paid<br/> to Non-PEO NEOs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: left">2024</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="0" unitRef="usd" id="ixv-14250">137,688</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-29">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-30">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="0" unitRef="usd" id="ixv-14251">137,688</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="0" unitRef="usd" id="ixv-14252">356,889</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-14253">2,602</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" id="ix_19_fact" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd">2,957</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="0" unitRef="usd" id="ixv-14255">351,330</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="0" unitRef="usd" id="ixv-14256">437,699</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-31">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" id="ix_2_fact" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd">428,790</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="0" unitRef="usd" id="ixv-14258">8,909</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(a)</sup></span></td> <td style="text-align: justify"><ix:footnote id="ix_8_footnote" xml:lang="en-US"><span style="font-size: 10pt">The amounts deducted or added in calculating the total average equity award adjustments are as follows:</span></ix:footnote></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Year<br/> End Fair<br/> Value of<br/> Outstanding<br/> and Unvested<br/> Equity Awards<br/> Granted in the Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year over Year<br/> Average Change in Fair Value of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding<br/> and Unvested<br/> Equity Awards<br/> Granted in<br/> Prior Years</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Fair<br/> Value as of<br/> Vesting Date of Equity<br/> Awards Granted and<br/> Vested in the<br/> Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year over<br/> Year Average Change<br/> in Fair Value of Equity<br/> Awards Granted in Prior Years<br/> that Vested<br/> in the Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Fair Value at the End of the<br/> Prior Year of<br/> Equity Awards<br/> that Failed to Meet Vesting<br/> Conditions in<br/> the Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Average Value of Dividends<br/> or other Earnings<br/> Paid on Stock<br/> or Option</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Awards not</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Otherwise Reflected in<br/> Fair Value<br/> or Total Compensation</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Average Equity<br/> Award<br/> Adjustments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-32">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-33">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-34">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-35">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-36">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-37">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-38">&#8212;</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 12%; text-align: left">2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-14259">859</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(<ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-14260">1,304</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-14261">3,612</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-14262">6,124</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-39">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-40">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-14263">2,957</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-14264">11,774</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-14265">367,087</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-14266">81,450</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-14267">154,927</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-41">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-42">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-14268">428,790</ix:nonFraction></td><td style="text-align: left">)</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(7)</sup></span></td> <td style="text-align: justify"><ix:footnote id="ix_9_footnote" xml:lang="en-US"><span style="font-size: 10pt">Assumes $100 invested in our common shares on December 31, 2021, and calculated based on the difference between the share price of our common stock at the end and the beginning of the measurement period, and reinvestment of all dividends. No cash dividends were paid in 2022, 2023 or 2024.</span></ix:footnote></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(8)</sup></span></td> <td style="text-align: justify"><ix:footnote id="ix_10_footnote" xml:lang="en-US"><span style="font-size: 10pt">The dollar amounts reported represent the amount of net loss reflected in our consolidated audited financial statements for the applicable year.</span></ix:footnote></td></tr> </table></ix:continuation><div>
</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>




</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="a_084"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Relationship Between
&#8220;Compensation Actually Paid&#8221; and Performance</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generally seek to incentivize
long-term performance, and therefore do not specifically align our performance measures with &#8220;compensation actually paid&#8221;
(as computed in accordance with Pay Versus Performance Rules) for a particular year. In accordance with the Pay Versus Performance Rules,
we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance table.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><div><a id="a_085"></a></div><ix:nonNumeric contextRef="c0" escape="true" name="ecd:CompActuallyPaidVsNetIncomeTextBlock" id="ixv-6825"><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation Actually
Paid and Net Loss</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our company has not historically
looked to net loss as a performance measure for our executive compensation program. Our net loss was $38.7 million in 2022, $19.9 million
in 2023 and $6.17 in 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_002.jpg"/></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_086"></a></div><ix:nonNumeric contextRef="c0" continuedAt="_CompActuallyPaidVsTotalShareholderRtnTextBlock-c0_cont_1" escape="true" name="ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock" id="ixv-6838"><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation Actually
Paid and Cumulative TSR</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As shown in the following
graph, the compensation actually paid to our PEOs and the average amount of compensation actually paid to our non-PEO NEOs as a group
during the periods presented do have some correlation because a portion of their compensation has historically been in the form of long-term
equity awards. The equity awards values are significantly impacted by changes in our stock price each period. These equity awards strongly
align our executive officers&#8217; interests with those of our stockholders by providing a continuing financial incentive to maximize
long-term value for our stockholders and by encouraging our executive officers to continue in our employment for the long-term.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><ix:continuation id="_CompActuallyPaidVsTotalShareholderRtnTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_003.jpg"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>All information provided
above under the &#8220;Pay Versus Performance&#8221; and &#8220;Relationship Between &#8220;Compensation Actually Paid&#8221; and Performance&#8221;,
headings will not be deemed to be incorporated by reference in any filing of our company under the Securities Act, whether made before
or after the date hereof and irrespective of any general incorporation language in any such filing.</i></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;&#160;</i></p><div>

</div><div><a id="a_087"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Outstanding Equity
Awards at Fiscal Year End</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no outstanding
equity awards held by Named Executive Officers as of December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_088"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Potential Payments
Upon Termination</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Jordan Consulting
Agreement, discussed above under &#8220;Current Compensation Arrangements&#8212;Jordan Consulting
Agreement&#8221; between the Company, Blair Jordan, the Chief Executive Officer of the Company, and Jordan Consulting, if the agreement
is terminated by Jordan Consulting for &#8220;<span style="text-decoration:underline">good reason</span>&#8221;, or by the Company without &#8220;<span style="text-decoration:underline">just cause</span>&#8221; (other
than due to death or disability), Jordan Consulting is required to be paid, in a lump sum on the tenth day following such termination,
a severance payment equal to: (i) two times the then current annualized Fee, together with all outstanding expenses and pro-rated Fee
(through the date of termination); (ii) any unvested equity grant (including but not limited to options, restricted shares, RSUs and other
equity incentives) will vest immediate; and (iii) two times any unpaid annual cash bonus in respect of any completed or partial fiscal
year that has ended prior to the date of such termination with such amount determined based on actual performance during such fiscal year
(and/or partial year, as the case may be) as determined by the compensation committee, which in any case shall be no less than 50% of
the Fee before being multiplied by 2; and (iv) immediate vesting of any and all equity or equity-related awards. Any equity awards that
vest based on various performance metrics will be vested only if such performance metrics have been met at the time of termination of
service and will be determined solely by the Compensation Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Jordan Consulting Agreement
is terminated without &#8220;<span style="text-decoration:underline">good reason</span>&#8221; by Jordan Consulting or for &#8220;<span style="text-decoration:underline">just cause</span>&#8221; by the Company, Jordan
Consulting is entitled to the Accrued Liabilities (as defined above), and any equity awards or equity-related awards that are not vested
as of the date of termination will be cancelled and forfeited and any vested awards will be exercisable pursuant to their terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><!-- Field: Split-Segment; Name: 002 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Jordan Consulting Agreement
is terminated due to Mr. Jordan&#8217;s death or disability, Jordan Consulting or Mr. Jordan&#8217;s estate or his beneficiaries, as the
case may be, will be entitled to receive (i) the Accrued Liabilities; (ii) any unpaid annual cash bonus in respect of any completed fiscal
year that has ended prior to the date of such termination, with such amount determined based on actual performance during such fiscal
year as determined by the Company&#8217;s Compensation Committee on the sixtieth day following termination; (iii) a lump sum payment of
any non-discretionary annual cash bonus that would have been payable based on actual performance with respect to the year of termination
in the absence of Mr. Jordan&#8217;s death or disability, pro-rated for the period that Mr. Jordan worked prior to his death or disability,
and payable at the same time as the bonus would have been paid in the absence of Mr. Jordan&#8217;s death or disability; and (iv) immediate
vesting of any and all equity or equity-related awards previously awarded to Jordan Consulting, irrespective of the type of award. As
a condition precedent to payment of any amount or provision of any benefit to Mr. Jordan upon termination, Jordan Consulting and Mr. Jordan
or Mr. Jordan&#8217;s estate, as applicable, shall execute and shall not rescind, a release in favor of the Company and all related companies,
individuals, and entities, in a form satisfactory to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon termination of the Jordan
Consulting Agreement or for any reason other than &#8220;<span style="text-decoration:underline">good reason</span>&#8221; by Jordan Consulting or the Company without &#8220;<span style="text-decoration:underline">just
cause</span>&#8221;, Jordan Consulting and Mr. Jordan agreed that, for a period ending six months from the date of termination, Jordan Consulting
and Mr. Jordan shall not (except on behalf of the Company or with the prior written consent of the Company), directly or indirectly, compete
with the Company for a period of one year, neither Mr. Jordan, nor Jordan Consulting shall solicit employees or consultants of the Company,
each as discussed in greater detail in the Jordan Consulting Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the EVL Consulting
Agreement, discussed above under &#8220;Current Compensation Arrangements&#8212;EVL Consulting Agreement&#8221;,
which is between the Company, Eric R. Van Lent, the Company&#8217;s Chief Accounting Officer, and EVL Consulting, respectively, the Company
has the right to terminate the EVL Consulting Agreement at any time, provided that we pay EVL Consulting $10,000 upon such termination,
payable within 60 days of such termination date.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><div><a id="a_089"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Director Compensation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth compensation information with respect to our non-employee directors during our fiscal year ended December 31, 2024 (director compensation
paid to our employee directors, if any, are included in the Summary Executive Compensation Table, above):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Name</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fees<br/>
    earned or<br/>
    paid in<br/>
    cash<br/>
    ($)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock<br/>
    awards<br/>
    ($)<sup>(5)</sup></b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/>
    Awards<br/>
    ($)<sup>(5)</sup></b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">All other<br/>
    compensation<br/>
    ($)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total<br/>
    ($)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Lawrence Steinman</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan Smith<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48,334</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jay Goodman<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen H. Shoemaker<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sir Marc Feldmann, Ph.D.<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">130,062</td><td style="text-align: left">&#160;<sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">130,062</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>*</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The table above does not include the amount of any expense reimbursements
    paid to the above directors. No directors received any Non-Equity Incentive Plan Compensation or Nonqualified Deferred Compensation.
    Does not include perquisites and other personal benefits, or property, unless the aggregate amount of such compensation is more than
    $10,000.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Appointed
                                            as a member of the Board of Directors on March 7, 2024.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Appointed
                                            as a member of the Board of Directors on October 24, 2024 and resigned effective on June
                                            13, 2025.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Appointed
                                            as a member of the Board of Directors on December 3, 2024.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Resigned
                                            as a member of the Board of Directors on March 7, 2024. Includes the fair value of 57,328
                                            shares of common stock and options to purchase 20,000 shares of common stock with an exercise
                                            price of $1.95 per share, issued pursuant to a settlement agreement, valued as set forth
                                            in footnote (5), below.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Represents
                                            the aggregate grant date fair value of the award computed in accordance with the provisions
                                            of Financial Accounting Standards Board (FASB)&#160;Accounting Standards Codification (ASC)&#160;Topic
                                            718. The assumptions used in calculating the aggregate grant date fair value of the awards
                                            reported in this column are set forth in our Consolidated Financial Statements. The values
                                            provided for these awards are based on applicable accounting standards and do not necessarily
                                            reflect the actual amounts realized or realizable.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective February 28, 2024,
March 7, 2024, March 7, 2024, October 24, 2024 and December 3, 2024, the Board of Directors of the Company appointed Blair Jordan, Omar
Jimenez, Ryan L. Smith, Jay Goodman and Stephen H. Shoemaker (collectively, the &#8220;<span style="text-decoration:underline">Appointees</span>&#8221; and the &#8220;<span style="text-decoration:underline">Appointments</span>&#8221;)
as members of the Board of Directors (&#8220;<span style="text-decoration:underline">Board</span>&#8221;), which Appointments were effective as of the same dates.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with Messrs.
Jordan&#8217;s, Jimenez&#8217;s, Smith&#8217;s, Goodman&#8217;s and Shoemaker&#8217;s appointments to the Board and on February 24, 2024,
March 4, 2024, March 5, 2024, October 25, 2024, and December 2, 2024, respectively, to be effective upon each of their appointments to
the Board, the Company entered into an offer letter with each of Messrs. Jordan, Jimenez, Smith, Goodman and Shoemaker (collectively,
the &#8220;<span style="text-decoration:underline">Offer Letters</span>&#8221;). The Offer Letters provide for each of Messrs. Jordan, Jimenez and Smith to be paid $40,000 per
year as an annual retainer fee for serving on the Board (which amounts were subsequently increased to $50,000 by the Board) and Mr. Goodman
and Mr. Shoemaker to be paid $50,000 per year as an annual retainer fee for serving on the Board; Mr. Jordan was to be paid $10,000 per
year for serving as the Chairman of the then Strategic and Alternatives Committee, and $15,000 per year for serving as the then Lead
Director; Mr. Jimenez was to be paid $10,000 per year for serving as the Chairman of the Audit Committee; Mr. Smith was to be paid $10,000
per year for serving as the Chairman of the Compensation Committee and Nominating and Corporate Governance Committee; and Mr. Goodman
was to be paid $15,000 per year for serving as the Chairman of the Compensation Committee. The Company agreed to pay each of Messrs.
Jordan, Jimenez, Smith, Goodman and Shoemaker in connection with their appointment to the Board, quarterly in arrears, and pro-rated
for partial quarters. Mr. Jordan was paid an initial fee of $7,500. Messrs. Jimenez, Smith, Goodman and Shoemaker have the option of
receiving half of their compensation in cash and half of their compensation in stock, or alternatively receiving all of their compensation
in cash. Subsequently, Mr. Jordan stepped down as Lead Independent Director upon his appointment as Interim Chief Executive Officer and
Mr. Jimenez stepped down as a member of the Audit Committee in connection with his appointment as Chief Financial Officer (which position
he has since resigned), and in connection therewith, Mr. Jordan&#8217;s Offer Letter, Mr. Jimenez&#8217;s Offer Letter and Mr. Goodman&#8217;s
Offer Letter, were terminated, effective October 24, 2024, December 2, 2024, and June 13, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_090"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Board of Director
Fees</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective on May 7, 2024,
the Board of Directors set the compensation payable to non-executive members of the Board of Directors for services on the Board of Directors,
at (a) $50,000 per year for service on the Board; (b) $15,000 for each Chairperson of a committee of the Board of Directors (provided
that only one additional $15,000 payment shall be made even if the Director chairs multiple committees); and $25,000 additional for each
member of the Strategy and Alternatives, Risk, Safety and Regulatory Committee (formerly the Strategy and Alternatives Committee) of
the Board of Directors, provided that on October 24, 2024, the Board of Directors determined that members of, and the Chairman of, the
Strategy and Alternatives, Risk, Safety and Regulatory Committee would not receive any compensation for their services on such committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">On February 4, 2025, the
Board of Directors of the Company appointed independent director Ryan Smith, as Lead Independent Director of the Company, and agreed
to pay Mr. Smith an additional $20,000 per year for his services in such role.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective February 20, 2025,
the Board of Directors, with the recommendation of the Compensation Committee of the Board of Directors, approved the grant of 65,000
shares of Restricted Common Stock to each of the then non-executive members of the Board of Directors, i.e., Mr. Smith, Mr. Goodman,
Dr. Steinman and Mr. Shoemaker, as long-term incentive plan compensation, for services to be rendered to the Company as non-executive
directors and committee members, as applicable, for 2025, with such shares subject to vesting, if at all, at the rate of 1/2 of such
shares on each of July 1, 2025 and December 31, 2025, subject to each holder&#8217;s continued service with the Company on such vesting
dates, and subject to the terms of a Notice of Restricted Stock Grant and Restricted Stock Grant Agreement entered into between the Company
and each of the non-executive directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_091"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Release Agreement</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 12, 2025, Mr. Jay
Goodman resigned as a member of the Board of Directors, of the Company effective on June 13, 2025, and entered into a Release Agreement
with the Company dated June 12, 2025 (the &#8220;<span style="text-decoration:underline">Release Agreement</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Release Agreement,
the Company paid Mr. Goodman (a) $7,583.33 which was due as of the date of the Release Agreement in consideration for Board of Directors
services rendered; (b)&#160;$36,750 representing the Board of Directors fees he would have received had he remained as a member of the
Board of Directors through December 31, 2025; and (c) an additional payment of $54,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Release Agreement,
Mr. Goodman agreed to provide a customary general release to the Company, and also agreed to certain confidentiality, non-disclosure,
non-solicitation, non-disparagement, and cooperation covenants in favor of the Company. Mr. Goodman also confirmed that the 65,000 shares
of common stock which he held which were subject to vesting and forfeiture were forfeited in connection with his resignation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Accelerated Vesting of February 2025 RSU
Awards</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective June 17, 2025,
the Board of Directors of the Company, with the recommendation of the Compensation Committee of the Board of Directors, approved the
accelerated vesting of 160,000 shares of restricted common stock originally issued to Blair Jordan, the Company&#8217;s Chief Executive
Officer, in February 2025, which were to vest at the rate of 1/2 of such shares on each of January 1, 2026 and December 31, 2026, subject
to Mr. Jordan&#8217;s continued service to the Company, and instead provided for such shares to vest in full as of June 17, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also effective June 17,
2025, the Board of Directors of the Company, with the recommendation of the Compensation Committee of the Board of Directors, approved
the accelerated vesting of 65,000 shares of Restricted Common Stock held by each of Stephen H. Shoemaker, Dr. Lawrence Steinman and Ryan
Smith, each non-executive members of the Board of Directors, which were to vest at the rate of 1/2 of such shares on each of July 1,
2025 and December 31, 2025, subject to such persons continued service to the Company and provided instead for such shares to vest in
full as of June 17, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">June 2025 Option Grants</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective June 17, 2025,
the Board of Directors of the Company, with the recommendation of the Compensation Committee of the Board of Directors, approved the
grant of stock options to certain individuals, including awards to the following named executive officers: (a)&#160;Blair Jordan, the
Chief Executive Officer of the Company (options to purchase 410,000 shares); and (b)&#160;Eric R. Van Lent, the Chief Accounting Officer
of the Company (options to purchase 25,000 shares), each in consideration for services rendered and to be rendered to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also effective June 17,
2025, the Board of Directors of the Company, with the recommendation of the Compensation Committee of the Board of Directors, approved
the grant of stock options to the non-executive members of the Board of Directors as follows: Ryan Smith, Lead Director, options to purchase
255,000 shares of common stock; Stephen H. Shoemaker, director, options to purchase 165,000 shares of common stock; and Dr. Lawrence
Steinman, director, options to purchase 110,000 shares of common stock, each in consideration for services rendered and to be rendered
to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The options were granted
under the 2025 Option Incentive Plan (the &#8220;<span style="text-decoration:underline">2025 Plan</span>&#8221;) and have a term of ten years, subject in all cases to the terms
and conditions of the 2025 Plan and the award agreements to be entered into to evidence such grants, and each officer&#8217;s continued
service with the Company. The options vest at the rate of 1/2 of such options on each of the six and twelve month anniversaries of the
grant date. The options have an exercise price of $0.9290 per share, the closing sales price of the Company&#8217;s common stock on the
Nasdaq Capital market on June 17, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">June 2025 Restricted Stock Awards</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 17, 2025, the Company
issued, after recommendation by the Compensation Committee of the Company&#8217;s Board of Directors and approval by the Board of Directors,
179,646 shares of restricted common stock to Blair Jordan, Chief Executive Officer of the Company and 8,763 shares of restricted common
stock to Eric R. Van Lent, Chief Accounting Officer of the Company, which vest at the rate of 1/2 of such shares on each of the six and
twelve month anniversaries of the grant date, subject to such persons continued service to the Company on the applicable vesting dates.
The grants are evidenced by Notice of Restricted Stock Grants and Restricted Stock Grant Agreements entered into between the Company
and each recipient. The grants were made under, and subject to the terms of, the Company&#8217;s Third Amended and Restated 2022 Omnibus
Incentive Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also effective on June 17,
2025, the Company issued, after recommendation by the Compensation Committee of the Company&#8217;s Board of Directors and approval by
the Board of Directors, 109,541 shares of restricted common stock to Ryan Smith, Lead Director, 72,297 shares of restricted common stock
to Stephen H. Shoemaker, director, and 48,198 shares of common stock to Dr. Lawrence Steinman, director, which vest at the rate of 1/2
of such shares on each of the six and twelve month anniversaries of the grant date, subject to such persons continued service to the
Company on the applicable vesting dates. The grants were evidenced by Notice of Restricted Stock Grants and Restricted Stock Grant Agreements
entered into between the Company and each recipient. The grants were made under, and subject to the terms of, the 2022 Plan.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_092"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Equity Compensation
Plan Information</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth information, as of December 31, 2024, with respect to our compensation plans under which common stock is authorized for issuance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Plan Category</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> securities<br/> to be<br/>
    issued upon<br/> exercise of<br/> outstanding<br/> options,<br/> warrants and<br/> rights<br/> (A)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> average<br/> exercise<br/>
    price of<br/> outstanding<br/> options,<br/> warrants and<br/> rights<br/> (B)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> securities<br/> remaining<br/>
    available for<br/> future&#160;issuance<br/> under equity<br/> compensation<br/> plans (excluding<br/> securities<br/> reflected in<br/>
    Column&#160;A)<br/> (C)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Equity compensation plans approved by stockholders<sup>(1)</sup>&#160;</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21,629</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">28.25</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">800,097</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Equity compensation plans not approved by stockholders<sup>(2)</sup>&#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">167</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">2,007.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">21,796</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">800,097</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Options
                                            granted and awards available for future issuance under the 2020 OIP (defined below)&#160;and
                                            2022 OIP (defined below), each discussed below.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">This
                                            relates to five-year warrants granted on March 12, 2021, for the purchase of 167 shares of
                                            our common stock at an exercise price of $2,007.00 held by Alliance Global Partners.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><div><a id="a_093"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2020 Omnibus Incentive
Plan</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have reserved 9,784 shares
of our common stock for grant under our 2020 Omnibus Incentive Plan (&#8220;<span style="text-decoration:underline">2020 OIP</span>&#8221;), of which&#160;6,935&#160;shares
are available for future awards as of the Record Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of the 2020 OIP
is to promote the interests of the Company and its subsidiaries and its stockholders by (i)&#160;attracting and retaining directors,
executive officers, employees and consultants of outstanding ability; (ii)&#160;motivating such individuals by means of performance-related
incentives to achieve the longer-range performance goals of the Company and its subsidiaries; and (iii)&#160;enabling such individuals
to participate in the long-term growth and financial success of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Awards under the 2020 OIP
may be made in the form of performance awards, restricted stock, restricted stock units, stock options, which may be either incentive
stock options or non-qualified stock options, stock appreciation rights, other stock-based awards and dividend equivalents. Awards are
generally non-transferable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_094"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2022 Omnibus Incentive
Plan</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have reserved 1,000,000
shares of our Common Stock for grant under our 2022 Omnibus Incentive Plan, as amended and restated (&#8220;<span style="text-decoration:underline">2022 OIP</span>&#8221;),
of which&#160;363,162&#160;shares are available for future awards as of the Record Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of the 2022 OIP
is to promote the interests of the Company and its subsidiaries and its stockholders by (i)&#160;attracting and retaining directors,
executive officers, employees and consultants of outstanding ability; (ii)&#160;motivating such individuals by means of performance-related
incentives to achieve the longer-range performance goals of the Company and its subsidiaries; and (iii)&#160;enabling such individuals
to participate in the long-term growth and financial success of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Awards under the 2022 OIP
may be made in the form of performance awards, restricted stock, restricted stock units, stock options, which may be either incentive
stock options or non-qualified stock options, stock appreciation rights, other stock-based awards and dividend equivalents. Awards are
generally non-transferable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2025 Option Incentive Plan</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 17, 2025, the Board
of Directors of the Company, with the recommendation of the Compensation Committee of the Board of Directors, adopted the Company&#8217;s
2025 Option Incentive Plan. Notwithstanding such adoption, in accordance with the rules of the Nasdaq Capital Market, following the date
of adoption, but prior to the Shareholder Approval Date (as defined below), (i) no stock options granted thereunder can be exercised,
and (ii) if Shareholder Approval (as defined below) is not received, the 2025 Plan is to be unwound, and the outstanding stock options
granted thereunder cancelled (the &#8220;<span style="text-decoration:underline">Nasdaq Pre-Approval Requirements</span>&#8221;). As discussed above, the 2025 Plan was approved
by the Board of Directors, but has not yet been approved by the Company&#8217;s stockholders, in accordance with the rules of The Nasdaq
Capital Market, which allow the Company to adopt an equity arrangement and grant options thereunder prior to obtaining stockholder approval,
provided that (i) no options can be exercised prior to obtaining stockholder approval, and (ii) the plan can be unwound, and the outstanding
options cancelled, if stockholder approval is not obtained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholder approval of the
2025 Plan is to be obtained in accordance with the Company&#8217;s Second Amended and Restated Certificate of Incorporation and Second
Amended and Restated Bylaws, each as amended and applicable laws, within twelve (12) months of the date of adoption (the &#8220;<span style="text-decoration:underline">Shareholder
Approval</span>&#8221; and the date of such Shareholder Approval, the &#8220;<span style="text-decoration:underline">Shareholder Approval Date</span>&#8221;). Additionally, the
grant of incentive stock options under the 2025 Plan is subject to Shareholder Approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Plan provides an opportunity
for any employee, officer, director or consultant of the Company, subject to the terms of the 2025 Plan (including as discussed above
and any limitations provided by federal or state securities laws), to receive (i) incentive stock options (to eligible employees only);
or (ii) nonqualified stock options. Incentive stock options granted under the 2025 Plan are intended to qualify as &#8220;<span style="text-decoration:underline">incentive
stock options</span>&#8221; within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended. Nonqualified (non-statutory
stock options) granted under the 2025 Plan are not intended to qualify as incentive stock options under the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A total of 1,000,000 shares
of common stock are reserved for awards under the 2025 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_095"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Certain Relationships
and Related Party Transactions</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as discussed below
or otherwise disclosed above under &#8220;Executive and Director Compensation&#8221;, beginning on page&#160;27, which information is
incorporated into this &#8220;Certain Relationships and Related Party Transactions&#8221;, by reference, there have been no transactions
over the last two fiscal&#160;years, and there is not currently any proposed transaction, in which the Company was or is to be a participant,
where the amount involved exceeds the lesser of (a)&#160;$120,000 or (b)&#160;one percent of the Company&#8217;s total assets at year-end&#160;for
the last two completed fiscal&#160;years, and in which any officer, director, or any stockholder owning greater than five percent (5%)&#160;of
our outstanding voting shares, nor any member of the above referenced individual&#8217;s immediate family, had or will have a direct
or indirect material interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_096"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Related Party Agreements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_097"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Service Agreement
with Prof. Sir Marc Feldmann</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>See &#8220;Service Agreement
with Prof. Sir Marc Feldmann (former Co-Executive Chairman)&#8221; under &#8220;Description of Material Consulting Agreements&#8221;,&#160;</i>in
the section entitled&#160;<i>&#8220;Executive and Director Compensation&#8221;, above.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_098"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prof. Jagdeep Nanchahal
Consulting Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;<i>Prof. Jagdeep
Nanchahal Consulting Agreement</i>&#8221; under &#8220;<i>Description of Material Consulting Agreements</i>&#8221;, in the section entitled
&#8220;<i>Executive and Director Compensation</i>&#8221;, above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_099"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prof. Lawrence Steinman
Consultancy Agreement and Consulting Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;<i>Consultancy
Agreement with Prof. Lawrence Steinman</i>&#8221; and &#8220;<i>Lawrence Steinman, M.D.&#160;Consulting Agreement</i>&#8221; under &#8220;<i>Description
of Material Consulting Agreements</i>&#8221;, in the section entitled &#8220;<i>Executive and Director Compensation</i>&#8221;, above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_100"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jordan Consulting
Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;<i>Jordan Consulting
Agreement</i>&#8221; under &#8220;<i>Current Compensation Agreements</i>&#8221;, in the section entitled &#8220;<i>Executive and Director
Compensation</i>&#8221;, above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><div><a id="a_101"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">EVL Consulting Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;<i>EVL Consulting
Agreement</i>&#8221; under &#8220;<i>Current Compensation Agreements</i>&#8221;, in the section entitled &#8220;<i>Executive and Director
Compensation</i>&#8221;, above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_102"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Voting Agreements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 7, 2024, Dr. James
N. Woody resigned as Chief Executive Officer of the Company and entered into a Separation and Release Agreement with the Company. Under
the Separation Agreement, the Company agreed to (a) pay Dr. Woody $50,000 in cash, less all applicable withholdings and required deductions;
(b)&#160;issue Dr. Woody 25,000 fully-vested shares of the Company&#8217;s common stock; and (c) provide Dr. Woody the right to earn
an additional $50,000 in the event we complete a change of control transaction (the &#8220;<span style="text-decoration:underline">Change of Control Bonus</span>&#8221;) within
24 months of the resignation date or we raise at least $5 million within 12 months from the resignation date, the total fair value of
which is included above in &#8220;All Other Compensation&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 5, 2025, we entered
into a First Amendment to Separation and Release Agreement with Dr. Woody (the &#8220;<span style="text-decoration:underline">First Amendment</span>&#8221;). Pursuant to the
First Amendment, Dr. Woody and the Company agreed to amend the terms of the May 7, 2024 Separation and Release Agreement, to terminate
the Change of Control Bonus and for the Company to instead issue Dr. Woody $60,000 in shares of restricted common stock of the Company
(or 43,166 shares of common stock, based on the closing sales price of the Company&#8217;s common stock on February 5, 2025, which closing
price was $1.39 per share, the &#8220;<span style="text-decoration:underline">Separation Shares</span>&#8221;). The Separation Shares include piggyback registration rights for
a resale registration statement relative to the Separation Shares for a period of six (6) months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The First Amendment also
required Dr. Woody to enter into a Voting Agreement with the Company. Pursuant to the Voting Agreement, which was entered into on February
5, 2025, by Dr. Woody, the Company, and Blair Jordan, the Company&#8217;s Chief Executive Officer, solely for the benefit of the Company,
Dr. Woody agreed to vote the Separation Shares as recommended by the Board of Directors of the Company, at any meeting of stockholders
or via any written consent of stockholders, which may occur prior to February 5, 2026; the date after August 5, 2025, that Dr. Woody
has sold all of the Separation Shares; or the date that the Company terminates the Voting Agreement. In order to enforce the terms of
the Voting Agreement, and solely for the benefit of the Company, Dr. Woody provided Mr. Jordan (or his assigns) an irrevocable voting
proxy to vote the Separation Shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent
of stockholders. The Voting Agreement also provides a restriction on Dr. Woody&#8217;s sale or transfer of any of the Separation Shares
until August 5, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 21, 2025, as
a required condition to the entry into a Mutual Settlement and General Release Agreement with&#160;Dr. Marlene Krauss (&#8220;<span style="text-decoration:underline">Dr.
Krauss</span>&#8221;), the former Chief Executive Officer and director of KBL Merger Corp. IV, the Company&#8217;s predecessor, and KBL
IV Sponsor, LLC, the Company&#8217;s former sponsor,&#160;the Company, Mr. Jordan and Dr. Krauss, entered into a Voting Agreement, whereby
Dr. Krauss agreed to vote a total of 200,000 shares of the Company&#8217;s common stock, as recommended by the Board of Directors of
the Company, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to August 21, 2025. In
order to enforce the terms of the Voting Agreement, Dr. Krauss provided Mr. Jordan (or his assigns), solely for the benefit of the Company,
an irrevocable voting proxy to vote the 200,000 shares pursuant to the guidelines set forth above at any meeting of stockholders or via
any written consent of stockholders. As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 200,000
shares of common stock of the Company held by Dr. Krauss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Elray
Settlement Agreement, discussed in greater detail below under &#8220;<i>Elray and Luxor Settlement Agreement</i>&#8221;, Elray was required
to enter into a Voting Agreement with the Company. Pursuant to the Voting Agreement, which was entered into on April 28, 2025, by Elray,
the Company, and Blair Jordan, the Company&#8217;s Chief Executive Officer, solely for the benefit of the Company, Elray agreed to vote
any Elray Shares which it continued to hold, as recommended by the Board of Directors of the Company, at any meeting of stockholders
or via any written consent of stockholders, which may occur prior to April 28, 2026. In order to enforce the terms of the Voting Agreement,
and solely for the benefit of the Company, Elray provided Mr. Jordan (or his assigns) an irrevocable voting proxy to vote the Elray Shares
pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except for the limited right
to vote such shares pursuant to the Voting Agreements, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest
therein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_103"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Conversion of Series
B Convertible Preferred Stock</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 27, 2025, Elray
Resources, Inc., the sole holder of the Series B Convertible Preferred Stock of the Company, and a greater than 5% stockholder, converted
all 1,000,000 outstanding shares of Series B Convertible Preferred Stock of the Company which it then held into 1,318,000 shares of common
stock (1.318 shares of common stock for each share of Series B Convertible Preferred Stock converted), in accordance with the terms of
such preferred stock and the optional conversion right set forth therein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_104"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Elray and Luxor
Settlement Agreement</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 28, 2025, the Company
entered into a Settlement and Mutual Release Agreement (the &#8220;<span style="text-decoration:underline">Settlement Agreement</span>&#8221;) with Elray Resources, Inc. (&#8220;<span style="text-decoration:underline">Elray</span>&#8221;),
a greater than 5% stockholder, and Luxor Capital, LLC (&#8220;<span style="text-decoration:underline">Luxor</span>&#8221;). Elray and Luxor are both controlled by Anthony Brian
Goodman, the father of our former director, Jay Goodman. The Settlement Agreement and related arrangements discussed below resolved certain
disputes which had arisen between the parties relating to among other things, certain potential acquisitions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Settlement
Agreement: (a) the Company agreed to acquire all 1,318,000 of the shares of its common stock (the &#8220;<span style="text-decoration:underline">Elray Shares</span>&#8221;) held
by Elray, which were issued in March 2025, upon the conversion of 1,000,000 shares of Series B Convertible Preferred Stock which Elray
then held (representing 23.1% of the Company&#8217;s currently outstanding shares of common stock), in exchange for an aggregate settlement
payment of $1 million, consisting of&#160;<i>(i)</i>&#160;$350,000 payable to Elray within five business days of the Settlement Agreement
(the &#8220;<span style="text-decoration:underline">Elray Payment</span>&#8221;) (which payment has been made) and&#160;<i>(ii)</i>&#160;$650,000 payable to Luxor (&#8220;<span style="text-decoration:underline">Luxor
Payment</span>&#8221;). Amounts due to Luxor will be payable by way of 20% of proceeds raised by the Company in future capital raises until
paid in full, but shall be paid no later than April 28, 2026; and (b) the Company, Elray, and Luxor exchanged mutual general releases
from claims arising from prior negotiations and agreements, with limited exceptions for obligations under the Settlement Agreement and
confidentiality requirements.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the settlement,
Elray agreed to deliver five stock powers authorizing cancellation of the Elray Shares, to be held in escrow and released proportionally
at the option of the Company, as settlement payments are made, with all remaining shares canceled once the full amounts of the Elray
Payment and Luxor Payment are made. The stock powers are to be released in tranches, with the stock power relating to the initial 461,300
Elray Shares eligible to be released from escrow upon payment of the Elray Payment, and the remaining four stock powers, each providing
for the transfer of 214,175 shares, to be released upon the payment by the Company to Luxor of each additional $162,500. To date, no
Elray Shares have been returned to the Company or cancelled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Luxor also agreed to indemnify
the Company against any claims brought by a third party related to certain prior negotiations involving an online casino asset acquisition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Settlement Agreement included customary representations and warranties of the parties and confidentiality requirements.&#160;The Settlement
Agreement also provides a restriction on Elray&#8217;s sale or transfer of any of the Elray Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Settlement Agreement
also required Elray to enter into the Voting Agreement with the Company, discussed in greater detail above under &#8220;<i><span style="text-decoration:underline">&#8212;Voting
Agreements</span></i>&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Settlement Agreement
and related transactions were approved by the Board of Directors of the Company, as well as the Company&#8217;s Audit Committee, with
Mr. Jay Goodman abstaining.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Settlement Agreement
has no effect on the Company&#8217;s ownership of, or rights associated with, certain source code and intellectual property relating
to an online blockchain casino which the Company acquired from Elray in September 2024, nor Elray&#8217;s ownership of warrants to purchase
3,000,000 shares of common stock with an exercise price of $1.68 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><div><a id="a_105"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">General and Administrative
- Related Parties</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and Administrative
Expenses &#8211; Related Parties during the years ended December 31, 2024 and 2023, were $0&#160;and $46,555, respectively. Of the expenses
incurred during 2024 and 2023, these primarily relate to professional fees paid to current or former officers, directors or greater than&#160;10%
investors, or affiliates thereof.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_106"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounts Payable
- Related Parties</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accounts payable - related
parties were $684,181&#160;and $266,009&#160;as of December 31, 2024 and 2023, respectively, and consist of amounts due to certain officers
and directors of the Company, as well as deferred compensation for certain executives. For the accounts payable &#8211; related party
balance as of December 31, 2024 and 2023, approximately $0&#160;and $210,000, respectively, relates to income taxes payable to the U.K.
government for the salary of Prof. Sir Marc Feldmann, who previously served as the Chairman, CEO and Executive Director of CannBioRex.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_107"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Research and Development
Expenses &#8211; Related Parties</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2024, we incurred research and development expenses &#8211; related parties of $567,832, compared to $480,777 incurred for the year
ended December 31, 2023, representing an increase of $87,055 or 18%. The change is mainly attributable to an overall increase in research
and development (R&amp;D) program spending based on Company resource allocation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Release Agreement with Jay Goodman</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;<span style="text-decoration:underline">Release Agreement</span>&#8221;,
in the section entitled &#8220;<span style="text-decoration:underline">Executive and Director Compensation</span>&#8221;, above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accelerated RSU Vesting, RSU Grants and Option
Grants</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;<span style="text-decoration:underline">Accelerated
Vesting of February 2025 RSU Awards</span>&#8221;, &#8220;<span style="text-decoration:underline">June 2025 Option Grants</span>&#8221; and &#8220;<span style="text-decoration:underline">June 2025 Restricted Stock
Awards</span>&#8221; in the section entitled &#8220;<span style="text-decoration:underline">Executive and Director Compensation</span>&#8221;, above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_108"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Related Party Litigation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_109"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Action Against Former
Executive of KBL</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 1, 2021, the
Company initiated legal action&#160;in the Chancery Court of Delaware against Dr. Marlene Krauss, the Company&#8217;s former Chief Executive
Officer and director (&#8220;<span style="text-decoration:underline">Dr. Krauss</span>&#8221;) and two of her affiliated companies, KBL IV Sponsor, LLC and KBL Healthcare Management,
Inc. (collectively, the &#8220;<span style="text-decoration:underline">KBL Affiliates</span>&#8221;)&#160;for, among other things, engaging in unauthorized monetary transfers
of the Company&#8217;s assets, non-disclosure of financial liabilities within the Company&#8217;s Consolidated Financial Statements,
issuing shares of stock without proper authorization; and improperly allowing stockholder redemptions to take place. The Company&#8217;s
complaint alleged multiple causes of action against Dr. Krauss and/or the KBL Affiliates, and sought compensatory damages in excess of
$11,286,570, together with interest, attorneys&#8217; fees and costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 5, 2021, Dr. Krauss
and the KBL Affiliates filed an Answer, Counterclaims and Third-Party Complaint against the Company and twelve individuals who are, or
were, directors and/or officers of the Company<i>, i.e</i>., Marc Feldmann, Lawrence Steinman, James N. Woody,&#160;Teresa&#160;DeLuca,
Frank Knuettel II, Pamela Marrone, Lawrence Gold, Donald A. McGovern, Jr., Russell T. Ray, Richard W. Barker, Shoshana Shendelman and
Ozan Pamir (collectively, the &#8220;<span style="text-decoration:underline">Third-Party Defendants</span>&#8221;).&#160;&#160;On February 24, 2022, Dr. Krauss filed an amended
Answer, Counterclaims and Third-Party Complaint (the &#8220;<span style="text-decoration:underline">Amended Counterclaims</span>&#8221;), which, among other things, dismissed
Teresa&#160;DeLuca, Frank Knuettel II, Pamela Marrone, Russell T. Ray, Richard W. Barker and Shoshana Shendelman.&#160; In essence, the
Amended Counterclaims allege that the Company and the remaining Third-Party Defendants made alleged misstatements against Dr. Krauss
in SEC filings, failed to register her shares in the Company so that they could be traded, and failed to pay to Dr. Krauss the amounts
alleged to be owing under a promissory note in the principal amount of $371,178, plus an additional $300,000&#160;under Dr. Krauss&#8217;s
resignation agreement. On April 19, 2022, Dr. Krauss stipulated to dismiss all of her counterclaims against both Donald A. McGovern,
Jr. and Lawrence Gold.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 25, 2024, Dr. Krauss
filed a Motion for partial summary judgment on her claim that the Company failed to register her shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;</p><div>

</div><div><a id="a_110"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Action Against the
Company by Dr. Krauss</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 19, 2021, Dr. Krauss
initiated legal action in the Chancery Court of Delaware against the Company.&#160; The Complaint alleged that the Company was obligated
to advance expenses including, attorney&#8217;s&#160;fees, to Dr. Krauss for the costs of defending against an SEC investigation and
Subpoenas, and that the Company is also required to reimburse Dr. Krauss for the costs of bringing this lawsuit against the Company.&#160;&#160;On
September 3, 2021, Dr. Krauss filed an Amended Complaint which further alleged that Dr. Krauss was also allegedly entitled to advancement
by the Company of her expenses, including attorney&#8217;s fees, for the costs of defending against the Third-Party Complaint in the
Tyche action referenced below, and the costs of defending against the Company&#8217;s own Complaint against Dr. Krauss as described above.&#160;&#160;On
or about September 23, 2021, the Company filed its Answer to the Amended Complaint in which the Company denied each of Dr. Krauss&#8217;
claims and raised numerous affirmative defenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 15, 2021, Dr.
Krauss filed a Motion for Summary Adjudication as to certain of the issues in the case, which was opposed by the Company.&#160; On March&#160;7,
2022, the Court issued a decision denying the Motion in part and granting it in part.&#160; The Court then issued an Order implementing
such decision on March&#160;29, 2022.&#160; The parties subsequently engaged in proceedings as set forth in that Order, and the Company
was required to pay a portion of those fees while objecting to the remaining portion of disputed fees. On October 10, 2022 and January
18, 2023, Dr. Krauss filed applications to compel the Company to pay the full amount of fees requested by Dr. Krauss for May-October
2022, and to modify the Court&#8217;s Order. On May 3, 2023, the Court issued an Order granting both of Dr. Krauss&#8217;s Applications
for payment of attorney&#8217;s fees totaling $714,557, which amount was paid in May 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022 and 2023, we made
payments in the aggregate amount of $2,566,850 and $1,115,254, respectively, to our former Chief Executive Officer, Dr. Marlene Krauss,
a then greater than 5% stockholder, in settlement of certain claims by Dr. Krauss for the advancement of expenses incurred by Dr. Krauss
in certain pending legal matters to which Dr. Krauss, pursuant to our organizational documents and Delaware law, was determined to be
owed indemnification for.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 21, 2025, we
entered into a Mutual Settlement and General Release Agreement with Dr. Krauss and KBL IV Sponsor, LLC (&#8220;<span style="text-decoration:underline">KBL Sponsor</span>&#8221;)
(the &#8220;<span style="text-decoration:underline">Settlement Agreement</span>&#8221;). Pursuant to the Settlement Agreement, the Company agreed to (1) pay $50,000 within twenty
days from February 21, 2025 (the &#8220;<span style="text-decoration:underline">Cash Payment</span>&#8221;), which amount was timely paid, and (2) issue 200,000 shares of restricted
common stock within three business days (the &#8220;<span style="text-decoration:underline">Krauss Shares</span>&#8221;), which shares were timely issued. The Krauss Shares
include piggyback registration rights for a resale registration statement relative to the Krauss Shares for a period of six (6) months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Settlement Agreement
also required Dr. Krauss to enter into a Voting Agreement with the Company, which is discussed in greater detail above under &#8220;<i><span style="text-decoration:underline">&#8212;Voting
Agreements</span></i>&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Settlement Agreement
required Dr. Krauss to file a dismissal of her court actions within ten days after receipt of the Cash Payment and that the Company,
Dr. Krauss and KBL Sponsor dismiss all of their claims against one another with prejudice, each of which requirements have occurred to
date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_111"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Action Against Tyche
Capital LLC</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company commenced and
filed an action against defendant Tyche Capital LLC (&#8220;Tyche&#8221;) in the Supreme Court of New York in the County of New York
on April 15, 2021.&#160; In its Complaint, the Company alleged claims against Tyche arising out of Tyche&#8217;s breach of its written
contractual obligations to the Company as set forth in a &#8220;Guarantee and Commitment Agreement&#8221; dated July 25, 2019, and a
&#8220;Term Sheet for KBL Business Combination With CannBioRex&#8221; dated April 10, 2019 (collectively, the &#8220;Subject Guarantee&#8221;),
and claimed that Tyche&#8217;s breach of the Subject Guarantee caused the Company damages in the amount of at least $6,776,686.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On or about May 17, 2021,
Tyche responded to the Company&#8217;s Complaint by filing an Answer and Counterclaims against the Company alleging that it was the Company,
rather than Tyche, that had breached the Subject Guarantee.&#160; Tyche also filed a Third-Party Complaint against six third-party defendants,
including three members of the Company&#8217;s management, Sir Marc Feldmann, Dr. James Woody, and Ozan Pamir (collectively, the &#8220;Individual
Company Defendants&#8221;), claiming that they allegedly breached fiduciary duties to Tyche with regards to the Subject Guarantee.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 23, 2021, the
Court granted the Company&#8217;s request to issue an Order of attachment against all of Tyche&#8217;s shares of the Company&#8217;s
stock that had been held in escrow.&#160; In so doing, the Court found that the Company had demonstrated a likelihood of success on the
merits of the case based on the facts alleged in the Company&#8217;s Complaint.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 18, 2022, Tyche
filed an Amended Answer, Counterclaims and Third-Party Complaint.&#160; On August 25, 2022, the Court granted the Company&#8217;s Motion
to Dismiss each of the Individual Company Defendants, and also three of the four Counterclaims brought against the Company, leaving only
Tyche&#8217;s declaratory relief claim. On August 26, 2022, Tyche filed a Motion to vacate or modify the Company&#8217;s existing attachment
Order against Tyche&#8217;s shares of the Company&#8217;s stock held in escrow, however, the Court summarily denied such Motion on January
3, 2023. Although Tyche subsequently filed a Notice of Appeal as to that denial, on May 4, 2023, the Appellate Court unanimously affirmed
the ruling of the lower Court in the Company&#8217;s favor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 30, 2023, the
Company filed a Notice of Motion for Summary Judgment. In hearings held on September 11 and 19, 2023, the Court granted the Company&#8217;s
Motion, but referred the question as to the amount of the Company&#8217;s damages against Tyche to a special referee. Tyche filed a Notice
of Appeal as to the Court&#8217;s ruling.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 30, 2024, the Company
entered into a written Settlement Agreement with Tyche and Ronald Bauer and Samantha Bauer to fully resolve this action with Tyche and
the Bauer action referenced below. The Settlement Agreement has been fully signed, and the parties have performed the following terms:
forgiveness of loans to the Company by the Bauer Defendants, exoneration of the Company&#8217;s $50,000&#160;bond in the Tyche action,
complete mutual releases of all claims and counterclaims in both actions, and dismissal of both the Tyche action and the Bauer action
in their entireties. As a result of forgiveness of loans payable to the Bauer Defendants totaling $81,720, and accrued interest of $25,171,
as well as release of the Company&#8217;s $50,000&#160;bond, the Company recognized a gain of $156,891&#160;during the three months ended
June 30, 2024. Pursuant to the Settlement Agreement the Company cancelled 2,385 shares of common stock previously held by Tyche on January
30, 2025. In addition, Ronald Bauer and Samantha Bauer agreed to indemnify the Company and its subsidiaries from any collection attempts,
actions or proceedings brought by Cambridge Capital Ltd. (&#8220;<span style="text-decoration:underline">Cambridge</span>&#8221;) and Park Lane Capital, Ltd. (&#8220;<span style="text-decoration:underline">Park
Lane</span>&#8221;). Cambridge and Park Lane have made certain loans to the Company or its subsidiaries in the aggregate amount of approximately
$130,000. Cambridge and Park Lane have made a demand for payment and the Company provides no assurance that Ronald and Samantha Bauer
will indemnify the Company or that the Company will not be forced to repay such amounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><div><a id="a_112"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Action Against Ronald
Bauer &amp; Samantha Bauer</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and two of its
wholly-owned subsidiaries, Katexco Pharmaceuticals Corp. and CannBioRex Pharmaceuticals Corp. (collectively, the &#8220;<span style="text-decoration:underline">Company Plaintiffs</span>&#8221;),
initiated legal action against Ronald Bauer and Samantha Bauer, as well as two of their companies, Theseus Capital Ltd. and Astatine
Capital Ltd. (collectively, the &#8220;Bauer Defendants&#8221;), in the Supreme Court of British Columbia on February 25, 2022. The Complaint
claims that the Bauer Defendants misappropriated funds and stock shares, engaged in unauthorized stock sales, and obtained improper travel
expenses. The Bauer Defendants filed a Response denying the Civil Claim Complaint of the Company on May 6, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 30, 2024, the Company
Plaintiffs, Tyche and the Bauer Defendants entered into the Settlement Agreement described above, which fully resolves this action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_113"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Declaratory Relief
Action Against the Company by AmTrust International</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 29, 2022, AmTrust
International Underwriters DAC (&#8220;<span style="text-decoration:underline">AmTrust</span>&#8221;), which was the premerger directors&#8217; and officers&#8217; insurance
policy underwriter for KBL, filed a declaratory relief action&#160;against the Company&#160;in the U.S. District Court for the Northern
District of California (the &#8220;<span style="text-decoration:underline">Declaratory Relief Action</span>&#8221;) seeking a declaration that AmTrust is not obligated to reimburse
the Company for fees advanced by the Company to Dr. Krauss and George Hornig under the directors&#8217; and officers&#8217; insurance
policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 20, 2022, the
Company filed its Answer and Counterclaims against AmTrust for bad faith breach of AmTrust&#8217;s insurance coverage obligations to
the Company under the subject insurance policy, seeking at least $2&#160;million in compensatory damages, and punitive damages. In addition,
the Company brought a Third-Party Complaint against its excess insurance carrier, Freedom Specialty Insurance Company (&#8220;<span style="text-decoration:underline">Freedom</span>&#8221;)
seeking declaratory relief that Freedom will also be required to honor its policy coverage as soon as the amount of AmTrust&#8217;s insurance
coverage obligations to the Company has been exhausted. On October 25, 2022, AmTrust filed its Answer to the Company&#8217;s Counterclaims
and, on October&#160;27, 2022, Freedom filed its Answer to the Third-Party Complaint.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November&#160;22, 2022,
the Company filed a Motion for Summary Adjudication against both AmTrust and Freedom and, on April 21, 2023, the Court issued an Order
Granting in Part and Denying in Part the Company&#8217;s Motion. This Order essentially ruled in favor of the Company on nearly all of
the issues in the case, but found there were still issues of disputed facts as to the Change in Control exclusion contained within the
policies, which precluded the Court from granting the remainder of the Company&#8217;s requests for summary adjudication as a matter
of law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 4, 2023, the Court
granted the Company&#8217;s request to file a second motion for partial summary judgment, this one being on the issue of whether AmTrust
should be required to advance to the Company the defense costs being incurred by Dr. Krauss and Mr. Hornig during the pendency of the
case. On February 12, 2024, the Court granted the Company&#8217;s Motion and ordered that: (a) AmTrust is obligated under its insurance
policy to advance to the Company all defense costs in excess of the deductible that the Company has advanced, or will advance, to Dr.
Krauss and Mr. Hornig in connection with the SEC Subpoenas, and (b) upon exhaustion of the AmTrust insurance policy, Freedom is obligated
to do the same pursuant to its excess liability insurance policy. This Order applies throughout the interim of the case, but does not
constitute a final judgment, and both the Company and the two insurers retain their rights to contest all applicable issues at trial,
which is scheduled for May 12, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 16, 2024, AmTrust
paid the Company $2.27 million in reimbursement of fees which the Company had advanced to Dr. Krauss and Mr. Hornig, of which the Company
received $1,512,711 after the payment of attorney&#8217;s fees. On May 9, 2024, AmTrust paid the Company a further $300,140 in reimbursement
of fees advanced by the Company, of which the Company received $200,093 after the payment of attorney&#8217;s fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, Freedom and
AmTrust held a mediation conference on August 21, 2024, during which, the Company agreed to the terms of a settlement with Freedom.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 23, 2024, Freedom
paid the Company a further $125,000 in reimbursement of fees advanced by the Company, of which the Company received $76,639 after the
payment of attorney&#8217;s fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequently, the Company
and AmTrust held an additional mediation conference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On, and effective on, April
6, 2025 (the &#8220;<span style="text-decoration:underline">Effective Date</span>&#8221;), the Company entered into a Confidential AmTrust Settlement Agreement and Release (the
&#8220;<span style="text-decoration:underline">AmTrust Settlement Agreement</span>&#8221;) with AmTrust, and its wholly-owned subsidiary, AmTrust Financial Services, Inc. (&#8220;<span style="text-decoration:underline">AFSI</span>&#8221;).
Pursuant to the AmTrust Settlement Agreement, the Company and AmTrust agreed to resolve the ongoing litigation and disputes discussed
above, relating to the Company&#8217;s pre-merger directors&#8217; and officers&#8217; insurance policy (the &#8220;<span style="text-decoration:underline">Coverage Action</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of
the AmTrust Settlement Agreement, the Company agreed to (i) pay AmTrust a cash payment of $250,000 (the &#8220;<span style="text-decoration:underline">Settlement Sum</span>&#8221;)
within 20 days of the Effective Date, and (ii) issue AFSI 509,707 shares of the Company&#8217;s common stock (the &#8220;<span style="text-decoration:underline">AmTrust Settlement
Shares</span>&#8221;), within three business days of the Effective Date, which have been issued to date. The AmTrust Settlement Shares were
valued at $575,000 (the &#8220;<span style="text-decoration:underline">Shares Value</span>&#8221;), based on the volume-weighted average price of the Company&#8217;s common
stock over the 30 trading days preceding the Effective Date and are subject to customary anti-dilution protections, including adjustments
for stock splits, combinations, and stock dividends.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Within ten days after delivery
of both the Settlement Sum and the AmTrust Settlement Shares, the parties agreed to file a joint stipulation of dismissal with prejudice
of the Coverage Action, which has been filed to date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the settlement,
the Company and AmTrust provided each other broad mutual releases of all claims, known and unknown, arising out of or relating to, among
other things, the Coverage Action, certain claims relating to an SEC investigation of certain of the Company&#8217;s pre-merger officers,
including Dr. Krauss, a lawsuit filed by the Company against Dr. Krauss, certain cross claims made by the Company against AmTrust, and
related insurance claims and matters, including any claims for bad faith, breach of the implied covenant of good faith and fair dealing,
or alleged unfair insurance practices. These releases extend to affiliates, officers, directors, employees, agents, and other related
parties of both entities. The AmTrust Settlement Agreement expressly provides that it does not release the parties from obligations arising
under the AmTrust Settlement Agreement itself.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the issuance
of the AmTrust Settlement Shares and pursuant to the AmTrust Settlement Agreement, the Company agreed to provide AFSI with certain registration
rights. Specifically, the Company is obligated to use commercially reasonable efforts to file a registration statement on Form S-1 (or
Form S-3, if available) with the SEC within 45 days of the Effective Date (i.e., prior to May 21, 2025) to register the resale of the
AmTrust Settlement Shares (the &#8220;<span style="text-decoration:underline">Resale Registration Statement</span>&#8221;). The Company has further agreed to use commercially
reasonable efforts to cause the Resale Registration Statement to be declared effective within 60 days following the Effective Date, or,
in the event of SEC notice that the Registration Statement will not be reviewed, by the third business day thereafter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is required to
keep the Resale Registration Statement continuously effective until such time as AFSI no longer holds any AmTrust Settlement Shares,
and to bear all related costs and expenses in connection with such registration, excluding AFSI&#8217;s legal fees. Additionally, the
Company must provide legal opinion coverage at its expense, if necessary, to enable AFSI to rely on Rule 144 resale exemptions after
six months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company fails to file
or cause the Resale Registration Statement to become effective within 105 days after the Effective Date (i.e., prior to July 20, 2025),
if the prospectus included in the registration statement can no longer be relied upon, or if the Company fails to maintain the effectiveness
of the Resale Registration Statement (each, a &#8220;<span style="text-decoration:underline">Registration Statement Failure Event</span>&#8221;), the Company is required to
pay liquidated damages equal to 3.0% of the Shares Value for each such failure and for each month such failure continues, subject to
a cap of 33.0% of the Shares Value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The AmTrust Settlement Agreement
included customary representations and warranties of the parties, including representations from AFSI confirming its status as an accredited
investor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_114"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Indemnification
Agreements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into indemnification
agreements with each of our directors and officers. The indemnification agreements and our Certificate of Incorporation and Bylaws require
us to indemnify our directors and officers to the fullest extent permitted by Delaware law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><div><a id="a_115"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Related Party Transaction
Policy</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Audit Committee must
review and approve any related party transaction we propose to enter into. Our Audit Committee charter details the policies and procedures
relating to transactions that may present actual, potential or perceived conflicts of interest and may raise questions as to whether
such transactions are consistent with the best interest of our company and our stockholders. A summary of such policies and procedures
is set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any potential related party
transaction that is brought to the Audit Committee&#8217;s attention will be analyzed by the Audit Committee, in consultation with outside
counsel or members of management, as appropriate, to determine whether the transaction or relationship does, in fact, constitute a related
party transaction. At its meetings, the Audit Committee will be provided with the details of each new, existing or proposed related party
transaction, including the terms of the transaction, the business purpose of the transaction and the benefits to us and to the relevant
related party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In determining whether to
approve a related party transaction, the Audit Committee must consider, among other factors, the following factors to the extent relevant:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the terms of the
    transaction are fair to us and on the same basis as would apply if the transaction did not involve a related party;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether there are business
    reasons for us to enter into the transaction;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the transaction
    would impair the independence of an outside director; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the transaction
    would present an improper conflict of interest for any director or executive officer.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any member of the Audit Committee
who has an interest in the transaction under discussion must abstain from any voting regarding the transaction, but may, if so, requested
by the Chairman of the Audit Committee, participate in some or all of the Audit Committee&#8217;s discussions of the transaction. Upon
completion of its review of the transaction, the Audit Committee may determine to permit or to prohibit the transaction.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_116"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Delinquent Section 16(a)&#160;Reports</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#160;16(a)&#160;of
the Exchange&#160;Act requires our directors and officers, and persons who beneficially own more than 10% of a registered class of the
Registrant&#8217;s equity securities, to file reports of beneficial ownership and changes in beneficial ownership of our securities with
the SEC on Forms&#160;3, 4 and 5. Officers, directors and greater than 10% stockholders are required by SEC regulation to furnish us
with copies of all Section&#160;16(a)&#160;forms they file.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based solely upon our review
of the Section&#160;16(a)&#160;filings that have been furnished to us and filed publicly, we believe that during the year ended December&#160;31,
2024, that no director, executive officer, or beneficial owner of more than 10% of our common stock failed to file a report on a timely
basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to SEC rules, we
are not required to disclose in this filing any failure to timely file a Section&#160;16(a)&#160;report that has been disclosed by us
in a prior annual report or proxy statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_117"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Proposal&#160;1<br/>
Election of Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_118"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">General</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the annual meeting, two
Class&#160;I directors are to be elected for a two-year term, to hold office until the 2027 annual meeting of stockholders and until
their respective successors are duly elected and qualified. The Nominating and Corporate Governance Committee has recommended, and the
Board of Directors has selected, the following nominees for election: Lawrence Steinman, M.D. and Stephen H. Shoemaker, each of whom
are currently directors of our company. If any nominee for any reason is unable to serve or for good cause will not serve, the proxies
may be voted for such substitute nominee as the proxy holder may determine. The Company is not aware of any nominee who will be unable
to, or for good cause will not, serve as a director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s Nominating
Committee has reviewed the qualifications of the director nominees and has recommended each of the nominees for election to the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_119"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">General Director
Qualifications</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors believes
that each of our director nominees is highly qualified to serve as a member of the Board of Directors. Each of the director nominees
has contributed to the mix of skills, core competencies and qualifications of the Board of Directors. When evaluating candidates for
election to the Board of Directors, the Board of Directors seeks candidates with certain qualities that it believes are important, including
integrity, an objective perspective, good judgment, and leadership skills. Our director nominees are highly educated and have diverse
backgrounds and talents and extensive track records of success in what we believe are highly relevant positions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_120"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">What Vote Is Required
To Elect the Director Nominees</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A plurality of the votes
cast in person or by proxy by the holders of our common stock entitled to vote at the annual meeting are required to elect each director.
A plurality of the votes cast means (1)&#160;the director nominee with the most votes for a particular seat is elected for that seat;
and (2)&#160;votes cast shall not include votes to &#8220;<span style="text-decoration:underline">withhold authority</span>&#8221; (shown as &#8220;<span style="text-decoration:underline">AGAINST</span>&#8221; on
the enclosed form of proxy)&#160;and exclude abstentions with respect to that director&#8217;s election. Therefore, abstentions and broker
non-votes&#160;(which occur if a broker or other nominee does not have discretionary authority and has not received instructions with
respect to a particular director nominee within ten&#160;days of the annual meeting)&#160;will not be counted in determining the number
of votes cast with respect to that director&#8217;s election.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Properly executed proxies
will be voted at the annual meeting in accordance with the instructions specified on the proxy; if no such instructions are given, the
persons named as agents and proxies in the enclosed form of proxy will vote such proxy &#8220;<span style="text-decoration:underline">FOR</span>&#8221; the election of the nominees
named herein. Should any nominee become unavailable for election, discretionary authority is conferred to the persons named as agents
and proxies in the enclosed form of proxy to vote for a substitute.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the power provided
to the Board of Directors in our Second Amended and Restated Bylaws (&#8220;<span style="text-decoration:underline">Bylaws</span>&#8221;), the Board has set the number of directors
that shall constitute the Board at four. Proxies cannot be voted for a greater number of persons than the number of nominees named on
the enclosed form of proxy, and stockholders may not cumulate their votes in the election of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_121"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Board Recommendation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board of Directors unanimously recommends
voting &#8220;<span style="text-decoration:underline">FOR</span>&#8221; each of the two nominees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_122"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Proposal&#160;2<br/>
Adoption of the Fourth Amendment to the 180 Life Sciences Corp. 2022<br/>
Omnibus Incentive Plan</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_123"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">General</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
share reserve under the Third Amended and Restated 180 Life Sciences Corp. 2022 Omnibus Incentive Plan (the &#8220;<span style="text-decoration:underline">2022 OIP</span>&#8221;)
is expected to be significantly depleted and significantly reduced by the effects of the proposed Reverse Stock Split, discussed in greater
detail below under &#8220;Proposal 5, Amendment to Second Amended and Restated Certificate of Incorporation, as Amended, to Effect a Reverse Stock Split&#8221;. If our stockholders do not approve an increase in the share reserve under the 2022 OIP, we expect that we
will not have sufficient shares to cover our annual equity award grants scheduled to be made after 2025, and we will lose access to an
important compensation tool that is key to our ability to attract, motivate, reward, and retain our key employees and directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Consequently,
on ________, 2025, upon the recommendation of our Compensation Committee, our Board adopted the Fourth Amendment (the &#8220;<span style="text-decoration:underline">Amendment</span>&#8221;)
to the 2022 OIP, subject to stockholder approval. The 2022 OIP, as amended by the Amendment, is hereinafter referred to as the &#8220;<span style="text-decoration:underline">Amended
Plan</span>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Amendment makes the following key changes to the 2022 OIP:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Increase to the maximum number of shares that may be issued pursuant
    to the 2022 OIP, and the maximum number of shares which may be issued upon the exercise of incentive stock options, from 1,000,000
    shares, to 5,000,000 shares (an increase of 4,000,000 shares); </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Change the 2022 OIP to an &#8220;evergreen&#8221; equity compensation
    plan, providing for automatic increases in the maximum number of shares that may be issued pursuant to the 2022 OIP on April 1st
    of each year for a period of seven years commencing on January 1, 2026, and ending on (and including) January 1, 2032, in an amount
    equal to ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding
    fiscal year; provided, however, that the Board may act prior to January 1st of a given year to provide that the increase for such
    year will be a lesser number of shares of common stock; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Increase the limit on the maximum number of shares of common stock that may be grated in connection
    with, and issued pursuant to the exercise of, incentive stock options under the 2022 OIP from 1,000,000 to 100,000,000.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
stockholders do not approve this Proposal 2, the Amendment will not become effective, the proposed additional shares will not become
available for issuance under the 2022 OIP, and the 2022 OIP will continue as in effect prior to the Amendment, subject to previously
authorized share limits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
copy of the Amendment is attached as&#160;<span style="text-decoration:underline">Appendix A</span>&#160;to this Proxy Statement, and a conformed copy of the 2022 OIP, as amended
by the Amendment, is attached as&#160;<span style="text-decoration:underline">Appendix B</span>&#160;to this Proxy Statement. Other than the limited amendments described herein,
we are not making other changes to the 2022 OIP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p><div>

</div><div><a id="a_124"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Background and
Purpose of the Amended Plan</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Compensation Committee and the Board are asking the Company&#8217;s stockholders to approve the Amendment because the Compensation Committee
and the Board believe that it is in the best interest of the Company and its stockholders to provide, through the Amended Plan, a comprehensive
equity and long-term compensation program designed to enable the Company to attract, retain, and reward employees, non-employee directors,
and other persons providing services to the Company. The Compensation Committee and the Board also believe that long-term equity compensation
is essential to link executive compensation with long-term stockholder value creation. Equity compensation represents a significant portion
of the compensation package for management. Since our equity awards generally vest over several years, the value ultimately realized
from these awards depends on the long-term value of our common stock. We strongly believe that granting equity awards motivates management
to think and act like owners, rewarding them when value is created for stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Amended Plan provides
for a broad range of awards to enable the Company to respond to market trends and to structure incentives to align to its business goals.
In particular, the Amended Plan authorizes awards under the 2022 OIP in the form of performance awards, restricted stock, restricted
stock units, stock options, which may be either incentive stock options or non-qualified&#160;stock options, stock appreciation rights,
other stock-based&#160;awards and dividend equivalents, as discussed in greater detail below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_125"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Current Overview
of Outstanding Equity Information</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
are only 7,000 shares available for future awards under the Company&#8217;s 2020 OIP and no shares available for future awards under
the Company&#8217;s 2022 OIP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Amended Plan authorizes an additional 4,000,000 shares for issuance of equity awards under the Amended Plan (representing approximately
65.9% of the outstanding shares of the Company common stock as of _______________, 2025). In setting and recommending to stockholders
the number of additional shares to authorize under the Amended Plan pursuant to the Amendment, the Compensation Committee and the Board
considered the historical number of equity awards granted under the 2020 OIP and 2022 OIP, as well as the Company&#8217;s average burn
rate for the preceding fiscal years, and the expected effects of the Reverse Stock Split (as discussed below in &#8220;Proposal 5, Amendment to Second Amended and Restated Certificate of Incorporation, as Amended, to Effect a Reverse Stock Split&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">When
considering the number of additional shares to add to the 2022 OIP, the Compensation Committee and the Board reviewed, among other things,
the potential dilution to the Company&#8217;s current stockholders as measured by burn rate, projected future share usage, and projected
future forfeitures. The projected future usage of shares for long-term incentive awards under the 2022 OIP was reviewed under scenarios
based on a variety of assumptions. Depending on assumptions, the 4,000,000 shares to be added to the 2022 OIP pursuant to the Amendment,
in combination with the remaining authorized shares and shares added back to the 2022 OIP from forfeitures of awards granted under the
2022 OIP, and the additional shares which will be added each year hereafter due to the &#8220;evergreen&#8221; provision thereof, are
projected to satisfy the Company&#8217;s equity compensation needs for the next seven years. In light of the factors considered by the
Board and Compensation Committee, the Board and Compensation Committee believe that this number of shares represents reasonable potential
equity dilution and provides a significant incentive for officers, employees, and non-employee directors to increase the value of the
Company for all stockholders. The Compensation Committee is committed to effectively managing the number of shares reserved for issuance
under the Amended Plan while minimizing stockholder dilution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
light of the factors described above, and the fact that our ability to continue to grant equity and equity-based compensation is vital
to our ability to continue to attract and retain key personnel in the labor markets in which we compete, the Board has determined that
the size of the share reserve under the Amended Plan is reasonable and appropriate at this time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
believe that the &#8220;evergreen&#8221; amendment will grant us greater flexibility to ensure consistent alignment between compensation
and performance over the term of the 2022 OIP. This is particularly important as we anticipate growing our operations over the next several
years and it is critical that we have sufficient shares to compensate anticipated new hires at market competitive levels. Note that the
evergreen provision, as proposed, has a six-year duration, after which annual share increase requests will require shareholder approval.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_126"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Summary of the
Material Terms of the Amended Plan</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of the principal features of the Amended Plan.&#160;This summary does not purport to be a complete description of all of the provisions
of the Amended Plan.&#160;It is qualified in its entirety by reference to the full text of the Amended Plan, following the approval of
the Amendment (included as&#160;<span style="text-decoration:underline">Appendix A</span>&#160;to this proxy statement), which is included as&#160;<span style="text-decoration:underline">Appendix B</span>&#160;to
this proxy statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Purpose.&#160;</i>The
purpose of the Amended Plan is to promote the interests of the Company and its subsidiaries and its stockholders by (i)&#160;attracting
and retaining directors, executive officers, employees and consultants of outstanding ability; (ii)&#160;motivating such individuals
by means of performance-related&#160;incentives to achieve the longer-range&#160;performance goals of the Company and its subsidiaries;
and (iii)&#160;enabling such individuals to participate in the long-term&#160;growth and financial success of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Administration.&#160;</i>The
Board of Directors, and unless otherwise determined by our Board, our Compensation Committee of the Board, have the power and authority
to administer the Amended Plan (the &#8220;<span style="text-decoration:underline">Administrator</span>&#8221;). The Administrator has the authority to (i)&#160;determine the
type or types of awards to be granted to each participant; (ii)&#160;select the participants to whom awards may from time to time be
granted; (iii)&#160;determine all matters and questions related to the termination of service of a participant with respect to any award
granted to him or her; (iv)&#160;determine the number of awards to be granted and the number of shares to which an award will relate;
(v)&#160;approve forms of agreement for use under the Amended Plan; (vi)&#160;determine the terms and conditions of any awards; (vii)&#160;prescribe,
amend and rescind rules and regulations relating to the Amended Plan; (viii)&#160;determine whether, to what extent, and pursuant to
what circumstances an award may be settled in, or the exercise or purchase price of an award may be paid in, cash, stock, other awards,
or other property, or an award may be canceled, forfeited or surrendered; (ix)&#160;suspend or accelerate the vesting of any award granted
under the Amended Plan or waive the forfeiture restrictions or any other restriction or limitation regarding any awards or the shares
of stock relating thereto; (x)&#160;construe and interpret the terms of the Amended Plan and awards granted pursuant to the Amended Plan;
and (xi)&#160;make all other decisions and determinations that may be required pursuant to the Amended Plan or as it deems necessary
or advisable to administer the Amended Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Eligibility.&#160;</i>Employees,
non-employee&#160;directors, and consultants of the Company and its subsidiaries are eligible to participate in the Amended Plan.&#160;Incentive
stock options may be granted under the Amended Plan only to employees of our company and its subsidiaries. Employees, directors and consultants
of our company and its affiliates are eligible to receive all other types of awards under the Amended Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Awards.&#160;</i>Awards
under the Amended Plan may be made in the form of performance awards, restricted stock, restricted stock units, stock options, which
may be either incentive stock options or non-qualified&#160;stock options, stock appreciation rights, other stock-based&#160;awards and
dividend equivalents. Awards are generally non-transferable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Shares Subject to the
Amended Plan.&#160;</i>Subject to adjustment in connection with the payment of a stock dividend, a stock split or subdivision or combination
of the shares of common stock, or a reorganization or reclassification of the Company&#8217;s common stock, upon approval of the Amendment,
the aggregate number of shares of common stock which may be issued pursuant to awards under the Amended Plan shall initially equal 5,000,000
shares, and will automatically increase on April 1st of each year for a period of seven years commencing on January 1, 2026 and ending
on (and including) January 1, 2032, in an amount equal to ten percent (10%) of the total shares of Company common stock outstanding on
the last day of the immediately preceding fiscal year (the &#8220;<span style="text-decoration:underline">Evergreen Measurement Date</span>&#8221;); provided, however, that
the Board may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares of
common stock. No more than 100,000,000 shares may be awarded under the plan upon exercise of incentive stock options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an award granted under
the Amended Plan entitles a holder to receive or purchase shares of our common stock, then on the date of grant of the award, the number
of shares covered by the award (or to which the award relates) will be counted against the total number of shares available for granting
awards under the Amended Plan.&#160;As a result, the shares available for granting future awards under the Amended Plan will be reduced
as of the date of grant. However, certain shares that have been counted against the total number of shares authorized under the Amended
Plan in connection with awards previously granted under such Amended Plan will again be available for awards under the Amended Plan as
follows: shares of our common stock covered by an award or to which an award relates which were not issued because the award terminated
or was forfeited or cancelled without the delivery of shares will again be available for awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shares issued under the Amended
Plan may be authorized but unissued shares or reacquired shares. Any shares covered by an award, or portion of an award, granted under
the Amended Plan that is forfeited, canceled, cash-settled, expired or otherwise terminated without the issuance of shares, shall again
be available for the grant of an award under the Amended Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Award Limitations on&#160;Non-Director&#160;Awards.&#160;</i>The
maximum number of shares subject to awards granted during a single compensation year (that is from one annual meeting of stockholders
to the next annual meeting) to any non-employee&#160;director, taken together with any cash fees paid during the compensation year to
the non-employee&#160;director, in respect of the director&#8217;s service as a member of the Board during such year (including service
as a member or chair of any committees of the Board), will not exceed $500,000 in total value (calculating the value of any such awards
based on the grant date fair value of such awards for financial reporting purposes); provided that in the event such non-employee&#160;director
is first appointed or elected to the Board during such compensation year, and/or in the case that the non-employee&#160;director is serving
as non-employee&#160;chairperson of the Board, such amount shall not exceed $750,000 in total value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Change in Capitalization
or Other Corporate Event.&#160;</i>If and to the extent necessary or appropriate to reflect any stock dividend, extraordinary dividend,
stock split or share combination or any recapitalization, merger, consolidation, exchange of shares, spin-off, liquidation or dissolution
of the Company or other similar transaction affecting our common stock, the Administrator shall adjust the number of shares of our common
stock available for issuance under the Amended Plan, and the number, class and exercise price or base price of any outstanding award,
and/or make such substitution, revision or other provisions or take such other actions with respect to any outstanding award or the holder
or holders thereof, in each case as it determines to be equitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Terms and Conditions of
Options.&#160;</i>An &#8220;<span style="text-decoration:underline">incentive stock option</span>&#8221; is an option that meets the requirements of Section&#160;422 of the
U.S.&#160;Internal Revenue Code (the &#8220;<span style="text-decoration:underline">Code</span>&#8221;), and a &#8220;<span style="text-decoration:underline">non-qualified&#160;stock option</span>&#8221; is an option
that does not meet those requirements. An option granted will be exercisable only to the extent that it is vested on the date of exercise.
No option may be exercisable more than ten&#160;years from the grant date. In general, the exercise price per share under each option
granted under the Amended Plan may not be less than 100% of the fair market value of our common stock on the option grant date, provided
that stockholders who own greater than 10% of the Company&#8217;s voting stock cannot be granted incentive stock options that have an
exercise price less than 110% of the fair market value of the Company&#8217;s common stock on the date of grant. For so long as our common
stock is listed on an established stock exchange, the fair market value of the common stock will be the closing price of our common stock
on the exchange on which it is listed on the option grant date. If there is no closing price reported on the option grant date, the fair
market value will be deemed equal to the closing price for the common stock on the last market&#160;trading day prior to the&#160;day
of determination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Terms and Conditions of
Stock Appreciation Rights.&#160;</i>A &#8220;<span style="text-decoration:underline">stock appreciation right</span>&#8221; (or a &#8220;<span style="text-decoration:underline">SAR</span>&#8221;) is the right to receive
payment from the Company in cash and/or shares of common stock equal to the product of (i)&#160;the excess, if any, of the fair market
value of one (1)&#160;share of our common stock on the exercise date over a specified price fixed by the Administrator on the grant date
(which price may not be less than the fair market value of a share of our common stock on the grant date), multiplied by (ii)&#160;a
stated number of shares of common stock. A SAR will be exercisable only to the extent that it is vested on the date of exercise. No SAR
may be exercisable more than ten&#160;years from the grant date. SARs may be granted to participants in tandem with options or on their
own. Tandem SARs will generally have substantially similar terms and conditions as the options with which they are granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Terms and Conditions of
Restricted Stock and Restricted Stock Units.&#160;</i>&#8220;<span style="text-decoration:underline">Restricted stock</span>&#8221; is an award of common stock on which certain
restrictions are imposed over specified periods that subject the shares to a substantial risk of forfeiture. A &#8220;<span style="text-decoration:underline">restricted stock
unit</span>&#8221; is a unit, equivalent in value to a share of common stock, credited by means of a bookkeeping entry in our books to a
participant&#8217;s account, which is settled in stock or cash upon vesting. Subject to the provisions of the Amended Plan, the Administrator
will determine the terms and conditions of each award of restricted stock or restricted stock units, including the restriction period
for the award, and the restrictions applicable to the award. Restricted stock and restricted stock units will vest based on a minimum
period of service or the occurrence of events specified by the Administrator.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Terms and Conditions of
Performance Awards.&#160;</i>A &#8220;<span style="text-decoration:underline">performance award</span>&#8221; is a contractual right to receive shares of our common stock or
a U.S.-denominated&#160;amount of cash which is earned (in whole or in part) based on the achievement of specified performance goals.
Vested performance awards may be settled in cash, stock or a combination of cash and stock, at the discretion of the Administrator. Performance
awards will vest based on the achievement of predetermined performance goals established by the Administrator. Performance goals may
be established on a company-wide&#160;basis, with respect to one or more business units, divisions, subsidiaries or products or based
on individual performance measures, and may be expressed in absolute terms or relative to other metrics including internal targets or
budgets, past performance of the Company, the performance of one or more similarly situated companies, performance of an index, outstanding
equity or other external measures. In the case of earning-based&#160;measures, performance goals may include comparisons relating to
capital (including but limited to, the cost of capital), stockholders&#8217; equity, shares outstanding, assets or net assets, or any
combination thereof. Performance goals may also be subject to such other terms and conditions as the committee may determine appropriate.
The committee may also adjust the performance goals for any performance cycle as it deems equitable in recognition of unusual or non-recurring&#160;events
affecting the Company; changes in applicable tax laws or accounting principles; other extraordinary events such as restructurings; discontinued
operations; asset write-downs; significant litigation or claims, judgments or settlements; acquisitions or divestitures; reorganizations
or changes in the corporate structure or capital structure of the Company; foreign exchange gains and losses; change in the fiscal year
of the Company; business interruption events; unbudgeted capital expenditures; unrealized investment gains and losses; impairments and/or
such other factors as the committee may determine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Other&#160;Stock-Based&#160;Awards.&#160;</i>The
Compensation Committee or Board of Directors may make other equity-based&#160;or equity-related&#160;awards not otherwise described by
the terms of the plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dividend Equivalents.&#160;</i>A
dividend equivalent is the right to receive payments in cash or in stock, based on dividends with respect to shares of stock. Dividend
equivalents may be granted to participants in tandem with another award or on their own, but not in respect of stock options or SARs.
In general, dividend equivalents will be paid to participants with respect to an award when the award becomes vested.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Termination of Employment.&#160;</i>All
of the terms relating to the exercise, cancellation or other disposition of any award upon a termination of employment or service with
the Company of the participant, whether due to disability, death or under any circumstances may be determined by the Administrator and
described in each participant&#8217;s award agreement. Unless otherwise set forth in the applicable agreement, the following provisions
will apply:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Termination for Cause;&#160;Post-Service&#160;Competitive
Activity.&#160;</i>If a participant&#8217;s employment or service terminates for cause or a participant breaches any restrictive covenants
(such as a non-competition&#160;or non-solicitation&#160;agreement) following the participant&#8217;s termination of employment or service,
all options and SARs, whether vested or unvested, and all other awards that are unvested or unexercisable or otherwise unpaid (or were
unvested or unexercisable or unpaid at the time of occurrence of cause or such breach) will be immediately forfeited and canceled. If
the participant breaches the restrictive covenants following the termination, any portion of the participant&#8217;s awards that became
vested after termination, and any shares or cash issued upon exercise or settlement of such awards, will be immediately forfeited, canceled,
and disgorged or paid to the Company together with all gains earned or accrued due to the sale of shares issued upon exercise or settlement
of such awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Termination due to Death.&#160;</i>If
a participant&#8217;s employment or service terminates by reason of death, all options and SARs (whether or not then otherwise exercisable)
will become exercisable in full and may be exercised at any time prior to the earlier of (i)&#160;the one-year&#160;anniversary of the
participant&#8217;s death or (ii)&#160;the expiration of the term of the options or SARs; provided that any in-the-money&#160;options
and SARs that are still outstanding on the last&#160;day of their term will automatically be exercised on such date, and all other awards
will immediately vest in full, and restricted stock units and performance awards that have not been settled or converted into shares
prior to the participant&#8217;s death will immediately be settled in shares. Performance awards will vest and be paid based on target
levels of performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Termination due to Disability.&#160;</i>If
a participant&#8217;s employment or service terminates by reason of disability, the participant will be treated as though the participant
continued in the employ or service of the Company and all unvested awards will remain outstanding and vest, or in the case of options
and SARs, vest and become exercisable, in accordance with the terms set forth in the applicable award agreement. Any options or SARs
that are or become exercisable may be exercised at any time prior to the earlier of (i)&#160;the fifth anniversary of the participant&#8217;s
termination for disability or (ii)&#160;the expiration of their term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Involuntary Termination
Without Cause.&#160;</i>If a participant&#8217;s employment or service is involuntarily terminated without cause, all options and SARs
that are unvested will be immediately forfeited and canceled, and all options and SARs that are vested will remain outstanding and exercisable
until the earlier of (i)&#160;30&#160;days after the termination date or (ii)&#160;the expiration of their term, all restricted stock
or restricted stock units that are unvested will be immediately forfeited and canceled, and provided that the participant signs a general
release and waiver of claims in the form provided by the Company and does not exercise any rights to revoke such release, the participant
will retain a pro-rated&#160;portion of any unvested performance awards granted earlier than one year prior to the termination date,
and be earned based on the attainment of the applicable performance goals (and any performance awards that are not so earned will be
forfeited and canceled).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Termination for Any Other
Reason.&#160;</i>If a participant&#8217;s employment or service terminates for any reason other than as set forth above, all options
and SARs that are unvested will be immediately forfeited and canceled, and all options and SARs that are vested will remain outstanding
and exercisable until the earlier of (i)&#160;30&#160;days after the termination date or (ii)&#160;the expiration of their term, and
all other awards that are unvested or have not otherwise been earned shall be immediately forfeited and canceled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Change in Control.&#160;</i>Unless
otherwise provided in an award agreement, and other than with respect to certain performance awards (described in the next paragraph),
no cancellation, acceleration or other payment will occur in connection with a change in control of the Company if the Administrator
reasonably determines in good faith, prior to the occurrence of the change in control, that the award will be honored or assumed, or
new rights substituted therefor following the change in control, provided that any such alternative award must (i)&#160;give the participant
rights and entitlements substantially equivalent to or better than the rights and terms applicable under the award immediately prior
to the change in control, (ii)&#160;have terms such that if a participant&#8217;s employment is involuntarily or constructively terminated
within the twenty-four&#160;months following the change in control at a time when any portion of the alternative award is unvested, the
unvested portion of the alternative award will immediately vest in full and the participant will receive either (1)&#160;a cash payment
equal in value to the excess (if any) of the fair market value of the stock subject to the alternative award at the date of exercise
or settlement over the price that the participant would be required to pay to exercise the alternative award, or (2)&#160;an equal value
of publicly-traded&#160;shares or equity interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise provided
in an award agreement, upon a change in control, then-outstanding&#160;performance awards will be modified to replace any performance
goals with vesting solely based on the requirement of continued service through, as nearly as is practicable, the date(s)&#160;on which
the satisfaction of the performance goals would have been measured if the change in control had not occurred or, if applicable, the later
period of required service following such measurement date, with accelerated vesting if the participant&#8217;s employment is involuntarily
or constructively terminated within the twenty-four&#160;months following the change in control. The number of such alternative awards
will be equal to (i)&#160;if less than 50% of the performance cycle has elapsed, the target number of performance awards, and (ii)&#160;if
50% or more of the performance cycle has elapsed, a number of awards based on actual performance through the date of the change in control
if determinable, or the target, if not determinable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
above or in an award agreement, upon a change in control: each vested and unvested option or SAR will be canceled in exchange for a payment
equal to the excess, if any, of the change in control price over the applicable exercise or base price, the vesting restrictions applicable
to all other unvested awards (other than freestanding dividend equivalents and performance awards) will lapse, and such awards will be
canceled in exchange for a payment equal to the change in control price, the alternative performance awards will be canceled in exchange
for a payment equal to the change in control price, all other awards (other than freestanding dividend equivalents) that were vested
prior to the change in control but that have not been settled or converted into shares prior to the change in control will be canceled
in exchange for a payment equal to the change in control price, and all freestanding dividend equivalents will be cancelled without payment
therefor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent any portion
of the change in control price is payable other than in cash and/or other than at the time of the change in control, the award holders
will receive the same value in respect of their awards (less any applicable exercise or base price) as is received by the Company&#8217;s
stockholders in respect of their shares. To the extent any portion of the change in control price is payable other than at the time of
the change in control, the committee will determine the time and form of payment to the award holders consistent with Section&#160;409A
of the Code and other applicable laws. Upon a change in control the committee may cancel options and SARs for no consideration if the
fair market value of the shares subject to such options or such SARs is less than or equal to their exercise or base price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Forfeiture, Cancellation
or &#8220;<span style="text-decoration:underline">Clawback</span>&#8221; of Awards</i>.<i>&#160;</i>Awards (and gains earned or accrued in connection with awards) will be subject
to such generally applicable policies as to forfeiture and recoupment as may be adopted by the Compensation Committee or the Board. Participants
will also forfeit and disgorge to the Company any awards granted or vested and any gains earned or accrued due to the exercise of options
or SARs or the sale of any shares of stock to the extent required by applicable law or as required by any stock exchange or quotation
system on which the stock is listed or quoted. Awards are also subject to any generally applicable clawback policy adopted by the Administrator,
the Board or the Company that is communicated to the participants or any such policy adopted to comply with applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Amendment or Termination
of the Amended Plan.&#160;</i>The Amended Plan may be wholly or partially amended or otherwise modified, suspended or terminated at any
time or from time to time by the Administrator; provided, that without the approval of the stockholders of the Company, no amendment
or modification to the Amended Plan may (i)&#160;except as otherwise expressly provided in the Amended Plan, increase the number of shares
subject to the Amended Plan; (ii)&#160;modify the class of persons eligible for participation in the Amended Plan or (iii)&#160;materially
modify the Amended Plan in any other way that would require stockholder approval under applicable law. Except as otherwise expressly
provided in the Amended Plan, neither the amendment, suspension nor termination of the Amended Plan shall, without the written consent
of the holder of the award, materially adversely alter or impair any rights or obligations under any award theretofore granted. No award
may be granted during any period of suspension nor after termination of the Amended Plan, and in no event may any award be granted under
the Amended Plan after the expiration of ten&#160;years from the original effective date of the Amended Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Amendment of an Award.&#160;</i>The
Administrator may at any time, and from time to time, amend the terms of any one or more existing award agreements, provided, however,
that the rights of a participant under an award agreement may not be materially adversely impaired without the participant&#8217;s written
consent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_127"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Federal Income
Tax Consequences</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Code provides that a
participant receiving a nonqualified stock option ordinarily does not realize taxable income upon the grant of the stock option. A participant
does, however, realize compensation income taxed at ordinary income tax rates upon the exercise of a nonqualified stock option to the
extent that the fair market value of the common stock on the date of exercise exceeds the stock option price. Subject to the deduction
limitation under Section&#160;162(m)&#160;of the Code (which disallows a federal income tax deduction to any publicly held corporation
for compensation paid in excess of $1.0&#160;million in any taxable year to certain &#8220;<span style="text-decoration:underline">covered employees</span>&#8221;, which term
includes the named executive officers of the Company), the Company is entitled to a federal income tax deduction for compensation in
an amount equal to the ordinary income so realized by the participant. When the participant sells the shares acquired pursuant to a nonqualified
stock option, any gain or loss will be capital gain or loss (this assumes that the shares represent a capital asset in the participant&#8217;s
hands), and there will be no tax consequences for the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The grant of an incentive
stock option does not result in taxable income to a participant. The exercise of an incentive stock option also does not result in taxable
income, provided that the circumstances satisfy the employment requirements in the Code. However, the exercise of an incentive stock
option may give rise to alternative minimum tax liability for the participant. In addition, if the participant does not dispose of the
common stock acquired upon exercise of an incentive stock option during the statutory holding period, then any gain or loss upon subsequent
sale of the common stock will be a long-term&#160;capital gain or loss. This assumes that the shares represent a capital asset in the
participant&#8217;s hands.<b>&#160;</b>The statutory holding period lasts until the later of two&#160;years from the date the stock option
is granted and one year from the date the common stock is transferred to the participant pursuant to the exercise of the stock option.
If the employment and statutory holding period requirements are satisfied, the Company may not claim any federal income tax deduction
upon either the exercise of the incentive stock option or the subsequent sale of the common stock received upon exercise. If these requirements
are not satisfied (a &#8220;<span style="text-decoration:underline">disqualifying disposition</span>&#8221;), the amount of ordinary income taxable to the participant is the
lesser of the fair market value of the common stock on the date of exercise minus the stock option price and the amount realized on disposition
minus the stock option price. Any excess is long-term&#160;or short-term&#160;capital gain or loss, assuming the shares represent a capital
asset in the participant&#8217;s hands. Subject to the deduction limitation under Section&#160;162(m)&#160;of the Code, in the case of
a disqualifying disposition, the Company is entitled to a federal income tax deduction in an amount equal to the ordinary income realized
by the participant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise of a stock option
through the exchange of previously-acquired&#160;stock will generally be treated as a non-taxable&#160;like-kind&#160;exchange as to
the number of shares given up and the identical number of shares received under the stock option. That number of shares will take the
same tax basis and, for capital gain purposes, the same holding period as the shares that are given up. The value of the shares received
upon such an exchange which are in excess of the number given up will be taxed to the participant at the time of the exercise as ordinary
income, taxed as compensation. The excess shares will have a new holding period for capital gains purposes and a tax basis equal to the
value of such shares determined at the time of exercise. If the tendered shares were acquired through the prior exercise of an incentive
stock option and do not satisfy the statutory two-year&#160;and one-year&#160;holding periods (&#8220;<span style="text-decoration:underline">disqualified shares</span>&#8221;),
then the tender will result in compensation income to the optionee taxed as ordinary income equal to the excess of the fair market value
of the disqualified shares, determined when the prior incentive stock option was exercised, over the exercise price of the disqualified
shares. The optionee will increase his tax basis in the number of shares received on exercise equal to the number of shares of disqualified
shares tendered by the amount of compensation income recognized by the optionee with respect to the disqualified shares. Generally, the
federal income tax consequences to the optionee are similar to those described above relating to the exercise of a stock option through
the exchange of non-disqualified&#160;shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an optionee exercises
a stock option through the cashless exercise method by authorizing a broker to sell a specified number of the shares to be acquired through
the stock option exercise having a market value equal to the sum of the stock option exercise plus any transaction costs (the &#8220;<span style="text-decoration:underline">cashless
shares</span>&#8221;), the optionee should be treated as constructively receiving the full amount of stock option shares, followed immediately
by a sale of the cashless shares by the optionee. In the case of an incentive stock option, the cashless exercise method would result
in the cashless shares becoming disqualified shares and taxed in a manner described above for disqualified shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the case of a nonqualified
stock option, the cashless exercise method would result in compensation income to the optionee with respect to both the cashless shares
and remaining stock option shares as discussed above relating to nonqualified stock options. Since the optionee&#8217;s tax basis in
the cashless shares that are deemed received and simultaneously sold on exercise of the stock option is equal to the sum of the exercise
price and the compensation to the optionee, no additional gain should be recognized by the optionee upon the deemed sale of the cashless
shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Section&#160;83(b)&#160;of
the Code, an employee may elect to include in ordinary income, as compensation at the time restricted stock is first issued, the excess
of the fair market value of the stock at the time of issuance over the amount paid, if any, by the employee. In this event, any subsequent
change in the value of the shares will be recognized for tax purposes as capital gain or loss upon disposition of the shares, assuming
that the shares represent a capital asset in the hands of the employee. An employee makes a Section&#160;83(b)&#160;election by filing
the election with the IRS no later than 30&#160;days after the restricted stock is transferred to the employee. If a Section&#160;83(b)&#160;election
is properly made, the employee will not be entitled to any loss deduction if the shares with respect to which a Section&#160;83(b)&#160;election
was made are later forfeited. Unless a Section&#160;83(b)&#160;election is made, no taxable income will generally be recognized by the
recipient of a restricted stock award until the shares are no longer subject to the transfer restrictions or the risk of forfeiture.
When either the transfer restrictions or the risk of forfeiture lapses, the employee will recognize ordinary income, taxable as compensation,
in an amount equal to the excess of the fair market value of the common stock on the date of lapse over the amount paid, if any, by the
employee for the stock. Absent a Section&#160;83(b)&#160;election, any cash dividends or other distributions paid with respect to the
restricted stock prior to the lapse of the transfer restrictions or risk of forfeiture will be included in the employee&#8217;s ordinary
income as compensation at the time of receipt and subsequent appreciation or depreciation will be recognized as capital gain or loss,
assuming that the shares represent a capital asset in the hands of the employee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, an employee will
not recognize any taxable income upon the grant of stock appreciation rights, performance shares, or other stock or cash-based&#160;award.
At the time the employee receives the payment for the stock appreciation right, performance shares, or other stock or cash-based&#160;award,
the fair market value of shares of common stock or the amount of any cash received in payment for such awards generally is taxable to
the employee as ordinary income, taxable as compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the deduction
limitation under Section&#160;162(m)&#160;of the Code, the Company or one of its subsidiaries will be entitled to a deduction for federal
income tax purposes at the same time and in the same amount that an employee recognizes ordinary income from awards under the Amended
Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercisability of a stock
option or a stock appreciation right, the payment of a performance share or the elimination of restrictions on restricted stock, may
be accelerated, and special cash settlement rights may be triggered and exercised, as a result of a change in control. If any of the
foregoing occurs, all or a portion of the value of the relevant award at that time may be considered a parachute payment under the Code.
This is relevant for determining whether a 20% excise tax (in addition to income tax otherwise owed) is payable by the participant as
a result of the receipt of an excess parachute payment pursuant to the Code. The Company will not be entitled to a deduction for that
portion of any parachute payment which is subject to the excise tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_128"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Vote Required</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This proposal to approve
the Amendment requires approval by the affirmative vote of a majority of the votes entitled to be cast at the annual meeting by holders
of voting capital stock who are present in person or by proxy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_129"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Recommendation
of the Board of Directors</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board of Directors recommends a vote &#8220;<span style="text-decoration:underline">FOR</span>&#8221;
the Amendment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
APPROVAL OF THE&#160;FOURTH AMENDMENT TO THE 180 LIFE SCIENCES CORP. 2022 OMNIBUS INCENTIVE PLAN.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_167"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Proposal 3<br/>
Approval of the 180 Life Sciences Corp. 2025 Option Incentive Plan<br/>
&#160;</p><div>

</div><div><a id="a_130"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">General</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 17, 2025, the Board
of Directors of the Company, with the recommendation of the Compensation Committee of the Board of Directors, adopted the Company&#8217;s
2025 Option Incentive Plan (the &#8220;<span style="text-decoration:underline">2025 Plan</span>&#8221;). Notwithstanding such adoption, in accordance with the rules of the Nasdaq
Capital Market, following the date of adoption, but prior to the Shareholder Approval Date (as defined below), (i) no stock options granted
thereunder can be exercised, and (ii) if Shareholder Approval (as defined below) is not received, the 2025 Plan is to be unwound, and
the outstanding stock options granted thereunder cancelled (the &#8220;<span style="text-decoration:underline">Nasdaq Pre-Approval Requirements</span>&#8221;). The 2025 Plan
was adopted in accordance with the rules of The Nasdaq Capital Market, which allow the Company to adopt an equity arrangement and grant
options thereunder prior to obtaining stockholder approval, provided that (i) no options can be exercised prior to obtaining stockholder
approval, and (ii) the plan can be unwound, and the outstanding options cancelled, if stockholder approval is not obtained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholder approval of the
2025 Plan is required to be received within twelve (12) months of the date of adoption of the 2025 Plan by the Board of Directors (the
&#8220;<span style="text-decoration:underline">Shareholder Approval</span>&#8221; and the date of such Shareholder Approval, the &#8220;<span style="text-decoration:underline">Shareholder Approval Date</span>&#8221;).
Additionally, the grant of incentive stock options under the 2025 Plan is subject to Shareholder Approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Plan provides an opportunity
for any employee, officer, director or consultant of the Company, subject to the terms of the 2025 Plan (including as discussed above
and any limitations provided by federal or state securities laws), to receive (i) incentive stock options (to eligible employees only);
or (ii) nonqualified stock options. Incentive stock options granted under the 2025 Plan are intended to qualify as &#8220;<span style="text-decoration:underline">incentive
stock options</span>&#8221; within the meaning of Section 422 of the Code. Nonqualified (non-statutory stock options) granted under the
2025 Plan are not intended to qualify as incentive stock options under the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A total of 1,000,000 shares
of common stock are reserved for awards under the 2025 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the 2025 Plan is
attached as&#160;<span style="text-decoration:underline">Appendix C</span>&#160;to this Proxy Statement, and the summary of the 2025 Plan below is qualified in its entirety
to the full 2025 Plan attached hereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">2025 Plan Option Grants</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective June 17, 2025,
the Board of Directors of the Company, with the recommendation of the Compensation Committee of the Board of Directors, approved the
grant of stock options to (A) the following named executive officers: (a)&#160;Blair Jordan, the Chief Executive Officer of the Company
(options to purchase 410,000 shares); and (b)&#160;Eric R. Van Lent, the Chief Accounting Officer of the Company (options to purchase
25,000 shares); (B) the non-executive members of the Board of Directors as follows: Ryan Smith, Lead Director, options to purchase 255,000
shares of common stock; Stephen H. Shoemaker, director, options to purchase 165,000 shares of common stock; and Dr. Lawrence Steinman,
director, options to purchase 110,000 shares of common stock; and (C) the Company&#8217;s outside legal counsel, options to purchase
35,000 shares of common stock, each in consideration for services rendered and to be rendered to the Company (the &#8220;<span style="text-decoration:underline">Prior 2025
Option Awards</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Prior 2025 Option Awards
were granted under the 2025 Plan and have a term of ten years, subject in all cases to the terms and conditions of the 2025 Plan and
the award agreements entered into to evidence such grants, and each service provider&#8217;s continued service with the Company. The
Prior 2025 Option Awards vest at the rate of 1/2 of such options on each of the six and twelve month anniversaries of the grant date.
The Prior 2025 Option Awards have an exercise price of $0.9290 per share, the closing sales price of the Company&#8217;s common stock
on the Nasdaq Capital market on June 17, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Background and Purpose of the 2025
Plan</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Compensation Committee and the Board are asking the Company&#8217;s stockholders to approve the 2025 Plan because the Compensation Committee
and the Board believe that it is in the best interest of the Company and its stockholders to approve the 2025 Plan, which will also effectively
approve and ratify the Prior 2025 Option Awards. In the event the 2025 Plan is not approved by stockholders by June 17, 2026, the 2025
Plan, and the Prior 2025 Option Awards, will be unwound, and the Prior 2025 Option Awards will be cancelled. Additionally, none of the
Prior 2025 Option Awards may be exercised, even if vested, until stockholders approve the 2025 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Summary of the Material Terms of the
2025 Plan</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of the principal features of the 2025 Plan.&#160;This summary does not purport to be a complete description of all of the provisions
of the 2025 Plan.&#160;It is qualified in its entirety by reference to the full text of the 2025 Plan (included as&#160;<span style="text-decoration:underline">Appendix C</span>&#160;to
this proxy statement).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Purpose.&#160;</i>The
purpose of the 2025 Plan is to promote the interests of the Company and its subsidiaries and its stockholders by (i)&#160;attracting
and retaining directors, executive officers, employees and consultants of outstanding ability; (ii)&#160;motivating such individuals
by means of performance-related&#160;incentives to achieve the longer-range&#160;performance goals of the Company and its subsidiaries;
and (iii)&#160;enabling such individuals to participate in the long-term&#160;growth and financial success of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Administration.&#160;</i>The
Board of Directors, and unless otherwise determined by our Board, our Compensation Committee of the Board, have the power and authority
to administer the 2025 Plan (the &#8220;<span style="text-decoration:underline">Administrator</span>&#8221;). The Administrator has the authority to (i)&#160;determine the type
or types of options to be granted to each participant; (ii)&#160;select the participants to whom awards may from time to time be granted;
(iii)&#160;determine all matters and questions related to the termination of service of a participant with respect to any award granted
to him or her; (iv)&#160;determine the number of awards to be granted and the number of shares to which an award will relate; (v)&#160;approve
forms of agreement for use under the 2025 Plan; (vi)&#160;determine the terms and conditions of any awards; (vii)&#160;prescribe, amend
and rescind rules and regulations relating to the 2025 Plan; (viii)&#160;determine whether, to what extent, and pursuant to what circumstances
an award may be settled in, or the exercise or purchase price of an award may be paid in, cash, stock, other awards, or other property,
or an award may be canceled, forfeited or surrendered; (ix)&#160;suspend or accelerate the vesting of any award granted under the 2025
Plan or waive the forfeiture restrictions or any other restriction or limitation regarding any awards relating thereto; (x)&#160;construe
and interpret the terms of the 2025 Plan and awards granted pursuant to the 2025 Plan; and (xi)&#160;make all other decisions and determinations
that may be required pursuant to the 2025 Plan or as it deems necessary or advisable to administer the 2025 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Eligibility.&#160;</i>Employees,
non-employee&#160;directors, and consultants of the Company and its subsidiaries are eligible to participate in the 2025 Plan.&#160;Incentive
stock options may be granted under the 2025 Plan only to employees of our company and its subsidiaries. Employees, directors and consultants
of our company and its affiliates are eligible to receive non-qualified stock options under the 2025 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Awards.&#160;</i>Awards
under the 2025 Plan may be made in the form of stock options, which may be either incentive stock options or non-qualified&#160;stock
options. Awards are generally non-transferable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Shares Subject to the
2025 Plan.&#160;</i>Subject to adjustment in connection with the payment of a stock dividend, a stock split or subdivision or combination
of the shares of common stock, or a reorganization or reclassification of the Company&#8217;s common stock, the aggregate number of shares
of common stock which may be issued pursuant to awards under the 2025 Plan is 1,000,000, of which no shares are currently available for
future awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an award granted under
the 2025 Plan entitles a holder to receive or purchase shares of our common stock, then on the date of grant of the award, the number
of shares covered by the award (or to which the award relates) will be counted against the total number of shares available for granting
awards under the 2025 Plan.&#160;As a result, the shares available for granting future awards under the 2025 Plan will be reduced as
of the date of grant. However, certain shares that have been counted against the total number of shares authorized under the 2025 Plan
in connection with awards previously granted under such 2025 Plan will again be available for awards under the 2025 Plan as follows:
shares of our common stock covered by an award or to which an award relates which were not issued because the award terminated or was
forfeited or cancelled without the delivery of shares will again be available for awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shares issued under the 2025
Plan may be authorized but unissued shares or reacquired shares. Any shares covered by an award, or portion of an award, granted under
the 2025 Plan that is forfeited, canceled, cash-settled, expired or otherwise terminated without the issuance of shares, shall again
be available for the grant of an award under the 2025 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Award Limitations on&#160;Non-Director&#160;Awards.&#160;</i>The
maximum number of shares subject to awards granted during a single compensation year (that is from one annual meeting of stockholders
to the next annual meeting) to any non-employee&#160;director, taken together with any cash fees paid during the compensation year to
the non-employee&#160;director, in respect of the director&#8217;s service as a member of the Board during such year (including service
as a member or chair of any committees of the Board), will not exceed $500,000 in total value (calculating the value of any such awards
based on the grant date fair value of such awards for financial reporting purposes); provided that in the event such non-employee&#160;director
is first appointed or elected to the Board during such compensation year, and/or in the case that the non-employee&#160;director is serving
as non-employee&#160;chairperson of the Board, such amount shall not exceed $750,000 in total value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Change in Capitalization
or Other Corporate Event.&#160;</i>If and to the extent necessary or appropriate to reflect any stock dividend, extraordinary dividend,
stock split or share combination or any recapitalization, merger, consolidation, exchange of shares, spin-off, liquidation or dissolution
of the Company or other similar transaction affecting our common stock, the Administrator shall adjust the number of shares of our common
stock available for issuance under the 2025 Plan, and the number, class and exercise price or base price of any outstanding award, and/or
make such substitution, revision or other provisions or take such other actions with respect to any outstanding award or the holder or
holders thereof, in each case as it determines to be equitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Terms and Conditions of
Options.&#160;</i>An &#8220;<span style="text-decoration:underline">incentive stock option</span>&#8221; is an option that meets the requirements of Section&#160;422 of the
Code, and a &#8220;<span style="text-decoration:underline">non-qualified&#160;stock option</span>&#8221; is an option that does not meet those requirements. An option granted
will be exercisable only to the extent that it is vested on the date of exercise. No option may be exercisable more than ten&#160;years
from the grant date. In general, the exercise price per share under each option granted under the 2025 Plan may not be less than 100%
of the fair market value of our common stock on the option grant date, provided that stockholders who own greater than 10% of the Company&#8217;s
voting stock cannot be granted incentive stock options that have an exercise price less than 110% of the fair market value of the Company&#8217;s
common stock on the date of grant. For so long as our common stock is listed on an established stock exchange, the fair market value
of the common stock will be the closing price of our common stock on the exchange on which it is listed on the option grant date. If
there is no closing price reported on the option grant date, the fair market value will be deemed equal to the closing price for the
common stock on the last market&#160;trading day prior to the&#160;day of determination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Termination of Employment.&#160;</i>All
of the terms relating to the exercise, cancellation or other disposition of any award upon a termination of employment or service with
the Company of the participant, whether due to disability, death or under any circumstances may be determined by the Administrator and
described in each participant&#8217;s award agreement. Unless otherwise set forth in the applicable agreement, the following provisions
will apply:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Termination for Cause;&#160;Post-Service&#160;Competitive
Activity.&#160;</i>If a participant&#8217;s employment or service terminates for cause or a participant breaches any restrictive covenants
(such as a non-competition&#160;or non-solicitation&#160;agreement) following the participant&#8217;s termination of employment or service,
all options, whether vested or unvested will be immediately forfeited and canceled. If the participant breaches the restrictive covenants
following the termination, any portion of the participant&#8217;s awards that became vested after termination, and any shares or cash
issued upon exercise or settlement of such awards, will be immediately forfeited, canceled, and disgorged or paid to the Company together
with all gains earned or accrued due to the sale of shares issued upon exercise or settlement of such awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Termination due to Death.&#160;</i>If
a participant&#8217;s employment or service terminates by reason of death, all options (whether or not then otherwise exercisable) will
become exercisable in full and may be exercised at any time prior to the earlier of (i)&#160;the one-year&#160;anniversary of the participant&#8217;s
death or (ii)&#160;the expiration of the term of the options; provided that any in-the-money&#160;options that are still outstanding
on the last&#160;day of their term will automatically be exercised on such date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Termination due to Disability.&#160;</i>If
a participant&#8217;s employment or service terminates by reason of disability, the participant will be treated as though the participant
continued in the employ or service of the Company and all unvested awards will remain outstanding and vest, or in the case of options,
vest and become exercisable, in accordance with the terms set forth in the applicable award agreement. Any options that are or become
exercisable may be exercised at any time prior to the earlier of (i)&#160;the one year anniversary of the participant&#8217;s termination
for disability or (ii)&#160;the expiration of their term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Involuntary Termination
Without Cause.&#160;</i>If a participant&#8217;s employment or service is involuntarily terminated without cause, all options that are
unvested will be immediately forfeited and canceled, and all options that are vested will remain outstanding and exercisable until the
earlier of (i)&#160;30&#160;days after the termination date, or (ii)&#160;the expiration of their term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Termination for Any Other
Reason.&#160;</i>If a participant&#8217;s employment or service terminates for any reason other than as set forth above, all options
that are unvested will be immediately forfeited and canceled, and all options that are vested will remain outstanding and exercisable
until the earlier of (i)&#160;30&#160;days after the termination date or (ii)&#160;the expiration of their term, and all other awards
that are unvested or have not otherwise been earned shall be immediately forfeited and canceled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Change in Control.&#160;</i>Unless
otherwise provided in an award agreement, no cancellation, acceleration or other payment will occur in connection with a change in control
of the Company if the Administrator reasonably determines in good faith, prior to the occurrence of the change in control, that the award
will be honored or assumed, or new rights substituted therefor following the change in control, provided that any such alternative award
must (i)&#160;give the participant rights and entitlements substantially equivalent to or better than the rights and terms applicable
under the award immediately prior to the change in control, (ii)&#160;have terms such that if a participant&#8217;s employment is involuntarily
or constructively terminated within the twenty-four&#160;months following the change in control at a time when any portion of the alternative
award is unvested, the unvested portion of the alternative award will immediately vest in full and the participant will receive either
(1)&#160;a cash payment equal in value to the excess (if any) of the fair market value of the stock subject to the alternative award
at the date of exercise or settlement over the price that the participant would be required to pay to exercise the alternative award,
or (2)&#160;an equal value of publicly-traded&#160;shares or equity interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
above or in an award agreement, upon a change in control: each vested and unvested option will be canceled in exchange for a payment
equal to the excess, if any, of the change in control price over the applicable exercise or base price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent any portion
of the change in control price is payable other than in cash and/or other than at the time of the change in control, the award holders
will receive the same value in respect of their awards (less any applicable exercise or base price) as is received by the Company&#8217;s
stockholders in respect of their shares. To the extent any portion of the change in control price is payable other than at the time of
the change in control, the committee will determine the time and form of payment to the award holders consistent with Section&#160;409A
of the Code and other applicable laws. Upon a change in control the committee may cancel options for no consideration if the fair market
value of the shares subject to such options is less than or equal to their exercise or base price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Forfeiture, Cancellation
or &#8220;<span style="text-decoration:underline">Clawback</span>&#8221; of Awards</i>.<i>&#160;</i>Awards (and gains earned or accrued in connection with awards) will be subject
to such generally applicable policies as to forfeiture and recoupment as may be adopted by the Compensation Committee or the Board. Participants
will also forfeit and disgorge to the Company any awards granted or vested and any gains earned or accrued due to the exercise of options
or the sale of any shares of stock to the extent required by applicable law or as required by any stock exchange or quotation system
on which the stock is listed or quoted. Awards are also subject to any generally applicable clawback policy adopted by the Administrator,
the Board or the Company that is communicated to the participants or any such policy adopted to comply with applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Amendment or Termination
of the 2025 Plan.&#160;</i>The 2025 Plan may be wholly or partially amended or otherwise modified, suspended or terminated at any time
or from time to time by the Administrator; provided, that without the approval of the stockholders of the Company, no amendment or modification
to the 2025 Plan may (i)&#160;except as otherwise expressly provided in the 2025 Plan, increase the number of shares subject to the 2025
Plan; (ii)&#160;modify the class of persons eligible for participation in the 2025 Plan or (iii)&#160;materially modify the 2025 Plan
in any other way that would require stockholder approval under applicable law. Except as otherwise expressly provided in the 2025 Plan,
neither the amendment, suspension nor termination of the 2025 Plan shall, without the written consent of the holder of the award, materially
adversely alter or impair any rights or obligations under any award theretofore granted. No award may be granted during any period of
suspension nor after termination of the 2025 Plan, and in no event may any award be granted under the 2025 Plan after the expiration
of ten&#160;years from the original effective date of the 2025 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Amendment of an Award.&#160;</i>The
Administrator may at any time, and from time to time, amend the terms of any one or more existing award agreements, provided, however,
that the rights of a participant under an award agreement may not be materially adversely impaired without the participant&#8217;s written
consent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Federal Income Tax Consequences</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Code provides that a
participant receiving a nonqualified stock option ordinarily does not realize taxable income upon the grant of the stock option. A participant
does, however, realize compensation income taxed at ordinary income tax rates upon the exercise of a nonqualified stock option to the
extent that the fair market value of the common stock on the date of exercise exceeds the stock option price. Subject to the deduction
limitation under Section&#160;162(m)&#160;of the Code (which disallows a federal income tax deduction to any publicly held corporation
for compensation paid in excess of $1.0&#160;million in any taxable year to certain &#8220;<span style="text-decoration:underline">covered employees</span>&#8221;, which term
includes the named executive officers of the Company), the Company is entitled to a federal income tax deduction for compensation in
an amount equal to the ordinary income so realized by the participant. When the participant sells the shares acquired pursuant to a nonqualified
stock option, any gain or loss will be capital gain or loss (this assumes that the shares represent a capital asset in the participant&#8217;s
hands), and there will be no tax consequences for the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The grant of an incentive
stock option does not result in taxable income to a participant. The exercise of an incentive stock option also does not result in taxable
income, provided that the circumstances satisfy the employment requirements in the Code. However, the exercise of an incentive stock
option may give rise to alternative minimum tax liability for the participant. In addition, if the participant does not dispose of the
common stock acquired upon exercise of an incentive stock option during the statutory holding period, then any gain or loss upon subsequent
sale of the common stock will be a long-term&#160;capital gain or loss. This assumes that the shares represent a capital asset in the
participant&#8217;s hands.<b>&#160;</b>The statutory holding period lasts until the later of two&#160;years from the date the stock option
is granted and one year from the date the common stock is transferred to the participant pursuant to the exercise of the stock option.
If the employment and statutory holding period requirements are satisfied, the Company may not claim any federal income tax deduction
upon either the exercise of the incentive stock option or the subsequent sale of the common stock received upon exercise. If these requirements
are not satisfied (a &#8220;<span style="text-decoration:underline">disqualifying disposition</span>&#8221;), the amount of ordinary income taxable to the participant is the
lesser of the fair market value of the common stock on the date of exercise minus the stock option price and the amount realized on disposition
minus the stock option price. Any excess is long-term&#160;or short-term&#160;capital gain or loss, assuming the shares represent a capital
asset in the participant&#8217;s hands. Subject to the deduction limitation under Section&#160;162(m)&#160;of the Code, in the case of
a disqualifying disposition, the Company is entitled to a federal income tax deduction in an amount equal to the ordinary income realized
by the participant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise of a stock option
through the exchange of previously-acquired&#160;stock will generally be treated as a non-taxable&#160;like-kind&#160;exchange as to
the number of shares given up and the identical number of shares received under the stock option. That number of shares will take the
same tax basis and, for capital gain purposes, the same holding period as the shares that are given up. The value of the shares received
upon such an exchange which are in excess of the number given up will be taxed to the participant at the time of the exercise as ordinary
income, taxed as compensation. The excess shares will have a new holding period for capital gains purposes and a tax basis equal to the
value of such shares determined at the time of exercise. If the tendered shares were acquired through the prior exercise of an incentive
stock option and do not satisfy the statutory two-year&#160;and one-year&#160;holding periods (&#8220;<span style="text-decoration:underline">disqualified shares</span>&#8221;),
then the tender will result in compensation income to the optionee taxed as ordinary income equal to the excess of the fair market value
of the disqualified shares, determined when the prior incentive stock option was exercised, over the exercise price of the disqualified
shares. The optionee will increase his tax basis in the number of shares received on exercise equal to the number of shares of disqualified
shares tendered by the amount of compensation income recognized by the optionee with respect to the disqualified shares. Generally, the
federal income tax consequences to the optionee are similar to those described above relating to the exercise of a stock option through
the exchange of non-disqualified&#160;shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an optionee exercises
a stock option through the cashless exercise method by authorizing a broker to sell a specified number of the shares to be acquired through
the stock option exercise having a market value equal to the sum of the stock option exercise plus any transaction costs (the &#8220;<span style="text-decoration:underline">cashless
shares</span>&#8221;), the optionee should be treated as constructively receiving the full amount of stock option shares, followed immediately
by a sale of the cashless shares by the optionee. In the case of an incentive stock option, the cashless exercise method would result
in the cashless shares becoming disqualified shares and taxed in a manner described above for disqualified shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the case of a nonqualified
stock option, the cashless exercise method would result in compensation income to the optionee with respect to both the cashless shares
and remaining stock option shares as discussed above relating to nonqualified stock options. Since the optionee&#8217;s tax basis in
the cashless shares that are deemed received and simultaneously sold on exercise of the stock option is equal to the sum of the exercise
price and the compensation to the optionee, no additional gain should be recognized by the optionee upon the deemed sale of the cashless
shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the deduction
limitation under Section&#160;162(m)&#160;of the Code, the Company or one of its subsidiaries will be entitled to a deduction for federal
income tax purposes at the same time and in the same amount that an employee recognizes ordinary income from awards under the 2025 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercisability of a stock
option may be accelerated as a result of a change in control. If any of the foregoing occurs, all or a portion of the value of the relevant
award at that time may be considered a parachute payment under the Code. This is relevant for determining whether a 20% excise tax (in
addition to income tax otherwise owed) is payable by the participant as a result of the receipt of an excess parachute payment pursuant
to the Code. The Company will not be entitled to a deduction for that portion of any parachute payment which is subject to the excise
tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Effect of Approval</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Approval of this Proposal
3 by our stockholders at the Annual Meeting will effectively ratify and approve the <span style="text-decoration:underline">Prior 2025 Option Awards, which will not be unwound
and will be exercisable for shares of common stock of the Company, subject to vesting, upon such stockholder approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_131"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Vote Required</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Proposal to approve
the 2025 Plan requires approval by the affirmative vote of a majority of the votes entitled to be cast at the annual meeting by holders
of voting capital stock who are present in person or by proxy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this Proposal 3 is not
approved by the Company&#8217;s stockholders at the Annual Meeting or within one (1) year of the adoption of the 2025 Plan, the 2025
Plan and the Prior 2025 Option Awards will be unwound, and the outstanding Prior 2025 Option Awards granted thereunder cancelled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="via_001"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Recommendation of the Board of Directors</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board of Directors recommends a vote &#8220;<span style="text-decoration:underline">FOR</span>&#8221;
the ratification of the 2025 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
APPROVAL OF THE&#160; 180 LIFE SCIENCES CORP. 2025 OPTION INCENTIVE PLAN.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_132"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Proposal 4<br/>
Approval of an Advisory Resolution on Named Executive Officer Compensation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_133"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">General</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the requirements
of Section 14A of the Exchange Act and the related rules of the SEC, our stockholders have the opportunity to cast an advisory vote to
approve the compensation of our named executive officers as disclosed pursuant to the SEC&#8217;s compensation disclosure rules, which
disclosure includes the executive compensation tables, and the narrative disclosures that accompany the executive compensation tables.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.8pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Motivating and retaining
a talented and experienced leadership team is a key component of the Company&#8217;s long-term success. We are committed to an effective
executive compensation program that incorporates sound policies and best practices. The compensation realized by our named executive
officers in 2024 reflected our executive compensation program&#8217;s alignment with Company performance and shareholder interests. We
encourage shareholders to read the section entitled &#8220;Executive and Director Compensation,&#8221; above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Section
14A of the Exchange Act, and as a matter of good corporate governance, stockholders will be asked at the annual meeting to approve the
following advisory resolution:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.8pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#8220;<i>RESOLVED, that the compensation
paid to the Company&#8217;s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation
tables and any related material disclosed in this proxy statement, is hereby APPROVED</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an advisory vote, this
proposal, commonly referred to as a &#8220;say on pay&#8221; resolution, is not binding on the Company, the Board, or the Compensation
Committee. However, the Compensation Committee and the Board value the opinions expressed by stockholders in their votes on this proposal
and will consider the outcome of the vote when making future compensation decisions regarding named executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.8pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect the next advisory
say on pay vote will occur at the 2026 annual meeting of shareholders and that the next advisory vote on the frequency of say on pay
votes will occur at the 2029 annual meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.8pt">&#160;</p><div>

</div><div><a id="a_134"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Vote Required</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Approval of Proposal 4 requires
the affirmative vote of a majority of the shares present or represented by proxy and voting at the annual meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_135"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Board Recommendation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board of Directors unanimously recommends
a vote &#8220;<span style="text-decoration:underline">FOR</span>&#8221; this proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Split-Segment; Name: 003 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><div><a id="a_136"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Proposal 5<br/>
Amendment to Second Amended and Restated Certificate of<br/>
Incorporation, as Amended, to Effect a Reverse Stock Split</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_137"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">General</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Meeting, stockholders
will be asked to grant discretionary authority for our Board of Directors to (A) amend <span style="text-decoration:underline">Article IV</span>&#160;of the Company&#8217;s
Second Amended and Restated Certificate of Incorporation, as amended (the &#8220;<span style="text-decoration:underline">Reverse Stock Split Amendment</span>&#8221;) to effect
a reverse stock split of the Company&#8217;s issued and outstanding shares of common stock by a ratio of between&#160;one-for-four&#160;and&#160;one-for-forty,&#160;inclusive
(the &#8220;<span style="text-decoration:underline">Reverse Stock Split</span>&#8221;), with the exact ratio to be set at a whole number to be determined by our Board of Directors
or a duly authorized committee thereof in its discretion, at any time after approval of the amendment and prior to ____________, 2026,
and (B) determine whether to arrange for the disposition of fractional interests by shareholder entitled thereto, to pay in cash the
fair value of fractions of a share of common stock as of the time when those entitled to receive such fractions are determined, or to
entitle shareholder to receive from the Company&#8217;s transfer agent, in lieu of any fractional share, the number of shares of common
stock rounded up to the next whole number</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A vote &#8220;<span style="text-decoration:underline">FOR</span>&#8221;
Proposal 5 will constitute approval of the Reverse Stock Split Amendment and will grant the Board the discretionary authority to determine
whether to implement the Reverse Stock Split, to select the Reverse Stock Split ratio out of the range approved by the Company&#8217;s
stockholders at the Meeting and to determine whether or not to round fractional shares up, or pay cash in lieu thereof. The Board expects
to authorize the consummation of the Reverse Stock Split only if and to the extent necessary to regain and maintain compliance with the
Nasdaq listing requirements, as further discussed under &#8220;<i><span style="text-decoration:underline">Purpose</span></i>&#8221; below. Upon the effectiveness of the Reverse
Stock Split (the &#8220;<span style="text-decoration:underline">Effective Date</span>&#8221;), the issued and outstanding shares of the Company&#8217;s common stock immediately
prior to the Effective Date will be reclassified into a fewer number of shares based on the Reverse Stock Split ratio selected by the
Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Reverse Stock Split,
as more fully described below, will not change the number of authorized shares of common stock or the par value of the Company&#8217;s
common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The description in this Proxy
Statement of the proposed Reverse Stock Split Amendment is qualified in its entirety by reference to, and should be read in conjunction
with, the full text of the Form of Amendment to the Second Amended and Restated Certificate of Incorporation, as amended (the &#8220;<span style="text-decoration:underline">Certificate
of Incorporation</span>&#8221;) attached to this Proxy Statement as&#160;<span style="text-decoration:underline">Appendix D</span>&#160;which is subject to non-material technical,
administrative or similar changes and modifications in the reasonable discretion of the officers of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Consistent with General Corporation
Law of the State of Delaware (the &#8220;DGCL&#8221;) Section 242(d)(2), the Board of Directors will not approve a Reverse Stock Split
in a ratio which results in the Company not meeting the listing requirements of Nasdaq, relating to the minimum number of holders immediately
after such amendment becomes effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Purpose</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sole purpose for the
Reverse Stock Split is based on the Board&#8217;s belief that the Reverse Stock Split will likely be necessary to maintain the listing
of our common stock on the Nasdaq Capital Market. In the event that the Board, in its sole discretion determines to implement the Reverse
Stock Split for such purpose, the Board believes that the Reverse Stock Split could also improve the marketability and liquidity of the
common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Maintain our listing on
the Nasdaq Capital Market</i>. Our common stock is traded on the Nasdaq Capital Market. Recently our common stock has traded below $1.00
per share, and has not closed above $1.00 per share since [_________________], 2025. Pursuant to Nasdaq Listing Rule 5550(a)(2), a Nasdaq
listed company must maintain a minimum bid price of at least $1.00 per share to meet the continued listing standards of Nasdaq (the &#8220;<span style="text-decoration:underline">Minimum
Bid Price Requirement</span>&#8221;). Typically, the Listing Qualifications Department (the &#8220;<span style="text-decoration:underline">Staff</span>&#8221;) of the Nasdaq Stock
Market (&#8220;<span style="text-decoration:underline">Nasdaq</span>&#8221;) will provide a listed company a deficiency letter if the corporation&#8217;s common stock closing
bid price is less than $1.00 per share for thirty consecutive business days. Upon receipt of such letter, the corporation will have 180
days to regain compliance with the continued listing requirements. Nasdaq also typically allows for an additional 180 days to regain
compliance, if after such initial 180 day period, the corporation meets all of the other requirements for continued listing on Nasdaq
and notifies Nasdaq in writing of its intention to cure the deficiency during the second compliance period by effecting a reverse stock
split, if necessary. Compliance with the Minimum Bid Price Requirement can be achieved during any compliance period, by having a minimum
bid price of at least $1.00, for a minimum of 10 consecutive business days during the applicable compliance period, unless the Staff
exercises its discretion to extend this 10 day period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were previously out of
compliance with the Minimum Bid Price Requirement from approximately September 30, 2022 to January 4, 2023, and from September 7, 2023
to March 13, 2024, which non-compliance was cured by affecting the Prior Reverse Stock Splits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the recent trading
of our common stock on Nasdaq, including a closing price of [____] per share on __________, 2025, the day prior to the date of this proxy
statement, an average closing price of [$___________] for the thirty trading days prior to the date of this proxy statement and an average
closing price of [$__________] for the ninety trading days prior to the date of the proxy statement, the Board of Directors believes
that it more likely that not that the Company, in the near future, will fail to meet the Minimum Bid Price Requirement and that it may
need to affect another reverse stock split in order to cure such non-compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Nasdaq Listing
Rule 5815(a)(1)(B)(ii)d, if a listed company fails to regain compliance with the Minimum Bid Price Requirement by the end of the second
compliance period (i.e., 360 days after the date of the initial notice), the security will be immediately suspended from Nasdaq; provided
that the issuer can still appeal that decision to a hearings panel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nasdaq Listing Rule 5810(c)(3)(A)(iv)
provides that if a listed company&#8217;s security fails to meet the Minimum Bid Price Requirement and (a) the Company has effected a
reverse stock split over the prior one-year period; or (b) has effected one or more reverse stock splits over the prior two-year period
with a cumulative ratio of 250 shares or more to one, then the Company is not eligible for a compliance period to address the Minimum
Bid Price Requirement and will be automatically suspended from Nasdaq, subject to rights to appeal the delisting to a hearings panel.
This restriction applies even if the listed company was in compliance with the Minimum Bid Price Requirement at the time of its prior
reverse stock split. As a result of the above, if a listed company effects a reverse stock split but its security subsequently falls
out of compliance with the Minimum Bid Price Requirement within a one-year period or has affected reverse stock splits with a cumulative
ratio of 1-to-250 or more over the prior two year period, it will be issued a delisting determination rather than being granted a compliance
period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As discussed above under
&#8220;Prior Reverse Stock Splits&#8221;, effective on February 28, 2024 at 12:01 a.m. Eastern Time, we affected a 1-for 19 reverse stock
split of our then outstanding common stock (the &#8220;<span style="text-decoration:underline">February 2024 Reverse Stock Split</span>&#8221;). As a result, if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">we again fail to meet the Minimum Bid Price Requirement within
one year of the effective date of the Reverse Stock Split; or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">we fail to meet the Minimum Bid Price Requirement more than
one year, but before two years after the effective date of the Reverse Stock Split, and the cumulative ratio of the Reverse Stock Split
and any future reverse stock split is greater than 1-to-250,</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nasdaq will issue a delisting notification and
our common stock will be automatically suspended from trading on Nasdaq, subject to our right to appeal the delisting determination to
a hearings panel, provided that our common stock will trade in the over-the-counter (OTC) market while the appeal is pending.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Separately, if we fail to
meet the Minimum Bid Price Requirement prior to the Reverse Stock Split being effective, and prior to February 28, 2026, we will be limited
to a Reverse Stock Split ratio of no more than 1-for-13 (which together with the February 2024 Reverse Stock Split ratio of 1-for-19,
would not exceed 1-for-250.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Separately, Nasdaq Listing
Rule 5810(c)(3)(A) provides that if a listed company takes a corporate action, such as a reverse stock split, to regain compliance with
the Minimum Bid Price Requirement, and that action results in the listed company to falling below the threshold for another Nasdaq listing
requirement (e.g., the Nasdaq Capital Market continued listing requirement that a listed company have at least 500,000 publicly held
shares), the listed company will not be granted a compliance period for the new deficiency. In that case, the listed company must cure
both deficiencies within the compliance period(s) applicable to the Minimum Bid Price Requirement deficiency.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, pursuant to Nasdaq
Listing Rule 5810(c)(3)(A)(iii), if our common stock has a closing bid price of $0.10 or less for 10 consecutive business days during
any compliance period imposed as a result of noncompliance with the Minimum Bid Price Requirement, Nasdaq will issue a delisting determination;
however, unlike the process as discussed above for the determination of excessive reverse stock splits, suspension of trading of our
common stock will generally be stayed while any appeal is pending.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board has considered
the potential harm to the Company and its stockholders should Nasdaq delist our common stock (and our publicly-traded warrants) from
the Nasdaq Capital Market. Delisting our common stock (and our publicly-traded warrants) could adversely affect the liquidity of our
common stock (and our publicly-traded warrants) because alternatives, such as the OTCQB Market maintained by OTC Markets, Inc. and/or
the pink sheets, are generally considered to be less efficient markets. An investor likely would find it less convenient to sell, or
to obtain accurate quotations in seeking to buy our common stock (and our publicly-traded warrants) on an&#160;over-the-counter&#160;market.
Many investors likely would not buy or sell our common stock (and our publicly-traded warrants) due to difficulty in accessing&#160;over-the-counter&#160;markets,
policies preventing them from trading in securities not listed on a national exchange or other reasons. The Board of Directors believes
that the Reverse Stock Split is a potentially effective means for us to maintain compliance with the rules of Nasdaq and to avoid, or
at least mitigate, the likely adverse consequences of our common stock (and our publicly-traded warrants) being delisted from the Nasdaq
Capital Market by producing the immediate effect of increasing the bid price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, the delisting
of our common stock from the Nasdaq Capital Market will result in the delisting of our publicly-traded warrants from the Nasdaq Capital
Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Improve the marketability
and liquidity of the common stock</i>. In the event the Board elects to implement the Reverse Stock Split in order to avoid the delisting
of our common stock from the Nasdaq Capital Market, we also believe that the increased market price of our common stock expected as a
result of implementing the Reverse Stock Split will improve the marketability and liquidity of our common stock and will encourage interest
and trading in our common stock. A reverse stock split could allow a broader range of institutions to invest in our common stock (namely,
funds that are prohibited from buying stocks whose price is below a certain threshold), potentially increasing the liquidity of our common
stock. A reverse stock split could help increase analyst and broker interest in our stock as their policies can discourage them from
following or recommending companies with low stock prices. Because of the trading volatility often associated with&#160;low-priced&#160;stocks,
many brokerage houses and institutional investors have internal policies and practices that either prohibit them from investing in&#160;low-priced&#160;stocks
or tend to discourage individual brokers from recommending&#160;low-priced&#160;stocks to their customers. Some of those policies and
practices may function to make the processing of trades in&#160;low-priced&#160;stocks economically unattractive to brokers. Additionally,
because brokers&#8217; commissions on&#160;low-priced&#160;stocks generally represent a higher percentage of the stock price than commissions
on higher-priced stocks, the current average price per share of our common stock can result in individual stockholders paying transaction
costs representing a higher percentage of their total share value than would be the case if the share price were substantially higher.
It should be noted, however, that the liquidity of our common stock may in fact be adversely affected by the proposed Reverse Stock Split
given the reduced number of shares of common stock that would be outstanding after the Reverse Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the above reasons, we
believe that providing the Board with the ability to effect the Reverse Stock Split, in the event that it determines, in its sole discretion,
that implementing the Reverse Stock Split will help us regain and maintain compliance with the Nasdaq listing requirements and, as a
result, could also improve the marketability and liquidity of our common stock, is in the best interests of the Company and our stockholders.
However, regardless as to whether or not the Board believes that implementing the Reverse Stock Split could help us regain and maintain
compliance with the Nasdaq listing requirements, the Board reserves the right not to implement the Reverse Stock Split if it determines,
in its sole discretion, that it otherwise would not be in our and our stockholders&#8217; best interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounting Matters</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The par value of the shares
of our common stock is not changing as a result of the implementation of the Reverse Stock Split. Our stated capital, which consists
of the par value per share of our common stock multiplied by the aggregate number of shares of our common stock issued and outstanding,
will be reduced proportionately on the effective date of the Reverse Stock Split. Correspondingly, our additional paid-in capital, which
consists of the difference between our stated capital and the aggregate amount paid to us upon the issuance of all currently outstanding
shares of our common stock, will be increased by a number equal to the decrease in stated capital. Further, net loss per share, book
value per share and other per share amounts will be increased as a result of the Reverse Stock Split because there will be fewer shares
of common stock outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Risks of the Proposed Reverse Stock
Split</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We cannot assure you
that the proposed Reverse Stock Split will increase our stock price and have the desired effect of maintaining compliance with the rules
of the Nasdaq</i></b>. The Board expects that the Reverse Stock Split of our common stock will increase the market price of our common
stock so that we are able to regain and maintain compliance with the Nasdaq minimum bid price listing standard. However, the effect of
the Reverse Stock Split upon the market price of our common stock cannot be predicted with any certainty, and the history of similar
reverse stock splits for companies in like circumstances is varied. Under applicable Nasdaq rules, in the event we fall out of compliance
with the Minimum Bid Price Requirement, in order to regain compliance with the $1.00 minimum closing bid price requirement and maintain
our listing on the Nasdaq Capital Market, the $1.00 closing bid price must be maintained for a minimum of ten (10)&#160;consecutive business
days. Accordingly, we cannot assure you that we will be able to maintain our Nasdaq listing after the Reverse Stock Split is effected
or that the market price per share after the Reverse Stock Split will exceed or remain in excess of the $1.00 minimum bid price for a
sustained period of time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is possible that the per
share price of our common stock after the Reverse Stock Split will not rise in proportion to the reduction in the number of shares of
our common stock outstanding resulting from the Reverse Stock Split, and the market price per post-Reverse Stock Split share may not
exceed or remain in excess of the $1.00 minimum bid price for a sustained period of time, and the Reverse Stock Split may not result
in a per share price that would attract brokers and investors who do not trade in lower priced stocks. Even if we effect the Reverse
Stock Split, the market price of our common stock may decrease due to factors unrelated to the stock split. In any case, the market price
of our common stock may also be based on other factors which may be unrelated to the number of shares outstanding, including our future
performance. If the Reverse Stock Split is consummated and the trading price of the common stock declines, the percentage decline as
an absolute number and as a percentage of our overall market capitalization may be greater than would occur in the absence of the Reverse
Stock Split. Even if the market price per post-Reverse Stock Split share of our common stock remains in excess of $1.00 per share, we
may be delisted due to a failure to meet other continued listing requirements, including Nasdaq requirements related to the minimum stockholders&#8217;
equity, the minimum number of shares that must be in the public float, the minimum market value of the public float and the minimum number
of round lot holders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The proposed Reverse
Stock Split may decrease the liquidity of our common stock</i></b>. The liquidity of our common stock may be harmed by the proposed Reverse
Stock Split given the reduced number of shares of common stock that would be outstanding after the Reverse Stock Split, particularly
if the stock price does not increase as a result of the Reverse Stock Split. In addition, investors might consider the increased proportion
of unissued authorized shares of common stock to issued shares to have an anti-takeover effect under certain circumstances, because the
proportion allows for dilutive issuances which could prevent certain stockholders from changing the composition of the Board or render
tender offers for a combination with another entity more difficult to successfully complete. The Board does not intend for the Reverse
Stock Split to have any anti-takeover effects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Principal Effects of the Reverse Stock
Split</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Common stock.</i>&#160;If
this proposal is approved by the stockholders at the Meeting and the Board determines to effect the Reverse Stock Split and thus amend
the Certificate of Incorporation, the Company will file a certificate of amendment to the Certificate of Incorporation with the Secretary
of State of the State of Delaware. Except for adjustments that may result from the treatment of fractional shares as described below,
each issued share of common stock immediately prior to the Effective Date will automatically be changed, as of the Effective Date, into
a fraction of a share of common stock based on the exchange ratio within the approved range determined by the Board. In addition, proportional
adjustments will be made to the maximum number of shares of common stock issuable under, and other terms of, our stock plans, as well
as to the number of shares of common stock issuable under, and the exercise price of, our outstanding options and warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except for adjustments that
may result from the treatment of fractional shares of common stock as described below, because the Reverse Stock Split would apply to
all issued shares of our common stock, the proposed Reverse Stock Split would not alter the relative rights and preferences of our existing
stockholders nor affect any stockholder&#8217;s proportionate equity interest in the Company. For example, a holder of two percent (2%)
of the voting power of the outstanding shares of our common stock immediately prior to the effectiveness of the Reverse Stock Split will
generally continue to hold two percent (2%) of the voting power of the outstanding shares of our common stock immediately after the Reverse
Stock Split. Moreover, the number of stockholders of record will not be affected by the Reverse Stock Split. The amendment to the Certificate
of Incorporation itself would not change the number of authorized shares of our common stock or the par value thereof. The Reverse Stock
Split will have the effect of creating additional unreserved shares of our authorized common stock. Although at present we have no current
definitive arrangements or understandings providing for the issuance of the additional shares of common stock that would be made available
for issuance upon effectiveness of the Reverse Stock Split, other than those shares needed to satisfy the conversion and/or exercise
of the Company&#8217;s outstanding warrants and options, these additional shares of common stock may be used by us for various purposes
in the future without further stockholder approval, including, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">raising
    capital to fund our operations and to continue as a going concern;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing strategic
    relationships with other companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing equity incentives
    to our employees, officers or directors; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expanding our business
    or product lines through the acquisition of other businesses or products.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, notwithstanding
the above, the Company is in preliminary discussions regarding a number of potential options to raise capital, certain of which may result
in significant dilution to existing shareholders if completed, provided that any future transactions will be structured to comply with
all Nasdaq stockholder approval requirements, and as such, are expected to either be sold at or above market, or will be subject to stockholder
approval. Future offering transactions may include common stock, warrant coverage, or other convertible securities, with such terms as
approved by the Board of Directors of the Company, again, subject in all cases to applicable Nasdaq stockholder approval rules and guidance
where applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the Reverse Stock Split
will make additional shares of common stock available for the Company to use in connection with the foregoing, the primary purpose of
the Reverse Stock Split is to increase our stock price in order to maintain compliance with the Nasdaq minimum bid price listing standard,
which compliance will be the sole factor in determining the ratio of the Reverse Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth the approximate number of issued and outstanding shares of common stock, net income (loss) per share for the nine months ended
December 31, 2024, and the approximate exercise prices of our outstanding warrants and options, each in the event of a 1:4 to 1:40 Reverse
Stock Split:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>




</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Pre-Reverse<br/>
    Stock Split</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">After a 1:4<br/>
    Reverse Stock<br/>
    Split</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">After a 1:10<br/>
    Reverse Stock<br/>
    Split</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">After a 1:20<br/>
    Reverse Stock<br/>
    Split</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">After a 1:30<br/>
    Reverse Stock<br/>
    Split</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">After a 1:40<br/>
    Reverse Stock<br/>
    Split</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; width: 37%; text-align: left"><span style="font-size: 10pt">Common
    Stock authorized&#160;<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt; width: 0.5%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">100,000,000</td><td style="padding-bottom: 1.5pt; width: 0.5%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 0.5%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">100,000,000</td><td style="padding-bottom: 1.5pt; width: 0.5%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 0.5%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">100,000,000</td><td style="padding-bottom: 1.5pt; width: 0.5%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 0.5%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">100,000,000</td><td style="padding-bottom: 1.5pt; width: 0.5%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 0.5%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">100,000,000</td><td style="padding-bottom: 1.5pt; width: 0.5%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 0.5%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">100,000,000</td><td style="padding-bottom: 1.5pt; width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common Stock outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,068,649</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,517,162</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">606,865</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">303,432</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">202,288</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">151,716</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Number of shares of Common Stock
    reserved for issuance&#160;upon exercise of outstanding warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,133,308</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,533,327</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">613,331</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">306,665</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">204,444</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">153,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Number of shares of Common Stock
    reserved for issuance&#160;upon exercise of outstanding options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,021,564</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">255,391</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">102,156</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,078</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34,052</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,539</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Number
    of shares of Common Stock reserved for issuance under outstanding equity incentive plans <sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,750</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">350</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">233</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">175</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Number of shares
    of Common Stock authorized but unissued and unreserved</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">86,769,479</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">96,692,370</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">98,676,948</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">99,338,475</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">99,558,983</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">99,669,237</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net income (loss) applicable to
    Common Stock per share for the quarter ended March 31, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.67</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2.68</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6.70</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13.40</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20.10</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26.80</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Weighted Average Exercise Price of Outstanding Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18.14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72.56</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">181.40</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">362.80</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">544.20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">725.60</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Weighted Average Exercise Price of Outstanding Options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">&#160;1.41</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14.10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28.20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42.30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">56.40</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These estimates do not reflect
the potential effects of rounding up of fractional shares that may result from the Reverse Stock Split, as discussed below, or the potential
effect of the increase in our authorized shares of common stock as described below in &#8220;Proposal 6, Approval of an Amendment to Our Second Amended and Restated Certificate of Incorporation to Increase the Company&#8217;s Authorized Number of Shares of Common Stock From One Hundred Million (100,000,000) to One Billion (1,000,000,000)&#8221;. In the event the increase in our authorized shares of common
stock is approved at the Annual Meeting and the Board of Directors determines to move forward with such increase in authorized shares,
the number of shares of common stock authorized but unissued and unreserved for each column of the table above will be 900,000,000 more
than as set forth above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">There
                                            will be no change to the 100,000,000 authorized shares of common stock of the Company as
                                            a result of the Reverse Stock Split, however as described below in &#8220;Proposal 6, Approval of an Amendment to Our Second Amended and Restated Certificate of Incorporation to Increase the Company&#8217;s Authorized Number of Shares of Common Stock From One Hundred Million (100,000,000) to One Billion (1,000,000,000)&#8221;, the Company is also seeking stockholder
                                            approval at the Annual Meeting for an increase in our authorized shares of common stock from
                                            100,000,000 to 1,000,000,000.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Does
                                            not include any increase in the number of shares reserved under the Company&#8217;s 2022
                                            Omnibus Incentive Plan (4,000,000) and/or 2025 Option Incentive Plan (1,000,000) in the event
                                            that Proposals 2 and/or 3 herein are approved by stockholders at the Meeting.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Employee Plans, Options,
Restricted Stock Awards and Convertible or Exchangeable Securities</i>. Pursuant to the terms of the 2022 Omnibus Incentive Plan, 2020
Omnibus Incentive Plan and 2025 Option Incentive Plan (which remains subject to stockholder approval as discussed below)(collectively,
the &#8220;<span style="text-decoration:underline">Plans</span>&#8221;), the number of shares of common stock issuable upon exercise of our stock options and other equity awards
(including shares reserved for issuance under the equity compensation plans) will be proportionately adjusted by the applicable plan
administrator, using the ratio approved by the Board of Directors for the Reverse Stock Split (between 1-for-4 and 1-for-40, inclusive),
and rounded down to the nearest whole share. In addition, the exercise price for each outstanding stock option will be increased in inverse
proportion to the ratio approved by the Board of Directors for the Reverse Stock Split (between 1-for-4 and 1-for-40, inclusive)such
that upon an exercise, the aggregate exercise price payable by the optionee to the Company for the shares subject to the option will
remain approximately the same as the aggregate exercise price prior to the Reverse Stock Split, subject to the terms of such securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon the Reverse Stock
Split ratio determined by the Board, proportionate adjustments are also generally required to be made to the per share exercise price
and the number of shares of common stock issuable upon the exercise or conversion of any convertible or exchangeable securities entitling
the holders to purchase, exchange for, or convert into, shares of common stock. This would result in approximately the same aggregate
price being required to be paid under such convertible or exchangeable securities upon exercise, and approximately the same value of
shares of common stock being delivered upon such exercise, exchange or conversion, immediately following the Reverse Stock Split as was
the case immediately preceding the Reverse Stock Split. The number of shares of common stock subject to restricted stock awards will
be similarly adjusted, subject to our treatment of fractional shares of common stock. The number of shares of common stock reserved for
issuance pursuant to these securities and our Plans will be adjusted proportionately based upon the Reverse Stock Split ratio determined
by the Board of Directors, subject to our treatment of fractional shares of common stock. See also the table above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Warrants.&#160;</i>As
a result of the Reverse Stock Split, the number of shares of common stock issuable upon exercise of each outstanding warrant to purchase
shares of common stock of the Company, including, but not limited to, our publicly-traded warrants, will decrease in proportion to the
final reverse stock ratio approved by the Board in connection with the Reverse Stock Split and the exercise price of each outstanding
warrant to purchase shares of common stock will increase in proportion to the final reverse stock ratio approved by the Board in connection
with the Reverse Stock Split, such that the aggregate exercise price payable upon exercise of each outstanding warrant to purchase shares
of common stock of the Company will remain the same both before and after the Reverse Stock Split. See also the table above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Listing</i>. Our shares
of common stock currently trade on the Nasdaq Capital Market. The Reverse Stock Split will not directly affect the listing of our common
stock on the Nasdaq Capital Market, although we believe that the Reverse Stock Split could potentially increase our stock price, facilitating
compliance with Nasdaq&#8217;s minimum bid price listing requirement. Following the Reverse Stock Split, our common stock will continue
to be listed on the Nasdaq Capital Market under the symbol &#8220;<span style="text-decoration:underline">ATNF</span>,&#8221; although our common stock is expected to have a
new CUSIP number, a number used to identify our common stock. The Reverse Stock Split will have no effect on our publicly-traded warrants,
which will continue to trade on the Nasdaq Capital Market under the symbol &#8220;<span style="text-decoration:underline">ATNFW</span>&#8221;, except for proportional adjustments
to the number of shares of common stock issuable upon exercise thereof and to the exercise price thereof, and expected adjustments to
the trading price thereof mirroring the Reverse Stock Split ratio which will affect our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#8220;<span style="text-decoration:underline">Public Company</span>&#8221;
Status</i>. Our common stock is currently registered under Section&#160;12(b) of the Exchange Act, and we are subject to the &#8220;<span style="text-decoration:underline">public
company</span>&#8221; periodic reporting and other requirements of the Exchange Act. The proposed Reverse Stock Split will not affect our
status as a public company or this registration under the Exchange Act. The Reverse Stock Split is not intended as, and will not have
the effect of, a &#8220;<span style="text-decoration:underline">going private transaction</span>&#8221; covered by Rule&#160;13e-3&#160;under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Odd Lot Transactions</i>.
It is likely that some of our stockholders will own&#160;&#8220;<span style="text-decoration:underline">odd-lots</span>&#8221;&#160;of less than 100 shares of common stock following
the Reverse Stock Split. A purchase or sale of less than 100 shares of common stock (an &#8220;<span style="text-decoration:underline">odd lot</span>&#8221; transaction) may
result in incrementally higher trading costs through certain brokers, particularly &#8220;<span style="text-decoration:underline">full service</span>&#8221; brokers, and generally
may be more difficult than a &#8220;round lot&#8221; sale. Therefore, those stockholders who own less than 100 shares of common stock
following the Reverse Stock Split may be required to pay somewhat higher transaction costs and may experience some difficulties or delays
should they then determine to sell their shares of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Authorized but Unissued
Shares; Potential Anti-Takeover Effects</i>. Our Certificate of Incorporation presently authorizes 100,000,000 shares of common stock
and 5,000,000 shares of blank check preferred stock, a total of one (1) of which authorized shares of preferred stock is designated as
the &#8220;Class C Special Voting Share&#8221; (the &#8220;<span style="text-decoration:underline">Class C Special Voting Share</span>&#8221;); one (1) of which authorized shares
of preferred stock is designated as the &#8220;Class K Special Voting Share&#8221; (the &#8220;<span style="text-decoration:underline">Class K Special Voting Share</span>,&#8221;
and together with the Class C Voting Share, the &#8220;<span style="text-decoration:underline">Special Voting Shares</span>&#8221;); one million (1,000,000) of which authorized
shares of preferred stock are designated as &#8220;Series A Convertible Preferred Stock&#8221; (the &#8220;<span style="text-decoration:underline">Series A Shares</span>&#8221;);
and one million (1,000,000) of which authorized shares of preferred stock are designated as &#8220;Series B Convertible Preferred Stock&#8221;
(the &#8220;<span style="text-decoration:underline">Series B Shares</span>&#8221;). The Reverse Stock Split would not change the number of authorized shares of the common stock
or blank check preferred stock as designated. Therefore, because the number of issued and outstanding shares of common stock would decrease,
the number of shares of common stock remaining available for issuance by us in the future would increase. See also the table above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Such additional shares would
be available for issuance from time to time for corporate purposes such as issuances of common stock in connection with capital-raising
transactions and acquisitions of companies or other assets, as well as for issuance upon conversion or exercise of securities such as
convertible preferred stock, convertible debt, warrants or options convertible into or exercisable for common stock. We believe that
the availability of the additional shares of common stock will provide us with the flexibility to meet business needs as they arise,
to take advantage of favorable opportunities and to respond effectively in a changing corporate environment. For example, we may elect
to issue shares of common stock to raise equity capital, to make acquisitions through the use of stock, to establish strategic relationships
with other companies, to adopt additional employee benefit plans or reserve additional shares of common stock for issuance under such
plans, where the Board determines it advisable to do so, without the necessity of soliciting further stockholder approval, subject to
applicable stockholder vote requirements under Delaware law and Nasdaq rules. If we issue additional shares of common stock for any of
these purposes, the aggregate ownership interest of our current stockholders, and the interest of each such existing stockholder, would
be diluted, possibly substantially.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The additional shares of
our common stock that would become available for issuance upon an effective Reverse Stock Split could also be used by us to oppose a
hostile takeover attempt or delay or prevent a change of control or changes in or removal of our management, including any transaction
that may be favored by a majority of our stockholders or in which our stockholders might otherwise receive a premium for their shares
of common stock over then-current market prices or benefit in some other manner. Although the increased proportion of authorized but
unissued shares of common stock to be issued shares of common stock could, under certain circumstances, have an anti-takeover effect,
the Reverse Stock Split is not being proposed in order to respond to a hostile takeover attempt or to an attempt to obtain control of
the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Reverse Stock Split will
also have no effect on our designated preferred stock, except for automatic adjustments to the voting and conversion rights associated
therewith in proportion to the Board approved Reverse Stock Split ratio, in order for such voting and conversion rights to remain proportional
to the common stock of the Company following the Reverse Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fractional Shares</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No scrip would be issued
if, as a result of the Reverse Stock Split, a stockholder would otherwise become entitled to a fractional share because the number of
shares of common stock they hold before the Reverse Stock Split is not evenly divisible by the final reverse ration. Instead, the Board
of Directors will have the discretionary authority to determine whether to arrange for the disposition of fractional interests by stockholders
entitled thereto, to pay in cash the fair value of fractions of a share as of the time when those entitled to receive such fractions
are determined, or to entitle stockholders to receive from the Company&#8217;s transfer agent, in lieu of any fractional share, the number
of shares rounded up to the next whole number.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Board of Directors
determines to arrange for the disposition of fractional interests by stockholders entitled thereto or to pay in cash the fair value of
fractions of a share as of the time when those entitled to receive such fractions are determined, stockholders who would otherwise hold
fractional shares because the number of shares of common stock they hold before the Reverse Stock Split is not evenly divisible by the
ratio ultimately selected by the Board of Directors will be entitled to receive cash (without interest or deduction) in lieu of such
fractional shares from either: (i) the Company, upon receipt by the transfer agent of a properly completed and duly executed transmittal
letter and, where shares are held in certificated form, upon due surrender of any certificate previously representing a fractional share,
in an amount equal to such holder&#8217;s fractional share based upon the closing sale price of the common stock on the trading day immediately
prior to the Effective Time as reported on the Nasdaq Capital Market, or other principal market of the common stock, as applicable, as
of the date the Reverse Stock Split is effected; or (ii) the transfer agent, upon receipt by the transfer agent of a properly completed
and duly executed transmittal letter and, where shares are held in certificated form, the surrender of all old certificate(s), in an
amount equal to the proceeds attributable to the sale of such fractional shares following the aggregation and sale by the transfer agent
of all fractional shares otherwise issuable. If the Board of Directors determines to dispose of fractional interests pursuant to clause
(ii) above, the Company expects that the transfer agent would conduct the sale in an orderly fashion at a reasonable pace and that it
may take several days to sell all of the aggregated fractional shares of common stock. In this event, such holders would be entitled
to an amount equal to their pro rata share of the proceeds of such sale. The Company will be responsible for any brokerage fees or commissions
related to the transfer agent&#8217;s open market sales of shares that would otherwise be fractional shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ownership of a fractional
share interest following the Reverse Stock Split will not give the holder any voting, dividend or other rights, except to receive the
cash payment, or, if the Company so determines, to receive the number of shares rounded up to the next whole number, as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholders should be aware
that, under the escheat laws of various jurisdictions, sums due for fractional interests that are not timely claimed after the effective
time of the Reverse Stock Split may be required to be paid to the designated agent for each such jurisdiction, unless correspondence
has been received by the Company or the transfer agent concerning ownership of such funds within the time permitted in such jurisdiction.
Thereafter, if applicable, stockholders otherwise entitled to receive such funds, but who do not receive them due to, for example, their
failure to timely comply with the transfer agent&#8217;s instructions, will have to seek to obtain such funds directly from the state
to which they were paid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Determination of the Reverse Stock
Split Ratio</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Board believes that stockholder approval of an amendment that gives the board the discretion to implement a reverse stock split at a
ratio of between one-for-four and one-for-forty, inclusive, for the potential Reverse Stock Split is advisable and in the best interests
of our Company and stockholders because it is not possible to predict market conditions at the time the Reverse Stock Split would be
implemented. We believe that the proposed Reverse Stock Split ratios provide us with the most flexibility to achieve the desired results
of the Reverse Stock Split. The Reverse Stock Split ratio to be selected by our Board will not be more than one-for-forty, nor less than
one-for-four. The Company will publicly announce the chosen ratio at least two business days prior to the effectiveness of the Reverse
Stock Split and the Reverse Stock Split will be implemented by the one-year anniversary of the date on which the Meeting is held, if
at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
selection of the specific Reverse Stock Split ratio will be based on several factors, including, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability
    to maintain the listing of our common stock on The Nasdaq Capital Market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the per share price of
    our common stock immediately prior to the Reverse Stock Split;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expected stability
    of the per share price of our common stock following the Reverse Stock Split;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the likelihood that the
    Reverse Stock Split will result in increased marketability and liquidity of our common stock;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevailing market conditions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic conditions
    in our industry; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our market capitalization
    before and after the Reverse Stock Split.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
believe that granting our Board the authority to set the ratio for the Reverse Stock Split is essential because it allows us to take
these factors into consideration and to react to changing market conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Potential Consequences if the Reverse
Split Proposal is Not Approved</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
the Reverse Stock Split is not approved by our stockholders, our Board will not have the authority to effect the Reverse Stock Split
to, among other things, facilitate the continued listing of our common stock on The Nasdaq Capital Market by increasing the per share
trading price of our common stock to help ensure a share price high enough to satisfy the $1.00 per share minimum bid price requirement.
Any inability of our Board to effect the Reverse Stock Split could expose us to delisting from The Nasdaq Capital Market in the event
we fail to meet the Minimum Bid Price Requirement in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Effective Date and Time of the Reverse
Stock Split</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
the Reverse Stock Split is approved by our stockholders, the Reverse Stock Split would become effective, if at all, when the amendment
to our Certificate of Incorporation to affect the Reverse Stock Split is accepted and recorded by the office of the Secretary of State
of the State of Delaware, or such later effective date and time as set forth in the amendment (the Effective Date). However, notwithstanding
approval of the Reverse Stock Split by our stockholders, the Board will have the sole authority to elect whether or not and when (prior
to _______, 2026, the one-year anniversary of the Meeting) to amend our Certificate of Incorporation to effect the Reverse Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_138"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">No Dissenters&#8217;
Rights</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Delaware law, our stockholders
would not be entitled to dissenters&#8217; rights or rights of appraisal in connection with the implementation of the Reverse Stock Split,
and we will not independently provide our stockholders with any such rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Certain United States Federal Income
Tax Consequences</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of certain U.S. federal income tax consequences of the Reverse Stock Split that are applicable to United States holders (as defined below).
It does not address any state, local or&#160;non-U.S.&#160;income or other tax consequences, or any U.S. federal estate, gift, or other&#160;non-income&#160;tax
consequences. The discussion is based on the Internal Revenue Code of 1986, as amended (the &#8220;<span style="text-decoration:underline">Internal Revenue Code</span>&#8221;),
Treasury Regulations promulgated under the Internal Revenue Code, published rulings and procedures of the Internal Revenue Service, and
court decisions, all as of the date hereof. These authorities are subject to change or differing interpretation, possibly on a retroactive
basis. We have not sought and will not seek an opinion of counsel or a ruling from the Internal Revenue Service regarding the U.S. federal
income tax consequences of the Reverse Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This discussion does not
address all U.S. federal income tax consequences relevant to United States holders of common stock. In addition, it does not address
consequences relevant to United States holders that are subject to special U.S. tax rules, including, without limitation, stockholders
that are:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons who do not hold their common stock as a &#8220;capital asset&#8221;
    within the meaning of Section 1221 of the Internal Revenue Code;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">brokers or dealers in securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">banks or other financial institutions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">insurance companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;real estate investment trusts&#8221;;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;regulated investment companies&#8221;;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;S corporations&#8221;;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">tax-exempt organizations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">governments, agencies or instrumentalities thereof, or entities they
    control;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">partnerships, grantor trusts or other entities that are treated as
    pass-through entities for U.S. federal income tax purposes, and their owners;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons who are subject to the alternative minimum tax provisions of
    the Internal Revenue Code;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons who hold their shares as part of a hedge, wash sale, synthetic
    security, conversion transaction, or other integrated transaction;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons that have a functional currency other than the U.S. dollar;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">traders in securities who elect to apply a mark-to-market method of
    accounting;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons who hold shares of common stock that may constitute &#8220;qualified
    small business stock&#8221; under Section 1202 of the Internal Revenue Code or &#8220;Section 1244 stock&#8221; for purposes of Section
    1244 of the Internal Revenue Code;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons who acquired their shares of stock in a transaction subject
    to the gain rollover provisions of Section 1045 of the Internal Revenue Code;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons subject to special tax accounting rules as a result of any
    item of gross income with respect to common stock being taken into account in an &#8220;applicable financial statement&#8221; (as
    defined in the Internal Revenue Code);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons deemed to sell common stock under the constructive sale provisions
    of the Internal Revenue Code;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons who acquired their shares of common stock pursuant to the exercise
    of options or otherwise as compensation or through a tax-qualified retirement plan or through the exercise of a warrant or conversion
    rights under convertible instruments; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">certain expatriates or former citizens or long-term residents of the
    United States.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholders subject to any
of the special U.S. tax rules that are described in this paragraph are urged to consult their own tax advisors regarding the consequences
to them of the Reverse Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an entity that is treated
as a partnership for U.S. federal income tax purposes holds common stock, the U.S. federal income tax treatment of a partner in the partnership
will generally depend upon the status of the partner, the activities of the partnership and certain determinations made at the partner
level. If you are a partnership or a partner of a partnership holding common stock or any other person not addressed by this discussion,
you should consult your tax advisors regarding the tax consequences of the Reverse Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Consequences to United States holders of the Reverse Stock Split
&#8212; Generally.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A United States holder, as
used herein, is a stockholder that is, for United States federal income tax purposes: (a)&#160;a citizen or individual resident of the
United States, (b)&#160;a corporation or any other entity taxable as a corporation created or organized in or under the laws of the United
States, any state thereof, or the District of Columbia, (c)&#160;an estate whose income is subject to United States federal income tax
regardless of its source, or (d)&#160;a trust, if either (i)&#160;a United States court can exercise primary supervision over the trust&#8217;s
administration and one or more United States persons (within the meaning of Section&#160;7701(a)(30) of the Internal Revenue Code) are
authorized to control all substantial decisions of the trust or (ii)&#160;the trust was in existence on August&#160;20, 1996 and has
a valid election in effect under applicable Treasury Regulations to be treated as a United States person for U.S. federal income tax
purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Reverse Stock Split should
constitute a &#8220;<span style="text-decoration:underline">recapitalization</span>&#8221; for U.S. federal income tax purposes. Accordingly, except for adjustments that may
result from the treatment of fractional shares of common stock as described below, no gain or loss should be recognized by a United States
holder upon such United States holder&#8217;s exchange of&#160;pre-Reverse&#160;Stock Split shares of common stock for post-Reverse Stock
Split shares of common stock pursuant to the Reverse Stock Split (except for cash, if any, received in lieu of a fractional share of
common stock). The aggregate adjusted basis of the post-Reverse Stock Split shares of common stock received should equal the aggregate
adjusted basis of the&#160;pre-Reverse&#160;Stock Split shares of common stock exchanged for such new shares (increased by any income
or gain recognized on receipt of a whole share in lieu of a fractional share), including any fractional shares of common stock not actually
received. Cash payments received by the U.S. holder for a fractional share of common stock generally should be treated as if such fractional
share had been issued pursuant to the Reverse Stock Split and then redeemed by us, and such U.S. holder generally should recognize capital
gain or loss with respect to such payment, measured by the difference between the amount of cash received and such U.S. holder&#8217;s
tax basis in such fractional share. However, in certain circumstances, it is possible that cash received in lieu of a fractional share
could be characterized as a dividend. In that case, U.S. holders may be required to provide their taxpayer identification number to the
exchange agent to avoid backup withholding. Except in the case of any portion of a share of common stock treated as a distribution or
as to which a United States holder recognizes capital gain as a result of the treatment of fractional shares, the United States holder&#8217;s
holding period for the post-Reverse Stock Split shares of common stock should include the period during which the United States holder
held the&#160;pre-Reverse&#160;Stock Split shares of common stock surrendered. The Treasury Regulations provide detailed rules for allocating
the tax basis and holding period of the&#160;pre-Reverse&#160;Stock Split shares of common stock surrendered to the post-Reverse Stock
Split shares of common stock received pursuant to the Reverse Stock Split. United States holders of shares of common stock acquired on
different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period
of such shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The treatment of fractional
shares of common stock being rounded up to the next whole share is uncertain, and a United States holder that receives a whole share
of common stock in lieu of a fractional share of common stock may recognize income, which may be characterized as either capital gain
or as a dividend, in an amount not to exceed the excess of the fair market value of such whole share over the fair market value of the
fractional share to which the United States holder was otherwise entitled. The holding period for the portion of a share of common stock
treated as a distribution or as to which a United States holder recognizes gain might not include the holding period of&#160;pre-Reverse&#160;Stock
Split shares of common stock surrendered. United States holders should consult their tax advisors regarding the U.S. federal income tax
and other tax consequences of fractional shares being rounded to the next whole share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Exchange of Stock Certificates</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the Effective Date,
each certificate representing shares of our common stock outstanding before the Reverse Stock Split will be deemed, for all corporate
purposes, to evidence ownership of the reduced number of shares of our common stock resulting from the Reverse Stock Split. All shares
underlying options, warrants and other securities exchangeable or exercisable for or convertible into common stock will also automatically
be adjusted on the Effective Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our transfer agent, Continental
Stock Transfer &amp; Trust Company, will act as the exchange agent for purposes of exchanging stock certificates subsequent to the Reverse
Stock Split. Shortly after the Effective Date, stockholders of record will receive written instructions requesting them to complete and
return a letter of transmittal and surrender their old stock certificates for new stock certificates reflecting the adjusted number of
shares as a result of the Reverse Stock Split. Certificates representing shares of common stock issued in connection with the Reverse
Stock Split will continue to bear the same restrictive legends, if any, that were borne by the surrendered certificates representing
the shares of common stock outstanding prior to the Reverse Stock Split. No new certificates will be issued until such stockholder has
surrendered any outstanding certificates, together with the properly completed and executed letter of transmittal, to the exchange agent.
Until surrendered, each certificate representing shares of common stock outstanding before the Reverse Stock Split would continue to
be valid and would represent the adjusted number of shares of common stock, based on the ratio of the Reverse Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any stockholder whose stock
certificates are lost, destroyed or stolen will be entitled to a new certificate or certificates representing post-Reverse Stock Split
shares of common stock upon compliance with the requirements that we and our transfer agent customarily apply in connection with lost,
destroyed or stolen certificates. Instructions as to lost, destroyed or stolen certificates will be included in the letter of instructions
from the exchange agent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the Reverse Stock Split,
we intend to treat stockholders holding our common stock in &#8220;<span style="text-decoration:underline">street name</span>,&#8221; through a bank, broker or other nominee,
in the same manner as registered stockholders whose shares of common stock are registered in their names. Banks, brokers and other nominees
will be instructed to effect the Reverse Stock Split for their beneficial holders holding our common stock in &#8220;<span style="text-decoration:underline">street name</span>.&#8221;
However, such banks, brokers and other nominees may have different procedures than registered stockholders for processing the Reverse
Stock Split. If you hold your shares in &#8220;<span style="text-decoration:underline">street name</span>&#8221; with a bank, broker or other nominee, and if you have any questions
in this regard, we encourage you to contact your bank, broker or nominee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>YOU SHOULD NOT DESTROY
YOUR STOCK CERTIFICATES AND YOU SHOULD NOT SEND THEM NOW. YOU SHOULD SEND YOUR STOCK CERTIFICATES ONLY AFTER YOU HAVE RECEIVED INSTRUCTIONS
FROM THE EXCHANGE AGENT AND IN ACCORDANCE WITH THOSE INSTRUCTIONS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any certificates for shares
of common stock are to be issued in a name other than that in which the certificates for shares of common stock surrendered are registered,
the stockholder requesting the reissuance will be required to pay to us any transfer taxes or establish to our satisfaction that such
taxes have been paid or are not payable and, in addition, (a)&#160;the transfer must comply with all applicable federal and state securities
laws, and (b)&#160;the surrendered certificate must be properly endorsed and otherwise be in proper form for transfer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Book-Entry Shares</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s registered
stockholders may hold some or all of their shares electronically in book-entry form with our transfer agent. These stockholders do not
have stock certificates evidencing their ownership of common stock. They are, however, provided with a statement reflecting the number
of shares of common stock registered in their accounts. If you hold registered shares of common stock in book-entry form, you do not
need to take any action to receive your post-Reverse Stock Split shares of common stock in registered book-entry form.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Interests of Directors and Executive
Officers</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors and executive
officers have no substantial interests, directly or indirectly, in the matters set forth in this proposal except to the extent of their
ownership of shares of our common stock and equity awards granted to them under our equity incentive plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_139"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Vote Required</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proposal 5 requires that
the votes cast in favor of the proposal exceed the votes cast against the proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_140"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Board Recommendation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board recommends that
you vote &#8220;<span style="text-decoration:underline">FOR</span>&#8221; Proposal 5 to amend the Company&#8217;s Certificate of Incorporation to effect a reverse stock split
of the Company&#8217;s issued and outstanding common stock by a ratio of between one-for-four and one-for-forty, inclusive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above,
even if approved by stockholders at the Annual Meeting, the Board of Directors reserves the right to abandon the Reverse Stock Split
if it deems such abandonment in the best interests of the stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_141"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proposal 6<br/>
Approval of an Amendment to Our Second Amended and Restated Certificate of <br/>
Incorporation to Increase the Company&#8217;s Authorized&#160;Number
of Shares of Common Stock From One Hundred <br/>
Million (100,000,000) to&#160;One Billion (1,000,000,000)<br/>
&#160;</b></p><div>

</div><div><a id="a_142"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal"><span style="text-decoration:underline">General</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our stockholders are also
being asked to adopt a Certificate of Amendment, amending our Second Amended and Restated Certificate of Incorporation in the form attached
hereto as&#160;<span style="text-decoration:underline">Appendix E</span>&#160;(the &#8220;<span style="text-decoration:underline">Authorized Shares Increase Amendment</span>&#8221;). The following is a summary of
the key provisions of the Authorized Shares Increase Amendment, but this summary is qualified in its entirety by reference to the full
text of the Authorized Shares Increase Amendment, a copy of which is included as&#160;<span style="text-decoration:underline">Appendix E</span>:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current Second Amended
and Restated Certificate of Incorporation authorizes one hundred million (100,000,000) shares of common stock, and the Board of Directors
has recommended that stockholders approve the Authorized Shares Increase Amendment to increase the number of authorized shares of common
stock to one billion (1,000,000,000)(the &#8220;<span style="text-decoration:underline">Authorized Share Increase</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Authorized Shares Increase
Amendment will have no effect on the par value of the Company&#8217;s common stock or preferred stock, or on the terms of any previously
designated series of preferred stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Authorized Shares Increase
Amendment is subject to non-material technical, administrative or similar changes and modifications in the reasonable discretion of the
officers of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The additional common stock
to be authorized by adoption of the amendment would have rights identical to the currently outstanding common stock of the Company. Although
at present the Board has not approved any plans or proposals to issue any of the additional shares of common stock that would become
authorized for issuance if this proposal is approved, the Board desires to have the shares available to provide additional flexibility
to use the common stock for financing and business purposes in the future. Adoption of the proposed amendment and issuance of the common
stock would not affect the rights of the holders of currently outstanding common stock of the Company, except for, with respect to the
issuance of additional shares, effects incidental to increasing the number of shares of the Company&#8217;s common stock outstanding,
such as dilution of the earnings per share and voting rights of current holders of common stock. If the amendment is adopted, it will
become effective upon filing of a Certificate of Amendment of the Certificate of Incorporation with the Secretary of State of the State
of Delaware.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal"><span style="text-decoration:underline">Reasons
for the Amendment</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of the Authorized
Shares Increase Amendment is to provide the Board of Directors the ability to issue additional shares of common stock of the Company
to enable the Company to complete transactions which the Board of Directors believes may be accretive to stockholders, including acquisitions,
consulting and employment relationships and fund raisings, provided that the Company does not currently have any definitive plans to,
or definitive agreements or understandings in place to, issue any such additional authorized but unissued shares of common stock which
will be made available as a result of the Authorized Shares Increase Amendment. Notwithstanding the above, the Company is in preliminary
discussions regarding a number of potential options to raise capital, certain of which may result in significant dilution to existing
shareholders if completed, provided that any future transactions will be structured to comply with all Nasdaq stockholder approval requirements,
and as such, are expected to either be sold at or above market, or will be subject to stockholder approval. Future offering transactions
may include common stock, warrant coverage, or other convertible securities, with such terms as approved by the Board of Directors of
the Company, again, subject in all cases to applicable Nasdaq stockholder approval rules and guidance where applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of the Authorized
Shares Increase Amendment is to increase the Company&#8217;s authorized shares of common stock from one hundred million (100,000,000)
shares of common stock to one billion (1,000,000,000) shares of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assuming the Authorized Shares
Increase Amendment is approved, there will be one billion five million (1,005,000,000) total authorized shares of capital stock the Company,
consisting of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">1,000,000,000 shares of common
stock, having a par value of $0.0001 per share; and</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">5,000,000 shares of preferred
stock, having a par value of $0.0001 per share, which currently includes:</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9675;</span></td><td style="text-align: justify">one
                                            (1) of which authorized shares of preferred stock is designated as the &#8220;Class C Special
                                            Voting Share&#8221;;</td></tr></table><div>

</div><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9675;</span></td><td style="text-align: justify">one
                                            (1) of which authorized shares of preferred stock is designated as the &#8220;Class K Special
                                            Voting Share&#8221;;</td></tr></table><div>

</div><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9675;</span></td><td style="text-align: justify">one
                                            million (1,000,000) of which authorized shares of preferred stock are designated as &#8220;Series
                                            A Convertible Preferred Stock&#8221;; and</td></tr></table><div>

</div><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9675;</span></td><td style="text-align: justify">one
                                            million (1,000,000) of which authorized shares of preferred stock are designated as &#8220;Series
                                            B Convertible Preferred Stock&#8221;.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assuming the Authorized Shares
Increase Amendment is approved, the Board of Directors will be authorized to issue the additional shares of common stock without having
to obtain the approval of the Company&#8217;s stockholders, except pursuant to applicable Nasdaq rules, which generally require stockholder
approval for the issuance of 20% or more of an issuer&#8217;s outstanding shares of common stock, subject to certain exceptions. The
issuance of additional shares could result in the dilution of the value of the shares now outstanding, if the terms on which the shares
were issued were less favorable than the contemporaneous market value of the Company&#8217;s common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The increase in the number
of shares of common stock available for issuance is not being done for the purpose of impeding any takeover attempt. Nevertheless, the
power of the Board of Directors to provide for the issuance of shares of common stock without stockholder approval has potential utility
as a device to discourage or impede a takeover of the Company. In the event that a non-negotiated takeover were attempted, the private
placement of stock into &#8220;friendly&#8221; hands, for example, could make the Company unattractive to the party seeking control of
the Company. This would have a detrimental effect on the interests of any stockholder who wanted to tender his or her shares to the party
seeking control or who would favor a change in control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Second Amended and Restated
Certificate of Incorporation of Incorporation provides the Board of Directors authority to designate and issue &#8216;blank check&#8217;
preferred stock, and the Authorized Shares Increase Amendment will have no effect on the Board of Director&#8217;s ability to designate
preferred stock, or the previously designated shares of preferred stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Summary Table of Potential Effects
of Authorized Share Increase</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The chart below illustrates
the number of shares of common stock that will be available for issuance if the Authorized Shares Increase Amendment is approved. The
number of shares disclosed in the column &#8220;Estimated Number of Shares of Common Stock after the Increase&#8221; gives further effect
to the Authorized Shares Increase in the number of authorized shares of common stock from 100,000,000 to 1,000,000,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Estimated
    Number<br/> of Shares of<br/> Common Stock<br/> Before Increase<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Estimated
    Number<br/> of Shares of<br/> Common Stock<br/> After the Increase<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Authorized</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,000,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,048,649</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,048,649</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Issuable upon exercise of outstanding warrants and options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,154,872</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,154,872</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 10pt">Reserved for issuance<sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Authorized but unissued<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86,769,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">986,769,479</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Does not take into account the effects of the Reverse Stock
Split discussed above.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Does not take into account the increase in shares available
for issuance under the 2022 OIP, as discussed in greater detail above under Proposal 2 and/or any shares of common stock issuable in
connection with awards under the 2025 Incentive Option Plan, as discussed in greater detail above under Proposal 3. Represents shares
currently reserved for future issuance under our existing equity incentive plans, excluding shares issuable under outstanding stock options,
and outstanding warrants.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">Shares authorized but unissued represent common stock available
for future issuance beyond shares currently outstanding, shares issuable under outstanding warrants and stock options, and shares reserved
for issuance under equity incentive plans.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless further stockholder
approval is required for a proposed issuance of additional shares by the rules of Nasdaq or other applicable laws or regulations, the
additional shares may be used for various purposes without further stockholder approval. These purposes may include: raising capital;
establishing strategic relationships with other companies; expanding the Company&#8217;s business or product lines through the acquisition
of other businesses or products; and other purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The additional shares of
common stock that would become available for issuance if the proposal is adopted could also be used by the Company to oppose a hostile
takeover attempt or to delay or prevent changes in control or management of the Company. For example, without further stockholder approval,
the Board could strategically sell shares of common stock in a private transaction to purchasers who would oppose a takeover or favor
the current Board of Directors. Although this proposal to increase the authorized common stock has been prompted by business and financial
considerations and not by the threat of any hostile takeover attempt (nor is the Board of Directors currently aware of any such attempts
directed at the Company), stockholders should be aware that approval of the proposal could facilitate future efforts by the Company to
deter or prevent changes in control of the Company, including transactions in which the stockholders might otherwise receive a premium
for their shares over then current market prices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this proposal is not approved
by our stockholders, our financing alternatives may be limited by the lack of sufficient unissued and unreserved authorized shares of
common stock, and stockholder value may be harmed by this limitation. In addition, our future success depends upon our ability to attract,
retain and motivate highly skilled scientific, commercial and managerial employees, and if this proposal is not approved by our stockholders,
the lack of sufficient unissued and unreserved authorized shares of common stock to provide future equity incentive opportunities as
the Board or the Compensation Committee thereof deems appropriate could adversely impact our ability to achieve these goals. In short,
if our stockholders do not approve this proposal, we may not be able to access the capital markets, complete corporate collaborations,
partnerships or other strategic transactions, attract, retain and motivate employees, and pursue other business opportunities integral
to our growth and success.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">No Dissenters&#8217; Rights</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Delaware law, our stockholders
would not be entitled to dissenters&#8217; rights or rights of appraisal in connection with the implementation of the Authorized Shares
Increase Amendment, and we will not independently provide our stockholders with any such rights.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal"><span style="text-decoration:underline">Effective
Time and Implementation&#160;of the Authorized Shares Increase Amendment</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The effective time for the
filing of the Authorized Shares Increase Amendment will be the date on which we file the Authorized Shares Increase Amendment with the
office of the Secretary of State of the State of Delaware or such later date and time as specified in the Authorized Shares Increase
Amendment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="via_002"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Vote Required</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proposal 6 requires that
the votes cast in favor of the proposal exceed the votes cast against the proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="via_003"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Board Recommendation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board recommends that
you vote &#8220;<span style="text-decoration:underline">FOR</span>&#8221; Proposal 6 to amend the Company&#8217;s Certificate of Incorporation to increase the authorized shares
of common stock of the Company to 1,000,000,000 shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above,
even if approved by stockholders at the Annual Meeting, the Board of Directors reserves the right to abandon the Authorized Shares Increase
if it deems such abandonment in the best interests of the stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_143"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Proposal&#160;7<br/>
Ratification of Appointment of Auditors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Change in Independent Registered Public
Accounting Firm</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 17, 2024, with the
approval of the Audit Committee of the Board of Directors of the Company, the Company dismissed Marcum LLP (&#8220;<span style="text-decoration:underline">Marcum</span>&#8221;)
as the Company&#8217;s independent registered public accounting firm, effective immediately. Also, on April 17, 2024, with the approval
of the Audit Committee, the Company engaged M&amp;K CPA&#8217;s, PLLC (&#8220;<span style="text-decoration:underline">M&amp;K CPAs</span>&#8221;), as the Company&#8217;s independent
registered public accounting firm for the fiscal year ending December 31, 2024, effective immediately.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The audit reports of Marcum
on the Company&#8217;s financial statements as of December 31, 2023 and 2022, and for the years ended December 31, 2023 and 2022 (the
&#8220;<span style="text-decoration:underline">Audit Periods</span>&#8221;), did not contain any adverse opinion or disclaimer of opinion, nor were such reports qualified or
modified as to uncertainty, audit scope or accounting principles, except that such opinions disclosed an uncertainty of the Company to
continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the Audit Periods
and during the period from December 31, 2023 through April 17, 2024, the Company had: (i) no disagreements with Marcum of the type contemplated
by Item 304(a)(1)(iv) of Regulation S-K on any matter of accounting principles or practices, financial statement disclosure or auditing
scope or procedure, which, if not resolved to Marcum&#8217;s satisfaction, would have caused it to make reference to the subject matter
of any such disagreement in connection with its reports; and (ii) no reportable events within the meaning of Item 304(a)(1)(v) of Regulation
S-K, except that the Audit Reports disclosed an uncertainty of the Company to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company provided Marcum
with the disclosures above and requested Marcum to furnish the Company with a letter addressed to the Securities and Exchange Commission
stating whether it agreed with the statements made by the Company and, if not, stating the respects in which it does not agree. A copy
of Marcum&#8217;s letter is filed as&#160;<span style="text-decoration:underline">Exhibit 16.1</span>&#160;to the Company&#8217;s Current Report on Form 8-K filed with the Securities
and Exchange Commission on April 19, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the Audit Periods
and during the period from December 31, 2023 through April&#160;17, 2024, neither the Company nor anyone on its behalf consulted M&amp;K
CPAs regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type
of audit opinion that might be rendered on the Company&#8217;s consolidated financial statements or (ii) any matter that was the subject
of a &#8220;<span style="text-decoration:underline">disagreement</span>&#8221; (within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions to that
Item) or a &#8220;<span style="text-decoration:underline">reportable event</span>&#8221; (within the meaning of Item 304(a)(1)(v) of Regulation&#160;S-K).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Principal Accounting Fees and Services</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our independent public accounting
firm for the year ended December 31, 2024 was&#160;M&amp;K CPAS, PLLC (Auditor Firm ID: 2738), and our independent accounting firm for
the year ended December 31, 2023, was Marcum LLP (Auditor Firm Id: 688).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of fees paid for audit, tax and related fees for services rendered by our independent auditing firms during the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Year Ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Audit Fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">511,813</td><td style="width: 1%; text-align: left">&#160;<sup>(1)</sup>&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">718,380</td><td style="width: 1%; text-align: left">&#160;<sup>(3)</sup>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Audit-Related Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,000</td><td style="text-align: left">&#160;<sup>(2)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,191</td><td style="text-align: left">&#160;<sup>(4)</sup>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">All Other Fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">523,813</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">795,571</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    $173,500 of fees charged by M&amp;K CPAs and $338,313 of fees charged by Marcum.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    $12,000 of fees charged by M&amp;K CPAs and $0 of fees charged by Marcum.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    $0 of fees charged by M&amp;K CPAs and $718,380 of fees charged by Marcum.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    $0 of fees charged by M&amp;K CPAs and $77,191 of fees charged by Marcum.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Audit Fees.&#160;</i></b>Audit
fees consist of fees billed for professional services rendered for the audit of our annual consolidated financial statements and services
that are normally provided by M&amp;K CPAs and Marcum, in connection with regulatory filings, including for professional services rendered
for the audit of our annual consolidated financial statements, review of the financial information included in our Form 10-Qs&#160;for
the respective periods and other required filings with the SEC for the applicable&#160;years. The above amounts include interim procedures
and audit fees, as well as attendance at Audit Committee meetings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Audit-Related&#160;Fees.&#160;</i></b>Audit-related&#160;services
consist of fees billed for assurance and related services that are reasonably related to performance of the audit or review of our consolidated
financial statements and are not reported under &#8220;<span style="text-decoration:underline">Audit Fees.</span>&#8221; These services include attest services that are not
required by statute or regulation and consultations concerning financial accounting and reporting standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Tax Fees.&#160;</i></b>Includes
fees paid for tax return services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>All Other Fees.&#160;</i></b>Includes
fees not included under &#8220;<span style="text-decoration:underline">Audit Fees</span>&#8221;, &#8220;<span style="text-decoration:underline">Audit-Related&#160;Fees</span>&#8221; and &#8220;<span style="text-decoration:underline">Tax Fees</span>&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i>&#160;</b></p><div>

</div><div><a id="a_144"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Audit Committee
Policy for Pre-approval of Independent Registered Public Accounting Firm Services</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Audit Committee of the
Board is required to pre-approve all audit and non-audit services provided by the Company&#8217;s independent registered public accounting
firm in order to assure that the provision of such services does not impair the independent registered public accounting firm&#8217;s
independence. The Audit Committee has established a policy regarding pre-approval of permissible audit, audit-related, and other services
provided by the independent registered public accounting firm, which services are periodically reviewed and revised by the Audit Committee.
Unless a type of service has received general pre-approval under the policy, the service will require specific approval by the Audit
Committee. All audit and permitted non-audit services and all fees associated with such services performed by our independent registered
public accounting firm in fiscal 2023 and 2022 were approved by the Audit Committee consistent with the policy described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_145"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Pre-Approval&#160;Policies</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is the policy of our Board
of Directors that all services to be provided by our independent registered public accounting firm, including audit services and permitted
audit-related&#160;and non-audit&#160;services, must be pre-approved&#160;by our Audit Committee. Our Audit Committee pre-approved&#160;all
services, audit and non-audit&#160;related, provided to us by Marcum for 2023 and M&amp;K CPAs for 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to assure continuing
auditor independence, the Audit Committee periodically considers the independent auditor&#8217;s qualifications, performance and independence
and whether there should be a regular rotation of our independent external audit firm. We believe the continued retention of M&amp;K
CPAs to serve as our independent auditor is in the best interests of the Company and its stockholders, and we are asking our stockholders
to ratify the appointment of M&amp;K CPAs as our independent auditor for the year ended December 31, 2025. While the Audit Committee
is responsible for the appointment, compensation, retention, termination and oversight of the independent registered public accounting
firm, the Audit Committee and our Board of Directors are requesting, as a matter of policy, that the stockholders ratify the appointment
of M&amp;K CPAs as our independent registered public accounting firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_146"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Vote Required</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ratification of this appointment
shall be effective upon the affirmative vote of a majority of the shares present in person or represented by proxy at the annual meeting
and entitled to vote on, and who voted for, against, or expressly abstained with respect to, this proposal, provided that a quorum exists
at the annual meeting. Abstentions with respect to the ratification of this appointment will have the effect of a vote &#8220;<span style="text-decoration:underline">Against</span>&#8221;
ratification of this appointment. Properly executed proxies will be voted at the annual meeting in accordance with the instructions specified
on the proxy; if no such instructions are given, the persons named as agents and proxies in the enclosed form of proxy will vote such
proxy &#8220;<span style="text-decoration:underline">For</span>&#8221; the ratification of the appointment of M&amp;K CPAs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Audit Committee is not
required to take any action as a result of the outcome of the vote on this proposal. In the event stockholders fail to ratify the appointment,
the Audit Committee may reconsider this appointment. Even if the appointment is ratified, the Audit Committee, in its discretion, may
direct the appointment of a different independent accounting firm at any time during the year if the committee determines that such a
change would be in our and the stockholders&#8217; best interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_147"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Board Recommendation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board of Directors unanimously recommends
a vote &#8220;<span style="text-decoration:underline">FOR</span>&#8221; this proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_148"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">P</span><span style="font-family: Times New Roman, Times, Serif">roposal
8</span><span style="text-transform: uppercase"><br/>
</span>Adjournment of the Annual Meeting to Solicit Additional Proxies</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><div><a id="a_149"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Overview</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are asking you to approve
a proposal to adjourn the Meeting to a later date or dates, if necessary, to solicit additional proxies if there are insufficient votes
to adopt the Reverse Split Proposal and/or Authorized Share Increase Proposal at the time of the Meeting (the &#8220;<span style="text-decoration:underline">Adjournment Proposal</span>&#8221;).
We intend to move to adjourn the Meeting to enable our Board to solicit additional proxies for approval of the Reverse Split Proposal
and/or Authorized Share Increase Proposal if, at the Meeting, the number of shares present in person or by proxy and voting in favor
of the proposals are insufficient to approve the proposals. If stockholders approve the Adjournment Proposal, we could adjourn the Meeting
and any adjourned session of the Meeting and use the additional time to solicit additional proxies, including proxies from stockholders
that have previously returned properly executed proxies voting against adoption of the Reverse Split Proposal and Authorized Share Increase
Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among other things, approval
of the Adjournment Proposal could mean that, even if we had received proxies representing a sufficient number of votes against adoption
of the Reverse Split Proposal and Authorized Share Increase Proposal, such that the proposals would be defeated, we could adjourn the
Meeting without a vote on the proposals and seek to convince the holders of those shares to change their votes to vote in favor of adoption
of the proposals. Additionally, we may seek to adjourn the Meeting if a quorum is not present.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, after the adjournment,
a new record date is fixed for the adjourned meeting, notice of the adjourned meeting will be given to each stockholder of record entitled
to vote at the meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the approval
or non-approval of this Proposal 8, pursuant to our Second Amended and Restated Bylaws, any meeting of stockholders may be adjourned
by the chairman of the meeting, from time to time, whether or not there is a quorum, to reconvene at the same or some other place, and
the approval or non-approval of this Proposal 8 shall not limit such right of the chairman.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_150"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Vote Required</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proposal 8 requires the affirmative
vote of the holders of a majority of the shares of common stock present in person or represented by proxy at the Meeting and entitled
to vote thereon, to be approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_151"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Board Recommendation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board recommends unanimously
that stockholders vote &#8220;<span style="text-decoration:underline">FOR</span>&#8221; the approval to adjourn the Meeting, if necessary, to solicit additional proxies if there
are not sufficient votes at the time of the Meeting to approve Proposal 8.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_152"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Other Matters</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_153"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Proposals for 2026
Annual Meeting of Stockholders and 2026 Proxy Materials</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><div><a id="a_154"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Proxy Statement Proposals</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Rule&#160;14a-8&#160;under
the Exchange&#160;Act, if a stockholder wants to submit a proposal for inclusion in our proxy materials for the 2026 annual meeting of
stockholders, it must be received by our Secretary by no later than _______, 2026, unless the date of the 2026 annual meeting of stockholders
is more than 30&#160;days before or after ____________, 2026, in which case the proposal must be received at least ten (10)&#160;days
before we begin to print and mail our proxy materials and must otherwise comply with Rule 14a-8 under the Exchange Act. In order to avoid
controversy, stockholders should submit proposals by means, including electronic means, which permit them to prove the date of delivery.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_155"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other Proposals and
Nominations</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For any proposal or director
nomination that is not submitted for inclusion in next year&#8217;s proxy statement pursuant to the process set forth above, but is instead
sought to be presented directly at the 2026 annual meeting of stockholders, stockholders are advised to review our Second Amended and
Restated Bylaws as they contain requirements with respect to advance notice of stockholder proposals and director nominations. To be
timely, the notice must be received at our principal executive offices not less than 90&#160;days nor more than 120&#160;days prior to
the first anniversary of the date of the prior year&#8217;s annual meeting of stockholders. Accordingly, any such stockholder proposal
or director nomination must be received between ________, 2026 and the close of business on ____________, 2026, for the 2026 annual meeting
of stockholders. In the event that the 2026 annual meeting of stockholders is convened more than 45&#160;days prior to or delayed by
more than 45&#160;days after the anniversary of the 2025 annual meeting, notice by the stockholder, to be timely, must be received no
earlier than the 120<sup>th</sup>&#160;day prior to the 2026 annual meeting of stockholders and no later than the later of (i)&#160;the
90<sup>th</sup>&#160;day prior to the 2026 annual meeting of stockholders and (ii)&#160;the tenth&#160;day following the&#160;day on
which we publicly announce the date of the 2026 annual meeting of stockholders. All proposals should be sent to our principal executive
offices at 3000 El Camino Rd., Bldg.&#160;4, Suite 200, Palo Alto, California 94306, Attention: Corporate Secretary. These advance notice
provisions are in addition to, and separate from, the requirements that a stockholder must meet in order to have a proposal included
in the proxy statement under the rules of the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A proxy granted by a stockholder
will give discretionary authority to the proxies to vote on any matters introduced pursuant to the above advance notice bylaw provisions,
subject to applicable rules of the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Copies of our Second Amended
and Restated Bylaws are filed as, or incorporated by reference as, an exhibit to our Annual Reports on Form&#160;10-K, which is available
at&#160;<i>www.sec.gov</i>&#160;available by request to the Secretary at 3000 El Camino Rd., Bldg.&#160;4, Suite 200, Palo Alto, California
94306.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to satisfying
the deadlines in the advance notice provisions of our Second Amended and Restated Bylaws, a stockholder who intends to solicit proxies
pursuant to Rule 14a-19 in support of nominees submitted under these advance notice provisions for the 2026 annual meeting must notify
our Secretary in writing not later than _____, 2026 comply with the other requirements of Rule 14a-19(b).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All submissions to, or requests
from, the Secretary of the Company should be made to: 180 Life Sciences Corp., 3000 El Camino Real, Bldg.&#160;4, Suite 200, Palo Alto,
CA, 94306.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The chairman of the annual
meeting of stockholders has the sole authority to determine whether any nomination or other proposal has been properly brought before
the meeting in accordance with our Second Amended and Restated Bylaws. If we receive a proposal other than pursuant to Rule 14a-8 or
a nomination for the 2026 annual meeting, and such nomination or other proposal is not delivered within the time frame specified in our
Second Amended and Restated Bylaws, then the person(s) appointed by the Board and named in the proxies for the 2026 annual meeting may
exercise discretionary voting power if a vote is taken with respect to that nomination or other proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_156"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Annual Report</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Copies of our Annual Report
on Form&#160;10-K&#160;(including our audited financial statements) filed with the SEC may be obtained without charge by writing to 180
Life Sciences Corp., 3000 El Camino Real, Bldg.&#160;4, Suite 200, Palo Alto, CA, 94306, attention: Secretary. Exhibits to the Form&#160;10-K&#160;will
be mailed upon similar request and payment of specified fees to cover the costs of copying and mailing such materials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audited financial statements
for the fiscal year ended December 31, 2024 and certain other related financial and business information are contained in our 2024 Annual
Report to stockholders, which is being made available to our stockholders along with this proxy statement, but which is not deemed a
part of the proxy soliciting material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_157"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Additional Filings</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s&#160;Form&#160;10-Ks,&#160;10-Qs,&#160;8-Ks&#160;and
all amendments to those reports are available without charge through the Company&#8217;s website on the Internet,&#160;<i>www.180lifesciences.com,</i>&#160;as
soon as reasonably practicable after they are electronically filed with, or furnished to, the Securities and Exchange Commission. Information
on our website does not constitute part of this proxy statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will provide,
without charge, to each person to whom a proxy statement is delivered, upon written or oral request of such person and by first class
mail or other equally prompt means within one business&#160;day of receipt of such request, a copy of any of the filings described above.
Individuals may request a copy of such information by sending a request to the Company, Attn: Corporate Secretary, 3000 El Camino Real,
Bldg.&#160;4, Suite 200, Palo Alto, California 94306.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_158"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Other Matters to
be Presented at the Annual Meeting</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this proxy
statement, our management has no knowledge of any business to be presented for consideration at the annual meeting other than that described
above. If any other business should properly come before the annual meeting or any adjournment thereof, it is intended that the shares
represented by properly executed proxies will be voted with respect thereto in accordance with the judgment of the persons named as agents
and proxies in the enclosed form of proxy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors does
not intend to bring any other matters before the annual meeting of stockholders and has not been informed that any other matters are
to be presented by others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_159"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Interest of Certain
Persons in or Opposition to Matters to Be Acted Upon:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No officer or director of us has any substantial interest in the matters
    to be acted upon, other than his or her role as an officer or director of us, or as a stockholder of us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No director of us has informed us that he or she intends to oppose
    the action taken by us set forth in this proxy statement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><div><a id="a_160"></a></div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Incorporation by
Reference</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to incorporate
by reference into this proxy statement information contained in documents that we file with it. This means that we can disclose important
information to you by referring you to those documents. We incorporate by reference each document we file under Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act after the date of the initial filing of this proxy statement and before the Annual Meeting (other than
current reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 of Form 8-K, including any exhibits included with such information,
unless otherwise indicated therein). We also incorporate by reference in this proxy statement the following documents filed by us with
the SEC under the Exchange Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt; width: 0.5in">&#160;</td>
    <td style="padding-top: 1.5pt; padding-right: 1pt; padding-left: 1pt; text-align: justify; font-size: 10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; background-color: white; padding-top: 1.5pt; padding-right: 1pt; padding-left: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Annual Report on <a href="https://www.sec.gov/Archives/edgar/data/1690080/000121390025026273/ea0235286-10k_180life.htm">Form 10-K</a> for the fiscal year ended December&#160;31, 2024, filed with the SEC on March&#160;31, 2025
    (a copy of which is being made available with the proxy statement). </span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We undertake to provide without
charge to each person to whom a copy of this proxy statement has been delivered, upon request, by first class mail or other equally prompt
means, a copy of any or all of the&#160;documents incorporated by reference&#160;in this proxy statement, other than the exhibits to
these documents, unless the exhibits are specifically incorporated by reference into the information that this proxy statement incorporates.
You may obtain&#160;documents incorporated by reference&#160;by requesting them in writing or by telephone at the address and telephone
number set forth below under &#8220;<i><span style="text-decoration:underline">Company Contact Information</span></i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Company Contact Information</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board has established
a process for stockholders to send communications to our Board or any individual director. Stockholders may send written communications
to the Board or any director to 180 Life Sciences Corp.:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">180 Life Sciences Corp.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn: Investor Relations</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3000 El Camino Real, Bldg.&#160;4, Suite 200,
Palo Alto, California 94306</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: ir@180lifesciences.com</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><div><a id="a_161"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Appendix A</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>FOURTH AMENDMENT TO<br/>
180 LIFE SCIENCES CORP.<br/>
2022 OMNIBUS INCENTIVE PLAN</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
Fourth Amendment (&#8220;<span style="text-decoration:underline">Fourth Amendment</span>&#8221;) to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan, as amended (the
&#8220;<span style="text-decoration:underline">2022 OIP</span>&#8221;), is made and adopted by the Board of Directors of 180 Life Sciences Corp., a Delaware corporation (the
&#8220;<span style="text-decoration:underline">Company</span>&#8221;), on __________, 2025, effective as of the date of the Annual Meeting that occurs in 2024, provided that
it is approved by the Company&#8217;s stockholders on that date (the &#8220;<span style="text-decoration:underline">Fourth Amendment Date</span>&#8221;). Capitalized terms used
in this Fourth Amendment and not otherwise defined herein shall have the meanings ascribed to such terms in the 2022 OIP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>RECITALS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">A.</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            Company currently maintains the 2022 OIP.</span></td>
</tr></table><div>

</div><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">B.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Board believes it is in the best interests of the Company and its
    stockholders to amend the 2022 OIP to (1) increase the Share Limit; (2) provide for automatic future annual increases in the Share
    Limit; and (3) increase the ISO Limit, and to incorporate the other terms and conditions set forth herein.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>AMENDMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
2022 OIP is hereby amended as follows, effective as of the date of the Annual Meeting that occurs in 2023, provided that it is approved
by the Company&#8217;s stockholders on that date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td><span style="text-decoration:underline">Section 3.1(a)</span>. Section 3.1(a) of the 2022 OIP is hereby deleted and replaced in its entirety with the following: &#160;
    &#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt">&#8220;(a) Subject to Section 3.3 and Section 3.6, the aggregate number of Shares which may be issued under this Plan shall initially equal 5,000,000 shares, and will automatically increase on April 1st of each year for a period of seven years commencing on January 1, 2026 and ending on (and including) January 1, 2032, in an amount equal to ten percent (10%) of the total shares of Company Common Stock outstanding on the last day of the immediately preceding fiscal year (the &#8220;<b><span style="text-decoration:underline">Evergreen Measurement Date</span></b>&#8221;); provided, however, that the Board may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares of Common Stock (the&#160;<b><span style="text-decoration:underline">&#8220;Share Limit</span></b>&#8221;). All of the Shares reserved under the Plan may be issued in the form of Incentive Stock Options under the Plan, subject to the limitation set forth in Section 3.6. The Shares issued under the Plan may be authorized but unissued, or reacquired Company Common Stock. No provision of this Plan shall be construed to require the Company to maintain the Shares in certificated form. Unless the Administrator shall determine otherwise, (x) Awards may not consist of fractional shares and shall be rounded down to the nearest whole Share, and (y) fractional Shares shall not be issued under the Plan (and shall instead also be rounded as aforesaid).&#8221;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td><span style="text-decoration:underline">Section 3.6</span>. Section 3.6 of the 2022 OIP is hereby deleted and replaced in its entirety with the following:</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt">&#8220;Section 3.6&#160;<span style="text-decoration:underline">Maximum Number of Incentive Stock Options</span>. Notwithstanding the Share Limit, and subject to adjustment in accordance with Section 3.3 hereof, the maximum number of Shares that may be granted in connection with, and issued pursuant to the exercise of, Incentive Stock Options granted under this Plan is 100,000,000 shares (the&#160;&#8220;<b><span style="text-decoration:underline">ISO Limit</span></b>&#8221;).&#8221; &#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Fourth Amendment shall
    be and, as of the Fourth Amendment Date, is hereby incorporated in and forms a part of the 2022 OIP.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as expressly provided
    herein, all terms and conditions of the 2022 OIP shall remain in full force and effect.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><!-- Field: Page; Sequence: 112; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><div><a id="a_162"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Appendix B</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FOURTH AMENDED AND RESTATED&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>180 LIFE SCIENCES CORP.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2022 OMNIBUS INCENTIVE PLAN</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Originally Adopted by the Board of Directors
on April 26, 2022 and the Stockholders on June 14, 2022</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Amended and Restated by the Stockholders
on July 6, 2023, February 16, 2024, December 27, 2024 and [____], 2025</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">PURPOSES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Fourth Amended and Restated
180 Life Sciences Corp. 2022 Omnibus Incentive Plan, as may be amended from time to time (the &#8220;<b><span style="text-decoration:underline">Plan</span></b>&#8221;), is intended
to promote the interests of 180 Life Sciences Corp. (the &#8220;<b><span style="text-decoration:underline">Company</span></b>&#8221;) and its Subsidiaries (as defined below)
and its stockholders by (i) attracting and retaining directors, executive officers, employees and consultants of outstanding ability;
(ii) motivating such individuals by means of performance-related incentives to achieve the longer-range performance goals of the Company
and its Subsidiaries; and (iii) enabling such individuals to participate in the long-term growth and financial success of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article I<br/>
<span style="text-decoration:underline">Definitions</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whenever the following terms
are used in this Plan, they shall have the meanings specified below unless the context clearly indicates to the contrary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.1 &#8220;<b><span style="text-decoration:underline">Administrator</span></b>&#8221;
means the Board or the Compensation Committee, as determined by the Board from time to time. In exercising its discretion hereunder,
the Board shall endeavor to cause the Administrator to satisfy any requirements applicable to qualify for an exemption available under
Rule 16b-3 promulgated under the Exchange Act or any other regulatory or administrative requirements that may be applicable with respect
to Awards granted hereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.2 &#8220;<b><span style="text-decoration:underline">Affiliate</span></b>&#8221;
means, with respect to any Person, any other Person directly or indirectly controlling, controlled by or under common control with, such
Person where &#8220;control&#8221; (including the terms &#8220;controlling,&#8221; &#8220;controlled by,&#8221; and &#8220;under common
control with&#8221;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies
of a Person, whether through the ownership of securities, by contract, or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.3 &#8220;<b><span style="text-decoration:underline">Alternative
Award</span></b>&#8221; has the meaning set forth in Section 10.1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.4 &#8220;<b><span style="text-decoration:underline">Alternative
Performance Awards</span></b>&#8221; has the meaning set forth in Section 10.2.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.5 &#8220;<b><span style="text-decoration:underline">Award</span></b>&#8221;
means any Option, Restricted Stock, Restricted Stock Unit, Performance Award, SAR, Dividend Equivalent or other Stock-Based Award granted
to a Participant pursuant to the Plan, including an Award combining two or more types of Awards into a single grant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.6 &#8220;<b><span style="text-decoration:underline">Award
Agreement</span></b>&#8221; means any written agreement, contract or other instrument or document evidencing an Award, including through
an electronic medium. The Administrator may provide for the use of electronic, internet or other non-paper Award Agreements, and the
use of electronic, internet or other non-paper means for the Participant&#8217;s acceptance of, or actions under, an Award Agreement
unless otherwise expressly specified herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.7 &#8220;<b><span style="text-decoration:underline">Board</span></b>&#8221;
means the Board of Directors of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.8 [Reserved]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 113; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.9 &#8220;<b><span style="text-decoration:underline">Cause</span></b>&#8221;
means, unless otherwise provided in the Award Agreement, any of the following: (A) the Participant&#8217;s commission of a crime involving
fraud, theft, false statements or other similar acts or commission of any crime that is a felony (or comparable classification in a jurisdiction
that does not use these terms); (b) the Participant&#8217;s engaging in any conduct that constitutes an employment disqualification under
applicable law with respect to a material portion of the Participant&#8217;s work duties; (c) the Participant&#8217;s willful or grossly
negligent failure to perform his or her material employment-related duties for the Company Group, or willful misconduct in the performance
of such duties; (d) the Participant&#8217;s material violation of any Company or Subsidiary policy as in effect from time to time; (e)
the Participant&#8217;s engaging in any act or making any public statement that materially impairs, impugns, denigrates, disparages or
negatively reflects upon the name, reputation or business interests of the Company or its Subsidiaries; or (f) the Participant&#8217;s
material breach of any Award Agreement, employment agreement, or noncompetition, nondisclosure or nonsolicitation agreement to which
the Participant is a party or by which the Participant is bound;&#160;<span style="text-decoration:underline">provided</span>&#160;that in the case of any Participant who, as
of the date of determination, is a party to an effective services, severance, consulting or employment agreement with the Company or
any Subsidiary of the Company that employs such individual, &#8220;Cause&#8221; has the meaning, if any, specified in such agreement.
A termination for Cause shall be deemed to include a determination by the Administrator following a Participant&#8217;s termination of
employment that circumstances existing prior to such termination would have entitled the Company or one of its Subsidiaries to have terminated
such Participant&#8217;s employment for Cause. All rights a Participant has or may have under the Plan shall be suspended automatically
during the pendency of any investigation by the Administrator or its designee, or during any negotiations between the Administrator or
its designee and the Participant, regarding any actual or alleged act or omission by the Participant of the type described in the applicable
definition of Cause.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.10 &#8220;<b><span style="text-decoration:underline">Change
in Control</span></b>&#8221; means the first to occur of any of the following events after the Effective Date:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(a)&#160;any Person
becomes the beneficial owner (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 30% or more of either (x) the then-outstanding
shares of common stock of the Company (the &#8220;<b><span style="text-decoration:underline">Outstanding Company Common Stock</span></b>&#8221;) or (y) the combined voting power
of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the &#8220;<b><span style="text-decoration:underline">Outstanding
Company Voting Securities</span></b>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(b)&#160;the individuals
who constitute the Board as of the Effective Date (the &#8220;<b><span style="text-decoration:underline">Incumbent Board</span></b>&#8221;) cease for any reason to constitute
at least a majority of the Board;&#160;<span style="text-decoration:underline">provided</span>,&#160;<span style="text-decoration:underline">however</span>, that any individual becoming a Director subsequent to the
Effective Date whose election, or nomination for election, by the Company&#8217;s stockholders, was approved by a vote of at least a
majority of the Directors then comprising the Incumbent Board shall be considered as though such individual was a member of the Incumbent
Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened
election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents
by or on behalf of a Person other than the Board; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(c)&#160;the consummation
of a reorganization, merger, statutory share exchange or consolidation or similar transaction involving the Company or any of its Subsidiaries,
a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or stock of another
entity by the Company or any of its Subsidiaries (each, a &#8220;<b><span style="text-decoration:underline">Business Combination</span></b>&#8221;), in each case, unless, following
such Business Combination, (i) all or substantially all of the individuals and entities that were the beneficial owners of the Outstanding
Company Common Stock and the Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly
or indirectly, more than 50% of the then-outstanding shares of common stock (or, for a non-corporate entity, equivalent securities) and
the combined voting power of the then-outstanding voting securities entitled to vote generally in the election of Directors (or, for
a non-corporate entity, equivalent governing body), as the case may be, of the entity resulting from such Business Combination (including,
without limitation, an entity that, as a result of such transaction, owns the Company or all or substantially all of the Company&#8217;s
assets either directly or through one or more Subsidiaries) in substantially the same proportions as their ownership immediately prior
to such Business Combination of the Outstanding Company Common Stock and the Outstanding Company Voting Securities, as the case may be,
(ii) no Person (excluding any corporation resulting from such Business Combination or any employee benefit plan (or related trust) of
the Company or such corporation resulting from such Business Combination) beneficially owns, directly or indirectly, 30% or more of,
respectively, the then-outstanding shares of common stock (or, for a non-corporate entity, equivalent securities) of the entity resulting
from such Business Combination or the combined voting power of the then-outstanding voting securities of such entity entitled to vote
generally in the election of directors (or, for a non-corporate entity, equivalent securities), except to the extent that such ownership
existed prior to the Business Combination, and (iii) at least a majority of the members of the board of directors (or, for a non-corporate
entity, equivalent governing body) of the entity resulting from such Business Combination were members of the Incumbent Board at the
time of the execution of the initial agreement or of the action of the Board providing for such Business Combination;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">in each case,&#160;<span style="text-decoration:underline">provided</span>&#160;that,
as to Awards subject to Section 409A of the Code, the payment or settlement of which will occur by reason of the Change in Control, such
event also constitutes a &#8220;change in control&#8221; within the meaning of Section 409A of the Code. In addition, notwithstanding
the foregoing, a &#8220;Change in Control&#8221; shall not be deemed to occur if the Company files for bankruptcy, liquidation or reorganization
under the United States Bankruptcy Code or as a result of any restructuring that occurs as a result of any such proceeding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.11 &#8220;<b><span style="text-decoration:underline">Change
in Control Price</span></b>&#8221; means the price per share of Company Common Stock paid in conjunction with any transaction resulting
in a Change in Control. If any part of the offered price is payable other than in cash, the value of the non-cash portion of the Change
in Control Price shall be determined in good faith by the Administrator as constituted immediately prior to the Change in Control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.12 &#8220;<b><span style="text-decoration:underline">Code</span></b>&#8221;
means the Internal Revenue Code of 1986, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.13 &#8220;<b><span style="text-decoration:underline">Company
Common Stock</span></b>&#8221; means the common stock, par value $0.0001 per share, of the Company and such other stock or securities into
which such common stock is hereafter converted or for which such common stock is exchanged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.14 &#8220;<b><span style="text-decoration:underline">Company
Group</span></b>&#8221; means the Company and its direct or indirect Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.15 &#8220;<b><span style="text-decoration:underline">Compensation
Year</span></b>&#8221; means the period from one annual meeting of stockholders to the next following annual meeting of stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.16 &#8220;<b><span style="text-decoration:underline">Competitive
Activity</span></b>&#8221; means a Participant&#8217;s material breach of restrictive covenants relating to noncompetition, nonsolicitation
(of customers or employees) or preservation of confidential information or other covenants having the same or similar scope, included
in an Award Agreement or other agreement to which the Participant and the Company or any of its Affiliates is a party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.17 &#8220;<b><span style="text-decoration:underline">Corporate
Event</span></b>&#8221; means, as determined by the Administrator, any transaction or event described in Section 3.3(a) or any unusual or
infrequently occurring transaction or event affecting the Company, any Subsidiary of the Company, or the financial statements of the
Company or any of its Subsidiaries, or changes in applicable laws, regulations or accounting principles (including, without limitation,
a recapitalization of the Company).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.18 &#8220;<b><span style="text-decoration:underline">Director</span></b>&#8221;
means a member of the Board or a member of the board of directors of any Subsidiary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.19 &#8220;<b><span style="text-decoration:underline">Disability</span></b>&#8221;
means (x) for Awards that are not subject to Section 409A of the Code, &#8220;disability&#8221; as such term is defined in the long-term
disability insurance plan or program of the Company or any Subsidiary then covering the Participant, and (y) for Awards that are subject
to Section 409A of the Code, &#8220;disability&#8221; has the meaning set forth in Section 409A(a)(2)(c) of the Code;&#160;<span style="text-decoration:underline">provided</span>&#160;that
with respect to Awards that are not subject to Section 409A, in the case of any Participant who, as of the date of determination, is
a party to an effective services, severance, consulting or employment agreement with the Company or any Subsidiary of the Company that
employs such individual, &#8220;Disability&#8221; has the meaning, if any, specified in such agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Split-Segment; Name: 004 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.20 &#8220;<b><span style="text-decoration:underline">Dividend
Equivalent</span></b>&#8221; means the right to receive payments, in cash or in Shares, based on dividends paid with respect to Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.21 &#8220;<b><span style="text-decoration:underline">Eligible
Representative</span></b>&#8221; for a Participant means such Participant&#8217;s personal representative or such other person as is empowered
under the deceased Participant&#8217;s will or the then applicable laws of descent and distribution to represent the Participant hereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.22 &#8220;<b><span style="text-decoration:underline">Employee</span></b>&#8221;
means any individual classified as an employee by the Company or one of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.23 &#8220;<b><span style="text-decoration:underline">Exchange
Act</span></b>&#8221; means the Securities Exchange Act of 1934, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.24 &#8220;<b><span style="text-decoration:underline">Executive
Officer</span></b>&#8221; means each person who is an officer or employee of the Company or any of its Subsidiaries and who is subject to
the reporting requirements under Section 16(a) of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.25 &#8220;<b><span style="text-decoration:underline">Fair
Market Value</span></b>&#8221; means, unless otherwise determined by the Administrator from time to time, the closing transaction price
of a Share as reported on the NASDAQ Stock Market LLC on the date as of which such value is being determined or, if Shares are not listed
on the NASDAQ Stock Market LLC, the closing transaction price of a Share on the principal national stock exchange on which Shares are
traded on the date as of which such value is being determined or, if there shall be no reported transactions for such date, on the next
preceding date for which transactions were reported; provided, however, that if Shares are not listed on a national stock exchange or
if Fair Market Value for any date cannot be so determined, Fair Market Value shall be determined by the Administrator by whatever means
or method as the Administrator, in the good faith exercise of its discretion, shall at such time deem appropriate and in compliance with
Section 409A of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.26 &#8220;<b><span style="text-decoration:underline">Good
Reason</span></b>&#8221; means, unless otherwise provided in the Award Agreement, a material reduction in the Participant&#8217;s base salary
or a material reduction in the Participant&#8217;s target annual cash incentive compensation opportunity, in each case, other than (a)
any isolated or inadvertent failure by the Company or the applicable Subsidiary that is not in bad faith and is cured within thirty (30)
business days after the Participant gives the Company or the applicable Subsidiary notice of such event or (b) a reduction of 10% or
less which is applicable to all employees in the same salary grade as the Participant;&#160;<span style="text-decoration:underline">provided</span>&#160;that in the case of
any Participant who, as of the date of determination, is a party to an effective services, severance, consulting or employment agreement
with the Company or any Subsidiary of the Company that employs such individual, &#8220;Good Reason&#8221; has the meaning, if any, specified
in such agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.27 &#8220;<b><span style="text-decoration:underline">Incentive
Stock Option</span></b>&#8221; means an Option which qualifies under Section 422 of the Code and is expressly designated as an Incentive
Stock Option in the Award Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.28 &#8220;<b><span style="text-decoration:underline">Non-Qualified
Stock Option</span></b>&#8221; means an Option that is not an Incentive Stock Option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.29 &#8220;<b><span style="text-decoration:underline">Option</span></b>&#8221;
means an option to purchase Company Common Stock granted under the Plan. The term &#8220;Option&#8221; includes both an Incentive Stock
Option and a Non-Qualified Stock Option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.30 &#8220;<b><span style="text-decoration:underline">Participant</span></b>&#8221;
means any Service Provider who has been granted an Award pursuant to the Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.31 &#8220;<b><span style="text-decoration:underline">Performance
Award</span></b>&#8221; means a Performance Shares or a Performance Unit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.32 &#8220;<b><span style="text-decoration:underline">Performance
Cycle</span></b>&#8221; means the period of time selected by the Administrator during which performance is measured for the purpose of determining
the extent to which a Performance Award has been earned or vested.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.33 &#8220;<b><span style="text-decoration:underline">Performance
Goals</span></b>&#8221; means the objectives established by the Administrator for a Performance Cycle pursuant to Section 6.5 for the purpose
of determining the extent to which a Performance Award has been earned or vested.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.34 &#8220;<b><span style="text-decoration:underline">Performance
Share</span></b>&#8221; means an Award granted pursuant to Article VI of the Plan of a Share or a contractual right to receive a Share (or
the cash equivalent thereof) upon the achievement, in whole or in part, of the applicable Performance Goals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.35 &#8220;<b><span style="text-decoration:underline">Performance
Unit</span></b>&#8221; means a U.S. Dollar-denominated unit (or a unit denominated in the Participant&#8217;s local currency) granted pursuant
to Article VI of the Plan, payable in cash or in Shares upon the achievement, in whole or in part, of the applicable Performance Goals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.36 &#8220;<b><span style="text-decoration:underline">Person</span></b>&#8221;
means an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated
association, joint venture, governmental authority or any other entity of whatever nature.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.37 &#8220;<b><span style="text-decoration:underline">Replacement
Awards</span></b>&#8221; means Shares or Awards issued in assumption of, or in substitution for, any outstanding awards of any entity acquired
in any form or combination by the Company or any of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.38 &#8220;<b><span style="text-decoration:underline">Restricted
Stock</span></b>&#8221; means an Award granted pursuant to Section 5.1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.39 &#8220;<b><span style="text-decoration:underline">Restricted
Stock Unit</span></b>&#8221; means an Award granted pursuant to Section 5.2.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.40 &#8220;<b><span style="text-decoration:underline">Securities
Act</span></b>&#8221; means the Securities Act of 1933, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.41 &#8220;<b><span style="text-decoration:underline">Service
Provider</span></b>&#8221; means an Employee, Director or consultant of the Company or any of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.42 &#8220;<b><span style="text-decoration:underline">Share</span></b>&#8221;
means a share of Company Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.43 &#8220;<b><span style="text-decoration:underline">Stock
Appreciation Right</span></b>&#8221; or &#8220;<b><span style="text-decoration:underline">SAR</span></b>&#8221; means the right to receive a payment from the Company in cash and/or
Shares equal to the excess, if any, of the Fair Market Value of one Share on the exercise date over a specified price (the &#8220;<b><span style="text-decoration:underline">Base
Price</span></b>&#8221;) fixed by the Administrator on the grant date (which specified price shall not be less than the Fair Market Value
of one Share on the grant date).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.44 &#8220;<b><span style="text-decoration:underline">Subsidiary</span></b>&#8221;
means any entity that is directly or indirectly controlled by the Company or any entity in which the Company directly or indirectly has
at least a 50% equity interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.45 &#8220;<b><span style="text-decoration:underline">Termination
of employment</span></b>,&#8221; &#8220;<b><span style="text-decoration:underline">termination of service</span></b>&#8221; and any similar term or terms means, with respect to
a Director who is not an Employee of the Company or any Subsidiary, the date upon which such Director ceases to be a member of the Board
or of the board of directors of any Subsidiary, with respect to a consultant of the Company or any of its Subsidiaries, the date upon
which such consultant ceases to provide services to the Company and its Subsidiaries and, with respect to an Employee, the date he or
she ceases to be an Employee;&#160;<span style="text-decoration:underline">provided</span>&#160;that with respect to any Award subject to Section 409A of the Code, such terms
shall mean &#8220;separation from service,&#8221; as defined in Section 409A of the Code and the rules, regulations and guidance promulgated
thereunder. Unless otherwise determined by the Administrator, a &#8220;termination of employment&#8221; or &#8220;termination of service&#8221;
shall not occur if an Employee, consultant or Director, immediately upon ceasing to provide services in such capacity, commences to or
continues to provide services to the Company or any of its Affiliates in another of such capacities.</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article II<br/>
<span style="text-decoration:underline">ADMINISTRATION</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2.1&#160;<span style="text-decoration:underline">Powers
of the Administrator</span>. The Plan shall be administered by the Administrator. The Administrator shall have the sole and complete authority
and discretion to: (i) determine the type or types of Awards to be granted to each Participant; (ii) select the Service Providers to
whom Awards may from time to time be granted; (iii) determine all matters and questions related to the termination of service of a Service
Provider with respect to any Award granted to him or her; (iv) determine the number of Awards to be granted and the number of Shares
to which an Award will relate; (v) approve forms of agreement for use under the Plan, which need not be identical for each Service Provider;
(vi) determine the terms and conditions of any Awards (including, without limitation, the exercise price, the time or times when Awards
may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions and any
restriction or limitation regarding any Award or the Company Common Stock relating thereto) based in each case on such factors as the
Administrator shall determine; (vii) prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations
relating to Subplans (as defined in Section 2.4) established for the purpose of satisfying applicable foreign laws; (viii) determine
whether, to what extent, and pursuant to what circumstances an Award may be settled in, or the exercise or purchase price of an Award
may be paid in, cash, Company Common Stock, other Awards, or other property, or an Award may be canceled, forfeited or surrendered; (ix)
suspend or accelerate the vesting of any Award granted under the Plan or waive the forfeiture restrictions or any other restriction or
limitation regarding any Awards or the Company Common Stock relating thereto; (x) construe and interpret the terms of the Plan and Awards
granted pursuant to the Plan; and (xi) make all other decisions and determinations that may be required pursuant to the Plan or as the
Administrator deems necessary or advisable to administer the Plan. Any determination made by the Administrator under the Plan, including,
without limitation, under Section 3.3, shall be final, binding and conclusive on all Participants and other persons having or claiming
any right or interest under the Plan. The Administrator&#8217;s determinations under the Plan need not be uniform and may be made by
the Administrator selectively among persons who receive, or are eligible to receive, Awards under the Plan, whether or not such persons
are similarly situated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2.2&#160;<span style="text-decoration:underline">Delegation
by the Administrator</span>. The Administrator may delegate, subject to such terms or conditions or guidelines as it shall determine, to
any officer or group of officers, or Director or group of Directors of the Company or its Subsidiaries any portion of its authority and
powers under the Plan with respect to Participants who are not Executive Officers or non-employee directors of the Board;&#160;<span style="text-decoration:underline">provided</span>&#160;that
any delegation to one or more officers of the Company shall be subject to and comply with applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2.3&#160;<span style="text-decoration:underline">Expenses,
Professional Assistance, No Liability</span>. All expenses and liabilities incurred by the Administrator in connection with the administration
of the Plan shall be borne by the Company. The Administrator may elect to engage the services of attorneys, consultants, accountants
or other persons. The Administrator, the Company and its officers and Directors shall be entitled to rely upon the advice, opinions or
valuations of any such persons. The Administrator (and its members) shall not be personally liable for any action, determination or interpretation
made with respect to the Plan or the Awards, and the Administrator (and its members) shall be fully protected by the Company with respect
to any such action, determination or interpretation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2.4&#160;<span style="text-decoration:underline">Participants
Based Outside the United States</span>. To conform with the provisions of local laws and regulations, or with local compensation practices
and policies, in foreign countries in which the Company or any of its Subsidiaries operate, but subject to the limitations set forth
herein regarding the maximum number of shares issuable hereunder and the maximum award to any single Participant, the Administrator may
(i) modify the terms and conditions of Awards granted to Employees employed and consultants who provide services outside the United States
(&#8220;<b><span style="text-decoration:underline">Non-U.S. Awards</span></b>&#8221;), (ii) establish subplans with such modifications as may be necessary or advisable under
the circumstances (&#8220;<b><span style="text-decoration:underline">Subplans</span></b>&#8221;) and (iii) take any action which it deems advisable to obtain, comply with or
otherwise reflect any necessary governmental regulatory procedures, exemptions or approvals with respect to the Plan. The Administrator&#8217;s
decision to grant Non-U.S. Awards or to establish Subplans is entirely voluntary, and at the complete discretion of the Administrator.
The Administrator may amend, modify or terminate any Subplans at any time, and such amendment, modification or termination may be made
without prior notice to the Participants. The Company, Affiliates and members of the Administrator shall not incur any liability of any
kind to any Participant as a result of any change, amendment or termination of any Subplan at any time. The benefits and rights provided
under any Subplan or by any Non-U.S. Award (x) are wholly discretionary and, although provided by either the Company or an Affiliate
of the Company, do not constitute regular or periodic payments and (y) except as otherwise required under applicable laws, are not to
be considered part of the Participant&#8217;s salary or compensation under the Participant&#8217;s employment with the Participant&#8217;s
local employer for purposes of calculating any severance, resignation, redundancy or other end of service payments, vacation, bonuses,
long-term service awards, indemnification, pension or retirement benefits, or any other payments, benefits or rights of any kind. If
a Subplan is terminated, the Administrator may direct the payment of Non-U.S. Awards (or direct the deferral of payments whose amount
shall be determined) prior to the dates on which payments would otherwise have been made, and determine if such payments may be made
in a lump sum or in installments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article III<br/>
<span style="text-decoration:underline">SHARES SUBJECT TO PLAN</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.1&#160;<span style="text-decoration:underline">Shares
Subject to Plan</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(a)&#160;Subject
to Section 3.3 and Section 3.6, the aggregate number of Shares which may be issued under this Plan shall initially equal 5,000,000 shares,
and will automatically increase on April 1st of each year for a period of seven years commencing on January 1, 2026 and ending on (and
including) January 1, 2032, in an amount equal to ten percent (10%) of the total shares of Company Common Stock outstanding on the last
day of the immediately preceding fiscal year (the &#8220;<b><span style="text-decoration:underline">Evergreen Measurement Date</span></b>&#8221;); provided, however, that the
Board may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares of Common
Stock (the&#160;<b><span style="text-decoration:underline">&#8220;Share Limit</span></b>&#8221;). All of the Shares reserved under the Plan may be issued in the form of Incentive
Stock Options under the Plan, subject to the limitation set forth in Section 3.6. The Shares issued under the Plan may be authorized
but unissued, or reacquired Company Common Stock. No provision of this Plan shall be construed to require the Company to maintain the
Shares in certificated form. Unless the Administrator shall determine otherwise, (x) Awards may not consist of fractional shares and
shall be rounded down to the nearest whole Share, and (y) fractional Shares shall not be issued under the Plan (and shall instead also
be rounded as aforesaid).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(b)&#160;If any
Award or portion thereof under this Plan is for any reason forfeited, canceled, cash-settled, expired or otherwise terminated without
the issuance of Shares, the Shares subject to such forfeited, canceled, cash-settled, expired or otherwise terminated Award, or portion
thereof, shall again be available for grant under the Plan. If Shares are tendered or withheld from issuance with respect to an Award
by the Company in satisfaction of any Exercise Price, Base Price or tax withholding or similar obligations, such tendered or withheld
Shares shall again be available for grant under the Plan. Notwithstanding the foregoing, and except to the extent required by applicable
law, Replacement Awards shall not be counted against Shares available for grant pursuant to this Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.2&#160;<span style="text-decoration:underline">Limitation
on Non-Employee Director Awards</span>. The maximum number of Shares subject to Awards granted during a single Compensation Year to any
non-employee Director, taken together with any cash fees paid during the Compensation Year to the non-employee Director, in respect of
the Director&#8217;s service as a member of the Board during such year (including service as a member or chair of any committees of the
Board), shall not exceed (i) $500,000 in total value; or&#160;(ii)&#160;in the event such&#160;non-employee Director&#160;is first appointed
or elected to the Board during such&#160;Compensation Year, $750,000 in total value, or (iii) in the event such non-employee Director
is serving as&#160;non-employee Chairperson (or co-Chairperson)&#160;of the Board, $750,000 in total value, in each case calculating
the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.3&#160;<span style="text-decoration:underline">Changes
in Company Common Stock; Disposition of Assets and Corporate Events</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(a)&#160;If and
to the extent necessary or appropriate to reflect any stock dividend, extraordinary dividend, stock split or share combination or any
recapitalization, merger, consolidation, exchange of shares, spin-off, liquidation or dissolution of the Company or other similar transaction
affecting the Company Common Stock (each, a &#8220;<b><span style="text-decoration:underline">Corporate Event</span></b>&#8221;), the Administrator shall adjust the number of
shares of Company Common Stock available for issuance under the Plan, the ISO Limit, and the number, class and Exercise Price (if applicable)
or Base Price (if applicable) of any outstanding Award, and/or make such substitution, revision or other provisions or take such other
actions with respect to any outstanding Award or the holder or holders thereof, in each case as it determines to be equitable. Without
limiting the generality of the foregoing sentence, in the event of any such Corporate Event, the Administrator shall have the power to
make such changes as it deems appropriate in (i) the number and type of shares or other securities covered by outstanding Awards, (ii)
the prices specified therein (if applicable), (iii) the securities, cash or other property to be received upon the exercise, settlement
or conversion of such outstanding Awards or otherwise to be received in connection with such outstanding Awards and (iv) any applicable
Performance Goals. After any adjustment made by the Administrator pursuant to this Section 3.3, the number of shares subject to each
outstanding Award shall be rounded down to the nearest whole number of whole or fractional shares (as determined by the Administrator),
and (if applicable) the Exercise Price or Base Price thereof shall be rounded up to the nearest cent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(b)&#160;Any adjustment
of an Award pursuant to this Section 3.3 shall be effected in compliance with Section 424 and 409A of the Code to the extent applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.4&#160;<span style="text-decoration:underline">Award
Agreement Provisions</span>. The Administrator may include such provisions and limitations in any Award Agreement as it shall determine,
subject to the terms of the Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.5&#160;<span style="text-decoration:underline">Prohibition
Against Repricing</span>. Except to the extent (i) approved in advance by the stockholders of the Company or (ii) pursuant to Section 3.3
as a result of any Corporate Event or pursuant to Article XI in connection with a Change in Control, the Administrator shall not have
the power or authority to reduce, whether through amendment or otherwise, the Exercise Price of any outstanding Option or Base Price
or any outstanding SAR or to grant any new Award, or make any cash payment, in substitution for or upon the cancellation of Options or
SARs previously granted and as to which the Exercise Price or Base Price thereof is in excess of the then-current Fair Market Value of
Share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.6&#160;<span style="text-decoration:underline">Maximum
Number of Incentive Stock Options</span>. Notwithstanding the Share Limit, and subject to adjustment in accordance with Section 3.3 hereof,
the maximum number of Shares that may be granted in connection with, and issued pursuant to the exercise of, Incentive Stock Options
granted under this Plan is 100,000,000 shares (the &#8220;<b><span style="text-decoration:underline">ISO Limit</span></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article IV<br/>
<span style="text-decoration:underline">OPTIONS AND SARS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.1&#160;<span style="text-decoration:underline">Grant
of Options and SARs</span>. The Administrator is authorized to make Awards of Options and/or SARs to any Service Provider in such amounts
and subject to such terms and conditions as determined by the Administrator, consistent with the Plan. SARs may be granted in tandem
with Options or may be granted on a freestanding basis, not related to any Option. Excluding Replacement Awards, the per Share purchase
price of the Shares subject to each Option (the &#8220;<b><span style="text-decoration:underline">Exercise Price</span></b>&#8221;) and the Base Price of each SAR shall be not
less than 100% of the Fair Market Value of a Share on the date such Option or SAR is granted. Each Option and each SAR shall be evidenced
by an Award Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.2&#160;<span style="text-decoration:underline">Exercisability
and Vesting; Exercise</span>. Each Option and SAR shall vest and become exercisable according to the terms and conditions as determined
by the Administrator. Except as otherwise determined by the Administrator, SARs granted in tandem with an Option shall become vested
and exercisable on the same date or dates as the Options with which such SARs are associated vest and become exercisable. SARs that are
granted in tandem with an Option may only be exercised upon the surrender of the right to exercise such Option for an equivalent number
of Shares, and may be exercised only with respect to the Shares for which the related Option is then exercisable. The Administrator shall
specify the manner of and any terms and conditions of exercise of an exercisable Option or SAR, including but not limited to net-settlement,
delivery of previously owned stock and broker-assisted sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.3&#160;<span style="text-decoration:underline">Settlement
of SARs</span>. Upon exercise of a SAR, the Participant shall be entitled to receive payment in Shares, or such other form as determined
by the Administrator, having an aggregate value equal to the Fair Market Value of one Share on the exercise date over (ii) the Base Price
of such SAR;&#160;<span style="text-decoration:underline">provided</span>,&#160;<span style="text-decoration:underline">however</span>, that on the grant date, the Administrator may establish a maximum amount per
Share that may be payable upon exercise of a SAR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.4&#160;<span style="text-decoration:underline">Expiration
of Options and SARs</span>. No Option or SAR may be exercised after the expiration of ten (10) years from the date the Option or SAR was
granted, unless a longer or shorter period is set forth in the Award Agreement. Notwithstanding the foregoing, in the event that on the
last business day of the term of the Option or SAR (x) the exercise of the Option or SAR is prohibited by applicable law or (y) Shares
may not be purchased or sold by certain employees or directors of the Company due to the &#8220;black-out period&#8221; of a Company
policy or a &#8220;lock-up&#8221; agreement undertaken in connection with an issuance of securities by the Company, the term of the Option
or SAR shall be extended but not beyond a period of thirty (30) days following the end of the legal prohibition, black-out period or
lock-up agreement (to the extent permissible under Section 409A of the Code) and provided further that no extension will be made if the
applicable Exercise Price or Base Price at the date the initial term would otherwise expire is below the Fair Market Value on such date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article V<span style="text-decoration:underline"><br/>
Restricted Stock Awards AND RESTRICTED STOCK UNIT AWARDS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.1&#160;<span style="text-decoration:underline">Restricted
Stock</span>. The Administrator is authorized to make Awards of Restricted Stock to any Service Provider selected by the Administrator in
such amounts and subject to such terms and conditions as determined by the Administrator. All Awards of Restricted Stock shall be evidenced
by an Award Agreement. Restricted Stock shall be subject to such restrictions on transferability and other restrictions as the Administrator
may impose. These restrictions may lapse separately or in combination at such times, pursuant to such circumstances, in such installments,
or otherwise, as the Administrator determines at the time of the grant of the Award or thereafter. The issuance of Restricted Stock granted
pursuant to the Plan may be evidenced in such manner as the Administrator shall determine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.2&#160;<span style="text-decoration:underline">Restricted
Stock Units</span>. The Administrator is authorized to make Awards of Restricted Stock Units to any Service Provider selected by the Administrator
in such amounts and subject to such terms and conditions as determined by the Administrator. The Administrator may specify any conditions
to vesting as it deems appropriate. For the avoidance of doubt, the Administrator may grant Restricted Stock Units that are fully vested
and nonforfeitable when granted. At the time of grant, the Administrator shall specify the settlement date applicable to each grant of
Restricted Stock Units. Unless otherwise provided in an Award Agreement, on the settlement date, the Company shall, subject to the terms
of this Plan, transfer to the Participant one Share (or a cash amount equal to the then Fair Market Value of a Share) for each Restricted
Stock Unit scheduled to be paid out on such date and not previously forfeited. A Participant shall not be, nor have any of the rights
or privileges of, a stockholder in respect of Restricted Stock Units awarded pursuant to the Plan unless and until the Shares attributable
to such Restricted Stock Units have been issued to such Participant. Notwithstanding the foregoing, unless otherwise determined by the
Administrator, the Restricted Stock Units awarded pursuant to the Plan will receive Dividend Equivalents in accordance with Article VIII.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article VI<br/>
<span style="text-decoration:underline">Performance AWARDS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 6.1&#160;<span style="text-decoration:underline">Grant
of Performance Awards</span>. The Administrator is authorized to make Performance Awards to any Participant selected by the Administrator
in such amounts and subject to such terms and conditions as determined by the Administrator. All Performance Shares and Performance Units
shall be evidenced by an Award Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 6.2&#160;<span style="text-decoration:underline">Issuance
and Restrictions</span>. The Administrator shall have the authority to determine the Participants who shall receive Performance Awards;
the number of Performance Shares, the number and value of Performance Units; the cash entitlement of any Participant with respect to
any Performance Cycle; and the Performance Goals applicable in respect of such Performance Awards for each Performance Cycle. The Administrator
shall determine the duration of each Performance Cycle (the duration of Performance Cycles may differ from one another), and there may
be more than one Performance Cycle in existence at any one time. An Award Agreement evidencing the grant of Performance Shares or Performance
Units shall specify the number of Performance Shares and the number and value of Performance Units awarded to the Participant, the Performance
Goals applicable thereto, and such other terms and conditions as the Administrator shall determine. Unless the Administrator shall determine
otherwise, no Company Common Stock will be issued at the time an Award of Performance Shares is made. The Company shall not be required
to set aside a fund for the payment of Performance Awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 6.3&#160;<span style="text-decoration:underline">Earned
Performance Awards</span>. Performance Awards shall become earned, in whole or in part, based upon the attainment of specified Performance
Goals or the occurrence of any event or events, as the Administrator shall determine or as set forth in an Award Agreement. In addition
to the achievement of the specified Performance Goals, the Administrator may condition payment of Performance Awards on such other conditions
as the Administrator shall determine. The Administrator may also provide in an Award Agreement for the completion of a minimum period
of service (in addition to the achievement of any applicable Performance Goals) as a condition to the vesting of any Performance Award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 6.4&#160;<span style="text-decoration:underline">Rights
as a Stockholder</span>. A Participant shall not have any rights as a stockholder in respect of Performance Awards (including, without limitation,
the right to vote on any matter submitted to the Company&#8217;s stockholders) until such time as the Shares attributable to such Performance
Awards have been issued to such Participant or his or her beneficiary. Performance Shares as to which Shares are issued prior to the
end of the Performance Cycle shall, during such period, be subject to such restrictions on transferability and other restrictions as
the Administrator may impose. Notwithstanding the foregoing, unless otherwise determined by the Administrator, the Performance Awards
awarded pursuant to the Plan will receive Dividend Equivalents settled in Shares in accordance with Article VIII.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 6.5&#160;<span style="text-decoration:underline">Performance
Goals and Related Provisions</span>. The Administrator shall establish the Performance Goals that must be satisfied in order for a Participant
to receive an Award for a Performance Cycle or for a Performance Award to be earned or vested. The Administrator may provide for a threshold
level of performance below which no amount of compensation will be paid and a maximum level of performance above which no additional
amount of compensation will be paid under the Plan, and it may provide for the payment of differing amounts of compensation for different
levels of performance. Performance Goals may be established on a Company-wide basis, with respect to one or more business units, divisions,
Subsidiaries or products or based on individual performance measures, and may be expressed in absolute terms or relative to other metrics
including internal targets or budgets, past performance of the Company, the performance of one or more similarly situated companies,
performance of an index, outstanding equity or other external measures. In the case of earning-based measures, performance goals may
include comparisons relating to capital (including but limited to, the cost of capital), stockholders&#8217; equity, shares outstanding,
assets or net assets, or any combination thereof. Performance Goals may also be subject to such other terms and conditions as the Administrator
may determine appropriate. The Administrator may also adjust the Performance Goals for any Performance Cycle as it deems equitable in
recognition of unusual or non-recurring events affecting the Company; changes in applicable tax laws or accounting principles; other
extraordinary events such as restructurings; discontinued operations; asset write-downs; significant litigation or claims, judgments
or settlements; acquisitions or divestitures; reorganizations or changes in the corporate structure or capital structure of the Company;
foreign exchange gains and losses; change in the fiscal year of the Company; business interruption events; unbudgeted capital expenditures;
unrealized investment gains and losses; impairments and/or such other factors as the Administrator may determine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 6.6&#160;<span style="text-decoration:underline">Determination
of Attainment of Performance Goals</span>. As soon as practicable following the end of a Performance Cycle and prior to any payment or vesting
in respect of such Performance Cycle, the Administrator shall determine the number of Performance Shares or other Performance Awards
and the number and value of Performance Units or the amount of any cash entitlement, in each case that has been earned or vested.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 6.7&#160;<span style="text-decoration:underline">Payment
of Awards</span>. Payment or delivery of Company Common Stock with respect to earned Performance Shares, earned Performance Units and earned
cash entitlements shall be made to the Participant or, if the Participant has died, to the Participant&#8217;s Eligible Representative,
as soon as practicable after the expiration of the Performance Cycle and the Administrator&#8217;s determination under Section 6.6 above
and (unless an applicable Award Agreement shall set forth one or more other dates) in any event no later than the earlier of (i) ninety
(90) days after the end of the fiscal year in which the Performance Cycle has ended and (ii) ninety (90) days after the expiration of
the Performance Cycle. The Administrator shall determine and set forth in the applicable Award Agreement whether earned Performance Shares
and the value of earned Performance Units are to be distributed in the form of cash, Shares or in a combination thereof, with the value
or number of Shares payable to be determined based on the Fair Market Value of the Company Common Stock on the date of the Administrator&#8217;s
determination under Section 6.6 above or such other date specified in the Award Agreement. The Administrator may, in an Award Agreement
with respect to the Award or delivery of Shares, condition the vesting of such Shares on the performance of additional service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 6.8&#160;<span style="text-decoration:underline">Newly
Eligible Participants</span>. Notwithstanding anything in this Article VI to the contrary, the Administrator shall be entitled to make such
rules, determinations and adjustments as it deems appropriate with respect to any Participant who becomes eligible to receive Performance
Shares, Performance Units or other Performance Awards after the commencement of a Performance Cycle.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article VII<br/>
<span style="text-decoration:underline">OTHER Stock-Based Awards</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.1&#160;<span style="text-decoration:underline">Grant
of Stock-Based Awards</span>. The Administrator is authorized to make Awards of other types of equity-based or equity-related awards and
fully vested stock awards, including grants of fully vested Shares (collectively, &#8220;<b><span style="text-decoration:underline">Stock-Based Awards</span></b>&#8221;) not
otherwise described by the terms of the Plan in such amounts and subject to such terms and conditions as the Administrator shall determine,
including without limitation the payment of cash bonuses or other incentives in the form of Stock-Based Awards. Unless otherwise determined
by the Administrator, all Stock-Based Awards shall be evidenced by an Award Agreement. Such Stock-Based Awards may be granted as an inducement
to enter the employ of the Company, any Affiliate or any Subsidiary or in satisfaction of any obligation of the Company, any Affiliate
or any Subsidiary to an officer or other key employee, whether pursuant to this Plan or otherwise, that would otherwise have been payable
in cash or in respect of any other obligation of the Company. Such Stock-Based Awards may entail the transfer of actual Shares, or payment
in cash or otherwise of amounts based on the value of Shares and may include, without limitation, Awards designed to comply with or take
advantage of the applicable local laws of jurisdictions other than the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article VIII<br/>
<span style="text-decoration:underline">Dividend Equivalents</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 8.1&#160;<span style="text-decoration:underline">Generally</span>.
Dividend Equivalents may be granted to Participants at such time or times as shall be determined by the Administrator. Dividend Equivalents
may be granted in tandem with other Awards, in addition to other Awards, or freestanding and unrelated to other Awards. Notwithstanding
the terms of this Section 8.1, no Dividend Equivalents shall be granted with respect to Options or SARs. The grant date of any Dividend
Equivalents will be the date on which the Dividend Equivalent is awarded by the Administrator, or such other date permitted by applicable
laws as the Administrator shall determine. Dividend Equivalents may, at the discretion of the Administrator, be fully vested and nonforfeitable
when granted or subject to such vesting conditions as determined by the Administrator;&#160;<span style="text-decoration:underline">provided</span>, that, unless the Administrator
shall determine otherwise in an Award Agreement, Dividend Equivalents with respect to Awards shall not be fully vested until the Awards
have been earned and shall be forfeited if the related Award is forfeited. Dividend Equivalents shall be evidenced in writing, whether
as part of the Award Agreement governing the terms of the Award, if any, to which such Dividend Equivalent relates, or pursuant to a
separate Award Agreement with respect to freestanding Dividend Equivalents, in each case, containing such provisions not inconsistent
with the Plan as the Administrator shall determine, including customary representations, warranties and covenants with respect to securities
law matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article IX<br/>
<span style="text-decoration:underline">Termination and Forfeiture</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 9.1&#160;<span style="text-decoration:underline">Termination
for Cause; Post-Service Competitive Activity</span>. Unless otherwise set forth in the Award Agreement, if a Participant&#8217;s employment
or service terminates for Cause or a Participant engages in Competitive Activity following the Participant&#8217;s termination of employment
or service, all Options and SARs, whether vested or unvested, and all other Awards that are unvested or unexercisable or otherwise unpaid
(or were unvested or unexercisable or unpaid at the time of occurrence of Cause or engagement in Competitive Activity) shall be immediately
forfeited and canceled, effective as of the date of the termination or engagement in Competitive Activity. If the Participant engages
in Competitive Activity following the termination, any portion of the Participant&#8217;s Awards that became vested after termination,
and any Shares or cash issued upon exercise or settlement of such Awards, shall be immediately forfeited, canceled, and disgorged or
paid to the Company together with all gains earned or accrued due to the sale of Shares issued upon exercise or settlement of such Awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 9.2&#160;<span style="text-decoration:underline">Termination
due to Death</span>. Unless otherwise set forth in the Award Agreement, if a Participant&#8217;s employment or service terminates by reason
of death:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(a)&#160;All Options
and SARs (whether or not then otherwise exercisable) shall become exercisable in full and the Participant&#8217;s Eligible Representative
may exercise all such Options and SARs at any time prior to the earlier of (i) the one-year anniversary of the Participant&#8217;s death
or (ii) the expiration of the term of the Options or SARs;&#160;<span style="text-decoration:underline">provided</span>&#160;that any in-the-money Options and SARs that are
still outstanding on the last day of the time period specified in this Section 9.2(a) shall automatically be exercised on such date;
and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(b)&#160;All other
Awards shall immediately vest in full upon the Participant&#8217;s death, and Restricted Stock Units and Performance Awards that have
not been settled or converted into Shares prior to the Participant&#8217;s death shall immediately be settled in Shares. Any Performance
Awards that vest as a result of this Section 9.2(b) shall vest and be paid based on target levels of performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 9.3&#160;<span style="text-decoration:underline">Termination
due to Disability</span>. Unless otherwise set forth in the Award Agreement, if a Participant&#8217;s employment or service terminates by
reason of Disability, the Participant shall be treated for purposes of the treatment of the Participant&#8217;s Awards under this Section
9.3 as though the Participant continued in the employ or service of the Company and all unvested Awards shall remain outstanding and
vest, or in the case of Options and SARs, vest and become exercisable, in accordance with the terms set forth in the applicable Award
Agreement. Any Options or SARs granted to such Participant that are exercisable at the date of termination by reason of Disability or
that thereafter become exercisable by reason of the operation of the immediately preceding sentence may be exercised at any time prior
to the earlier of (i) the fifth anniversary of the Participant&#8217;s termination for Disability or (ii) the expiration of the term
of such Options or SARs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 9.4&#160;<span style="text-decoration:underline">Involuntary
Termination Without Cause</span>. Unless otherwise set forth in the Award Agreement, if a Participant&#8217;s employment or service is involuntarily
terminated without Cause:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(a)&#160;All
Options and SARs that are unvested shall be immediately forfeited and canceled, effective as of the date of the termination, and all
Options and SARs that are vested shall remain outstanding and exercisable until the earlier of (i) 30 days after the effective date of
the termination under this Section 9.4 or (ii) the expiration of the term of such Options or SARs; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(b)&#160;All
Awards of Restricted Stock or Restricted Stock Units that are unvested shall be immediately forfeited and canceled, effective as of the
date of the termination; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(c)&#160;Provided
that the Participant signs a general release and waiver of claims in the form provided by the Administrator and does not exercise any
rights to revoke such release, the Participant shall retain a portion of any unvested Performance Awards granted earlier than one year
prior to the termination under this Section 9.4 equal to, for each grant of Performance Awards, the number of Performance Shares or Performance
Units specified in the Award Agreement multiplied by the quotient of (i) the number of full months elapsed between the grant date in
respect of such Performance Awards and the effective date of the termination under this Section 9.4 over (ii) the total number of months
in the Performance Cycle. Such retained Performance Awards will remain outstanding and vest subject to the attainment of the applicable
Performance Goals in respect thereof. Any Performance Awards that do not vest pursuant to this Section 9.4(c) shall be immediately forfeited
and canceled, effective as of the date of the termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 9.5&#160;<span style="text-decoration:underline">Termination
for Any Other Reason</span>. Unless otherwise set forth in the Award Agreement, if a Participant&#8217;s employment or service terminates
for any reason other as set forth in Sections 9.1 (other than post-service Competitive Activity) through 9.4:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(a)&#160;All Options
and SARs that are unvested shall be immediately forfeited and canceled, effective as of the date of the termination, and all Options
and SARs that are vested shall remain outstanding and exercisable until the earlier of (i) 30 days after the effective date of the termination
under this Section 9.5 or (ii) the expiration of the term of such Options or SARs; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(b)&#160;All other
Awards that are unvested or have not otherwise been earned shall be immediately forfeited and canceled, effective as of the date of termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 9.6&#160;<span style="text-decoration:underline">Post-Termination
Informational Requirements</span>. Before the settlement of any Award following termination of employment or service, the Administrator
may require the Participant (or the Participant&#8217;s Eligible Representative, if applicable) to make such representations and provide
such documents as the Administrator deems necessary or advisable to effect compliance with applicable law and the provisions of this
Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 9.7&#160;<span style="text-decoration:underline">Forfeiture
and Recoupment of Awards</span>. Awards granted under this Plan (and gains earned or accrued in connection with Awards) shall be subject
to such generally applicable policies as to forfeiture and recoupment (including, without limitation, upon the occurrence of material
financial or accounting errors, financial or other misconduct or Competitive Activity) as may be adopted by the Administrator or the
Board from time to time. Any such policies may (in the discretion of the Administrator or the Board) be applied to outstanding Awards
at the time of adoption of such policies, or on a prospective basis only. Participants shall also forfeit and disgorge to the Company
any Awards granted or vested and any gains earned or accrued due to the exercise of Options or SARs or the sale of any Company Common
Stock to the extent required by applicable law or as required by any stock exchange or quotation system on which the Company Common Stock
is listed or quoted, in each case in effect on or after the Effective Date, including but not limited to Section 304 of the Sarbanes-Oxley
Act of 2002 and Section 10D of the Exchange Act. The implementation of policies and procedures pursuant to this Section 9.7 and any modification
of the same shall not be subject to any restrictions on amendment or modification of Awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 9.8&#160;<span style="text-decoration:underline">Clawbacks</span>.
Awards shall be subject to any generally applicable clawback policy adopted by the Administrator, the Board or the Company that is communicated
to the Participants or any such policy adopted to comply with applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article X<br/>
<span style="text-decoration:underline">CHANGE IN CONTROL</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 10.1&#160;<span style="text-decoration:underline">Alternative
Award</span>. Unless otherwise provided in an Award Agreement, and other than with respect to the Performance Award Conversion, no cancellation,
acceleration or other payment shall occur in connection with a Change in Control pursuant to Section 10.3 with respect to any Award or
portion thereof as a result of the Change in Control if the Administrator reasonably determines in good faith, prior to the occurrence
of the Change in Control, that such Award shall be honored or assumed, or new rights substituted therefor following the Change in Control
(such honored, assumed or substituted award, an &#8220;<b><span style="text-decoration:underline">Alternative Award</span></b>&#8221;),&#160;<span style="text-decoration:underline">provided</span>&#160;that any Alternative
Award must (i) give the Participant who held the Award rights and entitlements substantially equivalent to or better than the rights
and terms applicable under the Award immediately prior to the Change in Control, including an equal or better vesting schedule and that
Alternative Awards that are stock options have identical or better methods of payment of the exercise price thereof and a post-termination
exercise period extending until at least the fifth anniversary of the Participant&#8217;s termination (or, if earlier, the expiration
of the term of such stock options); (ii) have terms such that if a Participant&#8217;s employment is involuntarily (<i>i.e.</i>, by the
Company or its successor other than for Cause) or constructively (<i>i.e.</i>, by the Participant with Good Reason) terminated within
the twenty-four (24) months following a Change in Control at a time when any portion of the Alternative Award is unvested, the unvested
portion of such Alternative Award shall immediately vest in full and such Participant shall receive (as determined by the Board prior
to the Change in Control) either (1) a cash payment equal in value to the excess (if any) of the fair market value of the stock subject
to the Alternative Award at the date of exercise or settlement over the price (if any) that such Participant would be required to pay
to exercise such Alternative Award or (2) publicly-traded shares or equity interests equal in value (as determined by the Administrator)
to the value in clause (1).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 10.2&#160;<span style="text-decoration:underline">Performance
Award Conversion</span>. Unless otherwise provided in an Award Agreement, upon a Change in Control, then-outstanding Performance Awards
shall be modified to remove any Performance Goals applicable thereto and to substitute, in lieu of such Performance Goals, vesting solely
based on the requirement of continued service through, as nearly as is practicable, the date(s) on which the satisfaction of the Performance
Goals would have been measured if the Change in Control had not occurred (or, if applicable, the later period of required service following
such measurement date) (such Awards, the &#8220;<b><span style="text-decoration:underline">Alternative Performance Awards</span></b>&#8221;), with such service-vesting of the
Alternative Performance Awards to accelerate upon the termination of service of the holder prior to such vesting date(s) thereof, if
such termination of service satisfies the requirements of clause (ii) of Section 10.1 hereof. The number of Alternative Performance Awards
shall be equal to (i) if less than 50% of the Performance Cycle has elapsed, the target number of Performance Awards, and (ii) if 50%
or more of the Performance Cycle has elapsed, a number of Performance Awards based on actual performance through the date of the Change
in Control if determinable, or the target, if not determinable (with the Administrator as constituted prior to the Change in Control
making any determinations necessary to determine performance and the vesting date(s) thereof). The conversion of the Performance Awards
into Alternative Performance Awards is referred to herein as the &#8220;<b><span style="text-decoration:underline">Performance Award Conversion</span></b>&#8221;. Following
the Performance Award Conversion, the Alternative Performance Awards shall either remain outstanding as Alternative Awards consistent
with this Section 10.2 or shall be treated as provided in Section 10.3.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 10.3&#160;<span style="text-decoration:underline">Accelerated
Vesting and Payment</span>. Except as otherwise provided in this Article X or in an Award Agreement, upon a Change in Control:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(a)&#160;each
vested and unvested Option or SAR shall be canceled in exchange for a payment equal to the excess, if any, of the Change in Control Price
over the applicable Exercise Price or Base Price;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(b)&#160;the vesting
restrictions applicable to all other unvested Awards (other than (x) freestanding Dividend Equivalents not granted in connection with
another Award and (y) Performance Awards) shall lapse, all such Awards shall vest and become non-forfeitable and be canceled in exchange
for a payment equal to the Change in Control Price;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(c)&#160;the Alternative
Performance Awards shall be canceled in exchange for a payment equal to the Change in Control Price;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(d)&#160;all other
Awards (other than freestanding Dividend Equivalents not granted in connection with another Award) that were vested prior to the Change
in Control but that have not been settled or converted into Shares prior to the Change in Control shall be canceled in exchange for a
payment equal to the Change in Control Price; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(e)&#160;all freestanding
Dividend Equivalents not granted in connection with another Award shall be cancelled without payment therefor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent any portion of the Change in Control
Price is payable other than in cash and/or other than at the time of the Change in Control, Award holders under the Plan shall receive
the same value in respect of their Awards (less any applicable Exercise Price, Base Price or similar feature) as is received by the Company&#8217;s
stockholders in respect of their Company Common Stock (as determined by the Administrator), and the Administrator shall determine the
extent to which such value shall be paid in cash, in securities or other property, or in a combination of cash and securities or other
property, consistent with applicable law. To the extent any portion of the Change in Control Price is payable other than at the time
of the Change in Control, the Administrator shall determine the time and form of payment to the Award holders consistent with Section
409A of the Code and other applicable laws. Upon a Change in Control the Administrator may cancel Options and SARs for no consideration
if the Fair Market Value of the Shares subject to such Options or such SARs is less than or equal to the Exercise Price of such Options
or the Base Price of such SARs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article XI<br/>
<span style="text-decoration:underline">OTHER PROVISIONS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 11.1&#160;<span style="text-decoration:underline">Awards
Not Transferable</span>. Except as otherwise determined by the Administrator, no Award or interest or right therein or part thereof shall
be liable for the debts, contracts or engagements of the Participant or his or her successors in interest or shall be subject to disposition
by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary
or by operation of law, by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy),
and any attempted disposition thereof shall be null and void and of no effect;&#160;<span style="text-decoration:underline">provided, however</span>, that nothing in this Section
11.1 shall prevent transfers by will, by the applicable laws of descent and distribution or pursuant to the beneficiary designation procedures
approved by the Company pursuant to Section 11.13 or, with the prior approval of the Company, estate planning transfers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 11.2&#160;<span style="text-decoration:underline">Amendment,
Suspension or Termination of the Plan or Award Agreements</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(a)&#160;The Plan
may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Administrator;&#160;<span style="text-decoration:underline">provided</span>,
that without the approval of the stockholders of the Company, no amendment or modification to the Plan may (i) except as otherwise expressly
provided in Section 3.3, increase the number of Shares subject to the Plan; (ii) modify the class of persons eligible for participation
in the Plan or (iii) materially modify the Plan in any other way that would require stockholder approval under applicable law. Except
as otherwise expressly provided in the Plan, neither the amendment, suspension or termination of the Plan shall, without the written
consent of the holder of the Award, materially adversely alter or impair any rights or obligations under any Award theretofore granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(b)&#160;The Administrator
at any time, and from time to time, may amend the terms of any one or more existing Award Agreements,&#160;<span style="text-decoration:underline">provided</span>,&#160;<span style="text-decoration:underline">however</span>,
that the rights of a Participant under an Award Agreement shall not be materially adversely impaired without the Participant&#8217;s
written consent. The Company shall provide a Participant with notice of any amendment made to a Participant&#8217;s existing Award Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(c)&#160;No Award
may be granted during any period of suspension nor after termination of the Plan, and in no event may any Award be granted under this
Plan after the expiration of ten (10) years from the Effective Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 11.3&#160;<span style="text-decoration:underline">Effect
of Plan upon Other Award and Compensation Plans</span>. The adoption of this Plan shall not affect any other compensation or incentive plans
in effect for the Company or any of its Affiliates. Nothing in this Plan shall be construed to limit the right of the Company or any
of its Affiliates (a) to establish any other forms of incentives or compensation for Service Providers or (b) to grant or assume options
or restricted stock other than under this Plan in connection with any proper corporate purpose, including, but not by way of limitation,
the grant or assumption of options or restricted stock in connection with the acquisition by purchase, lease, merger, consolidation or
otherwise, of the business, stock or assets of any corporation, firm or association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 11.4&#160;<span style="text-decoration:underline">At-Will
Employment</span>. Nothing in the Plan or any Award Agreement hereunder shall confer upon the Participant any right to continue as a Service
Provider of the Company or any of its Affiliates or shall interfere with or restrict in any way the rights of the Company or any of its
Affiliates, which are hereby expressly reserved, to discharge any Participant at any time for any reason whatsoever, with or without
Cause.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 11.5&#160;<span style="text-decoration:underline">Conformity
to Securities Laws</span>. The Plan is intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange
Act and any and all regulations and rules promulgated under any of the foregoing, to the extent the Company, any of its Affiliates or
any Participant is subject to the provisions thereof. Notwithstanding anything herein to the contrary, the Plan shall be administered,
and Awards shall be granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations. To the extent
permitted by applicable law, the Plan and Awards granted hereunder shall be deemed amended to the extent necessary to conform to such
laws, rules and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 11.6&#160;<span style="text-decoration:underline">Term
of Plan</span>. The Plan was approved by the Board of Directors of the Company on April 26, 2022 (the &#8220;<b><span style="text-decoration:underline">Adoption Date</span></b>&#8221;),
subject to stockholder approval. The Plan shall be effective on the date of its approval by the stockholders of the Company at the 2022
annual meeting of stockholders (the &#8220;<b><span style="text-decoration:underline">Effective Date</span></b>&#8221;) in accordance with applicable law. No awards shall be
issued or granted under this Plan until or unless this Plan is approved by stockholders. The Plan shall continue in effect, unless sooner
terminated pursuant to Section 11.2, until the tenth (10<sup>th</sup>) anniversary of the Adoption Date. The provisions of the Plan shall
continue thereafter to govern all outstanding Awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;Section 11.7&#160;<span style="text-decoration:underline">Governing
Law</span>. To the extent not preempted by federal law, the Plan shall be construed in accordance with and governed by the laws of the State
of Delaware regardless of the application of rules of conflict of law that would apply the laws of any other jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 11.8&#160;<span style="text-decoration:underline">Severability</span>.
In the event any portion of the Plan or any action taken pursuant thereto shall be held illegal or invalid for any reason, the illegality
or invalidity shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as if the illegal or invalid
provisions had not been included, and the illegal or invalid action shall be null and void.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 11.9&#160;<span style="text-decoration:underline">Governing
Documents</span>. In the event of any express contradiction between the Plan and any Award Agreement or any other written agreement between
a Participant and the Company or any Affiliate that has been approved by the Administrator, the express terms of the Plan shall govern,
unless it is expressly specified in such Award Agreement or other written document that such express provision of the Plan shall not
apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 11.10&#160;<span style="text-decoration:underline">Withholding
Taxes</span>. In addition to any rights or obligations with respect to the federal, state, local or foreign income taxes, withholding taxes
or employment taxes required to be withheld under applicable law, the Company or any Affiliate employing a Service Provider shall have
the right to withhold from the Service Provider, or otherwise require the Service Provider or an assignee to pay, any such required withholding
obligations arising as a result of grant, exercise, vesting or settlement of any Award or any other taxable event occurring pursuant
to the Plan or any Award Agreement, including, without limitation, to the extent permitted by law, the right to deduct any such withholding
obligations from any payment of any kind otherwise due to the Service Provider or to take such other actions (including, without limitation,
withholding any Shares or cash deliverable pursuant to the Plan or any Award) as may be necessary to satisfy such withholding obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 11.11&#160;<span style="text-decoration:underline">Section
409A</span>. To the extent applicable, the Plan and Award Agreements shall be interpreted in accordance with Section 409A of the Code and
Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations
or other guidance that may be issued after the adoption of the Plan. Notwithstanding any provision of the Plan to the contrary, in the
event that following the adoption of the Plan, the Administrator determines that any Award may be subject to Section 409A of the Code
and related regulations and Department of Treasury guidance (including such Department of Treasury guidance as may be issued after the
adoption of the Plan), the Administrator may adopt such amendments to the Plan and the applicable Award Agreement or adopt other policies
and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Administrator
determines are necessary or appropriate to (a) exempt the Award from Section 409A of the Code and/or preserve the intended tax treatment
of the benefits provided with respect to the Award, (b) comply with the requirements of Section 409A of the Code and related Department
of Treasury guidance or (c) comply with any correction procedures available with respect to Section 409A of the Code. Notwithstanding
anything else contained in this Plan or any Award Agreement to the contrary, if a Service Provider is a &#8220;specified employee&#8221;
at the time of the Service Provider&#8217;s &#8220;separation from service&#8221; (as determined under Section 409A of the Code) then,
to the extent necessary to comply with, and avoid imposition on such Service Provider of any tax penalty imposed under, Section 409A
of the Code, any payment required to be made to a Service Provider hereunder upon or following his or her separation from service shall
be delayed until the first to occur of (i) the six-month anniversary of the Service Provider&#8217;s separation from service and (ii)
the Service Provider&#8217;s death. Should payments be delayed in accordance with the preceding sentence, the accumulated payment that
would have been made but for the period of the delay shall be paid in a single lump sum during the ten (10) day period following the
lapsing of the delay period. No provision of this Plan or an Award Agreement shall be construed to indemnify any Service Provider for
any taxes incurred by reason of Section 409A (or timing of incurrence thereof), other than an express indemnification provision therefor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 11.12&#160;<span style="text-decoration:underline">Notices</span>.
Except as provided otherwise in an Award Agreement, all notices and other communications required or permitted to be given under this
Plan or any Award Agreement shall be in writing and shall be deemed to have been given if delivered personally, sent by email or any
other form of electronic transfer approved by the Administrator, sent by certified or express mail, return receipt requested, postage
prepaid, or by any recognized international equivalent of such delivery, (i) in the case of notices and communications to the Company,
to its current business address and to the attention of the Corporate Secretary of the Company or (ii) in the case of a Participant,
to the last known address, or email address or, where the individual is an employee of the Company or one of its Subsidiaries, to the
individual&#8217;s workplace address or email address or by other means of electronic transfer acceptable to the Administrator. All such
notices and communications shall be deemed to have been received on the date of delivery, if sent by email or any other form of electronic
transfer, at the time of dispatch or on the third business day after the mailing thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 11.13&#160;<span style="text-decoration:underline">Beneficiary
Designation</span>. Each Participant under the Plan may from time to time pursuant to procedures approved by the Company name any beneficiary
or beneficiaries by whom any right under the Plan is to be exercised in case of such Participant&#8217;s death.</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><div><a id="a_163"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Appendix C</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>180 LIFE SCIENCES CORP.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025 OPTION INCENTIVE PLAN</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Adopted by the Board of Directors on June
17, 2025,<br/>
subject to Stockholder Approval Prior to June 17, 2026</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article I.<span style="text-transform: uppercase"><br/>
PURPOSES AND BACKGROUND</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&#160;This 180 Life Sciences
Corp. 2025 Option Incentive Plan, as may be amended from time to time (the &#8220;<b><span style="text-decoration:underline">Plan</span></b>&#8221;), is intended to promote
the interests of 180 Life Sciences Corp. (the &#8220;<b><span style="text-decoration:underline">Company</span></b>&#8221;)&#160;and its Subsidiaries (as defined below)&#160;and
its stockholders by (i)&#160;attracting and retaining directors, executive officers, employees and consultants of outstanding ability;
(ii)&#160;motivating such individuals by means of performance-related incentives to achieve the longer-range performance goals of the
Company and its Subsidiaries; and (iii)&#160;enabling such individuals to participate in the long-term growth and financial success of
the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2&#160;The Company&#8217;s
Board of Directors adopted the Plan on June 17, 2025 (the &#8220;<b><span style="text-decoration:underline">Effective Date</span></b>&#8221;). The Plan shall become effective
on the Effective Date. In accordance with Nasdaq Listing Rule&#160;5635(c)&#160;and the guidance thereunder, on or following the Effective
Date but prior to the Shareholder Approval Date (as defined below), the Company may only grant Options, but no shares of Common Stock
or other securities, under the Plan. Additionally, (i)&#160;until the Shareholder Approval Date, no Options can be exercised, and (ii)&#160;if
Shareholder Approval is not received, the Plan shall be unwound, and the outstanding Options cancelled (the &#8220;<b><span style="text-decoration:underline">Nasdaq Pre-Approval
Requirements</span></b>&#8221;). All Options granted prior to the Shareholder Approval Date shall be granted subject to the Nasdaq Pre-Approval
Requirements and all Award Agreements memorializing such Stock Option grants shall include provisions making such Stock Options and grants
subject to such Nasdaq Pre-Approval Requirements for all purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3&#160;The grant of Incentive
Stock Options is subject to approval of this Plan by the Company&#8217;s shareholders within twelve (12)&#160;months of the Effective
Date. Shareholder approval is to be obtained in accordance with the Company&#8217;s Certificate of Incorporation and Bylaws, each as
amended, and Applicable Laws (the &#8220;<b><span style="text-decoration:underline">Shareholder Approval</span></b>&#8221; and the date of such Shareholder Approval, the &#8220;<b><span style="text-decoration:underline">Shareholder
Approval Date</span></b>&#8221;). The Administrator may grant Incentive Stock Options prior to Shareholder Approval, but until the Company
obtains this approval, a grantee shall not exercise them. If the Company does not timely obtain Shareholder Approval (or a grantee desires
to exercise such Incentive Stock Options prior to shareholder approval), a grantee may exercise previously granted Incentive Stock Options
(subject to the Nasdaq Pre-Approval Requirements)&#160;as Nonqualified Stock Options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Article II.<span style="text-transform: uppercase"><br/>
Definitions</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whenever the following terms
are used in this Plan, they shall have the meanings specified below unless the context clearly indicates to the contrary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1&#160;&#8220;<b><span style="text-decoration:underline">Administrator</span></b>&#8221;
means the Board or the Compensation Committee, as determined by the Board from time to time. In exercising its discretion hereunder,
the Board shall endeavor to cause the Administrator to satisfy any requirements applicable to qualify for an exemption available under
Rule 16b-3 promulgated under the Exchange Act or any other regulatory or administrative requirements that may be applicable with respect
to Awards granted hereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2&#160; &#8220;<b><span style="text-decoration:underline">Affiliate</span></b>&#8221;
means, with respect to any Person, any other Person directly or indirectly controlling, controlled by or under common control with, such
Person where &#8220;<b><span style="text-decoration:underline">control</span></b>&#8221; (including the terms &#8220;<b><span style="text-decoration:underline">controlling,</span></b>&#8221; &#8220;<b><span style="text-decoration:underline">controlled
by,</span></b>&#8221; and &#8220;<b><span style="text-decoration:underline">under common control with</span></b>&#8221;)&#160;means the possession, direct or indirect, of the power
to direct or cause the direction of the management and policies of a Person, whether through the ownership of securities, by contract,
or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 130; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3&#160; &#8220;<b><span style="text-decoration:underline">Alternative
Award</span></b>&#8221; has the meaning set forth in&#160;<span style="text-decoration:underline">Section&#160;7.1</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4&#160;&#8220;<b><span style="text-decoration:underline">Applicable
Laws</span></b>&#8221; means all applicable laws, rules, regulations and requirements, including, but not limited to, all applicable U.S.
federal, state or local laws, any stock exchange rules or regulations and the applicable laws, rules or regulations of any other country
or jurisdiction where Awards are granted under the Plan or Participants reside or provide services, as such laws, rules and regulations
shall be in effect from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5&#160; &#8220;<b><span style="text-decoration:underline">Award</span></b>&#8221;
means any granted to a Participant pursuant to the Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.6&#160; &#8220;<b><span style="text-decoration:underline">Award
Agreement</span></b>&#8221; means any written agreement, contract or other instrument or document evidencing an Award, including through
an electronic medium. The Administrator may provide for the use of electronic, internet or other non-paper Award Agreements, and the
use of electronic, internet or other non-paper means for the Participant&#8217;s acceptance of, or actions under, an Award Agreement
unless otherwise expressly specified herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.7&#160; &#8220;<b><span style="text-decoration:underline">Board</span></b>&#8221;
means the Board of Directors of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.8&#160; &#8220;<b><span style="text-decoration:underline">Cause</span></b>&#8221;
means, unless otherwise provided in the Award Agreement, any of the following: (A)&#160;the Participant&#8217;s commission of a crime
involving fraud, theft, false statements or other similar acts or commission of any crime that is a felony (or comparable classification
in a jurisdiction that does not use these terms); (b)&#160;the Participant&#8217;s engaging in any conduct that constitutes an employment
disqualification under applicable law with respect to a material portion of the Participant&#8217;s work duties; (c)&#160;the Participant&#8217;s
willful or grossly negligent failure to perform his or her material employment-related duties for the Company Group, or willful misconduct
in the performance of such duties; (d)&#160;the Participant&#8217;s material violation of any Company or Subsidiary policy as in effect
from time to time; (e)&#160;the Participant&#8217;s engaging in any act or making any public statement that materially impairs, impugns,
denigrates, disparages or negatively reflects upon the name, reputation or business interests of the Company or its Subsidiaries; or
(f)&#160;the Participant&#8217;s material breach of any Award Agreement, employment agreement, or noncompetition, nondisclosure or nonsolicitation
agreement to which the Participant is a party or by which the Participant is bound;&#160;<span style="text-decoration:underline">provided</span>&#160;that in the case of any
Participant who, as of the date of determination, is a party to an effective services, severance, consulting or employment agreement
with the Company or any Subsidiary of the Company that employs such individual, &#8220;<b><span style="text-decoration:underline">Cause</span></b>&#8221; has the meaning, if
any, specified in such agreement. A termination for Cause shall be deemed to include a determination by the Administrator following a
Participant&#8217;s termination of employment that circumstances existing prior to such termination would have entitled the Company or
one of its Subsidiaries to have terminated such Participant&#8217;s employment for Cause. All rights a Participant has or may have under
the Plan shall be suspended automatically during the pendency of any investigation by the Administrator or its designee, or during any
negotiations between the Administrator or its designee and the Participant, regarding any actual or alleged act or omission by the Participant
of the type described in the applicable definition of Cause.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.9&#160; &#8220;<b><span style="text-decoration:underline">Change
in Control</span></b>&#8221; or &#8220;<b><span style="text-decoration:underline">Change of Control</span></b>&#8221; means the first to occur of any of the following events after
the Effective Date:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(a)&#160;any Person
becomes the beneficial owner (within the meaning of Rule 13d-3 promulgated under the Exchange Act)&#160;of 30% or more of either (x)&#160;the
then-outstanding shares of common stock of the Company (the &#8220;<b><span style="text-decoration:underline">Outstanding Company Common Stock</span></b>&#8221;)&#160;or (y)&#160;the
combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors
(the &#8220;<b><span style="text-decoration:underline">Outstanding Company Voting Securities</span></b>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(b)&#160;the individuals
who constitute the Board as of the Effective Date (the &#8220;<b><span style="text-decoration:underline">Incumbent Board</span></b>&#8221;)&#160;cease for any reason to constitute
at least a majority of the Board;&#160;<span style="text-decoration:underline">provided</span>,&#160;<span style="text-decoration:underline">however</span>, that any individual becoming a Director subsequent to the
Effective Date whose election, or nomination for election, by the Company&#8217;s stockholders, was approved by a vote of at least a
majority of the Directors then comprising the Incumbent Board shall be considered as though such individual was a member of the Incumbent
Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened
election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents
by or on behalf of a Person other than the Board; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 33pt"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(c)&#160;the consummation
of a reorganization, merger, statutory share exchange or consolidation or similar transaction involving the Company or any of its Subsidiaries,
a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or stock of another
entity by the Company or any of its Subsidiaries (each, a &#8220;<b><span style="text-decoration:underline">Business Combination</span></b>&#8221;), in each case, unless, following
such Business Combination, (i)&#160;all or substantially all of the individuals and entities that were the beneficial owners of the Outstanding
Company Common Stock and the Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly
or indirectly, more than 50% of the then-outstanding shares of common stock (or, for a non-corporate entity, equivalent securities)&#160;and
the combined voting power of the then-outstanding voting securities entitled to vote generally in the election of Directors (or, for
a non-corporate entity, equivalent governing body), as the case may be, of the entity resulting from such Business Combination (including,
without limitation, an entity that, as a result of such transaction, owns the Company or all or substantially all of the Company&#8217;s
assets either directly or through one or more Subsidiaries)&#160;in substantially the same proportions as their ownership immediately
prior to such Business Combination of the Outstanding Company Common Stock and the Outstanding Company Voting Securities, as the case
may be, (ii)&#160;no Person (excluding any corporation resulting from such Business Combination or any employee benefit plan (or related
trust)&#160;of the Company or such corporation resulting from such Business Combination)&#160;beneficially owns, directly or indirectly,
30% or more of, respectively, the then-outstanding shares of common stock (or, for a non-corporate entity, equivalent securities)&#160;of
the entity resulting from such Business Combination or the combined voting power of the then-outstanding voting securities of such entity
entitled to vote generally in the election of directors (or, for a non-corporate entity, equivalent securities), except to the extent
that such ownership existed prior to the Business Combination, and (iii)&#160;at least a majority of the members of the board of directors
(or, for a non-corporate entity, equivalent governing body)&#160;of the entity resulting from such Business Combination were members
of the Incumbent Board at the time of the execution of the initial agreement or of the action of the Board providing for such Business
Combination;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">in each case,&#160;<span style="text-decoration:underline">provided</span>&#160;that,
as to Awards subject to Section&#160;409A of the Code, the payment or settlement of which will occur by reason of the Change in Control,
such event also constitutes a &#8220;<b><span style="text-decoration:underline">change in control</span></b>&#8221; within the meaning of Section&#160;409A of the Code. In addition,
notwithstanding the foregoing, a &#8220;<b><span style="text-decoration:underline">Change in Control</span></b>&#8221; shall not be deemed to occur if the Company files for
bankruptcy, liquidation or reorganization under the United States Bankruptcy Code or as a result of any restructuring that occurs as
a result of any such proceeding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.10&#160; &#8220;<b><span style="text-decoration:underline">Change
in Control Price</span></b>&#8221; means the price per share of Company Common Stock paid in conjunction with any transaction resulting
in a Change in Control. If any part of the offered price is payable other than in cash, the value of the non-cash portion of the Change
in Control Price shall be determined in good faith by the Administrator as constituted immediately prior to the Change in Control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.11&#160; &#8220;<b><span style="text-decoration:underline">Code</span></b>&#8221;
means the Internal Revenue Code of 1986, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.12&#160; &#8220;<b><span style="text-decoration:underline">Company
Common Stock</span></b>&#8221; means the common stock, par value $0.0001 per share, of the Company and such other stock or securities into
which such common stock is hereafter converted or for which such common stock is exchanged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.13&#160; &#8220;<b><span style="text-decoration:underline">Company
Group</span></b>&#8221; means the Company and its direct or indirect Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.14&#160; &#8220;<b><span style="text-decoration:underline">Compensation
Year</span></b>&#8221; means the period from one annual meeting of stockholders to the next following annual meeting of stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.15&#160; &#8220;<b><span style="text-decoration:underline">Competitive
Activity</span></b>&#8221; means a Participant&#8217;s material breach of restrictive covenants relating to noncompetition, nonsolicitation
(of customers or employees)&#160;or preservation of confidential information or other covenants having the same or similar scope, included
in an Award Agreement or other agreement to which the Participant and the Company or any of its Affiliates is a party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.16&#160; &#8220;<b><span style="text-decoration:underline">Corporate
Event</span></b>&#8221; means, as determined by the Administrator, any transaction or event described in&#160;<span style="text-decoration:underline">Section&#160;4.4(a)</span>&#160;or
any unusual or infrequently occurring transaction or event affecting the Company, any Subsidiary of the Company, or the financial statements
of the Company or any of its Subsidiaries, or changes in applicable laws, regulations or accounting principles (including, without limitation,
a recapitalization of the Company).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.17&#160; &#8220;<b><span style="text-decoration:underline">Director</span></b>&#8221;
means a member of the Board or a member of the board of directors of any Subsidiary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.18&#160; &#8220;<b><span style="text-decoration:underline">Disability</span></b>&#8221;
means (x)&#160;for Awards that are not subject to Section&#160;409A of the Code, &#8220;<b><span style="text-decoration:underline">disability</span></b>&#8221; as such term
is defined in the long-term disability insurance plan or program of the Company or any Subsidiary then covering the Participant, and
(y)&#160;for Awards that are subject to Section&#160;409A of the Code, &#8220;<b><span style="text-decoration:underline">disability</span></b>&#8221; has the meaning set forth
in Section&#160;409A(a)(2)(c)&#160;of the Code;&#160;<span style="text-decoration:underline">provided</span>&#160;that with respect to Awards that are not subject to Section&#160;409A,
in the case of any Participant who, as of the date of determination, is a party to an effective services, severance, consulting or employment
agreement with the Company or any Subsidiary of the Company that employs such individual, &#8220;<b><span style="text-decoration:underline">Disability</span></b>&#8221; has
the meaning, if any, specified in such agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.19&#160; &#8220;<b><span style="text-decoration:underline">Eligible
Representative</span></b>&#8221; for a Participant means such Participant&#8217;s personal representative or such other person as is empowered
under the deceased Participant&#8217;s will or the then applicable laws of descent and distribution to represent the Participant hereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.20&#160;&#8220;<b><span style="text-decoration:underline">Employee</span></b>&#8221;
means any individual classified as an employee by the Company or one of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.21&#160;&#8220;<b><span style="text-decoration:underline">Exchange
Act</span></b>&#8221; means the Securities Exchange Act of 1934, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.22&#160;&#8220;<b><span style="text-decoration:underline">Executive
Officer</span></b>&#8221; means each person who is an officer or employee of the Company or any of its Subsidiaries and who is subject to
the reporting requirements under Section&#160;16(a)&#160;of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.23&#160;&#8220;<b><span style="text-decoration:underline">Fair
Market Value</span></b>&#8221; means, unless otherwise determined by the Administrator from time to time, the closing transaction price
of a Share as reported on the NASDAQ Stock Market LLC on the date as of which such value is being determined or, if Shares are not listed
on the NASDAQ Stock Market LLC, the closing transaction price of a Share on the principal national stock exchange on which Shares are
traded on the date as of which such value is being determined or, if there shall be no reported transactions for such date, on the next
preceding date for which transactions were reported; provided, however, that if Shares are not listed on a national stock exchange or
if Fair Market Value for any date cannot be so determined, Fair Market Value shall be determined by the Administrator by whatever means
or method as the Administrator, in the good faith exercise of its discretion, shall at such time deem appropriate and in compliance with
Section&#160;409A of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.24&#160;&#8220;<b><span style="text-decoration:underline">Good
Reason</span></b>&#8221; means, unless otherwise provided in the Award Agreement, a material reduction in the Participant&#8217;s base salary
or a material reduction in the Participant&#8217;s target annual cash incentive compensation opportunity, in each case, other than (a)&#160;any
isolated or inadvertent failure by the Company or the applicable Subsidiary that is not in bad faith and is cured within thirty (30)&#160;business
days after the Participant gives the Company or the applicable Subsidiary notice of such event or (b)&#160;a reduction of 10% or less
which is applicable to all employees in the same salary grade as the Participant;&#160;<span style="text-decoration:underline">provided</span>&#160;that in the case of any Participant
who, as of the date of determination, is a party to an effective services, severance, consulting or employment agreement with the Company
or any Subsidiary of the Company that employs such individual, &#8220;<b><span style="text-decoration:underline">Good Reason</span></b>&#8221; has the meaning, if any, specified
in such agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.25&#160;&#8220;<b><span style="text-decoration:underline">Incentive
Stock Option</span></b>&#8221; means an Option which qualifies under Section&#160;422 of the Code and is expressly designated as an Incentive
Stock Option in the Award Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.26&#160;&#8220;<b><span style="text-decoration:underline">Non-Qualified
Stock Option</span></b>&#8221; means an Option that is not an Incentive Stock Option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.27&#160;&#8220;<b><span style="text-decoration:underline">Option</span></b>&#8221;
means an option to purchase Company Common Stock granted under the Plan. The term &#8220;<b><span style="text-decoration:underline">Option</span></b>&#8221; includes both an
Incentive Stock Option and a Non-Qualified Stock Option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.28&#160;&#8220;<b><span style="text-decoration:underline">Participant</span></b>&#8221;
means any Service Provider who has been granted an Award pursuant to the Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.29&#160;&#8220;<b><span style="text-decoration:underline">Person</span></b>&#8221;
means an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated
association, joint venture, governmental authority or any other entity of whatever nature.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.30&#160;&#8220;<b><span style="text-decoration:underline">Replacement
Awards</span></b>&#8221; means Shares or Awards issued in assumption of, or in substitution for, any outstanding awards of any entity acquired
in any form or combination by the Company or any of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.31&#160;&#8220;<b><span style="text-decoration:underline">Securities
Act</span></b>&#8221; means the Securities Act of 1933, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.32&#160;&#8220;<b><span style="text-decoration:underline">Service
Provider</span></b>&#8221; means an Employee, Director or consultant of the Company or any of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.33&#160;&#8220;<b><span style="text-decoration:underline">Share</span></b>&#8221;
means a share of Company Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.34&#160;&#8220;<b><span style="text-decoration:underline">Subsidiary</span></b>&#8221;
means any entity that is directly or indirectly controlled by the Company or any entity in which the Company directly or indirectly has
at least a 50% equity interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.35&#160;&#8220;<b><span style="text-decoration:underline">Termination
of employment,</span></b>&#8221; &#8220;<b><span style="text-decoration:underline">termination of service</span></b>&#8221; and any similar term or terms means, with respect to
a Director who is not an Employee of the Company or any Subsidiary, the date upon which such Director ceases to be a member of the Board
or of the board of directors of any Subsidiary, with respect to a consultant of the Company or any of its Subsidiaries, the date upon
which such consultant ceases to provide services to the Company and its Subsidiaries and, with respect to an Employee, the date he or
she ceases to be an Employee;&#160;<span style="text-decoration:underline">provided</span>&#160;that with respect to any Award subject to Section&#160;409A of the Code, such
terms shall mean &#8220;<b><span style="text-decoration:underline">separation from service,</span></b>&#8221; as defined in Section&#160;409A of the Code and the rules, regulations
and guidance promulgated thereunder. Unless otherwise determined by the Administrator, a &#8220;<b><span style="text-decoration:underline">termination of employment</span></b>&#8221;
or &#8220;<b><span style="text-decoration:underline">termination of service</span></b>&#8221; shall not occur if an Employee, consultant or Director, immediately upon ceasing
to provide services in such capacity, commences to or continues to provide services to the Company or any of its Affiliates in another
of such capacities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article III.<span style="text-transform: uppercase"><br/>
ADMINISTRATION</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&#160;<span style="text-decoration:underline">Powers of the
Administrator</span>. The Plan shall be administered by the Administrator. The Administrator shall have the sole and complete authority
and discretion to: (i)&#160;determine the type or types of Awards to be granted to each Participant; (ii)&#160;select the Service Providers
to whom Awards may from time to time be granted; (iii)&#160;determine all matters and questions related to the termination of service
of a Service Provider with respect to any Award granted to him or her; (iv)&#160;determine the number of Awards to be granted and the
number of Shares to which an Award will relate; (v)&#160;approve forms of agreement for use under the Plan, which need not be identical
for each Service Provider; (vi)&#160;determine the terms and conditions of any Awards (including, without limitation, the exercise price,
the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture
restrictions and any restriction or limitation regarding any Award or the Company Common Stock relating thereto)&#160;based in each case
on such factors as the Administrator shall determine; (vii)&#160;prescribe, amend and rescind rules and regulations relating to the Plan,
including rules and regulations relating to Subplans (as defined&#160;<span style="text-decoration:underline">in Section&#160;3.4</span>)&#160;established for the purpose of
satisfying applicable foreign laws; (viii)&#160;determine whether, to what extent, and pursuant to what circumstances an Award may be
settled in, or the exercise or purchase price of an Award may be paid in, cash, Company Common Stock, other Awards, or other property,
or an Award may be canceled, forfeited or surrendered; (ix)&#160;suspend or accelerate the vesting of any Award granted under the Plan
or waive the forfeiture restrictions or any other restriction or limitation regarding any Awards or the Company Common Stock relating
thereto; (x)&#160;construe and interpret the terms of the Plan and Awards granted pursuant to the Plan; and (xi)&#160;make all other
decisions and determinations that may be required pursuant to the Plan or as the Administrator deems necessary or advisable to administer
the Plan. Any determination made by the Administrator under the Plan, including, without limitation, under&#160;<span style="text-decoration:underline">Section&#160;4.4</span>,
shall be final, binding and conclusive on all Participants and other persons having or claiming any right or interest under the Plan.
The Administrator&#8217;s determinations under the Plan need not be uniform and may be made by the Administrator selectively among persons
who receive, or are eligible to receive, Awards under the Plan, whether or not such persons are similarly situated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&#160;<span style="text-decoration:underline">Delegation by
the Administrator</span>. The Administrator may delegate, subject to such terms or conditions or guidelines as it shall determine, to any
officer or group of officers, or Director or group of Directors of the Company or its Subsidiaries any portion of its authority and powers
under the Plan with respect to Participants who are not Executive Officers or non-employee directors of the Board;&#160;<span style="text-decoration:underline">provided</span>&#160;that
any delegation to one or more officers of the Company shall be subject to and comply with applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3&#160;<span style="text-decoration:underline">Expenses, Professional
Assistance, No Liability</span>. All expenses and liabilities incurred by the Administrator in connection with the administration of the
Plan shall be borne by the Company. The Administrator may elect to engage the services of attorneys, consultants, accountants or other
persons. The Administrator, the Company and its officers and Directors shall be entitled to rely upon the advice, opinions or valuations
of any such persons. The Administrator (and its members)&#160;shall not be personally liable for any action, determination or interpretation
made with respect to the Plan or the Awards, and the Administrator (and its members)&#160;shall be fully protected by the Company with
respect to any such action, determination or interpretation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4&#160;<span style="text-decoration:underline">Participants
Based Outside the United States</span>. To conform with the provisions of local laws and regulations, or with local compensation practices
and policies, in foreign countries in which the Company or any of its Subsidiaries operate, but subject to the limitations set forth
herein regarding the maximum number of shares issuable hereunder and the maximum award to any single Participant, the Administrator may
(i)&#160;modify the terms and conditions of Awards granted to Employees employed and consultants who provide services outside the United
States (&#8220;<b><span style="text-decoration:underline">Non-U.S. Awards</span></b>&#8221;), (ii)&#160;establish subplans with such modifications as may be necessary or advisable
under the circumstances (&#8220;<b><span style="text-decoration:underline">Subplans</span></b>&#8221;)&#160;and (iii)&#160;take any action which it deems advisable to obtain,
comply with or otherwise reflect any necessary governmental regulatory procedures, exemptions or approvals with respect to the Plan.
The Administrator&#8217;s decision to grant Non-U.S. Awards or to establish Subplans is entirely voluntary, and at the complete discretion
of the Administrator. The Administrator may amend, modify or terminate any Subplans at any time, and such amendment, modification or
termination may be made without prior notice to the Participants. The Company, Affiliates and members of the Administrator shall not
incur any liability of any kind to any Participant as a result of any change, amendment or termination of any Subplan at any time. The
benefits and rights provided under any Subplan or by any Non-U.S. Award (x)&#160;are wholly discretionary and, although provided by either
the Company or an Affiliate of the Company, do not constitute regular or periodic payments and (y)&#160;except as otherwise required
under applicable laws, are not to be considered part of the Participant&#8217;s salary or compensation under the Participant&#8217;s
employment with the Participant&#8217;s local employer for purposes of calculating any severance, resignation, redundancy or other end
of service payments, vacation, bonuses, long-term service awards, indemnification, pension or retirement benefits, or any other payments,
benefits or rights of any kind. If a Subplan is terminated, the Administrator may direct the payment of Non-U.S. Awards (or direct the
deferral of payments whose amount shall be determined)&#160;prior to the dates on which payments would otherwise have been made, and
determine if such payments may be made in a lump sum or in installments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article IV.<span style="text-transform: uppercase"><br/>
SHARES SUBJECT TO PLAN</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&#160;Shares Subject to
Plan. Subject to&#160;<span style="text-decoration:underline">Section&#160;4.3</span>&#160;and&#160;<span style="text-decoration:underline">Section&#160;4.7</span>, the aggregate number of Shares which may be issued
under this Plan shall be 1,000,000 (the&#160;<b><span style="text-decoration:underline">&#8220;Share Limit</span></b>&#8221;). All of the Shares reserved under the Plan may
be issued in the form of Incentive Stock Options under the Plan, subject to the limitation set forth in&#160;<span style="text-decoration:underline">Section&#160;4.7</span>.
The Shares issued under the Plan may be authorized but unissued, or reacquired Company Common Stock. No provision of this Plan shall
be construed to require the Company to maintain the Shares in certificated form. Unless the Administrator shall determine otherwise,
(x)&#160;Awards may not consist of fractional shares and shall be rounded down to the nearest whole Share, and (y)&#160;fractional Shares
shall not be issued under the Plan (and shall instead also be rounded as aforesaid).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2&#160;If any Award or
portion thereof under this Plan is for any reason forfeited, canceled, cash-settled, expired or otherwise terminated without the issuance
of Shares, the Shares subject to such forfeited, canceled, cash-settled, expired or otherwise terminated Award, or portion thereof, shall
again be available for grant under the Plan. If Shares are tendered or withheld from issuance with respect to an Award by the Company
in satisfaction of any Exercise Price, or tax withholding or similar obligations, such tendered or withheld Shares shall again be available
for grant under the Plan. Notwithstanding the foregoing, and except to the extent required by applicable law, Replacement Awards shall
not be counted against Shares available for grant pursuant to this Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3&#160;The maximum number
of Shares subject to Awards granted during a single Compensation Year to any non-employee Director, taken together with any cash fees
paid during the Compensation Year to the non-employee Director, in respect of the Director&#8217;s service as a member of the Board during
such year (including service as a member or chair of any committees of the Board), shall not exceed (i)&#160;$500,000 in total value;
or&#160;(ii)&#160;in the event such&#160;non-employee Director&#160;is first appointed or elected to the Board during such&#160;Compensation
Year, $750,000 in total value, or (iii)&#160;in the event such non-employee Director is serving as&#160;non-employee Chairperson (or
co-Chairperson)&#160;of the Board, $750,000 in total value, in each case calculating the value of any equity awards based on the grant
date fair value of such equity awards for</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4&#160;<span style="text-decoration:underline">Changes in Company
Common Stock; Disposition of Assets and Corporate Events</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(a)&#160;If and
to the extent necessary or appropriate to reflect any stock dividend, extraordinary dividend, stock split or share combination or any
recapitalization, merger, consolidation, exchange of shares, spin-off, liquidation or dissolution of the Company or other similar transaction
affecting the Company Common Stock (each, a &#8220;<b><span style="text-decoration:underline">Corporate Event</span></b>&#8221;), the Administrator shall adjust the number of
shares of Company Common Stock available for issuance under the Plan, the ISO Limit, and the number, class and Exercise Price (if applicable)&#160;of
any outstanding Award, and/or make such substitution, revision or other provisions or take such other actions with respect to any outstanding
Award or the holder or holders thereof, in each case as it determines to be equitable. Without limiting the generality of the foregoing
sentence, in the event of any such Corporate Event, the Administrator shall have the power to make such changes as it deems appropriate
in (i)&#160;the number and type of shares or other securities covered by outstanding Awards, (ii)&#160;the prices specified therein (if
applicable), (iii)&#160;the securities, cash or other property to be received upon the exercise, settlement or conversion of such outstanding
Awards or otherwise to be received in connection with such outstanding Awards and (iv)&#160;any applicable Performance Goals. After any
adjustment made by the Administrator pursuant to this&#160;<span style="text-decoration:underline">Section&#160;4.4</span>, the number of shares subject to each outstanding
Award shall be rounded down to the nearest whole number of whole or fractional shares (as determined by the Administrator), and (if applicable)&#160;the
Exercise Price thereof shall be rounded up to the nearest cent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(b)&#160;Any
adjustment of an Award pursuant to this&#160;<span style="text-decoration:underline">Section&#160;4.4</span>&#160;shall be effected in compliance with Section&#160;424 and 409A
of the Code to the extent applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5&#160;The Administrator
may include such provisions and limitations in any Award Agreement as it shall determine, subject to the terms of the Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6&#160;Except to the extent
(i)&#160;approved in advance by the stockholders of the Company or (ii)&#160;pursuant to&#160;<span style="text-decoration:underline">Section&#160;4.4</span>&#160;as a result
of any Corporate Event or pursuant to&#160;<span style="text-decoration:underline">Article VII</span>&#160;in connection with a Change in Control, the Administrator shall not
have the power or authority to reduce, whether through amendment or otherwise, the Exercise Price of any outstanding Option or to grant
any new Award, or make any cash payment, in substitution for or upon the cancellation of Options previously granted and as to which the
Exercise Price thereof is in excess of the then-current Fair Market Value of Share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7&#160;Notwithstanding
the Share Limit, and subject to adjustment in accordance with Section&#160;3.3 hereof, the maximum number of Shares that may be granted
in connection with, and issued pursuant to the exercise of, Incentive Stock Options granted under this Plan is 1,000,000 shares (the
&#8220;<b><span style="text-decoration:underline">ISO Limit</span></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article V.<span style="text-transform: uppercase"><br/>
OPTIONS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1&#160;<span style="text-decoration:underline">Grant of Options</span>.
The Administrator is authorized to make Awards of Options to any Service Provider in such amounts and subject to such terms and conditions
as determined by the Administrator, consistent with the Plan. Excluding Replacement Awards, the per Share purchase price of the Shares
subject to each Option (the &#8220;<b><span style="text-decoration:underline">Exercise Price</span></b>&#8221;)&#160;shall be not less than 100% of the Fair Market Value of
a Share on the date such Option is granted. Each Option shall be evidenced by an Award Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&#160;<span style="text-decoration:underline">Exercisability
and Vesting; Exercise</span>. Each Option shall vest and become exercisable according to the terms and conditions as determined by the Administrator.
Except as otherwise determined by the Administrator. The Administrator shall specify the manner of and any terms and conditions of exercise
of an exercisable Option, including but not limited to net-settlement, delivery of previously owned stock and broker-assisted sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3&#160;<span style="text-decoration:underline">Expiration of
Options</span>. No Option may be exercised after the expiration of ten (10)&#160;years from the date the Option was granted, unless a longer
or shorter period is set forth in the Award Agreement. Notwithstanding the foregoing, in the event that on the last business day of the
term of the Option (x)&#160;the exercise of the Option is prohibited by applicable law or (y)&#160;Shares may not be purchased or sold
by certain employees or directors of the Company due to the &#8220;<b><span style="text-decoration:underline">black-out period</span></b>&#8221; of a Company policy or a &#8220;<b><span style="text-decoration:underline">lock-up</span></b>&#8221;
agreement undertaken in connection with an issuance of securities by the Company, the term of the Option shall be extended but not beyond
a period of thirty (30)&#160;days following the end of the legal prohibition, black-out period or lock-up agreement (to the extent permissible
under Section&#160;409A of the Code)&#160;and provided further that no extension will be made if the applicable Exercise Price at the
date the initial term would otherwise expire is below the Fair Market Value on such date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article VI.<span style="text-transform: uppercase"><br/>
Termination and Forfeiture</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1&#160;<span style="text-decoration:underline">Termination for
Cause; Post-Service Competitive Activity</span>. Unless otherwise set forth in the Award Agreement, if a Participant&#8217;s employment
or service terminates for Cause or a Participant engages in Competitive Activity following the Participant&#8217;s termination of employment
or service, all Options, whether vested or unvested, and all other Awards that are unvested or unexercisable or otherwise unpaid (or
were unvested or unexercisable or unpaid at the time of occurrence of Cause or engagement in Competitive Activity)&#160;shall be immediately
forfeited and canceled, effective as of the date of the termination or engagement in Competitive Activity. If the Participant engages
in Competitive Activity following the termination, any portion of the Participant&#8217;s Awards that became vested after termination,
and any Shares or cash issued upon exercise or settlement of such Awards, shall be immediately forfeited, canceled, and disgorged or
paid to the Company together with all gains earned or accrued due to the sale of Shares issued</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2&#160;<span style="text-decoration:underline">Termination due
to Death</span>. Unless otherwise set forth in the Award Agreement, if a Participant&#8217;s employment or service terminates by reason
of death:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(a)&#160;All
Options (whether or not then otherwise exercisable)&#160;shall become exercisable in full and the Participant&#8217;s Eligible Representative
may exercise all such Options at any time prior to the earlier of (i)&#160;the one-year anniversary of the Participant&#8217;s death
or (ii)&#160;the expiration of the term of the Options;&#160;<span style="text-decoration:underline">provided</span>&#160;that any in-the-money Options that are still outstanding
on the last day of the time period specified in this&#160;<span style="text-decoration:underline">Section&#160;6.2(a)</span>&#160;shall automatically be exercised on such date;
and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(b)&#160;All
other Awards shall immediately vest in full upon the Participant&#8217;s death.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3&#160;<span style="text-decoration:underline">Termination due
to Disability</span>. Unless otherwise set forth in the Award Agreement, if a Participant&#8217;s employment or service terminates by reason
of Disability, the Participant shall be treated for purposes of the treatment of the Participant&#8217;s Awards under this&#160;<span style="text-decoration:underline">Section&#160;6.3</span>&#160;as
though the Participant continued in the employ or service of the Company and all unvested Awards shall remain outstanding and vest, or
in the case of Options, vest and become exercisable, in accordance with the terms set forth in the applicable Award Agreement. Any Options
granted to such Participant that are exercisable at the date of termination by reason of Disability or that thereafter become exercisable
by reason of the operation of the immediately preceding sentence may be exercised at any time prior to the earlier of (i)&#160;the one
year anniversary of the Participant&#8217;s termination for Disability or (ii)&#160;the expiration of the term of such Options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4&#160;<span style="text-decoration:underline">Involuntary Termination
Without Cause</span>. Unless otherwise set forth in the Award Agreement, if a Participant&#8217;s employment or service is involuntarily
terminated without Cause:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(a)&#160;All
Options that are unvested shall be immediately forfeited and canceled, effective as of the date of the termination, and all Options that
are vested shall remain outstanding and exercisable until the earlier of (i)&#160;30 days after the effective date of the termination
under this&#160;<span style="text-decoration:underline">Section&#160;6.4</span>&#160;or (ii)&#160;the expiration of the term of such Options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.5&#160;<span style="text-decoration:underline">Termination for
Any Other Reason</span>. Unless otherwise set forth in the Award Agreement, if a Participant&#8217;s employment or service terminates for
any reason other as set forth in&#160;<span style="text-decoration:underline">Sections 6.1</span>&#160;(other than post-service Competitive Activity)&#160;through&#160;<span style="text-decoration:underline">6.4</span>:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(a)&#160;All
Options that are unvested shall be immediately forfeited and canceled, effective as of the date of the termination, and all Options that
are vested shall remain outstanding and exercisable until the earlier of (i)&#160;30 days after the effective date of the termination
under this&#160;<span style="text-decoration:underline">Section&#160;6.5</span>&#160;or (ii)&#160;the expiration of the term of such Options; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(b)&#160;All
other Awards that are unvested or have not otherwise been earned shall be immediately forfeited and canceled, effective as of the date
of termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.6&#160;<span style="text-decoration:underline">Post-Termination
Informational Requirements</span>. Before the settlement of any Award following termination of employment or service, the Administrator
may require the Participant (or the Participant&#8217;s Eligible Representative, if applicable)&#160;to make such representations and
provide such documents as the Administrator deems necessary or advisable to effect compliance with applicable law and the provisions
of this Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.7&#160;<span style="text-decoration:underline">Forfeiture and
Recoupment of Awards</span>. Awards granted under this Plan (and gains earned or accrued in connection with Awards)&#160;shall be subject
to such generally applicable policies as to forfeiture and recoupment (including, without limitation, upon the occurrence of material
financial or accounting errors, financial or other misconduct or Competitive Activity)&#160;as may be adopted by the Administrator or
the Board from time to time. Any such policies may (in the discretion of the Administrator or the Board)&#160;be applied to outstanding
Awards at the time of adoption of such policies, or on a prospective basis only. Participants shall also forfeit and disgorge to the
Company any Awards granted or vested and any gains earned or accrued due to the exercise of Options or the sale of any Company Common
Stock to the extent required by applicable law or as required by any stock exchange or quotation system on which the Company Common Stock
is listed or quoted, in each case in effect on or after the Effective Date, including but not limited to Section&#160;304 of the Sarbanes-Oxley
Act of 2002 and Section&#160;10D of the Exchange Act. The implementation of policies and procedures pursuant to this&#160;<span style="text-decoration:underline">Section&#160;6.7</span>&#160;and
any modification of the same shall not be subject to any restrictions on amendment or modification of Awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.8&#160;<span style="text-decoration:underline">Clawbacks</span>.
Awards shall be subject to any generally applicable clawback policy adopted by the Administrator, the Board or the Company that is communicated
to the Participants or any such policy adopted to comply with Applicable Law, whether before or after the adoption date of this Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article VII.<span style="text-transform: uppercase"><br/>
CHANGE IN CONTROL</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1&#160;<span style="text-decoration:underline">Alternative Award</span>.
Unless otherwise provided in an Award Agreement, no cancellation, acceleration or other payment shall occur in connection with a Change
in Control pursuant to&#160;<span style="text-decoration:underline">Section&#160;7.2</span>&#160;with respect to any Award or portion thereof as a result of the Change in Control
if the Administrator reasonably determines in good faith, prior to the occurrence of the Change in Control, that such Award shall be
honored or assumed, or new rights substituted therefor following the Change in Control (such honored, assumed or substituted award, an
&#8220;<b><span style="text-decoration:underline">Alternative Award</span></b>&#8221;),&#160;<span style="text-decoration:underline">provided</span>&#160;that any Alternative Award must (i)&#160;give the Participant
who held the Award rights and entitlements substantially equivalent to or better than the rights and terms applicable under the Award
immediately prior to the Change in Control, including an equal or better vesting schedule and that Alternative Awards that are stock
options have identical or better methods of payment of the exercise price thereof and a post-termination exercise period extending until
at least the fifth anniversary of the Participant&#8217;s termination (or, if earlier, the expiration of the term of such stock options);
(ii)&#160;have terms such that if a Participant&#8217;s employment is involuntarily (<i>i.e.</i>, by the Company or its successor other
than for Cause)&#160;or constructively (<i>i.e.</i>, by the Participant with Good Reason)&#160;terminated within the twenty-four (24)&#160;months
following a Change in Control at a time when any portion of the Alternative Award is unvested, the unvested portion of such Alternative
Award shall immediately vest in full and such Participant shall receive (as determined by the Board prior to the Change in Control)&#160;either
(1)&#160;a cash payment equal in value to the excess (if any)&#160;of the fair market value of the stock subject to the Alternative Award
at the date of exercise or settlement over the price (if any)&#160;that such Participant would be required to pay to exercise such Alternative
Award or (2)&#160;publicly-traded shares or equity interests equal in value (as determined by the Administrator)&#160;to the value in
clause (1).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2&#160;<span style="text-decoration:underline">Accelerated Vesting
and Payment</span>. Except as otherwise provided in this&#160;<span style="text-decoration:underline">Article VII</span>&#160;or in an Award Agreement, upon a Change in Control:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(a)&#160;each
vested and unvested Option shall be canceled in exchange for a payment equal to the excess, if any, of the Change in Control Price over
the applicable Exercise Price;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(b)&#160;the
vesting restrictions applicable to all other unvested Awards shall lapse, all such Awards shall vest and become non-forfeitable and be
canceled in exchange for a payment equal to the Change in Control Price; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(c)&#160;all
other Awards that were vested prior to the Change in Control but that have not been settled or converted into Shares prior to the Change
in Control shall be canceled in exchange for a payment equal to the Change in Control Price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent any portion of the Change in Control
Price is payable other than in cash and/or other than at the time of the Change in Control, Award holders under the Plan shall receive
the same value in respect of their Awards (less any applicable Exercise Price)&#160;as is received by the Company&#8217;s stockholders
in respect of their Company Common Stock (as determined by the Administrator), and the Administrator shall determine the extent to which
such value shall be paid in cash, in securities or other property, or in a combination of cash and securities or other property, consistent
with applicable law. To the extent any portion of the Change in Control Price is payable other than at the time of the Change in Control,
the Administrator shall determine the time and form of payment to the Award holders consistent with Section&#160;409A of the Code and
other applicable laws. Upon a Change in Control the Administrator may cancel Options for no consideration if the Fair Market Value of
the Shares subject to such Options is less than or equal to the Exercise Price of such Options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Article VIII.<span style="text-transform: uppercase"><br/>
OTHER PROVISIONS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1&#160;<span style="text-decoration:underline">Awards Not Transferable</span>.
Except as otherwise determined by the Administrator, no Award or interest or right therein or part thereof shall be liable for the debts,
contracts or engagements of the Participant or his or her successors in interest or shall be subject to disposition by transfer, alienation,
anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation
of law, by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted
disposition thereof shall be null and void and of no effect;&#160;<span style="text-decoration:underline">provided, however</span>, that nothing in this&#160;<span style="text-decoration:underline">Section&#160;8.1</span>&#160;shall
prevent transfers by will, by the applicable laws of descent and distribution or pursuant to the beneficiary designation procedures approved
by the Company pursuant to&#160;<span style="text-decoration:underline">Section&#160;8.13</span>&#160;or, with the prior approval of the Company, estate planning transfers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2&#160;Amendment, Suspension
or Termination of the Plan or Award Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(a)&#160;The
Plan may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Administrator;&#160;<span style="text-decoration:underline">provided</span>,
that without the approval of the stockholders of the Company, no amendment or modification to the Plan may (i)&#160;except as otherwise
expressly provided in Section&#160;3.3, increase the number of Shares subject to the Plan; (ii)&#160;modify the class of persons eligible
for participation in the Plan or (iii)&#160;materially modify the Plan in any other way that would require stockholder approval under
applicable law. Except as otherwise expressly provided in the Plan, neither the amendment, suspension or termination of the Plan shall,
without the written consent of the holder of the Award, materially adversely alter or impair any rights or obligations under any Award
theretofore granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(b)&#160;The
Administrator at any time, and from time to time, may amend the terms of any one or more existing Award Agreements,&#160;<span style="text-decoration:underline">provided</span>,&#160;<span style="text-decoration:underline">however</span>,
that the rights of a Participant under an Award Agreement shall not be materially adversely impaired without the Participant&#8217;s
written consent. The Company shall provide a Participant with notice of any amendment made to a Participant&#8217;s existing Award Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 33pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">(c)&#160;No Award
may be granted during any period of suspension nor after termination of the Plan, and in no event may any Award be granted under this
Plan after the expiration of ten (10)&#160;years from the Effective Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3&#160;<span style="text-decoration:underline">Effect of Plan
upon Other Award and Compensation Plans</span>. The adoption of this Plan shall not affect any other compensation or incentive plans in
effect for the Company or any of its Affiliates. Nothing in this Plan shall be construed to limit the right of the Company or any of
its Affiliates (a)&#160;to establish any other forms of incentives or compensation for Service Providers or (b)&#160;to grant or assume
options or restricted stock other than under this Plan in connection with any proper corporate purpose, including, but not by way of
limitation, the grant or assumption of options or restricted stock in connection with the acquisition by purchase, lease, merger, consolidation
or otherwise, of the business, stock or assets of any</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.4&#160;<span style="text-decoration:underline">At-Will Employment</span>.
Nothing in the Plan or any Award Agreement hereunder shall confer upon the Participant any right to continue as a Service Provider of
the Company or any of its Affiliates or shall interfere with or restrict in any way the rights of the Company or any of its Affiliates,
which are hereby expressly reserved, to discharge any Participant at any time for any reason whatsoever, with or without Cause.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.5&#160;<span style="text-decoration:underline">Conformity to
Securities Laws</span>. The Plan is intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange
Act and any and all regulations and rules promulgated under any of the foregoing, to the extent the Company, any of its Affiliates or
any Participant is subject to the provisions thereof. Notwithstanding anything herein to the contrary, the Plan shall be administered,
and Awards shall be granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations. To the extent
permitted by applicable law, the Plan and Awards granted hereunder shall be deemed amended to the extent necessary to conform to such
laws, rules and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.6&#160;<span style="text-decoration:underline">Term of Plan</span>.
The Plan was approved by the Board of Directors of the Company on the Effective Date, subject to stockholder approval. The Plan shall
continue in effect, unless sooner terminated pursuant to&#160;<span style="text-decoration:underline">Section&#160;8.2</span>, until the tenth (10<sup>th</sup>)&#160;anniversary
of the Effective Date. The provisions of the Plan shall continue thereafter to govern all outstanding Awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.7&#160;<span style="text-decoration:underline">Governing Law</span>.
To the extent not preempted by federal law, the Plan shall be construed in accordance with and governed by the laws of the State of Delaware
regardless of the application of rules of conflict of law that would apply the laws of any other jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.8&#160;<span style="text-decoration:underline">Severability</span>.
In the event any portion of the Plan or any action taken pursuant thereto shall be held illegal or invalid for any reason, the illegality
or invalidity shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as if the illegal or invalid
provisions had not been included, and the illegal or invalid action shall be null and void.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.9&#160;<span style="text-decoration:underline">Governing Documents</span>.
In the event of any express contradiction between the Plan and any Award Agreement or any other written agreement between a Participant
and the Company or any Affiliate that has been approved by the Administrator, the express terms of the Plan shall govern, unless it is
expressly specified in such Award Agreement or other written document that such express provision of the Plan shall not apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.10&#160;<span style="text-decoration:underline">Withholding
Taxes</span>. In addition to any rights or obligations with respect to the federal, state, local or foreign income taxes, withholding taxes
or employment taxes required to be withheld under applicable law, the Company or any Affiliate employing a Service Provider shall have
the right to withhold from the Service Provider, or otherwise require the Service Provider or an assignee to pay, any such required withholding
obligations arising as a result of grant, exercise, vesting or settlement of any Award or any other taxable event occurring pursuant
to the Plan or any Award Agreement, including, without limitation, to the extent permitted by law, the right to deduct any such withholding
obligations from any payment of any kind otherwise due to the Service Provider or to take such other actions (including, without limitation,
withholding any Shares or cash deliverable pursuant to the Plan or any Award)&#160;as may be necessary to satisfy such withholding obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.11&#160;<span style="text-decoration:underline">Section&#160;409A</span>.
To the extent applicable, the Plan and Award Agreements shall be interpreted in accordance with Section&#160;409A of the Code and Department
of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other
guidance that may be issued after the adoption of the Plan. Notwithstanding any provision of the Plan to the contrary, in the event that
following the adoption of the Plan, the Administrator determines that any Award may be subject to Section&#160;409A of the Code and related
regulations and Department of Treasury guidance (including such Department of Treasury guidance as may be issued after the adoption of
the Plan), the Administrator may adopt such amendments to the Plan and the applicable Award Agreement or adopt other policies and procedures
(including amendments, policies and procedures with retroactive effect), or take any other actions, that the Administrator determines
are necessary or appropriate to (a)&#160;exempt the Award from Section&#160;409A of the Code and/or preserve the intended tax treatment
of the benefits provided with respect to the Award, (b)&#160;comply with the requirements of Section&#160;409A of the Code and related
Department of Treasury guidance or (c)&#160;comply with any correction procedures available with respect to Section&#160;409A of the
Code. Notwithstanding anything else contained in this Plan or any Award Agreement to the contrary, if a Service Provider is a &#8220;<b><span style="text-decoration:underline">specified
employee</span></b>&#8221; at the time of the Service Provider&#8217;s &#8220;<b><span style="text-decoration:underline">separation from service</span></b>&#8221; (as determined
under Section&#160;409A of the Code)&#160;then, to the extent necessary to comply with, and avoid imposition on such Service Provider
of any tax penalty imposed under, Section&#160;409A of the Code, any payment required to be made to a Service Provider hereunder upon
or following his or her separation from service shall be delayed until the first to occur of (i)&#160;the six-month anniversary of the
Service Provider&#8217;s separation from service and (ii)&#160;the Service Provider&#8217;s death. Should payments be delayed in accordance
with the preceding sentence, the accumulated payment that would have been made but for the period of the delay shall be paid in a single
lump sum during the ten (10)&#160;day period following the lapsing of the delay period. No provision of this Plan or an Award Agreement
shall be construed to indemnify any Service Provider for any taxes incurred by reason of Section&#160;409A (or timing of incurrence thereof),
other than an express indemnification provision therefor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.12&#160;<span style="text-decoration:underline">Notices</span>.
Except as provided otherwise in an Award Agreement, all notices and other communications required or permitted to be given under this
Plan or any Award Agreement shall be in writing and shall be deemed to have been given if delivered personally, sent by email or any
other form of electronic transfer approved by the Administrator, sent by certified or express mail, return receipt requested, postage
prepaid, or by any recognized international equivalent of such delivery, (i)&#160;in the case of notices and communications to the Company,
to its current business address and to the attention of the Corporate Secretary of the Company or (ii)&#160;in the case of a Participant,
to the last known address, or email address or, where the individual is an employee of the Company or one of its Subsidiaries, to the
individual&#8217;s workplace address or email address or by other means of electronic transfer acceptable to the Administrator. All such
notices and communications shall be deemed to have been received on the date of delivery, if sent by email or any other form of electronic
transfer, at the time of dispatch or on the third business day after the mailing thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.13&#160;<span style="text-decoration:underline">Beneficiary
Designation</span>. Each Participant under the Plan may from time to time pursuant to procedures approved by the Company name any beneficiary
or beneficiaries by whom any right under the Plan is to be exercised in case of such Participant&#8217;s death.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><div><a id="a_164"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Appendix D</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM OF</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTIFICATE OF AMENDMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OF</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECOND AMENDED AND RESTATED<br/>
CERTIFICATE OF INCORPORATION<br/>
OF</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>180 LIFE SCIENCES CORP.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">180 Life Sciences Corp.,
a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>FIRST</b>: The name of
the corporation is 180 Life Sciences Corp.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>SECOND</b>: The original
name of the Company was KBL Merger Corp. IV. The date on which the Company&#8217;s original Certificate of Incorporation was filed with
the Secretary of State of the State of Delaware is September 7, 2016. The Amended and Restated Certificate of Incorporation of the Company
was filed with the Secretary of State of the State of Delaware on June 2, 2017. The Second Amended and Restated Certificate of Incorporation
of the Company was filed with the Secretary of State of the State of Delaware on November 6, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>THIRD</b>: The Board of
Directors of the Company (the &#8220;<b><span style="text-decoration:underline">Board</span></b>&#8221;), acting in accordance with the provisions of&#160;<span style="text-decoration:underline">Sections 141</span>&#160;and&#160;<span style="text-decoration:underline">242</span>&#160;of
the General Corporation Law of the State of Delaware (the &#8220;<b><span style="text-decoration:underline">DGCL</span></b>&#8221;), adopted resolutions approving and deeming
advisable an amendment to the Company&#8217;s Second Amended and Restated Certificate of Incorporation, as amended (the &#8220;<b><span style="text-decoration:underline">Restated
Certificate</span></b>&#8221;), as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b><i><span style="text-decoration:underline">RESOLVED</span></i></b><i>:&#160;</i>That Article
IV of the Second Amended and Restated Certificate of Incorporation of the Corporation be and it hereby is amended to restate Section
4.6 as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#8220;4.6.&#160;<span style="text-decoration:underline">Reverse Stock Split
of Outstanding Common Stock</span>. Upon this Certificate of Amendment becoming effective pursuant to the General Corporation Law of the
State of Delaware (the &#8220;<b><span style="text-decoration:underline">Effective Time</span></b>&#8221;), each [<b>4 to 40, depending on the final ratio approved by the Board
of Directors</b>] shares of Common Stock, either issued and outstanding or held by the corporation as treasury stock, in each case immediately
prior to the Effective Time (the &#8220;<b><span style="text-decoration:underline">Old Common Stock</span></b>&#8221;), shall be automatically reclassified as and converted
into&#160;<b>one</b>&#160;share of Common Stock (the &#8220;<b><span style="text-decoration:underline">New Common Stock</span></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Notwithstanding the immediately preceding
paragraph, the Corporation shall not be required to issue or deliver any fractional shares of New Common Stock. At the Effective Time
any such fractional interest in such shares of New Common Stock shall be [converted into the right to receive, an amount in cash, without
interest, determined by multiplying (i) the closing sale price of the Common Stock (on a post-reverse-split basis as adjusted for the
amendment effected hereby) on the trading day immediately prior to the Effective Time as reported on the Nasdaq Capital Market, by (ii)
such fractional share interest to which the holder would otherwise be entitled]/[rounded up to the next whole share]. Shares of Common
Stock that were outstanding prior to the Effective Time and that are not outstanding after the Effective Time shall resume the status
of authorized but unissued shares of Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Each stock certificate that, immediately
prior to the Effective Time, represented shares of Old Common Stock shall, from and after the Effective Time, represent that number of
whole shares of New Common Stock into which the shares of Old Common Stock represented by such certificate shall have been reclassified
(as well as the right to receive [cash]/[whole shares] in lieu of any fractional shares of New Common Stock as set forth above); provided,
however, that each holder of record of a certificate that represented shares of Old Common Stock shall receive, upon surrender of such
certificate, a new certificate representing the number of whole shares of New Common Stock into which the shares of Old Common Stock
represented by such certificate shall have been reclassified, as well as any [cash]/[whole share] in lieu of fractional shares of New
Common Stock to which such holder may be entitled pursuant to the immediately preceding paragraph.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 142; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Reverse Stock Split shall have
no effect on the number of authorized shares of capital stock, previously designated series of preferred stock (except to the extent
such reverse stock split results in an adjustment to the conversion ratios thereof), or the par value thereof as set forth above in the
preceding paragraphs.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i><span style="text-decoration:underline">RESOLVED</span></i></b><i>:</i>&#160;That
except as expressly amended hereby no other aspect of such Article IV shall be modified hereby.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.5pt"><b>&#160; </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.5pt"><b>FOURTH:</b>&#160;&#160;The
foregoing amendment was submitted to the stockholders of the Company for their approval at a special meeting of stockholders which was
duly called and held, upon notice in accordance with&#160;<span style="text-decoration:underline">Section 222</span>&#160;of the DGCL, at which meeting the necessary number
of shares as required by statute were voted in favor of the amendment.&#160;&#160;Accordingly, said amendment was duly adopted in accordance
with the provisions of&#160;<span style="text-decoration:underline">Section 242</span>&#160;of the DGCL.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.5pt"><b>FIFTH:</b>&#160;This
Certificate of Amendment shall become effective on [_____], [_________] at [_____] Eastern Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.5pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, 180 Life
Sciences Corp. has caused this certificate to be signed by Blair Jordan, its Chief Executive Officer, this&#160;<span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;day
of&#160;<span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;</span>, 202__.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td colspan="3"><span style="font-size: 10pt"><b>180 LIFE SCIENCES CORP.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td>
    <td style="width: 60%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Its:</span></td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 7%"><span style="font-size: 10pt">Printed&#160;Name:</span></td>
    <td style="width: 33%; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="width: 60%">&#160;</td></tr>
  </table><div>
</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><div><a id="a_165"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Appendix E</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM OF</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTIFICATE OF AMENDMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OF</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECOND AMENDED AND RESTATED<br/>
CERTIFICATE OF INCORPORATION<br/>
OF</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>180 LIFE SCIENCES CORP.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">180 Life Sciences Corp.,
a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>FIRST</b>: The name of
the corporation is 180 Life Sciences Corp.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>SECOND</b>: The original
name of the Company was KBL Merger Corp. IV. The date on which the Company&#8217;s original Certificate of Incorporation was filed with
the Secretary of State of the State of Delaware is September 7, 2016. The Amended and Restated Certificate of Incorporation of the Company
was filed with the Secretary of State of the State of Delaware on June 2, 2017. The Second Amended and Restated Certificate of Incorporation
of the Company was filed with the Secretary of State of the State of Delaware on November 6, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>THIRD</b>: The Board of
Directors of the Company (the &#8220;<b><span style="text-decoration:underline">Board</span></b>&#8221;), acting in accordance with the provisions of&#160;<span style="text-decoration:underline">Sections 141</span>&#160;and&#160;<span style="text-decoration:underline">242</span>&#160;of
the General Corporation Law of the State of Delaware (the &#8220;<b><span style="text-decoration:underline">DGCL</span></b>&#8221;), adopted resolutions approving and deeming
advisable an amendment to the Company&#8217;s Second Amended and Restated Certificate of Incorporation, as amended (the &#8220;<b><span style="text-decoration:underline">Restated
Certificate</span></b>&#8221;), as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b><i><span style="text-decoration:underline">RESOLVED</span></i></b><i>:&#160;</i>That Article
IV of the Second Amended and Restated Certificate of Incorporation of the Corporation be and it hereby is amended to restate Section
4.1 as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#8220;<span style="text-decoration:underline">Section 4.1 Authorized Capital
Stock</span>. The total number of shares of all classes of capital stock, each with a par value of $0.0001 per share, which the Corporation
is authorized to issue is 1,005,000,000, shares, consisting of (a) 1,000,000,000 shares of common stock and (b) 5,000,000 shares of preferred
stock, par value $0.0001 per share (the &#8220;Preferred Stock&#8221;), which Preferred Stock is undesignated as to class or series other
than as contemplated by Sections 4.3 and 4.4 hereof.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i><span style="text-decoration:underline">RESOLVED</span></i></b><i>:</i>&#160;That
except as expressly amended hereby no other aspect of such Article IV shall be modified hereby.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.5pt"><b>&#160; </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.5pt"><b>FOURTH:</b>&#160;&#160;The
foregoing amendment was submitted to the stockholders of the Company for their approval at a special meeting of stockholders which was
duly called and held, upon notice in accordance with&#160;<span style="text-decoration:underline">Section 222</span>&#160;of the DGCL, at which meeting the necessary number
of shares as required by statute were voted in favor of the amendment.&#160;&#160;Accordingly, said amendment was duly adopted in accordance
with the provisions of&#160;<span style="text-decoration:underline">Section 242</span>&#160;of the DGCL.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.5pt"><b>FIFTH:</b>&#160;This
Certificate of Amendment shall become effective on [_____], [_________] at [_____] Eastern Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.5pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, 180 Life
Sciences Corp. has caused this certificate to be signed by Blair Jordan, its Chief Executive Officer, this&#160;<span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;day
of&#160;<span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;</span>, 202__.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td colspan="3"><span style="font-size: 10pt"><b>180 LIFE SCIENCES CORP.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td>
    <td style="width: 60%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Its:</span></td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 7%"><span style="font-size: 10pt">Printed&#160;Name:</span></td>
    <td style="width: 33%; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="width: 60%">&#160;</td></tr>
  </table><div>
</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 144; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>180 LIFE SCIENCES CORP.</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>THIS
    PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">ANNUAL
    MEETING OF STOCKHOLDERS &#8211; ______________, <br/>
2025 AT [______] P.M. PACIFIC TIME</span></p></td>
    <td rowspan="19" style="padding-right: 5.4pt; padding-left: 5.65pt; text-align: center"><img alt="" src="image_004.jpg"/></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="4" style="vertical-align: top; padding-right: 5.4pt; padding-left: 62.4pt">&#160;</td></tr>
  <tr>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><b>CONTROL ID:</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
  <tr>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt"><b>REQUEST ID:</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.65pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="font-size: 2pt">
    <td colspan="2" style="font-size: 2pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="font-size: 2pt; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="font-size: 2pt; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="font-size: 2pt; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="font-size: 2pt; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="2" rowspan="3" style="font-size: 2pt; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.65pt">&#160;</td>
    <td style="font-size: 2pt; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="font-size: 2pt; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
  <tr>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td rowspan="4" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td rowspan="4" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td rowspan="4" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td rowspan="4" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td rowspan="4" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
  <tr>
    <td colspan="3" style="text-align: justify"><span style="font-size: 10pt">The undersigned stockholder of 180 Life Sciences Corp.,
    a Delaware corporation (the &#8220;Company&#8221;), hereby acknowledges receipt of the Notice of Annual Meeting of Stockholders and
    Proxy Statement of the Company, each dated on or around [&#9679;], 2025, and hereby appoints Blair Jordan and Eric R. Van Lent (the
    &#8220;Proxies&#8221;) or any one of them, with full power of substitution and resubstitution, and authority to act in the absence
    of the other, each as proxies and attorneys-in-fact, to cast all votes that the undersigned is entitled to cast at, and with all
    powers that the undersigned would possess if personally present at, the Annual Meeting of Stockholders of the Company, to be held
    virtually on ______________, 2025, at [ ] p.m. Pacific Time, virtually via live audio webcast at&#160;<i>https://agm.issuerdirect.com/ATNF</i>,
    and at any adjournment or postponement thereof, and to vote all shares of the Company that the undersigned would be entitled to vote
    if then and there personally present, on the matters set forth on the reverse side, and all such other business as may properly come
    before the meeting. I/we hereby revoke all proxies previously given.</span></td></tr>
  <tr>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td colspan="2" rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>(CONTINUED
    AND TO BE SIGNED ON REVERSE SIDE.)</b></span></td></tr>
  <tr>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b><span style="text-decoration:underline">VOTING
    INSTRUCTIONS</span></b></span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>If you vote
    by phone, fax or internet, please DO NOT mail your proxy card.</b></span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
  <tr>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 2pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 2pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 2pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 2pt">&#160;</span></td>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 2pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 2pt">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 2pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="2" rowspan="5" style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.5pt"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.5pt"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.5pt">&#160;</p></td></tr>
  <tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><img alt="" src="image_005.jpg"/></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt"><b>MAIL:</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">Please mark, sign, date, and return this Proxy
    Card promptly using the enclosed envelope.</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
  <tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><img alt="" src="image_006.jpg"/></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt"><b>FAX:</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">Complete the reverse portion of this Proxy Card
    and Fax to&#160;<b>202-521-3464.</b></span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
  <tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><img alt="" src="image_007.jpg"/></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt"><b>INTERNET:</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">https://www.iproxydirect.com/ATNF</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
  <tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><img alt="" src="image_008.jpg"/></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt"><b>PHONE:</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">1-866-752-VOTE(8683)</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
  </table><div>
</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 145 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="text-align: center; vertical-align: bottom; width: 59%"><b>ANNUAL MEETING OF THE STOCKHOLDERS OF<br/>
    180 LIFE SCIENCES CORP</b></td>
    <td style="text-align: right; width: 41%; padding-left: 0.5in"><b>PLEASE COMPLETE, DATE, SIGN AND<br/>
    RETURN PROMPTLY IN THE ENCLOSED&#160;ENVELOPE.<br/>
    PLEASE MARK YOUR VOTE IN<br/>
    BLUE OR BLACK INK AS<br/>
    SHOWN HERE:&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></b></td></tr>
  <tr>
    <td style="text-align: center">THE BOARD OF DIRECTORS UNANIMOUSLY<br/>
    RECOMMENDS THAT YOU VOTE &#8220;FOR ALL&#8221; FOR<br/>
    PROPOSAL ONE, AND &#8220;FOR&#8221; PROPOSALS TWO<br/>
    THROUGH EIGHT.</td>
    <td style="padding-left: 0.5in">&#160;</td></tr>
  <tr>
    <td style="text-align: center">PROXY SOLICITED ON BEHALF OF THE BOARD OF<br/>
    DIRECTORS</td>
    <td style="padding-left: 0.5in">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="padding-left: 2pt; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; text-align: left; font-size: 10pt; width: 12%"><b>Proposal&#160;1</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: left; width: 16%">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt; width: 2%"><span>&#8594;</span></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt; width: 10%"><b>FOR<br/>
    ALL</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 3%">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 14%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WITHHOLD</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALL</b></p></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 3%">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 14%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FOR ALL</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXCEPT</b></p></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; vertical-align: top; width: 4%">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 22%">&#160;</td>
    </tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left; font-size: 10pt"><i>Election of Directors</i></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt">&#9744;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt">&#9744;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    </tr>
  <tr>
    <td>&#160;</td>
    <td style="padding-left: 0.125in; vertical-align: top; text-align: left; font-size: 10pt">Lawrence Steinman, M.D.</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt">&#9744;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    </tr>
  <tr>
    <td>&#160;</td>
    <td style="padding-left: 0.125in; vertical-align: top; text-align: left; font-size: 10pt">Stephen H. Shoemaker</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt">&#9744;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><b>CONTROL&#160;ID:</b></td>
    </tr>
  <tr>
    <td>&#160;</td>
    <td style="padding-left: 0.125in; vertical-align: top; text-align: left; font-size: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><b>REQUEST ID:</b></td>
    </tr>
  <tr>
    <td style="padding-left: 2pt; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; text-align: left; font-size: 10pt"><b>Proposal&#160;2</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><span>&#8594;</span></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><b>FOR</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><b>AGAINST</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><b>ABSTAIN</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; vertical-align: top">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    </tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: left; font-size: 10pt">Approval of the adoption of the Fourth Amendment to the 180 Life Sciences Corp. 2022
    Omnibus Incentive Plan</td>
    <td>&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#9744;</td>
    <td>&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#9744;</td>
    <td>&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#9744;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    </tr>
  <tr>
    <td style="padding-left: 2pt; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; text-align: left; font-size: 10pt"><b>Proposal&#160;3</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><span>&#8594;</span></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><b>FOR</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><b>AGAINST</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><b>ABSTAIN</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; vertical-align: top">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    </tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: left; font-size: 10pt">Approval of the adoption of the 180 Life Sciences Corp. 2025 Option&#160;&#160;Incentive
    Plan</td>
    <td>&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#9744;</td>
    <td>&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#9744;</td>
    <td>&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#9744;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    </tr>
  <tr>
    <td style="padding-left: 2pt; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; text-align: left; font-size: 10pt"><b>Proposal&#160;4</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><span>&#8594;</span></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><b>FOR</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><b>AGAINST</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><b>ABSTAIN</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; vertical-align: top">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    </tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: left; font-size: 10pt">Advisory vote to approve named executive officer compensation, as described in the
    180 Life Sciences Corp. Proxy Statement.</td>
    <td>&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#9744;</td>
    <td>&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#9744;</td>
    <td>&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#9744;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 146 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="padding-left: 2pt; border-left: Black 1.5pt solid; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 12%"><b>Proposal&#160;5</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 16%">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 2%"><span>&#8594;</span></td>
    <td style="text-align: center; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 10%"><b>FOR</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 3%">&#160;</td>
    <td style="text-align: center; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 14%"><b>AGAINST</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 3%">&#160;</td>
    <td style="text-align: center; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 14%"><b>ABSTAIN</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 4%">&#160;</td>
    <td style="border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; border-top: Black 1.5pt solid; width: 22%">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>Approval of an Amendment to the Company&#8217;s Second Amended and Restated Certificate of Incorporation to approve a reverse
    stock split of the Company&#8217;s outstanding common stock.</td>
    <td>&#160;</td>
    <td style="text-align: center">&#9744;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#9744;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#9744; &#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="padding-left: 2pt; border-left: Black 1.5pt solid; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><b>Proposal&#160;6</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><span>&#8594;</span></td>
    <td style="text-align: center; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><b>FOR</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="text-align: center; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><b>AGAINST</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="text-align: center; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><b>ABSTAIN</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; border-top: Black 1.5pt solid">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>Approval of an Amendment to the Company&#8217;s Second Amended and Restated Certificate of Incorporation to increase the Company&#8217;s
    authorized number of shares of common stock from one hundred million (100,000,000) shares to one billion (1,000,000,000) shares.</td>
    <td>&#160;</td>
    <td style="text-align: center">&#9744;&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#9744;&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#9744;&#160; &#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="padding-left: 2pt; border-left: Black 1.5pt solid; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><b>Proposal&#160;7</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><span>&#8594;</span></td>
    <td style="text-align: center; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><b>FOR</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="text-align: center; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><b>AGAINST</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="text-align: center; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><b>ABSTAIN</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; border-top: Black 1.5pt solid">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>Ratification of the appointment of M&amp;K CPAs, PLLC, as the company&#8217;s independent auditors for the fiscal year ending
    December 31, 2025.</td>
    <td>&#160;</td>
    <td style="text-align: center">&#9744;&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#9744;&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#9744;&#160; &#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>

<tr>
    <td style="padding-left: 2pt; border-left: Black 1.5pt solid; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><b>Proposal&#160;8</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><span>&#8594;</span></td>
    <td style="text-align: center; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><b>FOR</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="text-align: center; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><b>AGAINST</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="text-align: center; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><b>ABSTAIN</b></td>
    <td style="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; vertical-align: top">&#160;</td>
    <td style="border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; border-top: Black 1.5pt solid">&#160;</td></tr>
  <tr>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">Approval of the adjournment of the Annual Meeting, if necessary.</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#9744;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#9744;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#9744;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 147 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 25%">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="text-align: center; font-size: 10pt; width: 67%"><b>MARK &#8220;X&#8221; HERE IF YOU PLAN TO ATTEND THE<br/>
 MEETING:&#160;&#9744;</b></td></tr>
  <tr>
    <td rowspan="2" style="text-align: justify; font-size: 10pt">This Proxy, when properly executed will be voted as provided above,
    or if no contrary direction is indicated, it will be voted &#8220;For All&#8221; for Proposal One, &#8220;For&#8221; Proposals Two
    through Eight, and for all such other business as may properly come before the meeting in the sole determination of the Proxies.</td>
    <td>&#160;</td>
    <td style="text-align: justify"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">MARK HERE FOR ADDRESS
    CHANGE&#160;&#9744;&#160;New <br/>
Address (if applicable):</p>
    <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">____________________________<br/>
    ____________________________<br/>
    ____________________________</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>IMPORTANT:&#160;</b>Please sign exactly as your name or names
    appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee
    or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer,
    giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: ________________________, 2025</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font-size: 10pt">&#160;</td></tr>
  <tr>
    <td rowspan="5" style="font-size: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center; vertical-align: top; font-size: 10pt">(Print Name of Stockholder and/or Joint Tenant)</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: center; font-size: 10pt">(Signature of Stockholder)</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: center; font-size: 10pt">(Second Signature if held jointly)</td></tr>
  </table><div>
</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>




















































































































































































</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">PRE 14A</ix:nonNumeric>
<ix:nonNumeric contextRef="c9" escape="true" id="hidden-fact-1" name="ecd:Additional402vDisclosureTextBlock" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c4" id="hidden-fact-2" name="ecd:PeoTotalCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-3" name="ecd:PeoActuallyPaidCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-4" name="ecd:PeoTotalCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-5" name="ecd:PeoActuallyPaidCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-6" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-7" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-8" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-9" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-10" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-11" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-12" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-13" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-14" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-15" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-16" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-17" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-18" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-19" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-20" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-21" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-22" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-23" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-24" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-25" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-26" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-27" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-28" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-29" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-30" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-31" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-32" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-33" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-34" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-35" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-36" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-37" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-38" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-39" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-40" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-41" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c78" id="hidden-fact-42" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-14314">0001690080</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-14315">false</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="atnf-20250625.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_3_fact ix_4_fact ix_5_fact ix_6_fact hidden-fact-2 hidden-fact-3 ix_7_fact ix_8_fact ix_9_fact ix_10_fact hidden-fact-4 hidden-fact-5 ix_11_fact ix_12_fact ix_13_fact ix_15_fact ix_16_fact ix_17_fact ix_18_fact ix_20_fact ix_21_fact ix_22_fact ix_23_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_0_fact hidden-fact-3 hidden-fact-5 ix_15_fact ix_16_fact ix_18_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_0_fact hidden-fact-3 hidden-fact-5 ix_15_fact ix_16_fact ix_18_fact" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_1_fact hidden-fact-7 hidden-fact-9 hidden-fact-10" toRefs="ix_5_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_2_fact hidden-fact-30 ix_19_fact" toRefs="ix_8_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_3_fact ix_4_fact hidden-fact-2 ix_7_fact hidden-fact-4 ix_11_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_5_fact ix_8_fact ix_12_fact" toRefs="ix_6_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_6_fact ix_9_fact ix_20_fact" toRefs="ix_7_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_10_fact ix_13_fact ix_17_fact" toRefs="ix_10_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-6 hidden-fact-8 ix_14_fact hidden-fact-11" toRefs="ix_4_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_21_fact ix_22_fact ix_23_fact" toRefs="ix_9_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:typedMember dimension="ecd:RestatementDateAxis">
        <ecd:RestatementDateAxis.domain>2023-11-07</ecd:RestatementDateAxis.domain>
      </xbrldi:typedMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedSummaryCompensationTableTotalForPEOMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedValueOfEquityAwardsAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:EquityAwardAdjustmentsBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:CompensationActuallyPaidToPEOMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedSummaryCompensationTableTotalForPEOMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedValueOfEquityAwardsAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:EquityAwardAdjustmentsBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:CompensationActuallyPaidToPEOMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedSummaryCompensationTableTotalForPEOMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedValueOfEquityAwardsAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:EquityAwardAdjustmentsBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:CompensationActuallyPaidToPEOMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedSummaryCompensationTableTotalForPEOMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedValueOfEquityAwardsAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:EquityAwardAdjustmentsBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:CompensationActuallyPaidToPEOMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:TotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYM+UlHLczcqbucHL1cUHtO5ZA3CBy6Cnl1u0hNGYUJhU9MD+qgJoti/zZADG7OuMan4t3iVetxmlYo9mIYxg8aUc1sICnD6ZN9kGDNSMEWJyH/5VmDEDF+HH3jJpoE/3Xr9sIiQ2lg3f39PBQDOe4cNqZ5yD/bsJckSeUK02fsnO8Ow2XkqZ573IIYH33f5D/M1PPogapnohjWQWbv0965CSAChCFl925fjcRtOLrxKku8iOiwG7KXDCSxkeCt2uLmFQHQjRlllw==] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:TotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:TotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:TotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageEquityAwardAdjustmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageEquityAwardAdjustmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageEquityAwardAdjustmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:TotalAverageEquityAwardAdjustmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:TotalAverageEquityAwardAdjustmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:TotalAverageEquityAwardAdjustmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  X 2$# 2(  A$! Q$!_\0
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M59X6M/'T,SKPS;$2P]6;IRJU9?5XU:_L9PA3F_:*G&=6G&=1V2G)P1Y+XY\
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MI/ 8QN4I.4F_JU;5RDY2;\W)OS+W_!,C_DP?]ES_ +)C8_\ IRU.ONROA/\
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MJZ1KW@GQ-%I7B=] U?3;N2TOM)U#SK3[/,7C6&[AD:T@\ZVN89%3!!/YM_\
M!53]A7]E#P=^S%\1?V@? _@7PU\$_BK\.#H>N^%_$WP]CC\&IK6M3:_IMA#H
MM]I6DM:Z;?7NI_:V%C?06D>L6=_%!=P7BQ1W,<OO.K@L=FRCBL/F&49Y4QD:
M<\3@ZT*]"&8.:I^UEAJL57I*57EE/ZOB*BBI2G34H61X"HXW Y0Y83$9?F^1
M4\'*I3PV,HSH5YY<H2J>RCBJ4G0JM4N:,'B,/"4G&,*C4[M?6G[;/[5VA_\
M!/KX ?#GP9\.- E\8_$K7;/0OA-\"_!>I7ESJ<]P= TJPT6UUG7YC,-3U:VT
MFU338)ML@N]9UF^L;66X@%U/<Q?'&E?LA_\ !7KXB>'Q\3_%?[<\?PR^(>K0
M?VU;?"32K&[3POI$[QI<6FAW]QHODZ'8/G$-_;Q:#KMO:S-)%]KNXXQ(?E+X
MO_$KQ+J?CS_@BY^TS\?KBX?PO=>'-(B\:>(M9MF:RA\16^MZ/G7M7ED0Q"[U
MFQ&D^)YIG ^TQV%W<@"*,LO]3$,T5Q%%<6\L<\$\:30S0NLL4T4JAXY8I$+)
M)'(C*Z.C%74AE)!!K/$SGD>$P7L:&#KXK&SQ]3&XW$X6CC>>IA\?7PKPM%8B
M$Z=.$?9.M5<81K5)5TW*,5$TPL(9[B\;[:OC*&$P4,!3P6"PV*K8)PIXC 4,
M6L56>'G"I4G+VJHTE*4J,(X>45&4G(_+?]@/]JS]HOXAZY\2_P!G?]K?X::O
MX3^.'PBCN)E\>6'AV^LO!/Q$T2VN(K.6^L]3@LX_#S:K:RW5C<12Z7/'9:YI
M=]!>VEG;7-IJ<$?GO_!+3]JKXD_%CX4?M1^/?V@OB#)KVG?"KXL^(K2TUC5(
M;&RB\/\ A#1M%;4[J O;16R-;VZQ32H9MT@7;'O8\M^D?A_]H/X)^-?B-XQ^
M#?A+XD>%O$7Q0\#V%W<^+O!VDWRWFK^'X;:2VM;G^TEB1H8)+:YOK2"> S&:
M&:8121JZNJ_SI_L/>'/$/BW_ ()U?\%1O#OA6VN;W7M3\6_$B*PLK-#)=7WD
M^&6N;JQ@08WR7ME!<VJKD ^;R0,FG2HT,;A\TJ5,#3RUUL1P\E'DDHX>.+Q<
MJ=>OAO;QC.C0KQDZL:<9.FHVC&<Z:BT5JU?!8C*Z=/'5,R5'#\0MRYXN6(EA
M,'&K0H8GV$I0K5Z$HJE*I**J.3<I0C4<D_HOP7\2OV__ /@IYX@\5^-/@/\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $2 D # 2(  A$! Q$!_\0
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M)KFC>UVHU#%4)QE*-2/)&?L^=WC%R]G[6T6TKKDN[VBM':]DY?6-%?FQK_\
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MJOELZCW32=/1-Q#+L/&-/GYJDZ;BU.4GKRWM%1:DHTU>Z@MG=J>K1^+/P_\
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M5_YYW'_@/+_\319]@+%%5_M*_P#/.X_\!Y?_ (FC[2O_ #SN/_ >7_XFBS[
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M_P#/#PQ_X%WG_P A4<K[Q^]?Y!==G]S-SRV_Y]7_ / MO_BZ/+;_ )]7_P#
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M (%WG_R%1OU7_GAX8_\  N\_^0J.5]X_>O\ (+KL_N9N>6W_ #ZO_P"!;?\
MQ='EM_SZO_X%M_\ %UA[]5_YX>&/_ N\_P#D*C?JO_/#PQ_X%WG_ ,A4<K[Q
M^]?Y!==G]S-SRV_Y]7_\"V_^+H\MO^?5_P#P+;_XNL/?JO\ SP\,?^!=Y_\
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M%%%%8&H4444 %46><,P#3XW'&+9",9XP=W(]#WZU>J@T4NYL;L9/_+_,O?\
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M%3_XJCRI?1O_  83_P#QJCRI?1O_  83_P#QJC3R_KYA\Y?<'F3_ -ZX_P#
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M_;VVKZ1=>,K+6#H][:6;Z8MJEI;QQ]'IWA_]AO3/#/C'PC'X]^&]_HGC^_\
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MA'<'7/"'A'QSX/U"STY/%>C?%;XF:AXE^&OPM@\4^"/$.N_#2'[)X=TWPO\
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M$UQH_P 0/"D>F^--/,-WIL]W%:77A;5(K/5--OAIYBU/3XI\S]CGP;\4]/\
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MTW?NE_:=M_T$H_\ P)TG_P"/TTG;:7W2_P A-J[UC]Z_S)MT7_/.Q_[\2?\
MQNC=%_SSL?\ OQ)_\;J'^T[;_H)1_P#@3I/_ ,?KB?B+\7OAA\(/#ESXO^+'
MQ.\&?#3PI:0S3W/B/QWXI\+>%]&BBMT+S-]OUB_M8)"BCF.)I)"2%5"2 7KV
M?W2_4-.\7Z6?Y'>;HO\ GG8_]^)/_C=&Z+_GG8_]^)/_ (W7X3_$;_@X._9
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MS_%[^W93JH^';QC]H=M&;XNEO")T][K_ (1U!$_@L'ZI_9<O_CSI?AKX[_\
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M,4>0?^?8?^!<O_Q-'D'_ )]A_P"!<O\ \31KY?A_D%U_7,&YO[]__P!^8_\
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M^L=6T?4%&O6?A[POHLT,8$FEKJ\FI&YMM1L988$^N_F_ZB'_ )"H^;_J(?\
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MMKWQ'XO\2ZQXN\02V-NT1>WTY=7UR\BTZ&0F5+*. 2DR;J].WZO_ ,\_#/\
MWQ??_&JW/F_ZB'_D*CYO^HA_Y"K&51SE*<K.4FY-V2NV[O3GT\ET22Z&B@HI
M15[))+5O1;:N#;^9A[]7_P">?AG_ +XOO_C5&_5_^>?AG_OB^_\ C5;GS?\
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MJW/F_P"HA_Y"H^;_ *B'_D*CF\E]R_\ DPMYO^O^W##WZO\ \\_#/_?%]_\
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M_P */Z_K4/Z_K0FP?5/_  977_Q%&#ZI_P"#*Z_^(J'$7_/2+_P /^%&(O\
MGI%_X '_  H_K^M0_K^M#\MO^"A<GE^+?A@"5Y\-^)2,3O/TU32OXI-I'7L.
M>A^Z*_/3[0/;]/\ XJOOK_@HK(L?B[X6!64@^&?$Q^6(P]-6TKDKCGJ0/0@D
M?>-?G3]H'J?S/^%2]REL;GV@>WZ?_%5]X_\ !/R02?$_QP!MX\!1GF9X/^9B
MTW^./<Q^G _.OSR^T#U/YG_"OOK_ ()Y2+)\4?'89PH'P_C/S1&<9_X2/3/X
M,9'U_P *%N#V/U\P?5/_  977_Q%&#ZI_P"#*Z_^(J'$7_/2+_P /^%&(O\
MGI%_X '_  JOZ_K4G^OZT)L'U3_P977_ ,11@^J?^#*Z_P#B*AQ%_P ](O\
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MO_ O1_\ X]4GV>V_YYZ=_P!_G_PH^SVW_//3O^_S_P"%/W/[WWP_R)]_R_\
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M54"6>E:2EK:1%E1?,E$9FF8>9-))(6<]G_:UE_T%(O\ P+T?_P"/5)]GMO\
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M[;_GGIW_ '^?_"C[/;?\\]._[_/_ (4>Y_>^^'^0>_Y?^3$?]K67_04B_P#
MO1__ (]1_:UE_P!!2+_P+T?_ ./5)]GMO^>>G?\ ?Y_\*/L]M_SST[_O\_\
MA1[G][[X?Y![_E_Y,1_VM9?]!2+_ ,"]'_\ CU']K67_ $%(O_ O1_\ X]4G
MV>V_YYZ=_P!_G_PH^SVW_//3O^_S_P"%'N?WOOA_D'O^7_DQ'_:UE_T%(O\
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M\_\ A1[G][[X?Y![_E_Y,1_VM9?]!2+_ ,"]'_\ CU']K67_ $%(O_ O1_\
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M+1+^R@^!%]J7C#4M4^#5O>0:;J^EZ]##-XITB_TOQ?XILM(T+P[;ZI-$W?\
M@K]D34_A[X?^*WAK3O$'@_4=)^/%[IWAGQ]H_A/P!8_"/PEX>^'4?A'Q!X5U
M74O"?@[P[JVKZ)#\4-8BU>*[U_Q6D%IIGB"[M;!9/#6FVFGV\4?;4IX"TE3K
M3YO:6BVY-.E[5)OWJ4/?]ES-7?+S0CI>JE3YH3Q=XN=.-N3WK**?/[/;2I+W
M?:63TYK2:O:FW/N+']MS]G6^MO"MPOBO7+0^*]<ET&*TU+P-XTTV_P##DR7/
MAFUMM3\<V5[H4-SX'\/ZG-XW\#KI'B#Q1'IFDZFOC+PU)9W<L>IQ,/2OAO\
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MY86.E>B?\%(/C)X?^"G[,_B#Q#XN\7? [PKX3US4K;PIXB@^/&@_$'Q/X?\
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M;@U'FC:-U*-^6%;$MKGP[C'DNW=_%[-NUN9N*]I:*4DW9W=FG;["T_\ :(^
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M$9N(@YM"P0707?N-N794\_'E;B%W9(%?D9\4/V8_BWJ'Q5^,.N^#_A/>>(_
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M[+_P4M_\L:/LNL?]!.R_\%+?_+&BT>\?Q_R#7^5_A_\ )#O]'_YYV7_@9_\
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M -JH_P!'_P">=E_X&?\ VJF_9=8_Z"=E_P""EO\ Y8T?9=8_Z"=E_P""EO\
MY8T6CWC^/^0:_P K_#_Y(=_H_P#SSLO_  ,_^U4?Z/\ \\[+_P #/_M5-^RZ
MQ_T$[+_P4M_\L:/LNL?]!.R_\%+?_+&BT>\?Q_R#7^5_A_\ )#O]'_YYV7_@
M9_\ :J/]'_YYV7_@9_\ :J;]EUC_ *"=E_X*6_\ EC1]EUC_ *"=E_X*6_\
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M7Q2_Q2_]*D);+T7Y(****D84444 %%%% !1110 4444 %%%% !1110 4444
M%-WI_>7_ +Z'^-8/BW3KS6/"OB;2=.,:ZAJGA_6M.L&FD:&$7E[IMS;6IEF1
M)'BC$\J&218W9%RRHQ 4_P U5M_P2U_;OBM[>.36/A3OCAB1]OQ0\5%=Z(JM
M@GP@"1D'!(!(YP* /Z<]RGHR_F/\:X__ (6%X'_X3U_A=_PE.B_\+$C\)KXZ
MD\'?;HO[>3P>VJ_V&OB)K#/FKI9U?&G_ &D@+]I(3'S G\!/A%_P3:_;3\'_
M !9^%WB[Q)JWPS?P[X5^(G@OQ'KZV7Q&\2WEXVBZ)XBT_4M4%I9S>%8(;NZ-
ME;3""VEG@CGE*QO-&K%Q]Z^,_P!D'XO^/?B=XM^+?B3Q987+^,OB5XF\':O\
M,[:ZT.#03^S'XF\#2?":XCM?%1\&MXNA\;P:2T7Q,BT!]9D\*1^+83;Q1+>E
M=5&]"G2J.:JU522A[CM=RJ-VBK6^%)2<FW%*\%S+FNLJLZD%'V=-U&Y>\KVM
M!+5WOO=Q25G]IV=M?TU:2-,EY$0 HI+,JX:1@J*<D8+L0J#JS$ 9)ICS6Z[F
M>6%?*958NZ#RVDPJJQ)&QGR H."V0!G-?CSXI_8C_:'\4_!GP';>+]9\,^*O
MBE>^/_'/BWXVZ+I6OZ;%H?BJXU?X<CX4?#_5M)UWX@^ _&U@EYX'T'0_#>L1
M3W/A1=8TC5+[7=5\'ZAIOB"VL+V?*U/]@[XW:9^S+I?PDTC1_A;XJ\;ZO\5O
MC)XH^('BGQ+J>FZ_K6M6?BNP\<6'P[\47'B#QO\ #_Q!I6N:UH[:[I!URXU7
MP<=>TK35O!X$OM U:.WNDZEA,-[M\?2NZOLW:-HJ*<E*KS2:O#W;QT7.IPM:
M\E'!XBOK_LL[*GSJ[U;:34+):2]ZSU=G&2[-_L_O3?Y>]?,VAMFX;]I) ;;G
M=M)5@#C!*D \&J&HZOI.D:5?ZYJVIZ?IFBZ597>I:GJ^H7EO9Z9IVG6$4EQ?
M7U]?W$D=K:6=G!%+-=7,\L<-O%'))*Z*C$?A?+^S%\=M9^,-GX#M?#.KV?C:
M/P1XT74_VJ9%\<6UGX5@US]DG1/A'HWPVMO$VK>'M.B\5:1HOQ)CN?$.FW_A
M[7M<D+ZG?ZDVBZ9JD6LO+]8_#K]CWQ[;_LI_&[X+:Q<Z?X,UWXH:FFK:!H\N
MK^']>\(Z!>Z9H_A*!+9M+\"> /AUX>T3P]XIUSPO+<>(-*T#0[NXN;+5[[5[
M^ZOO$&HZC"54PF'IJ#EC(/FE1O&,4VJ=2;C*HN6<M(Q3FE)*5E[\(IP<G#$5
M9N26'DK*I9MM+GA%.,'>*U;?*W%N-_AD[2Y?N+X;?&;X7_%_3=4U?X;^,](\
M4V.B7L.GZPUH;FTN=,N;FUAOK,7UAJ5O97]M#J%E<0WFFW<ULEIJ5JXGL)[B
M(,X]*:6)"0\D:$*7(9U4A 54L02#M#,JEN@+*,Y(S^=7Q7^$WQ_^-VG6?B/Q
ME\%O@K;PZ)X]\$:QJWP5E\:S:E+\8?#7A_PSXWTF]TOXA?$O_A$H])N]'T7Q
M)XOTOQ1X&\-WGA"\MK*X\-7=[?74>H:M9V^F_,K?\$X/BAJLNBS>.E^'7C[5
MK%O VF:IXAUO6];O;O5/#GAW]DKQ7\*K[1V.I:3<74NDI\6;WPKJ\&G7<SQ:
ME;:#8^+-13^V].M+5".%PLM98N%+?W+PK2326G/!PC+J^914;-).4HSL.O76
MD</*IHGS6G33NW]EJ4H]-&V]&W9.-_VQWH7,8=3(%#E-PWA"2H8KG<%+ @-C
M!((SD&F":$JCB:(I*P6-Q(A61F.%5&SAV)! "DDG@"OPK\#_ +&7[2'BB?XQ
MV#:79_"[Q<M[\2?#H^.NH>)M9?Q+\1K;Q'^SA\-_A[IGANPA72SJ5U\/K/Q]
M8ZKXJC\07-W+I[7UI<7NG:#_ &_/J4IZV;_@GO\ %'6O"LEK>:/X2M)8/ G[
M1Q\&>&-;\6:-=V'PX^)OQ!3X2#X>:YX4M/ GPU\#^#?"JV6J>!_$'B#[3X8\
M/)/X;O\ 4S?6<]WJ.L:KY=/!86+M+'T]'%:13TE%2YM)M6]Y:7<DE)349\L2
M5B:[5UA)_:WDUM)JVL;WT?2S;CRMQYF?M.9H5\W=-$/( ,V9$'D@KN!ER?W8
M*_,"^ 5Y''-<9=?$KP)9^([WPC-XGTP^*--C\*3:AH%N\EWJMC;^.=0U#2O"
M5U=6=I%--!9ZYJ&E:E;6=Y*JVV^RG::6*-"]?F'XF_9%^.4FK?'*\\.>!OA;
M<V'Q \7>$]6N8O%>M^'O%6M^,;./XDCQ;XDN[/5M:^'#6<D<.E1K-I/A;XWZ
M5\6='T+6;E]&\,S6/A&PM+"7RJU_X)Z_M$1?#*\\(V%[X \+_$+7/AI\"O"<
MOQ6TCQ+=QZMX;U'X5_%3XEZ]?PV\VG>%=,U.\TU?"OBWPU/H46GOI=C:R>'8
M] ATW3[2TTR2$AA,(U>>.IJ_*E;E]WFC3E*4TFWRP<I)QC>4N5<OO<T4Y8BO
M>T<+-V4GK?6TI)1BVDN:246F[15W?2S?[AB2W \X20@2%8C*&0!V1V18_,S\
MQ61G14R2'9E #$BN6\>>/_!7PO\ "FJ^.?B'XGT?P=X/T,6AU?Q%KUY'8:5I
MXO[ZVTRS-U=2D)']IU"\M;2+/WIIXU'6OR G_P""?GQ3\4:7);:OX)^%7A;P
MX-&^+RZ#\++/Q9J&M>&O"/C'7?V;?#'PK\,^,]/F7PU8V)UCQ'\3=!G^(&H7
MUKIMO?>&[B2S\1)/J/BV2^N!]M?&?X!_$[XS>$O@)\+K_P 61>'?!^@0+K'Q
MH\264FC:_P"(]9UO0/ TFA^'M$TO2O&'ACQ%X?UW3-4\3ZM>Z]K6H:W8)/;G
M0M-N+.(:A.DUKG+#8:$Z2>+C.#E+VKBE>$(Q<O=:<U*<K<B23BYRCRN4;M4J
MU:49OZNXR45[--NTI.2CJFHN,5?F;;NHIWL['UIXE\6>&O!WAW6/%OBG7--T
M+PSH&D7NOZSK>HW4<&GZ=HNFVYNK_4[F=CM2SM;<>=-,,HB8)/(SKVEY:WUK
M;7MG<17-I>00W-K<0N'BN+>XB6>&:)P<.DL+I(C#AD8,.#7XW^(_V)OCWXR\
M%>,/!OQ$\'_"3XI>(=>^#6E_"_PI\2_%GC758KOX?I\/O"'C7P+ID^F:5'X1
MNIYG^*<=]X<\8^)M-MYK+0+?6]0UG^W+?59M#T22?K-7_98_:0'BK5'\)>%O
MAEI7A^ZU3QG\2=';5O'VL-IND^(?%7[(NC? ;3OAE<^&="\-Z?)+H>A^+M(E
MU"[U[3M6LK.ZT2[@FLM*ANDN;4W]4PUK+&TN=-ZMPY'&RMRZ\Z=WKS)-V=HV
M5W/UBM?_ ':?+9:)2YD];WTY6K+[+:U5W=V7Z4>+OBY\,O 6L^"O#WC+QQX=
M\.:W\1M4DT3P+INJ:A%;W/BG5HKBPM)=/T=3D7=S'<ZGI\#QJP*R7<*G&[CL
M]8UC2_#^DZKKVM7]MIFC:)IM[K&KZE=R"*TT[2].MI;R^O[J4\16UK:P33S2
M'A(XW8\ U^'^A?\ !/?X\3ZW\)[SQ3IGP\M?!?A+]H+5/B3XC\)6FLZ1$EA\
M/-:\*?"/0]9T30_#W@/X<^$?!D>K7<_@GQ)<7&F^'M T:ROY[ZTOKFZO=7O=
M1OI/L7]GKX+^/V_99^+>C^(XK^'Q[\4_#GCCP5X2C\:6VK:'K%G\/O#GA?4/
MA?\ !:S\6Z?J<4NHZ)?W7AG3K+Q/KUK/:->V-_XEU&.Y@>XB:(%;"X6G"$H8
MN-1\\854E&RYZJBG%IZ<E)3G.ZDM$T[2Y0IUZ\Y24L.X>[*4+WUY:;=GWYIN
M,8V<7JTU=7/JSX9?'_X.?&0:G_PK7Q[H_B=]'L=*U74(88]0TZXATG7!.='U
MB.VUBSTZXNM&U,VUPECJ]I'/IMS)!+%%=-(C(.[N_&7AC3T\4R7^L6UC!X)L
MX[_Q3<WBS6MIH]E+IS:LMU<7<\4=M)"-.1[F1[:680JI279+\E?G#XS_ &)_
M%FF?!;P3H_@Y8?B;\4)+7X2>&_B/=_&+Q=:^-[>W\$^!=(U2>;P[X#3Q_P"$
M_%G@B+3].\;7\.MVEAXD\"ZK8W5H;Z\2VAUZWT.YL/"E_8/_ &B(?A[HNC>)
M--^'?Q/ETKPKX+\-ZGX \1>/-77PSXCU/3/V:=9^#">*+C5+[PQ>)%<> _&%
M[:^*/#R/I+7<U@US>:=-I.O66G M87!3;E'&*$.=P49\OM&HM)RULE&6O(YJ
M*LU)V2LTZ^)C9/#N4N3F<H7Y+M-J.EW=:<RBV[Z+5W/V!LOB5X!U&_\ !>EV
M/BW1+K4?B-X;O/%_@6RBO8VN?%7AC3[;2;R]US1HN&N].MK77='GFG0;4CU&
MV8\/Q9\<>/\ P5\-?!^M_$#Q[XGT?PGX)\-V@O\ 7_%&M7D=GHVD61N(K7[5
M?7KGRH(!<3Q1-*Y"*[@,0,D? _Q(_9(^(_BC1/@+:Z _A#3/&'@/]D?XN?L^
MZIX_&H7$&L^"O%OC7X:>#] T'Q)X;OETF76=0T>/6_#FJZ9>/:7FD:O96&O-
MJMJ)I1<VCT+']D_XC7_[+G[0OPF;PA\// C?%_Q?HNK>$/@[IOB.YUOX?^"/
M#UC:?#K3/$6CRZNGA[3[5H_%]WX4\1^*=0L=+\/PV'VKQ&8)O-O;C4;MLUA\
M*^27UE).I"$X^YS*#KU(2G%]+4HPJ+FBUJW*R<$[]K7]Y>Q=U"4HOWN7F5*$
MHQ?>]1R@[-/16NU)GZ&:7XX\'ZWKFO\ AO2?$FD:CKOA:Q\.ZEXATVTO(IKC
M2=/\6P7MSX9O+P(Q1+;7+?3KZ;3I0[)<QVTK(2 ">HWIO\O>OF%2XCW#>4!"
ME]N=VT%E!;& 2 3DBOR#UC]B#XQZ5XB^(/E6'@#XM?"K3_'GPFD^'?PM\4^)
MM0T1?&_P?\#_  Z^)WAO2O ?Q!O[K0=<L([SX7^)OB'IMSX2N+BVUBTUS0O
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M=P3:YI7;Y4U)M[]&HK6^C[M)?:]%%%<)U!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!DZ!_R M%_[!.G?^D<-:U%%5+XI?XI
M?^E2$MEZ+\D%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
0* "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $> D # 2(  A$! Q$!_\0
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MM)+JV@LEJ]EJ]7_F9L?A728D6.,7B(@PJB^NL*/09D)_,T__ (1C3/6]_P#
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MX:DM8_$-OX,\4:5KE[HAOD>2P?5;&SN'O+""_2.1[&XN8([>]6.1K664(Q'
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MX:<:LFKR3DE3G&;<5)*+3;/J/_A&-,];W_P.N?\ XY1_PC&F>M[_ .!US_\
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M+'PE\0?#&N3^$[*Q=X[W4=<6PU*86.EV;QNEUJDI&GV[ ++<H67.?X&_:_\
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MKQE",E=:JZ5UJKK4J+A-*4'&47M*,E*+Z:.,FGKIH]SGO^$8TSUO?_ ZY_\
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MG=+GA=NR7-&[;M9+75ZK:^Z[H]EHHHK,L**** "BBB@ HHHH **** "BBB@
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M9^/FO02?M%^'=:^,%]\1I='\877]A^(M3LM8L5T33;2]BT*QCL+N1='L#/\
M0_@'X"_&GX4_&_XJ_#KQ5_P3R\.?M,Q_%+]NR]_:?\)_M2^+_%'PYT_PGX5\
M >)+[2]0TW4O$E[JZZI\1-/^(OP@M;2ZL= \*V6@7^EZA/N33KRWCEBFO_Z!
MZ*TGG->HI^THX>3G[17@JM!I2JRK02>'JTVU2J3FTG*U12Y:J:2(CEM*'+R5
M*J4>327LZJ;C35*3M6IS2=2$8IM+W&KT[-L_F'\4_LL?M4^&_#7QN\/>&OV3
M?$NO:I\*_P#@JWI/[;WA/6-#U?X9Z5:?'3X,7_C36+^W\(_#J9]>MKVV\1>%
MM-GAU*;1?$]OHVEV8U*2VTUI+N"Y@7>@^%?[=<NK_M3?&"T_9:\2>!)_C-^W
MC\ /BW?:#-I/P-^*_P 9/!GP6\/?"UO#NI>/?@E:>,]4UGX:I\9O#&HVND1/
MJ5Q.;WPO<:AJR^'GOS9M?C^EJBJ_MFJU:6&P\F[7<G7;:O1G*-O:<OOU*$*E
M[/E=XQ3A[DE_9M-/2M62ULDJ22=JD8N_)?W8590W7,M6U+WH_P S7PF_9+_:
MCT[PS\)-/UWX)_%*SU'0/^"U]G^T[KMSXVUCP'K'B4_!#6_#MC*WQ.\3ZQX9
MUI=!U*\@GA>+Q:FB0)-#KDL\5AI4ML%D'C_Q7\"?&7]CG]ECP=\?AI-C\/\
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M (,-1_\ DNK/F+_S]_\ CD?_ ,31YB_\_?\ XY'_ /$T7EY_=_P Y8^7W_\
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MI]KK^K:MI$OHWAK]G;X@>#/$7P_U2W\'ZK?VFA3?"/Q6OC?4V\ Z+JWPWM_
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MN?\ D'S_ "/R%_X=.>)O^DJW_!7;_P 2;\!?_.1H_P"'3GB;_I*M_P %=O\
MQ)OP%_\ .1K]>O,7_G[_ /'(_P#XFCS%_P"?O_QR/_XFBS[/[G_D'S_(_(7_
M (=.>)O^DJW_  5V_P#$F_ 7_P Y&C_ATYXF_P"DJW_!7;_Q)OP%_P#.1K]>
MO,7_ )^__'(__B:/,7_G[_\ '(__ (FBS[/[G_D'S_(_(7_ATWXE[_\ !5;_
M (*[_A^TWX"!_ _\*0.#^!K@_P!A_P"/WQ"_9W_:E^(?_!,/]L?XI^.?'OQ-
MCMK_ .+?[(/QN^)7B"^O-9_:6^"%[*YU*R.OE[2WOOB5\/+V&>P\8^%UCBDL
MYX+W4O#\ \*7>B6ME^VWF+_S]_\ CD?_ ,37Y8?\%9_V"]4_;>_9_P!)U;X/
MZ_'X(_;$_9K\31?&W]D/XH021V%]X>^*'AY$NI/"%[J*B-T\*?$FTLXO#>OP
M22I:I<?V1JESOCTMH9:B[-W3::L[+5=;Q;6C7;:2O%Z-.,R5UNKK;71^32>S
M^].S75/]1OLD'_45_P#!AJ/_ ,EUX5'^T7\#)/&'Q#\#?\)M?QZ[\+-'FUOQ
MJTMMXQ31M/M;.2*'5K:Q\0FU_L/7M7T.XNK"TUO1-"O]2U?3;[4;*PN+);V5
MK=/E[_@EQ^W!X>_;Q_9CTSXJ3V^J^"/C7X-UF^^$_P"TW\'->O[N?6?A%\=_
M!)_L_P 9^&YM+U-Y+W3=*U*\5]=\-R/O6?1;ZWLY+B6_TS4(X(_B!^R#\1;[
MXL?&+XM>%O%WA.+3_%R^"O$%K\/?#>GZMX5?XFZ]X'\;>'O&EAI_Q/6[UVZ\
M#W6K6,/AUM"T#QS8Z)IFOZ@-7">([Z'3;*^AUGHP\*$Y5%6JR@E!.G+6*<^>
M"::<)_8<K7<4G[TGRQ:,:KJ14'3IJ3<FIQO=J/+*S34X_:2OHVU[J7,TSZJN
M/VA/@E:RZ];3>+];%]X?OK/3)]+CT;XA3:MJ^HW_ (DN/!MO9^#]*ATJ2_\
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MOO\ _MBM]D@_ZBO_ (,-1_\ DNC[)!_U%?\ P8:C_P#)=6?,7_G[_P#'(_\
MXFCS%_Y^_P#QR/\ ^)HO+S^[_@!RQ\OO_P#MBM]D@_ZBO_@PU'_Y+H^R0?\
M45_\&&H__)=6?,7_ )^__'(__B:/,7_G[_\ '(__ (FB\O/[O^ '+'R^_P#^
MV*WV2#_J*_\ @PU'_P"2Z/LD'_45_P#!AJ/_ ,EU9\Q?^?O_ ,<C_P#B:/,7
M_G[_ /'(_P#XFB\O/[O^ '+'R^__ .V*WV2#_J*_^##4?_DNC[)!_P!17_P8
M:C_\EU9\Q?\ G[_\<C_^)H\Q?^?O_P <C_\ B:+R\_N_X <L?+[_ /[8K?9(
M/^HK_P"##4?_ )+H^R0?]17_ ,&&H_\ R75GS%_Y^_\ QR/_ .)H\Q?^?O\
M\<C_ /B:+R\_N_X <L?+[_\ [8K?9(/^HK_X,-1_^2Z/LD'_ %%?_!AJ/_R7
M5GS%_P"?O_QR/_XFCS%_Y^__ !R/_P")HO+S^[_@!RQ\OO\ _MBM]D@_ZBO_
M (,-1_\ DNC[)!_U%?\ P8:C_P#)=6?,7_G[_P#'(_\ XFCS%_Y^_P#QR/\
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M\48GU9-*^)MGHQT*.V\(_:=.T3Q!H=CKNO:?)XCO+*/18--^D/AIX#TOX7^
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M .@?:_E%_P#&:XU;K?Y6_4Z'?I;YW_0;]MB_Y_\ 3_\ OM?_ )(H^VQ?\_\
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M?RB_^-4?9X_^?"U_*+_XU1[O][_R7_(-?+\1OVV+_G_T_P#[[7_Y(H^VQ?\
M/_I__?:__)%.^SQ_\^%K^47_ ,:H^SQ_\^%K^47_ ,:H]W^]_P"2_P"0:^7X
MC?ML7_/_ *?_ -]K_P#)%'VV+_G_ -/_ .^U_P#DBG?9X_\ GPM?RB_^-4?9
MX_\ GPM?RB_^-4>[_>_\E_R#7R_$;]MB_P"?_3_^^U_^2*/ML7_/_I__ 'VO
M_P D4[[/'_SX6OY1?_&J/L\?_/A:_E%_\:H]W^]_Y+_D&OE^(W[;%_S_ .G_
M /?:_P#R11]MB_Y_]/\ ^^U_^2*=]GC_ .?"U_*+_P"-4?9X_P#GPM?RB_\
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M^"MWJDR".[\=_!:=K\1V*JT\V@6VI/&T>F66A1W"]WSM\KAKY?B?T1?;8O\
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MI?:]NM^G*%%%%8F@5^$?_!8J7XU?VI\/HO OQ#^%4'@6#P%XBN_$/PC\:?\
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MO@?HRR7$L3?V[XH.U('D7G6;@CYA;R G&"<,<$D'&,#Z?_M*S_Y_+C_P%?\
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M'_?P?_)%&U/^?:X_[^#_ .2*J_VE9_\ /Y<?^ K_ /R'1_:5G_S^7'_@*_\
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M'_?P?_)%&U/^?:X_[^#_ .2*J_VE9_\ /Y<?^ K_ /R'1_:5G_S^7'_@*_\
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M '\'_P D55_M*S_Y_+C_ ,!7_P#D.C^TK/\ Y_+C_P !7_\ D.G:79_=_P
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M=??_ ,$M;4_Y]KC_ +^#_P"2*-J?\^UQ_P!_!_\ )%5?[2L_^?RX_P# 5_\
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M'_(NV/0E5/Z"OFGS/;]?_K4AEG>/0_I_C1O'H?T_QJMYGM^O_P!:CS/;]?\
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MY!^2?_':E_>_\\H?^_K?_&*/WO\ SRA_[^M_\8HOZ?<%O7[R+S/^GR#\D_\
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M]^,CIZU\R[SZ#]?\:DI%C>?0?K_C1O/H/U_QJOO/H/U_QHWGT'Z_XT ?L/\
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MQ_\ DJKGR_\ /6[_ ._4G_QBCY?^>MW_ -^I/_C%%U_*OOE_F'+_ 'G]T?\
M(I[YO^@-/_X$6/\ \E4;YO\ H#3_ /@18_\ R55SY?\ GK=_]^I/_C%'R_\
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M_/6[_P"_4G_QBCY?^>MW_P!^I/\ XQ1=?RK[Y?YAR_WG]T?\BGOF_P"@-/\
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M.Z_E7WR_S#E_O/[H_P"13WS?] :?_P "+'_Y*HWS?] :?_P(L?\ Y*JY\O\
MSUN_^_4G_P 8H^7_ )ZW?_?J3_XQ1=?RK[Y?YAR_WG]T?\BGOF_Z T__ ($6
M/_R51OF_Z T__@18_P#R55SY?^>MW_WZD_\ C%'R_P#/6[_[]2?_ !BBZ_E7
MWR_S#E_O/[H_Y%/?-_T!I_\ P(L?_DJC?-_T!I__  (L?_DJKGR_\];O_OU)
M_P#&*/E_YZW?_?J3_P",477\J^^7^8<O]Y_='_(I[YO^@-/_ .!%C_\ )5&^
M;_H#3_\ @18__)57/E_YZW?_ 'ZD_P#C%'R_\];O_OU)_P#&*+K^5??+_,.7
M^\_NC_D4]\W_ $!I_P#P(L?_ )*HWS?] :?_ ,"+'_Y*JY\O_/6[_P"_4G_Q
MBCY?^>MW_P!^I/\ XQ1=?RK[Y?YAR_WG]T?\BGOF_P"@-/\ ^!%C_P#)5&^;
M_H#3_P#@18__ "55SY?^>MW_ -^I/_C%'R_\];O_ +]2?_&*+K^5??+_ ##E
M_O/[H_Y%/?-_T!I__ BQ_P#DJC?-_P! :?\ \"+'_P"2JN?+_P ];O\ []2?
M_&*/E_YZW?\ WZD_^,477\J^^7^8<O\ >?W1_P BGOF_Z T__@18_P#R51OF
M_P"@-/\ ^!%C_P#)57/E_P">MW_WZD_^,4?+_P ];O\ []2?_&*+K^5??+_,
M.7^\_NC_ )%/?-_T!I__  (L?_DJC?-_T!I__ BQ_P#DJKGR_P#/6[_[]2?_
M !BCY?\ GK=_]^I/_C%%U_*OOE_F'+_>?W1_R*>^;_H#3_\ @18__)5:%N6,
M0+6[6QR?W3O&[#_:W1/(GS=0 V1W J/Y?^>MW_WZD_\ C%6(\;>&=N3S(I5O
MR*H<>G%)M/HEZ-_JV-*W5OY+]$?&'[2'QN\6?#_Q9\,]-TBXU/PQHS^/]+M-
M:LX=+\-:MXP^*\$[Z*+;0/ACX?U36[>X\4Z/;/J5U!\0;71C8?$#2+<V&O>%
M]-UG2-*\0K7D7A/]K[QMK?PCU;5?$-YX;\*?$*]\7>#HWU V!UOPCX#\$^(]
M7^'MAX^U=8-^C7VJ2_ Y/&\>E^/D\0/IZ:%XE$46LW<EBDZI^DT]E9W4MG<7
M-I;7$^G7#W>GS3P12RV%U):7-A)<V<DB,]K<26-[>63S0,DC6EW<VS,89Y4=
MG]G:>=0&K&QL_P"U19MIPU/[-!_: T]IUN6L1>;/M(LVN56X:V$GD&=5E*>8
M PZHUZ"IPA+#*4HN[GS).34G*S3B[Q=_>YFWHHI*"M+"5*JYRDJS2EHHV=DK
M)75I*S5M+6W;?O.Z_(C2_P!L_P#: U&70HM<F\'^"[;6?$<OACQGJM]X!UEX
M?@_X)M8_"DGA7X_:Y%?>(+=9O#'Q>?6[J'P]I6K26&G:2UU8+%JNI2:#X@^T
M=7X[_;1^,6G:/H&I>%-)\,W/B^R^&_PWU/Q/\+O^$6\0:EJNI>,?%NE^*K_X
MH26US'J-O?Z5:_ G2M+\,>+/$6@):7][_9_B$:+K>H6&HZAI,T?ZL54L["PT
MY)H]/LK2QCN+N[O[B.SMH;5)[^_N)+N_O9D@1%EN[VZEEN;NY<--<W$DDTSO
M([,='BL,VG]2IJU_=4O=E>VDFUS62T5G?6]U+5S["M9KZS-WM[UM5:^JUM=M
MW?32UG'1?F]\'_VGOC%XO^,.C^!]4O/"WB'PW_PFEUX5TB_TKPC?Z5/\6/AP
M=$^(&J/^T!X=U ZU>V.F>&]#UWPMH?@Z[M+.+4]$O[[49YXM3@EUSPW;I^E$
MOFF*40&,3>6_DF4,T0EVGRS($*L8P^"X4ABN0"#@U)17-6J0JRC*%*-%**3C
M'52:>LGHE=]4EU:7NJ"CM3A*":E4E4;=TWT5MEJW9?HF]7)O^8[PWX>67_@H
M5#XU^,GPUL+;QI8_MG?#CP+K7C_X/_%SPGJ?@K2?BQ=?#*'Q-;V>E_"KXI:)
MX>^-7@[PY\0[8^![SQKXGTC5?%ECKMSX6G\)>')?^$>O[L1_TXU^$MYX<\2/
M_P %2=3\8_$33O$+ZWIWQ*\+:/\ "W7].^#O[,OQ=\-6GPFU'P1I%O;Z/K^O
MZ!J%O^T1\"=;D\0W&O\ V/QUXHCOM.NM+U2T%O!:VDLT$_[M5Z&:SY_J3NM,
M'3TC)NG&_(^6G=RM&.SL[7NN5<G-4Y,!#D6)6NN(GJTE)VYE>5DKM[[;:W?-
M:)7\UO\ P4X\&? >7X\^*_$&D>*?#\/BOQSX!\7_  ^\>67BSXC_ +8O@I?A
MW\4H]/\ !;>'?C5H=K\(?#GBOPSXL_X0_P (WNF6DG@6TAT*PU2XN1/%<W=]
M<ZT]K_2E7X1?M[^'-4_:_P#VE].^ ?P*_:/\3^ _BC\._!'B7P_)X#U+4OCU
M\,_A/KOC>>U\+>,-:@3XG?# V^B>)?&OA[X;^*M-\3ZOX+G^VZGIUE:>'&B>
MVT_6/$36RR>7)BW-SE3IQI3=6HE)PA!.#O548R?)S*-GHHM-N\7*+,QCS8=1
M45.;J15.#MS2D^96AS2BN;E;NM6T[*S46OVU\#P):^"O!]M'?C58[?POX?@C
MU18+BU74DATFTC6_%K=LUW;"\51<""Z9KB$2>7,QD5C745A^&-,N=$\-^'M&
MO;J.]O-(T/2=,N[R&.6**[N;"PM[2>ZBBGFN)HX[B6)Y4CFN)Y45PLDTK@NW
MY\?$GPU\6[OXK_M#7/A/PW\7]5AUGP7HFEZ?XLAU+6_#S:!?POX>G\(>'_AQ
M'H?QD\%:/XT\'I=3>,?$>N7%BG@;QIX,UJ\U2R\0:IXUT/Q'::):<-.DJU2H
MO:1@E>2E*R4KU%'K*"6D^:V[2LDGMU3FZ<8/DE*]DTMU:#?:5]8\O;6[??\
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M\--_[_7'_P C48U+_GAIO_?ZX_\ D:BWFOO_ . *_E+^OF6-P_Y_%_\ (/\
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M@_X4;A_S^+_Y!_PJOC4O^>&F_P#?ZX_^1J,:E_SPTW_O]<?_ "-1;S7W_P#
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M0?\ "C</^?Q?_(/^%5\:E_SPTW_O]<?_ "-1C4O^>&F_]_KC_P"1J+>:^_\
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M!_PHW#_G\7_R#_A5?&I?\\--_P"_UQ_\C48U+_GAIO\ W^N/_D:BWFOO_P"
M%_*7]?,L;A_S^+_Y!_PHW#_G\7_R#_A5?&I?\\--_P"_UQ_\C48U+_GAIO\
MW^N/_D:BWFOO_P" %_*7]?,L;A_S^+_Y!_PHW#_G\7_R#_A5?&I?\\--_P"_
MUQ_\C48U+_GAIO\ W^N/_D:BWFOO_P" %_*7]?,L;A_S^+_Y!_PHW#_G\7_R
M#_A5?&I?\\--_P"_UQ_\C48U+_GAIO\ W^N/_D:BWFOO_P" %_*7]?,L;A_S
M^+_Y!_PHW#_G\7_R#_A5?&I?\\--_P"_UQ_\C48U+_GAIO\ W^N/_D:BWFOO
M_P" %_*7]?,L;A_S^+_Y!_PHW#_G\7_R#_A5?&I?\\--_P"_UQ_\C48U+_GA
MIO\ W^N/_D:BWFOO_P" %_*7]?,L;A_S^+_Y!_PHW#_G\7_R#_A5?&I?\\--
M_P"_UQ_\C48U+_GAIO\ W^N/_D:BWFOO_P" %_*7]?,L;A_S^+_Y!_PHW#_G
M\7_R#_A5?&I?\\--_P"_UQ_\C48U+_GAIO\ W^N/_D:BWFOO_P" %_*7]?,L
M;A_S^+_Y!_PJ>,Y7_6"3D_,-OY?+QQ5#&I?\\--_[_7'_P C5<@\[R_WZPI)
MN/$#.T>W/!RZ(V['7Y<9Z$T6\U\G_P  :^?S_P"')J*^(OVF=)^+>J^,/A1<
M>'?#&L>*K71OB-8ZAX4\/^%]5UO3/#NH3VUMIU_?ZQ\5O$=CK7AN;P-?>'+6
MQURZ\"ZH]E\1/!.JR/J7AWQ7X1O=5U[PW''XQX(MOVF=-^''B?P#XLT;XV:U
MXCU3QIX1\;7NH)XH@MO$,GPST/4_AC8_$[P;X=\4_P#"=3MHWBGQ"K^,&T";
M1?%GAZU\4R6OB;7/#&A?#'3;O1-%3JAA5.G&I[>DG*UX.2NES.+?QJ_*DF[J
M.K44W:4EA*NXSE#V4VEM))V;Y4TOA=KNZ6KT7,UJHGZB45^0&E> /VU[:;0'
M\7_\+HUC3]/\2S7'Q1M_#_Q2L;:_\7?!>YB\*#P#X,\!2VOCC26TSXJ>%)[3
M6&^(_B6PN/"NH^(477/,\8>)%U_257=\6Z-^V?XJT+2+3PFOQ0L?'WA?P%X
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MY_Y%H#Y_@A?+_P"G.#\T_P#C5'E_].<'YI_\:I/E_P"GS_R+1\O_ $^?^1:
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M<'YI_P#&J/+_ .G.#\T_^-4GR_\ 3Y_Y%H^7_I\_\BT!\_P0OE_].<'YI_\
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M'D$'FLS[%;_W-3_\&-__ /)U<BMU=OE?]4;N_17^:7YIESRS_P ^UM_WV?\
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M%&@)XQ\*2*_B.=FMM<\,3WUBE]87*QF"2>PN].UG39&75-'U"SU2SM;A?:_
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M\^UM_P!]G_Y'H\L_\^UM_P!]G_Y'JG]CM_[FI_\ @QO_ /Y.H^QV_P#<U/\
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MD7/+/_/M;?\ ?9_^1Z/+/_/M;?\ ?9_^1ZI_8[?^YJ?_ (,;_P#^3J/L=O\
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M=_P0O+^7_P F7^1<\L_\^UM_WV?_ )'H\L_\^UM_WV?_ )'JG]CM_P"YJ?\
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M2#Y/[E_P2]]G_P"G:S_[Y_\ M='V?_IVL_\ OG_[75'[/J/_ #VC_P# ,?\
MRVH^SZC_ ,]H_P#P#'_RVH^:^^0K>3^Y?Y%[[/\ ].UG_P!\_P#VNC[/_P!.
MUG_WS_\ :ZH_9]1_Y[1_^ 8_^6U'V?4?^>T?_@&/_EM1\U]\@MY/[E_D7OL_
M_3M9_P#?/_VNC[/_ -.UG_WS_P#:ZH_9]1_Y[1_^ 8_^6U'V?4?^>T?_ (!C
M_P"6U'S7WR"WD_N7^1>^S_\ 3M9_]\__ &NC[/\ ].UG_P!\_P#VNJ/V?4?^
M>T?_ (!C_P"6U'V?4?\ GM'_ . 8_P#EM1\U]\@MY/[E_D7OL_\ T[6?_?/_
M -KH^S_].UG_ -\__:ZH_9M1_P">T8_[<_\ #5J_.SQ)^VMXQT+Q'XAT./P5
MX6N(]%U[6='CGEO]8CEGCTO4KFQ2:2-)W1))5@#NB.R*[%59E )/FOOD%O)_
M='_(_2'[/_T[6?\ WS_]KH^S_P#3M9_]\_\ VNOS%_X;K\:?]"+X3_\ !CK7
M_P =H_X;K\:?]"+X3_\ !CK7_P =H^:^^06\G]R_R/TZ^S_].UG_ -\__:Z/
ML_\ T[6?_?/_ -KK\PV_;L\:*K-_P@OA/A2>=1UK' SS^]K[.\.Z5\2/%GA_
M0_%4?Q0U+1X_$NCZ9KZ:1:>#_!-W:Z4FL64&H+IUM=7UF][<V]D+@6T-Q>.]
MU-'&LEP[2LYH_P"WH_?('Z-_*)X5^WC\#_&/QE^&WA&U^'W@2#QCXR\*^.M-
MUW1HEU[PC86FF-+%)IUU=ZYX8^(.D:AX(\<^%[BPNKNQ\2:'JDEAJUOIUP=1
M\-SW.H6[Z;>Y'P,_9\^*?@OXZS^,/$FE^'=$\+:=H_Q,N;UM%N-$N]/\5>+/
MBI?_  UUB[;1KN"RMO&4WAS0+_PCKD>F:5XZA2?PI87>D:%HNH^*;"WCU'3/
MJ3_A"OB7_P!%AUK_ ,(?X?\ _P @4?\ "%?$O_HL.M?^$/\ #_\ ^0*ZHXJI
M&A]73I\EJBNU-R2J.+:3;LK.+Y;1T<I/>Q@Z$'5]M:IS7@[)P4;P32OU=[J^
MNJ26USU;[/\ ].UG_P!\_P#VNC[/_P!.UG_WS_\ :Z\I_P"$*^)?_18=:_\
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M&B(/'_Q3(150$W7A3)"@ $XT;&<#FG?\.R?A5_T/WQ2_\"O"G_RFI6\U^/\
MD.[[/\/\S\Q?^$G@_P">OZBI;?QXF@W%OKT*Q7,V@SPZ[#;7#%;>YFT:5-3B
MMKAH_P!XL%Q):K#,T>)%C=BA# &OTU_X=D_"K_H?OBE_X%>%/_E-4-S_ ,$P
MOA1=6US:O\0/BHJ75O/;.R7?A,.J7$3PNR$Z*0'"N2I((#8)!'%%O-?>_P#(
M+OL_P_S/AU?^"QOQ(958_!_X8Y90Q_XFOB3J1G^[3O\ A\9\1_\ HC_PQ_\
M!KXD_P#B:]Y7_@BE\ 555'Q3^.F% '_(4\"]AC_H5*7_ (<I_ '_ **G\=/_
M  :>!?\ YE*=O[Z^^7^0O^W?_23P7_A\9\1_^B/_  Q_\&OB3_XFM/1/^"OO
MQ$U77-"TF3X1?#.*/5]=T729)8]4\1&2*/5-3M+"26,,NTR1I<%T#?*64!@1
MFO9_^'*?P!_Z*G\=/_!IX%_^92KVE_\ !&+X#:3JNDZO;_%#XX27&CZKIFKV
M\<VI^!V@DN-*O[?4((YU3PLCM!)+;(DRI)&[1,X21&(8%O[Z^^7^0?\ ;O\
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MGB3PMXI^#TWB6/Q=\2?"VC7?PXTBSUOX):0=,\*VVJ>*M?U;PWK%MK/CW1M
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MD,IY!! I#/FZ_P#VE?B/;7.N^&H_A;X7N_%T?CZ3P+X8N;3Q[J$W@#6)]/\
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M*:C%3E;>223>G*M7KI%+R13^WV/_ #WO?_ ?4/\ XQ1]OL?^>][_ . ^H?\
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MO?\ P'U#_P",4?;['_GO>_\ @/J'_P 8JYYG_3Y!^2?_ !VCS/\ I\@_)/\
MX[7)>/9_^!?_ &IT:]U]S_S*?V^Q_P">][_X#ZA_\8H^WV/_ #WO?_ ?4/\
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M[3MY_C'_ #%?R_"7^1HYN/[D/_?U_P#XS1FX_N0_]_7_ /C-9VZX_P"@._\
MX%6G_P =HW7'_0'?_P "K3_X[1;S_&/^87\OPE_D:.;C^Y#_ -_7_P#C-&;C
M^Y#_ -_7_P#C-9VZX_Z [_\ @5:?_':-UQ_T!W_\"K3_ ..T6\_QC_F%_+\)
M?Y&CFX_N0_\ ?U__ (S1FX_N0_\ ?U__ (S6=NN/^@.__@5:?_':-UQ_T!W_
M / JT_\ CM%O/\8_YA?R_"7^1HYN/[D/_?U__C-&;C^Y#_W]?_XS6=NN/^@.
M_P#X%6G_ ,=HW7'_ $!W_P# JT_^.T6\_P 8_P"87\OPE_D:.;C^Y#_W]?\
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MT<W']R'_ +^O_P#&:,W']R'_ +^O_P#&:SMUQ_T!W_\  JT_^.T;KC_H#O\
M^!5I_P#':+>?XQ_S"_E^$O\ (T<W']R'_OZ__P 9HS<?W(?^_K__ !FL[=<?
M] =__ JT_P#CM&ZX_P"@._\ X%6G_P =HMY_C'_,+^7X2_R-'-Q_<A_[^O\
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M =__  *M/_CM&ZX_Z [_ /@5:?\ QVBWG^,?\POY?A+_ "-'-Q_<A_[^O_\
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M>*;:U\"WVH_!BVAN/%W[/]R_B@>*_C1KT2^!-,%I\3O!\D&AP^&?!B6V@?\
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M:/W7_3U_Y.TWS%_Y^_\ QR/_ .)H\Q?^?O\ \<C_ /B:/G^##7S_  '?NO\
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MC_\ B:/G^##7S_ =^Z_Z>O\ R=H_=?\ 3U_Y.TWS%_Y^_P#QR/\ ^)H\Q?\
MG[_\<C_^)H^?X,-?/\!W[K_IZ_\ )VC]U_T]?^3M-\Q?^?O_ ,<C_P#B:/,7
M_G[_ /'(_P#XFCY_@PU\_P !W[K_ *>O_)VC]U_T]?\ D[3?,7_G[_\ '(__
M (FCS%_Y^_\ QR/_ .)H^?X,-?/\!W[K_IZ_\G:_.+]HCX!_%KQ9^U3\-?BO
M\*?!^G"33_!5_H&L^/O$^L^'-7\-Z.EB-4FTB>+PMK6G1^-O"OCG1;O6+NX\
M)^)/ &I7FG:VVH3V7C*TM--L)3??HWYB_P#/W_XY'_\ $T>8O_/W_P".1_\
MQ-:T*TJ$W.'*W*G.FU)2<7&I'E=TG&_>S=FUJFC.K256*C+F24HS3BXIIP=U
M9V=NJNM==#X%^&_PPM_#E_\ L]_'W2_ NM02> ?V4_'?@/X@V4DFJ)XT35[5
M/AEJ-CX1T_PUJDMG#+JMSXA\*^.WU*^L+;3TUG77MM1U"\OAJ%C=CS_XP?LW
M?$SXB?$FZ\5^%_AW%X0\.VNHV6I>([;2?$_@NWO/BGIEO\6? WQ+2?07N-&L
MK^W\<Z];^'Y!XPM?C$NH^&='U'P]X?T/P7J5O9W^K>(#^G7F+_S]_P#CD?\
M\31YB_\ /W_XY'_\36T<94C4=1*+ERR@N9SDE!SJ34;72;BZLE&33Y5RN*4H
M\SS>&A*/([\MU)V45>:C"+ELVKJ$;I/76[:=E\#_  ]^ VL:-+\,=>^,?@KP
MP_A3X.?"CXEZA'IVG:9HVKZK_P )EXMU_6K>UBU+3O#&D6UGK>M^%_@[-?Z!
M<77A[3XM$U/Q)XS\6'0K)DN+%8OI/]G72/$V@? KX3Z-XW74H_$^G>!M MM3
MM;QKU[[3PME&;'2M0?8A?4M)TYK33-19@SF]M)R\DKYE?V7S%_Y^_P#QR/\
M^)H\Q?\ G[_\<C_^)K.KB)UHM3Y?B4E;FM&WM+J*;=N:524I.]Y6BFM"X48T
MW>-_A<7?EN_@M=V5[*"45;2[MN._=?\ 3U_Y.T?NO^GK_P G:;YB_P#/W_XY
M'_\ $T>8O_/W_P".1_\ Q-8?/\&:Z^?X#OW7_3U_Y.T?NO\ IZ_\G:;YB_\
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M_P %%/"?B/\ X)>_MB^&_P#@L1\$M"U>^^ 'Q&_X1CX.?\%0_A?X;LKITO?
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M9Q7>DW>I^'=>L+=]*\2Z#%JUC#J48TZ\D=[C2;,#]):*+^2^[_@A;S?W_P#
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M\81_#[7-7>3QMJ?A_3_B&LL?A+45N+P0Z\-8L_"MY+I=EIL<'Z.T4YXQ2O\
MN8ZU%/5IK2M"MJE#XDH>QC*]E1G.+@VPCAW&W[QZ0<=$[ZTY4]W+9\WM&K7=
M2,6I*Q^"GC'Q-^TAH5WX.^%GC_Q!\3[RW\"?#+]GPW?Q7U67QSIO@[XG^!?%
MO[2WP?C@\2>/;WP1<:9>VGCW0/!UOXL\&_&B".YL-7GL+&]\6,]MX;\8&&W^
MGUU/0(_%/PXM?'/C"<_LV1^%OBG-JVM_"[Q1\8X_"5Q\<%UOP0?#.D^,?$HU
MW4/&]FT/@6?Q)>>%M,OM<@\-:AXA^UO;0/K]GH$+?J915SQZFHKV$8-*=W3<
M8WE.]ZD?W?N33;<+*48\TDE%.*A$<*XM_O923<;*:;LHVM!^_P"]%I)2NU*5
MDVVTW+\K/@A\:OVBM#\9?!'P5\3KSQ+JVB^*&?1['P_-X56Y^*X\.ZAJ_P 3
M9?"7C#XS6FLZ7I5[:V__  A.E^ ]1USQ=X6UZ>Y\.:L-2T?X@>#4UN^FO(?U
M3HHKEKU8UI*<:4*3L^90TC)N3E>UDDTG9O>6[MI%;TJ<J<7%U)5-59RW244K
M7N[W:OV6ROJW^<'[;_QI_P""EGPN\5>!M/\ V%_V*/A-^U)X3U7P_J5YX[\1
M?$3]H_0_@K?>%O$,.HK#INBZ?HFKZ7<OK-I>:;NOI-4@NRL4V;1[>,HLLOQ!
M_P -<_\ !PG_ -(AOV8__$]?!G_RGK]_J*P-3\&+CXY_\%=/BA\)?V@O#7[5
M'[%'A#]D3PF_PIW^#/BU^SU^U+8_%KXI1>.[OQKX1TJWTGP_X<\)Z,NK:?.?
M#^H:[JR>(5G2#3I]+ABGM[R&[D1.\U'XZ_M:>!/C%XY\)^*-/\5:8GA>T^"W
MPW\>?%F?2_,^'$^F6VD?'_Q+HWQ?\!6FKVVH>"],O/BP]KX \-^.4EL;Q?"G
MBR#4/"ERD4C^$K\_M71790Q4:--TIX>G63E.2E/247)4UHU%W25._+)N+DU*
MR::GSU:$JDU.-:=-I15HZIJ+F]4VM6Y[I*22:N[KE_,CP3XU^.?B70?VL=8\
M=:OXMTGQ=JG[+_PU\7>$? .EZ3KNE:=X4\2ZI\'/$K^(+WX<&_TVQ\41W$_C
M>WG62SG;^W--UE(K*\@CO;:WK.\0_M.>-+'X4? Y/AWXR>(Q_!75[[QMXPN/
M!6N?$'5[SXU>&? 7A"^\!_"#7;":W-YIVI_$K4;WQ5<7ES.B>(-6NO#$^B:-
M?Z=K5[YS_J113^M4W*\L-!I2C)032BDJ/L>6SINZLE)7O[UW+F=I)>PFE95I
M7Y6G)IN3O4]I>_.K/5Q=K:64>57B_P H_$O[2_[2%EXJ\7:'/>:!X;U2ZT?3
M-4T[2T\/75WX4^&5I;GX72>(=#^(?B6Y\*7FL^"O&]RVO^+])\'^,M5TOQ_\
M'_$NH+IM]._A^QT[4H*^^_@!XVU;XC?![P-XSURV\06VK:SIMT;Y?%&@6'AG
M6;B:PU6_TO\ M";2-*O=0TM+35$LEU+2;_3;G^S]9TB[L=:LK>RMM0BLK?V&
MBLZU>G4A&,</"E).+<H/5VBXM6M>ST>LFTTVVY2DU5.E.$W*5:51--*,EM>2
7:=[[K5:)73MHHJY1117,;A1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'P !H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBO%_C+
M\,Y_BUX+G\(P?$CXJ?"9[JZT^Z?Q7\'?$D'A?QQ$L)).G_VY+H/B=(XF5V\T
MQ0,7)1MPC4-)^<?QU_X)4:]\8_ \7@^T_P""B7_!0#PE=_\ "7>!O$Z:^WQD
MTG4=3L9_!&MKKL::2T'A3PR8$EDX>8"4H$W".0Y"@'["45RWA_0_[#T/1]&_
MM74];;2-)TS23JFNW9U'4;]M*CB!U3593&@EUF60---+@%YPDA"[ J=30 44
M5Q>C^-_!_B'6=?\ #NA^(M%U37O"]Q]C\1:'9WT;ZCHCR+PNJ:6)1*F<X#M&
M%<%=C9(% ':4444 %?@M^VO\!H/BE\3OB;\6OVMO^"G>L_LY?L3?!7Q'X5UJ
MT^$'P@\3>#_@#J^D^*M#T7P_KJ:Y\5?VAB4^)4T:>(V,OA#PKX6N() NM!(#
M++(4/[TU_-+^VO\ #;_@E\O[=-[\4/VP_"?[4?[3_P 9"WA^#P4FG?!_XR_&
MO]FS]D!8=+T%(;A=&\.>&O%OPNT'793"/%WC6/Q;'XO#I+%*O@J/RC%* ?MI
M\ S\0I-0\6ZQ=^)_#/B3X!^*-'^&.K_LY-93^,=2^(S>')_!S_\ "1ZW\3==
M\1F(7$GB69='G\*"*1FBA2X^T 3M$#]35Y_\-UTJ+P#X+CT76;;Q%HX\.Z3_
M &9K]G;K9V>M:<-+B$&JK$A=8UNH@LN P.7!89.:] H *_G)_:-F\%^+?VTO
MCAX:\2_\%5?BK_P3<LO!NL>!;WQ!\*- _:%_9MTK3?CII&N>#M!.L?$W1-%^
M(/A^X\4?"&58 /"4TQ,OFR>'W\?+'$' B_<KX[?$/5OAA\'/B=\0-%TS0]9\
M0^$/"6K:SX;TGQ%K*^'?#.H>(8M,E?0X=>U^6%QH6@W&NB&.ZUXA&@B,K1NK
MQH3^)'[,VG_"+XSZ[\1=8_X*P_#/_@CQXN^/=W?:;XAT#XJ_!/Q%X+^(GA?Q
M/X6C6;0SINLZQ\8[;_A+M&\1^%I5CM]JRB)HI!/$<J6D /WC^'VF^&=(\#^$
M=*\"WXU'PG:>'-)L_#FL?;?[5%_HZZ6G]D:F-69V&M>; (F$F\^89/,(0(H/
MH%<7X)A\*0>$O#4'@E-*'@Z#1M*_X14:1@Z4OASR!_8O]F')'E^0(0N3DC&[
MJ@KM* /+/BU\)O 'QT^&GC?X/_%3PY9^+/AM\1?#NK>%O&WA74?FTO7?#NNI
MY>L:5JBJ>4DC=]VR1&*L0&P7)_''XB?\$D?^" OP>TB^USXI?LL?L>_#?1-/
MU;3O#%UK'C;54\.Z99>(];.W1=):;7/%"PC79U9/*C/[\AF?85218OV/^*_Q
M'T_X0_#;QG\3-3\.>-O%^G^!?#>I>);SP[\/?#6J^,O&VN1:1 7?2M!\.Z-Y
MMQK>MR&)HTMT;)926'EJ\B?SJ?MDZ]^R?+^W#HGQ@^,GP5_X*<?&[5OA-HS>
M)_A?\-?!'[)S?%C]E;X9_&7QUX+T#R_C.N@#PN5\2?&;PGX;_L/>_BUO%@\%
ML-RQ@,$0 _I'\$Z%X>\*^$/#'AKPI&B^&=!\/:+HGAP6]R;XGPWH^EQP:,PE
M('F;851495(?Y "595';5Y1\&_L+?"CX;?V;;ZW:Z>O@;PL+.V\26#:5XE6(
MZ)$0-:T=A&NC:SC+W,89MLCO$6(5"/5Z /*?B[\0Q\*/AEXX^(=OX0\:_$BX
M\&^&M2URU\"_#K2&\2>/?%;:.CN='\'^'RX?6M>=A\D.<L^"S$ @?RK_ !=_
M:-_;%^-_Q?\ B?\ $#_A%_\ @O[\"_"-SK&F?\()\-?V>_V:_P!G_3/!'A+P
MRVA>'HVT;7#X@'B_Q1KWB(^((]9\2?\ "4 @"/7%B&$10/ZP/B#XX\%?#?P1
MXF\>?$/Q1I?@?P+X8T:^UGQ7XLU;4_[,TW0=)129-6FU8A1 D8"D.&!4NBJ"
MP2.3\=Y?^"4?Q!\4:A\1O&'A3_@JU_P4%\/>"/B_XFU;QYHO@[P;X^\"+X=L
M/#7C71M$0:.FL>(_A[XN\0:W') L<T/B8W(G$$H66*-HW! /UQ^#DUW-\)OA
MG+JLWB*;4;CP-X8EO+GQ;;I'XF>_;1K=IGUM2#C62Y;[1E3N=6/)<9]5K@_
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M_M75M%!<K_8=S,7>WZ?(5#H)&Y[^@ K^63]O?]I?XD>"?VP?'?@;]F?]M/\
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M-&U2QT_4M/U&S-I>6>J6/]I:=(I!7;)I,K;9!\VX LI&U"2=H)_!/5/V3?\
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M3_@A1HOBWX"7?@.P\$7_ .WUX3\=>,/VA'T_6O#_ (>\<:)K<6NZ!H+>'8-
M3Q ^N%/"R2^;"=%:3S/-D,C@']1'P5\8:A\0/A'\,/'FJSZ7<ZAXT\">%_$]
MW=Z27_LI[[7-$L]9D_LISD_V.=Y\@[B7C"@DG=CUVO,OA1KEYXH^&/P]\0:A
M<:'>7^N>!O"VNW5UX;^;PU=/K&B03@Z-G)&CY<26Z@;1$(R!CKZ;0 5_*Q_P
M4U_:,_:>^&G[0OQWO?!/CO\ X)__  :^%_P:\%:1XU\<7OQG_8P^-'Q[^(V@
M>!O$&/#^B?&;QOXY\.>'%\-R^&O%/Q#5O"RCPG'XK'@DZ''+XZ)99$K^J>OR
MJ^.W_!6+]F7X)_$SQO\ !;6OAY^U7\5?$?@.[D\,^/+SX(?LK?&/XM^ ] UJ
M31-$\0/X0USQEH'AR3PW_;\NA>(-$E: W;*JZS"H<;G% 'W'\ -9/B+X%?!K
MQ$FH:7JK:[\+_ FLC4] \-/X+TO4#K'A[0KE=2T7P<\Q;PSHC^:TT7AX 101
M!(5C^5?,]RKB?!GB.Q\:>$O#7BS3;:\T_3O$OA_2]?L;'5K0Z;J5GI^LZ6EQ
M -8TIF4(^-@:,X4'(1@D99NVH \J^+GPZ'Q8^&7CGX;CQCXT^'K>.?#.J>&_
M^$V^'6M/X9\=^%SK,3QG5_"&O>6[Z-KL9<,DGEL5;:=O!\S\*/"__!-/X(7/
MCSX[^%_#?[?G_!732[KX/6NCW?Q/\8']IKQCX>\$:AJ3Z+)KITK1?&NN^%F\
M*>(=?\*^'1"?%RI<,_A)9O#!E%LRLA_HLK^/G_@KSH.@^.OVL=<8_P#!-[XY
M?M!^%=+T]O"_CWQ)I7_!4OP5^QS\(OB]J6B:(->UG1_''P0USQ*8O$'A]?#&
MN'PO)XK\4)X.7QO(P\%0#Q8@6, ']6WPE_L,?##X>'PKXDG\:^&!X/\ #9T7
MQ9>7(U"^\3:,-(@?2M8>8 !GND*3\C*X/S91B?4*\3^!TVG77P7^$\NE^&='
M\%:4WPY\#1V7@KPOJND^(?#OA.PM]"T>,>#O#^L:,BPZQH?A0H_AV*YBA$-S
M'&7C#0M&P]LH IS_ &CRI?(\C[1\WV7S^F<?Q8^;&[[N.>F[BOY<_CM\,/VY
MOC)\8_VK?AQ\0_V0?^"/7QD\7_$/0/["UB[^)WQI\8:1\3?%G[,GAZY\/ZUX
M&UC7/ ^B^%_%_BCP_P##OPKXHC;Q$C^)V"R>,9/,MW8O!./Z1/BS\3O!WP5^
M&?C?XL^/]0GT;P3\//#&I>*O%&K6>DZUXCN['2="0MJ<D6C:'!-K^M%(U;Y+
M:"5F.R5T*!F'\AO[4_[:?[)_Q-^/OB[XX?LO?\%8O&'['FC^.M%2T^/.DZ1_
MP2_UOXN?$O4M/&CZ'H7B"/1OC?KWPSB\3^'D7PUH46/#?BEO%W@WP@S2^.EB
MMPB[P#^N[X+^&KSP9\(_AEX/U2T\(:??^%? WAG0[FQ\ 6SV'@BR;2=&M]-*
M^$;>1$>'1(E1?LJL<PP,GRJ"BUZQ7BWP'L?#.G_!3X0V7@W5=8UWPC;_  X\
M")X8UOQ4YD\1:WX<_P"$?T8Z)JVO.T49.N36XA>0,@59RVWC:1[30!3N((+N
M+RIX8;B#N+@!@2#UP5//Y=*_)O\ :;_8<_;1^)GQ0U_7_P!FS_@I9XP_95^$
MGQ#D^U_%'X.Q_LR? #XT#5-3DTE?#FM:MX(\:^/]#;Q-X";Q)X=TM()FF_X2
MY#<!Y88H@RHGZX5_+U^W1^WU^T#\,_VMOC/\,[+]O/Q%^S3X7\$W_ABS\'>"
M?!?_  3 ^)'[5&FWFFZWX&\/:Y_;2_$_P\[_ -M:]_;T^NIXU\,1HD7A$OX?
M*M(YN#0!_2-X#\'VG@#P-X2\#V%_J6IV?@OP]I/AO3]6UR[:_P!3OX]"TA=&
M34M7E8KYCR1P@SE2H+'HB;0._KR?X0:OJ'B/X6?#S7=4UH>(M0UWP/X6UN[\
M1-IQTE=:OM9T.TEEU1="=@NCB9GE=M#7*VYE,.?,1MWK% !7X/?M/_%C_@HQ
M\"OVK?B#JOPB_9'_ &B_VOO!GC[P$GACX6:;X)^,7P&^'7[-/PVU;5--\/[=
M8\9:1KD8^)VA>/U\3QZY)XT\63'Q4K>"-=*^!XXYO,MQ^Q'Q?UGXD>'?ACX[
MU_X2>"=.^(_Q.T[PUJEWX$\#ZOXB'@S2O%/B;#?V3HFJ^()4GCT&*5DCB?7G
M \E073;E!7\HGQ2_91_;/_:9^*OQF^-7QN_X)L>"OBAX@U'Q"G]K75K_ ,%C
M/B;X*TSX:1Z!X+T!!X+T+1O /AKPEX8T+P\NU?$[#+,O_"0>)2^"Z[@#^LCX
M7Q>-XOAOX A^(LNAW'Q"_P"$0\-CQW_PCHQX:/BH:'"-?.AC&[^QSK@E^SE<
MYA^8DJV*],KR#X*V3Z;\'_A;8#3H-+%M\/?"MK_95MKDGB1+/;H=F/[-77LA
M-:$1#+_;V5%RR-+C$C,?7Z *5Y]F^S2_:_(^S8/VG[3C9MP.O;Z>V,<U^,7B
M3_@AW_P2]\3>*/B#XT\0?"_Q)>:C\0O&&K>-?$UK9_M!_&?P[X<L]0UG/]NZ
M3H7A_P ,?$+PKX;T+0I0 WD1P?*=RKT53^J'Q<^&7@[XU?#/QS\)OB'I=UK'
M@/XA^'-5\+>+M,@U35M*?4?#^N0F+6=,76M"DM=>T8RQ,R-)!-"WEDP A25B
M_E<_:>_X)-^'/A5\3?%7@'X _P#!&G4?VKO 7Q$+?\('\:]#_P""E7C'X)Z=
M\*%UK2ET Z/XV\">._$\GB<#PQKS:UXNC\4^%Y/%[>,(W3SE68-;D _K&\&^
M&O#/@OPIX6\'>"[*STSPEX5\.Z3HGAG3--*BPL/#6BZ4NEZ/;1JH"M&D$:(K
M*"S^6&<L49CV]>/_  3\,:GX0^#?PL\(:V=(75O"GP\\*^&+T:%<O?:6M_H.
MA0:+(VD:K*(V96,3JDC(6^9U3Y-Q/L% 'D_Q;^%OA3XU?#3QQ\)_'=EJ5WX)
M^(?AG4O"WB&STG6-9\,ZC>Z7KR,-56WUO0Y(M>T21T=T9X)XR-P1C@D#^5+]
MH?\ X)W?LS> _C-J_@OX%_LK_!SQ+\.?AY='2OB-JWQV_P""LG[0/P3^)%]J
M(T9->UU?!/@W_A)/%\6@O_PCNO?+XI\6,CR+EDC"HY']/?[2/PT\;?%GX$?%
MGX:?#SQ<_@+QEXS\%:UH'A7Q4U[X@TD>'M7ECD?1+G^V?A_KOASQ7I6CB>..
MW>?PU>V_B:.VF:2*9I(_)D_F;^)/_!/+_@L/^T%X^TKXF?M%_L7_ /! /XT_
M$3X=W>G>&O WCKXJ:1^U?XH\33>&O#ZZ(= 8:N$DD\2Z%!LG\I/BGGQI\THV
M-D8 /ZC_ (*2^'I_A'\,Y/"%G?:;X8;P+X7'AZUU2]DU/4+/1_[&C.CI+JS,
MZZRZ6QC7S!(1)N\S:@=8QZ_7 ?#Z/Q):>!_"%OXRLM&L/%MKX:\/VWB.S\.J
MW_".6/B5='A.MKHN[81HB7)D6UQA1$I )<%J[^@ K^>W]N;_ (*:_M#_ +-/
MQV^)OP\\$_%K_@DOX=T/P;HVDW^C^%OVI?VFO&OPT^.5\[:(OB"8ZQX?T7P[
M+X:MA<$'_A#T5M[[F$S.Y9S_ $)5_/9^V=\8HM%_:4\4V6@?#W_@CO:67@_5
M-)7XCW'[<?Q0\'>!_P!H+QKJ*Z1HVO1:UH,?_"/7*:!HD?A>5(_!_BOQ;(\<
M[0K*L:1C8 #]OO@_XPE\??"KX;>/;F?2[BX\9>!?"_BBXO-(+?V4?[=T2TUC
M.ER-ECI!,A6 EB7CVY.[)'JM>>?#CQ+9>.?A_P""/%]GIO\ 9&G>)_#6CZU9
MZ1(J V-CJ^DQSQZ9\JQJ3&60D*J@[5&,@5Z'0 5_.+^VS\5?V6O%'[9H\ -_
MP3P_X>=?M6?#G5O"DECI6D_LK^"UE_9[\-S#1O$.CIXD_:A^(:+\-50L5\6>
M#/#7B::.X,I=6E@;:\_]'5?";?M??#;P[\9/C#\-;WP)XR\(Z-\,O#&I>+O&
MWQL\06OACP;\)]9\2:'HOA_6-8\':)XA\0^(H+C7?$_ACPQKNARW4K0Q^%K=
MYI5-Z(H$D4 ]U^&?QI\#_$/Q%XU^'VEW>FV/Q(^%%CX4;XG?#]-8T74]2^'\
MGCG19=;T/2M6.AR21!Y(--< !1O2-CEQA5]WKRWX=ZIX%\8^'=-^*7@.+3[G
M2/B?H_AKQ>GB.UL_[/O_ !1I=QHL7]A:IJTJ*'U<?V&T2P"7=MA4)&NT+Y?J
M5 !7\HO[=VD_\$TO&/[=GQCN?^"AO[%OQ)_:7\4_#U/A[_PI7QM\'OV0?C]X
METBR\,1Z%%K>M^#/BAXV^'OB/_A$/BUXA_M^,F-?%%H;=/"3?\(:;9R98Y?Z
MNJ_E^_X*(_M*_M&>!/VF/BKX8^%_[8_[?/PPMM.LM)?PY\/_ (%?\$R=*_:/
M^$=AJ;>$!(,?%*6-Y-=">(7DD\9P.RB%]MNH11O0 _H_^'>H>'=9\ ^"=6\*
M:4VB^&M2\+>'+_P]X>FTLZ3_ &-H\VDQ2:-IHT;:!HJVT!CB2/:%B$7D!RJQ
MD>A5Y-\&[WQ'J?PE^&FH>*H=<@\37'@;PI<^(_\ A+-.;2?$PUAM&@&LKK>D
M(4&D:T)S)]H3<Q61VC90%P/6: "OQ>_:TO/^"DWB[]I'P[\*?@=K(^ G[-6C
MZRWQ<^*/[3-MK'P=\1^-]>\-:%H\9T+X ?!'X4^(\C_A)/%7B2#5_P#A,/%_
MQ9C;P=%&,0.L;$2?M#7\I?[<7["7BWXS?MS_ ![U;3_V3/V!_P!IO4/$%EX5
M^(&C?\- _MK?M ?#WXW:%X4T7P5X=T+6'UOX9?#[?X:T+X=GQ&'_ .$*=MJA
M?^$D=G;S!L /Z>_A_<^(+_P)X0O_ !2+<>)[KP[I5YK(MO\ 5G4Y],1IB.N2
MS.2=V!G@ 8Q7<UY3\(-)O/#'PK^'/A^_TC3M$O\ 0? WA;1;S1]'O6U73K%M
M'T5(!IND:NT:_P!LQPB I'*KE&3S)006.[U:@ K\2OVJO^";G[4GQ*_:%U[X
MV_LG_MU:)^R+I?Q4TJ#1/CGI5M^R;\&OBS\3]?TJ73M"\,:T_@CXW>(7MO%N
MA07&@>'M(\CPQXG7Q;X2\*^,5/C>UC:X*0G]M:_FS_;T^*O[9O[*O[3/Q#^-
M'PETCX'?$OX>?$[2=(^"VG^/_P!HW]O>'X)_##X&:GXVT7P_%H?@]_V=]:\/
MHJ>(3K\4?BJ+Q/X0\5-XU\;1>(5CDCM]OE@ _H%^&_@6P^''P_\ !'P[TO4=
M9URP\#^&M(\,66L^(+XZKXCOXM#TB'1AJ>L:P5VS:W-&A$\N[+EI N$^6+T>
MO,/A3;^)=.^&W@#3_&GB;3?&GBRV\)^&[3Q%XLT%=ND^*/$D>DVZ:UK6CX<J
M=%N+@R3VC8!\GEU60;&]/H *_EN_;R^,W_!-_P"&?[?5K\2?CU<?MU?&;XM_
M _2=7U;P%\-/AO\ LX^*OC5^S5\'?C#KG@[15UCXK:'H=M\.I?"GB'XR>&O"
MZ:!/YGBCQ;XO7P6)$WVUH\@MHOZD:_FP_;4^)'[).I_M)_M7_#K]I'X^^,OV
M1]"_X4H+*S^):_M]^#_@MXET_P")N@Z1X?US_A-/@A\#PP\3?#[Q-XO\,:Y_
MPC)^**L\?QA?0O\ A!!X*N4C\R4 _?'X*3:-=?"+X97'AVV\0V>@W'@7PS<:
M1;>*]&D\/^)QIK:/$8/[<T0B#^P];>-Q)<Q9 60F-7<+YE>O5X;^S[>>'+WX
M$_!N[\(77BG4_"5Q\,/ ]WX7NO&UP;[QGJ'AN3P_I$^AZIXC)5]^NM;&*2X;
MD--N=2IVQ1^Y4 >"?M&ZIKF@? CXQ^(/"GQ*\)?!SQ)H7PZ\6:YI/Q6\::&G
MB7PS\-I- T6ZU?\ X3;7M 9PNO:/X5B1]>DT*8JDZQ&+>J,$'\O?P.^#7Q$_
MX*]M)^T'\.?^"AW_  3T_:\UCX)>(M-\.?\ "<_$'_@DSX+U'QOX%UC']O:)
M$G_"P_$Z^)X]!.W_ (2KP0N(T9G:0,7\YE_IX_:?\!?$+XH? +XM_#WX5ZGX
M/T#XD>+O!VJZ-X&UCX@Z(WBCP-HOB67S?[(U3QCH(D']O:"DY@EFT#RV$P!C
MV_-NA_&&Q_9"_P"#@'2O$.H>*]*_;_\ V =-U_4])3PY>75M^QMK5D][IFD,
MYT93M\22'Y68G8,Q01;40.JKM /WM\%Z9XATCP?X:TSQ9JMOKGB?3?#^EV?B
M/7[:S&FV&N:Q'IL,>K:JFE*[;8YIT:18W.<N1B/:R+W%<!\.K+Q7IOP_\#Z;
MXSOK?4O&EOX:T:U\8:M:[3%>^)(]'A77M1B0 #]]KBS,1R!NR2 0!W] !111
M0 4444 >+_&KXU^"?@'X*G^(/Q%D\1IX;MKS3='D_P"$5\&^,O'6J'4-6E"1
M^7H/@+PYXI\2+G(/F1VSQCHS!S$\GYV_&/\ X+5_L6_!7P4/&WB&+]H+4M)_
MX2#P[X;-OI/[-WQCBU#S]=UM=#A81>(O#'AGY0^YV8REE8+A)=V%_7JLJ^TV
MPU&***^L[2]@@N!=""YMEO0EXI9ED"ON4,AD;!*<9ZJ* ,W0/$%AXGT+1M?T
LQ;C[!KFD:=K%FMY;26>H#3]81)HFGTV2/S(F,15B) W).TR ;GZ>BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  B "(# 2(  A$! Q$!_\0
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'/:BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  B "(# 2(  A$! Q$!_\0
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@SSP0BGIP >I44ODCV_,T4 3T444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  B "(# 2(  A$! Q$!_\0
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M'+74/$'[;?\ P34^&7B>Z$1OOASXL\(^.]8\5^&O*\2-X?A7Q"OAC]H@E?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  B "(# 2(  A$! Q$!_\0
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M\+^$Y?%MY>7?B7QU\&?&)_X0+>LL?PWG\ 75Q*DH!\C?M(ZQ\>/^"GD?A_\
M9Q\"_ 3QK^R_\4?@9))\1OCE\3?C3>^.?".G?!?Q9XB\/^(/AB?A'\&_$GPU
M<-\>?^%R>$/$?Q AD\<>#IV^'8^'X\PRQ?$:>TL;/Y5\<?L/^$O@#<W6N?MB
M_!#XX_"#X1VVI#PSX._:5_8N_:8U[Q]\)_V7O"?Q$:X\,_$[P\/A]XH\*>"?
MB_\ #/X6_&M?'OB<?$/Q8L/QX9&UZ<O+X"7B+]M_!'_!3']C[Q-J<OA3Q]\4
MIOV;/BG;VS#4_@]^U'I,O[/OC_2993(QBMU^)!M/"?BIX23MO/ WC+QGX09/
M)"WF[<L7A7[3?Q/\,?MQ:_;?L'?LW^+=#^(?A?QTFBW'[9?QE\%:^VM>%_A-
M^S6[IK^N> $\4>'7G\,-\7?CA;K;^!/ _A5Y9;KPEX%\0^*_B-Y<:6]K'( ?
MJIX0\,^'/ _A/POX+\+Z&UIX:\(>'=$\+^';5((W2VT+0--MM)TFW5VVLRPV
M%I;QJS*K,%!(!.**WHM,TRVBCMXM."Q01I#&JQ958XE"(JDMD@*H )Y(Y-%
M&Q1110!P?B;P+X(^(?AU=+\?^#?"OCG3&B=FT[QAX>TCQ-8%LGYC9ZU9WMN3
MP.3'G@>E4?A[\-OAU\,=&O/#WPV\ ^"OA[H!UZ6\.A^!_"NA>$]'-VTD.ZZ.
;F:#86%D;EL#=/Y'FG RQP*** /2J*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>atnf-20250625.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Jun 25 21:05:44 UTC 2025 -->
<xs:schema xmlns:atnf="http://www.180lifesciences.com/20250625" elementFormDefault="qualified" targetNamespace="http://www.180lifesciences.com/20250625" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://xbrl.us/us-types/2009-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20250625_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20250625_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20250625_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:roleType roleURI="http://www.180lifesciences.com/role/AdditionalDimensions" id="atnf_r_AdditionalDimensions">
        <link:definition>999000 - Disclosure - Pay vs Performance Disclosure - Additional Dimensions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:element name="AllOtherCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnf_AllOtherCompensation"/>
  <xs:element name="Bonus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnf_Bonus"/>
  <xs:element name="EquityAwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnf_EquityAwards"/>
  <xs:element name="NonEquityIncentivePlanCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnf_NonEquityIncentivePlanCompensation"/>
  <xs:element name="NonqualifiedDeferredCompensationEarnings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnf_NonqualifiedDeferredCompensationEarnings"/>
  <xs:element name="OptionAwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnf_OptionAwards"/>
  <xs:element name="Pension" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnf_Pension"/>
  <xs:element name="Salary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnf_Salary"/>
  <xs:element name="StockAwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnf_StockAwards"/>
  <xs:element name="AverageEquityAwardAdjustmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_AverageEquityAwardAdjustmentsMember"/>
  <xs:element name="AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYM+UlHLczcqbucHL1cUHtO5ZA3CBy6Cnl1u0hNGYUJhU9MD+qgJoti/zZADG7OuMan4t3iVetxmlYo9mIYxg8aUc1sICnD6ZN9kGDNSMEWJyH/5VmDEDF+HH3jJpoE/3Xr9sIiQ2lg3f39PBQDOe4cNqZ5yD/bsJckSeUK02fsnO8Ow2XkqZ573IIYH33f5D/M1PPogapnohjWQWbv0965CSAChCFl925fjcRtOLrxKku8iOiwG7KX+X8QeIzK3WwkbJSBPFWeaw==] CSR-->
  <xs:element name="AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember"/>
  <xs:element name="AverageReportedValueOfEquityAwardsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_AverageReportedValueOfEquityAwardsMember"/>
  <xs:element name="AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember"/>
  <xs:element name="AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember"/>
  <xs:element name="BlairJordanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_BlairJordanMember"/>
  <xs:element name="ChangeInPensionValueAndEquityAwardValueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_ChangeInPensionValueAndEquityAwardValueMember"/>
  <xs:element name="CompensationActuallyPaidToPEOMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_CompensationActuallyPaidToPEOMember"/>
  <xs:element name="EquityAwardAdjustmentsBMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_EquityAwardAdjustmentsBMember"/>
  <xs:element name="EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember"/>
  <xs:element name="EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember"/>
  <xs:element name="EquityAwardsAdjustmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_EquityAwardsAdjustmentsMember"/>
  <xs:element name="EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember"/>
  <xs:element name="EquityAwardsValueInCompensationTableForTheApplicableYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_EquityAwardsValueInCompensationTableForTheApplicableYearMember"/>
  <xs:element name="FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember"/>
  <xs:element name="FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember"/>
  <xs:element name="JamesNWoodyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_JamesNWoodyMember"/>
  <xs:element name="NetAdjustmentsForEquityAwardsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_NetAdjustmentsForEquityAwardsMember"/>
  <xs:element name="NetAdjustmentsForPensionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_NetAdjustmentsForPensionMember"/>
  <xs:element name="PensionAdjustmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_PensionAdjustmentsMember"/>
  <xs:element name="PensionAdjustmentsPriorServiceCostMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_PensionAdjustmentsPriorServiceCostMember"/>
  <xs:element name="PensionAdjustmentsServiceCostMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_PensionAdjustmentsServiceCostMember"/>
  <xs:element name="PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember"/>
  <xs:element name="PensionValueInCompensationTableForTheApplicableYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_PensionValueInCompensationTableForTheApplicableYearMember"/>
  <xs:element name="ReportedSummaryCompensationTableTotalForPEOMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_ReportedSummaryCompensationTableTotalForPEOMember"/>
  <xs:element name="ReportedValueOfEquityAwardsAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_ReportedValueOfEquityAwardsAMember"/>
  <xs:element name="TotalAverageEquityAwardAdjustmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_TotalAverageEquityAwardAdjustmentsMember"/>
  <xs:element name="TotalEquityAwardAdjustmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_TotalEquityAwardAdjustmentsMember"/>
  <xs:element name="ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember"/>
  <xs:element name="YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember"/>
  <xs:element name="YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember"/>
  <xs:element name="YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember"/>
  <xs:element name="YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember"/>
  <xs:element name="YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnf_YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>atnf-20250625_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Jun 25 21:05:44 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="atnf-20250625.xsd#atnf_r_AdditionalDimensions" roleURI="http://www.180lifesciences.com/role/AdditionalDimensions"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.180lifesciences.com/role/AdditionalDimensions" xlink:type="extended"/>
  <definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <loc xlink:type="locator" xlink:label="atnf_BlairJordanMember" xlink:href="atnf-20250625.xsd#atnf_BlairJordanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="atnf_BlairJordanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_JamesNWoodyMember" xlink:href="atnf-20250625.xsd#atnf_JamesNWoodyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="atnf_JamesNWoodyMember" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <loc xlink:type="locator" xlink:label="atnf_ReportedSummaryCompensationTableTotalForPEOMember" xlink:href="atnf-20250625.xsd#atnf_ReportedSummaryCompensationTableTotalForPEOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_ReportedSummaryCompensationTableTotalForPEOMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_ReportedValueOfEquityAwardsAMember" xlink:href="atnf-20250625.xsd#atnf_ReportedValueOfEquityAwardsAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_ReportedValueOfEquityAwardsAMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_EquityAwardAdjustmentsBMember" xlink:href="atnf-20250625.xsd#atnf_EquityAwardAdjustmentsBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_EquityAwardAdjustmentsBMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_CompensationActuallyPaidToPEOMember" xlink:href="atnf-20250625.xsd#atnf_CompensationActuallyPaidToPEOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_CompensationActuallyPaidToPEOMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember" xlink:href="atnf-20250625.xsd#atnf_YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember" order="13" xbrldt:closed="true"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYM+UlHLczcqbucHL1cUHtO5ZA3CBy6Cnl1u0hNGYUJhU9MD+qgJoti/zZADG7OuMan4t3iVetxmlYo9mIYxg8aUc1sICnD6ZN9kGDNSMEWJyH/5VmDEDF+HH3jJpoE/3Xr9sIiQ2lg3f39PBQDOe4cNqZ5yD/bsJckSeUK02fsnO8Ow2XkqZ573IIYH33f5D/M1PPogapnohjWQWbv0965CSAChCFl925fjcRtOLrxKku8iOiwG7KXwyNP5gPGfipr96uOxbBkBQ==] CSR-->
    <loc xlink:type="locator" xlink:label="atnf_YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember" xlink:href="atnf-20250625.xsd#atnf_YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember" xlink:href="atnf-20250625.xsd#atnf_ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_TotalEquityAwardAdjustmentsMember" xlink:href="atnf-20250625.xsd#atnf_TotalEquityAwardAdjustmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_TotalEquityAwardAdjustmentsMember" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_AverageReportedValueOfEquityAwardsMember" xlink:href="atnf-20250625.xsd#atnf_AverageReportedValueOfEquityAwardsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_AverageReportedValueOfEquityAwardsMember" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_AverageEquityAwardAdjustmentsMember" xlink:href="atnf-20250625.xsd#atnf_AverageEquityAwardAdjustmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_AverageEquityAwardAdjustmentsMember" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember" xlink:href="atnf-20250625.xsd#atnf_YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember" xlink:href="atnf-20250625.xsd#atnf_AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember" order="41" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnf_TotalAverageEquityAwardAdjustmentsMember" xlink:href="atnf-20250625.xsd#atnf_TotalAverageEquityAwardAdjustmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="atnf_TotalAverageEquityAwardAdjustmentsMember" order="43" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>atnf-20250625_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Jun 25 21:05:44 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="atnf_AllOtherCompensation" xlink:href="atnf-20250625.xsd#atnf_AllOtherCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_AllOtherCompensation_lbl" xml:lang="en-US">All Other Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_AllOtherCompensation" xlink:to="atnf_AllOtherCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_AllOtherCompensation_lbl0" xml:lang="en-US">All other compensation for the period that could not be properly reported in any other column of the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_AllOtherCompensation" xlink:to="atnf_AllOtherCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_Bonus" xlink:href="atnf-20250625.xsd#atnf_Bonus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_Bonus_lbl" xml:lang="en-US">Bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_Bonus" xlink:to="atnf_Bonus_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_Bonus_lbl0" xml:lang="en-US">The dollar value of bonus (cash and non-cash) earned by the named executive officer during the period as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_Bonus" xlink:to="atnf_Bonus_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_EquityAwards" xlink:href="atnf-20250625.xsd#atnf_EquityAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_EquityAwards_lbl" xml:lang="en-US">Equity Awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwards" xlink:to="atnf_EquityAwards_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_EquityAwards_lbl0" xml:lang="en-US">The aggregate grant date fair value computed in accordance with FASB ASC Topic 718 of all equity awards granted during the period as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwards" xlink:to="atnf_EquityAwards_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_NonEquityIncentivePlanCompensation" xlink:href="atnf-20250625.xsd#atnf_NonEquityIncentivePlanCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_NonEquityIncentivePlanCompensation_lbl" xml:lang="en-US">Non-Equity Incentive Plan Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_NonEquityIncentivePlanCompensation" xlink:to="atnf_NonEquityIncentivePlanCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_NonEquityIncentivePlanCompensation_lbl0" xml:lang="en-US">The dollar value of (1) all earnings for services performed during the period pursuant to awards under non-equity incentive plans and (2) all earnings on any outstanding awards under such plans as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_NonEquityIncentivePlanCompensation" xlink:to="atnf_NonEquityIncentivePlanCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_NonqualifiedDeferredCompensationEarnings" xlink:href="atnf-20250625.xsd#atnf_NonqualifiedDeferredCompensationEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_NonqualifiedDeferredCompensationEarnings_lbl" xml:lang="en-US">Nonqualified Deferred Compensation Earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_NonqualifiedDeferredCompensationEarnings" xlink:to="atnf_NonqualifiedDeferredCompensationEarnings_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_NonqualifiedDeferredCompensationEarnings_lbl0" xml:lang="en-US">Above-market or preferential earnings on compensation that is deferred on a basis that is not tax-qualified, including any such earnings on nonqualified defined contribution plans, as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_NonqualifiedDeferredCompensationEarnings" xlink:to="atnf_NonqualifiedDeferredCompensationEarnings_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_OptionAwards" xlink:href="atnf-20250625.xsd#atnf_OptionAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_OptionAwards_lbl" xml:lang="en-US">Option Awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_OptionAwards" xlink:to="atnf_OptionAwards_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_OptionAwards_lbl0" xml:lang="en-US">The aggregate grant date fair value computed in accordance with FASB ASC Topic 718 for any awards of options, with or without tandem Stock Appreciation Rights (SARs), as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_OptionAwards" xlink:to="atnf_OptionAwards_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_Pension" xlink:href="atnf-20250625.xsd#atnf_Pension"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_Pension_lbl" xml:lang="en-US">Pension</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_Pension" xlink:to="atnf_Pension_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_Pension_lbl0" xml:lang="en-US">The aggregate pension value, as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_Pension" xlink:to="atnf_Pension_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_Salary" xlink:href="atnf-20250625.xsd#atnf_Salary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_Salary_lbl" xml:lang="en-US">Salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_Salary" xlink:to="atnf_Salary_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_Salary_lbl0" xml:lang="en-US">The dollar value of base salary (cash and non-cash) earned by the named executive officer during the period as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_Salary" xlink:to="atnf_Salary_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_StockAwards" xlink:href="atnf-20250625.xsd#atnf_StockAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_StockAwards_lbl" xml:lang="en-US">Stock Awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_StockAwards" xlink:to="atnf_StockAwards_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_StockAwards_lbl0" xml:lang="en-US">The aggregate grant date fair value computed in accordance with FASB ASC Topic 718 of all stock awards granted during the period as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_StockAwards" xlink:to="atnf_StockAwards_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_AverageEquityAwardAdjustmentsMember" xlink:href="atnf-20250625.xsd#atnf_AverageEquityAwardAdjustmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_AverageEquityAwardAdjustmentsMember_lbl" xml:lang="en-US">Average Equity Award Adjustments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_AverageEquityAwardAdjustmentsMember" xlink:to="atnf_AverageEquityAwardAdjustmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_lbl" xml:lang="en-US">Average Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" xlink:to="atnf_AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember_lbl" xml:lang="en-US">Average Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember" xlink:to="atnf_AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_AverageReportedValueOfEquityAwardsMember" xlink:href="atnf-20250625.xsd#atnf_AverageReportedValueOfEquityAwardsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_AverageReportedValueOfEquityAwardsMember_lbl" xml:lang="en-US">Average Reported Value of Equity Awards [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_AverageReportedValueOfEquityAwardsMember" xlink:to="atnf_AverageReportedValueOfEquityAwardsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember" xlink:href="atnf-20250625.xsd#atnf_AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember_lbl" xml:lang="en-US">Average Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember" xlink:to="atnf_AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember_lbl" xml:lang="en-US">Average Year End Fair Value of Outstanding and Unvested Equity Awards Granted in the Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" xlink:to="atnf_AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_BlairJordanMember" xlink:href="atnf-20250625.xsd#atnf_BlairJordanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_BlairJordanMember_lbl" xml:lang="en-US">Blair Jordan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_BlairJordanMember" xlink:to="atnf_BlairJordanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_ChangeInPensionValueAndEquityAwardValueMember" xlink:href="atnf-20250625.xsd#atnf_ChangeInPensionValueAndEquityAwardValueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_ChangeInPensionValueAndEquityAwardValueMember_lbl" xml:lang="en-US">Change In Pension Value and Equity Award Value [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_ChangeInPensionValueAndEquityAwardValueMember" xlink:to="atnf_ChangeInPensionValueAndEquityAwardValueMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_ChangeInPensionValueAndEquityAwardValueMember_lbl0" xml:lang="en-US">This member presents the total compensation adjustment for change in pension value and equity award value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_ChangeInPensionValueAndEquityAwardValueMember" xlink:to="atnf_ChangeInPensionValueAndEquityAwardValueMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_CompensationActuallyPaidToPEOMember" xlink:href="atnf-20250625.xsd#atnf_CompensationActuallyPaidToPEOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_CompensationActuallyPaidToPEOMember_lbl" xml:lang="en-US">Compensation Actually Paid to PEO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_CompensationActuallyPaidToPEOMember" xlink:to="atnf_CompensationActuallyPaidToPEOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_EquityAwardAdjustmentsBMember" xlink:href="atnf-20250625.xsd#atnf_EquityAwardAdjustmentsBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_EquityAwardAdjustmentsBMember_lbl" xml:lang="en-US">Equity Award Adjustments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardAdjustmentsBMember" xlink:to="atnf_EquityAwardAdjustmentsBMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" xlink:href="atnf-20250625.xsd#atnf_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl" xml:lang="en-US">Adjustments For Equity Awards Failed To Meet Performance Conditions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" xlink:to="atnf_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on adjustments for equity awards that failed to meet performance conditions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" xlink:to="atnf_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" xlink:href="atnf-20250625.xsd#atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl" xml:lang="en-US">Change In Fair Value As Of Vesting Date Of Current Year Awards Vested During Current Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" xlink:to="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value (as of vesting date) of current  year awards vested during current year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" xlink:to="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" xlink:href="atnf-20250625.xsd#atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl" xml:lang="en-US">Change In Fair Value As Of Vesting Date Of Prior Year Awards Vested During Current Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" xlink:to="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value (as of vesting date) of prior year awards vested during current year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" xlink:to="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" xlink:href="atnf-20250625.xsd#atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl" xml:lang="en-US">Change In Fair Value As Of Vesting Date Of Awards Vested During Current Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" xlink:to="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value (as of vesting date) of awards vested during current year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" xlink:to="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl0"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYM+UlHLczcqbucHL1cUHtO5ZA3CBy6Cnl1u0hNGYUJhU9MD+qgJoti/zZADG7OuMan4t3iVetxmlYo9mIYxg8aUc1sICnD6ZN9kGDNSMEWJyH/5VmDEDF+HH3jJpoE/3Xr9sIiQ2lg3f39PBQDOe4cNqZ5yD/bsJckSeUK02fsnO8Ow2XkqZ573IIYH33f5D/M1PPogapnohjWQWbv0965CSAChCFl925fjcRtOLrxKku8iOiwG7KXr21xmIo/YsxzPsBl/LX07Q==] CSR-->
    <loc xlink:type="locator" xlink:label="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" xlink:href="atnf-20250625.xsd#atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl" xml:lang="en-US">Change In Fair Value Of Outstanding And Unvested Awards Granted In Prior Fiscal Years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" xlink:to="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value from the end of the prior fiscal year of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" xlink:to="atnf_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" xlink:href="atnf-20250625.xsd#atnf_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl" xml:lang="en-US">Dividends Or Other Earnings Paid On Equity Awards Not Otherwise Reflected In Fair Value [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" xlink:to="atnf_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on dividends or other earnings paid on equity awards not otherwise reflected in fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" xlink:to="atnf_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_EquityAwardsAdjustmentsMember" xlink:href="atnf-20250625.xsd#atnf_EquityAwardsAdjustmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_EquityAwardsAdjustmentsMember_lbl" xml:lang="en-US">Total Equity Awards Adjustments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsMember" xlink:to="atnf_EquityAwardsAdjustmentsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_EquityAwardsAdjustmentsMember_lbl0" xml:lang="en-US">This member presents the total equity awards adjustments, which may be comprised of adjustments for (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the change in fair value from the end of the prior fiscal year of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards granted in prior years that vest in the applicable year, the amount equal to the change in value as of the vesting date (from the end of the prior fiscal year); (iv) adjustments for equity awards that failed to meet performance conditions; and (v) dividends or other earnings paid on equity awards not otherwise reflected in fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsMember" xlink:to="atnf_EquityAwardsAdjustmentsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" xlink:href="atnf-20250625.xsd#atnf_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl" xml:lang="en-US">Year-end Fair Value Of Awards Granted In The Current Fiscal Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" xlink:to="atnf_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" xlink:to="atnf_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_EquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:href="atnf-20250625.xsd#atnf_EquityAwardsValueInCompensationTableForTheApplicableYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl" xml:lang="en-US">Equity Awards Value In Summary Compensation Table (Grant Date Value) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="atnf_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl0" xml:lang="en-US">This member presents the adjustment (deduction) for equity awards value from summary compensation table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_EquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="atnf_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_lbl" xml:lang="en-US">Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" xlink:to="atnf_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember_lbl" xml:lang="en-US">Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember" xlink:to="atnf_FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_JamesNWoodyMember" xlink:href="atnf-20250625.xsd#atnf_JamesNWoodyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_JamesNWoodyMember_lbl" xml:lang="en-US">James N. Woody [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_JamesNWoodyMember" xlink:to="atnf_JamesNWoodyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_NetAdjustmentsForEquityAwardsMember" xlink:href="atnf-20250625.xsd#atnf_NetAdjustmentsForEquityAwardsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_NetAdjustmentsForEquityAwardsMember_lbl" xml:lang="en-US">Total Net Adjustments For Equity Awards [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_NetAdjustmentsForEquityAwardsMember" xlink:to="atnf_NetAdjustmentsForEquityAwardsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_NetAdjustmentsForEquityAwardsMember_lbl0" xml:lang="en-US">This member presents the net compensation adjustment for equity awards, which is comprised of equity awards value from summary compensation table, net of total equity awards adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_NetAdjustmentsForEquityAwardsMember" xlink:to="atnf_NetAdjustmentsForEquityAwardsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_NetAdjustmentsForPensionMember" xlink:href="atnf-20250625.xsd#atnf_NetAdjustmentsForPensionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_NetAdjustmentsForPensionMember_lbl" xml:lang="en-US">Total Net Adjustments For Pension [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_NetAdjustmentsForPensionMember" xlink:to="atnf_NetAdjustmentsForPensionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_NetAdjustmentsForPensionMember_lbl0" xml:lang="en-US">This member presents the net compensation adjustment for pension, which is comprised of pension value from summary compensation table, net of total pension adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_NetAdjustmentsForPensionMember" xlink:to="atnf_NetAdjustmentsForPensionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_PensionAdjustmentsMember" xlink:href="atnf-20250625.xsd#atnf_PensionAdjustmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_PensionAdjustmentsMember_lbl" xml:lang="en-US">Total Pension Adjustments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_PensionAdjustmentsMember" xlink:to="atnf_PensionAdjustmentsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_PensionAdjustmentsMember_lbl0" xml:lang="en-US">This member presents the total pension adjustments, which may be comprised of adjustments for service cost and prior service cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_PensionAdjustmentsMember" xlink:to="atnf_PensionAdjustmentsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_PensionAdjustmentsPriorServiceCostMember" xlink:href="atnf-20250625.xsd#atnf_PensionAdjustmentsPriorServiceCostMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnf_PensionAdjustmentsPriorServiceCostMember_lbl" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_PensionAdjustmentsPriorServiceCostMember" xlink:to="atnf_PensionAdjustmentsPriorServiceCostMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_PensionAdjustmentsPriorServiceCostMember_lbl0" xml:lang="en-US">This member presents the total pension adjustments, prior service cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_PensionAdjustmentsPriorServiceCostMember" xlink:to="atnf_PensionAdjustmentsPriorServiceCostMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_PensionAdjustmentsServiceCostMember" xlink:href="atnf-20250625.xsd#atnf_PensionAdjustmentsServiceCostMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnf_PensionAdjustmentsServiceCostMember_lbl" xml:lang="en-US">Pension Adjustments Service Cost [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_PensionAdjustmentsServiceCostMember" xlink:to="atnf_PensionAdjustmentsServiceCostMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_PensionAdjustmentsServiceCostMember_lbl0" xml:lang="en-US">This member presents the pension adjustments, service cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_PensionAdjustmentsServiceCostMember" xlink:to="atnf_PensionAdjustmentsServiceCostMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:href="atnf-20250625.xsd#atnf_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl" xml:lang="en-US">Pension Value And Equity Awards Value In Compensation Table For The Applicable Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="atnf_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl0" xml:lang="en-US">This member presents the total compensation adjustment for pension value and equity awards value in compensation table for the applicable year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="atnf_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_PensionValueInCompensationTableForTheApplicableYearMember" xlink:href="atnf-20250625.xsd#atnf_PensionValueInCompensationTableForTheApplicableYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_PensionValueInCompensationTableForTheApplicableYearMember_lbl" xml:lang="en-US">Pension Adjustments Pension Value In Summary Compensation Table [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_PensionValueInCompensationTableForTheApplicableYearMember" xlink:to="atnf_PensionValueInCompensationTableForTheApplicableYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnf_PensionValueInCompensationTableForTheApplicableYearMember_lbl0" xml:lang="en-US">This member presents the adjustment (deduction) for pension value from summary compensation table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_PensionValueInCompensationTableForTheApplicableYearMember" xlink:to="atnf_PensionValueInCompensationTableForTheApplicableYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnf_ReportedSummaryCompensationTableTotalForPEOMember" xlink:href="atnf-20250625.xsd#atnf_ReportedSummaryCompensationTableTotalForPEOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_ReportedSummaryCompensationTableTotalForPEOMember_lbl" xml:lang="en-US">Reported Summary Compensation Table Total for PEO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_ReportedSummaryCompensationTableTotalForPEOMember" xlink:to="atnf_ReportedSummaryCompensationTableTotalForPEOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_ReportedValueOfEquityAwardsAMember" xlink:href="atnf-20250625.xsd#atnf_ReportedValueOfEquityAwardsAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_ReportedValueOfEquityAwardsAMember_lbl" xml:lang="en-US">Reported Value of Equity Awards [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_ReportedValueOfEquityAwardsAMember" xlink:to="atnf_ReportedValueOfEquityAwardsAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_TotalAverageEquityAwardAdjustmentsMember" xlink:href="atnf-20250625.xsd#atnf_TotalAverageEquityAwardAdjustmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_TotalAverageEquityAwardAdjustmentsMember_lbl" xml:lang="en-US">Total Average Equity Award Adjustments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_TotalAverageEquityAwardAdjustmentsMember" xlink:to="atnf_TotalAverageEquityAwardAdjustmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_TotalEquityAwardAdjustmentsMember" xlink:href="atnf-20250625.xsd#atnf_TotalEquityAwardAdjustmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_TotalEquityAwardAdjustmentsMember_lbl" xml:lang="en-US">Total Equity Award Adjustments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_TotalEquityAwardAdjustmentsMember" xlink:to="atnf_TotalEquityAwardAdjustmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember" xlink:href="atnf-20250625.xsd#atnf_ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember_lbl" xml:lang="en-US">Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember" xlink:to="atnf_ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember" xlink:href="atnf-20250625.xsd#atnf_YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember_lbl" xml:lang="en-US">Year End Fair Value of Outstanding and Unvested Equity Awards Granted in Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember" xlink:to="atnf_YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember_lbl" xml:lang="en-US">Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" xlink:to="atnf_YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember" xlink:href="atnf-20250625.xsd#atnf_YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember_lbl" xml:lang="en-US">Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember" xlink:to="atnf_YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember_lbl" xml:lang="en-US">Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" xlink:to="atnf_YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnf_YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember" xlink:href="atnf-20250625.xsd#atnf_YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember_lbl" xml:lang="en-US">Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember" xlink:to="atnf_YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_PensionAdjustmentsPriorServiceCostMember_lbl1" xml:lang="en-US">Pension Adjustments Prior Service Cost Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_PensionAdjustmentsPriorServiceCostMember" xlink:to="atnf_PensionAdjustmentsPriorServiceCostMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnf_PensionAdjustmentsServiceCostMember_lbl1" xml:lang="en-US">Pension Adjustments Service Cost Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnf_PensionAdjustmentsServiceCostMember" xlink:to="atnf_PensionAdjustmentsServiceCostMember_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>atnf-20250625_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Jun 25 21:05:44 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"/>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <loc xlink:type="locator" xlink:label="BlairJordanMember" xlink:href="atnf-20250625.xsd#atnf_BlairJordanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="BlairJordanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="JamesNWoodyMember" xlink:href="atnf-20250625.xsd#atnf_JamesNWoodyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="JamesNWoodyMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <loc xlink:type="locator" xlink:label="BlairJordanMember" xlink:href="atnf-20250625.xsd#atnf_BlairJordanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="BlairJordanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="JamesNWoodyMember" xlink:href="atnf-20250625.xsd#atnf_JamesNWoodyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="JamesNWoodyMember" order="0.01" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <loc xlink:type="locator" xlink:label="BlairJordanMember" xlink:href="atnf-20250625.xsd#atnf_BlairJordanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="BlairJordanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="JamesNWoodyMember" xlink:href="atnf-20250625.xsd#atnf_JamesNWoodyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="JamesNWoodyMember" order="0.01" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <loc xlink:type="locator" xlink:label="BlairJordanMember" xlink:href="atnf-20250625.xsd#atnf_BlairJordanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="BlairJordanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="JamesNWoodyMember" xlink:href="atnf-20250625.xsd#atnf_JamesNWoodyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="JamesNWoodyMember" order="0.01" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <loc xlink:type="locator" xlink:label="ReportedSummaryCompensationTableTotalForPEOMember" xlink:href="atnf-20250625.xsd#atnf_ReportedSummaryCompensationTableTotalForPEOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="ReportedSummaryCompensationTableTotalForPEOMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYM+UlHLczcqbucHL1cUHtO5ZA3CBy6Cnl1u0hNGYUJhU9MD+qgJoti/zZADG7OuMan4t3iVetxmlYo9mIYxg8aUc1sICnD6ZN9kGDNSMEWJyH/5VmDEDF+HH3jJpoE/3Xr9sIiQ2lg3f39PBQDOe4cNqZ5yD/bsJckSeUK02fsnO8Ow2XkqZ573IIYH33f5D/M1PPogapnohjWQWbv0965CSAChCFl925fjcRtOLrxKku8iOiwG7KX8fKqaz65TIP2qZ1xHjoYXQ==] CSR-->
    <loc xlink:type="locator" xlink:label="ReportedValueOfEquityAwardsAMember" xlink:href="atnf-20250625.xsd#atnf_ReportedValueOfEquityAwardsAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="ReportedValueOfEquityAwardsAMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EquityAwardAdjustmentsBMember" xlink:href="atnf-20250625.xsd#atnf_EquityAwardAdjustmentsBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="EquityAwardAdjustmentsBMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CompensationActuallyPaidToPEOMember" xlink:href="atnf-20250625.xsd#atnf_CompensationActuallyPaidToPEOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="CompensationActuallyPaidToPEOMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember" xlink:href="atnf-20250625.xsd#atnf_YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember" xlink:href="atnf-20250625.xsd#atnf_YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember" xlink:href="atnf-20250625.xsd#atnf_ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TotalEquityAwardAdjustmentsMember" xlink:href="atnf-20250625.xsd#atnf_TotalEquityAwardAdjustmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="TotalEquityAwardAdjustmentsMember" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AverageReportedValueOfEquityAwardsMember" xlink:href="atnf-20250625.xsd#atnf_AverageReportedValueOfEquityAwardsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="AverageReportedValueOfEquityAwardsMember" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AverageEquityAwardAdjustmentsMember" xlink:href="atnf-20250625.xsd#atnf_AverageEquityAwardAdjustmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="AverageEquityAwardAdjustmentsMember" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember" xlink:href="atnf-20250625.xsd#atnf_YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember" xlink:href="atnf-20250625.xsd#atnf_AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember" xlink:href="atnf-20250625.xsd#atnf_AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember" order="42.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TotalAverageEquityAwardAdjustmentsMember" xlink:href="atnf-20250625.xsd#atnf_TotalAverageEquityAwardAdjustmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="TotalAverageEquityAwardAdjustmentsMember" order="44.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">PRE 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">180 LIFE SCIENCES CORP.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001690080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTableTextBlock', window );">Pay vs Performance Disclosure, Table</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Pay Versus Performance</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This section provides disclosure
about the relationship between executive compensation actually paid to our principal executive officer (&#8220;<span style="text-decoration:underline">PEO</span>&#8221;) and
non-PEO Named Executive Officers (&#8220;<span style="text-decoration:underline">NEOs</span>&#8221;) and certain financial performance measures of the Company for the fiscal
years listed below. This disclosure has been prepared in accordance with Item 402(v) of Regulation S-K under the Exchange Act (the &#8220;<span style="text-decoration:underline">Pay
Versus Performance Rules</span>&#8221;) and does not necessarily reflect how the Compensation Committee evaluates compensation decisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Fiscal Year<sup>(1)</sup></b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-decoration: none; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><b>Summary Compensation Table Total for Blair Jordan <sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Compensation Actually Paid to Blair Jordan<sup>(3)(4)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Summary Compensation Table Total for James N. Woody <sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Compensation Actually Paid to James N. Woody<sup>(3)(4)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Average Summary Compensation Table Total for Non-PEO NEOs<sup>(5)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Average Compensation Actually Paid to Non-PEO NEOs<sup>(6)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Value of Initial Fixed $100 Investment Based on Total shareholder Return (&#8220;TSR&#8221;)<sup>(7)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; text-decoration: none"><b>Net Loss (in thousands)<sup>(8)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">(a)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(b)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(b)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(c)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(c)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(d)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(e)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(f)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(g)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td></tr> <tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 12%; text-align: left">2024</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">140,107</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">140,107</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">100,250</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">100,250</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">137,688</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">137,688</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.12</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">(6,168</td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">2023</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-2">&#8212;</span></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-3">&#8212;</span></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">656,800</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">605,147</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">356,889</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">351,330</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">0.27</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">(19,935</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">2022</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-4">&#8212;</span></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-5">&#8212;</span></td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">463,500</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">(1,366,665</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">437,699</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">8,909</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">4.35</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: normal 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">(38,726</td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14pt; text-indent: -14pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">The following table lists the PEO and non-PEO&#160;NEOs for each of fiscal years 2024, 2023 and 2022:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14pt; text-indent: -14pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 7%"><span style="font-size: 10pt"><b>Year</b></span></td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 40%"><span style="font-size: 10pt"><b>PEO</b></span></td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 51%"><span style="font-size: 10pt"><b>Non-PEO NEOs</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt"><b>2024</b></span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><span style="font-size: 10pt">Blair Jordan and James N. Woody</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><span style="font-size: 10pt">Omar Jimenez, Ozan Pamir, Jonathan Rothbard</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt"><b>2023</b></span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><span style="font-size: 10pt">James N. Woody</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><span style="font-size: 10pt">Ozan Pamir, Jonathan Rothbard, and Quan Anh Vu</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt"><b>2022</b></span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><span style="font-size: 10pt">James N. Woody</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><span style="font-size: 10pt">Ozan Pamir, Jonathan Rothbard, and Quan Anh Vu</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><sup>(2)</sup></span></td><td style="text-align: justify"><span style="font-size: 10pt">The dollar amounts reported in
column (b) are the amounts of total compensation reported for our CEOs for each corresponding year in the &#8220;Total&#8221; column
of the Summary Executive Compensation Table. Refer to &#8220;Executive and Director Compensation&#8212;Summary Executive Compensation
Table&#8221;.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(3)</sup></span></td> <td style="text-align: justify"><span style="font-size: 10pt">The dollar amounts reported represent the amount of &#8220;compensation actually paid,&#8221; as calculated in accordance with the Pay Versus Performance Rules. These dollar amounts do not reflect the actual amounts of compensation earned by or paid to our PEOs during the applicable year. For purposes of calculating &#8220;compensation actually paid,&#8221; the fair value of equity awards is calculated in accordance with FASB ASC Topic 718 using the same assumption methodologies used to calculate the grant date fair value of awards for purposes of the Summary Compensation Table (refer to the Summary Compensation Table for additional information).</span></td></tr>
</table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(4)</sup></span></td> <td style="text-align: justify"><span style="font-size: 10pt">The following table shows the amounts deducted from and added to the Summary Compensation Table total to calculate &#8220;compensation actually paid&#8221; to our PEOs in accordance with the Pay Versus Performance Rules:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Blair Jordan</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Reported Summary Compensation<br/> Table Total for PEO</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Reported Value<br/> of Equity Awards (A)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity Award<br/> Adjustments (B)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Compensation<br/> Actually Paid to PEO</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 19%; text-align: left">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">140,107</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-6">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-7">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">140,107</td><td style="width: 1%; text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">James N. Woody</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Reported Summary Compensation<br/> Table Total for PEO</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Reported Value<br/> of Equity Awards (A)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity Award<br/> Adjustments (B)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Compensation<br/> Actually Paid to PEO</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 19%; text-align: left">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">100,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-8">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-9">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">100,250</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">656,800</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(39,025</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-10">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">605,147</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">463,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-11">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(1,830,165</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(1,366,665</td><td style="text-align: left">)</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">(A)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The grant date fair value of equity awards represents the sum of the totals of the amounts reported in the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; columns in the Summary Executive Compensation Table for the applicable year.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">(B)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards that are granted and vest in same applicable year, the fair value as of the vesting date; (iv) for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v) for awards granted in prior years that are determined to fail to meet the applicable vesting conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi) the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable year. The amounts deducted or added in calculating the equity award adjustments are as follows:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">Blair Jordan</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; width: 17%; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Year</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year End Fair Value of<br/> Outstanding<br/> and Unvested<br/> Equity Awards<br/> Granted in<br/> Year</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year over Year<br/> Change in Fair Value of<br/> Outstanding<br/> and Unvested<br/> Equity Awards<br/> Granted in<br/> Prior Years</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Fair Value<br/> as of<br/> Vesting<br/> Date of<br/> Equity<br/> Awards<br/> Granted<br/> and<br/> Vested in<br/> the Year</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year over Year<br/> Change in<br/> Fair Value of<br/> Equity Awards Granted in Prior Years that Vested<br/> in&#160;the Year</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Fair Value<br/> at the End of<br/> the Prior<br/> Year of Equity<br/> Awards that<br/> Failed to Meet<br/> Vesting<br/> Conditions in<br/> the Year</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Value of<br/> Dividends or<br/> other<br/> Earnings Paid<br/> on Stock or<br/> Option Awards not<br/> Otherwise<br/> Reflected in<br/> Fair Value or<br/> Total<br/> Compensation</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; width: 1%; font-weight: bold">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 9%">Total Equity Award Adjustments</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-12">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-13">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-14">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-15">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-16">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-17">&#8212;</span></td><td style="text-align: left">&#160;</td><td>$</td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-18">&#8212;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">James N. Woody</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year End Fair Value of<br/> Outstanding<br/> and Unvested<br/> Equity Awards<br/> Granted in<br/> Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year over Year<br/> Change in Fair Value of<br/> Outstanding<br/> and Unvested<br/> Equity Awards<br/> Granted in<br/> Prior Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value<br/> as of<br/> Vesting<br/> Date of<br/> Equity<br/> Awards<br/> Granted<br/> and<br/> Vested in<br/> the Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year over Year<br/> Change in<br/> Fair Value of<br/> Equity Awards Granted in Prior Years that Vested<br/> in&#160;the Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value<br/> at the End of<br/> the Prior<br/> Year of Equity<br/> Awards that<br/> Failed to Meet<br/> Vesting<br/> Conditions in<br/> the Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value of<br/> Dividends or<br/> other<br/> Earnings Paid<br/> on Stock or<br/> Option Awards not<br/> Otherwise<br/> Reflected in<br/> Fair Value or<br/> Total<br/> Compensation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Equity<br/> Award<br/> Adjustments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-19">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-20">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-21">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-22">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-23">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-24">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-25">&#8212;</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 16%; text-align: left">2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,596</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(8,108</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,445</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(31,561</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-26">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-27">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(12,628</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">40,138</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(1,426,068</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">406,256</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(850,492</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-28">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-1">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(1,830,165</td><td style="text-align: left">)</td></tr> </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(5)</sup></span></td> <td style="text-align: justify"><span style="font-size: 10pt">The dollar amounts reported in column (d) represent the average of the amounts reported for our company&#8217;s Non-PEO NEOs as a group in the &#8220;Total&#8221; column of the Summary Executive Compensation Table in each applicable year. </span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(6)</sup></span></td> <td style="text-align: justify"><span style="font-size: 10pt">The dollar amounts reported in column (e) represent the average amount of &#8220;compensation actually paid&#8221; to the Non-PEO NEOs as a group, as computed in accordance with the Pay Versus Performance Rules. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the Non-PEO NEOs as a group during the applicable year. In accordance with the Pay Versus Performance Rules, the following adjustments were made to average total compensation for the Non-PEO NEOs for each year to determine the compensation actually paid, using the same methodology described above in Note (4)(B):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Reported<br/> Summary<br/> Compensation<br/> Table Total<br/> for Non-PEO NEOs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Reported<br/> Value of Equity<br/> Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Average Equity<br/> Award Adjustments&#160;<sup>(a)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average<br/> Compensation<br/> Actually Paid<br/> to Non-PEO NEOs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: left">2024</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">137,688</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-29">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-30">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">137,688</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">356,889</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(2,602</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(2,957</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">351,330</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">437,699</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-31">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(428,790</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">8,909</td><td style="text-align: left">&#160;</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(a)</sup></span></td> <td style="text-align: justify"><span style="font-size: 10pt">The amounts deducted or added in calculating the total average equity award adjustments are as follows:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Year<br/> End Fair<br/> Value of<br/> Outstanding<br/> and Unvested<br/> Equity Awards<br/> Granted in the Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year over Year<br/> Average Change in Fair Value of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding<br/> and Unvested<br/> Equity Awards<br/> Granted in<br/> Prior Years</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Fair<br/> Value as of<br/> Vesting Date of Equity<br/> Awards Granted and<br/> Vested in the<br/> Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year over<br/> Year Average Change<br/> in Fair Value of Equity<br/> Awards Granted in Prior Years<br/> that Vested<br/> in the Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Fair Value at the End of the<br/> Prior Year of<br/> Equity Awards<br/> that Failed to Meet Vesting<br/> Conditions in<br/> the Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Average Value of Dividends<br/> or other Earnings<br/> Paid on Stock<br/> or Option</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Awards not</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Otherwise Reflected in<br/> Fair Value<br/> or Total Compensation</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Average Equity<br/> Award<br/> Adjustments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-32">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-33">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-34">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-35">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-36">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-37">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-38">&#8212;</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 12%; text-align: left">2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">859</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(1,304</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,612</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(6,124</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-39">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-40">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,957</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">11,774</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(367,087</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">81,450</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(154,927</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-41">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-42">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(428,790</td><td style="text-align: left">)</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(7)</sup></span></td> <td style="text-align: justify"><span style="font-size: 10pt">Assumes $100 invested in our common shares on December 31, 2021, and calculated based on the difference between the share price of our common stock at the end and the beginning of the measurement period, and reinvestment of all dividends. No cash dividends were paid in 2022, 2023 or 2024.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(8)</sup></span></td> <td style="text-align: justify"><span style="font-size: 10pt">The dollar amounts reported represent the amount of net loss reflected in our consolidated audited financial statements for the applicable year.</span></td></tr> </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NamedExecutiveOfficersFnTextBlock', window );">Named Executive Officers, Footnote</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">The following table lists the PEO and non-PEO&#160;NEOs for each of fiscal years 2024, 2023 and 2022:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 7%"><span style="font-size: 10pt"><b>Year</b></span></td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 40%"><span style="font-size: 10pt"><b>PEO</b></span></td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 51%"><span style="font-size: 10pt"><b>Non-PEO NEOs</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt"><b>2024</b></span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><span style="font-size: 10pt">Blair Jordan and James N. Woody</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><span style="font-size: 10pt">Omar Jimenez, Ozan Pamir, Jonathan Rothbard</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt"><b>2023</b></span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><span style="font-size: 10pt">James N. Woody</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><span style="font-size: 10pt">Ozan Pamir, Jonathan Rothbard, and Quan Anh Vu</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt"><b>2022</b></span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><span style="font-size: 10pt">James N. Woody</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td> <td><span style="font-size: 10pt">Ozan Pamir, Jonathan Rothbard, and Quan Anh Vu</span></td></tr> </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 137,688<span></span>
</td>
<td class="nump">$ 356,889<span></span>
</td>
<td class="nump">$ 437,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">$ 137,688<span></span>
</td>
<td class="nump">351,330<span></span>
</td>
<td class="nump">8,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock', window );">Compensation Actually Paid vs. Total Shareholder Return</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation Actually
Paid and Cumulative TSR</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As shown in the following
graph, the compensation actually paid to our PEOs and the average amount of compensation actually paid to our non-PEO NEOs as a group
during the periods presented do have some correlation because a portion of their compensation has historically been in the form of long-term
equity awards. The equity awards values are significantly impacted by changes in our stock price each period. These equity awards strongly
align our executive officers&#8217; interests with those of our stockholders by providing a continuing financial incentive to maximize
long-term value for our stockholders and by encouraging our executive officers to continue in our employment for the long-term.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_003.jpg"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>All information provided
above under the &#8220;Pay Versus Performance&#8221; and &#8220;Relationship Between &#8220;Compensation Actually Paid&#8221; and Performance&#8221;,
headings will not be deemed to be incorporated by reference in any filing of our company under the Securities Act, whether made before
or after the date hereof and irrespective of any general incorporation language in any such filing.</i></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsNetIncomeTextBlock', window );">Compensation Actually Paid vs. Net Income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation Actually
Paid and Net Loss</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our company has not historically
looked to net loss as a performance measure for our executive compensation program. Our net loss was $38.7 million in 2022, $19.9 million
in 2023 and $6.17 in 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_002.jpg"/></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnAmt', window );">Total Shareholder Return Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[4]</sup></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">0.27<span></span>
</td>
<td class="nump">4.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[5]</sup></td>
<td class="num">$ (6,168,000)<span></span>
</td>
<td class="num">$ (19,935,000)<span></span>
</td>
<td class="num">$ (38,726,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoName', window );">PEO Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Blair Jordan and James N. Woody<span></span>
</td>
<td class="text">James N. Woody<span></span>
</td>
<td class="text">James N. Woody<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Additional402vDisclosureTextBlock', window );">Additional 402(v) Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_EqtyAwrdsAdjFnTextBlock', window );">Equity Awards Adjustments, Footnote</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards that are granted and vest in same applicable year, the fair value as of the vesting date; (iv) for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v) for awards granted in prior years that are determined to fail to meet the applicable vesting conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi) the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable year. The amounts deducted or added in calculating the equity award adjustments are as follows<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=atnf_EquityAwardAdjustmentsBMember', window );">Equity Award Adjustments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=atnf_AverageReportedValueOfEquityAwardsMember', window );">Average Reported Value of Equity Awards [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,602)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=atnf_AverageEquityAwardAdjustmentsMember', window );">Average Equity Award Adjustments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,957)<span></span>
</td>
<td class="num">(428,790)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=atnf_AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember', window );">Average Year End Fair Value of Outstanding and Unvested Equity Awards Granted in the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">859<span></span>
</td>
<td class="nump">11,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=atnf_YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember', window );">Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,304)<span></span>
</td>
<td class="num">(367,087)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=atnf_AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember', window );">Average Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,612<span></span>
</td>
<td class="nump">81,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=atnf_YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember', window );">Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(6,124)<span></span>
</td>
<td class="num">(154,927)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=atnf_AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember', window );">Average Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=atnf_AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember', window );">Average Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAxis=atnf_TotalAverageEquityAwardAdjustmentsMember', window );">Total Average Equity Award Adjustments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,957)<span></span>
</td>
<td class="num">(428,790)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_BlairJordanMember', window );">Blair Jordan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[8]</sup></td>
<td class="nump">140,107<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[9],[10]</sup></td>
<td class="nump">140,107<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_BlairJordanMember', window );">Blair Jordan [Member] | Reported Summary Compensation Table Total for PEO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">140,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_BlairJordanMember', window );">Blair Jordan [Member] | Reported Value of Equity Awards [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[11]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_BlairJordanMember', window );">Blair Jordan [Member] | Equity Award Adjustments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_BlairJordanMember', window );">Blair Jordan [Member] | Compensation Actually Paid to PEO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">140,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_BlairJordanMember', window );">Blair Jordan [Member] | Year End Fair Value of Outstanding and Unvested Equity Awards Granted in Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_BlairJordanMember', window );">Blair Jordan [Member] | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_BlairJordanMember', window );">Blair Jordan [Member] | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_BlairJordanMember', window );">Blair Jordan [Member] | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_BlairJordanMember', window );">Blair Jordan [Member] | Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_BlairJordanMember', window );">Blair Jordan [Member] | Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_BlairJordanMember', window );">Blair Jordan [Member] | Total Equity Award Adjustments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_JamesNWoodyMember', window );">James N. Woody [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[8]</sup></td>
<td class="nump">100,250<span></span>
</td>
<td class="nump">656,800<span></span>
</td>
<td class="nump">463,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[9],[10]</sup></td>
<td class="nump">100,250<span></span>
</td>
<td class="nump">605,147<span></span>
</td>
<td class="num">(1,366,665)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_JamesNWoodyMember', window );">James N. Woody [Member] | Reported Summary Compensation Table Total for PEO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,250<span></span>
</td>
<td class="nump">656,800<span></span>
</td>
<td class="nump">463,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_JamesNWoodyMember', window );">James N. Woody [Member] | Reported Value of Equity Awards [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[11]</sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(39,025)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_JamesNWoodyMember', window );">James N. Woody [Member] | Equity Award Adjustments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,830,165)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_JamesNWoodyMember', window );">James N. Woody [Member] | Compensation Actually Paid to PEO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,250<span></span>
</td>
<td class="nump">605,147<span></span>
</td>
<td class="num">(1,366,665)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_JamesNWoodyMember', window );">James N. Woody [Member] | Year End Fair Value of Outstanding and Unvested Equity Awards Granted in Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,596<span></span>
</td>
<td class="nump">40,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_JamesNWoodyMember', window );">James N. Woody [Member] | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(8,108)<span></span>
</td>
<td class="num">(1,426,068)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_JamesNWoodyMember', window );">James N. Woody [Member] | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">18,445<span></span>
</td>
<td class="nump">406,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_JamesNWoodyMember', window );">James N. Woody [Member] | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(31,561)<span></span>
</td>
<td class="num">(850,492)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_JamesNWoodyMember', window );">James N. Woody [Member] | Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_JamesNWoodyMember', window );">James N. Woody [Member] | Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=atnf_JamesNWoodyMember', window );">James N. Woody [Member] | Total Equity Award Adjustments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (12,628)<span></span>
</td>
<td class="num">$ (1,830,165)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The dollar amounts reported in column (d) represent the average of the amounts reported for our company&#8217;s Non-PEO NEOs as a group in the &#8220;Total&#8221; column of the Summary Executive Compensation Table in each applicable year.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The following table lists the PEO and non-PEO&#160;NEOs for each of fiscal years 2024, 2023 and 2022:</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">The dollar amounts reported in column (e) represent the average amount of &#8220;compensation actually paid&#8221; to the Non-PEO NEOs as a group, as computed in accordance with the Pay Versus Performance Rules. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the Non-PEO NEOs as a group during the applicable year. In accordance with the Pay Versus Performance Rules, the following adjustments were made to average total compensation for the Non-PEO NEOs for each year to determine the compensation actually paid, using the same methodology described above in Note (4)(B):</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Assumes $100 invested in our common shares on December 31, 2021, and calculated based on the difference between the share price of our common stock at the end and the beginning of the measurement period, and reinvestment of all dividends. No cash dividends were paid in 2022, 2023 or 2024.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">The dollar amounts reported represent the amount of net loss reflected in our consolidated audited financial statements for the applicable year.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards that are granted and vest in same applicable year, the fair value as of the vesting date; (iv) for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v) for awards granted in prior years that are determined to fail to meet the applicable vesting conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi) the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable year. The amounts deducted or added in calculating the equity award adjustments are as follows:</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">The amounts deducted or added in calculating the total average equity award adjustments are as follows:</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">The dollar amounts reported in
column (b) are the amounts of total compensation reported for our CEOs for each corresponding year in the &#8220;Total&#8221; column
of the Summary Executive Compensation Table. Refer to &#8220;Executive and Director Compensation&#8212;Summary Executive Compensation
Table&#8221;.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">The dollar amounts reported represent the amount of &#8220;compensation actually paid,&#8221; as calculated in accordance with the Pay Versus Performance Rules. These dollar amounts do not reflect the actual amounts of compensation earned by or paid to our PEOs during the applicable year. For purposes of calculating &#8220;compensation actually paid,&#8221; the fair value of equity awards is calculated in accordance with FASB ASC Topic 718 using the same assumption methodologies used to calculate the grant date fair value of awards for purposes of the Summary Compensation Table (refer to the Summary Compensation Table for additional information).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[10]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">The following table shows the amounts deducted from and added to the Summary Compensation Table total to calculate &#8220;compensation actually paid&#8221; to our PEOs in accordance with the Pay Versus Performance Rules:</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[11]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">The grant date fair value of equity awards represents the sum of the totals of the amounts reported in the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; columns in the Summary Executive Compensation Table for the applicable year.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Additional402vDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Additional402vDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsNetIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsNetIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_EqtyAwrdsAdjFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br> -Sentence B<br> -Clause 1<br> -Subclause ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_EqtyAwrdsAdjFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NamedExecutiveOfficersFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NamedExecutiveOfficersFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgCompActuallyPaidAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoActuallyPaidCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoActuallyPaidCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_EquityAwardAdjustmentsBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_EquityAwardAdjustmentsBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_AverageReportedValueOfEquityAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_AverageReportedValueOfEquityAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_AverageEquityAwardAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_AverageEquityAwardAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_TotalAverageEquityAwardAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_TotalAverageEquityAwardAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=atnf_BlairJordanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=atnf_BlairJordanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_ReportedSummaryCompensationTableTotalForPEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_ReportedSummaryCompensationTableTotalForPEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_ReportedValueOfEquityAwardsAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_ReportedValueOfEquityAwardsAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_CompensationActuallyPaidToPEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_CompensationActuallyPaidToPEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=atnf_TotalEquityAwardAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=atnf_TotalEquityAwardAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=atnf_JamesNWoodyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=atnf_JamesNWoodyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recovery of Erroneously Awarded Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_RestatementDateAxis=2023-11-07', window );">Restatement Determination Date:: 2023-11-07</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ErrCompRecoveryTable', window );"><strong>Erroneously Awarded Compensation Recovery</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ErrCompAnalysisTextBlock', window );">Erroneous Compensation Analysis</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Compensation Recovery
and Clawback Policies</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Sarbanes-Oxley
Act of 2002 (the &#8220;<span style="text-decoration:underline">Sarbanes-Oxley Act</span>&#8221;), in the event of misconduct that results in a financial restatement that would
have reduced a previously paid incentive amount, we can recoup those improper payments from our Chief Executive Officer and Chief Financial
Officer (if any). The SEC also recently adopted rules which direct national stock exchanges to require listed companies to implement
policies intended to recoup bonuses paid to executives if the company is found to have misstated its financial results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 7, 2023, the
Board of Directors of the Company approved the adoption of a Policy for the Recovery of Erroneously Awarded Incentive Based Compensation
(the &#8220;<span style="text-decoration:underline">Clawback Policy</span>&#8221;), with an effective date of October 2, 2023, in order to comply with the final clawback rules
adopted by the SEC under Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (&#8220;<span style="text-decoration:underline">Rule 10D-1</span>&#8221;),
and the listing standards, as set forth in the Nasdaq Listing Rule 5608 (the &#8220;<span style="text-decoration:underline">Final Clawback Rules</span>&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Clawback Policy provides
for the mandatory recovery of erroneously awarded incentive-based compensation from current and former executive officers as defined
in Rule 10D-1 (&#8220;<span style="text-decoration:underline">Covered Officers</span>&#8221;) of the Company in the event that the Company is required to prepare an accounting
restatement, in accordance with the Final Clawback Rules. The recovery of such compensation applies regardless of whether a Covered Officer
engaged in misconduct or otherwise caused or contributed to the requirement of an accounting restatement. Under the Clawback Policy,
the Board of Directors may recoup from the Covered Officers erroneously awarded incentive compensation received within a lookback period
of the three completed fiscal years preceding the date on which the Company is required to prepare an accounting restatement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ErrCompAnalysisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br> -Paragraph 1<br> -Subparagraph i<br> -Sentence B<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 6<br> -Subsection F<br> -Paragraph 1<br> -Subparagraph i<br> -Sentence B<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Section 19<br> -Paragraph a<br> -Subparagraph 1<br> -Sentence ii<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-CSR<br> -Section 18<br> -Paragraph a<br> -Subparagraph 1<br> -Sentence ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ErrCompAnalysisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ErrCompRecoveryTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 6<br> -Subsection F<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Section 19<br> -Paragraph a<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-CSR<br> -Section 18<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ErrCompRecoveryTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_RestatementDateAxis=2023-11-07">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_RestatementDateAxis=2023-11-07</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgDiscLineItems', window );"><strong>Award Timing Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
and the Board have not established policies and practices (whether written or otherwise) regarding the timing of option grants, stock
appreciation rights and similar awards, or other awards, in relation to the release of material nonpublic information (&#8220;MNPI&#8221;)
and do not take MNPI into account when determining the timing and terms of stock option or other equity awards to executive officers,
provided that we do not currently grant stock options to employees or executives. The Company does not time the disclosure of MNPI, whether
positive or negative, for the purpose of affecting the value of executive compensation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMethodTextBlock', window );">Award Timing Method</a></td>
<td class="text">The Compensation Committee
and the Board have not established policies and practices (whether written or otherwise) regarding the timing of option grants, stock
appreciation rights and similar awards, or other awards, in relation to the release of material nonpublic information (&#8220;MNPI&#8221;)
and do not take MNPI into account when determining the timing and terms of stock option or other equity awards to executive officers,
provided that we do not currently grant stock options to employees or executives.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock', window );">Award Timing, How MNPI Considered</a></td>
<td class="text">the release of material nonpublic information (&#8220;MNPI&#8221;)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MnpiDiscTimedForCompValFlag', window );">MNPI Disclosure Timed for Compensation Value</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgDiscLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgDiscLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgHowMnpiCnsdrdTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMethodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMethodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MnpiDiscTimedForCompValFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MnpiDiscTimedForCompValFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>80</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>23</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>1</UnitCount>
  <MyReports>
    <Report instance="ea0246830-pre14a_180life.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0246830-pre14a_180life.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0246830-pre14a_180life.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995440 - Disclosure - Recovery of Erroneously Awarded Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/ErrCompDisclosure</Role>
      <ShortName>Recovery of Erroneously Awarded Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0246830-pre14a_180life.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0246830-pre14a_180life.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atnf-20250625.xsd</File>
    <File>atnf-20250625_def.xml</File>
    <File>atnf-20250625_lab.xml</File>
    <File>atnf-20250625_pre.xml</File>
    <File doctype="PRE 14A" isUsgaap="true" original="ea0246830-pre14a_180life.htm">ea0246830-pre14a_180life.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="113">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>25
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0246830-pre14a_180life.htm": {
   "nsprefix": "atnf",
   "nsuri": "http://www.180lifesciences.com/20250625",
   "dts": {
    "schema": {
     "local": [
      "atnf-20250625.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "atnf-20250625_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "atnf-20250625_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnf-20250625_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0246830-pre14a_180life.htm"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 3,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 22,
   "hidden": {
    "total": 45,
    "http://xbrl.sec.gov/ecd/2024": 42,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 80,
   "entityCount": 1,
   "segmentCount": 23,
   "elementCount": 288,
   "unitCount": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ecd/2024": 113,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 3
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0246830-pre14a_180life.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0246830-pre14a_180life.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0246830-pre14a_180life.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0246830-pre14a_180life.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
     "longName": "995440 - Disclosure - Recovery of Erroneously Awarded Compensation",
     "shortName": "Recovery of Erroneously Awarded Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "ecd:ErrCompAnalysisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0246830-pre14a_180life.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "ecd:ErrCompAnalysisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0246830-pre14a_180life.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0246830-pre14a_180life.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0246830-pre14a_180life.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0246830-pre14a_180life.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0246830-pre14a_180life.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r93",
      "r109",
      "r144"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r96",
      "r112",
      "r147"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148",
      "r152",
      "r160"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "atnf_AverageEquityAwardAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "AverageEquityAwardAdjustmentsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average Equity Award Adjustments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "atnf_AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "atnf_AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "atnf_AverageReportedValueOfEquityAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "AverageReportedValueOfEquityAwardsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average Reported Value of Equity Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "atnf_AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "atnf_AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average Year End Fair Value of Outstanding and Unvested Equity Awards Granted in the Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "atnf_BlairJordanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "BlairJordanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Blair Jordan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r77",
      "r89"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "atnf_CompensationActuallyPaidToPEOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "CompensationActuallyPaidToPEOMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid to PEO [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r116"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r116"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89",
      "r140"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89",
      "r140"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "atnf_EquityAwardAdjustmentsBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "EquityAwardAdjustmentsBMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Award Adjustments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r93",
      "r109",
      "r144"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r90",
      "r106",
      "r141"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "atnf_FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "atnf_FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r100"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148",
      "r152",
      "r160"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "atnf_JamesNWoodyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "JamesNWoodyMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "James N. Woody [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r183"
     ]
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r84",
      "r95",
      "r111",
      "r146"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r98",
      "r114",
      "r149"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r98",
      "r114",
      "r149"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r90",
      "r106",
      "r141"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "atnf_ReportedSummaryCompensationTableTotalForPEOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "ReportedSummaryCompensationTableTotalForPEOMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reported Summary Compensation Table Total for PEO [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "atnf_ReportedValueOfEquityAwardsAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "ReportedValueOfEquityAwardsAMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reported Value of Equity Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r80",
      "r91",
      "r107",
      "r142"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r81",
      "r92",
      "r108",
      "r143"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r88",
      "r99",
      "r115",
      "r150"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r83",
      "r94",
      "r110",
      "r145"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "atnf_TotalAverageEquityAwardAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "TotalAverageEquityAwardAdjustmentsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Average Equity Award Adjustments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "atnf_TotalEquityAwardAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "TotalEquityAwardAdjustmentsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Equity Award Adjustments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "atnf_ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "atnf_YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year End Fair Value of Outstanding and Unvested Equity Awards Granted in Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "atnf_YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "atnf_YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "atnf_YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "atnf_YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.180lifesciences.com/20250625",
     "localname": "YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>26
<FILENAME>0001213900-25-057905-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-057905-xbrl.zip
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MFS_B#X6?"JYO[V!/D9XK"%-.$Q0-1Z;PN'PV()"GBTB:I!N[7R;H'G K71)
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M+&UE#A*O+(MX"Q'H0L17:OKO$D)+UNMNO$.FNHT&70*V1N:\E(X1,$C-(CK
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M.800F^-M?8,@@#C>MK+3P=R"!(_\2-N!)?X. WWHTQ$+$(.MC>URB;\](UY
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M+@D4(PF"2K@B39)_5 H(Y)TBN0H$$.Q)"OISB1LUDH&0,W6/#0O;JNLIAK'
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M7.4&5/6!Q(^@+-#AQXYO]N0_]YV(1?E<R<2V]-[%Z$KHQ7_5)^]+ W^HV>5
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M.K?BRGU@;Y_P#<S3C=YL;=DW@[H;18D$V83"F=+NV]=GGQ;KXYCNV+_@%/X
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M9-8H1),R"YZ6*[#[G#Q-<N_F'1 *_']QV0*M!21U/)'TS\NW-&EZ-+TV=9?
MQE9CP,A1#AEY@6EBK1G'TN<E#W+6J";B;(3!_'(QYD4,M#D][ U +=WFY,59
M$L[8:V0TQ1FW,YH1 >87G9X7+9HZ4#I;0LPXNC>OU5.("7M<)VA(S?@TS"],
M-R]R;&<.QK\2F%U/>X!G0Y&7JO][FB;?>TZ9F%$U-+FLJA;9(.8"U?;\0G#S
M8D?$XD@& SL<9<RA7$CX&GUWE>3->=%D#^6UGT2S$M1+YQ?80SR,) PQBI+C
MA?9-*.7L G_/ILR$D!2W+L!_OQ%N#$-T9^&;Y;^6C9TG'AC%W"@&4_ 13X#*
MXS7EIB+<^,<6PF;5H"O8U\=?3E^6J-LS!O2<TX'=;Z@B:G$\&'K!B!)%9WQ8
MM^>?';]0_MH',_V?-AD@=?$U")R1: ^XO2/GD5#+1083**.R6.=6UOC0QEO&
MO9%#.RQ(SOFQZISR[Q>[*7![^!C6P1Z,^QVX0F'GW.;^VZAT!V@JB]Z%^:>L
M+G9#X/YR_E_0;1=@LX?B-Z#S]VYPSW9<I]M17:)7DO5W<I36>#L+IO3\\V(7
M2_1=!&L%HK?]OOB29.Y$E14X,\;EFY>%LH<H(MBL?J@!1S\#R4)$VRNSZ&9D
ML\P_)W:Q[+J/==;A+?9T3@T1RB2\"(->75RYB"X5=FD:GZ3G#&S?%^OHY* ,
MQ,W,I;]ONR'\O/$R@F1.6=^+W8X#\G4B,]M^=Y39$JIU-VS.<:BR_3JU[PAO
M0ES%TO4']G0I]E-MP ]^7=P_I'8%0--_VC>.E$-Q!GO2M_L3!,[<"+VS'&D/
M!WB%M%G!@7!&]#2P/$9OL65G4RA_F"H%Z8;8W#K"4L0KV[/#666([,PO(CTO
MJC4QKZ6U@TBF83(S-/SE\#H<M&CQ+6KKNDV\0;28I?-T"5EBFPZ2^"+#*(G$
MA0PI_V!663([RQ$ /D"0@4RIO/@@XSLI?8$W^%;C;=ZMW,5N)]X(!(Y+5_Q6
M\ZV)\3R&@/D9I3.=BK _^-7F8+=0ZY>C.I'Z3,;B-)@2Q'4J73@G$/'%$G;O
M0<(>)0,L0M.AR^NKR^J2^.4%)EQBSI,X IN9,G)5EC+E6T;8"^"3&\&TQ1_2
M#L6Q[\Q&C"Y'+/( FVX%L618>F6?1>+W(09FU35M5H6XSR;)RW/.82:9(I\"
M, MZS+A@;DY$.&R4X%C 77]6!MC21:\/FV1ZX!7EB=>[N='BA3@"['(E1'-Z
M"4L=\JB5L^B;-/^FIPO5[H?;=,EIB/.![W; H(?K+XKC6TGTG)L>?S9=JV@J
M'>[PC7'IB/EBJ>Z'SX'I5KA0-+4<3IF*8'OHTR4(CQ'6^X!<Z"X8TWMW.3P=
MAWOJ-FO(-^- Q;/I4'4I^J1 Q?SDP9SZ]"Z6Q@<5\7CO_N"90H<FM# 6KA&9
M\$\ARI,/ 2U@&WYHR(J]%3I%%IUB!4^Q@J>8WNHQ2VC]5"X&IQ"QY9_9WB_@
M6SPL;H&<STBHG@Y%O'!&,X 8+ZK_9H"T--_]>WC/FD]-UG[6AE7,2EFF#6N9
M)HB/O=HLSTZ]-'+99.NR2/5M2ABZ11QV3HI#50(ZYH/@/\<N:J:+$/O0A'#Y
M)/RX.6[+Q"U88DSHQ^_&#@@M+[09./(T^1Z$L!]Q[,E\VN<RTK^Z1V!W[?TO
MTI<AW%()SM,9N+X;(<(GN@4W<VZK!Q.-YD/\)8:A?OP^[*V]U^V8,=!()O$/
M0?WJLOX^>A4C:8?=/I<SRUOI!4.2-L??,7 #JH!*7IIO?X2=6(IS<%!T]9ZZ
ML7OSB(#9?&@^IXR993)-#U$RJ7(*V_6C6'SB_/4T>1TLI]\^G%;%7JT6>/R"
MMZ_9&-N^3"-F;'Z)!7Z_A7;R4.+9\FS@\A^Z9G-LUZY'7=PW>X@OB-/3HZKL
M5K6 [Q>]<:VQC;O$=J6.^& G(#/_;@^ "%?VP/;CODUSH1^JLID50"E?] XB
M1)#L>EA#&(34<<R5/3$N0VD:&3G:'ER'"?Q$K3LX,=!^H/_C\NSK,MB.S1V$
M&W3DP#>H3B_C39M$];UEZW;Z>%+O%LWT3$(+X]:.EI'@U6R4VFP^!_ST(P@P
M'R.07#"MVPDT]];M#86"^K@4I&=MV6P2EF9^HA:ZJ\_!5;T(@V$0J8;-37'L
MJ6W-0UXNR:[./XFU B+SP'A:%R$9YY3/6@&Z'J8>["=!.U:3WLO TJW&VONO
M?3L67X)8BI,(M,E?B8N!LNN )1+Y&J9$HJWF?E26_UL&W_92=H,!8F8MRELZ
M3Z9?I*)N/:=/?4Y1MT3;"0P$"QZ.3T$2QGW&.J/(0QS0WYL'#7'J]J2XZKJ8
M/!8);'A?%_?F[R^)NI]3^F\%SN+V0G7\_+/8*T!BN.1_,#/G$O4DA!,F]8G2
ML($/E[14<Q>JR]V[*2[M^2V6$X#, Z*75 \_NLQM/EM0K=RR.>W&7HH=K3C?
M0'IA;7)4E?/PPZ:/M>#^_DDZ=/, 31P,I+BVOU/2I<KX7HBE^QI<O:T#RI>4
MYL:Q $+O_[#>W=8A>G>SEXFGMCBL)N$K>LW8FYD_<%NTA\,PN 7!!'N%>)K.
MK1MQ-"L*O(2WU*?"%6>\$=/T_1PJ<*O8_V%O^-N-1=XJGDW79= GV\T*Z),Y
M87(NF+JWKOV?1J,Z3JIGD[FBVF-[9DZJG;PWZ@IV##/#2]#X!4(>L)^=KM]H
M!<-=G-&7:\*.]%LU'.BXUT.7L VO8\F%Y'(*<37TW ?[,!;H-6=54H$LF#G)
MN84ZJ)Y-UXJJ$N6 >F%J9B;_8W"JJG] -])G.XZIE^7R4;2B/'KI1M^,2XC%
MO73*)?'RT;Q*7'P1NG[7'<+5B_6=(?H/0NN*\O>GD)//@.Y7?3N42RD[JL3'
M'V6<(ES>P\/B$I]81FI7E)-3P-&L)UFXA1T@VFN[7;A@W >Q<OO@]77YMJ-*
MS,^B&UUB'_%J@W<>O#"M1/E+$/\L$!_=*"(*1*KEF+C$B]M*J#^3M JB4/SN
MNS'A&0!W1^+!(-;R$;VBK'W\O=NW_1L2)"P\,AZ4I21TE;C[0Q!\VSSVXW"T
MQ#9@13F7JIIDQ-<9$_TCS3@6/UI*NE>)D?,^NYT*Q"9^4,]=GM"[U0E2%.C]
M0X-'[J_ (W/@D2OTR%>/'KG00.)SB@US@<3=L324;%SQ/ F?'%O$]W4CO"R>
MA6E0W4[B?A"Z_U4=P\^204>&9'6388C_@E<&,!*;X9_"8"#.?2E^A0W""I;/
MKN?AA]:!(VH-_M\-FC8\],'\J'^BGQ<'Y+X_X]883V,Z U\Z"S3H_)B'C9^*
M;+K_R%!F@> 95-&Y47.!UL[] UW"@8&;/;!6F.8&,ZC>(\GW0]G@]P^DLZNO
M2<. Q$@]LYG03BII6+88N50-DE:6%?.'^> !M]\,FCP<+%M6Q_T#I2YJ\DQ3
M:]C!D,$R<S&;(H-&J>:LV/%?$EX]G.H^_D@"'BY;V= 4%-MI/.5B_5*$JZ@9
MOM.<E1F^ES/#422<1%&"'5WQOS_#+5%<]^$[K<9/^H&B.8TO*/L\6^V5,Z%=
M HCW%0X%-9?)=D0Z!WD5PDL+;'=TN&RE2-.<L=;3S.&YT:JRPMP4QZ7F7(8W
MJZ 'JP"B-F'PR6-K# XB[Z/I. V(605MC)<GLV95\=4.01[>%Q)?-*F7DHU_
MAW?#NQ!F7BR#JBJ9EYVC4S%\!<LDCY\?PU60R]2J2_>E9&\,XY*K]7<&3 !#
ML2NE4V$ILNSL_1D;\,"]_ E&QHJE'T/@-CRH,G^!FV_=B"&_JDKCRMK%9W;D
MV'\AG*<]D/=77RR9,3Q'![J^:%>#5I7EK6(Y: LIJ;#BT)<VFRMK!7#CYTBS
M[5F!,KP4.:OJ6-N>E6-MGVH?#-8T!H.&P\#U8PIQ4VP(5--C@5CGX_+Z4<\$
M;N0.*'^D,/DAW3B64D%/DWB^".6FG7%\GL!'AI*^)"[EC1MA0B.BAW7@%9I6
MI@#QDQL.A&J9/:/CM,0I=--LRBX>$KEI7,ZT(P]V3'HI(E:9G??F$E=Z)6RW
M/\\0TZRY;J'J[V!6ZN] M)T_@R3TM;JC:+/O)W#J/TM)<A3Q(T@ Q")_3_M.
M(F%A:O&'S?#)[_7AVGN-U#B;DU"!/+-Y$6NW,1?Y^SHX;?=) #^+XKI%RM_=
MY^#TG(.(#6D9!B%C42*TV9@C#%^5.'L[57OL]VDU6GM%/:?K^?I ,ZGJHN@Y
M5'4C@\PZ&ROX^:1?2D=O?EMV:%N ME3$2B:(V::IJ#R-![AJ3+_H3=A5(BDE
M/7$^-7IX3.^-A6Y%E6T1; ?-$H8[-,U(;BPQEN,TU-O/184^N1Z'W2I!PBIS
MW8$^SLJZP.M;!X,<DM*R'6'')9>\BA!V27CS,*VEIBHDA<AP >3&P!+\$TR,
M\R%(4U=7.F5VXX/$3I08OQ\&_IN*4+["++W70')G*\<Z"(+< _K[W=F$G9J-
M0@;R#UVL>[ JULT6Z]ZN:G5?EE<[[]^Y[]M##.2XWV4$(M"%E79*F'@F'],K
M*?O \E8>_^WHZ/CHTZ=QD:WGTOHI?YC^3*+8[8W*/!>1^U_)"R6"Z:T1;<%4
M4_Z)$B&K/K9-Y:('K6:K7/KK@LW=I\WI.0VV:"H3FFP]6F-.4(Q/I^P')*PH
MH^R]='PF[8KEV=,U**/)/(U^4S'P,TE[-)%I9TW:>\BW"^8?F2J5X[R/+\AY
MX4";QQD0@/04H\/M<> !-)LQ  'XPZ0M*"EDFH1]F:9_59FKCW';M"9[E7LW
ML4C[_AV<AR5/_Q<LW2(DD"*N^J.Y[="3\[.HGC:;J6X,AZL;0^;&L+HP9)CP
M7AJ7;<X<#L(3YO#.'=P(VXM_7@-S/^S^O.8.@"[8Y:3^Y_!F;6N6EY$JD$C)
MB@G$Z+R_N#S_]Q_BZKI]??SY^.SZ72?<>F]].K_DB9!%TSX[^[U]*CX?'U^?
MG/TBSC_!X^='O_UZ?OKQ^/)J/A>XB?.][U)'_\<6KO/SFNI;PTZBLAEA@'16
MT]+ED[G.F2]$D:PVGQ@<'J.<TI?SG6.Y'FJP&IID!*RC0=.">8XMS &S@XV(
M-PD6^GFN#PN[DS6U''JQ^=::<H DRK]?$U,. />L_ A"U1=,.8ZJV\^/M2'Z
M=B0P'=-%6PN&!;MGH"/2>!\>!0GZ10>VZ]7 A+*Z)294$1(@XK0N8Y$-.:>+
M(N0)?, &.R\)^3YC<[Q@D ;+HTRPO";N^FZW+^ZD"-$SBS.R(PO?SK]8>R)5
M3)PBOT<P[__D_J>F9AOKOS.[#^N#>@U4>!>-4A$#Z];(8(7G@" "S,=X&/@4
M@EZ/-OB=(+3L-#G._!F#*S+HU<4UK$*3X\[U/ RS]$''BELWC&')W@C^90L/
M+W]VXK@!4*<#QQ ^&:M#Z+[OQ_$P>K.U9=\,ZBXB-(0.50#4N\%@JWU]]@F=
M8W7K2L(87A1HLIWX41PFM+V1 &.=)O.%OUL([1A:=22<4)\VSR>K@R?1K"]4
M +R,IKMW"M>%TP26GQ0]-XQB*Z*[3BAN8!,ICI-E>J0C_&9W@B06__?O?SO<
MVS]\^_^8 ^OB#SB0>$UQ_5L"ZL83$6/E)K%_\3CYR.;,DB&>(; I(_76;0"7
M*(PBP6M#$Z-W9-0-W0X\XN)/;B0*J135W-:";F[=IYLY?6!&TRS3D>6B)J.^
M\2**H3WI6!.H_+(Z%.U60UIWL9H;)8Z;(94F$"J1D169C)Y0>H10KWRV*0=S
M8!JYV\&3I.+2176!?X-G\) ,L= YBOAOW4QA/VHC5#5.#M-::DQK*U"8UC6A
M71!2W 2W,O0108<U05<%<0,*GH>ZLBVSPCIZ'+P$]:_2J'JU(ETM_,F&KPQ'
M$V!XK%Q*"*X;72U*$C<V?^-_Z=+$D;1#P>Z5C[(K"0!SNTD29H=Z\_5<+YT.
M&%''1SCD9SL$7:P>W!7K3]"W^ 6KD+Z2,TB &CTR.E)9-0Q=RC! 'QLI)B9!
M3K8:$Z7X VDWEPFL&04HV[5#Q\+]03Z!WXW:0R-E8&HX\URS%*)ONY*B+V]6
M6)/-BM<L^."0T\D<-V\M;0C:)* \&4LR YF"FCW16@,MKY_U S'LCR+T+AN#
MP NZ2NB,F9E@*XSP-?2^)I1(4FYF5O,4O.1& 5UM]-J[0YN$!RL3W@S+:!B$
M&YC2(.>G2<G@_5LI)#\. T_X"J?81^D89L0877V4'9<19)$5]_$:TNV2IG!A
M/S,O&@'YZG?S*YK%JBZ!%$^W+PFR;LL+;L@\"\HLZ^:N&+A^@A8(>USI(?TK
MG.0(QG$2CVUM4.0A.J,%[PE<#6/9[?MT-!T7S0B$ H&Q!C:=0=MQ0C!)X&4>
MW,H.3A>NU<;A10C)11K<20CY*D,FJX.UOIX7W.D?LH=#V+=@+C!ZKY_;.I!R
M<&[+1@29R:S040EZ>)R^^<$=;/*-K&6E@)G$$(Q4LBB (WH)WMVC9(AF#T:V
MNF$0 ?N$P5V$U[YU2O[S92R.OP\]V/6PAL7&P #?:^*H'P;:NW!E]^S0W:!_
M.Y+JD,4Z7-R^Q<$0Z.K90_X'A:CBJ&:Q(0HR?M@/?!EMB##A&SNM+H#5)$/'
MSMA8!,H^'(*M0"2*@EY\AQ=('&CH)<1_" ?"0M"/@=W[0>*AW(H2/@LCT;=1
M=0!#A %\2B\NYT%"?77+@FXD7)^OL:7BU>Q!V5?)R+-QKV%VP"-L)2/V+0P&
MQQ@'8:FJ9F?'%GVR"^9+'U4N3%+: R0)ZSJP.8-0'WT^O<KP7B9;<*>"MN"_
MT*JG(_B13IA5EC7\6FU 4$8@,4CGH#,(3L]?BER;P+_PO]&=#'FN$>@'^+M%
MES28@GVC;HJ@R1S7)@,Q+__@X,$U2!]O$F3P7R /])TYM?Q*+\U58/D*Z9TH
MZ0S<.+-%EE;M*'C&U8>X7R$9)WQ>X E4%K '>D?8,,BXZ>Q.<"O9G#_JVVYH
MY>44.?A!Q=CP)&<Z@'2$[59[76;:D+ 4%%/WT%($<1W6U!T:?\=DC([G1GW\
MCQ!,'+J1JP'KHDU^"CV-XN_F=I)5P.RDK"K/+70*J;C4A$/'UT@ZEE).QM4;
MWH"5_U]=80A&!VALA\W/6#/'P/8+>HQ<':"$77E7%^G'0GD#;^/O@UR]ATWB
M(1D:QYI5#%6PC$+&[.$51MK=OAJ#65%*'WA=58V0LXF06$#A@LS*3J&'?5=R
M?G$_4&X_!1]@?'[F>HQ)4T.TFI''AZ#=2#K:\);ZI$TY<_K$PM_Q7'A!PGE&
MZ=PC/L5#[',<,T45'6&/4,Q&":SK+S-9)\#96>R4Q$?U!0O^[&\."4B&N2GC
M^8.;6Z^W21-5O\42\8=#Y2W4I.<86&X3X8RBN\!Q00Q('JLC/1>,J<A21A%2
M*W>56!VPLBE,E;#4A)$Y S-Z@U.Y8D/VK?AB>PG^_NH2FMJAW<%:S&(R4W.5
MS/0"!OYN!0W\:^/9^)CQ;%@83 ;IC J_W<5XB[:"M!]8U\M_Y0OXZ[T$* *Z
M=D;I&VO)H@R(R(4[.SJK7 Z6R.^@J2C199)CR<[1O."FT$X/$WR!D1#N3(9D
MT)8/9)4-E#%[R8\&:]-9#^893I. BSHFV<)$/7[B8&=G<_OP<'-[^V O#5?Q
M6C&>5DU-53B0>Q4\D B[$CJF7;VE6OT<^[$;*_\D VV^U@.G4RIDAB)@/;E=
M#/%JVX_<C*4FE#Z$E-]A9TU6M+5#IKZMPY:BZP4,L&UNWV"(_C.!&]!VXQF1
M5=YE"W>Y&%*MY,%YP2FTXW+"Z^R7S $A+R[&T/#_K-LJ-VNOUM@[J.WM'(K(
M](A$YV^7F]S0CL,?3/>;MV*]HU[U@\([N!89\8]M3 2A"A"4[!>4XH;7CZN2
M ;MF0.7_R8TZ-.\>>2 R^9$C<3647;R$?.%,!]WA,C>P4SJP==_ OSUF8#PW
MZW)#3*" ^)!=O+AG\:^>?Z\Y+R5E-91%*#:D15()+^-@)F0%C[HZUD4[HNMO
M!-J[AFF4?;SPPO,W-WC%Y_*;E+WC 'U-*B]&[5HJN3+GY-7OR8GRD*FD5@KR
M@4R.>B/*3OTK"<)DH/-]T#&K\HM,CE\/E0G:0)BM(S?COLM(S=G$)"P6H2<Q
M/)]IKI6>IZX]1*M"\45&@5E9?:45U0!6A-:D<H9P,J$V,1T)\W24GT<]H55;
M)L,P]3?I'XTCE$/+ZZFG,.Z#Q7_3Y^@EI>>@#]3^CB^CBT9ZDB)2.GE7QX@V
M.$[JHA^J*]U;=EX$83XLHV>RCI*&?4.WP3?IK!0>6_$ZUL_I9$/TYEJ<O*;*
MZ@QQ82\2PA?1,3.30*=2M<NRYQ03&M<:CY/Y;HX14/6J;-<G,X7F5)X:NJF[
M*)"H71TY^NCC6:]Z>J'A=6>GUTEBX006,H[RO2,1V&'HCW+#U/@]M>+\-)29
M1G<5O,IPCCZC3+-[$OM"<^ V?58_9\"QK.N[ +:_'TIX%HNK,?9["_^^<K\C
M/R#E<(AC!."K&1_AG1OAR8W13^DKQZ=*<@,=6X6#4('C@/J3LIN,+QNERYVT
M\-K<C?,B;Q+3TPTADC%N+;"(BM+P-8%[F.?<JLAXR$9Y3ZX^AZC.I<[MF'3
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M8OBF=,2:"B6I%WN89841(AQ 3]O:056*BJ'C<I\HE8!'BYQ2)RD'8D$C9?=
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M;=M-K@*CVQQ?1G&]EL:G@SE_MF%>^L'=)TF8<8SF8A5J)<_OR[;*2_LNFT8
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MU-R(W=_QA!ZL:1>9W9_TU\OGE9U3QH8@@!MEQIHSFS$),K_3C0_#"1K@_YP
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MR!L;*'7VI28.#IN-;>Y8F<*XT71R;H\Q)R-UURW-0FG[<3\ AOX0NC#=7X+
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MNZTFP]3?7F9 ,'K!KF"?_V0AV:%B'"X:@+>J1!D/=\+=G0,]_T4!QUU)9MJ
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MPJ=LJ!?[0Y8.>FRTOXK#*QL:ZQX=['=_^"GB;W@FS"L^137H)+2P^@#JP'3
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M%M-8;7..3^YL4_X81X6ZDYVX0 #\QPZ8SXG_!E[CP7;#C6_S=MS_#AP=M.[
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M/C!2_^>?7&J#;S""E<R]2@^&-GEI14N9"R+,<X6\_7VA_ O$VE=((YR76*E
M?Z7G8Y6.0EMAYUI.L;:U*&\"OY_;J,6"&E4==9^"HSL@H!'?CV!*P$"Y@R8+
M6N!D0>N8%O5VG@Y)V"_@?ASPV*\Y:HN()9*P#_C@>3TE 9OR+^EO,("U!/?!
M/%5]&:BI5&+,E&LI7*&HU]((1>JMX-_D3A%(P!:'[)#U4 ;<8<,('4\4I;P
MU5&HMD-KS52/HTKN0>10'XS1\D6=]=+&Q-KO@!DIA'7"PJ-"VCG<WR7CA$4C
MRVAQ6U\K1";V A%K.GC)2TF1/[:%\#O(E2,#X1._?0' PYHM^/H<DL;2";?
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M15FAC8[4(&\5RS9 KPX%#"FGJ>2(I.DC^M]MRL[66YH:&_M]O5]"#&7I<UW
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MKT00</978D#5*5PHP ?MH-UJ>2%?>^('$0+A:3:0B44I%\1-%$XH[S$ON,)
MMARG!!@*%;#[[LW'UY\O4-NA^,$=@DT?#H&M1"+8'NCO%&ODS/-U.P34(+-+
MOV;IJ=5@]^7^&=#[H 1Z3NA]66D\1$T0>+S86P$"35/I,Z3=/N8GF _+F0C'
MK1:$O]N2(/Q>B;[>BDZMFX7;=U@ME2T-Y%:8(P56?H!G4/G!:3<8]/HLA&2W
M>E#-\!&.T ^"5K]E_9VV@*))Z7AL5MFXBVM*IBOZP&[BW#.]:+C/M^D$CIXK
MRV5F[9+"FR)?@/6[1DF+MW9)R][YS?$6- L[YUHT^E&6I9DG,GE<]$%GKS*0
M)/$*8'W![\P&80:*R=0-M6NZ"E>_@ 2)Z2P3JPW:!,[\J,5941J>-81=C^7%
M2*B[P-C@A9[P.=#6B*M4KAASKE:!;Z2J#8?,^]E-6BVYGP=;=#\W)8ZW43[,
MXIE0P;W?!:B_LUQ)0N(^;=KYU<\_Q6K'8UC,E6-!I9T_W>+.7W+8JERJ^RE+
M0;)<QAGQ%/\]6+ P0>(?HA<,U9KT6.>WO+D)8_2-'>US36V#2 $YH$GT!O;O
M=9Q^CKZ*-&?_-]&A9M5B(CU2A1&BH\VL:/)U15.@M<RZT_UT<_+VQ(@DZ$@0
MG+<\Y:!J;95(:#V^+Q?A\AE4-+$*JGKU;;/NN>Z#R8D_DGF?^@NEUU;3N P;
M4[,<M?_46T, Z'&"T#"<A4.&A4GR.)^K&X7)(8B>C45(-<LQ YPS?/TJ!L4I
MUK#=**124+VT4B;U]BR=<+ZEJC.E3S/G\NQ/5V+-2D2 KT,RZ;YJM]TH9^P#
MMM[)HMLXNBOG/Y%93J[[F+PSN%(KR.ZI,JSZ+*H3<Z]%;Q)AN]52L=K%>1:"
MA44+X;.YDEX&::SMIAQ^PMB7W$-GY#<@TQLN?43F*](!& I (%BCR\#Q0VKU
M2F=8=^6H)X'2C$JU\ICCFUS+IETC3S2N [K6=/#B#^V+F]]5/:RY9;^A;47W
M=HZISR%</3R^&[B?I#?5G1>E+B*:G +E3 3FU9R[K?&=BG+3ML?+[%6@$"CJ
M(WPU,I,2@T/6Y<0-$DZ)FXC0T_$-CGTACOB0FSB!= ,6-X0IB4%BB*ZX L4(
M!!_<^Y'@:V$"?_1BZ:R5?<CT2$3.",(M !\8$@J7/0ZG,>:/2^P:7!.,VA=!
M1"R=G80YO:;7\>)ILXZ*XERAJA'%B:IDHYF:=K4;;O:U/#AI/C_^8@SRB3Q*
M)16"]TK6#F O/^8S1-U"AGLBJERE=B3'63IGWP;W"O1EKT!A:_^9T%?^$UX;
MP0UB18'RD%A/0-LRNS_QW^I;4[/RP!,7 <E0^$OT2NA^FE(2(<VPK>88NZ0A
M!*XTXID51!FW!I#7F+#L\3M!;9SBE:-\:>&=-+?&XXH^\IM6KC8/>946<ZV!
MX+W-+2\0C$)1=*XNK^4X AE->WK@F/#;Z:Z.J5H1%ZP_6HE\M2O<G01TJ)MX
MEJ,X CHMAE3M >N<SV'EW"<PY;]@8U#T1R+(/\K"\&_@%R/N%!F*SJVC^I/R
M^*1._/\Q&W(RX]!3Z*F-'ZF[HCX^WM*(W&N3*!3H2_*@%BQ!$ LW?EDH'G2V
MM2T<C!9\['2SPVLIL-?K4!3(Y_'P;[$^?/8V'(K<E7UN^ZJ1_L$^TE^-])_N
M(_W/_!(LUU*5:D5P7*$_CK^BY@\L[<1_9V*JH^RS>YOIM.(K+/&;($(V=02U
M(=S/I7:!HG=TBV$:RZ*$@5DML4=?S#U%BQB*OY <BJ?3:(225B84P)JNX]OJ
M>D[\#Y;S0*/4>\ML6<-&PCE1SG*0!F=1GVE/%Y T9P!%$""46!K/)](E+9M@
MP]U"0'^RQ3PL9QS*G$)\O=1(TAQ"5D:!>BU7(%4-L?\$HT*XC1Q_O$:\5D)C
MF81WRG>QT'?C<\D?O0!:Q[OD>@("Y\6+F"_20Q*46EUY1O?;:JYAI3^>:&Q=
M_X90E*G @8(<%+/&&\EZ#A;"U6ERTL/C5\K?_,-89P)*T!U&&Y2A<B2/J>C7
M9V3'BO4(&%#M4'KQ%/'1S"8_K92^E.G$7T@G@5E/?6,B#M<I[9A&T>GT;0RB
M%W\H%KJ@*+X_%<C.7LEHJ]O9<CF %785*"L54):@IC>[:IC.T7H5-_5,V(F.
MZ#A7+XYD7P>2#E<1HQ8S42DJ.&RW6M\?!2+[&88C+[E\4B::J"%$<@,5?CIA
MARW4[;<[6\3S+$"NZX M7069]6"7-12KHS,2OE*1;&TDIAK"KRR[%B4;/1&+
M4+(])VK1%6Z: ,?FD$<EV*&3 ,C+IW$GC/E%M*07M >G]#YG,8$4$W\YI9H,
M3PY]I'&W_:? W?:JN-M6XM<BX&UX#LXMVD-OEQ)N%/BV)&M/DS6%5"M=H<2]
M</<CO8DK)8ZA/V7)7MMM(+!;>J'<5Y#=+_ZD+#&LRT[[U'JKMSAJ3@;;%=P<
M(:8-[NF(A#?I-U[5DQ^:AJQTA1W*1]Z)@]>ID8XM6@Z,'N=Y$3E4LOYIT.V<
MU;04YX S&S64TEP CT RD("DI;<\?DM6L,G&>G>I:*M'&9:@!GZ-LF%,03O1
M5^Z@?7+>+_<1=W0P+QE]S@[F7NEB"(:F84G++YN:@L#N^AQ1=_"1_W&:Q%=%
MCD!0*"S@VGT"HYV*)F'C\_&]DC;I'6]TA7$NJ;&?8<Y!6N23>U5N3ZJ*NJIF
M5NS"VQ$XKF/3]-=%G,$B*/BC\:PQO#%8527RC.I-F5/+D5&VEZGTND*;&TO&
M=>#+>ROCRY>^7;0[XQN@O4ITS_9.G0M"*7+**J^_7'M'Q#VK1&JIX#&!2<84
MH;3?=Y&EQSSA;31!WP\YYDZ #:086B._#6;F7^>!D0!5Z4ZON,CK>W@]#P3J
M7MWBQ=6;*"CXW*OT,S^,C]3R[^O2&(B57F/HBS%89!X0_6$2ARK?BA:,65CB
M^L$F8?2?:DR4/5W-J4*WV%6DJJZO<,%ASE;* F-:Y,^5L/YE(%?I(K@PF8!=
M3("]S[G#Y]PSD$PP,(UV\ERDX9CGQ%4P,>R4<(;;FQ G5!)-KSDB^%5D#EP)
MUNH!25^+!/Y1-,;! C3"YA-1/IUAK4<43F3O<KV;@>C 51G:?LSL0;\@:XYS
MD(@^O844]>(YS6H1RM-]A+(:H3S;1RBW4(1PML54>.'H L9X;S:#3-S=4$P7
MV&_A74:G?SF/X@2F?^G\Q1V,6 ?^9L'>5W8]\'^OR5]7J=V44>:MFF^_O!E.
M-2/=]1(WNI++=;0",K1U5RN@PNQ9P0 MZ-Z;B#J">1H8P);X,@S%/3_0]8F0
MMB"5N=T%1O*NX?(8Z"456&.9!)9'$65_I@5<AR%H8'FL?!S3*+NFM/=D%*.O
M2=3:@FZ/;X#]2<93KKO-6;GMG!:.Y_5__I_S7O_5:7+QYN8SHF_.,?Q7+I5=
MJS"6MZ]\7I0F5>UF7T8LH^4E C5EG6S$#V(*S-0JK>%5R9EKSZZZF:+BZY&B
M-^+UR!)45*CDTKAJ%K/^YL+J-2?V#T4K\557?Z%:JGX&'?S.^1W*]C5G!&J]
MYC)H5N= SW2/A11-6N%:I^O850OT"(>4LWTVVDCYAR.J)+M";9=PI0.OY$O'
M8L#(S$(Q#DNBP9;239B""""0S!Z1_6>=)*OL&D.R0G8>3(Q.@;FJ;E;],FEY
MR4B^8IVPR.AT;[+ LXZ16=H?=6.A\I40G#GC4\ D&8L5A41VBD:6%M<W98[>
MMTY#M;Q5BZ3-R+E9(%Y(^A3@)4#8$S*E>+>BD2=Z&-5]GWV3P!CD-5KLEMSJ
MQX1GI'OWB6*5.3$A@7#TNVCEC58;.L<PD1430U6B#US(&6:_C&0RYHA3AV20
MT[U*^!X0IL @T003^<=Z!>-QC/D.+CQW77NEZ_15\;Q7,]DAMC$.XPG9C&)$
MT*ZG$?*,:))'Y:$5F3'BJ*[.=T]@@A;$L;'AGKGAHKV4D$44V<!V2ACE8 E!
MQ4M5D4!)!UIHC.!63M(9[4@)0$V9?Z8$\;0$68.KN#A&67[PYWZI$?0"<)JZ
MXEETH]'G@6MCNC%LQ8_>H4D/1$OT&+L9+!I.4I\J9#)1WU4^1,; D<_@[6XL
M@CVG"'ZEG ;RO._5TFFEZ)+A*ITK^ OSEL.V>%I K$1X-Q.1(!#ZMRE79H>@
M7_XGS00^F[H+'H)2"# Y\^/E"N84#E-75+UW1,E#AQW7W:^LHL2ZR3UDON&9
M_ '4NPLE=%$1N8L<28E.0C#/GOI$J.P]O&UB]GCLESE5D=#EIFJI,251H9K(
M*'2BYIP5&P& LSA?\D%+0XTY-8:/R=N+]BM6/;)+9RHKL17>DE8GJU._>/_+
MO\J8-Q;I68E4I-Z52JLJ2@.6YJ$'5@21@,4?4YJ=S/'$:%&O&YSV6P'V6P$&
M@+Q "J]XC$45J!Q<1?,[=,ACU@1675EUGL1;8"?,'P-D E09@RX<^!A.<A+V
MW .M(B!!3U:L2;<MFD!%PD! LNT"EKUF7,5F%H\&3;9M 7Q)74-23V.*\?L*
MI PG4.!E"KF&Y ?K-_6RXH:B_.V.0,%QX9AQJ1Z%PD2ME"=[K,J.C3MPKW;@
M=BW,NBN[V"W:VTJN'6>->':NG;F,1FEV_4'0Z;= W/67)=E5<NQ\(\?.V^?8
M;3G'[LM-G#5.L:OXN"R6ZI62ZTPB>LR,.N<U\,R,NH.UDND.#]IG**3L1+J*
M.%R20^<]=@Z=WRR'SMOGT#5M$G+JN#>EIGS^^Q3=!TTO#EX%AX.85($:U["5
M6[<6A FMT*OO+5*!6RA]4DD3N@L)H .Y-9(054DA^&$I59/RC>XDGL)4)^UX
MSNV1KAJZ@B.Z$!P7U_!P=;U)K-'=FS]-;P50 %6&J'8E!ZWRO0.F1#HK_*_U
MU8S/NB#GT<JS02]N;E8C<;G"-')^!+(&-F50P8H4#?!,>64JW8#ZI5_4U2+&
M9_N(<35B?+Z/&&\A8GR^Q8@Q1W]_#:]'432# T^&-^%-.''RW9?.0&I[[Q[*
M%$%1"V6#HYDM4L/1B,&Z0N&)*O=V]1%7"-5#=PS9CNR7^OEZH@MII9_O6Q L
M1DBC%9B1_\K9/QA2NEFP&2?W]*3H/:!,2ET4K')E%4[K#R+4:B64<5"HT\)N
M67>AE5D;^M<$YX32'I;>_YY3A3D:4A;$E"=1&H#^;FA7./D;^$J,A/D7H]LX
M3X$8&.AK?SU44X_Z?GD.W%4W:2^FT'546YI9CU$/Q4K7U6J5YUZB=46-]>HY
M4B?'(.040L,SF$8@L^1A5TEEL\HY/%W.4=$?36Z"?7<PAX*<*7!K9B/I/V>S
MS_TAI1Q::H4B_*Z(&4.*<_F^&A;JU;WU'13="K^B2VF6$AB6.;@)'B"&$'Q0
M>BV%HUY[**OQY6147C-91<!O.:"B'*#X);*$&S]$J_ZJ^Z$U](N_Q&4*QE@N
ML-OL.L(R#P[ Y>A*&1;<>=I(S\&=G*83L$@FB)8>P1!)G$_-\I)1G'/K)CK"
M+$SR"3O?":\L3D1^LK#O,&<VS( -SZCZ9"@8KS?'.$U.4$5TH/,T_9M&$.B?
MX\*L#__SY)\G_N_1B'CVYP@6@$SJ#5B@PWA"MWV2<T".'\GGQ8B"2XG_6YJ,
M1-A@0M4.D_ *1$I:S,0<Z#'" '^&J2S7&4,]\>HQ#D6(F;!Y-"Y\+NW3B7]!
M*2YHW4TX!CB.T!W.2$\P[30>9BEM>G8O<I&HL3S_(-&Y+B_H;Q<%ID)-XI!
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M#>!&+5>)=XF,^ANV&!J0$<B6LWXKZ)UW=HB(&DO&I2"!.VID[Y@?:0E5;MA
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MAT.E/M'"'U@<\BA !IVG!C)HE[-O&H6J-ER@6>_I122#_G(_[PZE1-3LY^*
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MAF8(XY T6_3MM&?R3,0.WS.LFKE*3P26PZN<>!?\M2F=:MM-!D$Y2LQKUJ/
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M)V&ZZA_0^M?_.CRH +1M; .>[:96R^O'X32>W/^XC,1=;9<U;CFM/=0X\^H
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M]CH-LQ'W/)97!<@*-8X;_U25^1LL@(AI3TE/2DF=YT-)'^&_\*%.3R2\<(,
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M,8=@C?S?HLW"5AC?TNYP3X<FL1*NP^D>UZ&*ZW#V#>(Z?+L$_TX9S^^CJZS
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MS4RPM*'_ +6;6+4%=8#QWA"+4%]X'/80&Y8;Q"RE%1_P];I90CT=]D;G @J
M::!+QZ5W6TI1O7_PY3)QM >.SBRR[R5[<5<S<X8:PI\F=WGF-=+Z(1"JSZ*C
ME6?_QY^<#],F>^-U[**8EBOO/D'5]_.F/:?*QI 2&OG2Q]<^R[#?8&BJ.CGI
M06W&2K**2!)&%7K<I( 6AO/H@2KC'=!;K[I8^R)C-X!N_$!=K)='IYW>YB$\
M/Y;9_,G;E%5WYC^8KQ:3JH K+$"P.#"W&]>024V+*I2>$>%-&M2/YRVMW(E?
M<C*)Z *5[DNFZ" BV^!O%7.A?V@FH+C+0%H!)<1^^DY0ES3$WD#$.3_&%%-7
M1A49SZN+:IX]QPK/D)M)VG]SS(D#=G?>:]_LL(1CE!M?9%!$(M]FU#A+JKQR
M+:,SKDMG?9?MW*#DXGKT&2^N%R8<?8SA:-<OP;7^T^'B70LQZB/8H)J!QG?I
M.M,2<JWBYR5QT9)DO\$U CXY9&5?'-X<PLN/'0%W2GX:%79[:CIM*VL-:D9F
M0)'/_):2L>C.&R]':P+XT3 %AI&K7AQ(5EC"JL$B3<-D]=ONVUU(PB @5I-W
M!(]_U6"I:^WT[\A$/J_\%VI_T=P&%-L7YHR$.?4XNK)\CXD1G2'F5>#"$OFN
M.K1]M>0Y*AZ.>LO!C(@@B!#_O=Z[<<4SX<&][UUF?X.IGIJ6M+?:PNW4:5^*
M=>U@SV0+DRR$*>,=1X6( ,"V3@HD(%F>&1 0_UV#%KH=WF0#6N[3,D%61<(2
M]KIC]$+X/6UG'J13P4('M,K<AAOLH2&F*[*%SE=@D4+-,'T:1QBBP6@.\PH<
M"JP;4VB9V1:MM]1;8+XIRUFSR-Y2 L0_X4B_)&^ZJ>[C9Z:E"[(R WH)#Z\,
M!5U73.-B]\Y0<WK6U.S(L_K3/0/(6\.9H"@--+K?;F2_$U "!SC+#V?^^"\!
M?&\J5$-N6\5NI."\#SPPP@L0-LQ_\G.YN/>9/%S69>SAPYGX>[VB.!I>T ->
MT%C_7[?BW%+VR';#B97=D4WD]NK[5];[$MTVTQ&^D;+Q%^S#R&?C& GPBBHN
M,R9F*2"[ =-Y-2>W"Y/< SY/719,# BD>O#'H=)YR+<*6 >*4+ 2Q2\XA*'H
MZU'Y-N%MPA'B1@A ]E OVV8..FB^PBIVP+&2QQ?H$>DZ1(^93"1O&G&O4(,=
M@EBHEDECXA]KRAGAM $21:4K0@14)%P"!=?I08)W7ES>GQT%LSSNB;&[)@"-
M"QTZ?T/4P+!Y)2M33JX>U!Q,2L+?9"J;5&E ?(]BL7=G0CEF+PEAMDE4.1IH
MQ,/!C"7TDN&"3CR*T$R2C3R3F8#ZSK*>2A=8!X<%;X4 JCJ(W>?K09[(6H3#
MS$#F[[.=XH&U:(,U2W9(M>SZ'L'X"L!QCU? <FOR LU6WN3&%%(?H!=L9&R;
M1M<T?2+$0&YX^:KA?N] #)30 .U,'E"?;KYQ34I/5Z)G<HD*KA*2HQDM0%<L
MRJC6UEA$PM6Z[CTV4J_(+8'!"#2Z .R,H@F7>+6P*$32F[,&H_M+@.S[22Q7
MD%Y BMBYD7>8L*8%4Z(_B"?BF, #;4O,;5!PD:OYD.+"#X!QG$Q_ 7O'ZADV
ML 5LE=.2L0Z NG@],*>%".N3.Z_S;@99>78/6>E#5KZ]AZQ\Y8<@L%P^E3M,
M;EMJO6D4U3<'NP?/,N/5:H!%6!.$#"BAU0*HMT9;^N&5<&_DH;[0!J*Q#!(Z
MY7VSGS_Q^NL9  M/ENR97T6(HXP\WR4SS'HS+)32#;E#]Q_O]:;I9)HCX:/A
M*61A"EB#_MVCFTS@KFOJ=W9YC?OE9",1M^%M^G)6D8GO[TD&-:&'QCAM[3W'
MUAVS!T<2H(@-O)(!JX3[8BE%T)SA8=SYO8FC>8]DA7EY^DK$'+']@R?(QC"J
M26Y[Q*!2[]%WX82Y^Q-V53\L ^*/DX"8N(Z.6<2Q/'3D[ACA/IGUY<D))?$S
M (;AG>J>?@3GR4M]W@OOW?2R2E;P$V#I<[\1U8R"0[IU@_E8A)8RQ@_&Z&Z7
M\AI\>)K#0:7)/\@5^#:,*%F'*]JTR2C;BVH*.T:-16XZUI_?'J4@,Y=""C=-
M*.\Y;1H4U#LCP&]!#$X;I(6J+ NNQ,\,F8?C9#@1L03VQ#1J<-Z6#V^5.Y3@
M^:VH=R1H/IB9N_-Z,Q4@,1C<#:4I$"M51*RDL@4QAC-K(GYSP)Q+'TD,]7;5
MR]=P</9@CSA(.,@1:R*.VE25<"K!P<J>['V7/]M[=D5-6@2[O5U3B'1%W1BE
MTCA_T\BTR*! 8"=F@#AX#U$E(#-!1-+ CKX-K$WN @($,PC#?//DV9/;;Q(]
M$L,-O8E%-:\7@/,J'UZ6$"""-_-A];?/=!2V3;O =;UPO/%;C_:PCP.FZV"5
M(!I?SB0&&B\6@<C;D!2%R)1?EX9B[?[F>3BKYBO4>>=MLRP%(V]8K&=PKI ]
M!EE-&2-V[K5EAXV<A4]".@;AW[$6M*QG]P;;[X-\0;-R[O>H73M;?A"?>0TW
MCLIR'M5R!-7$\?U_-9!KEOX7@=27"Q]BUJ#052NZ1L)IDWH2:<"PO<1!GY>'
M<RAZ'ES0.*-I;1%&F@N'.3I:D[8I9IL+7/+L?0T\[?"H58W_G*>$-4UK311N
MNN/BICN#>YWP;UH[9[!9@*'L'%%AQA02J\=2;%C*S4+[ 9",)6"?/AV]&6_;
M^#N#1XU@_Y$?6[/628=Z [T(-43,#AII0JCTH&]$&)8\8;(!DG HSP880UV0
M+7 *5 F$>.'F.Z #L.(G1])\9D-8U?@G8Q$"JQ!8T[L$5PYBX<6Q))[KPC1M
MTU4.IF>>E7Y$S1J[#_CMUGI\D@A>!B=Z1#02^"54WS1RH0;WI/S@][F#NARM
MGQ"Z%TFW:(F255F8-+8@#Q9D%] \&]_KKZ!R?G*OA8:U$-A%F'],LG1]FXC@
M3;?VL/3BX=TG2Q/'(2?44EHZRI+M$K )V'#G22PC3JGZ!Z\P,;KPFF3*0 HO
M2TV-*37OSS?MTC+XC?!G L2^ 6JLA_O93M,Z_I='_HQ[#7M15'-XWH,X"<KF
MZ>,G&TQ2;V3OEKLY&',-0G^0K)UY5!]$W8H(&($LGYRD'M^5VUBDQ_3L8[L"
MVK:R5[IEPK5XPVN;%-W1=.'=\,(C51=.;N, N(D8H<Q*&XKA97[*#HTI0AUP
M )HVYT+,K+Q@9POVJB8J!,V/CPS"UE]!16%Y"6ESOC&0%BKR0PAC@V;;G=<T
M[^(S:L =[GU9GE]# B O7M4KJN(,^[_RG\ZI^@T8=0'Y@TJD;K*Y-UZ@SU<S
MQUJ6]09[V''CATE9X)4J=QN#*C#Z%^C">TH37V^51T[(*+S]83AJUE!)$N6L
M#C7&REI,P;$+8^?Q3YKSJJ88K, C!06*PT)5Y,?D10^#:\A!BX<-5P,UR1R!
M8L<K_^'^X\>B3<H/VC061=4!Q]D]]R_=CS',#IK(Z74!QM>-M)?7AF5?<>WO
M/;'NW37N"&)PY&IEJ'<[X;*#!AGX5]+W*U!DC5QK4W\QA&.".@W-3\#J(!JH
M&ID^P/,$NQ)F!&I/+(;-R[$#1F\>."RO?T<-/NYG/RYHV/SRHG]5]:P#JWD@
M"C>O_+\3<Z50R?AO^ /GY_EH=^_/RC)I(C9HQ:/AC@?_A-\O)<+X%SQ!\=]9
M@X%<AJB*@_#?.;SET=CK[OPQO,J-<"KP(435EN!9^#^*@^ WY[)H$6<:PI?L
M3UAG+?TANAJH1"']5;4+ZO_4X4%:(3P6F6RG7J@J<(?(T_TD3%2?;C=NBI7Z
M]AXKU<=*?7>/E;J!R"8UEH\_8XWE=2^<H[CORA!K_B<XB!-=LLDG>,%-(M#,
M@A%EGY->-$[[*1/#O5([ D%CU/Y=(TSD/J8];<QS\,O [UAZ[8Q?0*?WJ/9[
M=,[;A%_Z:0V1/[G3W:J+>5C&AR"Q"JA+!K MAL260&BT ,HF0HZ;YCS;< 5?
M\QP]V<)S=,S>%-4SO?.7<,>T2&\P;_W)3M/M:$L^)[;$B^BA-SR63-T.].7@
M_3F*+U :#I@9+LJ,$%"TDD0_O0PK"7V\@&D!&C9&#4AVLZ%W0)_[T%J$"Y>Y
M6H>B>L \-%M!(YH(M1#>R*':10'!6[28,N*Q][Y*LV1P"M2&E"VCML" \J\@
MBE]EIJ*@^9JZK2H!I-0=<8$(]<R,WEZ02=U!?,PV59F46% 0>*] #4Q-(@7^
MW;03 T]<"U>(E/AL="TJR\-/7&I;H!J^Z! .@?U(-SP24&<%E +[@<=*PL6Q
M9&JD!-(H-8=8YG-P3XNZF*__'1(\R2]SCLP FUH18C/-:ME5,Z@-7=5=B1)I
MF-DM"SM8\H$$!6,HVHY-"Y4PU&=FI2DS_^*SZAS3%CD5ZDV7>1;5BMB$271X
MO012-&=1ELN09DL/K2R$9@!5YN480UL[N'_K\C(/;,-$)$:M<D?WQ_I $3 V
MF3$-3>.<YZL6=4[_BYJ&GI1U>5)1O'?528]5"DS,RXL"&^N84=WY$W54J^ 1
MAIE%KW%Z%8Q?!,.B@Q%%U);4"1@2NYS& T'%9!\:1!H_YX]EJ]A"DAW[?BOW
M:(D13V $/ < :WWZWW_:^]/-AW59S99G\-6]/ZMCZ@V4J7\@C/7##W\")^J_
MEJT\^@(,U6DQE\%[;^U/[&<M9_(E?FHRA>5L_(L'5,1DC2R8Q,.38E'-U]]?
M-0W\;E?]NZ19PSN_>_KLNQ_4VAIX]]5FWD>-(-*B1L'@,"+=T9:4ZPXZ@P%1
M6/DW*;H*+81++!>%.KFUA"OM8V;5#!,V57V!J,WDW$1+X?^KO<F^#FWAIFVU
M2XN)S$@(_I"W_X>*"L16VW#GX$ HG4B BE7:<R\1@R^VS3T4^_U&7Z$3C&L(
MHZ#C77G;O6JY.G=6<K4VVAQ^#&S@J:>/4.G['?^J=UP=RCH0"(KW&#F/V+P4
M^GOQYH.M6VJC:0[W[ Y*PU_06OB#C1C\[\??0J#V:FOFX?:8G.#$D5NDI?FQ
M!0G,H,074(?5YQ2@O7$)@,65#_ !6I[%I,.$H1(?7U!/5.H?I2Z'M6*AY'Y1
MK#&QW36YT%!X]TD@>F=>*2R*>F3 .25WIM4YA ^A8SCD7PDQ-_*3T%1"AS_D
M >UFOYTWM?"*,YP1_!N.V8SY3#V;O%@;!Q-04!A^S"C-ZZ7^K)I4R][;KY23
M2>-/T$<*"R5+KAV\?[HIZ/A'CN=%.:]JK&+S/R*)VW^Z4SR@<1Z7YP L^M0G
M20;3#W_B/@$G_O?9ZAP"7T57]B+ZGS/6.5(+6!K.0+-^7-7R\L,4F7[HP\/I
M4B+LW8:0.G.=^7_"9K=G#?O]C+L#Z/&B:1%D!:B'/U/-K>#;J*.FLI8X2?77
M@>8+AN!=W<XK][:BK*T@]UK:=T2@ZDOAE7XT$)1!;G^<$K'Z#WV' X7A\1A=
M<0+G8PQ@1VOR*,\>XU.?[&:O^\!9_)-T;]8)VY@C&K2*1? :#=[A%T, ]]CN
MH:V!Z7?5.4)$-N=5 '6/;2$('X9SB0;KSL=2?L)BFJZ9 _P)66A@ETE3"UIE
M="VQ<R7'N4/9$&^,X!P)]X'(\_/5Q%LH@.:ZA._.J_*"486&;&@-&#/JQ/:B
MG!HRLT?[N1..(?^3NE&!ROLV#0)T4D'&B&9ZR#C\'<JR (\2U7O0\0$1+[@M
MO4,'^\X+CZW]PP.Z0H+KR]+!\25P>F"I JMA#K%0-(NJ+G0^72L&")Q37&%9
M^S'9XSUAT>,:&GD#:@RO%[ 1, '#BKJFV@_:2HSX?E@'M->=W\N;X5N^N\>W
M]/ M3_?N\2V?@6S\V>>RI=]@3JB8L^[YKTG[EQ_=2^E'XV^.%V+/?$XD6[(:
MWVXAG.&O);2FFM]=U,(A>:5\YW#2,@=Z._<<K'@:YI$UB.GNFY19"0+&9'4%
M_.0A&D3@!N=$"#P7IX+!_? J;Q<]2]Z'N?K(I,;*1O\+,-J!4Z]$0#083=QH
M6$8R PBU# 1^!HC?ZJ0"+F# )KUJ%EB;C)?W#)N7@!B4V5\!?5\+D3+[\6?8
M1PN+7<"JTV9I[J>F:&?10<+O=OSF-.-6PUN!% =!Q'P.O\]^*2Z)YNCMLJQJ
MW,5?=U]0OQ'_T?F9-PS^MIN]/6O*1?$>+$.!8'DG;(&6"M)A8O?6L",Q,&(W
M.SI!0X4'H8$UBK-#WGY52Q^RKFPO,)0"7\("10+":WT,?B$76/H'[[8X"'9,
MH)Q=]AYA%L 'PNEQ>;&RZ(/Y0EL;1TKBZB-FA2>D5A// 9Q0R9G3Z!U4M8X/
M/.>I(7VL+-6=MYS,<JLS'DZ(2P\"U47A)O*QFC*46AA))5:K @^BG)RBJ$7T
MX,G0CGAPRK9SDY*[[+OMO<M41;G_&^W9W;WCWHEHQ0J<O?K.H6<V!'8-TNIU
MTUEU>N;5KMXO07T21744<N^_;C=[:8Y![PT.#@V4E;359+4,I':+Z@/>CN^]
M7D.N#83*+<Z]"JT5U39\.(?&\#M<,250G]"=./4_QYH9/)!N\$!&C\A'/L?&
M"IU]7E3[BR-<5J8H7%8?;_%J ;YN = MA2XYR$V<MM5RG6-N$,ML*NI5*M9
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MNV47*%&0[P!'M&6?C$M9:+RK^;):D!/70DM&;[0XM)F7V'"1'TF$=9VZ@KH
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MGL2+"980-)?0N#7"E;F5E)]C)^NM!6:AE,*E#U-]B9JH75&4FI;X![_GI(Q
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M)8K=#[RN'[VCZ/,<<72A)76V .R6*H!3H>NW=S,/A%A=D7-RP4@H6^9D< (
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MGQ#+%D=B5Y2Z;&90+)BL3;J<G:XGP1#,\ML#[^+V[OPNPSF:S">] 2$9,\/
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MPM5Y*$F-$^K2E!0M9^@B.U0S,-"+-@4R5"<#T60Z?%Z>US9Q[A]RVC0S2)Z
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M+O;LZ#JO.SQ=2NG'Q'&IKC\1@>P4S[>8;(EG#^-15 ,?1RF&=2GR4%KUC*\
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M45Q4Z'$/B_Q+C)&\680E2S5'/5=<Z*2&H\/()5B+C=6:YZ.J,YD#A:7CF#%
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M-1YO<LYW7-OY9%&/K MMW^Q.#KORB*;+Q+M^L44;[WB9PDJ0=M39@0"7)*(
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M'"7W@<9F%YLDK4UHC3U2Q894N9!*#]WS>H$23>Q0OH]S^[@9C?\6Z@#>-,(
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M3;/(7D+J"J!;*,C+C(DRPL-D92]Z)KWMCZ UCB(X2>'M]>65BK#2T_8;L))
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MNIGY@23%R^/PQ?&K\/#%NFBC5W==D3[E=<V?_Z@EUBL76),;L439QUO=GTN
M_Y2XDLD"G!T3"(2N09LR %X:5#&%@1V6N\N7S&_8Y.G99/]>V,3-6#=Q2907
M!*SU1.1@?V]_/_AP_C%D[ O-1/"$2QSA&&,?> 7/D,9=_J+!NMQ'P_-G3"5B
MQK)_>G'$P\)5<_2G8.E[RSE"3UR0\S\PNLG'%$_]+@L\V(7;(L@SI:Z9L'T
MA6MH2<-T@TB$Z"\-V#W0_E3B(LW\>MR@,=_E(4[1"8,0R#QVU42DUB;]P]]@
M_O?FBBYW10^6NZ(2<.I#.[!CE[M+1U07(P[C6\Q1Z]JB+@2>< G&\YQ%GPOY
M1_P$?2>Z)$;O:(OU5S:/.2<WXR(LR5ATUJXEI1UN-J%:#(/=-+^T3  (&!<
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M0O%02$$GS8,Z$S2N"L>KT-+*43ZC.('#SG"%@:(SPA,3[#&>.(OOD=>[G>M
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M\BBO+Q:(16A]A!K4U5/$@W/F(N\Y#>/4B>O/?A!,;30IHO(+=5@V(<%A$2B
M)[<ZNNY"UOEYBOY5+M$\=[2+59\&AMCW)\BL+6=XX'KD5&,UC.:OYQ2$EJK
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MRI#SH0,T@VT,//L%E9$VQ$$;@)6G[M7*"XR5%_*("PZ0.6&Q,_:*2^VE=M$
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M(2@I25G6#O(A#D),(^W12@$?]LMAC4!P%.[M[>'_I;V.=3RUSADS0B?BV22
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M%)X6JV**0'F@V2QKEE K4G"T5/7Z?E(\3KA62RLFAT3G5V[QCE*PD%T5^Q8
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MHJ,V,Z&I'&).5*\_#"!XZ ;Q@LZXDSFX1'U;-  E@GO][^FZ#GK59Q0I:,N
M[)%</V//SV)E[;U%]2_.G2[+]@IB7! N /7%O_:=%R7X!'VS[&YNYG/@-_WG
MFB_-,)G9V7O7&H&AFRRCN>9(,WS/2%-0-S%EK0T"AT=P]BK:@!WB7)&X)E%#
M8T&68@:K&Y;YF2TQSM!7<6YB'.B"?UU<OJ;(FP="TFMR:E^-OPT=1&LAS957
M=0R6F'(9H[^*2:+CKNPN$^43E<R@]:$I1B%M+Z$N5=KD<'DMH91\_W7CVG\F
M"B\';Q<4*'BU9/O2O[K,>>Z!N45X?!?QDDI,M)?@.T^ROW,$ N.%(DE795VV
MA4!> O<U@V;M):(5 F-3@V@CP1F7$E>JBZA\@''X6:7MT[E/0 B7VNCV[6"_
M*PE#2<"271_O=;O'$QY. <-%3O9@?CO"P1F"4R(0SW-;]0Q&C$0E%_@9@J'E
M-;GCJ@[KVW@%N%QFYD'*4FJ7<QT>DN%2K84=KP1/27 &PXY"/.$K$N#PL<<0
MF [J;.L@!#$DRL[.L6DD7H=['2,3XR59@Z!#4&X5Z E9/.4)@T2;X6[8(0+K
MG^Z(P8=17:K>W,C <DPIJ%A=P'61O@GUBX05!T->K^(!3S]/1[W--L$W: !(
MI/8\D#&C"D\W2I6J#,!CLDPU 58=$A^C] \H?D*[PZ_Y']:+'!C0.^+=*<;K
M>D=2R3T>CUL*T[@''D.L_*%*I3(>/<Z4W5&/RI':-!/ES0;5M(?"!K?03W8L
M;&B;ZVJ"CI!=;@I+ORWA6+4:W*WURU0D'$YVIGH@:O?9#6Y9ULAHK8OE,S28
M$<J>(IFV6L$D0+J1O9)%QY5@>O[G(G64%AEYA!DZA$B/.&[P0/ 1C![CC1YP
M+%R%(GHOLS585U(PVU^WB,H-$,0J<YDZ>8:V*[>'#,XD([!.==WE^5N&E%/$
MC>#OMRI5M!24/=HWC'3,4U3[<+4S;RA'M7"@Y]<.(F_L.P'3;.WF9@V]:#5/
M2-'Y9D/W/F,KU '$O^I0%M=E_8#ZC_1)#E;*]QQVN\<'[+;;_T8)#?/*&5KI
M3K1>RZ?29 I4(;4"OE[5VYF@$J9V%+/A00XG/_M")ETLQ(D6S6,@(C?<WS0*
MSLC'+ >>'L,Z7B.?:V*2"950?D2Y!P5PVA>CXQSB%!3E*U/.?28HYF=GO[,K
M< A]#T/?WQ]"W]_D?K@W-/G7W9#)K]\ Z]UE=O[J!9@'EP=,<GQ6/MX5D_P3
M' E&64&(J+5FT 8/J.H4#(\ <>]+%_X)'@7A232J.(PX:$8M;*R$4:52WS39
M1U3BNCT^D@MN+BR30EP,CFEXXL+Y7RZQND^9A?&%0+63S:TSY^R%26'?DZ--
MK1COX(.YUSGX%HP<&,)GR')> ?$/VAQ";V4<O54:?(7!53:G]P74!D;L6%$K
MYM8+;=034YVUT%UDPWZ[\?SZUISXMXUM!HJ091_3Z;C8WCV QU<.<V*G4'TN
M I<&8R@QAS(M$;?E(C/.[SY8U$Y+[(@L8C'AXE/<I+\2B]DSYP=Y-SI:)[]$
MP'R&OYK8MRR=T8J)%C*B%?7=]EV?I!1R;GQ0OKE55:!"&&@"02;)YXBDX>BI
ME:PA#)W_$);HSMHJW#*CY9H^8B!SB@6?K4C4<0BP)Z0YH!W)AAEC)8:^@[W+
M;!T\:+&F7D0<CLXM=A1VLF]=$Q+G6^@-2@A4W6F5W!JC,*.*Z,N_$(>0JD!G
M!0</]EZVJ%-^:X536(?S,#RA<)T,Y4ONF'3!^E*,S"+J_S'B!.5)X0>JI0UT
MDZ9E!"@Z*']I%FF_J"[[!SY]DAO@I;HI6TQCJ0A#<PLR23E?7.>V>6_M\@(9
M>N O=FX/O92\XMH1(G&I$ECST*[Y!00_6&Q:U3ZLI1YC]:&^/%(:[+K YIG4
M@5"RC0COMFJM7)CYH%S'E2\1M"QHY;-WSYXC20SJJ-O<:9Z/(P7+=[N;JW'D
M9M)A WC=6&6V9Y@H/)<*E3A9&XJ"9T%(1;KVKI,K?MA<;G/MF#YY":#^0OB\
M1AT(ZZN'1MW@2"CF0K!9ND?B*60U_=&CA\=<&N=:7\V$2C5\[FWA0ES I(G6
M:)$!^0 %MSOKLO2E,#]D51?6(Z&T11;C-@!] #Q08FR@),XW"%:U<=1I9IX8
M/A3^1*&\Q%45DFY@-B.&YP,5!28=[HZ%QUHJB";>JR"^VF:!-T/-$I03E(X;
MR!$:)&@.9VN7A&178P)QHP?(A(*3ZCI^P.;BVPQ2-Q$\2NY;V//NP7KE>IRX
MU!B*%\'#4QF..JA-45"*L% C'YEJPY/H=?H'++B8N1-\4MXU8""HZLS^N@*T
MQ-&9%42[D&"A+!;-K4@#$V' /X$*<>&6AS@PH@E"3E[Z>/751V'.:05'A;4
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M[=U)TGI0)9"*8%-*TE07"Z-0$4,KB6-GFE^/]FC^29,@B:ZR.@GRT5&<5*O
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M%'Y\7TG9$"&T/7=B:E'@3ZX/"1<;<6'^EN8.1HLQO-BWLL2*KUFYJ&X(0C[
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MX]TSNZVO3ZR#@I%PGJ<N4R-/'.R44+=K2]H>#-5:>D7::]?+->U6SP)3]&;
MOPN3#Z!'P9EZV#/F_>#U0[Z-(@-7%US[]=*:7NNE *<Y 45XY5GA4-3!:6J
MJ,S3V_)+Z$K,Q46'=K"!1P#\,<(5C+9E#64YZ/G%@C5GN )%,NQY0M3"$]_9
M.5*%V%+3&C$T:KZA]JTOX#3I/7='[4)F,A#)AOAOZ[\P*\]O(EZV8ZGC*RR:
M\+W$? FX.Q!]I&&L_1$%+^$YRMCU+<'0]G(ZJVE5?(04&/29J0=P_I'C1IGM
M&'$5LL\8Z0'$M&Z7TAN0W1=C%K"KL6X-2E5RW/L@NY <63CT=B^P;&P8L;"3
MW#;V@UR)[;;HLSQU6K8]G780!62QAC?E8%6MVYH(A5:DV+G'!_2 L8ZAL5>#
MTD!;B_L>0GO.J[KZ%Y&5$0<>-M-5'7:$2(6_UWXC,CQ3V![;&F)=ME^T:+G"
MKI%X((*51+NV=W!I"*FV1*OD,#50*5X'M#T.,&X%U7ZQ.@Y40).8H<,!!KD!
M=RHOH-/-^[JYK>7U.#NT>#(@K*$&!<%&X QXPK"!1H?:A>V.Q$"P6(N0&I?K
M25?-JJ+%MIST>N.?Y8Z?VZ9]OUH4<%RYUP_&@^7\O6<%&!.J*>Q 8<L<B-5)
M=L[TE&;#\FW<#(Z^*L*F>%FIYLDMD8UM":.($T(##L@"BGYZS3U-\4_7%=3Q
MB 3!(><=4W@;GW*(;CNH=D4,L)MJ_]%3$Y@7GIK LWT443N;B&<-O-)AT;0.
M]&HG9(3DH"Z6Y!XJH@2DMG _@L,)Q2+7'.RF,'DTEJKCH\*!#IFUS%-&I8K[
MR"S<L("I2.6NB[HEICD0(O/Q<K3QE9^$;^J'0Z0Y%6G^[A!IWJ+-</N.JT[\
MOR*K9O_W_U7\?X^>GH%@%G_YG",!#JH5$$14'[+G7X(^RK_WJQ!N/?K^8?;S
MQ5]?9I?/+UZ^>O[R,GO^^NV;DR\\BM.'IT^RUV_>7;Q^E5W84;QZ=_'KR^S-
MS^>OOO! OLH:_$=%L.+-@.8Z^Z]U79I'WR& ^4E.!&DZP*W0QN<"&GXCG,1P
M<\8W/X56AK^_UK\)'KF+DZ']0]:GM4K_G*WM5F_!+H";8#K?_/+VS>M+NPO.
M7[W(?CQ__G]^>OOZEU<OOD*WY/N/.Q!:'N=7M$$=S]P[B"2A?JGFUIF;5G#X
M=0;\NY.,=CPE/"Y<-38#"UV21.HOAH;EGO!U55,0-H6*BH>@;J?I"0'C>RK:
M#3GXGHR^9\_QL.&;&!(36 .[0>1:<HQZ3BQ[Y:*Y]1<;;'&J<?X3I/[A"WJD
MR9,8"#C7A.Z<B9I!Y,QT3;4(<VMRE_@[=G_%>:P!;5-P"B-H?D-@UV<&W'-Z
MIYW&ZJ;H78;,^\,X-N?<J@9%#R3QH6K;L>G6=55RFF;1U%?6/FR1[E;W-KK"
MMF?DIKO6KZE9?":Q8AEH"?V9DL-$<)(P%)42=8 A8-O=[*IM;AG(;1?%#J,J
M%L(L:(=BE(?SA_=0';O:N^LA$W;BV"OX8/0HH3HXRIY\MD*61*$.@O9<L8[A
M"$5$#(+0P2AW\*KH9L4_K>(@+-K;]:*D67CR].R)8TF1E*U*ROLD?YR/"=YL
MX,V85PAZ$" "*[8(\-*A"@DA@Z!_L4R/Z!>8@EGX&ES?V7G 2>YA!9[9.X]\
M\Y/LG&&5%$MUNLGGBD9'C8QG0BL]+>JHK%!R/_2\:FZ2#ZJ([U^B6JERC75]
MV]A1>]2Y5G'J_4S_OZ< LDR\:<L',CCS5J6'DR()T3P9@11*W7/)!\694;'H
MMO&X2M<!-&99+AN@<:K^Y=0G<=3S^8XO[!S? 6+Z=>43-[,;W$BOI+M-3"^>
M&&X6#!>K'Z"\EVA'#I51CJD']!K3JLR]\67"J0^KB4->0LD0IAL:D'80^X/Z
MGT/O\P6T!G]TZNP"['W. ?50DYT$8ERHK4MAO6;B 0>I-&T\H.>44IERY-I^
MLJ=G01G[\8[*=J'EF#4_#=N=I './8(&"L_WW>^IG3G<XT[G2)B==D7BWGT[
MIJIGF4!#C)Z!0_@128^WVT/1<0HI/6PX0[RVY[4RM*9<UEFXBPM65Z4J4'+-
MTNW]2WO>ACF965.2B@<_ <A!\<%IQ7B$?9WD#<#("Q2\@W[L6S^T2XCKL1X\
M3)I[)M ,5\VZD^/5"O+(&\S1=B4=:#VQ)*SZ:&KHK4"9Q."AOS-%N$]T6P4(
M=HT0O "K"0V8[JN3S'\[9\O?K\NZE :)RDB%*BH#T+UU%^'#4'W=J6H32NA9
M=Q )QCWF"\U37_1-T#$[A,PN'W;-!E=MBJ08$;;L=R;HNP_A5$(Q^_ <*)T_
M/!D,^>TJ5NEI\QS_'/@& -Q QOM$:P"Z<Q#;00^*E26R>5EC#CBJ  EMG^I]
M(N,?PEUY[:^+&U+)4VR"/43/JAH20D=H"S=H/4GJ\X[+:!E<BA:#@U#B. RX
M<]FCIY,'9PF^%[1NI,D;$,<$R7'&&S<,:?4CA:,@&)L&:*MQ:A G'%QCU":'
MO2"!AWU(/Z1R;FPCY ,P+9+S(&8H5\M-O^%PVX*;.+B?IM2S:8$55O(#;1>D
MO9@Q3JJIY:^,*T5\!S^;4"R[?R,_,6&1*OPWX0VA,G;O%^#7)=ZR_P/+F9G<
MI1X)IO3NCQV=Y]$@K=>%UM&TGB;U$J=EU4OLZ"-7S2T0C33J&J^NZ'<*$&4W
M 3<T(:B]X.X)\<0R)DU#=//ZYK:V?[VN5NA'J)#,Y,ZU3,E=T 8P>W]X+;$;
M[N',/IJ-ZC_#6!A^\SL'0SS?#PQQP$+\QO?&J<2/]CE!5?=E-%$2ZAIH&I0/
M .7:8'OUD(S9J_"/;OKNY-'GZZ[R6UO!QWO[ \[D-(I]42\?G8)@AD=-DI@-
M+Q]2)"K[-LD*C66,F)#-XP?_<G)Y8D*>!3A&B6F!WHJ5CQCX<$V6F1BI'0PE
MJI33)'[1U0%1TK19VV,4(8J:,XF-,+;%BW9(0N]+WA40$6#OT'<30>_<N8 +
M6SITH;8Q(AJ-=A="\X%[==@%3_;78VG=Q>XP"(:L=-Q"(LEY<%@+(8?<=RV,
MRT.-JR3@T(X)A7S30,_(4V%!DY3&.EZ>$EN&3PDU(<6=VB="B]M B, #])?E
MK%HOQ^+GLKNE"FQ-R&1_?\ZU&J4:7MW4#U;%JAQV#W.92K/C@VB"9!0I3#37
M%V"9Z1P+)X0.A//2PQ(?X49*M4_R83VBFSUL .$GW&,#8.CK/K&Y<6+4P_P+
MJ=\^X"WPV<=#0H-M$/<.&Y;&:6YHCJ'_.3LZYSC#V!Z%6$7520%GD4U;.S4&
MNX/>@(::M\6:@ YS^Y)Y 47;:#%Q&;I#;7#_>NFD&CT72LI;-"0@%(D%VO-R
MT=A?'W'GD8+8?;#9FRO!-%C &IA'^ "7I^/ 1\>AI>-GF6NM-?;%V..5.SU0
MJ7N-)$GX8"Q,K?IU7ZK:+51,LZKCG!A7AZ:XLX:A/->G:L#5F!@:%'=ELW6/
M$#,'[1FYVD!ST?EZ0;RW#:K(NKRR<@L'S[RH%NN6R+$(XJ:KL-V@_ <ZX!R]
M?]#,YB=[4JUR:M5 [[7KRW,G;?<TF,Z5!<KGS+:LBQO33=6032J2HRKF' KO
MCF)9=T@.*0:K&1BL]KWECO+ QSH#2ZA]ZL2^RHN]Q--= S)J.P9^R'*UOK+[
MUU@]45VUU$L#"]/:XHK\ ;M$Z,IB)XTYG+6=[QP"-4S@ZZS6S, "]4M2OA9@
M2:-*PB%"L6G-T?R^4PX!$JB<T\QF2K<H/CEE!#5H#6#7H+XB<C+[,V1;%DT'
MLD<7=!ASI.\QA>9RH"8CT>!(.0!F\HXK&4<OFP#2ZN/::,K\%/V@(+2^,T'C
MM^L&_2@IA'>5C*J[6*X'CX%\1<_MO;$.N5V1 (#QL$PREYIG$R-3) FDMD(D
M#_@Y]*PN1J3FG^ZLBH,N4,QIL.W D,G2?<Y)=A[T8P,U@\]/%9(*WJL(ISE9
M!*TRQX5)"7O4!4YS)*+FKUIKLW=HKJI>?1ZF 9^AGZ'H&0!^T2_*F$_4C-3W
MNAI911<^6EBHQNGFBK!\S"D9>HJP)NPHX"LHRSC$*?I6ML6ZMT:1?0"J,D4.
M@7^OIW>B%JQ1 'R(5QO6@#41M:>&W"WX0JY/G[&ZK^DK#H9H=M>-3_%DP:I"
MFXFL145;I;TFFLP"6'[+F:CQ1JP0'J]ZAK">]'<KQ.]8 V7B#2QUL,\<; -1
MJX<.16C[_K"_[4N=4"K(\H\E#NW2[?M@@A://=@[.$->F90-362>'16.FR%F
M^\^'[IV!=$1=MWTNVQ &GN;>%64O*-.8'0G64P7Q[5(0/.)L=B]X!+_2WG;V
M\-]<%US0]=1A^>B#MX=@)>L'&ISM<>F<O^7V?.'9NB> \[5ZD3Q*P]]'\\-
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MC1BE1\YV%[)P5Q%[;P%@;>K8,9D>/5M!F/H(C6W,1YJ^M8>;#^U$2XPOV&<
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M4BRM @5%-*<^U%\QQL;=KI49-J%:K)?67%TON5RCLKO%C@\O/L!Q=H7C/#G
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MIL;D0R+ [D2%EYT&ZDCT2T(XWJKA:."  L@U^D(@<A>?K*K<.JPR,MLC$[D
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M]1D/T]ZNO LO,05VH4V)AWTRQ9)'F5[(FXV"4(7^P"(M0' K1*/)VJHBF\B
M/3*8""/N\M?=!:@:FYB[B&MO !I&X$#>&>9B4Z_X/7KSR:G>G(P-6,D2S0\?
MI[%2)J-5(#VWF&4F?'%Z(&%)\-O4=LF+]!:# @>"5UVX=X3AD1N:42&-6=;K
M\F(YWF'H^^$-ISF$!Z-= !**+ZB!IKJEUA?1O.@J* B&;W0C_!CX.F%X,FUY
M)G2VDG0LDB.'DX@9X1R8'6TYILM(YT]SO6@K"LFFC%H.RU_C!YI<)@D4:\:5
M32>=T1A46KB=K- T*2B0-=E? R,W:5S+XMDJ90OP5CP6('*%%K;X?N\LJX6I
MRTZF9QTZD]C]V3X/XV23ZU$8(YAX:-=K %"9BJ>3 :6?=Z_12LS&G%V9VXM7
M)NM>A'C3D'4<(67/:@(X!<L1467I\:98FK'P^C3@>V4P)42>8\*%= 2 B$PO
MN$E ?V;9_AP54$#& K,"[8@_1]]114TM)&$28,0LQ$7>N/->8P\SB &*N#JD
MV/F1RZX3L7ITO;@YV;1D:3U0@=6W)+(DBM$B8E_6%<_6).?7E1(0-G\0&(B?
MVC&^U]9B>ZU50D]!EDVC!76[B-H#!=_9PC-I46G3XGJ%K!"'3AJ>X@*^&!4:
M5(U389$IW"9@6FMS:@1#?[X,HTN7)GS UJ>*$:0BL4G3&%EO$U$V<#GD)V8G
M*1(6J!^*BX#.XA5<8G/XZI(ZM\I7R>)"\.61ZR173\PW;3/?O.!9/J#:#F <
M[XN0V5DALPW?YRHDX%%K*)K@Z=1$0L&$4QPS8RT!<*<)Q':RB$O37C8YO&?'
M!7QG@+O!^MV(#,>Y"-HXI$U-PWFQ-30%<M1]CYH_M"C ,' W,?G!"0(P4M!(
MX.D,$8G&TJ('#!JS42&)'ZU&$$P1' ]7[N:(3.!.&G[YM4HV%ZY<)69-U8FE
M*LQ6BBHL,EX13]Z#PI@(HR!$9(AD<B8)(5N$9O=3!@A57?@9;I-<G\U[#&5)
MY^5NX;PT."_W"N?E.A^+AX=IDBM+TS58'K4B2:(EGU]"(D9H*KM_#::+.5+?
MDC9HD]0G'"]K(/K)P90R2I70/1+R/,,<T""S\-J$[[CJ,D=YDL$^#[I/4X =
ML<50TM+CYV7:!$ %71IU65)F9:ZA"Z5:.SB1"\ ,>L%N\@(\"A%YEL<C[*B]
M7-@$9KC+2J;(+>DURY"!8K3,. < TI_U:2D0F"A(J,LB1"/-;9?HFKE"MH)>
M;(U>:$(-?8]\CTIP=H*6]C;*F6-7EP]5?C2&7 N6=TN390S>F7M(MM8RDFVB
M6\!2<UY4W%6E\8)O+IL2V@H$3*:MUJ_E25=HM5HA_\0 5SXDS[\3L)@*R 6.
MJ5"C%U:CLZ;/V=:N^UL6I>U5[=N"OK6>IW!XE5$2 O#\J>RF7K'17:9XD,4H
MIXS->J1;40^Y?UF,:FT28'9X LQ]O25X":/,W<%;[WE$/!B) N3#TF7CA^-J
MQ?9.N:H1VIN0^UP#>PP^HGB&CTC0(V9)+#<"2>$%BRU8[+.PV.W'8+%8+&Q]
MR&;MR'BJ]<+H*<7\+"P(+A@K(@ SA]:C4+NE*T2%,,_S$1<OETON!56*;V$!
M#8=E?7<H0MA(Q6^Q/Z!9D?H?-?>HS"Q5G+K3'/6VZJC/A(NB"T7%8%35Y#?A
M5,CQ:2X9>F5GTM%5;(9(>8&ESEJB^@2:_,/^A,&PWZ?8'Z7A3%IT*CZ/NYMD
M#J^EHE46%,Y3\A:E<!F;A#O:(0]-QIQBM;(?Y33$6CH##A$OIWGE#=&!M+ET
M: 9+$+"X 8CADOA:J"8O,L.R/(?:) #V@D]B7HU?83G60TO("8>:O+X%U1N#
M/L30T;E T@6<6S>*0J@]IWU/F?[(BR$6>]+',SQ#F)1%4)Q!.%8**^D')Z0E
M$RCH6:84-;6>T;QVOBC0ZALFFRMEM8V5*ABOH+!O=%P7S%I'K7 &I)%45 Z.
M7@4GD26 H , J"?'%4%N8!4NG-@#4'S_KJR7RV/.10!)91NJA88P8YDE39YW
M:8H,1?@2CV-9($A$C13F$B!;%1X_PM")%)0BBR:%+@H8R4J@:@\(0"J)#A79
M_TQ"CB1\1R8RDL4#5&NOBI1DD<7T/2Y5P/L@$6B(0/"!<E>&724$T*80'(ZP
MR-+,G  ]+[>R)3)[G.C""=QXLWWKNW=6@P(:UBJ5&FZ#]EJU<L1?:_)IDQ=H
M^H,'A61&_(K!5 -QSFFX+*N.\YA@'3L":ED$YJ(&JE>3&3)Z(!2O8?]J51&U
MVMM8]T'+ID^W2(FWN++*>TN"[I$#=>'T?\@T.\W9D=T5XQ729ZWP(/E9/+@D
M>62Z>C/*]EZ,2)J3@$)<<W@ZC;LQA&+)(&672:B5TVS(09X"UBR/V:'^:OT
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MJW?6[';M;Q!)U#XNB7 82P^'0:">/B 3#ZBG0]-E,=X;<4/PU!)AG'"NW_!
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M:4RY-*RUO3/VBCNCN#.*.V.ECM;GNTA2 WG0X9WQ<C8R22E&-304WRI!Q:B
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M O2EVY$?Q&2_DF3,JGW?7D1^.8PNW]4JE?H[+X!4^SXSAT>NCY$/&&K 7MW
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MND9+M"/^35-W7#U<8?(:TR:/Z_7#UX# $T"?@2$;$N%(#UAM](FYLK8F/;C
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M;3.Y<Q\>8N/B,1-"R2%EN)QX@[;'X0*X-/^Q3HW/%17_8JL:EJI##].#])^
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MX.O7K]][!>DIY5S&MI1]=XL#C?:_BP8\5*:]G-+^WH?+O^Z+#/FV_+&V3V-
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MM<)]/PXAO^LL+J55UGK/,4T_C1<$AX81 AL>)CV8=QHL>[BP/&/AE[ND^/B
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M^*D:7<*13!!" N#,5*97&&<O_>XR.2.QIQH][]T,/F+I[<:H< U3L>IH$W-
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M$,+YZQ8YQ<?09O1>P7J$D-8?1['EHG[E\!<!6@@+(:0M7@CA!?YUGPZCDO[
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M1-"%99&:J\C "(MK3/?TLM'2O](>+C@W)8PNAFFQM)8EK.5ZO*!Y@$2+X@'
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M%+1=/;A:9^5$_87D3RG>D&/Y8X2H1FAQ 2%+N+D4X5DTZI9OY_)I<C^AM_<
MMQ?,N"HJOS3<S#\MD0^Y%&KU&EO2BRXILV?V*O?\&-N;L=-J$#KXYO=^S!%
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M9'+%H<L9' .1*: N4)09$RP$54SS%O ,G(CUMA@:""ITL="1^$#''M#KV1H
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M-3^P5H7L#G?<K4KJ:0>CMMZ^\QAI$#FZ^ZQE44,/DT2X3"9M\4 _O>#V>O!
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MI_#;A1M-,WZ>JI]V]27[$Y_W?I2'C9&FHHO[[FD']48[+S?+#P5RKKB.!/)
M(N[.CFR7MR-;.J/]9"@(94*!2E/QL1!+VE]<P\7@'>?HI*Z$Z<8ZAGV6GV[W
M\>+%8M]-TO(8RPY@\1&6>PZ1<UI1?&05+3.)/<RV9LQFTUPTDD[X:@*=HO&V
M'8QT)W&?>NIV;!Q:%P,F"];<WW:.>86^BH-_*3/JO:>-^5 %6#!*K6H90VDX
M1B]M*PD7N95(.@)<[.]MR5&HK67DD(K,=$=VYV)>15E>K=:ZLXU(C/?;,M32
M0OK]G@-7R28[:.$+47O?AYVB:"=/X@XN:!0!+]CP(NV7M":Y%B3;0[OW;$=Z
MY/#'XT%T)TC1SE)5[!"XVW+$] [M9CM-]<#1VY)*9/2'%H-3"9;A#0'&NM^"
MY_S=I^^<MVDW,>L^,IT2DCA;6PE'-F5:NWV[@6L<!58.K'"8P]3?JD*W"(_)
MY;/Q7IY3'&N7*L;,5NU+OE*U9<#>$V1%(\G'ZE'U6X%(F84-]%W2%_EV::+[
M\68<5PPA5(S6%^CAYNT#O\;5PMJ3%=D7 5DZ$KB)%8%8,"WHUD]\5]G')GF@
MPRA$F[L\\WG4]<'-[H6*+4.75JX:4R=&=P7YVT!UJ<4WPCVY]=D+8Q\LEB[H
M=C:EZ,!K #-&X<=>DX'EYJ-LP^HWC+EX3R8NMLP7+4-K"#<\T"G1H_R)HM%7
MGCM@>TRGO<K50G-]J59]?[%2OYG&A$RPQS2UFK2\H;HB[,GH,N>!HJ/I/%!,
M+>8 $)-SEC3"!2/2W668[6\(T6PSVGS@F@B0-N1Y$3+B$+92UY1B@7C>,#!5
M5RE6.JX4-X%6OF8L>$HLSTKB^:+;N<)TDH!:GX]EP"75H]7]Z9IRB??,TTY(
MEN!O#F7E'6WM495A?"B^8:5.ML0K#:>G^'7U4!E6HJ+ 3BM&%DBBK4E][U$%
MZKL]5.UF>ND+VX%UAOTS)_->SH8-D13AMV,QP!4'>CN&F]7?Y3B62]@V#\M]
M]H5^K*Y]NU&..\)-<^@%@S 'O4G[5]C7ZW4Z84E@F:GAM?+C#3CZ3OLW(V6C
M1Z%Y!>UG'>=3FK)?]5'LZSZ7(C8^:%:ZO)0^>_3 ?-A<QV#2/6/G9_!BW=6\
M\V[K'?K=-G7XH-)4W[4JDZ^HBX&W#X1WZ)7E:5W(=&Y1(X\IE=529O_Y'3'8
M81ZHQ9B__V IHP/P?I3^)*F5] 1[A*TU90B^SL@"2Z&/%:+&KC%R?<3&%\BU
MQ$+OL,+*5V/N%#>EM##(]L"BR9 6<GIPMI*4:D&,:9[]E^Z,-!B@[I[X"A6[
M[9UN,ER3'+^KM?J:*?1^.T?B'6!: '@Y,2.Z$K61?KZ;8U?OH;U*O)LEUQ7)
M+M_N- YON6A$G+T1=6VPW-W-O+^3'-Y26SFHX(8CUJQ<T+A@:= II6YE4_,M
MI5B^<R>X/B#.C.936-&4-I(PI$;^?+U8<@VA+^A$_KA-C,1\SA$!.&68%G<]
MQDA;[R$ 2HMM#R<E7.]EM(Y< 6 T4B1704X%-T7:"_,)ZR1-@@5173?C?J7>
M9GKBXN]D=O3[4#0'-/U^CKQZ9U!3*[8?"FJ68?LQJ!T<NP[84>X>;I>S_>L@
M6KGY(#H$V+N_B=:K@#@[X;[P%B>"H,@P=:)5AO('D,8-U''W;J;HC03R:O_!
M.V^>?QP)6N]J71->A.TG3>; I*W?AR?+8C[K9^@G;/G"3)")9(?(Y4(&]P4R
M@!:A@O#F@6@_#4$\7@&8;L<OOB<3>*"N]#,]83FJ=2-\N>NHF3:[2P?;<-+8
M"-:]):B,;J\4VX_IU9(LA@8#Q;1C+@ZQEX%P/N%>Q!P#G,I<J OV.%&VQB3'
MZJ-\[Q'46OM%[M/ZSJHIX9MLTW(@.%2[/";)WSL0.#'8L%3\P0,O>#O/<H20
MS\D_+>XGJ30E>#D_3Z,C0,VJP/N"^L0%<^GI_"F9Z"=Y;CVV^6N*9C8)LZ52
MZL67SS@W7#"1)%M='.6?W2(I8(AECSX)/&*>QBB[C++/,=/;"7$9HBM7:& )
M[XO&S\..\4"/_;C'7-'0+YO)L6T=NP?B@Y*%G1 XX;QLMG_AHG-Z-.1*(=#]
M7O%49KNBTD#%/<HJ=Q8YZJSQJ>V.<@RN^HF'ZBIYA1!C268.]UL6*PT-U=@;
M(&R2O-?-JFM&5>O-M\/<G'3)P2%]XVR+$>C=Y*1*H*K+ <Z WF"&/&PTGEH3
M0IL#$S2<F!M:OIFIWY&YA)7I*')#&P!N4Z66+E>8!YYP)>"[URJI+33"TYVP
M:V2U+X$1JA8YVRLZ2O7C59PL[AD V<$#[0^B)BK*-3+WITX2'L,.EC4?1UOR
MHTMI<ZEEX!Y!A!CA])$8KCY;-6W<1XN^)@'C,X9V135&UC9S04Z*FTIW23+2
MPMH.:6U!118J2<L=4OT;IWJ4:%8?M;4J, ASL4)R:FKU\SLI<&7O@2?/7UNI
M3VV=@A-[# ?+OH7ZY4^GFI]:((:4K\ZHU:@WH':6=_@ZR_H1[*!68^AVW]11
M(P7@LHY816%'C>Z0Q&]5+G%;*M"S/J?_$ =(:\+DGEEQ5FG=RRW8.9@6Y*+=
MIXB8&TT;YJOG-\ZU.V",MOM-EB>?N1E?]QW+Y$)W<0TSODMCD*D!\KNL;_@+
MZQT!'VW?.FO#S>V=.S\$.(4J!1:13R>-S=@DC0V1U=WF5R<JV&._$!=YH(W>
M-NA.Q\[WCGH8 @\$89_E@= P++-D_!MI\?CW+RK\YW5V'?: !YKN0.ISL&,Q
MBAP8-Q3PX@+-WSOK(?D2>PX7@UU+7./JN>#T.;]!UZ7 _W%1H%BLPMA_NO3P
M0+!M6BS)@0?*P<CR0,TZ)&!(?@O[;8Z&8]'Y3#?)?HX_QD:4'6WZGU?]%!:?
MY:I(;V!'..\PSEP*,AABPQA;T<#'\#<RI-W%^&&6:?**I;XR>_JR"&9>=OJJ
MU1F-R9ZY+QC2% R-;;ETE)!H)/O[Y[.T7G&/SYUKWP[!0UE97H4!8W<-1N:H
M?T(;L<ZQI5@\VX#=[:*SM E[%A"Z"28 (V/8-WD3X#BN+NO,5QG% \DA8^V=
M6J2Q7>S$^LTQC/_(WOW-1_]^B D+PKSW;: CD]Z?E>"!#BI@%_U)7)-C!JFD
M)Q$77GN/+/$)%>F7,#P'D[P.O;[S[RQYR;?&]''2MS-:LSP0@76_C5K*UQM0
M?LF@RE#9/DF[)/8&HY?#C.!K@M( _IBB6.[EO/^\9GZ(Z.:!4H5"24O<\5_^
MK7G_<ZM;*<A='HAXV/#'F8K^Z071"+D;AYT^];\N%_[V^!=B)I>TTB;ZSVGV
M(O9-FM)2K$'[FC\8X181&WG;?#D36<]MPU8:[@)GZ3H=F01%M&\S]BV W0X&
M5&_Q0%(8O:6,YYEI8]:*8HPW#7(2X]?$I&'BE/F%R@S']F+)!B-1V/?W@NY#
M)_.F32=%#WG#&%>QHUB'O5P-Z[C:-)(DUE=4<CZ@^OAL'_NHW,BO@&>$_SU*
MQ)NA_2]*OIXU/S&D[78GY2E6>0>[W3:S@0WCAVT]R .12=L;G'3H[;7#.$GN
M($P!(\;6C'$)P9DS9E]'A!:C-MJ?2#5F(@^CA,QB-CK"5CH^)4ZW#CN[D,N>
MR-%G#]J;V:T_%1W;X1[BIZ^ D%G@&J JNAQ?R.T&[PM2-VXBKN!9]^$A8<J4
MO,*K[U7CC&30 @F">N5NT[_VCUJ75U06_B+OA^F<59=?MAX]RSU8Q9+$=%/4
MD8GU?/Z%=F+98/J)_<K;#2PSS&!8"U#'5-EPT%3.O-[GP10E0Z"TRR.@'E].
M?'Y;^%V1]D&%L^F<>Z"'()E%T/N;1TH>7A2X#@*)@$"@\WLE*R@+.I9<+O*+
MEM_:")*CQ)8#]'F@?9J (31)=^TIECC2@97C+_!5'LB[-'1R\#83O")6ZF/)
MB&K5GZ<CJU 2D\%9:Y-+PN?(L)3A8TYZ&EBM$*WH!HM3X+$(F:N*\OVZ:Z*H
M$!.&4=0KN'2?$_RB8B+>K&!!SBWKE+B\I8%E94WDQX]DI9_N1)(/YB;]>O/7
M_1H5_Y*/Q1O:??^! Q%4"@_T3>)?$DO_'\E=WIO)S05_.Y3\'Y>G2.4='>XU
M^[\A!!W%3-YVJ06H3 ,:/AD-F\H$T%#&S%H%'0C"NRQ<,1ZL@:_,1HXX5#$%
M.J-U$B%G+X9.L>Z,_#:46\F4E$ZS3V<H"3[0QN5R>W8>H)"3,[$);&L/E2:&
M%Y_1@!]G*.;1AJ2WY9)C(0&Y\QA)WSN[7?9]6P)R6[C81IW<GL.WS HJ""KY
M?KXU\K*W'QDU_$N@I<AR^YG'%]*U= =E-&5.^9C;CZRH-]]=G2F@Q/5^M9M]
M7A>Q4#V]IN4\X]^,\WKAI*%<GE8&!+3R0&_W*1X$0@CHDPQB8J"%Z#Y@%2;#
M1YXCJZ*/V/N(86M)0<5H69%'I8[ 19U]JFU:9W_]4FTMJ/(H8'*^\03Z0NG"
M@(;[PEK$+*5*U_IK:5O8_FQ&:5L],KG1S'>2^G@WEJU$=GCLZ])6>Q%3,+55
MSS3*;S:\&)W^^/@P^D*Q61E0LG&CD<'/39WJY /4<YFOX40YL;Y-ZO(W[NR_
M@EK.V2-CF $GL\_6:3+/QUT5LL<:Z^0CP\YW71TKV6W2,NR-?M#E!)=2UKZ9
MNQ.:DNI<N!5BI#Y \N!HB^YCVS'<B<R]CDQ]MG:$B2^2+A-7L<D#"<YGU.+I
M0H82;7(R434< VL&*6H3*3R?@7\TR7B:7.1HB?>NU(D+>E$WV.C*9P@KKFZJ
MVR<8GY/I.@>!1C[SJN^*@T#+NZ; TCW%;O/;?>S;S,[,*1Y(G'V3L18'B=#.
MIEWU&C")Y_])&A&6+X>,[(S*M\"/N\P3PWPIZ7BR,X$"_D?5$Y*-<_T_V'OO
MJ*;2]U\T,Q841$0Z"E%I(D)&:8I Q@((")&NM(P%(6#(("U 2$:0#C*"P A"
M5)J4$ 4"4D($ @@,-10)0DB0WA*$L(60G,RZ]_Q^,[^SSCWEGG77/6=]_]AK
M[2=YW^?=S[.?]DG>,O)V,.-[6O+1T*@XVY<)9FKWG]\=M#WW'%8V&+(EU_!F
M)#RB%[?M@*P-6:4AK2P!8C,%Y(<7:U+R\3Q<3V&WOR]U^P)$NX^2KD\-G:@A
M<\!)/.MR= /UZ.?Q:K.5C9GAS>Y/U?/WU1TKG_Z@>=Z?:/O_&)G;G8[/:';U
MVOO;C&G5K&[,T3J#+'5B$T4US3P[54DHLYH*<<J+_Z'L[-#SM6E& .I\^K\V
M3?SW>//_(1GQ?P-1#^BU-VH;TK.L/:6\N8]ZY=<#9[]_:@P:KS6>N\"J0\5[
M0M^S35,PW 6O"F P4HP:CH_"*G<0$.'>"4TG?+'*@T5#,_V-YQ X(]A;SZX2
MZ4>[:9/S]').]UDOJ]B5J5XW*&(>.KK<P1-!X=Q')!*-99@0Q3&;.RS*X06C
ME<9Z;$EA+*4JT:W,3\F_9V/7]9@8NRRRB+290VK\AM@RH%4B3SG=-W>2.QPT
MFY,R//0PAU0]O,P?+LC-F?%U]LW.TK)#6-$-(R'8[N#!Q=$)_2 !"&HLL>/+
MN\5);87%0"6UL;(\O2$=8_AT!'0/0/RH*$?%R5ES%$<]R,-Z']8:+S*)!Y;P
MAS:TKT"E :U6P_"X9(Q?,;J;+]EPS$3":L<IL]@D[S4BTI/(QG'+1HSA[+YI
MR-,F5?1YB3WH8N;^F+= *Q5^8(31OAV:VJC/_%"MY$=UU:<D(C'!?RV(:=4I
MK/CLDQ5M.\P[J\\X (>A(F3Q%1.DE$^V92WP]_#EI:D$GDH$L^\ .K;#B>U4
MP#4RKS;5X#D8D6=($[TYP6$2"6M9[0B-Y+N-_/;!AQ6O.;=&3N M:&>#Y.+G
M,]\A%H;F<56&+;B#8Y.(2?%!?0GQ6TMYZC3>5=:\RNCF2@#/R[L(812;X#>U
M=L0=G6\_LJJ#V7?XQ=N^.\BIMS-)K:[!S_P\(-;OGYI7T#-^.CKG.-]EF/W<
MJ_LT:9]3)PW7]+9\(2(QA)OU'.5U\.)ZBSRI:\;^?+5KVJS-Q8A+FI")M@G8
M9 !%[3FA_$T^IQ'*OHE2H)-C<PF\4^RO1AUQ.N7!J,22(O3:S7I:]=K>I2W\
M7L*&6-^/[AYH^UYD!/6-1*JG7([+P": ,40<RE/F2#N[QC#HU;$YDZ;[L2.&
M%*D-B43^20XL2KM1%S$%V3</E]6[OF$3XA&.O,<D)KWF?&U2LK&!Z)$5-A@*
M5%,E/]RXT?V#8?E42!#EG>]H3D6R20U^YSBVQ]6K^,E9@JDL FOQ&&,6R")*
M',OU;C/< H^[N+CJ+W43/>%+M89Y.N]CYUJQBID=YIR@[=FD(OPA !FT8CJL
M)Z[TL $J@NV#BV#!K:Q+N/V #N-R=%O3B3AJDTHBS9FSIX@0\5 G<]2V3LZH
M&F 7OF$LBGE/H1LI^^@Z^6^3D#^>Q(6HGQGNGCEX!AW^+">@NL;R3$)7-[T[
M*UO4$J'CI"96*X'0.'!W*#WWEI5!J-M2U^#H6#LW(X>^<A'1T]5T.)4OJCE]
M0>_S,4? A/EYDW#,E@3$32>Y@949[@@NY< F6)2GQBE,Z8A9TS'61.@4<_;I
MX9+SP-6-_?KQ>B:2P292;NOZ8TB=H,Z"33QP&M_:)XF>8VH\(8%%@;+IK>C@
MM1]YUP:-78K025PL&YE%I1SQ<?GUUJ+!,R#:%? +)OBXF)ZE!7G5A:T<3@\(
M*_4)+\_,;C1R?BU.INHO<7'O<<MM=XI\7$TH+4B5'6AKGB9*?N'W+[[\TXW/
M-M.5GX'BG.L;1[T;.")Q=TGLK;AR)$^)V%<"7!FW9?.CB]WF V[-TY%D8@$O
MB"-!A1[DG0#B6/ G?*6X-HID$.R0KV)JC/$EO2M3OMD9E5I_W*GR6]$.%ONP
M$M/6]O0/>F9>?>&RP7:$)STIW0B*C+N5;,Q^3GZ9[\2@D^2M<]^:67:.)M]#
M=/$&TI+=8+F&JN0,%_/J )F+M*BJ*'_KC(N73I?:='&<JVQMU.L\TGFC0O3B
MCX$"=]A5;9.7:*8'?00@DC @/\:X,-<."?V:]P (J, 8LVWQ+.B!A=D^SY$*
M?XR?3@81W<V"INKO+*W '(:"R#^Z>>C:7@_J7+6?'#SHO8LC1@M =R$)#!**
MV@"+I\>M&/ZUG>>^8'$I>W;(,Z\W=)_LN)B5S>IA_UFV<C72V(:E/ZJ/EYC7
M9'I8NP][!!6]&^5=+@7NNWFF'&!T;\5XI3Z?2WR[>*$+<=G*KKRL1'\?D>2X
MT&ZC_N;[+QG3^6G5N4P5^?ZH*%_3;\E>L+$+Q1K%*B^_. T/?YTDZUO_%[/P
MX@2@J4(C)W[)SFGTGW2TR$?<$:1>#\QLF%0& 0,6S4W&-)Y)P9CEKUX<_R2F
M1+QB7QQ/A0"DFS6D_8EX[[M=8(V0&9[-]T.^G1P;1XSB?O4!K_\X@%N6*L8M
M'-<75I$\:>_K-%+J;ZYZH>'DD=R2,8P[$%"*=K&M HPHRD4<>.*R_K&2()P8
MKN7=AZ&-% CUX-O:W  5/Y<!1';XYYPMK>!]Y<_*U?]8E*@Y"24-.N"\VJV1
M-/?ZSLES:2A)_I)3Z)M1V_>)B]E+5;8[6@;9PM2Z=^+=;>B#8UK-[*J/T$/&
MABR<-)#NS)Z,GDH5!:ZV.!MMQ?FSWE4C<51/);;G>R+@JXVZ.40@^1V<JVV2
M\@TWQQ<R?!6Q.6&!)LFF?4S\YV[N3;8W51HH8T+&UIC06/X),^PV@9@0A!)!
M&$5.Q):I7%]?K+\O.\+YC @O()XE&.07N[I.=@U>3 LY&_@-QY-"?<0?;=2<
M2HVO'TT,)CCWM4R>XW"KB CXX<:K.T8(<%43@9DJY:']!T>6>(?9(]7&UZ#!
M8H,_L]XAS]-[+\EG<L<=A]2^K4%6'Z1O%!$5[(,XZ$+;ZN>^-M]VC#(<[V<G
M_9K#S2KI#E6X>+&MH?J[5U>Q^($^B<N]+]U?RW3WB2+;BG;GZ;(I6Y:GJ[-M
M/#R>VYG]FGO93/KF#XZWE'JVC/#?X]V)N-4G0OA1?T%)1":\2MZLKDKUY]6+
M^ZGOER;>]XU27'UNI(L,0]E>P0(0U2YZ$0^<%R)8UIGC9@*0R2D!Z.,>OO1=
MR/<%.3X(S"[E4PB6PNO@NT@' 6B_"YQG)F]:(@!%:Q'YIUY3X=\&(3P0E&DN
M[)?W##?U@P D"B4NW?R?ZB'1C0).N^?!D[#R/[K@Q8'GR;;?-H;UB*QTA%+$
MX7!PO=8WVLJ><2&V8)6M$8'3Y4G@I";9?5XG &]JQTQ\*\UYL$[K:?CO)@=4
M(Z?AN5 ?Y>)O4*;]EN9#_\C_^X03(5;8R_O=D@/M "&G/]KE/4!#9^_2<$]-
M_L2^E.BE&#?UF\!F<2U-PBHK*NQZ)<:.\]E;5*05Z.N1?.G-/VJB"YQ[MBE\
M8MDI+A3^TW^W@,2E[2'\TG9_SG]#[S+=Z/$.Y7V 'S/2K5T DL1X,Z$_H VO
MU$20O=NPYRF#/%WFA,[8#]KZW/<$C]L([M+Z[\;=,6<99Z*H/XILUHU.;1?S
M#U50@,1$E@]2>ZZQ/F^2/CBBJ5%7_V&X.':2?N!Y8Q7,^/'=V-,#M[^FF3N:
M[?OCMX/$CQ2P -3\* B>-*DU;'H8UWR&\@ ?SV#;222.A-H4,GA7V=P7T-^@
M7O ]GI<.I&VU,12"=]PB/&Q')J^X^D6*7GA5%W-[>3/K_KD\>S"@!ENIV@EV
MIZ/3^:*,'82?!)L;=I<"^QS'U<4[ G"V[:"<^'D?QA'LB6MR;8PC!340KMO,
MW7L9BBPMD^#7/W65[I+X9 O_;9QG7#^TVILGI\6] =R9+N'OQ?;40ZB0\34N
M'E%0606H[:B[3@#;8F*;)W]$][$\WKBCM5I" NJ@R#HWP@-6^X69M C)KY_*
MOGW>_0,W58EGVT5SB>-BW*@!8;#, 5?%5E2H[6;C[I.]C,UV?@:2KM0G!!;Q
M+("E0+6>HACMW8(\\T)O)F+U3LKDZJ2'NNR13_@J1E7J\NL=/?ZG/-%HYMIR
M'SN0N=5,%+VJ:&&2%8W1%D_AEW<*1Y'T&SQ+7XM?FZA2K=V>S(\,5DWN'5R]
M![_,^L^.E>_Y&MO1 G[?P9/2X)[>?:*W!:[J:)80FV\ZUY00%X_501=M+[4S
MY!M=@M6G W%$GCGG>&C]SA=/7;VLFXCTA6R_3]:%3[S^P)-__3<SO!I/F2N
M R!<2_+??!D''WF]BW.5^N4_V\9/_XT.0FRS9"?L]>3SOYEU,MA1:"$9PN0J
M>?/?19#$]5VGL$$"4 QX=//MOWK\J\?_QCUB/N\7BYR,+ARJ5287W)1;--I:
MN.6IR[%)?<Q38:4J+(;4YW)SF39[7#@RNWDI7NJ%9>YC\R-2BW(_(48D)=4F
MEG\?KQ__6(CIM"KQVON.7C.61?_TY=!*[4_WTH>F_+=#*E3:_]J62FUZ*07B
M,+*R*88Z H1W4&6QLASSI%+&//\$NUP( =VLAC:51-=[@Q+%K9<+Q4D]/23Z
M>(_T(U6+0^466;F!C,RE[*Y5.J+>=[MHI.12 =VRMJ?K.[('J;-<OU0U'I27
M^F 027QNK+L3AG:AFHH VAQE7$S3I8%&)4X^=21/CD8JRXU@QA;Z%7CZ?OMN
M))U(EWBZ>9451WZJ;2X .= PJO7M[YF1D*NC$)Y%\<+ K1^@!9C3NP2,",>B
M&7K4.&1;))&G4,#396]F/0V^A;% %?:%O>49C1IK!T_#Q-"C-Q0/EY2-FQ3'
M8PR]0B-DGP4$[F\H@J'4GA+N>/]ZSV4*8[BS%Z,_8"Q3B):P Z(Y?E2L$DKZ
MMK#\/IR.JT _Z+X&D(D+V?C8X$B#I8YPY72FEK818SFT27) V9(G(_<DV.;N
M!7\5CGHA@3#3]^(S^A+W&AO7BA=;XHNS<0G&=L&O@:6;@T%]X.+DM;,\L^!R
MWIF!1JVWZ$LV@'61#;)X0<6</9+^"JX$M:#47F5=ERFJ']+OL5\WSVCPQ7GK
MZ\/H)1&P 'HQI));,O:M=FU'QZ=H."<H-Q_BFW76],-+]^^*7[>RZK!8\^H9
MZXFYF?!+!46D5!5LH)\ M&\_6ZPH1K:0/<IR3BWI*3%ONCA8D=5B: @6Q^CB
M@MGT\:N<S ;]N(150C!9Y398CJ\$4RI^HCY*BI /3KFV*"O;]\KW>EXS.XG[
ME@UK(VBQ=$B'8UBI!Q$4";T("07K -8%O4XY.!! Z&"%&5^<)FOL2-D//PDQ
MZF?#$[@^](0JSF'\;G:</4T;.^ZC^BT']GG/5$^CI[(<5A4H+IM$N/8/\<Q*
M??.T:/>'3%46,K?R?F@<;%29KJUFS^22^F*"S $W]K:205]KYJ0B9<<P%LEJ
M&EK#59/:AR.UF!W+Q>PU9BQ^V@;2NMV70CR+":$[YQ#<ENCM+TI5/??TTZB2
M\PRQH(_TXZ>Z/])]T41JDK^T):M#L:WS \=]]M+5ATYA@4_(:>7%P0]V"PDK
M4AG/<R:/=QF/(B[ MQ)O_+H]=WXNZ,O#U2SMM:Z5"#5N'<J_<63+W8[)%8#8
M=M X9!%BM)8B;JJ!J"6<#:<D5$?$-ZKIKT7S%3U\\O9P]..HN^;6$&EW^F*]
M&B.N20, V_%;V<O;M8F$KT,DL6,I"CH;;O,=#=C/OP*^T]P[P!B*M8N#LREQ
M<VR=PGVSM4R_ \$>V$%$WH&-S]4KZHNLWC[G- '(T4_;U$.=S^VP'5I9G7T_
M!"DOK]"H3^I$4J;R<'OOT/0FC.:H<)E@#=+0/:/>8AQKQ80$DT>;BD.:C62*
M6\%2,#_FTJW[;)F\&/9<L^LU6;IV4Q++@-2?YI9ZM"_RK9]<>&H#=@ NB3DI
M5'#/<M,EX Y'C+46@W'1!0Q=V?!68NP60YHD?A4V>A9UC^SAW<(]LZ(15TAZ
MZN=QA<54'K.A_M15W.>JRIYD'&8'E-)+"T_7(JPS?WWNJ.3=E9NOX^GMQ5U=
M%AO?.=,M>09AA#0K#"(JF-6=UB*%F7-=< \^ 6[\@TGLULN -:0=+_H%(0#)
M&.MS3"\+T9\KD,!D)&:C?D/J$^XNN<>U&56#CU8$2\0V_<2IC24)L9K\XE;3
MR??'2'Z15UNS1>*,39@/:",=EI5-3;N_$'N)GSWA<2/9 E ;><]4UC*#)0"-
MC4Y-I. ?;XJ)22AA5$;X\NC4-L]+0SG4:>KVDUK34WESCARUV!<%=,#;]AWD
MDNO\.^+GL].Q^QV) Z[)+?9Y.N4S?Q:JV9 N7K%W*58"JQ;+W,]X56QJUBVG
MX>7;8F8A<:#"S:Q'QTE-#D%V.9^<NS4;D*K;^-QIL_,_SL>! IJPF(<8KQVC
MA6VUSX,DK6* R%Y<,V/;OA>*W@:5)IBJ^]6$QPQMHW[#,?>RXY(:Q4J7*GT'
MM>#[TML4;?%WE+/4BR,"CSO?O;93]1^1>0K%#RZ#.4WF:+1"HZ#@CM9=J2DB
M=0+2OCU9-PV-5]8<:I14*T["B M !U9&HX/@(*"FPV[@5+_QHU%7PEH\<TAU
MI!Q%,V?S\Y5_K^H[.ZO04F>A8!M@[Y]KZ>0K^BV@>$5-Y_J:IBLW.7*N-"F9
M<+I^P=B8]<7%6&7OUQ7IN4]9NF-:])7Y:J0^NEN+?Y!6B @'?S2Q,*MDCSXV
MEBQ!X"1YM[U9J7N 8TQX<I,X\8FQ^3.$O8?/I#H;EL(+Y8 =HZE%O6[BYM..
ME1R;V:2RA?#8C+"B,]3EP<@%N#RVU0%C"HO).S^ E?;)4ZP& IBX9-R11BA3
M0A8-\QS%W"[@V0QJ5RS[3W.6)W4X:ORR,G299WTV%R4!Y'M$NCF^:^2 XTB7
M"R9Q7AT())(;:7NN-K&"GN:?'Y)%K7BUHGV?5N5B:VL'W/^>?^K=XI"F*JWZ
M:&-(R"-7GW17_[2D2=.EA'6Y%9&=6^.\PY7 L^ B83;"GJ (,; X6M>38[U0
M_]O@QLH9N))O/;DHY3 1MYM59EF$<,[V?%RZY+H6K]@UVWW]<?4?&@GC#HB'
MVV 0?W#$TPC(G5J+U9I"!EK7<[R;]P&]>5H>WJVN6U%6ZF7,%?5O+7PEX7-O
M:IMWM\O)'D7'CK"6J(I:AG')VGN=M](GNP,1]U LZ/+8:Y[E"/84W /H:^=+
MOP/P4WT2Z'M4Q)3-HYT6_JG:8>,S_!,U SR+?""M:_[[H6V)Q&""R.W^8&T-
MYP']!HMW:=RA'!4E:B:^2N,WC'XAX,M@#K=738FCFN%BJWQ)]"5JN,=NV^9D
M-%,;1E64B-_TMK[T/:]]QVU('RPQ;JW^/E)Z5$NM;1S#^6)S*%LCBGLN*9E<
ME9R.7]-6L'IYT0L2WI=6BF\X4#U%0U8_DZ7NF*^!'V171W97%VN]70CNL>FX
M;:*:;:D^QIP\L]NPL28!,-H\1=X!;F5+AG;HD2TFKE7I&E!F3GO8I(*Q&C!&
M3(%!Z/36VA8_RQFV+;X0G<Y23ZO97EE?["Q!9/LW8#,-5KR0?\4)*/NF.*3=
M-2.C.,Y4$LC>[EWZN2$JH@1C\7K<XS;/B<970B>Q,K9:+8.FI:J:Y6(:(:46
M$LGVT\N&1D/9V.SLNX6T2;<=N7C</5B4J1K',(5W)]*+U8TZ@J8S]<]%% (T
MJJ(O8$CU=F53$E 8#_8ZG;Z";%1B$>#4O(/L3'+9DI&[=4!DR;R!P_6]J%"9
M7B,^E2)2?5%[$P92KYUB'/69W%O/1L6LY;B-;$Y(F _K&&N6H4^:GIQ .W]S
MCK8=Q9Z\RO0(=!Z )9 TL[FL+JY3'0)\6-^A.\R>&QSVW1[Y;;UD_;+!BCUW
M=K;!&HLXO?[ARL4/TV$Y<W':XY:/OCV:=+;BD%:0Q^@#_HOV.#L 1J7#4C#:
MS#[Y>2F3]C@60<R2(YMJ_/X/KZP;(^4GAAYZWKJ5&>M<\R&Y6^KH@&6=_(R-
MC7K)@S0C@T+%\Y>T3M8/.I;LC2KTO#GU](]?Y7%'>IS9N)AJ_!X UFHJUG\O
M4UNJQ75_*I-\ZN+7;\4>AM=H*QOC)XV;'7I?CH^;/\BZ^STM*S(_9%]';:T.
MM:,X[7:"MM:J:GH:8R5\9U2DKD<K\)&G>RWI>QA>>ZWP>QC*O]9H=_76Y)<1
M]Q$RT2O"K7#-;^.]!)>4M;OO+S!)!@M J7:[!"\!Z+*PVH98"$#3PQIC*Y2Y
MO%P!"(?GG=XQJ>5]HU'6O@D+<6C@#@,#_83'=0M ZBK\D4H!Z)40G<KE_[5)
M")143IG7E./OFQ> >.$%?^\']JX1@/+"0W?Y.';^%_X60V)=XG\9#Z@:92I_
ME-T]+1%C?NSYASVMIAJ'.O6K&V#<FO3?VH?'I)_U2WTZ_DB9<@$[O+8M '&=
MMO_:!?2LSQ0'W^*5?.45X-9V+5Z^$@^\1,AWGMA^&=K+[!?ET79@E.\"4).O
M4L5*1!"98B/F4MDD (T&!JYX"O&W .0%?P5GVY;-WP5*ID>RF<@AGDFR5G7-
MP(\XIBK-]*;_RY,7YD!S"CS<A9AFC3VJ>;\=2@>0Q"O 5>'@^W:?X>Y I='?
MVBC5<VUDL9:C</1A+0EQ &P;]:T-?A0#+^]DB1M%>,BU*N]C;QAFKW#ST<^>
M_? AJNN3OZ5&0^S1^S^2AM?\:Q@<D8A+_CAK/'T$OB$M3&H_;N#X)IY@CE#.
MLMU<J!=JKR?&?/<-WQ"0F-J*?CB5%E"&'J=F'\[>?ISJLV.04%A>Y:>X^ZVJ
MM.W.F\_PR>M__GCED1;G(M0/ FCU\:3M(5785@&HRC9! -J[N9N[6:.)W''!
MCAD]\H4K!/<<O9_^@,#NGE*JQ>^^,%FI"JN/%( 251JKGSI()Y3>[ML;'_F-
M*_PH2@[;-;F?TY;5@:*WMF&-A)_$8FEEJBZC<#F<;T\PS^,UPBC-<G:N&2RJ
M;)VZ%T#!8KH)A82)FAKN0,UG]=ASQP-H ?/XLH#:J00K#^3Z+&46[2PTF7WH
M72(4V=VP=D"(($]1[JV$MGE*I#V@K>*0./JZ6.H3:!7_:?FLW#!&CGF)^!YH
M96FU0 <))V-.I-V',WSZ9GK$48 N_T"^%V>TS=6EC0%H&:YX3PM P&D1JM:E
MZN%J >@)E#Z .;^;AI$,'^S4_8P.9<K%D<1D1I&_A-@IC51R)=U5K&5FGQD_
M_+#[O896O:1E[6':U6=>^>[]8^WRAV=;7,=NNUTK?39.=W4K".'VFR>6/KNJ
M:/X*)/V#0V3>.#]L@;$E-+26F.Z1K?4 B8A"ROJ]>  W)0#%0@_R- O14DQ<
MG#&8O=;L*BV&S$?#FEV]8S"&S)7S^YQ^S@QW3LNL>2;K"#]OIY#]0/G^H.5)
M;Q/\/_W;$?]WWUGF,K[U"0LK2A]?>K=O+?*O)3=;/,KZ7>B*'V1;U$P >AP.
M%8"4\W=<N_E1SW!3GJD"4$<IK&H<UV=RB2\ 00$[;@3J^UPQCC$G (F:_%\\
M3D;PX=_/@?\G(XORW%83@/O]7SS^Q>-?//[%X_\5#]^N=;'\$[$+_B'[SLKZ
M:8;<?RG%M7BDFSK]\<(TV9YCF* 'W0^$>G!0"23Y(/QAP,]R2'\BT/'#X5]H
M&P2=$;?QG4YGU31GZPB?^[^7VS6FU#[TZ;V2,_*L30&GC<PZX;V\^J?MP?:I
M<(FKFQ5B+(W6DL90I>K,R7,<2*S.QJY*FR*2E/MD)(M_=-B+H_Y,_7DE,-I<
MG]&X#4M>#JID+=*N#]$O6?S><SSNX;*3V>4>34-Y#P_Z*MU#QRD_O&!Y* BI
MEQWT_;E'VJ.:1*[+2 \CPH=>C[I/"_6\^HH_AMO3:%:(,1X]2\2$^N7S;@P3
MJE$2BZY]+91XNDQNRFQAQ+UB'WOTFVD7=L]+3[EW''U^X3T$,]?:U<]:/.1V
MSHXIZWY-0P3N*A#,66,RJ +0GB7X4=[%0.(8L,<L^B8%)0<4MS2=9&<FE/F$
M>Y';)A@)C2:A+'$HC/^%W46G]P4HUQ6KCDA=R;MO7WD^$UAKQK^#)@9!8@0@
M":S<H@"DN%'3;ZPUO:O%TN;G,H7OIO^V&SKP]H"^]E%^E\1C.7I6LKZVP]0P
M^:NB/[%PJ;_5,#$H:1?2QM>L'-2#'!Y?3+\V\=?B__LV,.9:'%\+[6?+$8G>
M5-*8;EO-9>+!/GPI]K[4%NA!= 1S""O)$8D)]K!NP1YFKQ+*YG_GW1PY-<QJ
M&.4Y_^Z*R#O10'IWVUB_B([@<BS&[?-^''1<@N707;7K]!8B''.V2JXRN.X]
M'NO?KAAYECI^?VWLP9JS-?BZ5?X&#ZT:MTK;BBQ,IV4/^G*+ONPD@<<#N<%-
M-6Q""T!TKS;5&E7KOUL]U"@^;6,@ +6FJ_7%(I$DZ/$QS_F;7P!PZ_;+24.V
MT8+R"<ZU\ ?I)<3D1GVUW"_O%P-^VB#&"D#5&BVIB=Q)_49V:/Q,WNC'H[&<
MX]M-J>5 R(7JA"S[" D9Q)S'>YH 1&I4*M=)(BC)M;G^6C>@#U]&.BR[I.TF
M(BG*S<*BC//A^4)6=E_[THK%K2'B\HJI!MP5 Z55CZ/D 0US,F 2_ J MV9J
M4&N+/VYQ?^5)L)$5KUD7=1H=M_]HY)P=6'"-6%3TG6^BL%.Y%NG,D#B.5.LW
MC'EZFZRR:3_O(GO)J^\)<[ W@8UK>8\>45)IJ9FEP3.(QAY5'?R3.ZBG%0K:
M.CD[%XJC"6T%94%.Q5EOK<><W\X%=V6G.W,3K,/MR*][ND./%2KH%6H<^#U/
MNS.0%I622Z\,G0FA/R+-=$=H//A:,6@?;D"IA2Y/A!;.TRL!BFMMS0AI^LT!
ME%"[;F(KBE_H:)Q]7!OV]+N&_M?U[([?5C>(<F@+ERI.39U,:NQJ$$5ZWO"]
MK[CX]OD-H<8H\:9GT-93L&3CVVR<T$-38YK.L/MIFSEX.9X#NZF.M28Z!F![
MM_>/$'#O&R^>'EX-3KG2GV,BJW5)VSF";.ZCMQ-ILEHQE<>8^0,W]=*^*==O
M?S&GVZYA&$58:01/F]B/,KDO[L@VL)^VMN+$,"KWIGKD8"C)"6(LYGJV7 OD
MD';?4Z^ZT?P/0ZC@G<\\;:3X3,S3C'D\VUXB.0\,:.[H M%44QU.Z,<U40#F
M/D1HU&2=-C7V@1[!P(0N(X.@DS-?P6(P^J]YYX<V\+*> ,T^;U)!SZ*JX>DE
M2)4[O%L?/Y:Y3<\XJ_?^UJT[Q\LNCE2_MC^,J/#JEE&P=]]*-;)L=Z=??.M*
MK<_($%VGJEF:YTZ?MC0K[EK]D@$+Z<NH*2"4)F6L0KDJP 1';#J8DAI,C(?+
MF8+1BZN#8-'. L#P(V-?DPI/(:>Y'KG%Y2%+ENBA;3;63ASSL@C6I1[3V<]A
M<KBQ^FO9^WIS567I];XWBR>#_SJ]9Z_OZ$-C"_8:JXGH783M"S_/ *);MS*W
M0UM029[G@?<<61,=UJAC%@S/^MJDR\$_)6)D3/K#5C$7ISZ0:M-OZ/JE+9ZK
M* QX!%O9Y_4'+>4X,MPN,>K)F^?WY-L@CW0Z+YN;!(?7K'XIV-1K[AEJM7^9
MDY[FO])9NV;54V? ]70>[-0^](]3@-\"Q.:F(YS9%,,XXP F7!SH:]TZ;Z;?
M'L,B2]S@'$XU[C]Z)Q.IZT)JK$R[92TEG?H#NE---,V7^X]%AZ[#G\8=D ;9
M+[,1U;39S)*B;"RB>-8_+<"R@)9HHY?MVVV>C2 Z_KFK83E8K6308=Z_T0,U
M']CH]BG?F-"PK!0B@PG3WGT'Q0DI*2]OTNEN5WX[>_.R=(#YJS,G]LB\-I/1
M9KB4A==L(LGC_BL4@ZYQLS<>LO&GWR2"_KK.1%\\Q%ALXBS=>=1!#!&/BNP0
M><LB#N_7KFORXQ>O%IB%"T 'SZ6GWGC)RI8ZUB@ T2 \N0D<QQ$%W1""Y'U;
M<)Z3CML./6Z7(_?7L3S:NRM7^8 0+Z;0:)_@AEOG#/';PDP;M4/DGTF9X[_
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M&BS8C^BKGI4<^&^F^KZ64]W6F[2-'F6N']+%<4CB)7"/>PMHFU*Z:LV1:X.
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MR$Q,^-9GE&-O"T!B%EP*NQ&\#Z/%<6.!5[1>]7"NVO1OYEI-FP&!A9.\JTW
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M6DWQ]*-W7@Q.LUU4"G,(]\DA+==10DX3VX7#/,6E\J5W7T-,CRRZ$I/T4*+
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MW?BA>(#\(;!%>)]1),0M588,4+]9/MX3XBP'JB^<,'J@UO:KOB^6<F![S'T
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MRSX<@?BZ6SHO@J7L^T<Z0?_O7UN."9<];\Q?^57_K_C'OTN7SFE).U'8Y.B
ML^\DO,<OU*7>:Q4#6R,OAL$E/*N:=L!(.5-23ZV[^#\24NE X<R*V/@^*?[6
M2F_AYC)A8DM;BB9  ,?,U)8W4AO)\=;JF%*ECL0:JR<'(*:E$1[$JH>Z!&0E
MQ@CGB$UD&<5CCD<3V_X2R',Y9C7%(2&?,2  Q,MDT _1D;NFS%@Q@"V;:JX5
MVT<0 VM)=S$(XF]YJ/T=B[#C+; 28&V\W>,#HE'V#=J7#X_-R5-!1/FREZJI
M1U(ZN&WLI:)X7;=CUWS0[TQ,H.57>\EPERQY;*O'=;U7!:_>%AA5*4=INE5
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M!^8AUVI)RZX/CE7KKX+L&G*^;PN6G1@N(PUO;,$#BA)7)W%"HVQ!_)[0H2V
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M<DS!6V,,WY6$5@.NP<=E\WU(JF4L1A-6#C99OL*]\59E[<RL*WH&1G26SBY
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M!UH6=.\U.K!QV>/.P6FE3]_G9A^?LR?VGDR*<5KH<_IR]>$<\ER%>^$7S\]
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MIY%P,9B3:.\FL*$$7+P*:H<#G#>1K@_049Q+:'/0@*Y$379DQ3V^<R<XE*Z
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MOA&I(;@6F;OILU;U!TV1OAJ6SA6U 6?=1]S\UP/&2+@/BW!097B,ZM7:Y".
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M1A-M=@,*K@4ZAWTZQ5*[ &)W8(XK*C9]O-&$6C]K:L=JR8XGUU+9@7:,11N
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M1M*MP5R_(H4]IL&[>7B[0;-SSS\M-K(+A,?%R:+!GRF8WT#$]%E=.O97M K
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M"7C:KH8\>CO<-&J\,CQOS^I I]Q(5>;TLI4.Z=I+M,7)5MFQKNR/?,G:9#N
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MKS6H0?/#\=':6'4R.*+T]Z'BRB9Y%;ZZ#TV6( <F\['K @AG&?O].*Y.V)!
MM[ \-IG[^,_O>_'G\2:V16A: /D-.0.F_$.1_P.>B'&FL*#%X.]U^0:6?Q[_
MKZEY9<R$C+!+FA= -JD"R*J%TI_!Y+%1 LA<^]AJL@"28O^7FV\"2)0 HB*
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M"D)\QN>FS)8BGT Z);XS+U8'1DI(+L;6'X?XUDD)ME$Y<58]?MCKB8F.F5*
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M; !A0@!E4W91MHCBN1GM02'LL?V!(WE]44:2V'JH8-_$29- 9,'G01B-!9/
M(M0TS5Z&W)L:VMD],]Q9ZW6[2*%Y\7'1GJ2M:&@QO9F_$PAOJM:)(TI(-6/V
MK&G$\#28ODJ67+%H@W,YDWJ^,\EEWB[-S_02DDM8J8_<?Y\A\LT;F$-S'YFG
M;1"A.8_,'*2A3,D[!M)<US>9IX#K7-ES)"[V3BV6@4?4"TYQR.5>RA]3":C
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M>!R=T6H/;TSC/Z3=QN<--7ANRJHF9EYL4SK\\I1S5I)N3H();[V(:EP#YEO
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M4K2"9<^R=9>&A+^1="HK'&3"(.LY!EP<6O<*QQ#0H+>)(3WH-;AH?;51RRU
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M7WH1:<\3EF$=2+G" 0-NJ9>:>4H4A4EC3)6%0"TTH01\_Q+"%"!K,T6!#V+
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M<:]U7GNLHWK%)B T);-L3G*Y?:ZK:U A6[&M!1RH*#Y<]:EC.=D;[SZG6%D
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MI.P%ZO,'D7+]9H W=;?^64;FA>6ZMOPI0]5NDTA]*8:!XZBI2F4[:4+GSQ'
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M'2_*V<\40P;1EOX  EC]=5F:/6CU*;)W./T*,1-2GTHVB:1ZRG0RZ=.4O2Y
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MS1*/WAL+*OA@;%KPH7;PHVI:W]W"P<H7@<;J=V*P0VB9",9P/7E3S= K?:.
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M=GERP.B*#Q[DV=:-42.:D'8,1+H,P1U>5F)5=&)H^#3)?V2HDGG8*;B1\ M
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M3#:?TBK*>Z-RK':&->12Z^#HFQ\V*#FGXD/U->HB.JPSMTM?UOXL'7F%%^U
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MVE7;=3(XO^5"%G=B]W'!-Z]V\<B@A,P6T?Y9;D\2O@6C:$4MTY.7;;?S9$C
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MP^^** @@M:*"C,8U-@'Z%BLM.Q!5\+/1R3D^_<,7G!+XV*:?8I^#?(04_HN
M/2MM_L-D)&6W3B?E*55@GTO]D)@/V@%)8E(:XHR\9Y.4:D(_2KXV#W<K,JR0
MYOXBU4E@YB'=I8I]2\^JR(GC(ML$&?JW4;>]]LU@4@6Z2#NIVE^Q:&R1?SO[
ME<E_@+C8X.C 39XU]"2J8P=2,^B2>;;(R=W,W*;0<RC"_-:DS5(Z_GQIMVFC
MJCJ^6C 4Z)QT,SPLV6=__DSOWTLOGXW7-@8E-:7UT?DE73N0$_)3%&Q_Z XD
MGM^50+=%CZV*+#N$9,[%8!'N.Y3(%2R1WN^Z!:2,T$O&-;9)[5@(&%Q!;NSD
MA\<;&-UM'@Y94?2_K7K1;I^\XA0GNQT*H^" C:58(.CSR*PGL)]10B%):8\1
MI\#1MEUA"-+*9,X@"=8)BUU/)V==%3K<K?#;O%_@6P:6M#9\:A(F'6!*;*\-
ML*!*\^L7Y]ER%/6/ ?<NE0.=B9M-9A:7BK].9N24F'>_'^ V]7:/!PT0(L[_
MZ5EJ[URZ73GD;T/(QEB_OY@R/$,T#ZC,JK;)OI0M+FFOWD-Q 'T FI!5DBP+
M+?'#*5*"RV3>HR&"?0LX)80EF"%,^_W,@.RDE'9CD-G(U<"/-BL#AA4,,,,K
MJ8.J-[@V&61II6"7[33*8&KH)17_V931#(Q4'P"@J;9I<"= JZWU1VH?#CJS
MG5DE/^;/51YU'.4$:F>+A@'&KJ4Y-U"U'"!S!Q PY9)'KZ3K\>+&O'M?.$C#
M]/4ZMZR<DJ1SV5],$WF+O9^#G9,R_R6:.'4WO.^D;M=&$#,GL<1T:&)Z-L(<
M54,MSS;3GRPZ=[8H C,9.$-=(VF\>Z][I?2=3?? C6GJ\5YQ;EKL#D1Q&:'3
MMH_;7B;;-_VU^?0XGU'NT2+^@V)5@DPZ7>>@33CWR"""]6TL\23CMHE30._1
M:Q3!>CF0W4&"4!2 OB3J 3!LHX-^+*2H'QK'5+1LRZ;J<[AF+[0'*D/1.C_5
M_%K/-=TT>?\J1&0*\TU5:""EJZJLF:BTZ?3JVG?#!S/K[S%.K-HU6H<D-J7/
MI7L=R:Q,;PRS\UJ83'<C580UKCZ01W&%;VC3Y?2U /FN.VD/^V??Q[.C-=0^
M&@LF.V[905>7:X+!HHT6M,JN9,^JJ,1:B]%'_6'?4JX*&PUT;K#[OQ"&&^I'
M TJBHB\AV1CWCMGNRLK!2HC:'X3UNL3KR%,R2P"]7BD5)'"<@"**WC^8NLN4
M37H=6B92A5@9*K2,7.LX<$QHPX"E(+3 ,PY2N&G_).7"$,)(WNNAEJP?ZL9-
MY$=0C1Q>;=<H#.L\&FX@8M9?;%<T3TIG76NDS$C';$"MS<*V?66OG_KLX]!#
M>GW*=\BK(GE!R=P.Y*#,[KA'V)NJ,7+M6]I^I%!IF(,BYF/N$$9>: /$$7;Y
MLG0TCJ6ALGT_OW'J4F9.4,M-HJ'7C/3\GRZW:]P2;W[*V"BZOQ;$B=AM8/=[
M_@P23Q3T*5=P?X*A61#"LN\#XMNYK!*)^_1NU](.P*TO>!*H1H#9PY#J)_+O
M^[] 8[,MCN15HLHH-P9E%Z.DX[9I:-Z7R: -IT&*1;;;AKI547$*PZ^.7P[R
MVJG&\6TC3^?O9E _()D)@%?JPR-L_&\-H[&[?)<M>O84#(;&KW#O5PB4P!61
M87S5G(#/'W++"6 5CWN2"6W-"FQ (6')I,( L;!).B&80!<1/'XQI3%-VLFV
MPNJV'<@>=-D$:-32K"EMZJSYB_^<K_T,?_<<WUI_M>7!RK=^[WQ(5L,3ZR-*
MQVOJ<I87,%'DC_5YA:SDMJ">W+T.N5.!; .Z<:[=%&*AN%+87?4Q/2-D(G]&
M6.&%47')GFQ:">U.)[HO?%HN"O\U-] >;T<AB$F:%#\ N50@)752S]6,&&ML
M1W72#L]LO_0!:=ZB)AWL:]#2[,F4H#-''OMKEND+LP&#E;4[3(9+.VU,]=^+
M#;#84.C1WL*)TS5Q8 0ZD6JZ2(>^KRZF[!F6GQVG7/*R%,4_H<!$*Z= VP[N
ML1"C!*0:QZR 8K7;ZK;39FV:USW-$&?0>\"JSSN0CN#>L@GTN4^O1)/(=@_8
M[R9;!(,?,!C:<*3>B7NO-$KB'Z=9V97J>J@^'TH/_"W[<G'V.=./Z3&%]9[U
M'H.NVDO#>-V@:W 9.T^LILIS3K0GKO:>KYLYL1CPZP[DS .JE7Q,X:?70'&U
M^1M.@[2D P?SQQUQ$QZN[2KPAQW9@> U%82I*=*QT/]\LBB:K&N<]@J2[T!<
MADUW(,0%,PL#[A.9B55J JG2=U9FN86E#C9P'[+H2N1[RSVBWW*Z[>#>E?,X
M1<,0E.6T=3N-J4^#:M\)T"RN!0@>,GUB5,<H@=I0_F$"O"X_IO%O.70XPYXT
M=J&K'V[U$G2YP>R'7R[ OX#UKP%7W@P:1^E%6Z)JU<PN8ST/$2SOB-@QZ/!
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MNDS7M='\'*F6M*7O4\^:MN?S>H>-U);3$0O,(HYN+X^1&[,%RB,+D2@X\!%
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MN?NX($AKW=]U6>\4ES2%U5=O)6)T.E5O3E=;/@)/E]^BX/ENU_"%\\=']G)
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MQA0R">\5BPOTZ3P^Z %5>RO-R<?1P-7,'[@ZZM,-?R/.3(J9@$D7MA"#8#O
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M3OG3HM JJ7(\1'=7=K5A%+&'8V5PR(5!50\P!&,_L;R;;XU,4 VLM.H\;H)
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MQ<1+^J>X5Z'^P/+OFXT^_ -02P,$%     @ ^8O96K-GI 60!   =04   T
M  !I;6%G95\P,#<N:G!GI=%Y4!-7' ?PMV3#D>"$:* $*%L"'@4M15#:@ G(
MI7A$0:6MUBA*H:64<MC$BD$.PZ6"6+':4>N!5(5&CM2+$B )"-9!J142VY(E
MVJ S;7<%PB+);D-U[#_]HU-_;]Z\>?/[SF_>9QXU2!F 2WSL\E@ 01#88EN
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M86=E7S P."YJ<&>EU'M04U<: / ;DA !,81G!26" :02$9!&)24J%51L*3Y
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MXZ$1B<H1/64L[!S#7+HL;KD9G4A-GC *5I3H]F5F9RTYQ[Q;YX1HB[ETB.>
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M-C(U7V1E9BYX;6Q02P$"% ,4    " #YB]E:Q@G*PZH0  !JR   %0
M        @ $_#P  871N9BTR,#(U,#8R-5]L86(N>&UL4$L! A0#%     @
M^8O96M(6;0M^!@  SCX  !4              ( !'"   &%T;F8M,C R-3 V
M,C5?<')E+GAM;%!+ 0(4 Q0    ( /F+V5H#K(VU=_\" !=#%0 <
M      "  <TF  !E83 R-#8X,S M<')E,31A7S$X,&QI9F4N:'1M4$L! A0#
M%     @ ^8O96H+Z=_FA,@  "C0   T              ( !?B8# &EM86=E
M7S P,2YJ<&=02P$"% ,4    " #YB]E:R'@?R/;Q   Q&@$ #0
M    @ %*60, :6UA9V5?,# R+FIP9U!+ 0(4 Q0    ( /F+V5H9):D,E.D
M ,\H 0 -              "  6M+! !I;6%G95\P,#,N:G!G4$L! A0#%
M  @ ^8O96CJB</W%)0  7R<   T              ( !*C4% &EM86=E7S P
M-"YJ<&=02P$"% ,4    " #YB]E::_YB<M8&  ##!P  #0
M@ $:6P4 :6UA9V5?,# U+FIP9U!+ 0(4 Q0    ( /F+V5I/2Z.P,04  !H&
M   -              "  1MB!0!I;6%G95\P,#8N:G!G4$L! A0#%     @
M^8O96K-GI 60!   =04   T              ( !=V<% &EM86=E7S P-RYJ
M<&=02P$"% ,4    " #YB]E:@V/"5&<'  !>"   #0              @ $R
F; 4 :6UA9V5?,# X+FIP9U!+!08     #0 - "H#  #$<P4    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>ea0246830-pre14a_180life_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:atnf="http://www.180lifesciences.com/20250625"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="atnf-20250625.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:RestatementDateAxis">
                    <ecd:RestatementDateAxis.domain>2023-11-07</ecd:RestatementDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedSummaryCompensationTableTotalForPEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedValueOfEquityAwardsAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:EquityAwardAdjustmentsBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:CompensationActuallyPaidToPEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedSummaryCompensationTableTotalForPEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedValueOfEquityAwardsAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:EquityAwardAdjustmentsBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:CompensationActuallyPaidToPEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedSummaryCompensationTableTotalForPEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedValueOfEquityAwardsAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:EquityAwardAdjustmentsBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:CompensationActuallyPaidToPEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedSummaryCompensationTableTotalForPEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ReportedValueOfEquityAwardsAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:EquityAwardAdjustmentsBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:CompensationActuallyPaidToPEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:TotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:BlairJordanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:TotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:ValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:TotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:FairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:TotalEquityAwardAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">atnf:JamesNWoodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:TotalAverageEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:TotalAverageEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearAverageChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageFairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInTheYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:YearOverYearAverageChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageFairValueAtTheEndOfThePriorYearOfEquityAwardsThatFailedToMeetVestingConditionsInTheYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:AverageValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsNotOtherwiseReflectedInFairValueOrTotalCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">atnf:TotalAverageEquityAwardAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-100">180 LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <ecd:ErrCompAnalysisTextBlock contextRef="c1" id="ixv-3746">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Compensation Recovery
and Clawback Policies&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Under the Sarbanes-Oxley
Act of 2002 (the &#x201c;&lt;span style="text-decoration:underline"&gt;Sarbanes-Oxley Act&lt;/span&gt;&#x201d;), in the event of misconduct that results in a financial restatement that would
have reduced a previously paid incentive amount, we can recoup those improper payments from our Chief Executive Officer and Chief Financial
Officer (if any). The SEC also recently adopted rules which direct national stock exchanges to require listed companies to implement
policies intended to recoup bonuses paid to executives if the company is found to have misstated its financial results.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On November 7, 2023, the
Board of Directors of the Company approved the adoption of a Policy for the Recovery of Erroneously Awarded Incentive Based Compensation
(the &#x201c;&lt;span style="text-decoration:underline"&gt;Clawback Policy&lt;/span&gt;&#x201d;), with an effective date of October 2, 2023, in order to comply with the final clawback rules
adopted by the SEC under Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (&#x201c;&lt;span style="text-decoration:underline"&gt;Rule 10D-1&lt;/span&gt;&#x201d;),
and the listing standards, as set forth in the Nasdaq Listing Rule 5608 (the &#x201c;&lt;span style="text-decoration:underline"&gt;Final Clawback Rules&lt;/span&gt;&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Clawback Policy provides
for the mandatory recovery of erroneously awarded incentive-based compensation from current and former executive officers as defined
in Rule 10D-1 (&#x201c;&lt;span style="text-decoration:underline"&gt;Covered Officers&lt;/span&gt;&#x201d;) of the Company in the event that the Company is required to prepare an accounting
restatement, in accordance with the Final Clawback Rules. The recovery of such compensation applies regardless of whether a Covered Officer
engaged in misconduct or otherwise caused or contributed to the requirement of an accounting restatement. Under the Clawback Policy,
the Board of Directors may recoup from the Covered Officers erroneously awarded incentive compensation received within a lookback period
of the three completed fiscal years preceding the date on which the Company is required to prepare an accounting restatement.&lt;/p&gt;</ecd:ErrCompAnalysisTextBlock>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c0" id="ixv-14201">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="c0" id="ixv-3838">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Compensation Committee
and the Board have not established policies and practices (whether written or otherwise) regarding the timing of option grants, stock
appreciation rights and similar awards, or other awards, in relation to the release of material nonpublic information (&#x201c;MNPI&#x201d;)
and do not take MNPI into account when determining the timing and terms of stock option or other equity awards to executive officers,
provided that we do not currently grant stock options to employees or executives. The Company does not time the disclosure of MNPI, whether
positive or negative, for the purpose of affecting the value of executive compensation.&lt;/p&gt;</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:AwardTmgMethodTextBlock contextRef="c0" id="ixv-14202">The Compensation Committee
and the Board have not established policies and practices (whether written or otherwise) regarding the timing of option grants, stock
appreciation rights and similar awards, or other awards, in relation to the release of material nonpublic information (&#x201c;MNPI&#x201d;)
and do not take MNPI into account when determining the timing and terms of stock option or other equity awards to executive officers,
provided that we do not currently grant stock options to employees or executives.</ecd:AwardTmgMethodTextBlock>
    <ecd:AwardTmgHowMnpiCnsdrdTextBlock contextRef="c0" id="ixv-14203">the release of material nonpublic information (&#x201c;MNPI&#x201d;)</ecd:AwardTmgHowMnpiCnsdrdTextBlock>
    <ecd:AwardTmgMnpiCnsdrdFlag contextRef="c0" id="ixv-14204">false</ecd:AwardTmgMnpiCnsdrdFlag>
    <ecd:MnpiDiscTimedForCompValFlag contextRef="c0" id="ixv-14205">false</ecd:MnpiDiscTimedForCompValFlag>
    <ecd:PvpTableTextBlock contextRef="c0" id="ixv-5738">&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Pay Versus Performance&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;This section provides disclosure
about the relationship between executive compensation actually paid to our principal executive officer (&#x201c;&lt;span style="text-decoration:underline"&gt;PEO&lt;/span&gt;&#x201d;) and
non-PEO Named Executive Officers (&#x201c;&lt;span style="text-decoration:underline"&gt;NEOs&lt;/span&gt;&#x201d;) and certain financial performance measures of the Company for the fiscal
years listed below. This disclosure has been prepared in accordance with Item 402(v) of Regulation S-K under the Exchange Act (the &#x201c;&lt;span style="text-decoration:underline"&gt;Pay
Versus Performance Rules&lt;/span&gt;&#x201d;) and does not necessarily reflect how the Compensation Committee evaluates compensation decisions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;b&gt;Fiscal Year&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-decoration: none; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"&gt;&lt;b&gt;Summary Compensation Table Total for Blair Jordan &lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;b&gt;Compensation Actually Paid to Blair Jordan&lt;sup&gt;(3)(4)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;b&gt;Summary Compensation Table Total for James N. Woody &lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;b&gt;Compensation Actually Paid to James N. Woody&lt;sup&gt;(3)(4)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;b&gt;Average Summary Compensation Table Total for Non-PEO NEOs&lt;sup&gt;(5)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;b&gt;Average Compensation Actually Paid to Non-PEO NEOs&lt;sup&gt;(6)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;b&gt;Value of Initial Fixed $100 Investment Based on Total shareholder Return (&#x201c;TSR&#x201d;)&lt;sup&gt;(7)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;b&gt;Net Loss (in thousands)&lt;sup&gt;(8)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;(a)&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center"&gt;(b)&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center"&gt;(b)&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center"&gt;(c)&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center"&gt;(c)&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center"&gt;(d)&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center"&gt;(e)&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center"&gt;(f)&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center"&gt;(g)&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 12%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;140,107&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;140,107&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;100,250&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;100,250&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;137,688&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;137,688&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;0.12&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;(6,168&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-2"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-3"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;656,800&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;605,147&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;356,889&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;351,330&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.27&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;(19,935&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-4"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-5"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;463,500&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,366,665&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;437,699&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,909&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;4.35&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"&gt;(38,726&lt;/td&gt;&lt;td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14pt; text-indent: -14pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify"&gt;The following table lists the PEO and non-PEO&#160;NEOs for each of fiscal years 2024, 2023 and 2022:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14pt; text-indent: -14pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; width: 7%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 40%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;PEO&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 51%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Non-PEO NEOs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Blair Jordan and James N. Woody&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Omar Jimenez, Ozan Pamir, Jonathan Rothbard&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;James N. Woody&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Ozan Pamir, Jonathan Rothbard, and Quan Anh Vu&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;James N. Woody&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Ozan Pamir, Jonathan Rothbard, and Quan Anh Vu&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The dollar amounts reported in
column (b) are the amounts of total compensation reported for our CEOs for each corresponding year in the &#x201c;Total&#x201d; column
of the Summary Executive Compensation Table. Refer to &#x201c;Executive and Director Compensation&#x2014;Summary Executive Compensation
Table&#x201d;.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The dollar amounts reported represent the amount of &#x201c;compensation actually paid,&#x201d; as calculated in accordance with the Pay Versus Performance Rules. These dollar amounts do not reflect the actual amounts of compensation earned by or paid to our PEOs during the applicable year. For purposes of calculating &#x201c;compensation actually paid,&#x201d; the fair value of equity awards is calculated in accordance with FASB ASC Topic 718 using the same assumption methodologies used to calculate the grant date fair value of awards for purposes of the Summary Compensation Table (refer to the Summary Compensation Table for additional information).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The following table shows the amounts deducted from and added to the Summary Compensation Table total to calculate &#x201c;compensation actually paid&#x201d; to our PEOs in accordance with the Pay Versus Performance Rules:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Blair Jordan&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Reported Summary Compensation&lt;br/&gt; Table Total for PEO&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Reported Value&lt;br/&gt; of Equity Awards (A)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Equity Award&lt;br/&gt; Adjustments (B)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Compensation&lt;br/&gt; Actually Paid to PEO&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 19%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;140,107&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-6"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-7"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;140,107&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;James N. Woody&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Reported Summary Compensation&lt;br/&gt; Table Total for PEO&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Reported Value&lt;br/&gt; of Equity Awards (A)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Equity Award&lt;br/&gt; Adjustments (B)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Compensation&lt;br/&gt; Actually Paid to PEO&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 19%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;100,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-8"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-9"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;100,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;656,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,025&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-10"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;605,147&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;463,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-11"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,830,165&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,366,665&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;(A)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The grant date fair value of equity awards represents the sum of the totals of the amounts reported in the &#x201c;Stock Awards&#x201d; and &#x201c;Option Awards&#x201d; columns in the Summary Executive Compensation Table for the applicable year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;(B)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards that are granted and vest in same applicable year, the fair value as of the vesting date; (iv) for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v) for awards granted in prior years that are determined to fail to meet the applicable vesting conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi) the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable year. The amounts deducted or added in calculating the equity award adjustments are as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Blair Jordan&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 17%; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year End Fair Value of&lt;br/&gt; Outstanding&lt;br/&gt; and Unvested&lt;br/&gt; Equity Awards&lt;br/&gt; Granted in&lt;br/&gt; Year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year over Year&lt;br/&gt; Change in Fair Value of&lt;br/&gt; Outstanding&lt;br/&gt; and Unvested&lt;br/&gt; Equity Awards&lt;br/&gt; Granted in&lt;br/&gt; Prior Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;br/&gt; as of&lt;br/&gt; Vesting&lt;br/&gt; Date of&lt;br/&gt; Equity&lt;br/&gt; Awards&lt;br/&gt; Granted&lt;br/&gt; and&lt;br/&gt; Vested in&lt;br/&gt; the Year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year over Year&lt;br/&gt; Change in&lt;br/&gt; Fair Value of&lt;br/&gt; Equity Awards Granted in Prior Years that Vested&lt;br/&gt; in&#160;the Year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;br/&gt; at the End of&lt;br/&gt; the Prior&lt;br/&gt; Year of Equity&lt;br/&gt; Awards that&lt;br/&gt; Failed to Meet&lt;br/&gt; Vesting&lt;br/&gt; Conditions in&lt;br/&gt; the Year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Value of&lt;br/&gt; Dividends or&lt;br/&gt; other&lt;br/&gt; Earnings Paid&lt;br/&gt; on Stock or&lt;br/&gt; Option Awards not&lt;br/&gt; Otherwise&lt;br/&gt; Reflected in&lt;br/&gt; Fair Value or&lt;br/&gt; Total&lt;br/&gt; Compensation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center; width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 9%"&gt;Total Equity Award Adjustments&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-12"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-13"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-14"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-15"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-16"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-17"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-18"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;James N. Woody&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid"&gt;Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year End Fair Value of&lt;br/&gt; Outstanding&lt;br/&gt; and Unvested&lt;br/&gt; Equity Awards&lt;br/&gt; Granted in&lt;br/&gt; Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year over Year&lt;br/&gt; Change in Fair Value of&lt;br/&gt; Outstanding&lt;br/&gt; and Unvested&lt;br/&gt; Equity Awards&lt;br/&gt; Granted in&lt;br/&gt; Prior Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair Value&lt;br/&gt; as of&lt;br/&gt; Vesting&lt;br/&gt; Date of&lt;br/&gt; Equity&lt;br/&gt; Awards&lt;br/&gt; Granted&lt;br/&gt; and&lt;br/&gt; Vested in&lt;br/&gt; the Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year over Year&lt;br/&gt; Change in&lt;br/&gt; Fair Value of&lt;br/&gt; Equity Awards Granted in Prior Years that Vested&lt;br/&gt; in&#160;the Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair Value&lt;br/&gt; at the End of&lt;br/&gt; the Prior&lt;br/&gt; Year of Equity&lt;br/&gt; Awards that&lt;br/&gt; Failed to Meet&lt;br/&gt; Vesting&lt;br/&gt; Conditions in&lt;br/&gt; the Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Value of&lt;br/&gt; Dividends or&lt;br/&gt; other&lt;br/&gt; Earnings Paid&lt;br/&gt; on Stock or&lt;br/&gt; Option Awards not&lt;br/&gt; Otherwise&lt;br/&gt; Reflected in&lt;br/&gt; Fair Value or&lt;br/&gt; Total&lt;br/&gt; Compensation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total Equity&lt;br/&gt; Award&lt;br/&gt; Adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-19"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-20"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-21"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-22"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-23"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-24"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-25"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 16%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,596&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(8,108&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,445&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(31,561&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-26"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-27"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(12,628&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;40,138&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,426,068&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;406,256&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(850,492&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-28"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-1"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,830,165&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;sup&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The dollar amounts reported in column (d) represent the average of the amounts reported for our company&#x2019;s Non-PEO NEOs as a group in the &#x201c;Total&#x201d; column of the Summary Executive Compensation Table in each applicable year. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;sup&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The dollar amounts reported in column (e) represent the average amount of &#x201c;compensation actually paid&#x201d; to the Non-PEO NEOs as a group, as computed in accordance with the Pay Versus Performance Rules. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the Non-PEO NEOs as a group during the applicable year. In accordance with the Pay Versus Performance Rules, the following adjustments were made to average total compensation for the Non-PEO NEOs for each year to determine the compensation actually paid, using the same methodology described above in Note (4)(B):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Average Reported&lt;br/&gt; Summary&lt;br/&gt; Compensation&lt;br/&gt; Table Total&lt;br/&gt; for Non-PEO NEOs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Average Reported&lt;br/&gt; Value of Equity&lt;br/&gt; Awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Average Equity&lt;br/&gt; Award Adjustments&#160;&lt;sup&gt;(a)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Average&lt;br/&gt; Compensation&lt;br/&gt; Actually Paid&lt;br/&gt; to Non-PEO NEOs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 20%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;137,688&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-29"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-30"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;137,688&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;356,889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,602&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,957&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;351,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;437,699&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-31"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(428,790&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;sup&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The amounts deducted or added in calculating the total average equity award adjustments are as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Average Year&lt;br/&gt; End Fair&lt;br/&gt; Value of&lt;br/&gt; Outstanding&lt;br/&gt; and Unvested&lt;br/&gt; Equity Awards&lt;br/&gt; Granted in the Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Year over Year&lt;br/&gt; Average Change in Fair Value of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Outstanding&lt;br/&gt; and Unvested&lt;br/&gt; Equity Awards&lt;br/&gt; Granted in&lt;br/&gt; Prior Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Average Fair&lt;br/&gt; Value as of&lt;br/&gt; Vesting Date of Equity&lt;br/&gt; Awards Granted and&lt;br/&gt; Vested in the&lt;br/&gt; Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year over&lt;br/&gt; Year Average Change&lt;br/&gt; in Fair Value of Equity&lt;br/&gt; Awards Granted in Prior Years&lt;br/&gt; that Vested&lt;br/&gt; in the Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Average Fair Value at the End of the&lt;br/&gt; Prior Year of&lt;br/&gt; Equity Awards&lt;br/&gt; that Failed to Meet Vesting&lt;br/&gt; Conditions in&lt;br/&gt; the Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Average Value of Dividends&lt;br/&gt; or other Earnings&lt;br/&gt; Paid on Stock&lt;br/&gt; or Option&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Awards not&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Otherwise Reflected in&lt;br/&gt; Fair Value&lt;br/&gt; or Total Compensation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total Average Equity&lt;br/&gt; Award&lt;br/&gt; Adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-32"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-33"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-34"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-35"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-36"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-37"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-38"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 12%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;859&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(1,304&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,612&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(6,124&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-39"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-40"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,957&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11,774&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(367,087&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;81,450&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(154,927&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-41"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-42"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(428,790&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;sup&gt;(7)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Assumes $100 invested in our common shares on December 31, 2021, and calculated based on the difference between the share price of our common stock at the end and the beginning of the measurement period, and reinvestment of all dividends. No cash dividends were paid in 2022, 2023 or 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;sup&gt;(8)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The dollar amounts reported represent the amount of net loss reflected in our consolidated audited financial statements for the applicable year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ecd:PvpTableTextBlock>
    <ecd:PeoTotalCompAmt contextRef="c2" decimals="0" id="ix_3_fact" unitRef="usd">140107</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c2" decimals="0" id="ix_15_fact" unitRef="usd">140107</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt contextRef="c3" decimals="0" id="ix_4_fact" unitRef="usd">100250</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c3" decimals="0" id="ix_16_fact" unitRef="usd">100250</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c0" decimals="0" id="ix_5_fact" unitRef="usd">137688</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c0" decimals="0" id="ix_6_fact" unitRef="usd">137688</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c0" decimals="2" id="ix_21_fact" unitRef="usd">0.12</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ix_17_fact" unitRef="usd">-6168000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt contextRef="c5" decimals="0" id="ix_7_fact" unitRef="usd">656800</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c5" decimals="0" id="ix_18_fact" unitRef="usd">605147</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c6" decimals="0" id="ix_8_fact" unitRef="usd">356889</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c6" decimals="0" id="ix_9_fact" unitRef="usd">351330</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c6" decimals="2" id="ix_22_fact" unitRef="usd">0.27</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ix_10_fact" unitRef="usd">-19935000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt contextRef="c8" decimals="0" id="ix_11_fact" unitRef="usd">463500</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c8" decimals="0" id="ix_0_fact" unitRef="usd">-1366665</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c9" decimals="0" id="ix_12_fact" unitRef="usd">437699</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c9" decimals="0" id="ix_20_fact" unitRef="usd">8909</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c9" decimals="2" id="ix_23_fact" unitRef="usd">4.35</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c9" decimals="-3" id="ix_13_fact" unitRef="usd">-38726000</us-gaap:NetIncomeLoss>
    <ecd:NamedExecutiveOfficersFnTextBlock contextRef="c0" id="ixv-14226">The following table lists the PEO and non-PEO&#160;NEOs for each of fiscal years 2024, 2023 and 2022:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; width: 7%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 40%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;PEO&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 51%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Non-PEO NEOs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Blair Jordan and James N. Woody&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Omar Jimenez, Ozan Pamir, Jonathan Rothbard&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;James N. Woody&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Ozan Pamir, Jonathan Rothbard, and Quan Anh Vu&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;James N. Woody&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Ozan Pamir, Jonathan Rothbard, and Quan Anh Vu&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ecd:NamedExecutiveOfficersFnTextBlock>
    <ecd:PeoName contextRef="c0" id="ixv-5960">Blair Jordan and James N. Woody</ecd:PeoName>
    <ecd:PeoName contextRef="c6" id="ixv-5971">James N. Woody</ecd:PeoName>
    <ecd:PeoName contextRef="c9" id="ixv-5982">James N. Woody</ecd:PeoName>
    <ecd:AdjToCompAmt contextRef="c10" decimals="0" id="ixv-14228" unitRef="usd">140107</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c13" decimals="0" id="ixv-14229" unitRef="usd">140107</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c14" decimals="0" id="ixv-14230" unitRef="usd">100250</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c17" decimals="0" id="ixv-14231" unitRef="usd">100250</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c18" decimals="0" id="ixv-14232" unitRef="usd">656800</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c19" decimals="0" id="ix_14_fact" unitRef="usd">-39025</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c21" decimals="0" id="ixv-14234" unitRef="usd">605147</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c22" decimals="0" id="ixv-14235" unitRef="usd">463500</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c24" decimals="0" id="ix_1_fact" unitRef="usd">-1830165</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c25" decimals="0" id="ixv-14237" unitRef="usd">-1366665</ecd:AdjToCompAmt>
    <ecd:EqtyAwrdsAdjFnTextBlock contextRef="c0" id="ixv-14238">The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards that are granted and vest in same applicable year, the fair value as of the vesting date; (iv) for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v) for awards granted in prior years that are determined to fail to meet the applicable vesting conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi) the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable year. The amounts deducted or added in calculating the equity award adjustments are as follows</ecd:EqtyAwrdsAdjFnTextBlock>
    <ecd:AdjToCompAmt contextRef="c40" decimals="0" id="ixv-14239" unitRef="usd">8596</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c41" decimals="0" id="ixv-14240" unitRef="usd">-8108</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c42" decimals="0" id="ixv-14241" unitRef="usd">18445</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c43" decimals="0" id="ixv-14242" unitRef="usd">-31561</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c46" decimals="0" id="ixv-14243" unitRef="usd">-12628</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c47" decimals="0" id="ixv-14244" unitRef="usd">40138</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c48" decimals="0" id="ixv-14245" unitRef="usd">-1426068</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c49" decimals="0" id="ixv-14246" unitRef="usd">406256</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c50" decimals="0" id="ixv-14247" unitRef="usd">-850492</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c52" decimals="0" id="ixv-14248" unitRef="usd">-1830165</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c0" decimals="0" id="ixv-14250" unitRef="usd">137688</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c0" decimals="0" id="ixv-14251" unitRef="usd">137688</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c6" decimals="0" id="ixv-14252" unitRef="usd">356889</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt contextRef="c55" decimals="0" id="ixv-14253" unitRef="usd">-2602</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c56" decimals="0" id="ix_19_fact" unitRef="usd">-2957</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c6" decimals="0" id="ixv-14255" unitRef="usd">351330</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c9" decimals="0" id="ixv-14256" unitRef="usd">437699</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt contextRef="c58" decimals="0" id="ix_2_fact" unitRef="usd">-428790</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c9" decimals="0" id="ixv-14258" unitRef="usd">8909</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:AdjToCompAmt contextRef="c66" decimals="0" id="ixv-14259" unitRef="usd">859</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c67" decimals="0" id="ixv-14260" unitRef="usd">-1304</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c68" decimals="0" id="ixv-14261" unitRef="usd">3612</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c69" decimals="0" id="ixv-14262" unitRef="usd">-6124</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c72" decimals="0" id="ixv-14263" unitRef="usd">-2957</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c73" decimals="0" id="ixv-14264" unitRef="usd">11774</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c74" decimals="0" id="ixv-14265" unitRef="usd">-367087</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c75" decimals="0" id="ixv-14266" unitRef="usd">81450</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c76" decimals="0" id="ixv-14267" unitRef="usd">-154927</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c79" decimals="0" id="ixv-14268" unitRef="usd">-428790</ecd:AdjToCompAmt>
    <ecd:CompActuallyPaidVsNetIncomeTextBlock contextRef="c0" id="ixv-6825">&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Compensation Actually
Paid and Net Loss&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our company has not historically
looked to net loss as a performance measure for our executive compensation program. Our net loss was $38.7 million in 2022, $19.9 million
in 2023 and $6.17 in 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;img alt="" src="image_002.jpg"/&gt;&lt;/p&gt;</ecd:CompActuallyPaidVsNetIncomeTextBlock>
    <ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock contextRef="c0" id="ixv-6838">&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Compensation Actually
Paid and Cumulative TSR&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As shown in the following
graph, the compensation actually paid to our PEOs and the average amount of compensation actually paid to our non-PEO NEOs as a group
during the periods presented do have some correlation because a portion of their compensation has historically been in the form of long-term
equity awards. The equity awards values are significantly impacted by changes in our stock price each period. These equity awards strongly
align our executive officers&#x2019; interests with those of our stockholders by providing a continuing financial incentive to maximize
long-term value for our stockholders and by encouraging our executive officers to continue in our employment for the long-term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;img alt="" src="image_003.jpg"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;All information provided
above under the &#x201c;Pay Versus Performance&#x201d; and &#x201c;Relationship Between &#x201c;Compensation Actually Paid&#x201d; and Performance&#x201d;,
headings will not be deemed to be incorporated by reference in any filing of our company under the Securities Act, whether made before
or after the date hereof and irrespective of any general incorporation language in any such filing.&lt;/i&gt;&lt;/p&gt;</ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">PRE 14A</dei:DocumentType>
    <ecd:Additional402vDisclosureTextBlock contextRef="c9" id="hidden-fact-1" xsi:nil="true"/>
    <ecd:PeoTotalCompAmt
      contextRef="c4"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="c4"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:PeoTotalCompAmt
      contextRef="c7"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="c7"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c11"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c12"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c15"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c16"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c20"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c23"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c26"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c27"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c28"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c29"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c30"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c31"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c32"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c33"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c34"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c35"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c36"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c37"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c38"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c39"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c44"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c45"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c51"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c53"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c54"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c57"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c59"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c60"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c61"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c62"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c63"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c64"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c65"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c70"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c71"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c77"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c78"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-14314">0001690080</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-14315">false</dei:AmendmentFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-4"
          xlink:label="hidden-fact-4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_20_fact"
          xlink:label="ix_20_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-2"
          xlink:label="hidden-fact-2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-3"
          xlink:label="hidden-fact-3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_23_fact"
          xlink:label="ix_23_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_22_fact"
          xlink:label="ix_22_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_21_fact"
          xlink:label="ix_21_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-5"
          xlink:label="hidden-fact-5"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The following table lists the PEO and non-PEO&#160;NEOs for each of fiscal years 2024, 2023 and 2022:</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-4"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-2"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-3"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_23_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_22_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-5"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">The dollar amounts reported represent the amount of &#x201c;compensation actually paid,&#x201d; as calculated in accordance with the Pay Versus Performance Rules. These dollar amounts do not reflect the actual amounts of compensation earned by or paid to our PEOs during the applicable year. For purposes of calculating &#x201c;compensation actually paid,&#x201d; the fair value of equity awards is calculated in accordance with FASB ASC Topic 718 using the same assumption methodologies used to calculate the grant date fair value of awards for purposes of the Summary Compensation Table (refer to the Summary Compensation Table for additional information).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-3"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-5"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">The following table shows the amounts deducted from and added to the Summary Compensation Table total to calculate &#x201c;compensation actually paid&#x201d; to our PEOs in accordance with the Pay Versus Performance Rules:</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-3"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-5"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-9"
          xlink:label="hidden-fact-9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-10"
          xlink:label="hidden-fact-10"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-7"
          xlink:label="hidden-fact-7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards that are granted and vest in same applicable year, the fair value as of the vesting date; (iv) for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v) for awards granted in prior years that are determined to fail to meet the applicable vesting conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi) the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable year. The amounts deducted or added in calculating the equity award adjustments are as follows:</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-9"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-10"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-7"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-30"
          xlink:label="hidden-fact-30"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_19_fact"
          xlink:label="ix_19_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_8_footnote" xlink:label="ix_8_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">The amounts deducted or added in calculating the total average equity award adjustments are as follows:</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-30"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_19_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">The dollar amounts reported in
column (b) are the amounts of total compensation reported for our CEOs for each corresponding year in the &#x201c;Total&#x201d; column
of the Summary Executive Compensation Table. Refer to &#x201c;Executive and Director Compensation&#x2014;Summary Executive Compensation
Table&#x201d;.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-4"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-2"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The dollar amounts reported in column (d) represent the average of the amounts reported for our company&#x2019;s Non-PEO NEOs as a group in the &#x201c;Total&#x201d; column of the Summary Executive Compensation Table in each applicable year.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnote id="ix_7_footnote" xlink:label="ix_7_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">The dollar amounts reported in column (e) represent the average amount of &#x201c;compensation actually paid&#x201d; to the Non-PEO NEOs as a group, as computed in accordance with the Pay Versus Performance Rules. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the Non-PEO NEOs as a group during the applicable year. In accordance with the Pay Versus Performance Rules, the following adjustments were made to average total compensation for the Non-PEO NEOs for each year to determine the compensation actually paid, using the same methodology described above in Note (4)(B):</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnote id="ix_10_footnote" xlink:label="ix_10_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">The dollar amounts reported represent the amount of net loss reflected in our consolidated audited financial statements for the applicable year.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-8"
          xlink:label="hidden-fact-8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-6"
          xlink:label="hidden-fact-6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-11"
          xlink:label="hidden-fact-11"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">The grant date fair value of equity awards represents the sum of the totals of the amounts reported in the &#x201c;Stock Awards&#x201d; and &#x201c;Option Awards&#x201d; columns in the Summary Executive Compensation Table for the applicable year.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-8"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-6"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-11"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnote id="ix_9_footnote" xlink:label="ix_9_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Assumes $100 invested in our common shares on December 31, 2021, and calculated based on the difference between the share price of our common stock at the end and the beginning of the measurement period, and reinvestment of all dividends. No cash dividends were paid in 2022, 2023 or 2024.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_22_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_23_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
